

INTERNATIONAL SOCIETY FOR HEART  
AND LUNG TRANSPLANTATION

# NICE 2015

*Nice la Belle*

**35th Annual Meeting  
and Scientific Sessions  
April 15 - 18, 2015**

---

## FINAL PROGRAM

**CONVENING AT THE ACROPOLIS  
CONGRÈS CENTRE, NICE, FRANCE**

# Changing tomorrow



Astellas (formerly Fujisawa) has been committed to the European transplant community since the early 1990s. By taking a leadership role in addressing the needs of surgeons, physicians, and patients, we are **CHANGING TOMORROW**.

Through sustained investment in almost 100 European clinical studies, Astellas is continually striving to advance transplant care by developing both new treatment regimens and innovative therapies that target specific pathways.

By partnering with you, and by supporting many of the patient organisations that offer hope for the future, we are all **CHANGING TOMORROW** as we work to fulfil the promise of transplantation.

[www.astellas.eu](http://www.astellas.eu)

© February 2015 Astellas Pharma Europe Ltd. ADV/15/0005/GMSa

ASTELLAS, Leading Light for Life, the Star logo, **CHANGING TOMORROW** and the Ribbon logos are trade marks of Astellas Pharma Inc. and/or its related entities.

TRANSPLANTATION  
ONCOLOGY  
UROLOGY  
DERMATOLOGY  
ANTI-INFECTIVES  
PAIN MANAGEMENT



astellas  
Leading Light for Life

INTERNATIONAL SOCIETY FOR  
HEART AND LUNG TRANSPLANTATION

**Thirty-fifth Annual Meeting and  
Scientific Sessions** · APRIL 15-18, 2015  
THE ACROPOLIS · NICE, FRANCE

# FINAL PROGRAM

## TABLE OF CONTENTS

About ISHLT.....	2
Board of Directors .....	4
Scientific Program Committee .....	6
Abstract Reviewers.....	8
QR Codes .....	19
Daily Time Table Schedule .....	20
Continuing Medical Education .....	30
Highlights of the Annual Meeting .....	34
Nice Acropolis Floor Plans .....	52
Annual Meeting Schedule At a Glance.....	56
Unrestricted Educational Grants .....	73
Corporate Partners.....	74
Annual Meeting Scientific Program .....	75
Moderated Poster Sessions.....	194
Independent Events.....	266
ISHLT 2015 Exhibitors .....	270
Exhibit Hall & Posters Floor Plan .....	272



# ABOUT ISHLT

**The International Society for Heart and Lung Transplantation (ISHLT)** is a not-for-profit, multi-disciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies via research, education and advocacy.

ISHLT was created in 1981 at a small gathering of about 15 cardiologists and cardiac surgeons. Today we have over 3,000 members from over 45 countries, representing over 15 different professional disciplines involved in the management and treatment of end-stage heart and lung disease. This multinational, multidisciplinary mix is one of the biggest strengths of the Society. It brings greater breadth and depth to our educational offerings and provides an exceptional environment for networking and exchanging information on an informal basis.

Our members include anesthesiologists, basic scientists, cardiologists, cardiothoracic surgeons, ethicists, immunologists, nurses, pathologists, perfusionists, pharmacists, pulmonologists, tissue engineers, transplant coordinators and infectious disease specialists. Despite their differing specializations, all ISHLT members share a common dedication to the advancement of the science and treatment of end-stage heart and lung disease.

## The purposes of the Society are:

1. To associate persons interested in the fields of heart and lung transplantation, end-stage heart and lung disease and related sciences.
2. To encourage and stimulate basic and clinical research in these disciplines and to promote new therapeutic strategies.
3. To hold scientific meetings featuring presentations and discussions relevant to these disciplines.
4. To sponsor a scientific journal for the publication of manuscripts related to these disciplines.
5. To establish and maintain an international registry for heart and lung transplantation.
6. To award research grants and establish endowments for the study of these disciplines.



# 2014-2015 Board of Directors

## OFFICERS

Hermann Reichenspurner, MD, PhD, PRESIDENT

Duane Davis, MD, MBA, PRESIDENT-ELECT

Allan R. Glanville, MBBS, MD, FRACP,  
PAST-PRESIDENT

Stuart C. Sweet, MD, PhD, SECRETARY-TREASURER

## DIRECTORS

Christian Benden, MD, DIRECTOR

Lara Danziger-Isakov, MD, MPH, DIRECTOR

Andrew J. Fisher, FRCP, PhD, DIRECTOR

Daniel R. Goldstein, MD, PhD, DIRECTOR

Maryl R. Johnson, MD, DIRECTOR

Bronwyn J. Levvey, RN, Grad Dip Clin Ep,  
DIRECTOR

Francis D. Pagani, MD, PhD, DIRECTOR

Myung H. Park, MD, DIRECTOR

Joseph G. Rogers, MD, DIRECTOR

Martin Strueber, MD, DIRECTOR

Jeffrey J. Teuteberg, MD, DIRECTOR

## EX OFFICIO BOARD MEMBERS

Andreas Zuckermann, MD,  
2015 SCIENTIFIC PROGRAM COMMITTEE CHAIR

Mandeep R. Mehra, MD, MBBS FACP,  
EDITOR-IN-CHIEF *JOURNAL OF HEART AND LUNG  
TRANSPLANTATION*

Josef Stehlik, MD, MPH,  
TRANSPLANT REGISTRY MEDICAL DIRECTOR

Lori J. West, MD, DPhil,  
DEVELOPMENT COMMITTEE CHAIR

Christopher H. Wigfield, MD FRCS (C/Th),  
DIRECTOR OF EDUCATIONAL AFFAIRS

Amanda W. Rowe, ISHLT EXECUTIVE DIRECTOR



## **STAFF**

**Amanda W. Rowe**  
EXECUTIVE DIRECTOR

**Phyllis Glenn**  
DIRECTOR OF  
MEMBERSHIP SERVICES

**Lisa A. Edwards**  
DIRECTOR OF MEETINGS

**Lee Ann Mills**  
DIRECTOR OF OPERATIONS

**Susie Newton**  
COMMUNICATIONS MANAGER

**Megan Barrett**  
COMMUNICATIONS ASSISTANT



14673 MIDWAY ROAD  
SUITE 200  
ADDISON, TX 75001  
PHONE: 972 490-9495  
FAX: 972 490-9499  
WWW.ISHLT.ORG

# ANNUAL MEETING Scientific Program Committee

## ◆ SYMPOSIUM PLANNING COMMITTEE

- ◆ ✧ **Andreas O. Zuckermann, MD,**  
Vienna, Austria, 2015 PROGRAM CHAIR
- ◆ ✧ **Hermann Reichenspurner, MD, PhD,**  
Hamburg, Germany, ISHLT PRESIDENT
- ◆ ✧ **Jason Christie, MD, MS,**  
Philadelphia, PA, USA, 2014 PROGRAM CHAIR
- ◆ ✧ **Andrew J. Fisher, MD, FRCP, PhD,**  
Newcastle upon Tyne, UK, 2016 PROGRAM CHAIR
- ◆ ✧ **Ruchan Akar, MD,** Ankara, Turkey
- ◆ ✧ **Annalisa Angelini, MD,** Padua, Italy
- ◆ ✧ **Carla C. Baan, PhD,**  
Rotterdam, The Netherlands
- ◆ ✧ **David A. Baran, MD,** Newark, NJ, USA
- ◆ ✧ **Tuvia Ben Gal, MD,** Petah Tikva, Israel
- ◆ ✧ **Emma Birks, MBBS, PhD, BSc, FRCP,**  
Louisville, KY, USA
- ◆ ✧ **Kevin Carney, MSN, CRNP, CCTC**  
Philadelphia, PA, USA
- ◆ ✧ **Adam B. Cochrane, PharmD,**  
Falls Church, VA, USA
- ◆ ✧ **Teresa De Marco, MD, FACC,**  
San Francisco, CA, USA
- ◆ ✧ **Howard J. Eisen, MD,** Philadelphia, PA, USA
- ◆ ✧ **Stephan Ensminger, MD, DPhil,**  
Bad Oeynhausen, Germany
- ◆ ✧ **Michele Estabrook, MD,** St. Louis, MO, USA
- ◆ ✧ **Peter M. Hopkins, FRACP,** Brisbane, Australia
- ◆ ✧ **Annemarie Kaan, MCN, RN,**  
Vancouver, Canada
- ◆ ✧ **Manreet Kanwar, MD,** Pittsburgh, PA, USA
- ◆ ✧ **Cassie C. Kennedy, MD,** Rochester, MN, USA
- ◆ ✧ **Ivan Knezevic, MD,** Ljubljana, Slovenia





## ★ ABSTRACT SELECTION COMMITTEE

- ★ Kiran K. Khush, MD, Stanford, CA, USA
- ★ Pascal Leprince, MD, PhD, Paris, France
- ◆ ★ Haifa Lyster, MSc, Harefield, UK
- ★ Peter MacDonald, MD, PhD, Sydney, Australia
- ◆ ★ Claudius Mahr, DO, Seattle, WA, USA
- ◆ ★ Nicolas Manito, MD, Barcelona, Spain
- ◆ ★ Marco Masetti, MD, Bologna, Italy
- ◆ ★ Mandeep R. Mehra, MD, MBBS, FACC, FACP, Boston, MA, USA
- ★ Bruno M. Meiser, MD, Munich, Germany
- ◆ ★ Dylan V. Miller, MD, Murray, UT, USA
- ◆ ★ Jignesh K. Patel, MD, PhD, Los Angeles, CA, USA
- ★ Martin Schweiger, MD, Zurich, Switzerland
- ◆ ★ Amparo Sole, MD, PhD, Valencia, Spain
- ◆ ★ Zsolt Szepefalusi, MD, Vienna, Austria
- ◆ ★ Jeffrey J. Teuteberg, MD, Pittsburgh, PA, USA
- ★ Mitesh V. Thakrar, MD, Calgary, Canada
- ◆ ★ Steven SL Tsui, MD, FRCS, Cambridge, UK
- ★ Marian Urban, MD, Prague, Czech Republic
- ◆ ★ Simon Urschel, MD, Edmonton, Canada
- ★ Vincent G. Valentine, MD, Galveston, TX, USA
- ◆ ★ Carmine Dario Vizza, MD, Rome, Italy
- ◆ ★ Florian M. Wagner, MD, Hamburg, Germany
- ◆ ★ Lori J. West, MD, DPhil, Edmonton, Canada
- ◆ ★ Christopher H. Wigfield, MD FRCS(C/Th), Chicago, IL, USA
- ◆ ★ Martin R. Zamora, MD, Aurora, CO, USA



**Keith D. Aaronson, MD**, University of Michigan Medical Center, Ann Arbor, MI, USA

**Richa Agarwal, MD**, W. Penn Allegheny Hospital, Pittsburgh, PA, USA

**Zargham Ahmadi, MD**, Shahid Beheshti University of Medical School, Tehran, Iran

**Clemens Aigner, MD**, Medical University of Vienna, Vienna, Austria

**Dimpna C. Albert, MD**, Vall d 'Hebron Hospital, Barcelona, Spain

**Arezu Z. Aliabadi, MD**, Medical University of Vienna, Vienna, Austria

**Christopher Almond, MD**, Boston Children's Hospital, Boston, MA, USA

**Rolando J. Alvarez, MD**, Instituto Nacional de Cardiología, Mexico City, Mexico

**Samantha J. Anthony, PhD, MSW**, Hospital for Sick Children, Toronto, ON, Canada

**Abbas Ardehali, MD**, UCLA School of Medicine, Los Angeles, CA, USA

**Saima Aslam, MD, MS**, University of California, San Diego, San Diego, CA, USA

**Pavan Atluri, MD**, University of Pennsylvania, Philadelphia, PA, USA

**Agnes M. Azimzadeh, PhD**, University of Maryland School of Medicine, Baltimore, MD, USA

**Fernando Bacal, MD**, Heart Institute, University of Sao Paulo, Sao Paulo, Brazil

**Matthew D. Bacchetta, MD**, NY Presbyterian Hospital/Columbia Univ, New York, NY, USA

**Markus J. Barten, MD, PhD**, Heart Center Leipzig, Sazonia, Germany

**Christian Benden, MD**, University Hospital Zurich, Zurich, Switzerland



**Raymond L Benza, MD**, Allegheny General Hospital, Pittsburgh, PA, USA

**Alexander Bernhardt, MD**, University Heart Center Hamburg, Hamburg, Germany

**Gerald J. Berry, MD**, Stanford University, Stanford, CA, USA

**Sangeeta M. Bhorade, MD**, Northwestern Memorial Hospital, Chicago, IL, USA

**Nancy P. Blumenthal, CRNP**, Hospital of University of Pennsylvania, Philadelphia, PA, USA

**Hilde Bollen, RN**, UZLeuven, Leuven, Belgium

**Michael Bowdish, MD**, Keck School of Medicine of USC, Los Angeles, CA, USA

**Andrew J. Boyle, MD**, Cleveland Clinic Florida, Weston, FL, USA

**Nicolas A. Brozzi, MD**, Cleveland Clinic Florida, Weston, FL, USA

**Marie M. Budev, DO, MPH**, The Cleveland Clinic, Cleveland, OH, USA

**Deborah Budge, MD**, Intermountain Medical Center, Murray, UT, USA

**Caron L. Burch, MSN**, Stanford Hospital & Clinics, Stanford, CA, USA

**Margaret M. Burke, MD, FRCPath**, Harefield Hospital, Harefield, UK

**Marco A. Caccamo, DO**, Indiana University Health, Indianapolis, IN, USA

**Martin Cadeiras, MD**, University of California Los Angeles, Los Angeles, CA, USA

**Fiorella Calabrese, MD**, University of Padova, Padova, Italy

**Charles E. Canter, MD**, St. Louis Children's Hospital, St. Louis, MO, USA

**Edward Cantu, MD**, Hospital of University of Pennsylvania, Philadelphia, PA, USA

- Lilibeth M. Carlos**, St. Vincent's Hospital, Sydney, NSW, Australia
- Chesney Castleberry, MD**, Cincinnati Children's Hospital MC, Cincinnati, OH, USA
- Alexandre S. Cauduro, MD**, Heart Institute Sao Paulo University, Sao Paulo, Brazil
- Daniel Chambers, MBBS, MRCP, FRACP, MD**, The Prince Charles Hospital, Brisbane, QLD, Australia
- Kevin M. Chan, MD**, University of Michigan Health System, Ann Arbor, MI, USA
- Cecilia Chaparro, MD**, Toronto General Hospital, Toronto, ON, Canada
- Richard Cheng, MD**, University of Washington, Seattle, WA, USA
- Anson W. Cheung, MD**, St. Paul's Hospital, Vancouver, BC, Canada
- Laveena Chhatwani, MD**, Duke University Medical Center, Durham, NC, USA
- Stephen C. Clark, MD**, Freeman Hospital, Newcastle, United Kingdom
- Rebecca J. Cogswell, MD**, University of Minnesota, Minneapolis, MN, USA
- Jennifer Conway, MD**, Stollery Children's Hospital, Edmonton, AB, Canada
- Hannah Copeland, MD**, Loma Linda University, Redlands, CA, USA
- Maria Rosa Costanzo, MD**, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA
- Jennifer Cowger, MD**, St. Vincent Heart Center, Indianapolis, ID, USA
- Lara Danziger-Isakov, MD, MPH**, Children's Hospital Medical Center, Cincinnati, OH, USA
- John Dark, MB, FRCS**, Freeman Hospital, Newcastle Upon Tyne, UK
- Marc De Perrot, MD**, Toronto General Hospital, Toronto, Canada
- Juan F. Delgado Jimenez, PhD**, University Hospital 12 de Octubre, Madrid, Spain
- Goran Dellgren, MD, PhD**, Sahlgrenska University Hospital, Goteborg, Sweden
- Mario C. Deng, MD**, David Geffen School of Medicine, Los Angeles, CA, USA
- Eugene C. DePasquale, MD**, David Geffen School of Medicine, Los Angeles, CA, USA
- Shashank S. Desai, MD**, Inova Fairfax Hospital, Falls Church, VA, USA
- Tobias Deuse, MD, PhD**, University Heart Center Hamburg, Hamburg, Germany
- Gundeep S. Dhillon, MD**, Stanford University, Stanford, CA, USA

**Kumud K. Dhital, MD, PhD**, St. Vincent's Hospital,  
Sydney, NSW, Australia

**Joshua M. Diamond, MD**, University of  
Pennsylvania, Philadelphia, PA, USA

**Enrique Diaz Guzman Zavala, MD**, University of  
Alabama at Birmingham, Birmingham, AL, USA

**Esme Dijke, PhD**, University of Alberta,  
Edmonton, AB, Canada

**Daniel F. Dilling, MD**, Loyola University Medical  
Center, Maywood, IL, USA

**Anne I. Dipchand, MD**, Hospital for Sick Children,  
Toronto, ON, Canada

**Christina T. Doligalski, PharmD, BCPS**, Tampa  
General Hospital, Lutz, FL, USA

**Stavros G. Drakos, MD**, University of Utah School  
of Medicine, Salt Lake City, UT, USA

**Sitaramesh Emani, MD**, Ohio State University,  
Columbus, OH, USA

**Michiel E. Erasmus, MD, PhD**, University Medical  
Center Groningen, Groningen, The Netherlands

**Fardad Esmailian, MD**, Cedars-Sinai Heart Institute,  
Los Angeles, CA, USA

**Roger W. Evans, PhD, UNRTP**, Transplant  
Professionals.com, LLC, Rochester, MN, USA

**Melanie D. Everitt, MD**, Primary Children's Medical  
Center, Salt Lake City, UT, USA

**Rafid Fadul, MD, MBA**, Cleveland Clinic,  
Cleveland, OH, USA

**Carol F. Farver, MD**, Cleveland Clinic,  
Cleveland, OH, USA

**Marny Fedrigo, MD, PhD**, University of Padova,  
Padova, Italy

**Savitri E. Fedson, MD**, Univ of Chicago Hospitals,  
Chicago, IL, USA

**Mark E. Fenton, MD, FRCPC**, Royal University  
Hospital, Saskatoon, SK, Canada

**Arnt E. Fiane, MD**, Rikshospitalet, Oslo, NORWAY

**Roberto Fiocchi, MD, PhD**, Papa Giovanni XXIII  
Hospital, Bergamo, Italy

**Katrina Ford, Bpharm**, Great Ormond St Hospital,  
London, UK

**Veronica Franco, MD**, Ohio State University,  
Columbus, USA

**Jennifer L. Franzwa, MSN, RN, CCTC**, University of  
Iowa Hospitals and Clinics, Iowa City, IA, USA

**Laura K. Frye, MD**, University of Pennsylvania,  
Philadelphia, PA, USA

**Louise M. Fuller, PT**, Alfred Hospital, Melbourne,  
VIC, Australia

**Kimberly L. Gandy, MD, PhD**, University of  
Missouri, Kansas City, KS, USA

- Rochelle M. Gellatly, PharmD**, Alfred Hospital, Melbourne, VIC, Australia
- James F. George, PhD**, University of Alabama, Birmingham, AL, USA
- Helen Gibbs, RN**, Auckland City Hospital, Auckland, New Zealand
- Simon R. Gibbs, MD**, Hammersmith Hospital, London, UK
- Patricia Ging, PharmD**, Mater Misericordiae University Hospital, Dublin, Ireland
- Allan R. Glanville, MBBS, MD, FRACP**, St. Vincent's Hospital, Sydney, NSW, Australia
- Martin J. Goddard, FRCS, MRCPa**, Papworth Hospital, Cambridge, UK
- Samuel B. Goldfarb, MD**, Children's Hospital of Philadelphia, Philadelphia, PA, USA
- Daniel J. Goldstein, MD**, Montefiore Medical Center, Bronx, NY, USA
- Ranny Goldwasser, MD**, University Children's Hospital Heidelberg, Heidelberg, Germany
- Mardi Gomberg-Maitland, MD**, University of Chicago Medical Center, Chicago, IL, USA
- Jose Gonzalez-Costello, MD**, Hospital Universitari de Bellvitge, Barcelona, Spain
- Robert A. Gordon, MD**, Northwestern University, Chicago, IL, USA
- Jens Gottlieb, MD**, Medical School Hannover, Hannover, Germany
- Bartley P. Griffith, MD**, University of Maryland, Baltimore, Baltimore, MD, USA
- Paolo A. Grossi, MD, PhD**, University of Insubria, Varese, Italy
- Jan F. Gummert, MD, PhD**, Herz-und Diabeteszentrum NRW, Bad Oeynhausen, Germany
- Finn Gustafsson, MD, PhD**, ViCare Medical, Birkerød, Denmark
- Kieran Halloran, MD**, University of Alberta, Edmonton, AB, Canada
- Michele Hamilton, MD**, University Cardiovascular Medical Group, Beverly Hills, CA, USA
- Christopher S. Hayward, MD**, St. Vincent's Hospital, Sydney, NSW, Australia
- Heather T. Henderson, MD**, Duke University, Chapel Hill, NC, USA
- Robert S. D. Higgins, MD, MSHA**, Ohio State University Wexner Medical Center, Columbus, OH, USA
- Alim Hirji, MD**, University of Toronto, Toronto, ON, Canada
- Seth A. Hollander, MD**, Stanford University, San Carlos, CA, USA

**Edward Horn, PharmD, BCPS**, Allegheny General Hospital, Pittsburgh, PA, USA

**Manon H. Huibers, MSc**, University Medical Center Utrecht, Utrecht, The Netherlands

**Sharon A. Hunt, MD**, Stanford University Medical Center, Stanford, CA, USA

**David M. Hwang, MD, PhD**, Toronto General Hospital, Toronto, ON, Canada

**Amanda Ingemi, PharmD**, Sentra Norfolk General Hospital, Norfolk, VA, USA

**Debra L. Isaac, MD**, Foothills Hospital, Calgary, AB, Canada

**Jennifer A. Iuppa, PharmD**, Barnes-Jewish Hospital, St. Louis, MO, USA

**Mylvaganam Jeyakanthan, MD**, University of Alberta, Edmonton, AL, Canada

**Ranjit John, MD**, University of Minnesota, Minneapolis, MN, USA

**Ulrich P. Jorde, MD**, Columbia University, New York, NY, USA

**Steven M. Kawut, MD**, University of Pennsylvania, Philadelphia, PA, USA

**Feras Khaliel, MD, PhD**, King Faisal Specialist Hospital & RC, Riyadh, Saudi Arabia

**Daniel H. Kim, MD**, University of Alberta Medical School, Edmonton, AB, Canada

**Kyung-Hee Kim, MD**, Sejong General Hospital, Seoul, Korea

**Jolanda Kluin, MD, PhD**, UMC Utrecht, Utrecht, The Netherlands

**Christiane Knoop, MD**, Erasme University Hospital, Brussels, Belgium

**Christoph Knosalla, MD, PhD**, Deutsches Herzzentrum Berlin, Berlin, Germany

**Evan P. Kransdorf, MD, PhD**, Mayo Clinic Arizona, Scottsdale, AZ, USA

**Daniel Kreisel, MD, PhD**, Washington University School of Medicine, St. Louis, MO, USA

**Sudhir S. Kushwaha, MD**, Mayo Clinic, Rochester, MN, USA

**Brandon T. Larsen, MD, PhD**, Mayo Clinic, Rochester, MN, USA

**Lorriana E. Leard, MD**, University of California, San Francisco, San Francisco, CA, USA

**David J. Lederer, MD**, Columbia University Medical Center, New York, NY, USA

**Sangjin Lee, MD**, Cleveland Clinic, Cleveland, OH, USA

**Karl B. Lemstrom, MD, PhD**, Helsinki University, Helsinki, Finland

- Andrew J. Lenneman, MD**, University of Louisville Health Center, Louisville, KY, USA
- Ugolino Livi, MD**, S. Maria della Misericordia General Hospital, Udine, Italy
- Me-Linh Luong, MD**, St. Luc Hospital, Montreal, QC, Canada
- Joseph J. Maleszewski, MD, FACC**, Mayo Clinic, Rochester, MN, USA
- Monique Malouf, FRACP**, St. Vincent's Hospital, Sydney, NSW, Australia
- Pradeep P. A. Mammen, MD, FACC, FAHA**, UT Southwestern Medical, Dallas, TX, USA
- Donna M. Mancini, MD**, New York Presbyterian Hospital, New York, NY, USA
- Charles C. Marboe, MD**, Columbia University, New York, NY, USA
- Stanley I. Martin, MD**, Ohio State University, Columbus, OH, USA
- Tereza Martinu, MD**, Toronto General Hospital, Toronto, ON, Canada
- Sophia C. Masri, MD**, University of Washington, Seattle, WA, USA
- Oliver Mauthner, PhD**, University of Basel, Basel, Switzerland
- Dana P. McGlothlin, MD**, Kaiser San Francisco, San Francisco, CA, USA
- Tanya J. McWilliams, MD, PhD**, Auckland City Hospital, Auckland, New Zealand
- Hirsch S. Mehta, MD**, San Diego Cardiac Center, San Diego, CA, USA
- Vojtech Melenovsky, MD, PhD**, Institution for Clinical & Experimental Medicine, Prague, Czech Republic
- Anna Meyer, MD**, Leipzig Heart Center, Leipzig, Germany
- Deborah E. Meyers, MD, FRACP, FACC**, Texas Heart Institute, Houston, TX, USA
- Hendrik Milting, PhD**, Herz & Diabeteszentrum NRW, Bad Oeynhausen, Germany
- Elna Minami, MD**, University of Washington, Seattle, WA, USA
- Sonia Mirabet, MD**, Hospital Sant Pau, Barcelona, Spain
- Nader Moazami, MD**, Cleveland Clinic, Cleveland, OH, USA
- Paul J. Mohacsi, MD**, University Hospital, Bern, Switzerland
- Nahush A. Mokadam, MD**, University of Washington, Seattle, WA, USA
- Joshua J. Mooney**, Stanford University, Stanford, CA, USA



**Martha L. Mooney, MD**, Sentara Norfolk Transplant Center, Norfolk, VA, USA

**David Morales, MD**, Cincinnati Children's Hospital, Cincinnati, OH, USA

**Allana Morris, MD**, Emory University, Atlanta, GA, USA

**C. Orla Morrissey, MD**, Alfred Hospital, Melbourne, VIC, Australia

**Francesco Moscato, PhD**, Medical University of Vienna, Vienna, Austria

**Michael S. Mulligan, MD**, University of Washington School of Medicine, Seattle, WA, USA

**Nandini Nair, MD, PhD**, Sacred Heart Medical Center, Spokane, WA, USA

**Takeshi Nakatani, MD, PhD**, National Cerebral & Cardiovascular Center, Osaka, Japan

**Jose N. Nativi, MD**, University of Utah, Salt Lake City, UT, USA

**Desley Neil, FRCPath**, Queen Elizabeth Hospital, Birmingham, UK

**Ivan Netuka, MD, PhD**, Institution for Clinical and Experimental Medicine, Prague, Czech Republic

**Nicola E. Nienhues, MD**, Berlin Heart Center, Berlin, Germany

**Kari Nytroen**, Oslo University Hospital Rikshospitalet, Rendalen, NORWAY

**Francis D. Pagani, MD, PhD**, University of Michigan Health, Ann Arbor, MI, USA

**Elfriede Pahl Schuette, MD**, Lurie Children's Hospital, Wilmette, IL, USA

**Jay D. Pal, MD, PhD**, University of Washington, Seattle, WA, USA

**Scott M. Palmer, MD, MHS**, Duke University, Durham, NC, USA

**Salpy V. Pamboukian, MD**, University of Alabama at Birmingham, Birmingham, Ala, USA

**Chetan B. Patel, MD**, Duke University Medical Center, Durham, NC, USA

**Michael Pham, MD, MPH**, Stanford University, Palo Alto, CA, USA

**Sean P. Pinney, MD**, Mt Sinai Medical Center, New York, NY, USA

**Evgenij V. Potapov, MD, PhD**, Deutsches Herzzentrum, Berlin, Germany

**Luciano Potena, MD, PhD**, University of Bologna, Bologna, Italy

**Piotr Przybylowski, MD, PhD**, Jagiellonian University Medical College, Krakow, Poland

**Axel Rahmel, MD**, German Procurement Organization DSO, Frankfurt, Germany

- Amresh Raina, MD**, Allegheny General Hospital, Pittsburgh, PA, USA
- Angela Rajek, MD**, Medical University of Vienna, Vienna, Austria
- Reinaldo Rampolla, MD**, Ochsner Clinic Foundation, New Orleans, LA, USA
- Vivek Rao, MD, PhD**, Toronto General Hospital, Toronto, ON, Canada
- Leigh C. Reardon, MD**, UCLA, Los Angeles, CA, USA
- Alex Reyentovich, MD**, New York University School of Medicine, Brooklyn, NY, USA
- Joseph G. Rogers, MD**, Duke University Medical Center, Durham, NC, USA
- Antonio B. Roman, MD, PhD**, Hospital General Vall D' Hebron, Barcelona, Spain
- Heather J. Ross, MD, MHSc, FRCPC**, Toronto General Hospital, Toronto, ON, Canada
- Christopher T. Salerno, MD**, St. Vincent's Heart Center, Indianapolis, IN, USA
- Juan F. Sanchez, MD**, Baylor Scott & White, Texas A&M, Temple, TX, USA
- Gianluca Santise, MD**, Sant'Anna Hospital, Catanzaro, Italy
- Murat Sargin, MD**, Siyami Ersek Hospital, Istanbul, Turkey
- Joanna M. Schaenman, MD, PhD**, UCLA, Los Angeles, CA, USA
- Jan D. Schmitto, MD, PhD**, Medical University of Hannover, Hannover, Germany
- Sonja Schrepfer, MD, PhD**, University of Hamburg, Hamburg, CA, Germany
- Stephan Schubert, MD**, German Heart Center Berlin, Berlin, Germany
- Paul Christian Schulze, MD, PhD**, Columbia University, New York, NY, USA
- Kurt R. Schumacher, MD**, University of Michigan Congenital Heart Center, Ann Arbor, MI, USA
- Mace M. Schuurmans, MD**, University Hospital, Zurich, Switzerland
- Nicolaus Schwerk, MD**, Hannover Medical School, Hannover, Germany
- Laurent Sebbag, MD**, Hospital Louis Pradel, Bron Cedex, FRANCE
- Javier Segovia, MD, PhD**, Hospital Puerta De Hierro, Madrid, Spain
- Ana Maria Segura, MD**, Texas Heart Institute, Houston, TX, USA
- Nedim Selimovic, MD, PhD**, King Faisal Specialist Hospital & Research, Riyadh, Saudi Arabia

**Ashish S. Shah, MD**, Johns Hopkins Hospital,  
Baltimore, MD, USA

**Jooyoung J. Shin, MD**, Montefiore Medical  
Center, New York, NY, USA

**Michael Shullo, PharmD**, University of Pittsburgh  
Medical Center, Pittsburgh, PA, USA

**Sara J. Shumway, MD**, University of Minnesota,  
Minneapolis, MN, USA

**Fernanda P. Silveira, MD**, University of Pittsburgh  
Medical Center, Pittsburgh, PA, USA

**Scott C. Silvestry, MD**, Washington University  
School of Medicine, St. Louis, MO, USA

**Kathleen Simpson, MD**, Washington  
University St. Louis, St. Louis, MO, USA

**Cumara C. Sivathasan, MBBS, FRCS**, National  
Heart Centre, Singapore, Singapore

**Greg Snell, MD**, Alfred Hospital,  
Melbourne, Australia

**Heike Spaderna, PhD**, Bergische Universitaet  
Wuppertal, Wuppertal, Germany

**Joshua D. Sparks, MD**, Kosair Children's Hospital,  
Louisville, KY, USA

**Ajay V. Srivastava, MD**, Stanford University,  
San Jose, CA, USA

**Lynne W. Stevenson, MD**, Brigham & Women's  
Hospital, Boston, MA, USA

**Valentina Stosor, MD**, Northwestern  
University/Feinberg School of Medicine,  
Chicago, IL, USA

**Martin Strueber, MD**, Spectrum Health Hospital,  
Grand Rapids, MI, USA

**Linda J. Stuckey, PharmD, BCPS**, University of  
Michigan Hospital, Ann Arbor, MI, USA

**Stuart C. Sweet, MD, PhD**, St. Louis Children's  
Hospital, St. Louis, MO, USA

**Jose A. Tallaj, MD**, University of Alabama  
Birmingham, Birmingham, AL, USA

**Carmela D. Tan, MD**, Cleveland Clinic,  
Cleveland, Ohio, USA

**Inna Tchoukina, MD**, Virginia Commonwealth  
University, Chester, VA, USA

**Ryan J. Tedford, MD**, Johns Hopkins University,  
Baltimore, MD, USA

**Sunu S. Thomas, MD**, Massachusetts General  
Hospital, Boston, MA, USA

**Veli Topkara, MD**, Columbia University,  
New York, NY, USA

**Guillermo Torre-Amione, MD, PhD**,  
The Methodist Hospital, Houston, TX, USA

**Wayne M. Tsuang, MD**, Cleveland Clinic,  
Cleveland, OH, USA

- Patricia A. Uber, PharmD**, University of Hawaii, Hilo, HI, USA
- Walter Uber, PharmD**, Medical University of South Carolina, Charleston, SC, USA
- Nir Uriel, MD**, University of Chicago, Chicago, IL, USA
- Jean-Luc Vachier, MD**, Erasme University Hospital ULB, Brussels, Belgium
- Adrian B. Van Bakel, MD, PhD**, Medical University of South Carolina, Charleston, SC, USA
- Dirk Van Raemdonck, MD, PhD**, University Hospital Gasthuisberg, Leuven, Belgium
- Johan Vanhaecke, MD**, University Hospital Gasthuisberg, Leuven, Belgium
- Andres Varela de Ugarte, MD**, Hospital University Puerta de Hierro, Madrid, Spain
- Rhea A. Varughese, MD**, Alberta Health Services, Edmonton, AB, Canada
- Rajamiyer Venkateswaran, FRCS**, Wythenshawe Hospital, Manchester, UK
- Geert M. Verleden, MD, PhD**, University Hospital Gasthuisberg, Leuven, Belgium
- Robin Vos, MD, PhD**, University Hospital Gasthuisberg, Leuven, Belgium
- Gregor Warnecke, MD**, Hannover Medical School, Hannover, Germany
- Aaron B. Waxman, MD, PhD**, Brigham & Women's Hospital, Boston, MA, USA
- Thomas Wekerle, MD**, Medical University of Vienna, Vienna, Austria
- Glen P. Westall, FRACP, PhD**, Alfred Hospital, Melbourne, VIC, Australia
- Michel White, MD**, Montreal Heart Institute, Montreal, QC, Canada
- Helen M. Whitford, MBBS, FRACP**, Alfred Hospital, Melbourne, VIC, Australia
- Neil M. Wrightson, RN**, Freeman Hospital, Newcastle Upon Tyne, UK
- Tahir Yagdi, MD**, Ege University Hospital, Izmir, Turkey
- Quincy Young, PhD, Rpsych**, St. Paul's Hospital, Vancouver, BC, Canada
- Michal Zakliczynski, MD**, Slaskie Center Chorb Serca, Gliwice, Poland
- Daniel Zimpfer, MD**, Medical University of Vienna, Vienna, Austria
- Mark J. Zucker, MD**, Newark Beth Israel Medical Center, Newark, NJ, USA

**NEW FOR THIS MEETING!**



**FOR ISHLT 35TH ANNUAL  
MEETING DELEGATES**

A QR code will be printed on all meeting registrant name badges. This QR code will contain contact information that can be scanned by any QR reader.


Exhibitors can use the QR code as a lead generation tool and registrants can use it as a networking tool.

A QR reader is needed to scan a QR code. A QR reader is provided in the ISHLT Meeting Mobile App. There are free QR Readers available for iPhone and Android phones.


For iPhone go to the APP store, search for a QR code reader (free), select, get and install.

For Android phones go to Google Play, search for QR code reader (free) then download and install.

(QR codes will only be included for registrants as of March 23, 2015).



# ANNUAL MEETING Daily Time Table Schedule



4/15		ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	RHODES	AGORA 2
8 AM								Exhibitor Set-up 8 am - 10 am	Poster Mount 8 am - 10 am
8:15									
8:30	<b>SYMPOSIUM 1</b> Intermacs 0: Treatment of the Patient in Shock	<b>SYMPOSIUM 2</b> Heart Allocation Policies	<b>SYMPOSIUM 3</b> Antibodies in LTX	<b>SYMPOSIUM 4</b> Bloody Virus: HIV Hepatitis B and C	<b>SYMPOSIUM 5</b> Allograft Vasculopathy	<b>SYMPOSIUM 6</b> Psychosocial Assessment			
8:45									
9 AM									
9:15									
9:30									
9:45									
10 AM									
10:15								<b>EXHIBIT HALL OPEN</b> 10 am - 8 pm	<b>POSTER HALL OPEN</b> 10 am - 8 pm
10:30	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>		
10:45	<b>SYMPOSIUM 7</b> Moving MCS Therapy Forward	<b>SYMPOSIUM 8</b> When Worlds Collide: Heart and Kidney	<b>SYMPOSIUM 9</b> Maximizing Donor Utilization	<b>SYMPOSIUM 10</b> Therapeutic Strategies in PH	<b>SYMPOSIUM 11</b> Drug Disposition in the Critically Ill Patient	<b>SYMPOSIUM 12</b> The Future of Tolerance			
11 AM									
11:15									
11:30									
11:45									
12 PM									
12:15									
12:30									
12:45	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>LUNCH BREAK</b> 12:45 - 2:45 pm	<b>JFT COUNCIL MTG</b> 12:45 - 1:45 pm	<b>Box Lunch Distribution</b>	
1 PM									
1:15									
1:30									
1:45									



4/15		ATHENA		CLIO/THALIE		ERATO/URANIE		HERMES		CALLIOPE		EUTERPE		RHODES		AGORA 2	
2 PM	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK			EXHIBIT HALL OPEN until 8 pm	POSTER HALL OPEN until 8 pm		
2:15																	
2:30																	
2:45	<b>SYMPOSIUM 13</b> Early Implantation: Is it too Soon?	<b>SYMPOSIUM 14</b> Extreme Donors: Pushing the Boundaries	<b>SYMPOSIUM 15</b> Optimizing Outcomes in the High Risk LTX Recipient	<b>SYMPOSIUM 16</b> Challenges in PH Due to Left Heart Disease	<b>SYMPOSIUM 17</b> Lung and Heart Lung TX	<b>SYMPOSIUM 18</b> B Cells in Transplantation											
3 PM																	
3:15																	
3:30																	
3:45																	
4 PM																	
4:15																	
4:30																	
4:45	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>				
5 PM	<b>SYMPOSIUM 19</b> When Things Don't Go as Planned in VAD Patients	<b>SYMPOSIUM 20</b> Management of Unusual Cardiomyopathies	<b>SYMPOSIUM 21</b> 13T: Infection, Inflammation, and Immunity after LTX	<b>SYMPOSIUM 22</b> Chronic Lung Disease Associated PH	<b>SYMPOSIUM 23</b> Frontiers in Pediatric TX	<b>SYMPOSIUM 24</b> Clinical Thoracic TX Pathology: A Primer for Members of the TX Team											
5:15																	
5:30																	
5:45																	
6 PM																	
6:15																	
6:30																	
6:45																	
7 PM														EXHIBIT HALL OPENING RECEPTION 7 pm - 8 pm	POSTER SESSION 01 7 pm - 8 pm		
7:15																	
7:30																	
7:45																	

4/16		APOLLON	ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	RHODES	AGORA 2	ΕΞ
8 AM										Poster Renumbering 8 am - 9 am	8 AM
8:15											8:15
8:30	<b>OPENING</b>										8:30
8:45	<b>PLENARY</b>										8:45
9 AM	8:30 - 10:30 am									Poster Mount 9 am - 10 am	9 AM
9:15											9:15
9:30											9:30
9:45											9:45
10 AM									<b>EXHIBIT HALL OPEN</b> 10 am - 7 pm	<b>POSTER HALL OPEN</b> 10 am - 7 pm	10 AM
10:15											10:15
10:30	<b>BREAK</b>										10:30
10:45											10:45
11 AM	<b>CONCURRENT 1</b>	<b>CONCURRENT 2</b>	<b>CONCURRENT 3</b>	<b>CONCURRENT 4</b>	<b>CONCURRENT 5</b>	<b>CONCURRENT 6</b>	<b>CONCURRENT 7</b>				11 AM
11:15	Outcomes with MCS	Anticoag for VADS	Best Recipients for Lung TX	DMD Heart Extending Margins	Clinical Case Dilemmas	Collected Experience Registries	Supporting MCS Patient and Caregiver				11:15
11:30											11:30
11:45											11:45
12 PM											12 PM
12:15											12:15
12:30	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>				12:30
12:45	12:30 - 2:30 pm	12:30 - 2:30 pm	12:30 - 2:30 pm	12:30 - 2:30 pm	12:30 - 2:30 pm	12:30 - 2:30 pm	12:30 - 2:30 pm		Box Lunch Distribution		12:45
1 PM											1 PM
1:15											1:15
1:30											1:30
1:45											1:45

4/16		APPOLON		ATHENA		CLIO/THALIE		ERATO/URANIE		HERMES		CALLIOPE		EUTERPE		RHODES		AGORA 2		
2 PM		LUNCH BREAK		LUNCH BREAK		LUNCH BREAK		LUNCH BREAK		LUNCH BREAK		LUNCH BREAK		LUNCH BREAK		EXHIBIT HALL OPEN until 7 pm	POSTER HALL OPEN until 7 pm			
2:15		<b>CONCURRENT 8</b> LVADS PreOp Factors Post Op Outcomes		<b>CONCURRENT 9</b> Drivelines and Device Malfunction		<b>CONCURRENT 10</b> Lung CLAD I Translational Markers		<b>CONCURRENT 11</b> New Tools Rejection		<b>CONCURRENT 12</b> DMD Heart Lessons from Registries		<b>CONCURRENT 13</b> Long Live the Graft		<b>CONCURRENT 14</b> Caves Award Presentations						
2:30																				
2:45																				
3 PM																				
3:15																				
3:30																				
3:45																				
4 PM		<b>BREAK</b>		<b>BREAK</b>		<b>BREAK</b>		<b>BREAK</b>		<b>BREAK</b>		<b>BREAK</b>		<b>BREAK</b>						
4:15																				
4:30		<b>CONCURRENT 15</b> Myocardial Recovery		<b>CONCURRENT 16</b> Strokes, Arrhythmias and LVADs		<b>CONCURRENT 17</b> Lung CLAD II New Observations Therapies		<b>CONCURRENT 18</b> Crystal Ball Outcomes in HTX		<b>CONCURRENT 19</b> Emerging Country Session 1		<b>CONCURRENT 20</b> Basic Science Inflammation, Immun. Mon, Immun Supp		<b>CONCURRENT 21</b> Kinetics, Coagulation, Cardiology						
4:45																				
5 PM																				
5:15																				
5:30																				
5:45																				
6 PM				<b>MINI ORALS 1</b> MCS		<b>MINI ORALS 2</b> HTX/MCS		<b>MINI ORALS 3</b> MCS-Complic.		<b>MINI ORALS 4</b> DMD-H/HF		<b>MINI ORALS 5</b> NNSAH/PEEQ		<b>MINI ORALS 6</b> PEDS		<b>WINE &amp; CHEESE</b> 6 pm - 7 pm	<b>POSTER</b>	<b>SESSION 02</b> 6 pm - 7 pm		
6:15																				
6:30																				
6:45																				
7 PM																	<b>POSTER 02</b>	<b>REMOVAL 7-7:30</b>		
7:15																				
7:30																				
7:45																				

4/17		APOLLON	ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	RHODES	AGORA 2	T	
8 AM										Poster Renumbering 8 am - 9 am	8 AM	
8:15	<b>PLENARY</b> 8:30 - 10:30 am	<b>BIZ MTG</b>	<b>CONCURRENT 22</b> LVADS Outcomes	<b>CONCURRENT 23</b> Update on Short Term Support	<b>CONCURRENT 24</b> Immuno Tor Inhibitors	<b>CONCURRENT 25</b> Pump Up the Jam	<b>CONCURRENT 26</b> HF-Omics, Kines, Stem Cells	<b>CONCURRENT 27</b> BS2 Organ Pres including ExVivo	<b>CONCURRENT 28</b> JHLT@ISHLT	<b>EXHIBIT HALL</b> <b>OPEN</b> 10 am - 4:30 pm	<b>POSTER HALL</b> <b>OPEN</b> 10 am - 7 pm	8:15
8:30												8:30
8:45												8:45
9 AM												9 AM
9:15											9:15	
9:30											9:30	
9:45											9:45	
10 AM											10 AM	
10:15											10:15	
10:30											10:30	
10:45											10:45	
11 AM											11 AM	
11:15											11:15	
11:30											11:30	
11:45											11:45	
12 PM											12 PM	
12:15											12:15	
12:30	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>LUNCH BREAK</b>	<b>PH COUNCIL</b>	<b>MCS COUNCIL</b>	<b>Box Lunch Distribution</b>		12:30	
12:45							<b>LUNG COUNCIL</b>	<b>HFTX COUNCIL</b>			12:45	
1 PM											1 PM	
1:15											1:15	
1:30											1:30	
1:45											1:45	

4/17		APOLON	ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	RHODES	AGORA 2	TI
2 PM	LUNCH BREAK		LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNCH BREAK	LUNG COUNCIL	HFTX COUNCIL	EXHIBIT HALL OPEN until 4:30 pm	POSTER HALL OPEN until 7:00 pm	2 PM
2:15											2:15
2:30	<b>CONCURRENT 29</b> TX Patients with Machines	<b>CONCURRENT 30</b> EVLV Learning Technology	<b>CONCURRENT 31</b> CAV and Rejection	<b>CONCURRENT 32</b> MCS in Children	<b>CONCURRENT 33</b> Emerging Issues in PED LTX	<b>CONCURRENT 34</b> Complement, CAV, Lung Allo Path	<b>CONCURRENT 35</b> Complex Patients Complex Solutions				2:30
2:45											2:45
3 PM											3 PM
3:15											3:15
3:30											3:30
3:45											3:45
4 PM	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>			4 PM
4:15											4:15
4:30	<b>CONCURRENT 36</b> Pump Thrombosis	<b>CONCURRENT 37</b> Fate of Right Heart After LVAD	<b>CONCURRENT 38</b> Cloudy with Chance of Meatballs	<b>CONCURRENT 39</b> Adv in Prog Strat in PH	<b>CONCURRENT 40</b> Lung AMR HLA and Beyond	<b>CONCURRENT 41</b> Heart Matters	<b>CONCURRENT 42</b> The Silent Partner		Exhibit Hall Strike 4:30 - 11:59 pm		4:30
4:45											4:45
5 PM											5 PM
5:15											5:15
5:30											5:30
5:45											5:45
6 PM	Strike 6 pm - 11 pm	<b>MINI ORALS 7</b> MCS	<b>MINI ORALS 8</b> HTX	<b>MINI ORALS 9</b> LTX	<b>MINI ORALS 10</b> LF/DMD-L	<b>MINI ORALS 11</b> ID/PHARM/PH	<b>MINI ORALS 12</b> BSI			<b>POSTER</b>	6 PM
6:30										<b>SESSION 03</b> 6 pm - 7 pm	6:15
7 PM											6:30
7:30											6:45
8 PM	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm	<b>GALA</b> 8 pm - 9:30 pm		<b>POSTER 03</b> <b>REMOVAL</b> 7-7:30	7 PM
8:30											7:15
9 PM											7:30
9:30											7:45

4/18		ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	GALLIENI I
8 AM								
8:15	<b>CONCURRENT 43</b> MCS New Surgical	<b>CONCURRENT 44</b> Aortic Valve in LVAD Patients	<b>CONCURRENT 45</b> Candidate Selection	<b>CONCURRENT 46</b> Emerging Countries	<b>CONCURRENT 47</b> Enhanced Surg Therapeutics in	<b>CONCURRENT 48</b> Old Problems New Solutions	<b>COMMITTEE/ COUNCIL REPORTS TO BOARD</b>	
8:30								
8:45								
9 AM								
9:15								
9:30								
9:45	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>		
10 AM	<b>PLENARY</b> 10 am - 12 noon							
10:15								
10:30								
10:45								
11 AM								
11:15								
11:30								
11:45								
12 PM	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>	<b>BREAK</b>		
12:15	<b>CONCURRENT 49</b> LVADs Patient Classification	<b>CONCURRENT 50</b> LVADs and Mitral Valve	<b>CONCURRENT 51</b> Risky Business TX in High Risk Pop	<b>CONCURRENT 52</b> Understanding Complications LTX	<b>CONCURRENT 53</b> Beneficence Nonmaleficence	<b>CONCURRENT 54</b> Basic Bazaar		
12:30								
12:45								
1 PM								
1:15								
1:30								
1:45								

4/18	ATHENA	CLIO/THALIE	ERATO/URANIE	HERMES	CALLIOPE	EUTERPE	GALLIENI I	5
2 PM	Strike 2:00 - 7:30 pm	Strike 2:00 - 7:30 pm	Strike 2:00 - 7:30 pm	Strike 2:00 - 7:30 pm	Strike 2:00 - 7:30 pm	Strike 2:00 - 7:30 pm	ISHLT BOARD OF DIRECTORS MTG 2:00 - 7:30 pm	2 PM
2:15								2:15
2:30								2:30
2:45								2:45
3 PM								3 PM
3:15								3:15
3:30								3:30
3:45								3:45
4 PM								4 PM
4:15								4:15
4:30								4:30
4:45								4:45
5 PM								5 PM
5:15								5:15
5:30								5:30
5:45								5:45
6 PM							6 PM	
6:15							6:15	
6:30							6:30	
6:45							6:45	
7 PM							7 PM	
7:15							7:15	
7:30							7:30	
7:45							7:45	

# ANNUAL MEETING

# Continuing Medical Education Information

## ACCME Accreditation Statement

The International Society for Heart and Lung Transplantation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

## CME Credit Designation Statement

ISHLT designates this live activity for a maximum of 27.50 *AMA PRA Category 1 Credits*.™ Physicians should claim only the credit commensurate with the extent of their participation in the activity.

## ABTC Accreditation

The ABTC Board of Governors has granted a total of 27.75 Category 1 Continuing Education Points for Transplant Certification (CEPTCs) to International Society for Heart & Lung Transplantation's *ISHLT 35th Annual Meeting and Scientific Sessions*.

## ACPE Accreditation

Continuing Pharmacy Education Credits (CPE) will not be offered for this meeting.

## Disclosure

Current guidelines state that participants in continuing medical and allied health profession education activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker's presentation. Planners, Faculty, and Chairs participating in this meeting are required to disclose to the program





audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation any financial interest or affiliations and to indicate if a product they are discussing is not labeled for the use under discussion or is still investigational.

## Target Audience

The audience for this program includes physicians, surgeons, scientists, nurses, and transplant coordinators engaged in the practice of heart and lung transplantation, the management and treatment of heart and lung transplant recipients, the management and treatment of patients with end-stage heart or lung disease, basic science or clinical research related to these fields, or specialties which cause them to become involved in the treatment of transplant recipients or patients with end-stage heart or lung disease.

## Educational Goals

The educational goals of this activity are: to enable participants to learn about current practices, emerging technologies, and medical advances related to heart and lung transplantation and end-stage heart and lung disease and to provide a forum for participants to engage in discussion, debate, and examination regarding the efficacy and applicability of these current practices, emerging technologies, and medical advances.



# Learning Objectives


- 1. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the latest information and approaches regarding transplant research, surgical techniques, medical therapies, donor management, and patient management for the treatment of patients suffering from end-stage heart and lung disease.**
- 2. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding the state-of-the-art treatment approaches, risk factors, risk management approaches, patient selection criteria, disease prevention strategies outcome implications, and psychosocial management strategies for patients with end-stage heart and lung failure.**
- 3. At the conclusion of this meeting, participants will have improved competence and professional performance in the areas of understanding emerging technologies, medical advances, and the clinical applications of basic science models of end-stage heart and lung disease management and prevention.**


# ACRONYMS

To help you navigate your way through the meeting content and find those sessions most likely to be of interest to you, we have coded each session according to the primary professional audience it was designed for.

## THESE CODES ARE EXPLAINED AS FOLLOWS:

- (ALL)** All ISHLT Members
- (BSI) or (BSTR)** Basic Science and Translational Research
- (DMD)** Donor Management/Organ Allocation
- (HF)** Adult Heart Failure
- (HTX)** Adult Heart Transplantation
- (ID)** Infectious Diseases
- (LF)** Adult Lung Failure
- (LTX)** Adult Lung Transplantation
- (MCS)** Adult Mechanical Circulatory Support
- (NNSAH)** Nursing, Allied Health, Social Science
- (PATH)** Pathology
- (PEDS)** Pediatrics
- (PEEQ)** Public Policy, Economics, Ethics, Quality of Life
- (PHARM)** Pharmacology
- (PH)** Pulmonary Hypertension





# HIGHLIGHTS of the Annual Meeting

It is springtime and you are headed to Nice on the French Riviera. What a great time to take in the sun, beach, French cuisine and the 2015 ISHLT Annual Meeting.

Following are some of the highlights of what the meeting has to offer. These symposia are certain to offer a feast for the hungry brain truly comparable to any gastronomic delights of the local French cuisine. As you can see, while there are many attractions in Nice (why do you think they call it nice?), there is nothing compelling enough to drag you away from the ISHLT Annual Meeting!





**BRUNO REICHAERT, MD,**  
Past President of ISHLT

## Pioneer Lecture

Bruno Reichart, MD, Past President of ISHLT, has been selected to give the Pioneer Lecture at the ISHLT 2015 Annual Meeting. After his education and training in Munich and Memphis, Professor Reichart directed the first successful heart transplant program in Germany and performed the first heart-lung transplant there. In 1984, he was elected as the Christiaan Barnard Chair of Cardiothoracic Surgery at the University of Cape Town, South Africa. In 1990, he became the Chair of Cardiac Surgery at the University of Munich. In Munich, Professor Reichart started a successful multi-institutional research program on xenotransplantation which has been funded by the German Research Council for many years. We are pleased to have Professor Reichart deliver this esteemed address to his colleagues during the ISHLT 2015 meeting in Nice.

# HIGHLIGHTS

## BASIC SCIENCE AND TRANSLATIONAL RESEARCH

The 2015 ISHLT Annual Meeting will highlight important advances in transplantation for basic science and translational research. Leading this off are two outstanding pre-meeting symposia. The first, **B Cells in Transplantation 2015**, will explore the current state of understanding of a variety of aspects of the role of B cells in the allo-immune response as well as how these can be modified therapeutically. The second symposium, **The Future of Tolerance: Definitions, Directions and Design**, will review both the present understanding of transplant tolerance as well as the novel approaches to implement tolerance clinically. Both symposia will bring together basic, translational, and clinical investigators who are experts in various aspects of these fields and will include leaders in clinical trials to induce tolerance in patients. The symposia will also take advantage of the proximity to Nice of many of the leaders in these fields to bring together an outstanding faculty.

## HEART FAILURE AND CARDIAC TRANSPLANTATION

The 2015 ISHLT Annual Meeting will provide an opportunity to focus on several areas of emerging interest in the fields of heart failure and cardiac transplantation. There will be four exciting pre-meeting symposia to lure you from the distractions of the Cote D'Azur. In an era of donor scarcity, the **Extreme Donors: Pushing the Boundaries** session will focus on the transplantation of hearts from extended criteria and DCD donors. Experts will discuss a broad arrange of topics including the definition of death, cardiac physiology during withdrawal of life support,



*Explore Nice's  
old town,  
"Vieux Nice."*



ex-vivo assessment of heart function, and donor heart protection. The fairness of organ allocation has become a subject of widespread discussion in recent years due to changing patient demographics. This subject will be the focus in **Heart Allocation Policies: The Times Are A-Changin'**. A highlight of this session will include debates by prominent authorities. The need for renal support or combined heart-kidney transplant is an area of increasing interest as older and sicker patients present for advanced therapies for heart failure. **When Worlds Collide: Heart and Kidney** will provide a comprehensive insight into our current understanding of cardio-renal syndrome and management options before and after transplant. The fourth symposium, **The Road Less Traveled: The Management of Unusual Cardiomyopathies**, will provide a grand tour of some of the rarer forms of cardiomyopathy.

## INFECTIOUS DISEASES

Join us at the 2015 ISHLT Annual Meeting for a provocative, cutting edge pre-meeting symposium entitled **Bloody Virus: HIV, Hepatitis B and C** as a multidisciplinary forum of experts discuss the new frontier of transplantation for recipients infected with one of these blood borne viruses. Previously, these were considered a relative or absolute contraindication for transplant but no more! Come learn how to guide these complex patients through a successful transplant and update your knowledge of epidemiology, new drugs, and how monitor the graft and the viral infection itself. The symposium will cap with a session on expanding the donor pool with Hepatitis B or C infected donors. This is your unique opportunity to spend these two hours sharing experiences and asking questions about this emerging area. Vampires however, are banned!

## MECHANICAL CIRCULATORY SUPPORT

The 2015 ISHLT Annual Meeting program includes many outstanding sessions on mechanical circulatory support which will provide important new insights in the field. The most currently challenging and captivating MCS topics will be addressed in the session, **Fifty Shades of Gray: When Things Don't Go as Planned in VAD Patients**, which will include pump thrombosis, RV failure, GI bleeding, aortic insufficiency, driveline infection and stroke in VAD patients. The controversial area of **Early Implantation: Is It Too Soon?** will be addressed in another lively symposium, with an animated debate, plus new results to be presented from trials along with what is needed from the patient's and the engineer's perspective. More provocative topics will be discussed in a symposium entitled **Moving MCS Therapy Forward** which will focus on the pivotal areas required to advance these current and emerging technologies. An update on the status of full implantability will be given, followed by a discussion on whether the field can move on from the strict indications of bridge to transplantation and destination therapy. Included will be a discussion on how to improve resource utilization, followed by two controversial debates. There are also many important MCS talks included in the pulmonary hypertension and pediatric symposia along with very relevant discussions on organ allocation in VAD patients in the transplant symposia. And finally, we can plan on numerous abstract presentations with new data from the MCS field throughout the meeting.

## NURSING, HEALTH SCIENCES AND ALLIED HEALTH

The 2015 ISHLT Annual Meeting will showcase clinical care and research initiatives through a diverse program of informative sessions significant to nursing, health science, and allied health specialists. The pre-meeting symposium entitled **Psychosocial Assessment: Tools, Tips and Opportunities** will bring together seven experts in the area of psychosocial assessment and psychological distress to discuss the factors that affect post-transplant outcomes, the available tools to assess these factors, along with opportunities for future research.

## PATHOLOGY

The 2015 ISHLT Annual Meeting will feature a pathology-focused symposium entitled **Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team**. The target audience for this session will be transplant clinicians and trainees, nurses, pharmacists, and other non-pathologist health care team members. Terminology and concepts from the ISHLT Working Formulations for scoring and reporting rejection will be reviewed with relevant examples. Clinical correlations and treatment options will be discussed. There have been significant changes in the diagnostic criteria and reporting schemes in thoracic transplant pathology in the last 5 years, especially for antibody mediated rejection. The goal of this simplified review is to help foster better communication and understanding between pathologists and other care team members.

## PEDIATRIC TRANSPLANTATION

Children are unique; nevertheless there is much of relevance to learn from the much larger experience in adult transplant patients. The pediatric symposia focus on unsolved problems, ongoing challenges, and edges experienced in the daily routine of pediatric heart and lung transplantation. The session **Allograft Vasculopathy – A Challenge for All Ages** illuminates a problem with only limited improvement in the last 3 decades from various angles: standards and novelties in imaging of CAV. The concepts and clinical evidence of new treatments will also be discussed from an adult and pediatric perspective. The latest research on the role of endothelial function and recently discovered potential therapeutic targets will provide an outlook into a brighter future. **Lung and Heart Lung Transplantation: Coming of Age** will address optimal wait list management and allocation besides specific challenges including heart lung transplantation as an option for the patient with congenital heart disease and secondary pulmonary hypertension or which alternative therapies can be considered for these patients. In addition, ex-vivo regeneration as a window to successful pediatric DCD transplantation and the everlasting challenge of non-adherence in adolescence will be discussed. The session **Frontiers in Pediatric Transplantation** will explore the limits of pediatric transplantation: where are the margins of a “marginal donor”? Are HLA and ABO antibodies really relevant for organ allocation? Should we transplant children with genetic abnormalities and what are the outcomes if we do so? Can children with secondarily elevated pulmonary vascular resistance be transplanted with the option of a back-up RVAD or should they be prepared with an LVAD? Or should we use VADs as a destination therapy in childhood after all? Last but not least the everlasting afterthought: when and how should we involve palliative care in children needing VAD and transplantation?

*Sample  
local  
specialties:*





10€ les  
10 fleurs

*Pick up fresh local  
produce and flowers  
every morning, except  
Mondays, when  
Vieux Nice becomes  
a flea market...*

## PHARMACY AND PHARMACOLOGY

Critical illness causes changes to the normal physiology of the body – there are ECMO circuits attached, renal replacement therapies, a ventilator. Following dosing guidelines, you put a drug in and then what? What happens to it with all this machinery attached? The symposium entitled **Drug Dosing in the Critically Ill Patient** is designed to try and explain what happens next, how to get drugs into the body despite these devices, and how to get drugs to very difficult to access places. This session will appeal to all members of ISHLT, so when you attend you will be able to see your Infectious Disease practitioner, your VAD surgeon, your pulmonologist and, of course, your pharmacist.



## PULMONARY HYPERTENSION

Every five years the world's experts in Pulmonary Hypertension unite in an attempt to redefine the characteristics and treatment advances in this disease area. In 2013 it was Nice that played host to the World Symposium in Pulmonary Hypertension, so it's therefore very fitting that the 2015 ISHLT Annual Meeting in Nice will have an outstanding program of PH symposia which again bring together those at the forefront of this field. The therapeutic options for patients with PAH and PH associated with chronic thromboembolic disease continue to grow and in the symposium entitled **Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions**, the current and future strategies will be reviewed in detail, especially how the combination of different drug classes might be used together. The management of patients with secondary pulmonary hypertension continues to cause challenges to clinicians, and the paucity of clinical trials in this area makes it difficult to decide how or whether to use PH targeted therapies in these conditions. In two cutting edge symposia, the issues of secondary PH in chronic lung and chronic heart disease will be discussed. **Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact** will help clinicians evaluate the pathophysiological mechanisms underlying this process in chronic lung disease and decide if targeted therapy might have a role to play. Finally, in **Challenges in Pulmonary Hypertension Due to Left Heart Disease**, the approach to the investigation and management of secondary PH in a range of left heart pathologies from cardiomyopathy to valvular disease or in association with LVAD insertion will be presented.



## PULMONARY TRANSPLANTATION

At ISHLT 2015, four pre-meeting symposia will provide up-to-date information for all professionals involved in the care of patients with advanced lung diseases and lung transplantation. Content integrating the latest basic biological and clinical approaches will focus on areas including donor optimization, high risk recipients, auto- and allo-antibodies, and the interplay between infections and immune-mediated outcomes. The symposium entitled **Making the Most of What We Have: Maximizing Donor Utilization** will contain Pro-Con debates on the most burning topics in lung donor utilization including donor age, cold ischemic time, and DCD status, followed by lectures on donor scoring, use of ECMO and how these factors affect children and adolescents. Assessment and management of the high risk recipient will be detailed in **Before, During and After - Optimizing Outcomes in the High Risk Recipient for Lung Transplantation**. Topics covered include modifiable recipient factors, use of ECMO through the transplant process, and specific topics for recipients with secondary PH, connective tissue diseases and CF. The symposium entitled **Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management** is a highly translational update on recent advances in the understanding of the importance of allo- and auto-antibodies to the pre- and post-transplant management of lung transplant patients. Included will be updates from the ISHLT multidisciplinary working group, case-based discussions, integrative immunology lectures, and pragmatic updates on therapeutic approaches. The lung is a unique transplant organ in that it constantly interfaces with environmental pathogens. The symposium entitled **Infection, Inflammation, and Immunity After Lung Transplantation** will consider emerging evidence about the role of viral, bacterial, and fungal pathogens in determining the fate of the lung allograft. This symposium will integrate state-of-the-art information on new detection techniques

with emerging basic and epidemiological data on the interplay between microbes and recipient immunity to help the lung transplant professional understand present and future approaches to managing infections in their patients.

## **SPECIAL ABSTRACT SESSION: FOCUS ON INTERNATIONAL TRANSPLANTATION**

The 2015 ISHLT Annual Meeting in Nice will be a truly International meeting. To recognize ISHLT's global network in the science and treatment of end-stage heart and lung disease, a special abstract session will be organized to showcase the developments in thoracic transplantation, mechanical circulatory support, and pulmonary hypertension treatment in emergent regions of the world. Countries and single programs from these regions are encouraged to submit abstracts that present their latest data to global leaders in the field.



...Or spend some  
free time at one of  
Nice's acclaimed art  
museums.





# PRESIDENT'S COCKTAIL RECEPTION

The President's Cocktail Reception will be held Friday, April 17 at the Negresco Palace. The Negresco is one of the most unique hotels in the world. A famous Belle Époque landmark that graces the promenade des Anglais, the hotel has welcomed celebrities and heads of state for over 100 years. The owner, Madam Jeanne Augier, reinvigorated the hotel with luxurious decorations and furnishings, including an outstanding art collection and rooms with mink bedspreads. The hotel-cum-museum has been listed as a Historical Monument since 1974, and is home to 3,000 objets d'art including 1,600 original paintings (one of three full-length portraits of Louis XIV is in the Versailles Ballroom, the other two being the Louvre and Versailles). The spectacular Baccarat 16,309 crystal chandelier in the Negresco's Royal Lounge was



commissioned by Czar Nicholas II who, due to the October revolution, was unable to take delivery. Noted for its doormen dressed in the manner of the staff 18th-century elite bourgeois households, the hotel also offers renowned Michelin 2-star gourmet dining at the Regency-style Le Chantecler restaurant. Normally, access to the hotel and its artworks is limited to guests of the hotel. This gala will provide a special opportunity for ISHLT members to visit this unique venue.

As always, you can expect plenty of food, drink, music and friends.

Tickets are not included in the registration fee and must be purchased in advance. **Tickets will not be sold on-site.** Attendance is limited to 1200.

**Level 1**

**AGORA 1** Registration

**Level 2**

**APOLLON** Plenary

**AGORA 2** Posters

**HERMES LOUNGE** Speaker  
Ready Room

**GALLIENI 1,2,3,4,5,7** Meetings

**GALLIENI 6** Press Office

**RHODES** Exhibits

**HERMES** Symposiums/  
Sessions

**ATHENA** Symposiums/  
Sessions


**Level 3**

**CLIO/THALIE** Symposiums/  
Sessions


**ERATO/URANIE** Symposiums/  
Sessions

**EUTERPE** Symposiums/  
Sessions


**CALLIOPE** Symposiums/  
Sessions




**LEVEL**  
**1**




main entrance





LEVEL 2





LEVEL 3

ANNUAL MEETING

# Schedule at a Glance



All meetings and activities will take place at the Acropolis, Nice, France unless otherwise specified. All papers will be presented in English. Please check the ISHLT website ([www.isHLT.org](http://www.isHLT.org)) for updates. This Final Program reflects the latest session schedule and room assignments.

## WEDNESDAY | *April 15, 2015*

### 7:00 AM – 7:00 PM

REGISTRATION OPEN (Agora 1)

SPEAKER READY ROOM OPEN (Hermes Lounge)

### 8:00 AM – 10:00 AM

EXHIBITOR SET-UP (Rhodes)

POSTER SESSION 01 MOUNT (Agora 2)

### 8:30 AM – 10:30 AM

#### PRE-MEETING SYMPOSIUM 01:

*INTERMACS 0: Treatment of the Patient in Shock* (Athena)

(MCS, HF, HTX, PEEQ)

#### PRE-MEETING SYMPOSIUM 02:

*Heart Allocation Policies: The Times They Are A-Changin'* (Clio/Thalie)

(DMD, HF, HTX, MCS, NHSAH, PEEQ)

#### PRE-MEETING SYMPOSIUM 03:

*Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management* (Erato/Uranie)

(LTX, BSTR, DMD, ID, LF, NHSAH, PATH, PEDS, PHARM)

#### PRE-MEETING SYMPOSIUM 04:

*Bloody Virus: HIV, Hepatitis B and C* (Hermes)

(ID, HTX, LTX, PHARM)

#### PRE-MEETING SYMPOSIUM 05:

*Allograft Vasculopathy – A Challenge for All Ages* (Calliope)

(ALL)

#### PRE-MEETING SYMPOSIUM 06:

*Psychosocial Assessment: Tools, Tips and Opportunities* (Euterpe)

(NHSAH, HF, HTX, LF, LTX, MCS, PEDS)

# Schedule at a Glance

## 9:00 AM – 7:00 PM

PRESS OFFICE OPEN (Gallieni 6)

## 10:00 AM – 8:00 PM

EXHIBIT HALL OPEN (Rhodes)

POSTER HALL OPEN (Agora 2)

## 10:00 AM – 8:00 PM

### POSTER SESSION 01 VIEWING (Agora 2)

*Adult Heart Failure*

(HF, BSI, DMD, HTX, MCS, NHSAH, PATH, PEDS, PH, PEEQ)

*Mechanical Circulatory Support*

(MCS, BSI, DMD, HF, HTX, ID, NHSAH,  
PATH, PEDS, PH, PHARM, PEEQ)

*Nursing, Health Science and Allied Health*

(NHSAH, HF, HTX, LF, LTX, MCS, PEDS)

*Pharmacy and Pharmacology*

(PHARM, ID, LTX, MCS)

## 10:30 AM – 10:45 AM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

## 10:45 AM – 12:45 PM

### PRE-MEETING SYMPOSIUM 07:

*Moving MCS Therapy Forward* (Athena)

(MCS, HF, HTX, NHSAH)

### PRE-MEETING SYMPOSIUM 08:

*When Worlds Collide: Heart and Kidney*

(Clio/Thalie)

(HF, HTX, NHSAH, MCS, PATH)

### PRE-MEETING SYMPOSIUM 09:

*Making the Most of What We Have:*

*Maximizing Donor Utilization* (Erato/Uranie)

(LTX, DMD, LF, PEEQ)

### PRE-MEETING SYMPOSIUM 10:

*Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions* (Hermes)

This session is supported by educational grants from Actelion and Gilead.

(PH, HF, HTX, LF, LTX, MCS, PHARM)

### PRE-MEETING SYMPOSIUM 11:

*Drug Disposition in the Critically Ill Patient*

(Calliope)

(PHARM, HTX, ID, LTX, NHSAH, PEDS)

### PRE-MEETING SYMPOSIUM 12:

*The Future of Tolerance: Definitions, Directions, and Design* (Euterpe)

(ALL)

## 12:45 PM – 1:45 PM

### JUNIOR FACULTY AND TRAINEE COUNCIL MEETING (Euterpe)

BOX LUNCH DISTRIBUTION (Rhodes)

## 12:45 PM – 2:45 PM

LUNCH BREAK

### JHLT EDITORIAL BOARD LUNCH MEETING (Gallieni 1 & 2)

EDUCATION COMMITTEE MEETING (Gallieni 4)

GRANTS AND AWARDS COMMITTEE MEETING (Gallieni 5)

STANDARDS AND GUIDELINES COMMITTEE MEETING (Gallieni 7)

I2C2 COMMITTEE MEETING (Gallieni 3)

## 2:45 PM – 4:45 PM

### PRE-MEETING SYMPOSIUM 13:

*Early Implantation: Is It Too Soon?* (Athena)  
(MCS, HF, HTX, NHSAH, PEEQ)

### PRE-MEETING SYMPOSIUM 14:

*Extreme Donors: Pushing the Boundaries* (Clio/Thalie)  
(HTX, BSTR, DMD, HF, PEDS, PEEQ)

### PRE-MEETING SYMPOSIUM 15:

*Before, During, and After – Optimizing Outcomes in the High Risk Recipient for Lung Transplantation* (Erato/Uranie)  
(LTX, BSTR, LF)

### PRE-MEETING SYMPOSIUM 16:

*Challenges in Pulmonary Hypertension Due to Left Heart Disease* (Hermes)

This session is supported by educational grants from Actelion and Gilead.

(PH, BSTR, HF, HTX, MCS, NHSAH, PEDS)

### PRE-MEETING SYMPOSIUM 17:

*Lung and Heart Lung Transplantation: Coming of Age* (Calliope)

(PEDS, BSTR, DMD, LF, LTX)

### PRE-MEETING SYMPOSIUM 18:

*B Cells in Transplantation 2015* (Euterpe)

(BSTR, HF, HTX, LTX, PATH, PEDS)

## 4:45 – 5:00 PM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

# Schedule at a Glance

## 5:00 PM – 7:00 PM

### PRE-MEETING SYMPOSIUM 19:

*50 Shades of Gray: When Things Don't Go as Planned in VAD Patients* (Athena)  
(MCS, HF, HTX, ID, NHSAH)

### PRE-MEETING SYMPOSIUM 20:

*The Road Less Traveled: The Management of Unusual Cardiomyopathies* (Clio/Thalie)  
(HF, BSTR, HTX, MCS, NHSAH, PEDS)

### PRE-MEETING SYMPOSIUM 21:

*I3T: Infection, Inflammation and Immunity After Lung Transplantation* (Erato/Uranie)  
(LTX, BSTR, ID, LF)

### PRE-MEETING SYMPOSIUM 22:

*Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact* (Hermes)  
(PH, LF, LTX, NHSAH, PATH)

### PRE-MEETING SYMPOSIUM 23:

*Frontiers in Pediatric Transplantation* (Calliope)  
(PEDS, DMD, HTX, MCS)

### PRE-MEETING SYMPOSIUM 24:

*Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team* (Euterpe)  
(ALL)

## 7:00 PM – 8:00 PM

EXHIBIT HALL OPENING RECEPTION (Rhodes)

**MODERATED POSTER SESSION 01** (Agora 2)

## 8:00 PM – 8:30 PM

POSTER SESSION 01 REMOVAL (Agora 2)

# THURSDAY | *April 16, 2015*

## 7:30 AM - 7:00 PM

REGISTRATION OPEN (Agora 1)

SPEAKER READY ROOM OPEN (Hermes Lounge)

## 8:00 AM - 9:00 AM

POSTER BOARD RENUMBERING (Agora 2)

## 8:30 AM - 10:30 AM

**OPENING PLENARY SESSION** (Apollon)

## 9:00 AM - 10:00 AM

POSTER SESSION 02 MOUNT (Agora 2)

## 9:00 AM - 7:00 PM

PRESS OFFICE OPEN (Gallieni 6)

## 10:00 AM - 7:00 PM

EXHIBITS OPEN (Rhodes)

POSTER HALL OPEN (Agora 2)

## 10:00 AM - 7:00 PM

**POSTER SESSION 02 VIEWING** (Agora 2)

*Adult Lung Failure*

(LF, BSI, DMD, LTX, MCS)

*Adult Lung Transplant*

(LTX, BSI, DMD, ID, LF, MCS, PATH, PEDS, PHARM)

*Basic Science*

(ALL)

*Donor Management/Organ*

*Preservation Heart*

(DMD-HEART, HTX)

*Donor Management/Organ*

*Preservation Lung*

(LTX, DMD)

*Heart Transplantation*

(ALL)

*Infectious Diseases*

(ALL)

## 10:30 AM - 11:00 AM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

# Schedule at a Glance

## 11:00 AM – 12:30 PM

### CONCURRENT SESSION 01

*Outcomes With Mechanical Circulatory Support* (Apollon)

(MCS, BSI, HF, HTX, NHSAH, PHARM)

### CONCURRENT SESSION 02

*Anticoagulation For VADs: How Anticoagulated Do We Need To Be?* (Athena)

(MCS, BSI, HF, NHSAH, PATH, PHARM)

### CONCURRENT SESSION 03

*Choosing the Best Recipients for Lung Transplant in the Era of Urgency* (Clio/Thalie)

(LF, LTX, PEDS)

### CONCURRENT SESSION 04

*Donor Management/Organ Preservation-Heart: Extending the Margins* (Erato,Uranie)

(DMD-HEART, HF, HTX)

### CONCURRENT SESSION 05

*JFTC Clinical Case Dilemmas in Thoracic Transplantation: The Best of the Best* (Hermes)

(ALL)

### CONCURRENT SESSION 06

*Collected Experience: What Can We Learn from the Registries?* (Calliope)

(PEDS, DMD, HF, HTX, ID, MCS, NHSAH, PEEQ)

### CONCURRENT SESSION 07

*Supporting the MCS Patient and Caregiver* (Euterpe)

(NHSAH, HF, HTX, MCS)

## 12:30 PM – 2:30 PM

LUNCH BREAK

**JUNIOR FACULTY MENTOR LUNCH** (Gallieni 1)

## 12:30 PM – 1:30 PM

BOX LUNCH DISTRIBUTION (Rhodes)

**DCD REGISTRY MEETING** (Gallieni 3)



## 12:45 PM – 1:45 PM

### BASIC SCIENCE AND TRANSLATIONAL RESEARCH SCIENTIFIC COUNCIL MEETING

(Gallieni 4)

### NURSING, HEALTH SCIENCE, AND ALLIED HEALTH SCIENTIFIC COUNCIL MEETING

(Gallieni 7)

### PHARMACY AND PHARMACOLOGY SCIENTIFIC COUNCIL MEETING (Gallieni 5)

## 1:30 PM – 2:30 PM

### REGISTRIES AND DATABASES COMMITTEE MEETING (Gallieni 3)

## 2:30 PM – 4:00 PM

#### CONCURRENT SESSION 08

*LVADs - Pre-Operative Factors Affecting Post-Operative Outcomes* (Apollon)

(MCS, BSI, HF, HTX, NHSAH)

#### CONCURRENT SESSION 09

*Drivelines and Device Malfunction* (Athena)

(MCS, HF, HTX, NHSAH, ID)

#### CONCURRENT SESSION 10

*Lung CLAD I: Translational Insights and Novel Markers* (Clio/Thalie)

(LTX, BSI, LF, PATH, PEDS)

#### CONCURRENT SESSION 11

*New Tools in the Fight Against Rejection*

(Erato/Uranie)

(HTX, DMD, ID, NHSAH, PATH, PEDS, PHARM)

#### CONCURRENT SESSION 12

*Donor Management/Organ Preservation-Heart: Lessons from the Registries* (Hermes)

(DMD-HEART, HTX)

#### CONCURRENT SESSION 13

*Long Live the Graft! Factors Impacting Long-term Outcome* (Calliope)

(PEDS, BSI, DMD, HF, HTX, ID, LTX, MCS, NHSAH, PATH, PH, PHARM, PEEQ)

#### CONCURRENT SESSION 14

*Philip K. Caves Award Candidate Presentations* (Euterpe)

(ALL)

# Schedule at a Glance

## 4:00 PM - 4:30 PM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

## 2016 ANNUAL MEETING SYMPOSIUM

PLANNING COMMITTEE MEETING (Gallieni 4)

## 4:30 PM - 6:00 PM

### CONCURRENT SESSION 15

*Myocardial Recovery - Moving Forward* (Apollon)  
(MCS, BSI, HF, HTX, PHARM)

### CONCURRENT SESSION 16

*Strokes, Arrhythmias and LVADs* (Athena)  
(MCS, BSI, HF, HTX, NHSAH, PHARM)

### CONCURRENT SESSION 17

*Lung CLAD II: New Observations and Therapies on the Horizon* (Clio/Thalie)  
(LTX, BSI, LF)

### CONCURRENT SESSION 18

*Crystal Ball: Predicting Outcomes in Heart Transplantation* (Erato/Uranie)  
(HTX, BSI, DMD, HF, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

### CONCURRENT SESSION 19

*Emerging Countries Session 1* (Hermes)  
(ALL)

### CONCURRENT SESSION 20

*Basic Science 1: Inflammation, Immune Monitoring, Immune Suppression* (Calliope)  
(ALL)

### CONCURRENT SESSION 21

*Kinetics, Coagulation, and Cardiology - Pharmacy of MCS and Transplant* (Euterpe)  
(PHARM, HTX, ID, LTX, MCS)

## 6:00 PM – 7:00 PM

### MINI ORAL SESSION 01

*Fear and Loathing in Mechanical Circulatory Support* (Athena)  
(MCS, HTX)

### MINI ORAL SESSION 02

*Biology and the Rise of the Machine* (Clio/Thalie)  
(HTX, MCS, HF)

### MINI ORAL SESSION 03

*For Whom the Bell Tolls: Complications of Mechanical Circulatory Support* (Erato,Uranie)  
(MCS)

### MINI ORAL SESSION 04

*The Big Chill: Heart Failure and Donor Management* (Hermes)  
(HF, BSI, DMD, HTX, MCS, PH)

### MINI ORAL SESSION 05

*Last Tango in Nice: Motion is the Potion – A Guide for Clinicians* (Calliope)  
(NNSAH, PEEQ, HF, HTX, LTX, MCS)

### MINI ORAL SESSION 06

*The Heartbreak Kid: Donors, VADs and Long-Term Outcomes* (Euterpe)  
(PEDS, BSI, DMD, HF, HTX, ID, MCS, NNSAH, PATH, PH, PHARM, PEEQ)

## 6:00 PM – 7:00 PM

WINE AND CHEESE RECEPTION (Rhodes)

PAST PRESIDENT'S MEETING (Gallieni 3)

MODERATED POSTER SESSION 02 (Agora 2)

## 6:00 PM – 7:30 PM

COMMITTEE/COUNCIL LEADERSHIP ORIENTATION (Gallieni 1 & 2)

## 7:00 PM – 7:30 PM

POSTER SESSION 02 REMOVAL (Agora 2)

## FRIDAY | *April 17, 2015*

### 7:30 AM - 7:00 PM

REGISTRATION OPEN (Agora 1)

SPEAKER READY ROOM OPEN (Hermes Lounge)

### 8:00 AM - 9:00 AM

POSTER BOARD RENUMBERING (Agora 2)

### 8:30 AM - 10:30 AM

**PLENARY SESSION** (Apollon)

### 9:00 AM - 10:00 AM

POSTER SESSION 03 MOUNT (Agora 2)

### 9:00 AM - 7:00 PM

PRESS OFFICE OPEN (Gallieni 6)

### 10:00 AM - 4:30 PM

EXHIBITS OPEN (Rhodes)

### 10:00 AM - 7:00 PM

POSTER HALL OPEN (Agora 2)

### 10:00 AM - 7:00 PM

**POSTER SESSION 03 VIEWING** (Agora 2)

*Emerging Countries*  
(ALL)

*Junior Faculty Case Reports*  
(ALL)

*Pathology*  
(PATH, BSI, HF, HTX, LF, LTX, MCS)

*Pediatrics*  
(PEDS, BSI, DMD, HF, HTX, ID, MCS,  
NNSAH, PATH, PH, PHARM, PEEQ)

*Public Policy, Economics, Ethics  
and Quality of Life*  
(MCS, HF, HTX, MCS, NNSAH)

*Pulmonary Hypertension*  
(PH, BSI, HF, HTX, LF, LTX, MCS, NNSAH, PHARM)

### 10:30 AM - 11:00 AM

**ANNUAL BUSINESS MEETING** (Apollon)

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

## 11:00 AM – 12:30 PM

### CONCURRENT SESSION 22

*LVADs: Factors Influencing Outcomes* (Apollon)  
(MCS, DMD, HF, HTX, NHSAH)

### CONCURRENT SESSION 23

*An Update On Short Term Support* (Athena)  
(MCS, DMD, HF, HTX, NHSAH)

### CONCURRENT SESSION 24

*Immunosuppression: The Tor Inhibitors  
Strike Back* (Clio/Thalie)  
(HTX, BSI, HF, ID, NHSAH, PATH, PEDS, PHARM)

### CONCURRENT SESSION 25

*Pump Up the Jam, Don't Jam Up the Pump!  
VAD-Management and Complications*  
(Erato/Uranie)  
(PEDS, DMD-LUNG, HF, HTX, ID, LF, MCS, NHSAH, PH)

### CONCURRENT SESSION 26

*Heart Failure – Omics, Kines and Stem Cells*  
(Hermes)  
(BSI, HF, PATH)

### CONCURRENT SESSION 27

*Basic Science 2: Organ Preservation  
Including Ex-Vivo Management, Ischemia/  
Reperfusion* (Calliope)  
(ALL)

### CONCURRENT SYMPOSIUM 28

*JHLT at ISHLT: The Year in a Capsule* (Euterpe)  
(ALL)

## 12:30 PM – 2:30 PM

LUNCH BREAK

## 12:30 PM – 1:30 PM

BOX LUNCH DISTRIBUTION (Rhodes)

**PULMONARY HYPERTENSION  
SCIENTIFIC COUNCIL MEETING** (Calliope)

**MECHANICAL CIRCULATORY SUPPORT  
SCIENTIFIC COUNCIL MEETING** (Euterpe)

**PEDIATRIC TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING** (Gallieni 1)

**INFECTIOUS DISEASES SCIENTIFIC  
COUNCIL MEETING** (Gallieni 4)

**PATHOLOGY SCIENTIFIC  
COUNCIL MEETING** (Gallieni 5)

# Schedule at a Glance

**1:00 PM – 2:30 PM**

**IMACS REGISTRY MEETING** (Gallieni 7)

**1:30 PM – 2:30 PM**

**PULMONARY TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING** (Calliope)

**HEART FAILURE AND TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING** (Euterpe)

**PEDIATRIC HEART FAILURE  
WORKFORCE MEETING** (Gallieni 1)

**IPLTC MEETING** (Gallieni 4)

**2:30 PM – 4:00 PM**

**CONCURRENT SESSION 29**

*Transplanting Patients with Machines*  
(Apollon)

(MCS, DMD-HEART, HF, HTX, NHSAH)

**CONCURRENT SESSION 30**

*EVLP – Learning To Handle This Technology*  
(Athena)

(LTX, DMD)

**CONCURRENT SESSION 31**

*CAV and Rejection: A Tangled Web*  
(Clio/Thalie)

(HTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

**CONCURRENT SESSION 32**

*Mechanical Cardiac Support in Children:  
Outcomes and Registry Data* (Erato/Uranie)

(PEDS, BSI, DMD, HF, HTX, ID, LF, MCS,  
NHSAH, PATH, PH, PHARM, PEEQ)

**CONCURRENT SESSION 33**

*Emerging Issues in Pediatric  
Lung Transplant* (Hermes)

(LTX, LF, PEDS)

**CONCURRENT SESSION 34**

*Complement, CAV, and Lung Allograft  
Pathology* (Calliope)

(PATH, BSI, HTX, PEDS, LTX)

**CONCURRENT SESSION 35**

*Complex Patients Require Complex Solutions:  
Predicting Adherence* (Euterpe)

(NHSAH, HF, HTX, LTX, MCS)

**4:00 PM – 4:30 PM**

**COFFEE BREAK/VISIT EXHIBITS** (Rhodes)

**VIEW POSTERS** (Agora 2)

**4:30 PM – 11:59 PM**

**EXHIBIT HALL STRIKE** (Rhodes)

## 4:30 PM – 6:00 PM

### CONCURRENT SESSION 36

*Pump Thrombosis – Diagnosis and Outcomes* (Apollon)  
(MCS, BSI, HF, HTX, NHSAH, PATH)

### CONCURRENT SESSION 37

*The Fate of the Right Heart after LVAD* (Athena)  
(MCS, BSI, HF, HTX, NHSAH, PHARM)

### CONCURRENT SESSION 38

*Cloudy with a Chance of T-Cells: Rejection Forecast* (Clio/Thalie)  
(HTX, BSI, ID, NHSAH, PATH, PEDS, PHARM)

### CONCURRENT SESSION 39

*Advances in Prognostic Stratification in Pulmonary Hypertension* (Erato/Uranie)  
This session is supported by educational grants from Actelion and Gilead.

(PH, HF, HTX, LF, LTX, MCS)

### CONCURRENT SESSION 40

*Lung AMR: HLA and Beyond* (Hermes)  
(LTX, BSI, LF, PATH, PEDS)

### CONCURRENT SESSION 41

*Heart Matters: Truth and Justice* (Calliope)  
(PEEQ, HF, HTX, MCS, NHSAH)

### CONCURRENT SESSION 42

*The Silent Partner* (Euterpe)  
(ID, BSI, HTX, LTX, PEDS)

## 6:00 PM – 7:00 PM

### MINI ORAL SESSION 07

*Mechanical Circulatory Support: Apocalypse Tomorrow* (Athena)  
(MCS, HF)

### MINI ORAL SESSION 08

*A Heart Day's Night* (Clio/Thalie)  
(HTX, BSI, DMD, HF, ID, MCS, NHSAH, PATH, PEDS, PHARM, PEEQ)

### MINI ORAL SESSION 09

*The Man With The Golden Lungs*  
(Erato/Uranie)  
(LTX, BSI, DMD, LF, MCS, PATH, PHARM)

### MINI ORAL SESSION 10

*Breathless: Insights on Lung Failure and Donor Lungs* (Hermes)  
(LTX, BSI, DMD, LF)

### MINI ORAL SESSION 11

*What's Up, Doc? Bugs, Drugs and PH* (Calliope)  
(PH, HF, HTX, LF, LTX, MCS, PHARM)

### MINI ORAL SESSION 12

*Basic Instinct* (Euterpe)  
(ALL)

# Schedule at a Glance

## 6:00 PM – 7:00 PM

WINE AND CHEESE RECEPTION (Rhodes)

**MODERATED POSTER SESSION 03** (Agora 2)

## 7:00 PM – 7:30 PM

POSTER SESSION 03 REMOVAL (Agora 2)

## 8:00 PM – 9:30 PM

**PRESIDENT'S GALA COCKTAIL**

**RECEPTION** (Negresco Palace)

A Registration Badge and Ticket will be required at the door.



# SATURDAY | April 18, 2015

**7:30 AM - 12:15 PM**

REGISTRATION OPEN (Agora 1)

**7:30 AM - 1:45 PM**

SPEAKER READY ROOM OPEN (Hermes Lounge)

**8:00 AM - 10:00 AM**

**COUNCIL AND COMMITTEE REPORTS  
TO THE BOARD AND MEMBERSHIP** (Gallieni 1)

**8:15 AM - 9:45 AM**

**CONCURRENT SESSION 43**

*Mechanical Circulatory Support -  
New Surgical Approaches* (Athena)  
(MCS, HF, HTX, NHSAH)

**CONCURRENT SESSION 44**

*The Aortic Valve in LVAD Patients* (Clio/Thalie)  
(MCS, BSI, HF, HTX, NHSAH, PHARM)

**CONCURRENT SESSION 45**

*Candidate Selection - The Who,  
When and Why* (Erato/Uranie)  
(HF, DMD, HTX, MCS)

**CONCURRENT SESSION 46**

*Emerging Countries Session 2* (Hermes)  
(ALL)

**CONCURRENT SESSION 47**

*Enhancing Surgical Therapeutics in  
Pulmonary Hypertension: Thrombectomy  
to Transplant* (Calliope)

This session is supported by educational grants from  
Actelion and Gilead.

(PH, HF, LF, LTX)

**CONCURRENT SESSION 48**

*Old Problems - New Solutions?* (Euterpe)  
(PEDS, BSI, HF, HTX, NHSAH, PATH)

**9:45 AM - 10:00 AM**

COFFEE BREAK (Agora 1)

**10:00 AM - 12:00 NOON**

**PLENARY SESSION** (Athena)

**12:00 PM - 12:15 PM**

COFFEE BREAK (Agora 1)

# Schedule at a Glance

## 12:15 PM – 1:45 PM

### CONCURRENT SESSION 49

*LVADs – From Patient Classification to Cost*

(Athena)

(MCS, BSI, HF, HTX, PEEQ)

### CONCURRENT SESSION 50

*LVADs and the Mitral Valve* (Clio/Thalie)

(MCS, HF, HTX, NHSAH)

### CONCURRENT SESSION 51

*Risky Business: Transplant in High Risk*

*Populations* (Erato/Uranie)

(HTX, BSI, HF, ID, NHSAH, PATH, PEDS, PHARM, PEEQ)

### CONCURRENT SESSION 52

*Understanding Complications and*

*Improving Lung Transplant Outcomes* (Hermes)

(LTX, DMD, LF)

### CONCURRENT SESSION 53

*Beneficence and Nonmaleficence:*

*The Breath of it All* (Calliope)

(PEEQ, LF, LTX, NHSAH)

### CONCURRENT SESSION 54

*Basic Bazaar* (Euterpe)

(ALL)


## 1:45 PM

## ANNUAL MEETING ADJOURNS

## 2:00 PM – 7:30 PM

## ISHLT BOARD OF DIRECTORS MEETING

(Gallieni 1)



The International Society  
for Heart and Lung  
Transplantation extends its heartfelt  
gratitude to the following companies  
for their *unrestricted educational  
grants* in support of the

# Thirty-fifth Annual Meeting and Scientific Sessions

Actelion  
Gilead Sciences  
Medtronic



ISHLT Academy:  
Core Competencies  
in Pulmonary  
Hypertension

Bayer HealthCare

The International Society for  
Heart and Lung Transplantation  
is grateful for the support of the  
following companies for the

# Society and its endeavors in 2015

## **TIER 1**


Actelion  
Bayer HealthCare  
HeartWare  
Thoratec

## **TIER 2**

Gilead

## **TIER 3**

Astellas  
CareDx  
Maquet  
Medtronic  
Volkswagen Germany



INTERNATIONAL SOCIETY FOR HEART & LUNG TRANSPLANTATION

# 35th Annual Meeting and Scientific Sessions

APRIL 15-18, 2015

# SCIENTIFIC PROGRAM

All meetings and activities will take place at the Nice Acropolis Congress Centre unless otherwise specified. All papers will be presented in English. Please check the ISHLT web site ([www.isHLT.org](http://www.isHLT.org)) for updates. The ISHLT 2015 mobile app, which will be available approximately 2 weeks prior to the Annual Meeting, and the Final Program, which is distributed on site, will reflect the latest session schedule and room assignments.

WEDNESDAY | *April 15, 2015***7:00 AM – 7:00 PM**

REGISTRATION OPEN (Agora 1)

SPEAKER READY ROOM OPEN (Hermes Lounge)

**8:30 AM – 10:30 AM****PRE-MEETING SYMPOSIUM 01:****INTERMACS 0: Treatment of the Patient in Shock**

(Athena)

(MCS, HF, HTX, PEEQ)

**CHAIRS:** Filip R.I. Rega, MD and Savitri E. Fedson, MD

**SESSION SUMMARY:** There is substantial evidence showing that patients presenting with critical cardiogenic shock/INTERMACS 1 profile have an overall dismal outcome when referred for durable mechanical circulatory support and/or heart transplantation. In this context, several centers have provided major contributions to the role of temporary mechanical circulatory support as rescue therapy and as a bridge to decision in patients presenting in critical cardiogenic shock, but most have been anecdotal. The clinical and hemodynamic profiles associated with the selection of the various available options for temporary bridging warrants further discussion supported by a combination of available literature and a review from experienced front-line clinicians providing therapy for this particular subset of patients. This session will first discuss the different types and outcomes of patients presenting in INTERMACS Profile 1, then will review the options available for the patient in shock – counterpulsation, percutaneous MCS, ECMO, Centrimag and Impella. This will be followed by a discussion of the subsequent steps. The different hemodynamic profiles each has to offer, the data presently available and the future technologies and relevant studies will be discussed.

**8:30 AM** *Are All INTERMACs Profile I Patients the Same? Definition, Categorization and Outcomes with Shock*Shashank S. Desai, MD, Inova Fairfax Hospital,  
Falls Church, VA, USA**8:45 AM** *Q & A***8:50 AM** *Is There a Role for Counterpulsation in Shock?*Valluvan Jeevanandam, MD, University of Chicago  
Medical Center, Chicago, IL, USA**9:05 AM** *Q & A***9:10 AM** *Percutaneous Devices in Shock: Options and Outcomes*Shelley A. Hall, MD, Baylor University Medical Center,  
Dallas, TX, USA**9:25 AM** *Q & A***9:30 AM** *When is it Time to Call the Surgeons? ECMO, Centrimag and Impella 5.0*Axel Haverich, MD, PhD, Hannover Medical School,  
Hannover, Germany**9:45 AM** *Q & A***9:50 AM** *Weaning versus Bridge to Bridge: What is the Next Step?*Daniel J. Goldstein, MD, Montefiore Medical Center,  
Bronx, NY, USA**10:05 AM** *Q & A***10:10 AM** *Case Presentation of a Patient Presenting in Shock*Jaime A. Hernandez-Montfort, MD, MPH, Newark  
Beth Israel Medical Center, Newark, NJ, USA**10:15 AM** *Panel Discussion*

## 8:30 AM – 10:30 AM

### PRE-MEETING SYMPOSIUM 02:

#### Heart Allocation Policies: The Times They Are A-Changin' (Clio, Thalie)

(DMD, HF, HTX, MCS, NNSAH, PEEQ)

**CHAIRS:** Jon A. Kobashigawa, MD and  
Pascal N. Leprince, MD, PhD

**SESSION SUMMARY:** Organ allocation remains a challenging issue, as there continues to be a shortage of available organs to meet the needs of those on transplant waiting lists. Organ allocation algorithms and listing priorities continue to be re-evaluated and adjusted in an effort to use this scarce resource fairly. This session will provide a forum to discuss this critical issue.

**8:30 AM** *Experience with U.S. Policy for Heart Allocation*

Joseph G. Rogers, MD, Duke University Medical Center,  
Durham, NC, USA

**8:45 AM** *Experience with European Policy for Heart Allocation*

Florian M. Wagner, MD, University Heart Center Hamburg  
Eppendorf, Hamburg, Germany

**9:00 AM** *Experience with Canadian Policy for Heart Allocation*

Debra L. Isaac, MD, Foothills Hospital, Calgary, AB, Canada

**9:15 AM** *DEBATE: VAD Patients Should NOT Receive Priority for Urgent Heart Transplant*

**9:15 AM** *PRO:*

Uwe Schulz, MD, Heart and Diabetes Center NRW,  
Bad Oeynhausen, Germany

**9:30 AM** *CON:*

Martin Strueber, MD, Spectrum Health Hospitals,  
Grand Rapids, MI, USA

**9:45 AM** *DEBATE: Heart Organ Allocation Should Be Done By Scoring Systems, Not Time On List*

**9:45 AM** *PRO:*

Jacqueline M. Smits, MD, PhD, Eurotransplant International,  
Leiden, Netherlands

**10:00 AM** *CON:*

David O. Taylor, MD, Cleveland Clinic Foundation,  
Cleveland, OH, USA

**10:15 AM** *Panel Discussion*

**8:30 AM – 10:30 AM**

## PRE-MEETING SYMPOSIUM 03:

### **Antibodies in Lung Transplant: Mayhem, Mediators, Mechanisms and Management (Erato, Uranie)**

**(LTX, BSTR, DMD, ID, LF, NHSAH, PATH, PEDS, PHARM)**

**CHAIRS:** Deborah J. Levine, MD and Monique Malouf, FRACP

**SESSION SUMMARY:** Antibodies are associated with graft dysfunction but there is little reliable information in the literature to define this process. The ISHLT Pulmonary AMR working group is a multi-disciplinary group made up of clinicians, HLA experts and pathologists who have met to create a set of criteria and a standard working definition of pulmonary AMR. The group will discuss the results of the international survey, diagnosis, and working definition of pulmonary AMR. A review HLA versus non-HLA antibodies and the role of complement pathways will be undertaken. The interplay of the innate and the adaptive immune system in AMR will be discussed. The session will provide a comprehensive review of management strategies. Cases will be used to discuss HLA issues and the management of pulmonary AMR.

**8:30 AM** *Pulmonary AMR: Recent Debates on Definitions and Diagnosis*

Roger D. Yusen, MD, Washington University,  
St. Louis, MO, USA

**8:45 AM** *Q & A*

**8:50 AM** *Are All Antibodies Created Equal? Complement and Non-Complement Mechanisms of Injury*

William Baldwin, MD, PhD, Cleveland Clinic,  
Cleveland, OH, USA

**9:05 AM** *Q & A*

**9:10 AM** *Role of HLA- and Non-HLA Antibodies in AMR*

Kathryn J. Tinckam, MD, University Health Network,  
Toronto, ON, Canada

**9:25 AM** *Q & A*

**9:30 AM** *The Role of the Innate and Adaptive Immune System in AMR*

Tereza Martinu, MD, Toronto Medical Center,  
Toronto, ON, Canada

**9:45 AM** *Q & A*

**9:50 AM** *Management of Pulmonary AMR 2015: Where Are We Now?*

Ramsey R. Hachem, MD, Washington University  
School of Medicine, St. Louis, MO, USA

**10:05 AM** *Q & A*

**10:10 AM** *HLA: A Tale of Two Cases:*

*1) Sensitized Patient*

*2) Patient With AMR*

Adriana Zeevi, PhD, University of Pittsburgh  
Medical Center, Pittsburgh, PA, USA

**10:25 AM** *Q & A*



## 8:30 AM – 10:30 AM

### PRE-MEETING SYMPOSIUM 04:

#### **Bloody Virus: HIV, Hepatitis B and C (Hermes)** **(ID, HTX, LTX, PHARM)**

**CHAIRS:** Antonio B. Roman, MD, PhD and  
Patricia A. Uber, PharmD

**SESSION SUMMARY:** Cardiothoracic transplantation for patients with HIV, and hepatitis B and C remains a controversial topic. Historically, infection with any of these viruses was considered a relative or even absolute contraindication for transplantation. However, favorable experience in liver and kidney recipients has led some programs to progressively adjust selection criteria. The recent ISHLT listing criteria guidelines now include HIV, HCV and HBV positive patients and more programs are performing transplantation in these complex populations. Having a current understanding of these diseases, therapy and monitoring will assist the transplant team. This includes knowledge of drug interactions and the concerns for the various types of immunosuppression (Induction, maintenance) on these patients and if there are preferred agents to use. Lastly developing an approach with an understanding of how to manage complications is necessary for success. Therefore, the focus of this symposium is to increase the knowledge of the CT transplant community about the management and pharmacological treatment options for CT transplants candidates with HIV, hepatitis B or C, before and after transplant.

**8:30 AM** *What Transplant Professionals Need to Know About HIV Disease*

Paolo A. Grossi, MD, PhD, University of Insubria,  
Varese, Italy

**8:45 AM** *Balancing Immunosuppression Medications and HIV: Don't Try This at Home*

Kyle L. Dawson, PharmD, Houston Methodist,  
Houston, TX, USA

**9:00 AM** *Dangerous Curves Ahead: Developing a Plan to Approach the HIV-Infected Patient*

Donna M. Mancini, M.D, New York Presbyterian  
Hospital, New York, NY, USA

**9:15 AM** *HCV Up-to-Date Management: Review of Pre- and Post-Transplant Treatment*

Luciano Potena, MD, PhD, University of Bologna,  
Bologna, Italy

**9:30 AM** *HBV Epidemiology and Treatment Guidelines*

Emily A. Blumberg, MD, University of Pennsylvania,  
Philadelphia, PA, USA

**9:45 AM** *Expanding the Pool of High Risk Donors, HCV- and HBV-Infected Donors: What to Expect and How to Manage Transplant Recipients*

Piedad Ussetti, MD, Hospital Puerta Hierro, Madrid, Spain

**10:00 AM** *Case Presentation: Not for the Faint of Heart*

Irina Timofte, MD, University of Maryland Medical  
Center, Baltimore, MD, USA

**10:05 AM** *Panel Discussion*

**8:30 AM – 10:30 AM**

**PRE-MEETING SYMPOSIUM 05:**

## **Allograft Vasculopathy – A Challenge for All Ages**

(Calliope)

(ALL)

**CHAIRS:** Elfriede Pahl Schuette, MD and  
Richard Kirk, FRCP, FRCPC

**SESSION SUMMARY:** Cardiac Allograft Vasculopathy limits intermediate and late survival in children, as well as adult transplant recipients, and affects even infant transplants. This symposium will address mechanisms and pathophysiology, as well as newer diagnostic tools and treatment agents, including basic science talks on potential targets for therapy. Our goal is to have pediatric and adult cardiologists share their experiences, and perhaps forge new collaborations to study this most challenging problem. We will invite experts in CAV from both Pediatric and Adult transplant community to speak of their experience with these patients, as well as start with basic science background. The ending 15 minute panel discussion will have opinions from the group on an ideal research proposal to study this complex problem in the future. Attendees can ask questions regarding optimal immunosuppression for 2015, help design the ideal randomized clinical trial for all ages, and determine what endpoints and tools should be used for study.

**8:30 AM** *Cardiac Allograft Vasculopathy, the Unsolved Problem: Registry Experience and Clinical Correlations*  
Steve Kindel, MD, Children's Hospital of Omaha,  
Omaha, NE, USA

**8:45 AM** *Endothelial Dysfunction and Cardiac Allograft Vasculopathy: New Assessment Tools for Patient Risk Stratification?*  
Monica M. Colvin-Adams, MD, University of Minnesota,  
Minneapolis, MN, USA

**9:00 AM** *Imaging Techniques for Graft Vasculopathy in Adults: Angiogram, IVUS, OCT, Coronary Flow Reserve*  
Daniel H. Kim, MD, University of Alberta Medical School,  
Edmonton, AB, Canada

**9:15 AM** *Smaller Vessels – Same Approach? Angiogram, IVUS, OCT and Coronary Flow Reserve in Children After Heart Transplant*  
Stephan Schubert, MD, German Heart Center, Berlin,  
Germany

**9:30 AM** *mToR Inhibitors: Where's the Beef?*  
Howard J. Eisen, MD, Drexel University College of Medicine,  
Philadelphia, PA, USA

**9:45 AM** *mToR Inhibitors: Where's the Chicken Fingers?*  
Richard E. Chinnock, MD, Loma Linda University Children's  
Hospital, Loma Linda, CA, USA

**10:00 AM** *The Future is Friendly: New Treatment Targets to Prevent or Delay Cardiac Allograft Vasculopathy*  
Sonja Schrepfer, MD, PhD, University Heart Center Hamburg,  
Hamburg, Germany

**10:15 AM** *Panel Discussion*

## 8:30 AM – 10:30 AM

### PRE-MEETING SYMPOSIUM 06:

#### Psychosocial Assessment: Tools, Tips and Opportunities (Euterpe)

(NNSAH, HF, HTX, LF, LTX, MCS, PEDS)

**CHAIRS:** Annemarie Kaan, MCN, RN and Jo Wray, PhD

Session Summary: This session will review a range of tools available for teams to use to assist with the difficult process of psychosocial evaluation. Seven experts in the area of psychosocial assessment and psychological distress will present the available tools with supporting evidence, as well as provide an opportunity to discuss and explore future opportunities for research.

**8:30 AM** *Soft Factors, Hard Outcomes: Psychosocial Predictors of Post-transplant Success*

Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Leuven, Belgium

**8:45 AM** *The Psychosocial Assessment of Adult Organ Transplant Candidates: A Comprehensive Approach*

Jose R. Maldonado, MD, Stanford University School of Medicine, Stanford, CA, USA

**9:00 AM** *The Psychosocial Assessment of the Pediatric Transplant Candidate: Issues and Controversies*

Samantha J. Anthony, PhD, MSW, Hospital for Sick Children, Toronto, ON, Canada

**9:15 AM** *Screening and Managing Nonadherence to Medical Therapy*

Sabina M. De Geest, RN, PhD, University of Basel, Basel, Switzerland

**9:30 AM** *Screening and Addressing Psychosocial Distress: How Best to Do It?*

Quincy Young, PhD, RPsych, St. Paul's Hospital, Vancouver, BC, Canada

**9:45 AM** *Caregiver Psychosocial Distress: Now What Should We Do?*

Michael G. Petty, PhD, RN, CNS, University of Minnesota Medical Center, Minneapolis, MN, USA

**10:00 AM** *If I Had a Crystal Ball: When to Implement Palliative Care in Heart and Lung Transplant Recipients*

Mi-Kyung Song, PhD, University of North Carolina School of Nursing, NC, USA

**10:15 AM** *Panel Discussion*

## 9:00 AM – 7:00 PM

PRESS OFFICE OPEN (Gallieni 6)

## 10:00 AM – 8:00 PM

EXHIBIT HALL OPEN (Rhodes)

POSTER HALL OPEN (Agora 2)

## 10:30 AM – 10:45 AM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

**10:45 AM – 12:45 PM**

## **PRE-MEETING SYMPOSIUM 07:**

### **Moving MCS Therapy Forward (Athena)** **(MCS, HF, HTX, NHTSAH)**

**CHAIRS:** Steven S.L. Tsui, MD, FRCS and Robert L. Kormos, MD

**SESSION SUMMARY:** This session will focus on the key topics pivotal to advancing the field. We will first address where we are with fully implantable LVADs, followed by the need for them and both the current and projected status. Next to be discussed are the traditional indications of bridge to transplantation, bridge to recovery and destination therapy and whether or not it is now appropriate, and possible, to start moving away from these indications. Then there will be a presentation on how to improve resource utilization – how to reduce length of stay and reduce readmissions, including the use of long term care facilities, rehabilitation units, etc., to reduce the cost of this therapy and make it more widely useable. Finally there will be two debates; one on whether all VAD patients should be started on heart failure medications and the second, on whether, going forward, it will be desirable for the VAD to be run with patients having a pulse again or not.

**10:45 AM** *Fully Implantable LVADs: Where Are We?*

Mark S. Slaughter, MD, University of Louisville,  
Louisville, KY, USA

**11:00 AM** *Q & A*

**11:05 AM** *BTT, BTR and Destination Therapy:  
Is it Time to Get Rid of These Terms?*

Francis D. Pagani, MD, PhD, University of Michigan  
Medical Center, Ann Arbor, MI, USA

**11:20 AM** *Q & A*

**11:25 AM** *Improving Resource Utilization: Reducing  
Length of Stay, Readmissions, etc.*

Claudius Mahr, DO, University of Washington,  
Seattle, WA, USA

**11:40 AM** *Q & A*

**11:45 AM** *DEBATE: All VAD Recipients Should Be on  
Heart Failure Medications*

**11:45 AM** *PRO:*

Emma Birks, MD, PhD, University of Louisville,  
Louisville, KY, USA

**11:55 AM** *CON:*

Jeffrey J. Teuteberg, MD, University of Pittsburgh,  
Pittsburgh, PA, USA

**12:05 PM** *Rebuttal PRO*

Emma Birks, MD, PhD

**12:10 PM** *Rebuttal CON*

Jeffrey J. Teuteberg, MD

**12:15 PM** *DEBATE: All VAD Patients Should Have a Pulse*

**12:15 PM** *PRO:*

Stephan Schueler, MD, PhD, FRCS, Freeman Hospital,  
Newcastle upon Tyne, United Kingdom

**12:25 PM** *CON:*

Evgenij V. Potapov, MD, PhD, Berlin Heart Institute,  
Berlin, Germany

**12:35 PM** *Rebuttal PRO*

Stephan Schueler, MD, PhD, FRCS

**12:40 PM** *Rebuttal CON*

Evgenij V. Potapov, MD, PhD

**10:45 AM – 12:45 PM**

**PRE-MEETING SYMPOSIUM 08:**

**When Worlds Collide: Heart and Kidney (Clio, Thalie)**  
**(HF, HTX, NHSAH, MCS, PATH)**

**CHAIRS:** Jose Gonzalez-Costello, MD and David A. Baran, MD

**SESSION SUMMARY:** This session will focus on venous congestion in acute and advanced heart failure and will review: 1) the relationship between venous congestion and outcome; 2) the role of venous congestion in the pathophysiology of end-organ dysfunction and damage; 3) the epidemiology and outcome of the cardiorenal syndrome; 4) the hemodynamic and intrabdominal contributors to acute kidney injury; 5) the treatment strategies for decongestion; 6) the role of hemoconcentration as a potential treatment target during decongestion.

**10:45 AM** *The Role of Venous Congestion in the Pathophysiology of Acute Heart Failure*

Paolo Colombo, MD, Columbia University, New York, NY, USA

**11:00 AM** *Q & A*

**11:05 AM** *Cardiorenal Syndrome*

Maria Rosa Costanzo, MD, Midwest Heart Specialists-Advocate Medical, Naperville, IL, USA

**11:20 AM** *Q & A*

**11:25 AM** *Hemoconcentration as a Treatment Goal in Acute Heart Failure*

Jeffrey M. J. Testani, MD, MTR, Yale University, New Haven, CT, USA

**11:40 AM** *Q & A*

**11:45 AM** *Management of the Failing Fontan*

Michael Burch, MD, Great Ormond Street Hospital, London, United Kingdom

**12:00 PM** *Q & A*

**12:05 PM** *Heart-Kidney Transplantation*

Lawrence S. C. Czer, MD, Cedars-Sinai Medical Center, Los Angeles, CA, USA

**12:20 PM** *Q & A*

**12:25 PM** *Renal Sparing Strategies in Heart Transplantation*

Markus J. B. Barten, MD, PhD, Heart Center Leipzig, Leipzig, Germany

**12:40 PM** *Q & A*

**10:45 AM – 12:45 PM**

## **PRE-MEETING SYMPOSIUM 09:**

### **Making the Most of What We Have: Maximizing Donor Utilization** (Erato, Uranie)

(LTX, DMD, LF, PEEQ)

**CHAIRS:** Gabriel Loor, MD and Dirk E. Van Raemdonck, MD, PhD

**SESSION SUMMARY:** This session will focus on maximizing donor yield through reevaluation of key issues that cause practitioners to decline offers. There are clearly differences between high volume and low volume centers related to perception of donor quality, mechanisms for evaluating offers and strategies for optimizing donor organs. The data supporting donor criteria is not perfectly consistent. This leaves difficult decisions to the discretion of implanting surgeons. Centers with high import to export ratios often accept organs that others have refused while maintaining similar if not superior outcomes. This session will review and debate important donor criteria that raise concern for potential implanters. There is no right or wrong answer, rather a spectrum that requires thoughtful consideration for the benefit of recipients on the wait list. The session will evaluate the strongest available data on donor ischemic time, donor age and donation after cardiac death. There will be an update on the status of donor scoring systems and checklists that integrate a variety of elements into positive or negative scores. There will be discussion on implementation of donor screening programs to maximize the interpretation, evaluation and management of donor offers. Furthermore, this session will highlight the practical aspects of using extracorporeal optimization technology to increase donor yield. Finally, donor selection and management relevant to pediatric transplantation will be highlighted.

**10:45 AM DEBATE:** *Cold Ischemic Time Should Affect the Decision to Decline a Donated Lung*

**10:45 AM PRO:**

Michiel E. Erasmus, MD, PhD, University Medical Center, Groningen, Netherlands.

**10:55 AM CON:**

Marcelo Cypel, MD, University of Toronto, Toronto, ON, Canada

**11:05 AM DEBATE:** *DCD Status Should Influence Refusal of a Donated Lung*

**11:05 AM PRO:**

Christopher H. Wigfield, MD, FRCS, University of Chicago, Chicago, IL, USA

**11:15 AM CON:**

Bronwyn J. Levvey, RN, Grad Dip Clin Ep, Alfred Hospital, Melbourne, Australia

**11:25 AM DEBATE:** *We Should Use Older Donors for Lung Transplantation*

**11:25 AM PRO:**

Christian A. Bermudez, MD, UPMC Presbyterian, Pittsburgh, PA, USA

**11:35 AM CON:**

Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

**11:45 AM Pooling Complex Factors – Can Donor Scores Remove Bias in Donor Selection?**

Takahiro Oto, MD, Okayama University Hospital, Okayama, Japan

**12:00 PM Current Status of Extra Corporeal Optimization Technology for Maximizing Donor Yield**

Robert B. Love, MD, Medical College of Wisconsin, Milwaukee, WI, USA

**12:15 PM** *Donor Selection and Management in Children and Adolescents Awaiting Lung Transplantation*  
George B. Mallory, Jr, MD, Texas Children's Hospital,  
Houston, TX, USA

**12:30 PM** *Panel Discussion*

## 10:45 AM – 12:45 PM

### PRE-MEETING SYMPOSIUM 10:

#### **Therapeutic Strategies in Pulmonary Hypertension: Current Evidence and New Directions** (Hermes) (PH, HF, HTX, LF, LTX, MCS, PHARM)

*This session is supported by educational grants from Actelion and Gilead.*

**CHAIRS:** Myung H. Park, MD and Irene Lang, MD

**SESSION SUMMARY:** Pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension now have multiple therapeutic options for the practicing physician. This session will present focused discussions on combination therapeutic approaches. It will discuss the results of recent clinical trials in support of sequential versus upfront combination therapies and look at new options in medical and non-surgical management of chronic thromboembolic pulmonary hypertension.

**10:45 AM** *The Rationale for Combination Therapy in Pulmonary Arterial Hypertension*  
Mardi Gombert-Maitland, MD, University of Chicago  
Medical Center, Chicago, IL, USA

**11:05 AM** *Sequential or Upfront Combination Therapy for Pulmonary Arterial Hypertension?*  
Nazzareno Galie, MD, Università degli Studi di Bologna,  
Bologna, Italy

**11:25 AM** *Therapies in Development: Investigational and Emerging*  
Marc Humbert, MD, PhD, Hôpital Bicêtre, Paris, France

**11:45 AM** *The Hemodynamic/Phenotypic Paradox: Pulmonary Hypertension Classification in Clinical Trials*  
J. Simon R. Gibbs, FRCP, Hammersmith Hospital,  
London, United Kingdom

**12:05 PM** *Evolving Management of Chronic Thromboembolic Pulmonary Hypertension: Medical, Interventional and Surgical*  
David P. Jenkins, FRCS, Papworth Hospital, Cambridge,  
United Kingdom

**12:25 PM** *Panel Discussion*

**10:45 AM – 12:45 PM**

## **PRE-MEETING SYMPOSIUM 11:**

### **Drug Disposition in the Critically Ill Patient (Calliope)** **(PHARM, HTX, ID, LTX, NNSAH, PEDS)**

**CHAIRS:** Adam B. Cochrane, PharmD and  
Martha L. Mooney, MD, FACP

**SESSION SUMMARY:** Critically ill patients constitute unique and complex pharmacologic challenges to clinicians. These patients are often dealing with altered gastrointestinal absorption, hepatic function, volume of distribution, numerous drug-drug interactions and dependence on various devices, all of which can cause significant alteration in drug pharmacokinetics and pharmacodynamics. Many of the drugs used in transplantation and MCS show great degree of interindividual and intraindividual pharmacokinetic and pharmacodynamic variability. Moreover, these drugs often have a narrow therapeutic window, with potential toxicity or treatment failure. In this setting, pharmacokinetics and pharmacodynamics play an important role in the optimal management of these patients to improve patient outcomes.

**10:45 AM** *ECMO: Hungry, Hungry Circuits*

Haifa Lyster, MSc, Royal Brompton & Harefield NHS Trust,  
Harefield, United Kingdom

**11:05 AM** *Renal Replacement Therapy and Plasmapheresis:  
Where is the Drug Going?*

Christopher R. Ensor, PharmD, BCPS-CV, University of  
Pittsburgh, Pittsburgh, PA, USA

**11:20 AM** *Up in the Air: Can My Drug Be Nebulized?*

Katie Watkins, PharmD, University of California,  
San Francisco, CA, USA

**11:35 AM** *Sanctuary Sites of Infection: Hide and Seek*

Kate Gould, FRCPATH, Freeman Hospital, Newcastle  
Upon Tyne, United Kingdom

**11:55 AM** *Therapeutic Drug Monitoring in Special Populations*

Eliane Billaud, PhD, PharmD, Hospital Georges  
Pompidou, Paris Cedex, France.

**12:15 PM** *A Sticky Situation – Device Infections and Biofilms*

Stanley I. Martin, MD, Ohio State University Medical  
Center, Columbus, OH, USA

**12:30 PM** *Panel Discussion*



## 10:45 AM – 12:45 PM

### PRE-MEETING SYMPOSIUM 12:

#### The Future of Tolerance: Definitions, Directions, and Design (Euterpe)

(ALL)

**CHAIRS:** James George, PhD and Stephan M. Ensminger, MD, DPhil

**SESSION SUMMARY:** This session approaches tolerance from a conceptual perspective, shedding light on the forces that moved tolerance in the past and the directions that it will likely take in the future. While, to many, the concept of tolerance is a fading dream, this session will show that with fresh insight, persistence, and a creative approach using new technologies, the entity of tolerance may still be achievable.

**10:45 AM** *Tolerance, Chimerism, and Cytokines: Definitions and Historical Perspective*

Kimberly L. Gandy, MD, PhD, University of Missouri, Kansas City, MO, USA

**11:00 AM** *Myeloid and Mesenchymal Stem Cells: The Rising Tolerizers*

Jos Domen, PhD, Children's Mercy Hospital and Clinics, Kansas City, MO, USA

**11:15 AM** *The Role of Cytokines in Tolerance*

Carla C. Baan, PhD, Erasmus Medical Center, Rotterdam, Netherlands.

**11:30 AM** *T Regulatory Cells in Tolerance Induction: Translation From Bench to Bedside*

Manuella Battaglia, PhD, Ospedale San Raffaele, Milan, Italy

**11:45 AM** *The Role of Cellular Immunotherapy in Solid Organ Transplantation: Lessons from the ONE Study*

Edward Geissler, PhD, University of Regensburg, Regensburg, Germany

**12:00 PM** *Inflammation and Transplantation Tolerance*

Daniel R. Goldstein, MD, Yale New Haven Hospital, New Haven, CT, USA

**12:15 PM** *Immune Monitoring for Clinical Tolerance*

Birgit S. Sawitzki, PhD, Institute of Medical Immunology Charite, Berlin, Germany

**12:30 PM** *Tolerance in Pediatric Transplant Recipients: A Window of Opportunity*

Lori J. West, MD, DPhil, University of Alberta, Edmonton, AB, Canada

## 12:45 PM – 1:45 PM

### JUNIOR FACULTY AND TRAINEE

### COUNCIL MEETING (Euterpe)

BOX LUNCH DISTRIBUTION (Rhodes)

## 12:45 PM – 2:45 PM

LUNCH BREAK

JHLT EDITORIAL BOARD LUNCH MEETING (Gallieni 1 & 2)

EDUCATION COMMITTEE MEETING (Gallieni 4)

GRANTS AND AWARDS COMMITTEE MEETING (Gallieni 5)

STANDARDS AND GUIDELINES COMMITTEE MEETING (Gallieni 7)

I2C2 COMMITTEE MEETING (Gallieni 3)

**2:45 PM – 4:45 PM**

## PRE-MEETING SYMPOSIUM 13:

### **Early Implantation: Is It Too Soon?** (Athena) (MCS, HF, HTX, NNSAH, PEEQ)

**CHAIRS:** Salpy V. Pamboukian, MD, MSPH and  
Jan F. Gummert, MD, PhD

**SESSION SUMMARY:** This symposium will explore the movement to extend the benefits of MCS to the earlier stage, principally class III, HF patient. This area is ripe for discussion and debate. Strong arguments exist on both sides as to whether the field is ready for this. In the era of expanded use of MCS, this topic merits further debate, especially within the international context of our society, as treatment availability and application varies between countries. The fate of the Class III patient with medical therapy will be presented with new data from the current MEDAMACs trial, followed by a debate as to whether or not the timing is right for an evaluation of the outcomes of implantation in INTERMACs profile 4-7 patients. The needs from the patient's perspective and ideal pump requirements from an engineering perspective will be discussed. New data on outcomes in ambulatory Class IV patients will be discussed, followed by a case presentation and panel discussion.

**2:45 PM** *Results From MEDAMACs – What is the Fate of the Class III Patient with Medical Therapy?*

Garrick C. Stewart, MD, Brigham & Women's Hospital, Boston, MA, USA

**3:00 PM** *DEBATE: INTERMACS Profile 4+: The Timing is Right*

**3:00 PM** *PRO:*

Keith D. Aaronson, MD, University of Michigan Medical Center, Ann Arbor, MI, USA

**3:10 PM** *CON:*

Randall C. Starling, MD, MPH, Cleveland Clinic, Cleveland, OH, USA

**3:20 PM** *Rebuttal PRO*

Keith D. Aaronson, MD

**3:25 PM** *Rebuttal CON*

Randall C. Starling, MD, MPH

**3:30 PM** *What are the Needs for Class III Patients: The Patient's Perspective*

Tonya I. Elliot, MSN, RN, CCTC, CHF, MedStar Washington Hospital Center, Washington, DC, USA

**3:45 PM** *Future Needs for Functional Class III Patients: The Engineering Perspective*

Francesco Moscato, PhD, Medical University of Vienna, Vienna, Austria

**4:00 PM** *Highlights From ROADMAP: Outcomes in Ambulatory Class IV Patients*

Douglas A. Horstmannshof, MD, Integris Baptist Medical Center, Oklahoma City, OK, USA

**4:15 PM** *Case Presentation of a Patient Presenting with Ambulatory Class III Heart Failure*

Alexander Bernhardt, MD, University Heart Center, Hamburg, Germany

**4:25 PM** *Panel Discussion*

**2:45 PM – 4:45 PM**

**PRE-MEETING SYMPOSIUM 14:**

**Extreme Donors: Pushing the Boundaries** (Clio, Thalie)  
**(HTX, BSI, DMD, HF, HTX, PEDS, PEEQ)**

**CHAIRS:** Ivan Knezevic, MD and Kumud K. Dhital, MD, PhD

**SESSION SUMMARY:** This session will focus on the transplantation of hearts from extended criteria and DCD donors. Subjects to be covered are:  
1) definition of death: implications for retrieving hearts from DCD donors;  
2) pathophysiology of myocardial injury during withdrawal of life support – implications for retrieval and transplantation of hearts from DCD donors;  
3) surgical Perspective on procuring and transplanting extended criteria donors;  
4) human heart transplantation from DCD donors – a pediatric perspective; and  
5) human heart transplantation from DCD donors – an adult perspective.

**2:45 PM** *Definition of Death – Implications for Heart Donation from DCD Donors*

Sam Shemie, MD, Montreal Children's Hospital,  
McGill University, Montreal, QC, Canada

**3:00 PM** *Myocardial Injury During Withdrawal of Life Support*

Peter MacDonald, MD, PhD, St. Vincent's Hospital,  
Sydney, Australia

**3:15 PM** *Ex-Vivo Assessment of Hearts from DCD Donors*

Darren H. Freed, MD, PhD, FRCSC, University of  
Alberta Hospital, Edmonton, AB, Canada

**3:30 PM** *Heart Transplantation from DCD Donors – A Pediatric Perspective*

Richard Kirk, FRCP, FRCPC, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**3:45 PM** *Human Heart Transplantation from DCD Donors – An Adult Perspective*

Stephen R. Large, MB, FRCS, FRCP, Papworth Hospital,  
Cambridge, United Kingdom

**4:00 PM** *Donor Heart Protection – What Works, What Doesn't*

Yoshifumi Naka, MD, PhD, New York Presbyterian Hospital,  
New York, NY, USA

**4:15 PM** *Would You Take This Donor? When is the Risk Too High?*

David A. Baran, MD, Newark Beth Israel Med Center,  
Newark, NJ, USA

**4:30 PM** *Panel Discussion*

**2:45 PM – 4:45 PM**

## PRE-MEETING SYMPOSIUM 15:

### Before, During, and After – Optimizing Outcomes in the High Risk Recipient for Lung Transplantation

(Erato, Uranie)  
(LTX, BSI, LF)

**CHAIRS:** Vibha N. Lama, MD and Cassie C. Kennedy, MD

**SESSION SUMMARY:** This session will focus on modifiable factors in the pre-, peri- and post- transplant period and steps needed to improve outcomes after lung transplantation. The role of ECMO as a bridge to transplant and perioperative recovery will be reviewed. Challenging patient cohorts, including those with connective tissue disease and pulmonary hypertension complicating ILD, will be highlighted. Complex medical issues in the CF patient will be reviewed.

**2:45 PM** *Modifiable Factors Pre-Transplantation – Improving Survival by Candidate Selection*

Andrew Chang, MD, University of Michigan Medical Center, Ann Arbor, MI, USA

**3:05 PM** *ECMO and Lung Transplantation- Bridge to and After*

Walter Klepetko, MD, Medical University of Vienna, Vienna, Austria

**3:25 PM** *Managing Secondary Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis Patients Before, During, and After Transplant*

Paul A. Corris, MB, FRCP, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**3:45 PM** *Connective Tissue Disease in Interstitial Lung Disease – Is the Baggage Too Heavy?*

Elana J. Bernstein, MD, Columbia University, New York, NY, USA

**4:05 PM** *The Medically-Challenging Cystic Fibrosis Patient – Diabetes, Digestion, and Drug-Seeking Behavior*

A. Whitney Brown, MD, Inova Advanced Lung Disease & Transplant, Fairfax, VA, USA

**4:25 PM** *Panel Discussion*

**2:45 PM – 4:45 PM**

**PRE-MEETING SYMPOSIUM 16:**

**Challenges in Pulmonary Hypertension Due to Left Heart Disease** (Hermes)

**(PH, BSTR, HF, HTX, MCS, NNSAH, PEDS)**

*This session is supported by educational grants from Actelion and Gilead.*

**CHAIRS:** Jean-Luc Vachieri, MD and Van N. Selby

**SESSION SUMMARY:** Pulmonary hypertension (PH) is common among patients with left heart disease (LHD), and the development of PH-LHD is associated with a worse prognosis. This session will review evidence in several sub-categories of left heart disease including heart failure with preserved ejection fraction (HFpEF), restrictive, and hypertrophic cardiomyopathies and valvular disease in the setting of LVAD implantation. The prevalence, prognostic significance, and diagnostic evaluation of PH in each of these conditions will be discussed, as will the implications for management.

**2:45 PM** *Pulmonary Hypertension Due to Left Heart Disease: Novel Hemodynamic Predictors*

Rebecca J. Cogswell, MD, University of Minnesota  
Division of Cardiology, Minneapolis, MN, USA

**3:05 PM** *Q & A*

**3:09 PM** *Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction*

Marco Guazzi, MD, PhD, IRCCS, Policlinico San Donato  
University Hospital, Milan, Italy

**3:29 PM** *Q & A*

**3:33 PM** *Pulmonary Hypertension in Restrictive, Infiltrative and Hypertrophic Cardiomyopathy*

Robert P. Frantz, MD, Mayo Clinic, Rochester, MN, USA

**3:53 PM** *Q & A*

**3:57 PM** *Pulmonary Hypertension in Mitral and Aortic Valve Disease*

Evelyn M. Horn, MD, Weill Cornell Medical Center,  
New York, NY, USA

**4:17 PM** *Q & A*

**4:21 PM** *Pulmonary Hypertension Pre and Post LVAD: Should It Be Treated?*

Ryan J. Tedford, MD, Johns Hopkins University Hospital,  
Baltimore, MD, USA

**4:41 PM** *Q & A*

**2:45 PM – 4:45 PM**

## PRE-MEETING SYMPOSIUM 17:

### Lung and Heart-Lung Transplantation: Coming of Age (Calliope)

(PEDS, BSTR, DMD, LF, LTX)

**CHAIRS:** Carol K. Conrad, MD and Nicolaus Schwerk, MD

**SESSION SUMMARY:** The primary aim of this session is to present and discuss child specific aspects of lung and heart lung transplantation. Due to the scarcity of potential donors, lung allocation remains a big challenge, especially in children. Different approaches to expand the donor pool, like single lobe transplantation or atypical size reduction, have been developed to resolve this dilemma. Recent advances, as well existing challenges and limitations, of donor pool expansion will be discussed, including the option of ex-vivo perfusion and DCD-donation. A further talk will give insights into the current state of pediatric lung transplantation from the surgical point of view. The number of children with congenital heart disease developing pulmonary hypertension prohibiting a cardiac transplantation is rising. Heart-lung transplantation may be the only solution in these patients. Possibilities and challenges of this approach will be discussed. Non-adherence is another major problem, especially in adolescents and is responsible for a significant amount of morbidity and mortality after lung transplantation. Therefore, options for early detection and intervention are crucial.

**2:45 PM** *Waiting List Management and Allocation Policies – What Works Best for Children?*

Samuel B. Goldfarb, MD, Children's Hospital of Philadelphia, Philadelphia, PA, USA

**3:00 PM** *Q & A*

**3:05 PM** *Ex-vivo Perfusion: An Option to Preserve and Rehabilitate Pediatric Donor Lungs*

Jayan Nagendran, MD, University of Alberta, Edmonton, AB, Canada

**3:20 PM** *Q & A*

**3:25 PM** *Surgical Challenges in Pediatric Lung Transplantation*

Gregor Warnecke, MD, Hannover Medical School, Hannover, Germany

**3:40 PM** *Q & A*

**3:45 PM** *Under Pressure – Type II Pulmonary Hypertension in Children with End-Stage Heart Failure*

Maurice Beghetti, MD, HUG Children's University Hospital, Geneva, Switzerland

**4:00 PM** *Q & A*

**4:05 PM** *Heart-Lung Transplantation for Children with Congenital Heart Disease and Pulmonary Hypertension: A Feasible Option?*

Stuart C. Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

**4:20 PM** *Q & A*

**4:25 PM** *Non-Adherence: How to Detect and How to Deal With It?*

Doris Staab, MD, Charite University, Berlin, Berlin, Germany

**4:40 PM** *Q & A*

## 2:45 PM – 4:45 PM

### PRE-MEETING SYMPOSIUM 18:

#### **B Cells in Transplantation 2015 (Euterpe)**

(BSTR, HF, HTX, LTX, PATH, PEDS)

**CHAIRS:** Marilia Cascalho, MD, PhD and A. G. Kfoury, MD, FACC

**SESSION SUMMARY:** This session will illustrate the cutting edge of knowledge and present key questions yet unanswered concerning basic B cell function and control, and the clinical impact of immune therapeutics on humoral immunity, rejection and potentially tolerance. These presentations will be followed by a panel discussion, in workshop format, designed to draw from the speakers and from the audience a synthesis of how basic knowledge can potentially be applied and what information and level of resolution are needed for clinical applications.

**2:45 PM** *The Role of B cells in the Alloimmune Response*

Esme Dijke, PhD, University of Alberta,  
Edmonton, AB, Canada

**3:05 PM** *Tolerance and Accommodation After Transplantation: The Role of B cells*

Jeffrey L. Platt, MD, University of Michigan,  
Ann Arbor, MI, USA

**3:25 PM** *Harnessing the Power of B Regulatory Cells to Modulate the Immune Response*

Paul Blair, PhD, University College London,  
London, United Kingdom

**3:45 PM** *Targeting Plasma Cells in Transplantation*

Meena Clatworthy, PhD, University of Cambridge,  
Cambridge, United Kingdom

**4:05 PM** *B cell Therapeutics in Transplantation*

Jignesh K. Patel, MD, PhD, Cedars-Sinai Heart Institute,  
Los Angeles, CA, USA

**4:25 PM** *Panel Discussion*

## 4:45 PM – 5:00 PM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

**5:00 PM – 7:00 PM**

## PRE-MEETING SYMPOSIUM 19:

### **50 Shades of Gray: When Things Don't Go as Planned in VAD Patients (Athena)**

**(MCS, HF, HTX, ID, NNSAH)**

**CHAIRS:** Ulrich P. Jorde, MD and O. Howard Frazier, MD

**SESSION SUMMARY:** The common, serious adverse events that occur in LVAD patients, which result in morbidity and mortality, will be discussed. Their incidence, diagnosis and management will be presented and discussed by experts in the field. These topics will include: 1) Device thrombosis: when/how to screen for and diagnose device thrombosis, when/how to treat device thrombosis medically and surgically; 2) Post-operative right ventricular failure: when to treat, followed by a discussion of the medical and surgical treatment options and when to use each; 3) Aortic Insufficiency: when/how to adjust pump speed to prevent/treat aortic insufficiency, when/how to repair/replace the aortic valve, including a discussion on the use of TAVR in VAD patients; 4) Driveline infection with/without pocket involvement, when/how to perform ID and when/how to replace the device; 5) GI bleeding in VAD patients: why it occurs and its current incidence, when/how to adjust anticoagulation, how to identify and treat AVMs; 6) Stroke: incidence and changing trends, how to prevent, diagnose and manage stroke in VAD patients.

**5:00 PM** *Device Thrombosis – What Now?*

Nir Uriel, MD, University of Chicago, Chicago, IL, USA

**5:15 PM** *Q & A*

**5:20 PM** *Post-Operative RV Failure: Medicine or Machines?*

Alexander M. Bernhardt, MD, University Heart Center  
Hamburg, Hamburg, Germany

**5:35 PM** *Q & A*

**5:40 PM** *Aortic Insufficiency in VAD Patients –  
Observe, Treat or Fix?*

Daniel Zimpfer, MD, Medical University Vienna,  
Vienna, Austria.

**5:55 PM** *Q & A*

**6:00 PM** *Driveline Infection – Debride, Reroute, Replace?*

Scott C. Silvestry, MD, Washington University,  
St Louis, MO, USA

**6:15 PM** *Q & A*

**6:20 PM** *GI Bleeding in VAD Patients- Why, Where, What Now?*

Anna L. Meyer, MD, Leipzig Heart Center, Leipzig, Germany

**6:35 PM** *Q & A*

**6:40 PM** *Strokes in VAD Patients – Incidence,  
Changing Trends and Management*

Jeffrey A. Morgan, MD, Henry Ford Hospital, Detroit, MI, USA

**6:55 PM** *Q & A*



**5:00 PM – 7:00 PM**

**PRE-MEETING SYMPOSIUM 20:**

**The Road Less Traveled: The Management of Unusual Cardiomyopathies** (Clio, Thalie)

(HF, BSTR, HTX, MCS, NHAH, PEDS)

**CHAIRS:** Eugene C. DePasquale, MD and Marco Masetti, MD

**SESSION SUMMARY:** Inherited cardiomyopathies, which may include dilated, hypertrophic, restrictive and arrhythmogenic right ventricular cardiomyopathy, can progress to end stages and may ultimately lead to the requirement of heart transplantation. A better understanding of the pathophysiology and management specific to these heritable conditions is crucial to the heart failure/transplant specialist to aid in overall care, as well as timing of listing for heart transplantation. It is also critical for the heart failure/transplant physician to understand the role and limitations of presently available genetic testing and the potential medical and psychological impact of testing on the patient and their family members. This symposium will review genetic testing for cardiomyopathies, when to consider testing in patients with cardiomyopathy, the limitations of presently available testing, and the importance of genetic counseling.

**5:00 PM** *Chagas Cardiomyopathy*

Alejandro M. F. Bertolotti, Sr., MD, University Hospital  
Favaloro Foundation, Buenos Aires, Argentina

**5:15 PM** *Hypertrophic Cardiomyopathy*

Neal K. Lakdawala, MD, Brigham & Women's Hospital,  
Boston, MA, USA

**5:30 PM** *Arrhythmogenic Right Ventricular Cardiomyopathy*

Ray E. Hershberger, MD, Ohio State University College of  
Medicine, Columbus, OH, USA

**5:45 PM** *Amyloid Heart Disease*

Marc J. Semigran, MD, Massachusetts General Hospital,  
Boston, MA, USA

**6:00 PM** *Adults with Congenital Heart Disease:  
When is Transplant the Answer?*

Evan M. Zahn, MD, Cedars-Sinai Medical Center,  
Los Angeles, CA, USA

**6:15 PM** *Muscular Dystrophies and Mitochondrial Myopathies*

Pradeep P.A. Mammen, MD, FACC, FAHA, UT Southwestern  
Medical Center, Dallas, TX, USA

**6:30 PM** *Role of Genetic Counseling*

Kathleen Hickey, EdD, FNP, ANP, FAHA, FAAN,  
Columbia University, New York, NY, USA

**6:45 PM** *Panel Discussion*

**5:00 PM – 7:00 PM**

## PRE-MEETING SYMPOSIUM 21:

### I3T: Infection, Inflammation, and Immunity After Lung Transplantation (Erato, Uranie)

(LTX, BSTR, ID, LF)

**CHAIRS:** Tanya J. McWilliams, MD, PhD and Peter M. Hopkins, FRACP

**SESSION SUMMARY:** A growing body of evidence suggests that there are important links between infection and rejection in the setting of lung transplantation. In addition, there is an increasing appreciation that colonization with pathogenic organisms may both predispose to future invasive disease, as well as influence the inflammatory and allo-immune environment of the lung allograft. Both colonization and invasive infection with certain bacteria, including *Pseudomonas aeruginosa* may predispose to development of CLAD. Fungal colonization and infection with *Aspergillus* spp. has also been shown to be associated with a decrease in FEV1, even in the absence of invasive fungal infection. Viruses, including CMV and community-acquired respiratory viruses, have also been shown to exert pro-inflammatory and immune modulating effects that can lead to CLAD via cytokine and chemokine expression. The delineation of these links and potential mechanisms for these effects have important implications for the screening and response to colonizing pathogens and should lead to new interventions to prevent and possibly reverse CLAD.

**5:00 PM** *Epidemiology of Infections, Inflammation, Immunity and Lung Transplant Outcomes*  
Shahid Husain, MD, MS, University Health Network, Toronto, ON, Canada

**5:15 PM** *Q & A*

**5:20 PM** *The Many Deleterious Roles of Viral Infection in the Lung Allograft*  
Joanna M. Schaenman, MD, PhD, UCLA School of Medicine, Los Angeles, CA, USA

**5:35 PM** *Q & A*

**5:40 PM** *Bacterial and Fungal Pathogens and Progression to CLAD*  
Andrew J. Fisher, FRCP, PhD, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**5:55 PM** *Q & A*

**6:00 PM** *A Tale of Two Viruses: Understanding How Virology and Host Response to Influenza and RSV Impact Lung Pathobiology Leading to CLAD*  
Tereza Martinu, MD, Toronto General Hospital, Toronto, ON, Canada

**6:15 PM** *Q & A*

**6:20 PM** *To Treat, Not to Treat or How to Treat: Novel Antiviral Therapies in Development*  
Jens Gottlieb, MD, Hannover Medical School, Hannover, Germany

**6:35 PM** *Q & A*

**6:40 PM** *Interplay Between Infection and Immunity*  
Andrew E. Gelman, PhD, Washington University School of Medicine, St. Louis, MO, USA

**6:55 PM** *Q & A*

**5:00 PM – 7:00 PM**

**PRE-MEETING SYMPOSIUM 22:**

**Chronic Lung Disease Associated Pulmonary Hypertension: Mechanism, Pathology, and Clinical Impact (Hermes)**

**(PH, LF, LTX, NNSAH, PATH)**

**CHAIRS:** Teresa De Marco, MD, FACC and Rajeev Sagar, MD

**SESSION SUMMARY:** The use of targeted pulmonary vascular therapies in patients with pulmonary hypertension secondary to chronic lung disease is controversial. The 5th World PH symposium developed recommendations for the diagnosis and management of this entity. This symposium will present the key aspects in the pathology, mechanisms, and treatment opportunities for patients in this group.

- 5:00 PM** *Pathology of Pulmonary Fibrosis Associated Pulmonary Hypertension*  
Gerald J. Berry, MD, Stanford University, Stanford, CA, USA
- 5:20 PM** *Q & A*
- 5:25 PM** *Combined Pulmonary Fibrosis and Emphysema: A Unique Pattern of Pulmonary Vascular Disease*  
Vincent Cottin, MD, Université Claude Bernard Lyon, Lyon, France.
- 5:45 PM** *Q & A*
- 5:50 PM** *Gas Exchange in Lung Disease and Pulmonary Hypertension: The Myths and Facts*  
Joan A. Barbera, MD, University of Barcelona, Barcelona, Spain
- 6:10 PM** *Q & A*
- 6:15 PM** *When to Treat Pulmonary Hypertension in Association with Pulmonary Fibrosis*  
Steven D. Nathan, MD, Inova Fairfax Hospital, Falls Church, VA, USA
- 6:35 PM** *Q & A*
- 6:40 PM** *Case Presentation: Applying the Evidence to the Individual Patient*  
Ioana R. Preston, MD, Tufts Medical Center, Boston, MA, USA
- 6:45 PM** *Panel Discussion*

**5:00 PM – 7:00 PM**

## PRE-MEETING SYMPOSIUM 23:

### **Frontiers in Pediatric Transplantation (Calliope)** (PEDS, DMD, HTX, MCS)

**CHAIRS:** Martin Schweiger, MD and Jennifer Conway, MD

**SESSION SUMMARY:** Heart transplantation during childhood remains a last treatment resort fraught with many risks and subjected to very difficult decisions involving medical, psychosocial and ethical aspects with small case numbers and treatments at the current limits of modern medicine. This session includes some newer and disputed approaches as well as the most challenging ethical aspects of pediatric heart transplantation. In this session, we hope to address the pitfalls and perils of managing pediatric patients with advanced heart failure requiring consideration for transplant or mechanical circulatory support, the limitations and problems of heart and lung transplantation with respect to systemic genetic diseases, such as chromosomal abnormalities or Duchenne's muscular dystrophy, and the roles of alternative therapies such as MCS. Outcomes and quality of life of children who have been transplanted with chromosomal abnormalities and the implications for advanced heart failure management decisions, outcomes of thoracic transplantation with organs from extended criteria heart donors including those with high risk infections, CPR, or other concerning features and to discuss the future of MCS for children, including feasibility of permanent support including total artificial hearts in teenager, algorithm for myocardial recovery testing and the role of MCS therapy in patients with failing, surgically palliated congenital heart disease will also be discussed.

**5:00 PM** *Organ Donor Shortage – How Far Can We Extend the Donor Pool?*

John Dark, MB, FRCS, Freeman Hospital,  
Newcastle upon Tyne, United Kingdom

**5:15 PM** *Q & A*

**5:20 PM** *Antibodies to HLA and Blood Groups: Match, Treat or Ignore for Allocation?*

Simon Urschel, MD, University of Alberta,  
Edmonton, AB, Canada

**5:35 PM** *Q & A*

**5:40 PM** *Thoracic Transplantation in Children with Genetic Abnormalities*

Rachel E. Andrews, MD, Great Ormond Street Hospital,  
London, United Kingdom

**5:55 PM** *Q & A*

**6:00 PM** *Elevated Pulmonary Vascular Resistance in Congenital Heart Disease: LVAD Before or RVAD After Heart Transplantation?*

Holger W. Buchholz, MD, University of Alberta Hospital,  
Edmonton, AB, Canada

**6:15 PM** *Q & A*

**6:20 PM** *Lifetime VAD: A Destination for Children?*

Angela Lorts, MD, Cincinnati Children's Hospital,  
Cincinnati, OH, USA

**6:35 PM** *Q & A*

**6:40 PM** *Facing the Truth: When and How to Include Palliative Care for Children Before and After Transplant and VAD*

Roxanne E. Kirsch, MD, Children's Hospital of Philadelphia,  
Philadelphia, PA, USA

**6:55 PM** *Q & A*

## 5:00 PM – 7:00 PM

### PRE-MEETING SYMPOSIUM 24:

#### Clinically Relevant Thoracic Transplant Pathology: A Primer for Clinicians, Nurses, Pharmacists and Other Members of the Transplant Team (Euterpe) (ALL)

**CHAIRS:** Annalisa Angelini, MD and Carol F. Farver, MD

**SESSION SUMMARY:** The aim of this session will be to provide clinicians, nurses, pharmacists and other allied health members with a tutorial of current criteria, terminology, and classifications of cellular and antibody-mediated rejection of the heart and lung allograft, as well as an update on risk factors and morphologic lesions that constitute chronic allograft rejection in both organs. Appropriate treatment options for each form of rejection will also be discussed. The speakers are all experienced transplant pathologists who have actively participated in the elucidation of current grading schemes.

- 5:00 PM** *Acute Cellular Rejection of the Heart*  
Carmela Tan, MD, Cleveland Clinic, Cleveland, OH, USA
- 5:15 PM** *Q & A*
- 5:20 PM** *Antibody-Mediated Rejection of the Heart*  
Dylan Miller, MD, Intermountain Medical Center,  
Salt Lake City, UT, USA
- 5:35 PM** *Q & A*
- 5:40 PM** *Cardiac Allograft Vasculopathy*  
Claus B. Andersen, MD, DMSc, Rigshospitalet,  
Copenhagen, Denmark
- 5:55 PM** *Q & A*
- 6:00 PM** *Acute Cellular Rejection of the Lung*  
Desley Neil, FRCPath, Queen Elizabeth Hospital,  
Birmingham, United Kingdom
- 6:15 PM** *Q & A*
- 6:20 PM** *Antibody-Mediated Rejection of the Lung*  
Joseph J. Maleszewski, MD, FACC, Mayo Clinic,  
Rochester, MN, USA
- 6:35 PM** *Q & A*
- 6:40 PM** *Chronic Lung Allograft Dysfunction*  
Alexandra Rice, MD, Royal Brompton and Harefield NHS,  
London, United Kingdom
- 6:55 PM** *Q & A*

## 7:00 PM – 8:00 PM

EXHIBIT HALL OPENING RECEPTION (Rhodes)

**MODERATED POSTER SESSION 1** (Agora 2)

## THURSDAY | April 16, 2015

### 7:30 AM – 7:00 PM

Registration Open (Agora 1)

Speaker Ready Room Open (Hermes Lounge)

### 8:00 AM – 9:00 AM

Poster Board Renumbering (Agora 2)

### 8:30 AM – 10:30 AM

#### OPENING PLENARY SESSION

(Apollon)

(ALL)

**CHAIRS:** Hermann Reichenspurner, MD, PhD and  
Andreas Zuckermann, MD

**8:30 AM** *Welcome/Program Chair Report*

Andreas Zuckermann, MD, Medical University of Vienna,  
Vienna, Austria

**8:35 AM** *Thoracic Registry Report*

Josef Stehlik, MD, MPH, University of Utah School of  
Medicine, Salt Lake City, UT, USA

**8:50 AM** *IMACS Registry Report*

James K. Kirklin, MD, University of Alabama at Birmingham,  
Birmingham, AL, USA

**9:00 AM** *Presidential Address: Youth and Enthusiasm –  
Our Obligations Towards the Next Generation*

Hermann Reichenspurner, MD, PhD, University  
Heart Centre Hamburg, Hamburg, Germany

**9:30 AM** *Vision ZERO – Cutting Edge Technology For  
Ultimate Protection*

Wolfgang Müller-Pietralla, Volkswagen Group,  
Wolfsburg, Germany

**9:50 AM** **(1) FEATURED ABSTRACT: HeartWare HVAD for  
the Treatment of Patients With Advanced Heart Failure  
Ineligible for Cardiac Transplantation: Results of the  
ENDURANCE Destination Therapy Trial;**

F. D. Pagani<sup>1</sup>, C. A. Milano<sup>2</sup>, A. J. Tatóoles<sup>3</sup>, G. Bhat<sup>3</sup>, M. S.  
Slaughter<sup>4</sup>, E. J. Birks<sup>4</sup>, S. W. Boyce<sup>5</sup>, S. S. Najjar<sup>5</sup>, V. Jee-  
vanandam<sup>6</sup>, A. S. Anderson<sup>7</sup>, I. D. Gregoric<sup>8</sup>, R. M. Delgado<sup>9</sup>,  
K. Leadley<sup>10</sup>, K. D. Aaronson<sup>1</sup>, J. G. Rogers<sup>2</sup>. <sup>1</sup>University of  
Michigan, Ann Arbor, MI, <sup>2</sup>Duke University School of Medi-  
cine, Durham, NC, <sup>3</sup>Advocate Christ Medical Center, Oak  
Lawn, IL, <sup>4</sup>University of Louisville, Louisville, KY, <sup>5</sup>MedStar  
Heart Institute, Washington, DC, <sup>6</sup>University of Chicago Med-  
icine, Chicago, IL, <sup>7</sup>Northwestern Memorial Hospital, Chicago,  
IL, <sup>8</sup>Surgical Associates of Texas, Houston, TX, <sup>9</sup>Texas Heart  
Institute, Houston, TX, <sup>10</sup>HeartWare, Framingham, MA.

**10:05 AM** *PIONEER LECTURE: From Allogeneic to Xenogeneic  
Heart and Lung Transplantation – A 30 Year Journey*

Bruno Reichart, MD, University of Munich/Grosshadern,  
Munich, Germany

## 9:00 AM – 7:00 PM

Press Office Open (Gallieni 6)

## 10:00 AM – 7:00 PM

EXHIBITS OPEN (Rhodes)

POSTER HALL OPEN (Agora 2)

## 10:30 AM – 11:00 AM

COFFEE BREAK/VISIT EXHIBITS (Rhodes)

VIEW POSTERS (Agora 2)

## 11:00 AM – 12:30 PM

### CONCURRENT SESSION 1

#### Outcomes With Mechanical Circulatory Support

(Apollon)

(MCS, BSI, HF, HTX, NHSAH, PHARM)

**CHAIRS:** Emma Birks, MD, PhD and Gianluca Santise, MD

**11:00 AM (2) *Long Term Support of Patients Receiving an LVAD for Advanced Heart Failure: A Subgroup Analysis of the Registry to Evaluate the HeartWare® Left Ventricular Assist System (The REVOLVE Registry);***

J. D. Schmitto<sup>1</sup>, D. Zimpfer<sup>2</sup>, A. E. Fiane<sup>3</sup>, R. Larbalestier<sup>4</sup>, S. Tsui<sup>5</sup>, P. Jansz<sup>6</sup>, A. Simon<sup>7</sup>, S. Schueler<sup>8</sup>, M. Strueber<sup>9</sup>. <sup>1</sup>Hannover Medical School, Hannover, Germany, <sup>2</sup>Medical University of Vienna, Vienna, Austria, <sup>3</sup>Oslo University Hospital, Oslo, Norway, <sup>4</sup>Royal Perth Hospital, Perth, Australia, <sup>5</sup>Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom, <sup>6</sup>St Vincent's Clinic, Sydney, Australia, <sup>7</sup>Royal Brompton and Harefield Hospital, London, United Kingdom, <sup>8</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>9</sup>University Heart Center Leipzig, Leipzig, Germany

**11:15 AM (3) *A Multi-Institutional Outcome Analysis of Patients Undergoing Left Ventricular Assist Device Implantation Stratified By Sex and Race;***

J. Van Meeteren<sup>1</sup>, S. Maltais<sup>2</sup>, S. Dunlay<sup>3</sup>, N. Haglund<sup>4</sup>, M. E. Davis<sup>2</sup>, F. D. Pagani<sup>5</sup>, K. D. Aaronson<sup>6</sup>, J. Cowger<sup>7</sup>, P. Shah<sup>8</sup>, J. M. Stulak<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>3</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>4</sup>Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>5</sup>Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, <sup>6</sup>Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI, <sup>7</sup>Cardiovascular Diseases, St. Vincent's Health System, Indianapolis, IN, <sup>8</sup>Cardiovascular Diseases, Inova Fairfax, Fairfax, VA

**11:30 AM (4) *The HeartMate II Pump in Clinical Practice – Results From 479 Patients Analyzed in a Retrospective European Multi-Center Study;***

E. V. Potapov<sup>1</sup>, J. Garbade<sup>2</sup>, K. Hakim-Meibodi<sup>3</sup>, M. Strueber<sup>2</sup>, J. Gummert<sup>4</sup>, F. Mohr<sup>2</sup>, V. Falk<sup>1</sup>, T. Krabatsch<sup>1</sup>, M. Morshuis<sup>4</sup>. <sup>1</sup>Thoracic and Cardiovascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Thoracic and Cardiovascular Surgery, Herzzentrum Leipzig, Leipzig, Germany, <sup>3</sup>Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Leipzig, Germany, <sup>4</sup>Thoracic and Cardiovascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany

**11:45 AM (5) *The HeartWare HVAD Pump in Clinical Practice – Results From 1,035 Patients Analyzed in a Retrospective European Multi-Center Study;***

T. Krabatsch<sup>1</sup>, M. Morshuis<sup>2</sup>, J. Garbade<sup>3</sup>, D. Zimpfer<sup>4</sup>, E. Potapov<sup>1</sup>, G. Laufer<sup>4</sup>, F. Mohr<sup>3</sup>, V. Falk<sup>1</sup>, J. Gummert<sup>5</sup>. <sup>1</sup>Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Cardiothoracic and Vascular Surgery, Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany, <sup>3</sup>Herzzentrum Leipzig, Leipzig, Germany, <sup>4</sup>Medizinische Universität Wien, Vienna, Austria, <sup>5</sup>Herz- und Diabeteszentrum Nordrhein-Westfalen, Bad Oeynhausen, Germany

**12:00 PM (6) *Temporal Analysis of Outcomes During Long-Term Mechanical Circulatory Support: An Initial Report From the Mechanical Circulatory Support Research Network;***

S. Maltais<sup>1</sup>, N. A. Haglund<sup>2</sup>, M. E. Davis<sup>3</sup>, M. R. Danter<sup>1</sup>, M. Xu<sup>4</sup>, S. M. Dunlay<sup>5</sup>, J. Cowger<sup>6</sup>, P. Shah<sup>7</sup>, K. D. Aaronson<sup>8</sup>, F. D. Pagan<sup>9</sup>, J. M. Stulak<sup>10</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>5</sup>Cardiovascular Medicine, Mayo Clinic, Rochester, MN, <sup>6</sup>Cardiovascular Medicine, St Vincent Heart, Indianapolis, IN, <sup>7</sup>Cardiovascular Medicine, Inova Fairfax, Falls, VA, <sup>8</sup>Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, <sup>9</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>10</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN

**12:15 PM (7) *Preliminary Results From ITAMACS, the Italian Multi Center Registry for Mechanically Assisted Circulatory Support;***

G. Feltrin<sup>1</sup>, M. Frigerio<sup>2</sup>, L. Martinelli<sup>2</sup>, M. De Bonis<sup>3</sup>, M. Rinaldi<sup>4</sup>, M. Pilato<sup>5</sup>, F. Musumeci<sup>6</sup>, G. Faggian<sup>7</sup>, U. Livi<sup>8</sup>, M. Maccherini<sup>9</sup>, A. Iacovoni<sup>10</sup>, A. Barbone<sup>11</sup>, G. Di Giammarco<sup>12</sup>, C. Maiello<sup>13</sup>, G. Marinelli<sup>14</sup>, F. Alamanni<sup>15</sup>, G. Ambrosio<sup>16</sup>, A. Grimaldi<sup>17</sup>, G. Leonardi<sup>18</sup>, F. Pagani<sup>19</sup>, M. Massetti<sup>20</sup>, L. Rizzato<sup>21</sup>, G. Gerosa<sup>22</sup>, A. Nanni Costa<sup>23</sup>. <sup>1</sup>Veneto Region, Regional Centre for Transplant Coordination, Padova, Italy, <sup>2</sup>De Gasperis Cardiocenter, Ospedale Niguarda Ca'Granda, Milan, Italy, <sup>3</sup>Cardiac Surgery, San Raffaele Vita-Salute University, Milan, Italy, <sup>4</sup>Cardiac Surgery, University of Turin, Città della Salute e della Scienza, Turin, Italy, <sup>5</sup>Department of Cardiothoracic Surgery, ISMETT Mediterranean Institution for Transplant and High Specialty Therapy, Palermo, Italy, <sup>6</sup>Department of Cardiac Surgery, Azienda Ospedaliera San Camillo Forlanini, Roma, Italy, <sup>7</sup>Division of Cardiac Surgery, University of Verona, Verona, Italy, <sup>8</sup>Cardiothoracic Department, University Hospital of Udine, Udine, Italy, <sup>9</sup>Cardiac, Thoracic and Vascular Department, Cardiac Surgery and Transplantation Unit, Siena, Italy, <sup>10</sup>Cardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy, <sup>11</sup>Cardiac Surgery Unit, Humanitas Research Hospital, Milan, Italy, <sup>12</sup>Neuroscienze, Imaging e Scienze Cliniche, Università "G. D'Annunzio" Chieti, Chieti, Italy, <sup>13</sup>Department of Cardiac Surgery, AORN Ospedali dei Colli, Napoli, Italy, <sup>14</sup>Department of Cardiothoracic and Vascular Surgery, Cardiac Surgery and Transplantation Unit, Bologna, Italy, <sup>15</sup>Cardiovascular Surgery Cardiological Center Monzino, University of Milan, Milan, Italy, <sup>16</sup>Cardiothoracic Department, University of Perugia School of Medicine, Perugia, Italy, <sup>17</sup>Cardiac Surgery, University of Bari, Bari, Italy, <sup>18</sup>Department of Cardiology, Azienda Ospedaliero Universitaria "Policlinico - V- Emanuele," Catania, Italy, <sup>19</sup>Cardiac Surgery Department, IRCCS Foundation Policlinico San Matteo, Pavia, Italy, <sup>20</sup>UOC Cardiocirurgia, Università Cattolica del Sacro Cuore, Rome, Italy, <sup>21</sup>Istituto Superiore di Sanità, National Transplant Centre, Rome, Italy, <sup>22</sup>Cardiac, Thoracic and Vascular Sciences, University of Padua Medical School, Padova, Italy, <sup>23</sup>Superior Health Institute, National Transplant Centre, Rome, Italy



11:00 AM – 12:30 PM

CONCURRENT SESSION 2

**Anticoagulation For VADs: How Anticoagulated Do We Need To Be? (Athena)**

(MCS, BSI, HF, NNSAH, PATH, PHARM)

**CHAIRS:** Jeffrey Teuteberg, MD and Anna L. Meyer, MD

**11:00 AM (8) Long Term Outcomes in HeartMate II Patients Managed With Vitamin K Antagonists Without Antiplatelet Therapy – Results of the EU-TRACE Study;**

P. Y. Litzler<sup>1</sup>, J. D. Schmitto<sup>2</sup>, M. Berchtold-Herz<sup>3</sup>, E. Flecher<sup>4</sup>, D. Zimpfer<sup>5</sup>, L. Damme<sup>6</sup>, K. S. Sundareswaran<sup>7</sup>, D. J. Farrar<sup>7</sup>, I. Netuka<sup>8</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Charles Nicolle University Hospital, Rouen, France, <sup>2</sup>Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>3</sup>Department of Cardiovascular Surgery Freiburg, University Heart Center Freiburg-Bad Krozingen, Freiburg, Germany, <sup>4</sup>Department of Thoracic and Cardiovascular Surgery, CHU Pontchaillou, Rennes, France, <sup>5</sup>Department of Cardiothoracic Surgery, University of Vienna, Vienna, Austria, <sup>6</sup>Thoratec Europe Limited, London, United Kingdom, <sup>7</sup>Research and Scientific Affairs, Thoratec Corporation, Pleasanton, CA, <sup>8</sup>Department of Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

**11:15 AM (9) Chronic Management With Reduced Anti-Thrombotic Therapy in HeartMate II Patients With Persistent Bleeding – Results From the US-TRACE Study;**

U. P. Jorde<sup>1</sup>, J. N. Katz<sup>2</sup>, R. John<sup>3</sup>, A. Tatoes<sup>4</sup>, K. Sundareswaran<sup>5</sup>, F. Kalle<sup>5</sup>, D. Farrar<sup>5</sup>, R. M. Adamson<sup>6</sup>. <sup>1</sup>Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY, <sup>2</sup>University of North Carolina, Chapel Hill, NC, <sup>3</sup>University of Minnesota, Minneapolis, MN, <sup>4</sup>Advocate Christ Medical Center, Oak Lawn, IL, <sup>5</sup>Thoratec Corporation, Pleasanton, CA, <sup>6</sup>Sharp Memorial Hospital, San Diego, CA

**11:30 AM (10) LVAD-Associated von Willebrand Factor Degradation Alters Angiogenesis: A Mechanistic Link Between LVAD Support, Gastrointestinal Angiodysplasia, and Bleeding?;**

D. M. Zhang, J. Kang, D. J. Restle, M. A. Acker, P. Atluri, C. R. Bartoli. Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA

**11:45 AM (11) Association of Warfarin Genotype With Thrombosis and Bleeding Events in Continuous-Flow Left Ventricular Assist Device (CF-LVAD) Patients;**

V. K. Topkara<sup>1</sup>, A. Levin<sup>1</sup>, K. Mody<sup>1</sup>, A. Garan<sup>1</sup>, K. O. Ronquillo<sup>2</sup>, M. Tiburcio<sup>2</sup>, J. S. Murphy<sup>2</sup>, G. Parkis<sup>2</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, D. Mancini<sup>1</sup>, Y. Naka<sup>2</sup>, P. C. Colombo<sup>1</sup>, U. P. Jorde<sup>3</sup>. <sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, <sup>3</sup>Cardiology, Montefiore Medical Center, New York, NY

**12:00 PM (12) Thrombophilias Prospective Detection Tailored Anticoagulation Protocol Without Antiplatelet Therapy in Patients With Axial-Flow Ventricular Assist Device;**

I. Netuka<sup>1</sup>, M. Urban<sup>1</sup>, P. Ivak<sup>1</sup>, J. Maly<sup>1</sup>, J. Besik<sup>1</sup>, H. Riha<sup>2</sup>, Z. Dorazilova<sup>3</sup>, M. Hegarova<sup>3</sup>, J. Pirk<sup>1</sup>, O. Szarszo<sup>1</sup>. <sup>1</sup>Dept. Cardiac Surgery, Inst Clinical & Exp Med, Prague, Czech Republic, <sup>2</sup>Dept. of Cardiac Anaesthesia, Inst Clinical & Exp Med, Prague, Czech Republic, <sup>3</sup>Dept. of Cardiology, Inst Clinical & Exp Med, Prague, Czech Republic

**12:15 PM (13) *Blood Product Utilization With Left Ventricular Assist Device Implantation: A Decade of Statewide Data;***

M. A. Quader<sup>1</sup>, L. G. Wolfe<sup>1</sup>, G. Ailawadi<sup>2</sup>, J. B. Rich<sup>3</sup>, A. M. Speir<sup>4</sup>, D. LaPar<sup>2</sup>, C. E. Fonner<sup>3</sup>, V. Kasirajan<sup>1</sup>. <sup>1</sup>Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Division of Thoracic and Cardiovascular Surgery, University of Virginia, Charlottesville, VA, <sup>3</sup>Research & Writing Committee, Virginia Cardiac Surgery Quality Initiative, Washington, DC, <sup>4</sup>Cardiothoracic Surgery, Inova Heart and Vascular Institute, Falls Church, VA

## 11:00 AM – 12:30 PM

### CONCURRENT SESSION 3

#### Choosing the Best Recipients for Lung Transplant in the Era of Urgency (Clio, Thalie)

(LF, LTX, PEDS)

**CHAIRS:** Christopher H. Wigfield, MD, FRCS and Michiel E. Erasmus, MD, PhD

**11:00 AM (14) *Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation Based on Intent to Treat: A Single-Center Experience;***

M. Biscotti<sup>1</sup>, W. D. Gannon<sup>2</sup>, C. Agerstrand<sup>2</sup>, D. Abrams<sup>2</sup>, J. Sonett<sup>1</sup>, D. Brodie<sup>2</sup>, M. Bacchetta<sup>1</sup>. <sup>1</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Pulmonary, Allergy, and Critical Care, Columbia University Medical Center, New York, NY

**11:15 AM (15) *Impact of Diastolic Dysfunction on Primary Graft Dysfunction (PGD) After Lung Transplantation;***

M. K. Porteous<sup>1</sup>, B. Ky<sup>1</sup>, J. Kirkpatrick<sup>1</sup>, T. Plappert<sup>2</sup>, J. M. Diamond<sup>1</sup>, R. J. Shah<sup>1</sup>, M. Brown<sup>2</sup>, J. D. Christie<sup>1</sup>, S. M. Kawut<sup>1</sup>. <sup>1</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA

**11:30 AM (16) *Outcomes of High Emergency for More Than 1000 Lung Transplant Recipients Results of the Cohort of Lung Transplantation (COLT) Study;***

P. Lacoste<sup>1</sup>, A. Tissot<sup>2</sup>, P. Royer<sup>3</sup>, C. Gomez<sup>4</sup>, A. Roux<sup>5</sup>, R. Kessler<sup>6</sup>, C. Dromer<sup>7</sup>, F. Philit<sup>8</sup>, V. Boussaud<sup>9</sup>, C. Pison<sup>10</sup>, S. Mussot<sup>11</sup>, O. Brugière<sup>12</sup>, M. Dahan<sup>13</sup>, C. Knoop<sup>14</sup>, A. Magnan and the COLT consortium<sup>2</sup>. <sup>1</sup>cardio-thoracic surgery, CHU Nantes, Nantes, France, <sup>2</sup>pneumology, CHU Nantes, Nantes, France, <sup>3</sup>Institut du Thorax, Inserm UMR 1087, Nantes, France, <sup>4</sup>Marseille Hospital, Marseille, France, <sup>5</sup>Hopital Foch, Suresnes, France, <sup>6</sup>Nouvel Hopital Civil, Strasbourg, France, <sup>7</sup>Hopital Haut Leveque, Bordeaux, France, <sup>8</sup>Hopital louis Pradel, Lyon, France, <sup>9</sup>Hopital Europeen Georges Pompidou, Paris, France, <sup>10</sup>CHU Grenoble, Grenoble, France, <sup>11</sup>Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, <sup>12</sup>Bichat Hospital, Paris, France, <sup>13</sup>Larrey Hospital, Toulouse, France, <sup>14</sup>Brussels Hospital, Brussels, France

**11:45 AM (17) *Frailty Is Associated With Pre-Operative Delisting and Death in Lung Transplant Candidates;***

J. P. Singer<sup>1</sup>, J. M. Diamond<sup>2</sup>, C. J. Gries<sup>3</sup>, J. McDonnough<sup>4</sup>, P. D. Blanc<sup>1</sup>, R. Shah<sup>2</sup>, M. Y. Dean<sup>1</sup>, B. Hersch<sup>3</sup>, J. Dolan<sup>2</sup>, S. Arcasoy<sup>4</sup>, J. R. Greenland<sup>1</sup>, N. Smith<sup>4</sup>, S. Patterson<sup>3</sup>, L. Shah<sup>4</sup>, J. A. Golden<sup>1</sup>, N. Blumenthal<sup>2</sup>, J. Sonett<sup>4</sup>, S. Hays<sup>1</sup>, M. Oyster<sup>2</sup>, F. D'Ovidio<sup>5</sup>, P. P. Katz<sup>1</sup>, H. Robbins<sup>4</sup>, M. Brown<sup>2</sup>, L. E. Leard<sup>1</sup>, J. Kukreja<sup>6</sup>, M. Bacchetta<sup>5</sup>, M. Rushefski<sup>2</sup>, K. Raza<sup>4</sup>, J. D. Christie<sup>2</sup>, D. J. Lederer<sup>4</sup>. <sup>1</sup>Medicine, UC San Francisco, San Francisco, CA, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Medicine, Columbia, New York, NY, <sup>5</sup>Surgery, Columbia, New York, NY, <sup>6</sup>Surgery, UC San Francisco, San Francisco, CA

**12:00 PM (18) *Association of Thoracic Muscle Cross-Sectional Area and Clinical Outcomes in Lung Transplant Candidates;***

D. Rozenberg<sup>1</sup>, L. G. Singer<sup>1</sup>, P. Mendes<sup>2</sup>, S. Mathur<sup>2</sup>. <sup>1</sup>Medicine, Division of Respiriology, Toronto Lung Transplant Program, University of Toronto, Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Physical Therapy, University of Toronto, Toronto, ON, Canada,

**12:15 PM (19) *Body Mass Index Impacts Short, Intermediate, and Long-Term Survival in Lung Transplantation;***

B. A. Whitson<sup>1</sup>, A. Pope-Harman<sup>2</sup>, P. Lee<sup>1</sup>, A. Kilic<sup>1</sup>, C. B. Sai-Sudhakar<sup>3</sup>, S. Kirkby<sup>4</sup>, R. S. Higgins<sup>1</sup>, J. D. Tobias<sup>5</sup>, D. Hayes, Jr.<sup>4</sup>. <sup>1</sup>Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>2</sup>Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>3</sup>Division of Cardio-Thoracic Surgery, Baylor Scott and White Heart and Vascular Institute, Temple, TX, <sup>4</sup>Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, <sup>5</sup>Department of Anesthesia, Nationwide Children's Hospital, Columbus, OH

**11:00 AM – 12:30 PM**

## CONCURRENT SESSION 4

### Donor Management/Organ Preservation-Heart: Extending the Margins (Erato,Uranie)

(DMD-HEART, HF, HTX)

**CHAIRS:** Christoph Knosalla, MD, PhD and  
Darren Freed, MD, PhD, FRCSC

**11:00 AM (20) *Heart Transplantation From Donors Outside Standard Acceptability Criteria Using Ex-Vivo Normothermic Perfusion: The End of Donor Shortage?;***

D. García Sáez, B. Zych, P. N. Mohite, A. Sabashnikov, F. De Robertis, A. Popov, C. T. Bowles, N. P. Patil, M. Zeriuoh, O. Mauz, T. Pitt, M. Amrani, T. Bahrami, N. R. Banner, A. R. Simon. Harefield Hospital NHS Trust, Harefield, London, United Kingdom

**11:15 AM (21) *Technique of Adult Heart Procurement in the Donation After Circulatory Death Multi-Organ Retrieval Scenario;***

M. Connellan<sup>1</sup>, A. Iyer<sup>1</sup>, H. Chew<sup>1</sup>, C. Soto<sup>1</sup>, E. Granger<sup>1</sup>, P. Jansz<sup>1</sup>, P. Spratt<sup>1</sup>, M. Crawford<sup>2</sup>, D. Verran<sup>2</sup>, H. Pleass<sup>3</sup>, P. MacDonald<sup>1</sup>, K. Dhital<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Unit, St. Vincent 's Hospital, Sydney, Australia, <sup>2</sup>Transplant Institute, Royal Prince Alfred Hospital, Sydney, Australia, <sup>3</sup>Transplant Unit, Westmead Hospital, Sydney, Australia

**11:30 AM (22) *Functional Assessment of the DCD Heart Within the Donor and Ex-Vivo;***

S. Messer<sup>1</sup>, R. Axell<sup>2</sup>, P. White<sup>2</sup>, M. Roman<sup>1</sup>, S. Colah<sup>3</sup>, A. Ali<sup>1</sup>, S. Large<sup>4</sup>. <sup>1</sup>Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, <sup>2</sup>Clinical Engineering, Addenbrookes Hospital, Cambridgeshire, United Kingdom, <sup>3</sup>Cambridge Perfusion Service, Papworth Hospital, Cambridgeshire, United Kingdom, <sup>4</sup>Cardiothoracic Surgery, Papworth Hospital, Cambridgeshire, United Kingdom

**11:45 AM (23) *Shorter Cold Ischemic Time in Older Donors Post-Heart Transplant Appears to Be Protective;***

F. Esmailian, J. Patel, M. Kittleson, T. Kao, F. Liou, S. Siddiqui, B. Azarbal, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**12:00 PM (24) *Donor Under Sizing Results in Worse Post-Transplant Survival in LVAD Patients: A UNOS Database Analysis;***

E. M. Schumer<sup>1</sup>, J. R. Trivedi<sup>1</sup>, E. J. Birks<sup>2</sup>, A. J. Lenneman<sup>2</sup>, A. Cheng<sup>1</sup>, M. S. Slaughter<sup>1</sup>. <sup>1</sup>Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, <sup>2</sup>Department of Medicine, Cardiovascular Medicine, University of Louisville, Louisville, KY

**12:15 PM (25) *Do Donor Lifestyle Choices and Polysubstance Abuse Affect Long Term Survival in Heart Transplant Recipients?;***

Y. Ravi<sup>1</sup>, S. Bansal<sup>2</sup>, K. Jeong<sup>3</sup>, S. Emani<sup>4</sup>, B. Whitson<sup>5</sup>, C. Tong<sup>6</sup>, C. B. Sai-Sudhakar<sup>1</sup>. <sup>1</sup>Cardio-Thoracic Surgery, Baylor-Scott & White, Temple, TX, <sup>2</sup>Cardio-Thoracic Surgery, Mayo Clinic Florida, Jacksonville, FL, <sup>3</sup>Department of Bio-Statistics, University of Pittsburg, PA, PA, <sup>4</sup>Cardiology, The Ohio State University, Columbus, OH, <sup>5</sup>Cardio-Thoracic Surgery, The Ohio State University, Columbus, OH, <sup>6</sup>Cardiology, Baylor-Scott & White, Temple, TX

11:00 AM – 12:30 PM

CONCURRENT SESSION 5

JFTC Clinical Case Dilemmas: The Best of the Best

(Hermes)

(ALL)

**CHAIRS:** Marian Urban, MD and Pali Shah, MD

**11:00 AM (26) *Fatal Fulminant Accelerated Rejection in a Cardiac Transplant Recipient With Natural Killer Cell Infiltrate;***

A. R. Wang<sup>1</sup>, A. Javaheri<sup>2</sup>, E. L. Prak<sup>1</sup>, P. Lal<sup>1</sup>, Z. Arany<sup>2</sup>, M. Jessup<sup>2</sup>, M. Kamoun<sup>1</sup>. <sup>1</sup>Department of Pathology and Laboratory Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Internal Medicine, Cardiovascular Division, Hospital of the University of Pennsylvania, Philadelphia, PA

**11:10 AM EXPERT DISCUSSANT:**

Dolly B Tyan, PhD, Stanford University, Palo Alto, CA, USA

**11:18 AM (27) *Autoantibodies Against Lung Tissue Can Cause Hyper Acute as Well as Acute Antibody Mediated Rejection Following Lung Transplantation;***

A. Bharat<sup>1</sup>, N. Steward<sup>2</sup>, M. M. DeCamp<sup>1</sup>, P. Garcha<sup>3</sup>, S. Bhorade<sup>4</sup>, M. Ison<sup>5</sup>, T. Mohanakumar<sup>2</sup>, C. Farver<sup>6</sup>, M. Askar<sup>7</sup>, M. Budev<sup>3</sup>. <sup>1</sup>Thoracic Surgery, Northwestern Univ, Chicago, IL, <sup>2</sup>Surgery, Washington University, St Louis, MO, <sup>3</sup>Pulmonary, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Pulmonary, Northwestern Univ, Chicago, IL, <sup>5</sup>Infectious Diseases, Northwestern Univ, Chicago, IL, <sup>6</sup>Pathology, Cleveland Clinic, Cleveland, OH, <sup>7</sup>Cleveland Clinic, Cleveland, OH

**11:28 AM EXPERT DISCUSSANT:**

Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

**11:36 AM (28) *Successful Treatment of Severe Acute Graft Versus Host Disease Post Lung Transplantation;***

A. Ataya, A. Biswas, S. Chandrashekar, J. C. Salgado, A. Emtiazjoo. Lung Transplantation Program, Division of Pulmonary, Sleep and Critical Care Medicine, University of Florida, Gainesville, FL

**11:46 AM EXPERT DISCUSSANT:**

Stuart C Sweet, MD, PhD, St. Louis Children's Hospital, St. Louis, MO, USA

**11:54 AM (29) *Breaking Bad: Dissimulated Amphetamine Abuse as a Rare Cause of Recurrent LVAD Pump Thrombosis;***

C. Heim, M. Weyand, R. Tandler. University of Erlangen Department of Cardiac Surgery, Erlangen, Germany

**12:04 PM EXPERT DISCUSSANT:**

Martin Strueber, MD, PhD, Spectrum Health Hospital, Grand Rapids, MI, USA

**12:12 PM (30) *A Case of Reversible Pulmonary Hypertension: Culprit in the Kidney;***

L. Letarte, Z. Wang, G. Ruiz, S. S. Najjar, D. T. Majure. MedStar Heart Institute, Washington, DC

**12:22 PM EXPERT DISCUSSANT:**

Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA, USA

**11:00 AM – 12:30 PM**

## CONCURRENT SESSION 6

### Collected Experience: What Can We Learn from the Registries? (Calliope)

(PEDS, DMD, HF, HTX, ID, MCS, NNSAH, PEEQ)

**CHAIRS:** Charles E. Canter, MD and Dimpna C. Albert, MD

**11:00 AM (31) *Comparison of Transplant Waitlist Outcomes for Pediatric Candidates Supported By Ventricular Assist Devices vs. Medical Therapy Alone;***

S. Law<sup>1</sup>, A. Oron<sup>2</sup>, M. Kemna<sup>3</sup>, E. Albers<sup>3</sup>, D. McMullan<sup>3</sup>, J. Chen<sup>4</sup>, Y. Law<sup>3</sup>. <sup>1</sup>Columbia University College of Physicians and Surgeons, New York, NY, <sup>2</sup>Seattle Children's Research Institute, Seattle, WA, <sup>3</sup>Seattle Children's Hospital, Seattle, WA, <sup>4</sup>Seattle Children's Hospital, New York, WA

**11:15 AM (32) *Recipient-Donor Height Ratio and Outcomes in Pediatric Heart Transplantation;***

A. Patel<sup>1</sup>, M. J. Bock<sup>2</sup>, A. Wollstein<sup>1</sup>, K. Nguyen<sup>3</sup>, S. Malerba<sup>1</sup>, I. D. Lytrivi<sup>1</sup>. <sup>1</sup>Pediatrics, Mt Sinai Med Ctr, New York, NY, <sup>2</sup>Pediatrics, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>3</sup>Cardiothoracic Surgery, Mt Sinai Med Ctr, New York, NY

**11:30 AM (33) *Donor to Recipient Age Difference in Weight-Matched Pediatric Heart Transplants Predicts Mortality;***

F. Zafar<sup>1</sup>, M. S. Khan<sup>1</sup>, C. D. Castleberry<sup>2</sup>, R. Bryant<sup>1</sup>, C. Chin<sup>2</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital Med Ctr, Cincinnati, OH, <sup>2</sup>Cardiology, Cincinnati Children's Hospital Med Ctr, Cincinnati, OH

**11:45 AM (34) *The Impact of Ischemic Time on Early Rejection After Pediatric Heart Transplant;***

H. S. Magdo, J. M. Friedland-Little, S. Yu, R. J. Gajarski, K. S. Schumacher. Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI,

**12:00 PM (35) *High BMI Predicts Poor Outcomes in DCM But Not CHD Patients: The Differential Impact of Obesity on Outcomes in Pediatric Heart Transplantation;***

R. R. Davies, S. S. Gidding, M. A. McCulloch, S. Haldeman, C. Pizarro. Nemours Cardiac Center, Nemours Cardiac Center Lucile Packard Children's Hospital, Wilmington, DE

**12:15 PM (36) *United States Trends in Pediatric Heart Transplantation: Are We Busier or Does It Just Feel That Way?;***

K. Maeda, D. N. Rosenthal, E. Liu, N. McDonald, B. Kaufman, K. Jensen, L. Barkoff, L. N. Doan, M. E. Burge, L. Mikula Schneider, D. Bernstein, C. Almond. Stanford University, Stanford, CA

11:00 AM – 12:30 PM

CONCURRENT SESSION 7

**Supporting the MCS Patient and Caregiver (Euterpe)**  
(NLSAH, HF, HTX, MCS)

**CHAIRS:** Annette DeVito Dabbs, PhD, RN and Fabienne Dobbels, MSc, PhD

**11:00 AM (37) *Quality of Life and Burden in Caregivers at 3 Months After Left Ventricular Assist Device Implantation;***

N. Kato<sup>1</sup>, T. Jaarsma<sup>1</sup>, I. Okada<sup>2</sup>, Y. Kagami<sup>3</sup>, M. Endo<sup>3</sup>, M. Ono<sup>4</sup>, K. Kinugawa<sup>2</sup>. <sup>1</sup>Social and Welfare Studies, Linköping University, Norrköping, Sweden, <sup>2</sup>Therapeutic Strategy for Heart Failure, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, <sup>3</sup>Organ Transplantation, The University of Tokyo Hospital, Tokyo, Japan, <sup>4</sup>Cardiovascular Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan

**11:15 AM (38) *Mechanical Circulatory Support (MCS) Caregivers After Hospital Discharge: How Do They Want to Be Supported?;***

M. G. Petty<sup>1</sup>, D. Christensen<sup>2</sup>. <sup>1</sup>University of Minnesota Medical Center, Minneapolis, MN, <sup>2</sup>Innovative Program Solutions, LLC, Pine Grove, PA

**11:30 AM (39) *Pre-Hospital Care for VAD Patients: Where Are the Gaps?;***

K. R. Powell<sup>1</sup>, M. P. Flattery<sup>1</sup>, L. F. Ceil<sup>1</sup>, S. P. Pinney<sup>2</sup>, M. Pemberdy<sup>1</sup>, K. B. Shah<sup>1</sup>. <sup>1</sup>Pauley Heart Center, Va Commonwealth Univ, Richmond, VA, <sup>2</sup>Division of Cardiology, Mount Sinai Hospital, New York, NY

**11:45 AM (40) *Use of Facebook as a Virtual Community and Support Group By Left Ventricular Assist Device (LVAD) Patients;***

B. Boling, A. Hart, T. Halcomb, P. El-Mallakh. University of Kentucky UK HealthCare, Lexington, KY

**12:00 PM (41) *Evolution of Depressive Symptomatology and Caregiver Burden in Partners of LVAD Patients;***

H. Bollen<sup>1</sup>, K. Vandersmissen<sup>1</sup>, J. Driesen<sup>1</sup>, S. Mijten<sup>1</sup>, W. Droogné<sup>2</sup>, B. Meyns<sup>1</sup>, F. Dobbels<sup>3</sup>. <sup>1</sup>Cardiac Surgery, UZ Leuven, Leuven, Belgium, <sup>2</sup>Cardiology, UZ Leuven, Leuven, Belgium, <sup>3</sup>KULeuven, Leuven, Belgium

**12:15 PM (42) *Improving Bone Health in Children Supported on Ventricular Assist Devices;***

B. Hawkins, J. Nobrega, S. Reidy, F. Fynn-Thompson, C. J. VanderPluym. Cardiology, Boston Children's Hospital, Boston, MA



## **12:30 PM – 2:30 PM**

LUNCH BREAK

**JUNIOR FACULTY MENTOR LUNCH** (Gallieni 1)

## **12:30 PM – 1:30 PM**

BOX LUNCH DISTRIBUTION (Rhodes)

**DCD REGISTRY MEETING** (Gallieni 3)

## **12:45 PM – 1:45 PM**

**BASIC SCIENCE AND TRANSLATIONAL  
RESEARCH SCIENTIFIC COUNCIL MEETING** (Gallieni 4)

**NURSING, HEALTH SCIENCE AND ALLIED  
HEALTH SCIENTIFIC COUNCIL MEETING** (Gallieni 7)

**PHARMACY AND PHARMACOLOGY  
SCIENTIFIC COUNCIL MEETING** (Gallieni 5)

## **1:30 PM – 2:30 PM**

**REGISTRIES AND DATABASES  
COMMITTEE MEETING** (Gallieni 3)



2:30 PM – 4:00 PM

CONCURRENT SESSION 8

**LVADs – Pre-Operative Factors Affecting Post-Operative Outcomes (Apollon)**

(MCS, BSI, HF, HTX, NHSAH)

**CHAIRS:** Claudius Mahr, DO and Andrew J. Lenneman, MD

**2:30 PM (43) Risk Assessment for HeartWare HVAD Support as a Bridge to Transplant: Is the HeartMate II Risk Score Applicable?;**

L. Castle<sup>1</sup>, K. Aaronson<sup>2</sup>, M. Slaughter<sup>3</sup>, C. Salerno<sup>1</sup>, S. Moainie<sup>1</sup>, M. Walsh<sup>1</sup>, J. Cowger<sup>1</sup>. <sup>1</sup>St. Vincent Hospital, Indianapolis, IN, <sup>2</sup>University of Michigan Health System, Ann Arbor, MI, <sup>3</sup>University of Louisville, Louisville, KY

**2:45 PM (44) Predictors of Late Survival Following Continuous-Flow Left Ventricular Assist Devices;**

S. K. Singh, J. Anand, R. M. Shah, L. Simpson, W. E. Cohn, A. B. Civitello, H. R. Mallidi. Transplant and Assist Devices, Baylor College of Medicine, Houston, TX

**3:00 PM (45) Gender Differences in Mechanical Circulatory Support – Insights From a European Registry;**

A. M. Bernhardt<sup>1</sup>, B. Sill<sup>1</sup>, F. M. Wagner<sup>1</sup>, T. M. deBy<sup>2</sup>, J. Gummert<sup>3</sup>, P. Mohacsi<sup>4</sup>, H. Reichenspurner<sup>1</sup>, T. Deuse<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany, <sup>2</sup>EUROMACS, Berlin, Germany, <sup>3</sup>Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany, <sup>4</sup>Clinic of Cardiology, University Hospital Bern, Bern, Switzerland

**3:15 PM (46) Characteristics and Outcomes in Patients Receiving Mechanical Circulatory Support With a History of Diabetes;**

R. S. Cantor, MSPH<sup>1</sup>, S. V. Pamboukian, MD, MSPH<sup>2</sup>, J. A. Tallaj, MD<sup>2</sup>, D. C. Naftel, PhD<sup>1</sup>, J. K. Kirklin, MD<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL

**3:30 PM (47) Inclusion of Cognitive and Mood Domains in the Assessment of Frailty Enhances Outcome Prediction in Patients Undergoing Ventricular Assist Device Implantation;**

M. K. Hannu<sup>1</sup>, S. Jha<sup>2</sup>, K. Wilhelm<sup>3</sup>, E. Montgomery<sup>2</sup>, P. Tunnicliff<sup>2</sup>, S. Shaw<sup>2</sup>, C. Hayward<sup>2</sup>, M. Harkess<sup>2</sup>, E. Kotlyar<sup>2</sup>, A. Jabbour<sup>2</sup>, A. M. Keogh<sup>2</sup>, E. Granger<sup>2</sup>, K. Dhital<sup>2</sup>, P. C. Jansz<sup>2</sup>, P. Newton<sup>4</sup>, D. Robson<sup>2</sup>, P. MacDonald<sup>5</sup>, P. M. Spratt<sup>2</sup>. <sup>1</sup>Occupational Therapy, St. Vincent's Hospital, Sydney, Australia, <sup>2</sup>Heart & Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, <sup>3</sup>Psychiatry, St. Vincent's Hospital, Sydney, Australia, <sup>4</sup>Health Science, Univeristy of Technology, Sydney, Australia, <sup>5</sup>St. Vincent's Hospital, Sydney, Australia

**3:45 PM (48) Postoperative Liver Dysfunction Adversely Affects Survival After Continuous Flow LVAD Placement;**

K. Majumder<sup>1</sup>, L. Harvey<sup>1</sup>, S. Roy<sup>1</sup>, C. Holley<sup>1</sup>, P. M. Eckman<sup>2</sup>, K. Liao<sup>1</sup>, R. John<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Division of Cardiology, Department of Medicine, University of Minnesota, Minneapolis, MN

2:30 PM – 4:00 PM

## CONCURRENT SESSION 9

### Drivelines and Device Malfunction (Athena)

(MCS, HF, HTX, NNSAH, ID)

**CHAIRS:** Jan D. Schmitto, MD, PhD, MBA and  
Steven W. Boyce, MD

**2:30 PM (49) *Device Malfunction in Contemporary Rotary Blood Pumps: The Relevant Burden of All Components;***

R. L. Kormos<sup>1</sup>, M. McCall<sup>2</sup>, R. D. Schaub<sup>2</sup>, K. L. Lockard<sup>1</sup>, C. A. Bermudez<sup>1</sup>, N. M. Kunz<sup>1</sup>, E. M. Dunn<sup>1</sup>, L. F. Lagazzi<sup>1</sup>, J. J. Teuteberg<sup>1</sup>. <sup>1</sup>Heart and Vascular Institute, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, <sup>2</sup>Bioengineering, Univ of Pittsburgh Med Ctr, Pittsburgh, PA

**2:45 PM (50) *Outcomes of External Repair of HeartMate II Percutaneous Leads;***

J. D. Pal<sup>1</sup>, J. W. Smith<sup>1</sup>, T. Dardas<sup>2</sup>, C. Mahr<sup>2</sup>, D. J. Farrar<sup>3</sup>, J. Pinette<sup>3</sup>, N. A. Mokadam<sup>1</sup>. <sup>1</sup>Surgery, Univ of Washington, Seattle, WA, <sup>2</sup>Medicine, Univ of Washington, Seattle, WA, <sup>3</sup>Thoratec Corporation, Pleasanton, CA

**3:00 PM (51) *Driveline Infection Is Not Associated With Increased Risk of Thrombotic Events in CF-LVAD Patients;***

J. Fried<sup>1</sup>, B. Cagliostro<sup>1</sup>, A. Levin<sup>1</sup>, O. Wever-Pinzon<sup>1</sup>, A. R. Garan<sup>1</sup>, R. Te-Frey<sup>1</sup>, K. O. Ronquillo<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, D. M. Mancini<sup>1</sup>, Y. Naka<sup>1</sup>, P. C. Colombo<sup>1</sup>, U. Jorde<sup>2</sup>, N. Uriel<sup>3</sup>, V. Topkara<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Cardiology, Montefiore, New York, NY, <sup>3</sup>Cardiology, University of Chicago, Chicago, IL

**3:15 PM (52) *The Impact of Inflow Cannula Misalignment on Unloading in Patients With a Ventricular Assist Device;***

C. Swinney, A. Itoh, A. Keith, K. Balsara, S. Silvestry. Cardiovascular Surgery, Washington University School of Medicine, St. Louis, MO

**3:30 PM (53) *Does Device Type Differentially Influence Pulmonary Vascular Resistance in Patients Bridged to Transplantation With a Continuous Flow Left Ventricular Assist Device?;***

L. Doss<sup>1</sup>, M. E. Davis<sup>2</sup>, M. Djunaidi<sup>2</sup>, M. Ruel<sup>3</sup>, S. Maltais<sup>2</sup>, N. A. Haglund<sup>1</sup>. <sup>1</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>University of Ottawa Heart Institute, Ottawa, ON, Canada

**3:45 PM (54) *Ventricular Assist Device in Acute Myocardial Infarction-Findings From INTERMACS;***

D. Acharya<sup>1</sup>, R. Y. Loyaga-Rendon<sup>2</sup>, J. A. Tallaj<sup>2</sup>, S. V. Pamboukian<sup>2</sup>, W. L. Holman<sup>3</sup>, J. F. George<sup>3</sup>, R. S. Cantor<sup>3</sup>, D. C. Naftel<sup>3</sup>, J. K. Kirklin<sup>3</sup>. <sup>1</sup>Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL

2:30 PM – 4:00 PM

CONCURRENT SESSION 10

**Lung CLAD I: Translational Insights and Novel Markers (Clio, Thalie)**

(LTX, BSI, LF, PATH, PEDS)

**CHAIRS:** Marie M. Budev, DO, MPH and Erik A.M. Verschuuren, MD, PhD

(55) *WITHDRAWN*

**2:30 PM (364) Lung Transplant Recipients Carrying rs2241880 GG Genotype of the Autophagy Gene ATG16L1 Are at Accelerated Risk for BOS Development;**

C. Chen<sup>1</sup>, C. Santos<sup>1</sup>, H. J. Huang<sup>2</sup>, A. E. Gelman<sup>3</sup>. <sup>1</sup>Medicine, Washington Univ Sch Med, St. Louis, MO, <sup>2</sup>Medicine, Baylor University Medical Center at Dallas, St. Louis, MO, <sup>3</sup>Surgery, Washington Univ Sch Med, St. Louis, MO

**2:45 PM (56) Soluble CD59 Is a Novel Biomarker for the Prediction of the Bronchiolitis Obliterans Syndrome After Lung Transplantation;**

K. Budding<sup>1</sup>, E. A. van de Graaf<sup>2</sup>, T. Kardol-Hoefnagel<sup>1</sup>, J. M. Kwakkel-van Erp<sup>2</sup>, B. Luijk<sup>2</sup>, E. D. Oudijk<sup>3</sup>, D. A. van Kessel<sup>3</sup>, J. C. Grutters<sup>3</sup>, C. E. Hack<sup>1</sup>, H. G. Otten<sup>1</sup>. <sup>1</sup>Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, <sup>2</sup>Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, <sup>3</sup>Center of Interstitial Lung Diseases, St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands

**3:00 PM (57) The Role of B-Cells in Phenotypes of Chronic Lung Allograft Dysfunction;**

E. Vandermeulen, S. E. Verleden, D. Ruttens, H. Bellon, J. Somers, D. E. Van Raemdonck, L. J. Dupont, D. Schols, R. Vos, G. M. Verleden, B. M. Vanaudenaerde. Department of Pneumology, KULeuven, Leuven, Belgium

**3:15 PM (58) New Predictive Proteic Biomarkers of Chronic Lung Allograft Dysfunction Identified in SysCLAD FP-7 Project;**

J. Claustre<sup>1</sup>, C. Trocmé<sup>2</sup>, S. Bourgoin-Voillard<sup>3</sup>, H. Flamant-Waret<sup>3</sup>, I. Bérard<sup>3</sup>, B. Toussaint<sup>2</sup>, K. Botturi<sup>4</sup>, A. Magnan<sup>4</sup>, L. P. Nicod<sup>5</sup>, C. Pison<sup>6</sup>, M. Seve<sup>3</sup>, S. Consortium<sup>7</sup>. <sup>1</sup>CHU de Grenoble, Grenoble, France, <sup>2</sup>Laboratoire BEP, TIMC-IMAG, CHU de Grenoble, Grenoble, France, <sup>3</sup>Prométhée Proteomic Platform, INSERM - IAB, Grenoble, France, <sup>4</sup>Institut du Thorax, CHU de Nantes, Nantes, France, <sup>5</sup>Service de Pneumologie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, <sup>6</sup>Clinique Universitaire de Pneumologie, CHU de Grenoble, Grenoble, France, <sup>7</sup>FP-7 EU funded project, Lyon, France

**3:30 PM (59) Transbronchial Brush (Tbbr) Reliably Quantifies Lymphocytic Bronchiolitis and Predicts Subsequent Chronic Lung Allograft Dysfunction;**

S. T. Yerkovich, L. Samson, K. Sinclair, M. Tan, H. Gallagher, A. Fiene, P. Hopkins, D. Chambers. The Prince Charles Hospital, Brisbane, Australia

**3:45 PM (60) Differential Airway Involvement in Restrictive Phenotypes of Chronic Lung Allograft Dysfunction;**

S. E. Verleden<sup>1</sup>, R. Vos<sup>1</sup>, D. Ruttens<sup>1</sup>, E. Vandermeulen<sup>1</sup>, H. Bellon<sup>1</sup>, J. McDonough<sup>1</sup>, E. Verbeken<sup>1</sup>, J. Verschakelen<sup>1</sup>, D. E. Van Raemdonck<sup>1</sup>, B. Rondelet<sup>2</sup>, C. Knoop<sup>3</sup>, J. Hogg<sup>4</sup>, G. Verleden<sup>1</sup>, B. M. Vanaudenaerde<sup>1</sup>. <sup>1</sup>Department of Clinical and Experimental Medicine, Division of Pneumology, KU Leuven, Leuven, Belgium, <sup>2</sup>Unité de Transplantation Cardiaque et Pulmonaire, Université Libre de Bruxelles, Brussel, Belgium, <sup>3</sup>Unité de Transplantation Cardiaque et Pulmonaire, Université Libre de Bruxelles, Brussels, Belgium, <sup>4</sup>Center for Heart and Lung Innovation, University of British Columbia, Vancouver, DC, Canada

**2:30 PM – 4:00 PM**

## CONCURRENT SESSION 11

### **New Tools in the Fight Against Rejection (Erato,Uranie) (HTX, DMD, ID, NNSAH, PATH, PEDS, PHARM)**

**CHAIRS:** Michal Zakliczynski, MD and Tuvia Ben Gal, MD

**2:30 PM (61) *Plasmapheresis and Bortezomib for Sensitized Patients Awaiting Heart Transplantation – Worth the Effort?***

J. Patel, N. Reinsmoen, M. Kittleson, D. Dilibero, F. Liou, D. H. Chang, M. Hamilton, L. Czer, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**2:45 PM (62) *Terminal Complement Inhibition for Highly Sensitized Patients Undergoing Heart Transplantation – Doable?***

J. Patel, D. Dilibero, M. Kittleson, S. Sana, F. Liou, D. H. Chang, A. Hage, L. Czer, A. Trento, N. Reinsmoen, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**3:00 PM (63) *Personalized Therapeutic Use of Intravenous Immunoglobulin in Heart Recipients With Severe Infections and IgG Hypogammaglobulinemia: Impact on Clinical Outcomes;***

J. Carbone<sup>1</sup>, P. Diez<sup>2</sup>, J. Fernandez-Yañez<sup>2</sup>, J. Palomo<sup>2</sup>, P. Muñoz<sup>3</sup>, J. Hortal<sup>4</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>3</sup>Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>4</sup>Anesthesiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

**3:15 PM (64) *Increased Plasma Levels of Donor-Derived Cell-Free DNA Correlate With Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial;***

M. Crespo-Leiro<sup>1</sup>, A. Zuckermann<sup>2</sup>, J. Stypmann<sup>3</sup>, P. Mohacsi<sup>4</sup>, M. Grskovic<sup>5</sup>, J. Beausang<sup>5</sup>, D. Hiller<sup>5</sup>, R. Sit<sup>5</sup>, B. Christie<sup>5</sup>, J. Elechko<sup>5</sup>, R. Woodward<sup>5</sup>, J. Yee<sup>5</sup>, J. Vanhaecke<sup>6</sup>. <sup>1</sup>Hospital Universitario A Coruña, La Coruña, Spain, <sup>2</sup>Medical University of Vienna, Vienna, Austria, <sup>3</sup>University Hospital Münster, Münster, Germany, <sup>4</sup>University Hospital Bern, Bern, Switzerland, <sup>5</sup>CareDx, Inc, Brisbane, CA, <sup>6</sup>University Hospital Leuven, Leuven, Belgium

**3:30 PM (65) *Multicentre Study to Evaluate Conversion From Standard-Release Tacrolimus (SRT) to Extended-Release Tacrolimus (ERT) in a Large Series of Heart Transplanted Patients;***

F. J. Gonzalez Vilchez<sup>1</sup>, M. Crespo-Leiro<sup>2</sup>, J. Palomo<sup>3</sup>, S. Mirabet<sup>4</sup>, B. Diaz Molina<sup>5</sup>, L. Almenar<sup>6</sup>, J. M. Arizon<sup>7</sup>, D. Rangel<sup>8</sup>, F. Perez Villa<sup>9</sup>, J. F. Delgado<sup>10</sup>, I. Garrido<sup>11</sup>, L. de la Fuente<sup>12</sup>, M. Gomez Bueno<sup>13</sup>, M. L. Sanz<sup>14</sup>. <sup>1</sup>Cardiology, H.U. Marques de Valdecilla, Santander, Spain, <sup>2</sup>CHU A Coruña, A Coruña, Spain, <sup>3</sup>Cardiology, H.U. Gregorio Marañón, Madrid, Spain, <sup>4</sup>H.U. Sant Pau, Barcelona, Spain, <sup>5</sup>H.U. C. de Asturias, Oviedo, Spain, <sup>6</sup>H.U. La Fe, Valencia, Spain, <sup>7</sup>H.U. Reina Sofia, Cordoba, Spain, <sup>8</sup>H.U. Virgen del Rocío, Sevilla, Spain, <sup>9</sup>H.Clinic i Provincial, Barcelona, Spain, <sup>10</sup>H. de Octubre, Madrid, Spain, <sup>11</sup>H.U. Virgen de la Arrixaca, Murcia, Spain, <sup>12</sup>H.U. Clinico de Valladolid, Valladolid, Spain, <sup>13</sup>H.U. Puerto de Hierro, Madrid, Spain, <sup>14</sup>H.U. Miguel Servet, Zaragoza, Spain

3:45 PM **(66)** *The Effect of Everolimus Initiation and Calcineurin Inhibitor Reduction on Allograft Vasculopathy in Maintenance Heart Transplant Recipients: Results of the NOCTET Trial After 5 Years;* S. Arora<sup>1</sup>, K. Karason<sup>2</sup>, H. Eijsjær<sup>3</sup>, H. Bøtker<sup>3</sup>, F. Gustafsson<sup>4</sup>, K. Saunamäki<sup>5</sup>, G. Radegran<sup>6</sup>, E. Gude<sup>1</sup>, L. Aaberge<sup>1</sup>, T. Ueland<sup>7</sup>, P. Aukrust<sup>7</sup>, D. Solbu<sup>8</sup>, L. Gullestad<sup>1</sup>. <sup>1</sup>Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>2</sup>Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Cardiology, Skejby University Hospital, Aarhus, Denmark, <sup>4</sup>Cardiology, Rigshospitalet, Copenhagen, Djibouti, <sup>5</sup>Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>6</sup>Cardiology, Lund Hospital, Lund, Sweden, <sup>7</sup>Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>8</sup>Novartis Norge, Oslo, Norway



2:30 PM – 4:00 PM

## CONCURRENT SESSION 12

### Donor Management/Organ Preservation-Heart: Lessons from the Registries (Hermes)

(DMD-HEART, HTX)

**CHAIRS:** Ugolino Livi, MD and Rajamiyer Venkateswaran, FRCS

**2:30 PM (67) Heart Transplant Survival Based on Recipient and Donor Risk Scoring: A UNOS Database Analysis;**

J. R. Trivedi<sup>1</sup>, M. Ising<sup>1</sup>, A. Cheng<sup>1</sup>, A. Lenneman<sup>2</sup>, E. Birks<sup>2</sup>, M. S. Slaughter<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, <sup>2</sup>Cardiovascular Medicine, University of Louisville, Louisville, KY

**2:45 PM (68) Virtual Size Matching in Heart Transplantation: Novel Method Outperforms Weight-Based Matching;**

Z. Taimeh<sup>1</sup>, S. Duval<sup>1</sup>, C. Martin<sup>2</sup>, P. Eckman<sup>1</sup>. <sup>1</sup>Cardiovascular Medicine, University of Minnesota School of Medicine, Minneapolis, MN, <sup>2</sup>Cardiovascular Medicine, University of Minnesota School of Medicine, Minneapolis, MN

**3:00 PM (69) Cardiac Donor Characteristics Predictive of One Year Post-Heart Transplant Mortality: Analysis of the UNOS Transplant Database;**

R. A. Sorabella<sup>1</sup>, M. Najjar<sup>1</sup>, E. Castillero<sup>1</sup>, A. Kantor<sup>1</sup>, A. Liu<sup>1</sup>, V. Topkara<sup>2</sup>, P. Colombo<sup>2</sup>, M. Farr<sup>2</sup>, H. Takayama<sup>1</sup>, P. C. Schulze<sup>2</sup>, D. Mancini<sup>2</sup>, Y. Naka<sup>1</sup>, I. George<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY, <sup>2</sup>Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

**3:15 PM (70) Transplantation of Center for Disease Control “High Risk” Donor Hearts Does Not Adversely Impact Long Term Outcomes in Adults;**

A. C. Gaffey<sup>1</sup>, A. J. Cucchiara<sup>2</sup>, G. Hung<sup>1</sup>, L. R. Goldberg<sup>3</sup>, E. A. Blumberg<sup>4</sup>, M. A. Acker<sup>1</sup>, P. Atlrui<sup>1</sup>. <sup>1</sup>Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Institute for Translational Medicine & Therapeutics; Clinical & Translational Research Center, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Division of Infectious Disease, Department of Medicine, University of Pennsylvania, Philadelphia, PA

**3:30 PM (71) Does Lung Donation By Heart Donors Impact Survival in Heart Transplant Recipients?;**

Y. Xia<sup>1</sup>, P. Friedmann<sup>2</sup>, R. Bello<sup>1</sup>, D. Goldstein<sup>1</sup>, D. D'Alessandro<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Albert Einstein College of Medicine, Bronx, NY

**3:45 PM (72) Prediction of Primary Graft Dysfunction After Heart Transplantation;**

J. Nilsson<sup>1</sup>, M. Ohlsson<sup>2</sup>, J. Stehlik<sup>3</sup>, L. Lund<sup>4</sup>, B. Andersson<sup>5</sup>. <sup>1</sup>Clinical Sciences Lund, Cardiothoracic Surgery, Lund University and Skane University Hospital, Lund, Sweden, <sup>2</sup>Astronomy and Theoretical Physics, Computational Biology and Biological Physics, Lund University, Lund, Sweden, <sup>3</sup>Cardiovascular Medicine, University of Utah School of Medicine, Utah, UT, <sup>4</sup>Medicine, Unit of Cardiology, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden, <sup>5</sup>Clinical Sciences Lund, Surgery, Lund University and Skane University Hospital, Lund, Sweden

2:30 PM – 4:00 PM

CONCURRENT SESSION 13

**Long Live the Graft! Factors Impacting Long-term Outcome (Calliope)**

(PEDS, BSI, DMD, HF, HTX, ID, LTX, MCS, NNSAH, PATH, PH, PHARM, PEEQ)

**CHAIRS:** Anne I. Dipchand, MD and Tajinder P. Singh, MD, MSc

**2:30 PM (73) Hemodynamic Profiles in Children With End-Stage Heart Failure: Analysis of Data From the Pediatric Heart Transplant Study Group;**

S. Chen<sup>1</sup>, R. J. Gajarski<sup>2</sup>, A. Lin<sup>1</sup>, L. J. May<sup>1</sup>, D. N. Rosenthal<sup>1</sup>, M. D. Everitt<sup>3</sup>, D. B. McElhinney<sup>4</sup>, A. Y. Shin<sup>1</sup>, S. A. Hollander<sup>1</sup>, E. Pruitt<sup>5</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>2</sup>University of Michigan Congenital Heart Center, C. S. Mott Children's Hospital, Ann Arbor, MI, <sup>3</sup>Division of Pediatric Cardiology, Primary Children's Hospital, Salt Lake City, UT, <sup>4</sup>Department of Cardiovascular Surgery, Stanford University, Palo Alto, CA, <sup>5</sup>Data Coordinating Center, University of Alabama at Birmingham, Birmingham, AL

**2:45 PM (74) Does Oversizing Donors Have Any Benefit for Pediatric Heart Transplant Recipients With Elevated Pulmonary Vascular Resistance?;**

F. Zafar<sup>1</sup>, M. S. Khan<sup>1</sup>, R. Bryant<sup>1</sup>, C. D. Castleberry<sup>2</sup>, C. Chin<sup>2</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital Med Ctr, Cincinnati, OH, <sup>2</sup>Cardiology, Cincinnati Children's Hospital Med Ctr, Cincinnati, OH

**3:00 PM (75) Improved Transplant Survival in Failed Fontan Patients With Preserved Ventricular Function in the Current Era;**

K. Simpson<sup>1</sup>, J. Miller<sup>2</sup>, T. Lancaster<sup>2</sup>, M. Henn<sup>2</sup>, D. Epstein<sup>2</sup>, R. Schuessler<sup>2</sup>, D. Balzer<sup>1</sup>, S. Shahanavaz<sup>1</sup>, J. Murphy<sup>1</sup>, P. Eghtesady<sup>2</sup>, U. Boston<sup>2</sup>, C. Canter<sup>1</sup>. <sup>1</sup>Washington Univ St Louis Saint Louis Children's Hospital, Saint Louis, MO, <sup>2</sup>Washington Univ St Louis, Saint Louis, MO

**3:15 PM (76) Early Cardiac Graft Performance in Pediatric Retransplantation: What Can We Learn?;**

M. Naguib<sup>1</sup>, C. A. Cundiff<sup>2</sup>, B. Shehata<sup>2</sup>, W. Mahle<sup>3</sup>, S. R. Deshpande<sup>3</sup>. <sup>1</sup>Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Department of Pathology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, <sup>3</sup>Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA

**3:30 PM (77) A Multi-Institutional Evaluation of Antibody-Mediated Rejection Utilizing the PHTS Database: Incidence, Therapies, and Outcomes;**

P. T. Thrush<sup>1</sup>, E. Pahl<sup>2</sup>, D. C. Naftel<sup>3</sup>, E. Pruitt<sup>3</sup>, M. D. Everitt<sup>4</sup>, H. Missler<sup>1</sup>, S. D. Zangwill<sup>5</sup>, M. Burch<sup>6</sup>, T. M. Hoffman<sup>1</sup>, R. J. Butts<sup>7</sup>, W. T. Mahle<sup>8</sup>. <sup>1</sup>Cardiology, Nationwide Children's Hospital, Columbus, OH, <sup>2</sup>Cardiology, Ann & Robert H. Lurie Children's Hospital, Chicago, IL, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>Primary Children's Medical Center, Salt Lake City, UT, <sup>5</sup>Children's Hospital of Wisconsin, Milwaukee, WI, <sup>6</sup>Great Ormond Street Hospital, London, United Kingdom, <sup>7</sup>Medical University of South Carolina, Charleston, SC, <sup>8</sup>Children's Healthcare of Atlanta, Atlanta, GA

**3:45 PM (78) Lipid Levels in the Post Heart Transplant Patient: Are They Predictive of Graft Failure?;**

S. Sexson Teitel<sup>1</sup>, A. Jeewa, A. Cabrera, J. F. Price, W. J. Dreyer, S. W. Denfield. Pediatric Cardiology, Texas Childrens Hospital/ Baylor College of Medicine, Houston, TX

**2:30 PM – 4:00 PM**

## CONCURRENT SESSION 14

### Philip K Caves Award Candidate Presentations

(Euterpe)

(ALL)

**CHAIRS:** Bruno Reichart, MD and Stuart W. Jamieson, MB, FRCS

**2:30 PM (79) *Impact of the 18th Birthday on Wait-list Outcome for US Patients Listed for Heart Transplant;***

D. M. Peng<sup>1</sup>, N. McDonald<sup>1</sup>, O. Reinhartz<sup>2</sup>, L. Barkoff<sup>1</sup>, S. A. Hollander<sup>1</sup>, A. Lin<sup>1</sup>, J. Yeh<sup>1</sup>, D. N. Rosenthal<sup>1</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Department of Pediatrics, Division of Pediatric Cardiology, Stanford University/Lucile Packard Children's Hospital Stanford, Palo Alto, CA, <sup>2</sup>Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA

**2:45 PM (80) *The Amount of Autophagy-Related Cardiomyocyte Cell Death Is Associated With the Type of Pathogenic Mutation in Genetic Dilated Cardiomyopathy;***

Z. J. van der Klooster<sup>1</sup>, S. Sepehrkhouy<sup>1</sup>, M. Harakalova<sup>1</sup>, R. Goldschmeding<sup>1</sup>, N. de Jonge<sup>1</sup>, A. J. Suurmeijer<sup>2</sup>, R. A. de Weger<sup>1</sup>, F. W. Asselbergs<sup>1</sup>, A. Vink<sup>1</sup>. <sup>1</sup>Pathology, University Medical Center Utrecht, Utrecht, Netherlands, <sup>2</sup>Pathology, University Medical Center Groningen, Groningen, Netherlands

**3:00 PM (81) *Coronary Allograft Arteriosclerosis: Local MicroRNA Modulation Using a Novel Anti-Mir-21-Eluting Stent Prevents in-Stent Restenosis;***

D. Wang<sup>1</sup>, T. Deuse<sup>2</sup>, M. Stubbendorff<sup>1</sup>, E. Chernogubova<sup>3</sup>, R. G. Erben<sup>4</sup>, S. M. Eken<sup>5</sup>, H. Jin<sup>5</sup>, C. Heeger<sup>5</sup>, B. Behnisch<sup>6</sup>, H. Reichenspurner<sup>2</sup>, R. C. Robbins<sup>7</sup>, J. M. Spin<sup>8</sup>, P. S. Tsao<sup>9</sup>, L. Maegdefessel<sup>3</sup>, S. Schrepfer<sup>10</sup>. <sup>1</sup>University Heart Center Hamburg, Transplant and Stem Cell Immunobiology Lab (TSI), Hamburg, Germany, <sup>2</sup>CT Surgery, University Heart Center Hamburg, Hamburg, Germany, <sup>3</sup>Atherosclerosis Research Unit, Karolinska Institute, Stockholm, Sweden, <sup>4</sup>Veterinary Medicine, University of Vienna, Vienna, Austria, <sup>5</sup>Department of Cardiology Asklepios Clinic St. Georg, Hamburg, Germany, <sup>6</sup>Translumina GmbH, Hechingen, Hechingen, Germany, <sup>7</sup>CT Surgery, Stanford University, Stanford, CA, <sup>8</sup>Veterans Affairs Palo Alto Health Care System, Stanford University, Stanford, CA, <sup>9</sup>josh.spin@gmail.com, Stanford University, Stanford, CA, <sup>10</sup>Stanford University Transplant and Stem Cell Immunobiology Lab (TSI), Stanford, CA

**3:15 PM (82) *Human Induced Pluripotent Stem Cells for Tissue Engineered Cardiac Repair;***

S. Pecha<sup>1</sup>, F. Weinberger<sup>2</sup>, K. Breckwoldt<sup>2</sup>, B. Geertz<sup>2</sup>, J. Starbatty<sup>2</sup>, A. Hansen<sup>1</sup>, H. Reichenspurner<sup>3</sup>, T. Eschenhagen<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Univ Hospital Hamburg, Hamburg, Germany, <sup>2</sup>Experimental Pharmacology and Toxicology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, <sup>3</sup>Cardiovascular Surgery, University Hospital Hamburg, Hamburg, Germany

**3:30 PM (83) *Towards Donor Lung Recovery – Gene Expression Changes During Ex-Vivo Lung Perfusion;***

J. C. Yeung, R. Zamel, X. Bai, T. N. Machuca, M. Liu, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada

**3:45 PM (84) *Long Term Measurements of Aortic Root and Left Ventricular Dimensions in Patients on HeartWare® Ventricular Assist Device – An Explanation for the Development of Aortic Incompetence in Chronic LVAD Support?;***

S. K. Bhagra<sup>1</sup>, C. J. Bhagra<sup>1</sup>, N. Wrightson<sup>2</sup>, G. A. MacGowan<sup>1</sup>, S. Schueler<sup>3</sup>. <sup>1</sup>Cardiology, Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Cardipulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>3</sup>Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom



**4:00 PM – 4:30 PM**

Coffee Break/Visit Exhibits (Rhodes)

VIEW POSTERS (Agora 2)

**2016 ANNUAL MEETING SYMPOSIUM PLANNING  
COMMITTEE MEETING (Gallieni 4)**



4:30 PM – 6:00 PM

## CONCURRENT SESSION 15

### Myocardial Recovery – Moving Forward (Apollon) (MCS, BSI, HF, HTX, PHARM)

**CHAIRS:** Stavros G. Drakos, MD and J Eduardo Rame, MD

- 4:30 PM (85) *Remission From Stage D Heart Failure (RESTAGE-HF): Early Results From a Prospective Multi-Center Study of Myocardial Recovery;***  
 E. J. Birks<sup>1</sup>, S. Drakos<sup>2</sup>, C. Selzman<sup>3</sup>, R. Starling<sup>4</sup>, C. Cunningham<sup>5</sup>, M. Slaughter<sup>6</sup>, D. M. Spevack<sup>7</sup>, A. Salahuddin<sup>7</sup>, P. Alturi<sup>8</sup>, J. Um<sup>9</sup>, B. Lowes<sup>10</sup>, S. Patel<sup>11</sup>, D. Farrar<sup>12</sup>, F. Kallel<sup>12</sup>, J. E. Rame<sup>13</sup>.  
<sup>1</sup>Cardiovascular Medicine, University of Louisville, Louisville, KY, <sup>2</sup>Cardiovascular Medicine, University of Utah, Salt Lake City, UT, <sup>3</sup>Cardiovascular Surgery, University of Utah, Salt Lake City, UT, <sup>4</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, <sup>5</sup>Clinical Trials Unit, University of Louisville, Louisville, KY, <sup>6</sup>Cardiovascular Surgery, University of Louisville, Louisville, KY, <sup>7</sup>Department of Echocardiography, Montefiore, New York, NY, <sup>8</sup>Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, <sup>9</sup>Cardiovascular Surgery, University of Nebraska, Omaha, NE, <sup>10</sup>Cardiovascular Medicine, University of Nebraska, Omaha, NE, <sup>11</sup>Cardiovascular Medicine, Montefiore, New York, NY, <sup>12</sup>Thoratec Corporation, Pleasanton, CA, <sup>13</sup>Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA
- 4:45 PM (86) *Myocardial Recovery From Short- and Long-Term Cardiac Support Devices: Results From the UNOS Registry;***  
 S. Pan, O. Wever-Pinzon, S. Rao, A. Levin, A. Garan, K. Takeda, H. Takayama, M. Yuzefpolskaya, D. Mancini, Y. Naka, P. C. Colombo, V. K. Topkara. Cardiology, Columbia University New York Presbyterian Hospital, New York, NY
- 5:00 PM (87) *Explantation of Left Ventricular Assist Devices After Myocardial Recovery: A Single Center Study;***  
 A. Ghotra, Z. Hussain, S. Spayd, A. Cheng, A. Lenneman, M. Slaughter, E. J. Birks. University of Louisville, Louisville, KY
- 5:15 PM (88) *Ventricular Reconditioning Enables De-Escalation of Therapy in Young Patients Supported By Continuous Flow Left Ventricular Assist Devices;***  
 A. C. Baldwin, E. Sandoval, S. K. Singh, W. E. Cohn, H. R. Mallidi, O. Frazier. Cardiothoracic Transplant, Texas Heart Institute, Houston, TX
- 5:30 PM (89) *Absolute Reduction in Left Ventricular End Diastolic Diameter (Greater Than 0.65cm) in Patients With Continuous Flow Left Ventricular Assist Devices (CF-LVAD) Reflects Complete LV Unloading Defined By Invasive Hemodynamics;***  
 C. Eshelbrenner, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, B. Elias, M. Loebe, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX
- (90) WITHDRAWN**
- 5:45 PM (323) *Structural and Functional Myocardial Improvement Following Continuous-Flow Mechanical Unloading in Chronic Ischemic and Non-Ischemic Cardiomyopathy;***  
 J. Wever-Pinzon, M. Al-Sarie, A. Catino, R. McCubrey, J. Stehlik, A. Kfoury, B. Reid, O. Wever-Pinzon, R. Alharethi, S. Wright, D. Li, E. Gilbert, S. Mckellar, J. Barney, J. Fang, C. Selzman, S. Drakos. U.T.A.H Cardiac Transplant Program, (University of Utah, Intermountain Medical Center, VA Medical Center), Salt Lake City, UT

4:30 PM – 6:00 PM

CONCURRENT SESSION 16

**Strokes, Arrhythmias and LVADs (Athena)**  
**(MCS, BSI, HF, HTX, NNSAH, PHARM)**

**CHAIRS:** Chetan B. Patel, MD and  
Cumara C. Sivathasan, MBBS, FRCS

- 4:30 PM (91) *Neurological Events in Patients Bridged to Long-Term Mechanical Circulatory Support: A Device Specific Comparative Analysis;***  
S. Maltais<sup>1</sup>, N. A. Haglund<sup>2</sup>, M. E. Davis<sup>3</sup>, M. R. Danter<sup>1</sup>, M. Xu<sup>4</sup>, S. M. Dunlay<sup>5</sup>, J. A. Cowger<sup>6</sup>, P. Shah<sup>7</sup>, K. Aaronson<sup>8</sup>, F. D. Pagan<sup>9</sup>, J. M. Stulak<sup>10</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Cardiac Surgery, Vanderbilt University, Nashville, TN, <sup>4</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>5</sup>Cardiovascular Medicine, Mayo Clinic, Rochester, MN, <sup>6</sup>Cardiovascular Medicine, St Vincent Heart, Indianapolis, IN, <sup>7</sup>Cardiovascular Medicine, Inova Fairfax, Falls Church, VA, <sup>8</sup>Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, <sup>9</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>10</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN
- 4:45 PM (92) *Ventricular Assist Device Patients Have Different Clinical Outcomes and Altered Pattern of Bleeding With Intracranial Hemorrhage;***  
M. Ahmed<sup>1</sup>, M. Rahman<sup>2</sup>, D. Neal<sup>2</sup>, J. Aranda, Jr<sup>1</sup>, C. T. Klodell, Jr<sup>3</sup>. <sup>1</sup>Division of Cardiovascular Medicine, University of Florida, Gainesville, FL, <sup>2</sup>Department of Neurosurgery, University of Florida, Gainesville, FL, <sup>3</sup>Division of Thoracic and Cardiovascular Surgery, University of Florida, Gainesville, FL
- 5:00 PM (93) *Persistent Neural Dysregulation Despite MCS/CD Implantation;***  
C. Starling, E. Chang, M. Cadeiras, G. Bondar, N. Wisniewski, M. Bakir, J. Maque, J. Chittoor, A. Shubov, W. Zhou, X. Vela, D. Ticas, M. Deng. University of California Los Angeles, Los Angeles, CA
- 5:15 PM (94) *Preoperative Atrial Fibrillation Does Not Increase Thromboembolic Events Following LVAD Implantation: An INTERMACS Registry Analysis;***  
D. Stern<sup>1</sup>, Y. Xia<sup>1</sup>, P. Friedmann<sup>2</sup>, D. Goldstein<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Albert Einstein College of Medicine, Bronx, NY
- 5:30 PM (95) *Temporal Differences in Adverse Event Rates in Patients Bridged With the HeartWare Left Ventricular Assist Device;***  
S. Maltais<sup>1</sup>, K. D. Aaronson<sup>2</sup>, J. J. Teuteberg<sup>3</sup>, M. S. Slaughter<sup>4</sup>, S. S. Najjar<sup>5</sup>, V. Jeevanandam<sup>6</sup>, D. T. Pham<sup>7</sup>, E. C. McGee<sup>8</sup>, K. Najarian<sup>9</sup>, R. L. Kormos<sup>3</sup>. <sup>1</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>University of Michigan, Ann Arbor, MI, <sup>3</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>4</sup>University of Louisville, Louisville, KY, <sup>5</sup>MedStar Heart Institute, Washington, DC, <sup>6</sup>University of Chicago Medicine, Chicago, IL, <sup>7</sup>Tufts Medical Center, Boston, MA, <sup>8</sup>Northwestern Memorial Hospital, Chicago, IL, <sup>9</sup>HeartWare, Framingham, MA
- 5:45 PM (96) *The Location of Intractable Ventricular Arrhythmias Following Left Ventricular Assist Device Implantation;***  
A. R. Garan<sup>1</sup>, W. Whang<sup>1</sup>, V. K. Topkara<sup>1</sup>, A. P. Levine<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, D. M. Mancini<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>, N. Uriel<sup>2</sup>, U. P. Jorde<sup>3</sup>. <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>University of Chicago, Chicago, IL, <sup>3</sup>Montefiore Medical Center, New York, NY

4:30 PM – 6:00 PM

## CONCURRENT SESSION 17

### Lung CLAD II: New Observations and Therapies on the Horizon (Clio, Thalie)

(LTX, BSI, LF)

**CHAIRS:** Geert M. Verleden, MD, PhD and Tereza Martinu, MD

- 4:30 PM (97) *Chronic Lung Allograft Dysfunction After Bilateral Living Donor Lobar Lung Transplantation;***  
K. Miyoshi, T. Oto, S. Sugimoto, M. Yamane, S. Miyoshi. Department of Thoracic Surgery / Organ Transplant Centre, Okayama University Hospital, Okayama, Japan
- 4:45 PM (98) *Long-Term Effects of Preemptive Azithromycin Therapy for CLAD After Lung Transplantation: Post Hoc Analysis of a Randomized Controlled Trial;***  
D. Ruttens, S. E. Verleden, E. Vandermeulen, H. Bellon, D. E. Van Raemdonck, L. Dupont, B. M. Vanaudenaerde, G. M. Verleden, R. Vos. KULeuven, Leuven, Belgium
- 5:00 PM (99) *Interleukin-1 Induced Interleukin-8 Production in Human Airway Epithelial Cells Pretreated With Azithromycin: A Possible Mechanism for Neutrophilic BOS?;***  
H. Bellon, E. Vandermeulen, S. E. Verleden, D. Ruttens, H. Vriens, P. H. Hoet, B. M. Vanaudenaerde, R. Vos, G. M. Verleden. Department of Clinical and Experimental Medicine, KU Leuven University, Leuven, Belgium
- 5:15 PM (100) *KL-6 Changes in Serum Can Be Predictive of Chronic Lung Allograft Dysfunction in Lung Transplant Recipients;***  
V. Besa<sup>1</sup>, F. Bonella<sup>2</sup>, S. Ohshimo<sup>3</sup>, G. Weinreich<sup>1</sup>, U. Costabel<sup>2</sup>, M. Kamler<sup>4</sup>, H. Teschler<sup>1</sup>, U. Sommerwerck<sup>1</sup>. <sup>1</sup>Pneumology, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, <sup>2</sup>Interstitial and Rare Lung Disease Unit, Ruhrlandklinik, West German Lung Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany, <sup>3</sup>Molecular and Internal Medicine, Graduate School of Biomedical Sciences, Hiroshima University, Hiroshima, Japan, <sup>4</sup>Thoracic Transplantation, University Hospital Essen, University Duisburg-Essen, Essen, Germany
- 5:30 PM (101) *The Association of Donor Age and Survival Is Independent of Ischemic Time Following Cadaveric Lung Transplantation;***  
B. C. Gulack<sup>1</sup>, A. M. Ganapathi<sup>1</sup>, P. J. Speicher<sup>1</sup>, B. R. Englum<sup>1</sup>, L. D. Snyder<sup>2</sup>, R. D. Davis<sup>1</sup>, M. G. Hartwig<sup>1</sup>. <sup>1</sup>Department of General Surgery, Duke University, Durham, NC, <sup>2</sup>Department of Medicine, Duke University, Durham, NC
- 5:45 PM (102) *Impact of Repeated Mismatch Human Leukocyte Antigen on the Outcome of Lung Retransplantation;***  
H. Wang<sup>1,2</sup>, L. Wan<sup>1</sup>, Q. Yang<sup>3</sup>, W. E. Hanshew<sup>1</sup>, R. D. Davis<sup>4</sup>, D. Chen<sup>1</sup>. <sup>1</sup>Clinical Transplantation Immunology Laboratory, Duke University Medical Center, Durham, NC, <sup>2</sup>Transfusion Service, The Affiliate Hospital of Qingdao University, Qingdao, China, <sup>3</sup>School of Nursing, Duke University, Durham, NC, <sup>4</sup>Department of Surgery, Duke University Medical Center, Durham, NC

4:30 PM – 6:00 PM

CONCURRENT SESSION 18

**Crystal Ball: Predicting Outcomes in Heart Transplantation** (Erato,Uranie)

(HTX, BSI, DMD, HF, MCS, NNSAH, PATH, PEDS, PHARM, PEEQ)

**CHAIRS:** Donna M. Mancini, MD and Paul J. Mohacsi, MD

- 4:30 PM (103) *Institutional Volume Impacts Failure to Rescue Following Heart Transplantation;***  
J. C. Grimm, A. Kilic, A. S. Shah, J. Magruder, V. Valero, <sup>3</sup>rd, S. D. Russell, R. J. Tedford, G. J. Whitman, C. M. Sciortino. Surgery, The Johns Hopkins Medical Institution, Baltimore, MD
- 4:45 PM (104) *The Impact of Postoperative Pulmonary Hypertension and Elevated Diastolic Pressure Difference on Outcome After Heart Transplantation;***  
J. Lundgren, G. Rådegran. Dept. of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
- 5:00 PM (105) *Influence of Liver Dysfunction in Patients Undergoing Heart Transplantation With Left Ventricular Assist Device Explantation: Comparative Analysis Using the MELD Excluding INR (MELD-XI) Scoring System;***  
S. Maltais<sup>1</sup>, M. E. Davis<sup>1</sup>, M. R. Danter<sup>1</sup>, J. M. Stulak<sup>2</sup>, N. A. Haglund<sup>3</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiac Surgery, Mayo Clinic, Rochester, TN, <sup>3</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN
- 5:15 PM (106) *Rubidium Positron Emission Tomography and Coronary Flow Reserve Predicts Graft Function After Heart Transplant;***  
J. Kawano, J. Patel, M. Kittleson, F. Liou, D. Wong, G. Jamero, B. Azarbal, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- 5:30 PM (107) *Do Abnormal Regadenoson Scans Predict Subsequent Poor Outcome?;***  
J. Kawano, M. Kittleson, J. Patel, B. Azarbal, F. Liou, S. Siddiqui, D. Wong, D. H. Chang, D. Ramzy, L. Czer, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- 5:45 PM (108) *Prolonged LVAD Support Effects Morbidity But Not Mortality Following Heart Transplant;***  
J. C. Grimm<sup>1</sup>, A. S. Shah<sup>1</sup>, G. J. Whitman<sup>1</sup>, C. M. Sciortino<sup>1</sup>, J. Magruder<sup>1</sup>, S. D. Russell<sup>2</sup>, G. A. Ewald<sup>3</sup>, S. C. Silvestry<sup>4</sup>. <sup>1</sup>Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>2</sup>Medicine, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>3</sup>Medicine, Barnes Jewish Hospital, St. Louis, MO, <sup>4</sup>Surgery, Barnes Jewish Hospital, St. Louis, MO

4:30 PM – 6:00 PM

## CONCURRENT SESSION 19

### Emerging Countries Session I (Hermes) (ALL)

**CHAIRS:** Mandeep R. Mehra, MD, MBBS, FACC, FACP  
Lori J. West, MD, DPhil and  
Theodoros Kofidis, MD, PhD, FRCS

**4:30 PM (109) *Effective Percutaneous Energy Transfer Allows for More Than 6 Hours of Freedom From External Gear – The Future Is Here;***  
Y. Kassif<sup>1</sup>, M. Zilbershlag<sup>2</sup>, M. Levy<sup>2</sup>, S. Schueler<sup>3</sup>. <sup>1</sup>Cardiac Surgery, Sheba Medical Center, Ramat Gan, Israel, <sup>2</sup>Leviticus Cardio, Ramat Gan, Israel, <sup>3</sup>cardiac surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom

**4:45 PM (110) *VAD Destination Therapy Outcomes – Kazakhstan’s Experience;***  
Y. Pya<sup>1</sup>, A. Medressova<sup>2</sup>, S. Novikova<sup>2</sup>, M. Murzagaliyev<sup>2</sup>, S. Dzhetbayeva<sup>3</sup>, S. Andossova<sup>4</sup>, S. Bekbossynov<sup>2</sup>, M. Bekbossynova<sup>5</sup>. <sup>1</sup>CEO, National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>2</sup>Cardiac Surgery, National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>3</sup>Cardiology, National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>4</sup>VAD Department, National Research Center for Cardiac Surgery, Astana, Kazakhstan, <sup>5</sup>National Research Center for Cardiac Surgery, Astana, Kazakhstan

**5:00 PM (111) *Outcomes of Implantable Left Ventricular Assist Devices in a South East Asian Population;***  
L. L. Chan<sup>1</sup>, C. Lim<sup>1</sup>, C. Sivathasan<sup>2</sup>, C. Lim<sup>2</sup>, T. Tan<sup>2</sup>, J. Soon<sup>2</sup>, K. Kerk<sup>2</sup>, D. Sim<sup>1</sup>. <sup>1</sup>Cardiology, National Heart Centre Singapore, Singapore, Singapore, <sup>2</sup>Cardiothoracic and Vascular Surgery, National Heart Centre Singapore, Singapore, Singapore

**5:15 PM (112) *The Current Status of Heart Transplantation and Mechanical Circulatory Support in Turkey: Facts and Factors;***  
M. Sargin<sup>1</sup>, G. Orhan<sup>1</sup>, S. A. Aka<sup>1</sup>, M. E. Mete<sup>1</sup>, R. Akar<sup>2</sup>, M. A. Ozatik<sup>3</sup>, C. Engin<sup>4</sup>, M. Balkanay<sup>5</sup>, B. Omer<sup>6</sup>. <sup>1</sup>Cardiovascular Surgery, Siyami Ersek Hospital, Istanbul, Turkey, <sup>2</sup>Cardiovascular Surgery, Ankara University, Ankara, Turkey, <sup>3</sup>Heart Transplantation Council, Ministry of Health, Ankara, Turkey, <sup>4</sup>Cardiovascular Surgery, Ege University, Istanbul, Turkey, <sup>5</sup>Cardiovascular Surgery, &#304; zmir Ataturk EAH, Istanbul, Turkey, <sup>6</sup>Cardiovascular Surgery, Akdeniz University, Antalya, Turkey

**5:30 PM (113) *More Than 200 Heart Transplantation From the Single Centre in the Middle East; Twenty Two Heart Transplantation During the First 10 Months at King Faisal Specialist Hospital and Research Centre, Riyadh;***  
N. Selimovic, J. Alburaiqi, F. Khaliel, A. Alsanei, A. Eyjolfsson, U. Kjellman, E. Saad, Z. Halees. Heart Centre, King Faisal Specialist Hospital&Research, Riyadh, Saudi Arabia

**5:45 PM (114) *Primary Immunosuppression and Outcome Differences After Heart Transplantation: Cyclosporin/Azathioprine/Steroid vs. Tacrolimus/Mycophenolate mofetil/Steroid – 22 Years’ National Experience of Korea;***  
H. Lee<sup>1</sup>, J. Kim<sup>2</sup>, G. Lee<sup>3</sup>, E. Jeon<sup>3</sup>. <sup>1</sup>Internal Medicine, Seoul National University Hospital, Seoul, Korea, Republic of, <sup>2</sup>Internal Medicine, Asan Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Internal Medicine, Samsung Medical Center, Seoul, Korea, Republic of

4:30 PM – 6:00 PM

CONCURRENT SESSION 20

**Basic Science 1: Inflammation, Immune Monitoring, Immune Suppression (Calliope) (ALL)**

**CHAIRS:** Kyung-Hee Kim, MD and Esme Dijke, PhD

**4:30 PM (115) *Correlative Changes in Macrophage Polarization and Pulmonary Microbiota in Lung Transplant Recipients;***  
E. Bernasconi<sup>1</sup>, A. Koutsokera<sup>1</sup>, C. Pattaroni<sup>1</sup>, D. Dumas<sup>1</sup>, B. Camara<sup>2</sup>, B. J. Marsland<sup>1</sup>, C. Benden<sup>3</sup>, C. Pison<sup>2</sup>, J. Aubert<sup>4</sup>, L. P. Nicod<sup>5</sup>. <sup>1</sup>Pulmonary Division, CHUV, Lausanne, Switzerland, <sup>2</sup>CHU, Grenoble, France, <sup>3</sup>University Hospital Zurich, Zurich, Switzerland, <sup>4</sup>Pulmonary Division, CHUV and STCS, Lausanne, Switzerland, <sup>5</sup>Pulmonary Division, CHUV and SysCLAD FP<sup>7</sup> Consortium, Lausanne, Switzerland

**4:45 PM (116) *Cardiac Allograft Tolerance Induction via Anti-LFA-1 Monotherapy Is Dependent on an Indirect CD8 T-Cell;***  
R. J. Plenter<sup>1</sup>, M. K. Nelsen<sup>2</sup>, M. R. Zamora<sup>1</sup>, R. G. Gill<sup>2</sup>, B. A. Pietra<sup>3</sup>. <sup>1</sup>Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Denver, Aurora, CO, <sup>2</sup>Colorado Center for Transplantation Care, Research and Education, University of Colorado Denver, Aurora, CO, <sup>3</sup>Division of Pediatric Cardiology, University of Florida, Gainesville, FL

**5:00 PM (117) *In Vivo Development of Transplant Arteriosclerosis in Humanized Mice Reflects Alloantigen Recognition of Lung Transplant Recipients and Is Controlled By Autologous Regulatory T Cells;***  
T. Siemeni, A. Knoefel, N. Madrahimov, W. Sommer, N. Frank, K. Jansson, F. Ius, J. Salman, M. Avsar, I. Tudorache, C. Kuehn, A. Haverich, G. Warnecke. Hannover HTTG, Hannover, Germany

**5:15 PM (118) *Acute Allograft Rejection Is Attenuated By CD26-Inhibition Through IL-17 Suppression in Mouse Lung Transplants;***  
Y. Yamada<sup>1</sup>, J. Jang<sup>1</sup>, I. De Meester<sup>2</sup>, I. Inci<sup>1</sup>, W. Weder<sup>1</sup>, W. Jungraithmayr<sup>1</sup>. <sup>1</sup>Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Department of Medical Biochemistry, University of Antwerp, Antwerp, Belgium

**5:30 PM (119) *A Novel Ex-Vivo Intrabronchial Delivery of Lentivirus IL-10 Gene Therapy Attenuates Both Acute Allograft Rejection and Bronchiolitis Obliterans After Murine Orthotopic Lung Transplantation;***  
H. Oishi<sup>1</sup>, T. Martinu<sup>1</sup>, M. Sato<sup>2</sup>, Z. Guan<sup>1</sup>, T. Saito<sup>1</sup>, J. Sakamoto<sup>1</sup>, S. Hirayama<sup>3</sup>, Y. Matsuda<sup>4</sup>, M. Cypel<sup>1</sup>, D. M. Hwang<sup>1</sup>, M. Liu<sup>1</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>Latner Thoracic Surgery Research Laboratories, University Health Network, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Department of Thoracic Surgery, Kyoto University, Kyoto, Japan, <sup>3</sup>Department of Surgery, Okayama Rosai Hospital, Okayama, Japan, <sup>4</sup>Department of Thoracic Surgery, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan

**5:45 PM (120) *Quantification of Donor Specific Cell-Free DNA Yields Extremely High Sensitivity for Detection of Rejection Following Cardiac Transplantation;***  
M. E. Mitchell<sup>1</sup>, P. Hidestrand<sup>2</sup>, P. Simpson<sup>2</sup>, M. Goetsch<sup>1</sup>, G. Stendahl<sup>2</sup>, H. Liang<sup>1</sup>, J. Tweddell<sup>1</sup>, A. Tomita-Mitchell<sup>1</sup>, M. Hidestrand<sup>1</sup>, S. Zangwill<sup>2</sup>. <sup>1</sup>Surgery, Pediatric Cardiothoracic Surgery, Children's Hospital of Wisconsin, Milwaukee, WI, <sup>2</sup>Pediatrics, Children's Hospital of Wisconsin, Milwaukee, WI

4:30 PM – 6:00 PM

## CONCURRENT SESSION 21

### Kinetics, Coagulation, and Cardiology – Pharmacy of MCS and Transplant (Euterpe)

(PHARM, HTX, ID, LTX, MCS)

**CHAIRS:** Michael Shullo, PharmD and Katrina Ford, BPharm

**4:30 PM (121) *Assessing Anticoagulation Practice Patterns in Patients on Durable Mechanical Circulatory Support Devices: An International Survey;***

D. L. Jennings<sup>1</sup>, E. Horn<sup>2</sup>, H. Lyster<sup>3</sup>, A. Panos<sup>4</sup>, J. Teuteberg<sup>5</sup>, H. Lehmkuhl<sup>5</sup>, W. Wolowich<sup>1</sup>, M. Shullo<sup>5</sup>. <sup>1</sup>Nova Southeastern University, Miami, FL, <sup>2</sup>Allegheny General Hospital, Pittsburgh, PA, <sup>3</sup>Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom, <sup>4</sup>Miami Transplant Institute, Miami, FL, <sup>5</sup>University of Pittsburgh Medical Center, Pittsburgh, PA

**4:45 PM (122) *Optimal Low Density Lipoprotein Levels Prevent Cardiac Allograft Vasculopathy;***

J. Harris, J. Teuteberg, J. Coons, D. Winger, M. Shullo. University of Pittsburgh Medical Center, Pittsburgh, PA

**5:00 PM (123) *The Use of Three Factor Prothrombin Complex Concentrate to Reverse Warfarin Treated Mechanical Circulatory Device Patients Immediately Prior to Heart Transplant;***

R. H. Cosgrove<sup>1</sup>, A. E. Patanwala<sup>2</sup>, B. L. Sears<sup>2</sup>, Z. Khalpey<sup>3</sup>, R. Basken<sup>1</sup>, S. D. Lick<sup>1</sup>. <sup>1</sup>Department of Pharmacy Services, University of Arizona Medical Center, Tucson, AZ, <sup>2</sup>Department of Pharmacy Practice, University of Arizona College of Pharmacy, Tucson, AZ, <sup>3</sup>Department of Cardiothoracic Surgery, University of Arizona Medical Center, Tucson, AZ

**5:15 PM (124) *Achieving Therapeutic Posaconazole Levels for Fungal Prophylaxis After Lung Transplantation: Oral Suspension Versus Delayed-Release Tablets;***

M. L. Hurtik<sup>1</sup>, R. Bag<sup>2</sup>, D. C. Neujahr<sup>2</sup>. <sup>1</sup>Pharmaceutical Services, Emory University Hospital, Atlanta, GA, <sup>2</sup>Emory Transplant Center, Emory University, Atlanta, GA

**5:30 PM (125) *Trough Blood Levels Are a Poor Marker of Tacrolimus Exposure in Lung Transplantation;***

D. R. Darley, A. R. Glanville. Thoracic Medicine, St. Vincent's Hospital, Darlinghurst, Australia

**5:45 PM (126) *Potent P2Y12 ADP Receptor Inhibition With Ticagrelor Can Normalize Lactate Dehydrogenase and Avoid Pump Exchange in Acute HeartMate II Thrombosis;***

G. H. Oliveira, S. Al-Kindi, M. Qattan, M. Ginwalla, C. ElAmm, S. Deo, S. J. Park, D. I. Simon. University Hospitals Case Medical Center, Cleveland, OH



6:00 PM – 7:00 PM

MINI ORAL SESSION 1

**Fear and Loathing in Mechanical Circulatory Support (Athena)**

(MCS, HTX)

**CHAIRS:** Andrew J. Boyle, MD and Francesco Moscato, PhD

**6:00 PM (127) *High Early Event Rates in Patients With Questionable Eligibility for Advanced Heart Failure Therapies;***

A. V. Ambardekar, MD<sup>1</sup>, R. C. Forde-McLean, MD, MHS<sup>2</sup>, M. M. Kittleson, MD, PhD<sup>3</sup>, G. C. Stewart, MD<sup>4</sup>, M. Palardy, MD<sup>5</sup>, J. T. Thibodeau, MD<sup>6</sup>, A. D. DeVore, MD<sup>7</sup>, M. M. Mountis, DO<sup>8</sup>, L. Cadaret, MD<sup>9</sup>, J. J. Teuteberg, MD<sup>10</sup>, S. V. Pamboukian, MD, MSPH<sup>11</sup>, R. S. Cantor, MSPH<sup>12</sup>, J. Lindenfeld, MD<sup>13</sup>.

<sup>1</sup>Medicine-Cardiology, The University of Colorado, Aurora, CO, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>4</sup>Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, <sup>5</sup>Internal Medicine/Cardiovascular, The University of Michigan, Ann Arbor, MI, <sup>6</sup>Internal Medicine/Cardiology, UT Southwestern, Dallas, TX, <sup>7</sup>Cardiology, Duke Clinical Research Institute, Durham, NC, <sup>8</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, <sup>9</sup>Cardiology, The University of Iowa, Iowa City, IA, <sup>10</sup>Heart and Vascular Institute, The University of Pittsburgh, Pittsburgh, PA, <sup>11</sup>Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, <sup>12</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, <sup>13</sup>Medicine, The University of Colorado, Aurora, CO

**6:05 PM (128) *DeRitis-Quotient Predicts Mortality After LVAD Implantation;***

H. Carstens, K. Pilarczyk, J. Heckmann, A. Canbay, H. Jakob, N. Pizanis, M. Kamler. University Essen, Essen, Germany

**6:10 PM (129) *Early Reassessment of Ambulatory Advanced Heart Failure Detects High-Risk Trajectories Along a Dynamic Baseline;***

G. C. Stewart<sup>1</sup>, M. M. Mountis<sup>2</sup>, M. M. Kittleson<sup>3</sup>, A. V. Ambardekar<sup>4</sup>, M. Palardy<sup>5</sup>, R. C. Forde-McLean<sup>6</sup>, J. T. Thibodeau<sup>7</sup>, J. J. Teuteberg<sup>8</sup>, S. V. Pamboukian<sup>9</sup>, A. D. DeVore<sup>10</sup>, L. Cadaret<sup>11</sup>, R. S. Cantor<sup>12</sup>, L. W. Stevenson<sup>1</sup>.

<sup>1</sup>Advanced Heart Disease, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Cardiology, Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>4</sup>Medicine-Cardiology, The University of Colorado, Aurora, CO, <sup>5</sup>Cardiovascular/Internal Medicine, The University of Michigan, Ann Arbor, MI, <sup>6</sup>Medicine, The University of Pennsylvania, Philadelphia, PA, <sup>7</sup>Internal Medicine/Cardiology, UT Southwestern, Dallas, TX, <sup>8</sup>Heart and Vascular Institute, The University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>9</sup>Cardiovascular Diseases, The University of Alabama at Birmingham, Birmingham, AL, <sup>10</sup>Cardiology, Duke Clinical Research Institute, Durham, NC, <sup>11</sup>Cardiovascular Medicine, The University of Iowa, Iowa City, IA, <sup>12</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL

**6:15 PM (130) *Low Cardiac Power Index (CPI) Is Associated With Higher Mortality in Cardiogenic Shock: Stratifying INTERMACS 1 and 2 Patients Undergoing Continuous-Flow LVAD (CF-LVAD) Implantation;***

F. Kamdar, N. Sathnur, A. Klaassen Kamdar, P. M. Eckman, R. John. University of Minnesota, Minneapolis, MN

**(131) *Moved to Concurrent Session 44***

- 6:20 PM (500) *A Weekly Dressing Protocol Reduces the Incidence of Driveline Infection;***  
M. Puhlman, L. Wang, R. Sullivan, K. Evenson, J. Remick, G. Ott, J. Abraham. Center for Advanced Heart Disease, Providence St Vincent Medical Center, Portland, OR
- 6:25 PM (132) *Does Indication for Destination Therapy Affect Left Ventricular Assist Device Outcomes?;***  
D. Abramov<sup>1</sup>, N. A. Haglund<sup>1</sup>, M. E. Davis<sup>2</sup>, Y. Song<sup>3</sup>, K. Aaronson<sup>4</sup>, F. D. Pagani<sup>5</sup>, S. Dunlay<sup>6</sup>, J. Stulak<sup>7</sup>, S. Maltais<sup>2</sup>. <sup>1</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, <sup>5</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>6</sup>Cardiovascular Medicine, Mayo Clinic, Rochester, MN, <sup>7</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN
- (133) *WITHDRAWN***
- 6:30 PM (504) *Continuous Flow LVAD Support in Restrictive and Obstructive Cardiomyopathies: An INTERMACS Registry Report;***  
D. J. Goldstein<sup>1</sup>, S. R. Patel<sup>2</sup>, S. L. Myers<sup>3</sup>, D. C. Naftel<sup>3</sup>, J. K. Kirklin<sup>3</sup>. <sup>1</sup>Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY, <sup>2</sup>Cardiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, <sup>3</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL
- 6:35 PM (134) *Patterns of Mechanical Circulatory Support By Heart Failure Etiology in Patients Listed for Heart Transplantation;***  
S. Al-Kindi, S. Kumar, M. Ige, M. Ginwalla, C. ElAmm, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH
- 6:40 PM (135) *MELDing a High Risk Patient for Continuous Flow Left Ventricular Assist Device (CF-LVAD) into a Low Risk Patient;***  
J. Amione-Guerra, A. M. Cordero-Reyes, A. Bhimaraj, G. Ashrith, M. Loebe, E. E. Suarez, L. Loza, G. Torre-Amione, J. D. Estep, B. H. Trachtenberg. Cardiology, Houston Methodist Hospital, Houston, TX
- 6:45 PM (136) *The Effect of Pre and Post Implant Anemia on Outcomes of Patients With Left Ventricular Assist Device;***  
E. Y. Birati<sup>1</sup>, T. C. Hanff<sup>2</sup>, J. A. Mazurek<sup>1</sup>, S. Banerji<sup>1</sup>, E. Grandin<sup>1</sup>, D. Pedrotty<sup>1</sup>, E. Vorovich<sup>1</sup>, J. L. Howard<sup>3</sup>, M. Acker<sup>3</sup>, J. N. Kirkpatrick<sup>1</sup>, L. R. Goldberg<sup>1</sup>, P. Atluri<sup>3</sup>, M. Jessup<sup>1</sup>, K. B. Margulies<sup>1</sup>, J. Rame<sup>1</sup>. <sup>1</sup>Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Cardiothoracic Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA
- 6:50 PM (137) *Pre-MCS Prothrombin and Factor V Leiden Gene Mutation Testing May Lead to More Bleeding;***  
A. K. Ravichandran<sup>1</sup>, J. A. Cowger<sup>1</sup>, T. P. Schleeter<sup>1</sup>, S. Moainie<sup>2</sup>, C. T. Salerno<sup>2</sup>. <sup>1</sup>Division of Cardiology, St. Vincent Medical Group, Indianapolis, IN, <sup>2</sup>Division of Cardiothoracic Surgery, St. Vincent Medical Group, Indianapolis, IN
- 6:55 PM (138) *A Novel Socioeconomic Metric for Evaluating Outcomes After Left Ventricular Assist Device Implantation;***  
A. D. Keith<sup>1</sup>, S. M. Joseph<sup>2</sup>, A. Godishala<sup>2</sup>, A. Khan<sup>1</sup>, N. Jarvis<sup>1</sup>, K. Balsara<sup>1</sup>, S. LaRue<sup>2</sup>, S. Silvestry<sup>1</sup>, A. Itoh<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Washington University, St. Louis, MO, <sup>2</sup>Cardiology, Washington University, St. Louis, MO

6:00 PM – 7:00 PM

MINI ORAL SESSION 2

**Biology and the Rise of the Machine** (Clio, Thalie)  
(HTX, MCS, HF)

**CHAIRS:** Ivan Knezevic, MD and Tobias Deuse, MD, PhD

- 6:00 PM (139) *Outcomes in Adult Congenital Heart Failure Patients Undergoing Heart Transplantation: A Systematic Review and Meta-Analysis;***  
B. S. Doumouras<sup>1</sup>, A. C. Alba<sup>1</sup>, F. Foroutan<sup>1</sup>, L. J. Burchill<sup>2</sup>, A. I. Dipchand<sup>3</sup>, H. J. Ross<sup>1</sup>. <sup>1</sup>Heart Failure and Transplantation Program, Toronto General Hospital, University Health Network, Toronto, ON, Canada, <sup>2</sup>Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, <sup>3</sup>Hospital for Sick Children, Toronto, ON, Canada
- 6:05 PM (140) *Correlation Between Lipid Levels and Cardiovascular Events in Heart Transplant Recipients: 24-Month Analysis of the A2310 Study;***  
L. Potena<sup>1</sup>, C. Bara<sup>2</sup>, G. Dong<sup>3</sup>, P. Lopez<sup>4</sup>, E. Epailly<sup>5</sup>. <sup>1</sup>Academic Hospital S.Orsola-Malpighi, Bologna University, Bologna, Italy, <sup>2</sup>Hannover Medical School, Hannover, Germany, <sup>3</sup>Novartis Pharmaceuticals, East Hanover, NJ, <sup>4</sup>Novartis Pharma AG, Basel, Switzerland, <sup>5</sup>Chirurgie Cardiaque Les Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- 6:10 PM (141) *Transition to Adulthood: Heart Transplant (HT) Recipient Outcomes By Age Group;***  
L. Reardon, J. Alejos, M. Deng, A. Nsair, B. Reemtsen, R. Biniwale, E. Depasquale. UCLA, Los Angeles, CA
- 6:15 PM (142) *Right Ventricular Assist Device Support for Right Ventricular Dysfunction following Heart Transplantation: Risk Factors and Clinical Outcome;***  
A. Ali<sup>1</sup>, M. Schechter<sup>2</sup>, L. Harling<sup>3</sup>, K. Southerland<sup>2</sup>, H. Ashrafian<sup>3</sup>, T. Athanasiou<sup>3</sup>, J. Schroder<sup>2</sup>, C. Milano<sup>2</sup>. <sup>1</sup>Cardiothoracic Surgery, Papworth Hospital, Cambridge, United Kingdom, <sup>2</sup>Cardiothoracic Surgery, Duke University Medical Center, Durham, NC, <sup>3</sup>Cardiothoracic Surgery, Imperial College, London, United Kingdom
- 6:20 PM (143) *Donor- and Recipient-Related Predictors of Mortality After Heart Transplantation: Results From a Contemporary French National Cohort;***  
C. Jasseron<sup>1</sup>, C. Legeai<sup>1</sup>, C. Cantrelle<sup>1</sup>, L. Sebbag<sup>2</sup>, A. Mouly-Bandini<sup>3</sup>, O. Huot<sup>1</sup>, R. Dorent<sup>1</sup>. <sup>1</sup>Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, <sup>2</sup>Hospices Civils de Lyon, Lyon, France, <sup>3</sup>AP-HM Marseille, Marseille, France
- 6:25 PM (144) *Early Diagnosis of Acute Kidney Injury After Heart Transplantation – The Prominent Role of Cystatin-C;***  
L. Hoskova<sup>1</sup>, J. Franeckova<sup>2</sup>, I. Malek<sup>1</sup>, J. Kautzner<sup>1</sup>, J. Pirk<sup>1</sup>, O. Szarszoi<sup>1</sup>, A. Jabor<sup>2</sup>, O. Viklicky<sup>3</sup>, V. Melenovsky<sup>1</sup>. <sup>1</sup>Heart Center, IKEM, Prague, Czech Republic, <sup>2</sup>Department of Laboratory Methods, IKEM, Prague, Czech Republic, <sup>3</sup>Department of Nephrology, IKEM, Prague, Czech Republic
- 6:30 PM (145) *Cardiac Allograft Vasculopathy in Redo-Transplants: Is It More or Less (or) the Same the Second Time around?;***  
L. McCreath, R. McCubrey, J. Folsom, S. Wright, J. Stehlik, D. Budge, S. H. McKellar, M. Everitt, G. Snow, B. Reid, K. Skedros, A. Ragnhildstveit, K. Afshar, J. Nativi, S. G. Drakos, A. G. Kfoury. UTAH Cardiac Transplant Program, Salt Lake City, UT

- 6:35 PM (146) *Influence of HLA Mismatch on Outcomes After Heart Transplantation: UNOS Registry Data;***  
 K. Pandya, J. Zhang, M. Hickey, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, E. Reed, E. Depasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA
- 6:40 PM (147) *MELD-XI Score Predicts Early and Late Mortality in Patients Following Heart Transplantation;***  
 J. C. Grimm<sup>1</sup>, J. Magruder<sup>1</sup>, V. Valero,<sup>3rd</sup> A. Kilibi<sup>1</sup>, G. J. Whitman<sup>1</sup>, R. J. Tedford<sup>2</sup>, S. D. Russell<sup>2</sup>, A. S. Shah<sup>1</sup>, C. M. Sciortino<sup>1</sup>.  
<sup>1</sup>Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>2</sup>Medicine, The Johns Hopkins Medical Institution, Baltimore, MD
- 6:45 PM (148) *Restoration of Pulsatile Flow Leads to a Reduction in Sympathetic Nerve Activity Among Patients With Continuous-Flow Left Ventricular Assist Devices;***  
 W. K. Cornwell<sup>1</sup>, T. Tarumi<sup>2</sup>, A. Stickford<sup>2</sup>, J. Kibe<sup>3</sup>, C. Fitzsimmons<sup>3</sup>, J. Moore<sup>2</sup>, M. Roberts<sup>2</sup>, R. Parker<sup>2</sup>, D. Markham<sup>4</sup>, M. Drazner<sup>1</sup>, B. Levine<sup>2</sup>. <sup>1</sup>Cardiology, Univ of Texas SW, Dallas, TX, <sup>2</sup>Institute of Exercise and Environmental Medicine, Dallas, TX, <sup>3</sup>Cardiology, Univ of Texas SW, Coppell, TX, <sup>4</sup>Cardiology, Emory University, Atlanta, GA
- 6:50 PM (149) *Right Ventricular Adaptation to Afterload Worsens Up to 6 Months After LVAD Implantation But Improves Over Time;***  
 B. A. Houston<sup>1</sup>, R. J. Kalathiya<sup>2</sup>, S. Maltais<sup>3</sup>, M. E. Keebler<sup>4</sup>, G. R. Stevens<sup>1</sup>, S. D. Russell<sup>1</sup>, J. Rickard<sup>1</sup>, E. Tampakakis<sup>1</sup>, C. M. Sciortino<sup>5</sup>, G. J. Whitmann<sup>5</sup>, A. Shah<sup>5</sup>, R. J. Tedford<sup>1</sup>. <sup>1</sup>Cardiology, Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Internal Medicine, Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>Cardiology, Vanderbilt University, Nashville, TN, <sup>4</sup>Cardiology, Vanderbilt, Nashville, TN, <sup>5</sup>Cardiovascular Surgery, Johns Hopkins Hospital, Baltimore, MD
- 6:55 PM (150) *What is the Role of Standard Heart Failure Drug Therapy in the Context of VAD-Induced Unloading of the Failing Human Heart?;***  
 A. B. Catino, M. Al-Sari, R. McCubrey, J. Wever-Pinzon, C. Selzman, S. Wright, W. Caine, A. Kfoury, R. Alharethi, S. McKellar, K. Afshar, J. Nativi-Nicolau, M. Hawkins, P. Bremjit, D. Li, J. Fang, J. Stehlik, S. Drakos. Cardiology, U.T.A.H Cardiac Transplant Program (University of Utah, Intermountain Medical Center and VA Medical Center), Salt Lake City, UT

6:00 PM – 7:00 PM

MINI ORAL SESSION 3

**For Whom the Bell Tolls: Complications of Mechanical Circulatory Support (Erato,Uranie) (MCS)**

**CHAIRS:** M. Angela Rajek, MD and Lars H. Lund, MD, PhD

**6:00 PM (151) *Readmissions After Discharge to Home With Total Artificial Heart;***

A. J. Green<sup>1</sup>, L. G. Wolfe<sup>1</sup>, V. Kasirajan<sup>1</sup>, G. Katlaps<sup>1</sup>, D. Tang<sup>1</sup>, K. Shah<sup>2</sup>, M. Smallfield<sup>2</sup>, I. F. Tcoukina<sup>2</sup>, M. A. Quader<sup>1</sup>. <sup>1</sup>Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Cardiology, Virginia Commonwealth University, Richmond, VA

**6:05 PM (152) *Can Thrombolysis Safely Avert LVAD Exchange? A Single Center Experience;***

N. Nair, A. A. Schmitt, E. M. Rau, S. Anders, D. Sandler, T. B. Icenogle. Cardiology, Sacred Heart Medical Center, Spokane, WA

**6:10 PM (153) *Mucosal Abnormalities on Nasal Endoscopy Are Associated With Bleeding in Patients on CF LVAD Support;***

S. R. Patel, D. J. Goldstein, D. B. Sims, D. D'Alessandro, J. Nguyen, C. Nucci, J. J. Shin, U. Jorde. Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY

**6:15 PM (154) *Late Right Heart Failure Is Associated With Reduced Quality of Life and Functional Capacity in Continuous-Flow Left Ventricular Assist Device Recipients;***

M. S. Kiernan<sup>1</sup>, I. Gosev<sup>2</sup>, K. Sundareswaran<sup>3</sup>, J. Abraham<sup>4</sup>, B. Bethea<sup>5</sup>, J. Cowger<sup>6</sup>, P. Eckman<sup>7</sup>, S. Joseph<sup>8</sup>, J. N. Katz<sup>9</sup>, A. Kilic<sup>10</sup>, S. Lee<sup>11</sup>, B. Lima<sup>12</sup>, C. Patel<sup>13</sup>, J. Rich<sup>14</sup>, D. Farrar<sup>3</sup>, N. Uriel<sup>15</sup>. <sup>1</sup>Tufts Medical Center, Boston, MA, <sup>2</sup>Brigham and Women's Hospital, Boston, MA, <sup>3</sup>Thoratec Corporation, Pleasanton, CA, <sup>4</sup>Providence Health, Portland, OR, <sup>5</sup>Tenet Florida, Delray, FL, <sup>6</sup>St. Vincent Heart Center, Indianapolis, IN, <sup>7</sup>University of Minnesota, Minneapolis, MN, <sup>8</sup>Washington University in St. Louis, St. Louis, MO, <sup>9</sup>University of North Carolina, Chapel Hill, Chapel Hill, NC, <sup>10</sup>The Ohio State University, Columbus, OH, <sup>11</sup>Spectrum Health, Grand Rapids, MI, <sup>12</sup>Baylor University Medical Center, Dallas, TX, <sup>13</sup>Duke University Medical Center, Durham, NC, <sup>14</sup>Northwestern University, Chicago, IL, <sup>15</sup>University of Chicago, Chicago, IL

**6:20 PM (155) *Late Right Heart Failure in Destination Therapy Patients With HeartMate II Continuous Flow Device;***

I. Gosev<sup>1</sup>, J. N. Katz<sup>2</sup>, C. B. Patel<sup>3</sup>, S. Joseph<sup>4</sup>, J. Cowger<sup>5</sup>, J. Rich<sup>6</sup>, M. Kiernan<sup>7</sup>, J. T. Abraham<sup>8</sup>, B. T. Bethea<sup>9</sup>, P. Eckman<sup>10</sup>, A. Kilic<sup>11</sup>, S. Lee<sup>12</sup>, B. Lima<sup>13</sup>, N. Mokadam<sup>14</sup>, B. Soleimani<sup>15</sup>, D. Farrar<sup>16</sup>, K. Sundareswaran<sup>16</sup>, N. Uriel<sup>17</sup>. <sup>1</sup>Surgery, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Medicine, University of North Carolina Hospital, Chapel Hill, NC, <sup>3</sup>Medicine, Duke University Medical Center, Durham, NC, <sup>4</sup>Medicine, Barnes and Jewish Hospital, St. Louis, MO, <sup>5</sup>Medicine, St Vincents Hospital, Indianapolis, IN, <sup>6</sup>Medicine, Northwestern Memorial Hospital, Chicago, IL, <sup>7</sup>Medicine, Tufts Medical Center, Boston, MA, <sup>8</sup>Medicine, Providence Portland Medical Center, Portland, OR, <sup>9</sup>Surgery, Delrey Beach Hospital, Delrey Beach, FL, <sup>10</sup>Medicine, University of Minnesota Medical Center, Minneapolis, MN, <sup>11</sup>Surgery, Wexner Medical Center, Columbus, OH, <sup>12</sup>Medicine, Devos Childrens Hospital, Grand Rapids, MI, <sup>13</sup>Surgery, Baylor University Medical Center, Dallas, TX, <sup>14</sup>Surgery, Northwest Hospital and Medical Center, Seattle, WA, <sup>15</sup>Surgery, Milton S Hershey Medical Center, Hershey, PA, <sup>16</sup>Thoratec Corporation, Pleasanton, CA, <sup>17</sup>Medicine, University of Chicago Medicine, Chicago, IL

- 6:25 PM (156) *Percutaneous Driveline Infection Does Not Increase Subsequent Risk of Stroke and Pump Thrombus During Support With a Left Ventricular Assist Device;***  
 J. Van Meeteren<sup>1</sup>, S. Maltais<sup>2</sup>, S. Dunlay<sup>3</sup>, N. Haglund<sup>4</sup>, M. E. Davis<sup>2</sup>, F. D. Pagani<sup>5</sup>, K. Aaronson<sup>6</sup>, J. Cowger<sup>7</sup>, P. Shah<sup>8</sup>, J. M. Stulak<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>3</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>4</sup>Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>5</sup>Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, <sup>6</sup>Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI, <sup>7</sup>Cardiovascular Diseases, St. Vincent's Health System, Indianapolis, IN, <sup>8</sup>Cardiovascular Diseases, Inova Fairfax, Fairfax, VA
- 6:30 PM (157) *Systemic Inflammatory Response Syndrome in End-Stage Heart Failure Patients Following Contentious-Flow Left Ventricular Assist Device Implantation: Differences in Plasma Redox Status and Leukocyte Activation;***  
 N. K. Mondal<sup>1</sup>, E. N. Sorensen<sup>2</sup>, N. Hiiivala<sup>2</sup>, E. D. Feller<sup>1</sup>, S. Pham<sup>1</sup>, B. P. Griffith<sup>1</sup>, Z. J. Wu<sup>1</sup>. <sup>1</sup>Surgery, University of Maryland School of Medicine, Baltimore, MD, <sup>2</sup>Department of Clinical Engineering, University of Maryland Medical Center, Baltimore, MD
- 6:35 PM (158) *Stroke Subtype Impacts Outcomes and Transplant Eligibility in CF-LVADS;***  
 J. Z. Willey<sup>1</sup>, M. Gavalas<sup>2</sup>, A. Levin<sup>2</sup>, A. Breskin<sup>2</sup>, V. K. Topkara<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, K. Orlanes<sup>3</sup>, M. R. Torres<sup>3</sup>, M. Tiburcio<sup>3</sup>, K. Ross<sup>3</sup>, R. A. Garan<sup>2</sup>, K. Wong<sup>2</sup>, U. P. Jorde<sup>4</sup>, D. M. Mancini<sup>2</sup>, K. Takeda<sup>3</sup>, H. Takayama<sup>3</sup>, Y. Naka<sup>3</sup>, P. C. Colombo<sup>2</sup>. <sup>1</sup>Neurology, Columbia University, New York, NY, <sup>2</sup>Medicine, Columbia University, New York, NY, <sup>3</sup>Surgery, Columbia University, New York, NY, <sup>4</sup>Medicine, Montefiore Medical Center, Bronx, NY
- 6:40 PM (159) *Low Prevalence of Acquired von Willebrand Syndrome in Japanese Recipients of Continuous-Flow Ventricular Assist Devices;***  
 S. Nakajima<sup>1</sup>, O. Seguchi<sup>1</sup>, K. Kuroda<sup>1</sup>, E. Hisamatsu<sup>1</sup>, T. Sato<sup>1</sup>, H. Sunami<sup>1</sup>, T. Sato<sup>1</sup>, M. Yanase<sup>1</sup>, H. Hata<sup>2</sup>, T. Fujita<sup>2</sup>, J. Kobayashi<sup>2</sup>, T. Nakatani<sup>1</sup>. <sup>1</sup>Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>2</sup>Department of Adult Cardiac Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan
- 6:45 PM (160) *Fortuity or Causality in Minimally Invasive LVAD Implantation: Relation Between Outflow Graft Height of Implantation Along the Ascending Aorta and Cerebral Ischemic Events;***  
 J. Bejko, T. Bottio, G. Bortolussi, M. Gallo, R. Bianco, V. Tarzia, A. Guariento, G. Gerosa. Cardiac Surgery, Padova, Italy
- 6:50 PM (161) *Anemia After Continuous Flow Left Ventricular Assist Device (CF-LVAD) Implantation Is Associated With Morbidity and Mortality;***  
 J. Amione-Guerra, A. M. Cordero-Reyes, N. Fida, A. Bhimaraj, B. Trachtenberg, M. Loebe, G. Torre-Amione, J. D. Estep, G. Ashrith. Cardiology, Houston Methodist Hospital, Houston, TX
- 6:55 PM (162) *Does Delayed Sternal Closure Cause Increased Infection Rates After Left Ventricular Assist Device Implantation?;***  
 G. Yost, P. Pappas, A. Tatooles, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL

6:00 PM – 7:00 PM

MINI ORAL SESSION 4

The Big Chill: Heart Failure and Donor Management

(Hermes)

(HF, BSI, DMD, HTX, MCS, PH)

**CHAIRS:** Uwe Schulz, MD and Peter MacDonald, MD, PhD

**6:00 PM (163) *Favorable Outcomes in Dialysis Dependent Patients on LVAD BTT Support;***

A. Levin<sup>1</sup>, R. A. Garan<sup>1</sup>, V. K. Topkara<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, D. M. Mancini<sup>1</sup>, Y. Naka<sup>2</sup>, P. C. Colombo<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Surgery, Columbia University, New York, NY

**6:05 PM (164) *Efficacy of Left Ventricular Assist Devices or Inotropes for Bridging Patients With Pulmonary Hypertension to Heart Transplantation;***

G. H. Oliveira, S. Al-Kindi, S. Kumar, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park. University Hospitals Case Medical Center, Cleveland, OH

**6:10 PM (165) *Control of Sinus Node Tachycardia as Additional Therapy in Patients With Decompensated Heart Failure (CONSTATHE);***

M. S. Lofrano-Alves, V. S. Issa, E. A. Bocchi. Cardiology, University of Sao Paulo, Sao Paulo, Brazil

**6:15 PM (166) *Increased Cardiorespiratory Fitness on Exercise Stress Testing Predicts Long-Term Survival in Patients With HFpEF;***

A. J. Hicks, S. D. Russell, S. J. Keteyian, C. A. Brawner, M. Al-Mallah, M. J. Blaha. Cardiology, Johns Hopkins Hospital, Baltimore, MD

**6:20 PM (167) *The Impact of Miniaturized Hemodynamic Transesophageal Echocardiography (hTEE) on Decision-Making in Hemodynamically Unstable Patients in a Cardiothoracic Intensive Care Unit;***

M. Hlaing<sup>1</sup>, A. Jayaraman<sup>2</sup>, B. Flynn<sup>1</sup>, R. Sladen<sup>1</sup>. <sup>1</sup>Anesthesiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Anesthesiology, Weill Cornell Medical Center, NYPH, New York, NY

**6:25 PM (168) *The Role of Bortezomib in Advanced Cardiac AL Amyloidosis;***

I. Sayago<sup>1</sup>, I. Krsnik<sup>2</sup>, N. Jaramillo<sup>1</sup>, M. Gómez-Bueno<sup>1</sup>, P. García-Pavía<sup>1</sup>, L. Alonso-Pulpón<sup>1</sup>, J. Segovia<sup>1</sup>. <sup>1</sup>Heart Transplant (Cardiology), Puerta de Hierro Hospital, Madrid, Spain, <sup>2</sup>Hematology, Puerta de Hierro Hospital, Madrid, Spain

**6:30 PM (169) *Multiple Listing for Adult Heart Transplantation in the United States: Analysis of OPTN Data From 2000 to 2013;***

R. C. Givens<sup>1</sup>, T. Dardas<sup>2</sup>, K. J. Clerkin<sup>1</sup>, S. Restaino<sup>1</sup>, P. C. Schulze<sup>1</sup>, D. M. Mancini<sup>1</sup>. <sup>1</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine, University of Washington, Seattle, WA

**6:35 PM (170) *Longer Waiting Time Increases Mortality in Heart Transplantation: An Instrumental Variable Analysis;***

K. K. Khush<sup>1</sup>, J. G. Zaroff<sup>2</sup>, J. Nguyen<sup>3</sup>, B. A. Goldstein<sup>4</sup>. <sup>1</sup>Cardiovascular Medicine, Stanford University, Stanford, CA, <sup>2</sup>Division of Research, Kaiser Northern California, Oakland, CA, <sup>3</sup>California Transplant Donor Network, Oakland, CA, <sup>4</sup>Department of Biostatistics and Bioinformatics, Duke University, Durham, NC

**6:40 PM (171) *Adult Heart Transplant Survival Is Not Affected By Use of Centers of Disease Control High-Risk Donor Hearts;***

G. H. Oliveira, S. Kumar, S. Al-Kindi, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park. University Hospitals Case Medical Center, Cleveland, OH

**6:45 PM (172) *Tolerance to Perioperative Cold Ischemia in Donor Myocardium: Gender Differences;***

O. Szarszoj<sup>1</sup>, M. Smetana<sup>1</sup>, L. Hoskova<sup>2</sup>, I. Netuka<sup>1</sup>, J. Besik<sup>1</sup>, J. Maly<sup>1</sup>, J. Maluskova<sup>3</sup>, A. Lodererova<sup>3</sup>, J. Pirk<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>2</sup>Department of Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>3</sup>Department of Pathology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic

**6:50 PM (173) *Successful Orthotropic Heart Transplantation Using Donors With Left Ventricular Systolic Dysfunction: Evidence for Brain Death-Induced Takotsubo Cardiomyopathy;***

S. D. Rao, A. Watson, P. Lo, A. Jabbour, C. S. Hayward, A. M. Keogh, E. Kotlyar, E. Granger, P. Jansz, P. Spratt, K. Dhital, P. S. Macdonald. Heart and Lung Transplantation Unit, St Vincent's Hospital, Darlinghurst, Australia

**6:55 PM (174) *Right Ventricular Dysfunction in Brain Death: Effect of Corticosteroids;***

A. Belhaj<sup>1</sup>, L. Dewachter<sup>2</sup>, C. Dewachter<sup>2</sup>, K. Mc Entee<sup>2</sup>, R. Naeije<sup>2</sup>, B. Rondelet<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, CHU Dinant Godinne UCL, Yvoir, Belgium, <sup>2</sup>Laboratory of Physiology, Université Libre de Bruxelles, Bruxelles, Belgium



6:00 PM – 7:00 PM

MINI ORAL SESSION 5

**Last Tango in Nice: Motion is the Potion –  
A Guide for Clinicians (Calliope)**

(NNSAH, PEEQ, HF, HTX, LTX, MCS)

**CHAIRS:** Kevin C. Carney, MSN, CRNP, CCTC and  
Johan Vanhaecke, MD

**6:00 PM (175) *Physical Activity Measurement in Advanced  
Chronic Lung Disease;***

S. S. Dhillon<sup>1</sup>, R. D. Levy<sup>2</sup>, P. G. Wilcox<sup>2</sup>, J. A. Guenette<sup>1</sup>, B. S. Quon<sup>2</sup>, C. J. Ryerson<sup>2</sup>, P. G. Camp<sup>1</sup>. <sup>1</sup>Centre for Heart Lung Innovation, St. Paul's Hospital/University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Medicine, St. Paul's Hospital/University of British Columbia, Vancouver, BC, Canada

**6:05 PM (176) *A Supervised Pulmonary Rehabilitation  
Program Pre Lung Transplantation Is Associated  
With Higher 6-Minute Walk Distance in the Immediate  
Period Following Surgery;***

L. M. Fuller<sup>1</sup>, H. Whitford<sup>2</sup>, G. Snell<sup>2</sup>, A. E. Holland<sup>3</sup>. <sup>1</sup>Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, <sup>2</sup>Lung Transplant & Respiratory Medicine Department, The Alfred Hospital, Melbourne, Australia, <sup>3</sup>Physiotherapy Department, La Trobe University, The Alfred Hospital, Melbourne, Australia

**6:10 PM (177) *Predictors of Discharge Destination After  
Lung Transplantation;***

M. O. Alrawashdeh<sup>1</sup>, A. DeVito Dabbs<sup>1</sup>, M. Dew<sup>2</sup>, M. Song<sup>3</sup>, R. Zomak<sup>4</sup>, J. Pilewski<sup>4</sup>, C. Bermudez<sup>4</sup>. <sup>1</sup>School of Nursing, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>School of Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>3</sup>School of Nursing, University of North Carolina, Chapel Hill, NC, <sup>4</sup>Cardiothoracic Transplant Program, UPMC, Pittsburgh, PA

**6:15 PM (178) *Acute Blood Pressure Adaptations During  
Heavy Resistance Exercise in Patients With Heart  
Failure and Transplant Recipients: A Clinical Investiga-  
tion Using Continued Blood Pressure Surveillance;***

C. H. Dall<sup>1</sup>, F. Gustafsson<sup>2</sup>, B. Belhage<sup>3</sup>, H. Langberg<sup>4</sup>, E. Prescott<sup>1</sup>. <sup>1</sup>Department of Cardiology, Bispebjerg, University Hospital, Copenhagen, Denmark, <sup>2</sup>The Heart Centre, Rigshospitalet, University Hospital, Copenhagen, Denmark, <sup>3</sup>BRAIN, Bispebjerg, University Hospital, Copenhagen, Denmark, <sup>4</sup>Department of Public Health, University of Copenhagen, Copenhagen, Denmark

**6:20 PM (179) *Functional Outcomes and Quality of Life in  
Heart Transplant Patients Requiring Extracorporeal  
Membrane Oxygenation;***

K. Hayes<sup>1</sup>, A. E. Holland<sup>2</sup>, V. Pellegrino<sup>3</sup>, A. S. Leet<sup>4</sup>, L. M. Fuller<sup>1</sup>, C. L. Hodgson<sup>5</sup>. <sup>1</sup>Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, <sup>2</sup>Physiotherapy Department, La Trobe University, Alfred Health, Melbourne, Australia, <sup>3</sup>Intensive Care Unit, The Alfred Hospital, Melbourne, Australia, <sup>4</sup>Heart Transplant Unit, The Alfred Hospital, Baker Heart Institute, Melbourne, Australia, <sup>5</sup>Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, Australia

**6:25 PM (180) *In-Patient Rehab for Prolonged Hospital  
Stay After Heart Transplantation Prevents Hospital  
Readmissions and Infections;***

M. Johnson, A. Velleca, M. Kittleson, J. Patel, F. Liou, S. Sidiqui, T. Aintablian, D. H. Chang, B. Azarbal, L. Czer, F. Esmaillan, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

- 6:30 PM (181) *Presence and Type of Caregiver in LVAD Patient Populations: Does It Matter?***  
 G. A. Wright, A. Rauf, A. K. Johnson, A. C. Miller, S. Stoker, R. Alharethi, B. B. Reid, W. T. Caine, B. Y. Rasmusson, D. Budge, K. Afshar, A. G. Kfoury. Artificial Heart Program, Intermountain Medical Center, Murray, UT
- 6:35 PM (182) *Pre and Post Operative Factors Relate to Change in Health-Related Quality of Life From Before to 6 Months Following LVAD Implantation: An INTERMACS Analysis***  
 K. L. Grady<sup>1</sup>, D. C. Naftel<sup>2</sup>, S. L. Myers<sup>2</sup>, J. K. Kirklin<sup>2</sup>.  
<sup>1</sup>Surgery/Cardiac Surgery, Northwestern University, Chicago, IL, <sup>2</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL
- (183) *WITHDRAWN***
- 6:40 PM (929) *Improvements in Six Minute Walk Distance After Continuous Flow Ventricular Assist Device Placement: Comparison of Pre-Implant Ambulatory and Non-Ambulatory Patients***  
 S. V. Pamboukian<sup>1</sup>, F. D. Pagani<sup>2</sup>, D. C. Naftel<sup>1</sup>, S. L. Myers<sup>1</sup>, K. A. Hollifield<sup>1</sup>, J. K. Kirklin<sup>1</sup>. <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI
- 6:45 PM (184) *Temporal Benefits of Continuous Flow Left Ventricular Assist Device Therapy Assessed With SF-36***  
 F. Downey III, R. Pedersen, N. Sulemanjee, T. Hastings, O. Cheema, D. Zwicke, J. Crouch, C. Downey, V. Thohan. Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, Milwaukee, WI
- 6:50 PM (185) *Health-Related Quality of Life Improves Dramatically From Pre-Implant to Post Implant (6 months) for Continuous Flow LVAD Patients in INTERMACS***  
 S. Wissman<sup>1</sup>, D. C. Naftel<sup>2</sup>, S. L. Myers<sup>2</sup>, J. K. Kirklin<sup>2</sup>, A. C. Gelijs<sup>3</sup>, A. J. Moskowitz<sup>4</sup>, J. B. Young<sup>5</sup>, K. L. Grady<sup>6</sup>. <sup>1</sup>Mechanical Circulatory Support, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>2</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Department of Population Health Sciences and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>4</sup>Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>5</sup>Lerner College of Medicine, Cleveland Clinic, Cleveland, OH, <sup>6</sup>Surgery/Cardiac Surgery, Northwestern University, Chicago, IL
- 6:55 PM (186) *Factors Influencing Gains in Six Minute Walk Distance After Continuous Flow Ventricular Assist Device Placement***  
 S. V. Pamboukian<sup>1</sup>, F. D. Pagani<sup>2</sup>, D. C. Naftel<sup>1</sup>, S. L. Myers<sup>1</sup>, K. A. Hollifield<sup>1</sup>, J. K. Kirklin<sup>1</sup>. <sup>1</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI

6:00 PM – 7:00 PM

MINI ORAL SESSION 6

**The Heartbreak Kid: Donors, VADs and Long-Term Outcomes (Euterpe)**

(PEDS, BSI, DMD, HF, HTX, ID, MCS, NNSAH, PATH, PH, PHARM, PEEQ)

**CHAIRS:** Christina J. VanderPluym, MD and Francesco Parisi, MD

**6:00 PM (187) *Determinates of Non-Utilization in Pediatric Heart Donors;***

C. Castleberry<sup>1</sup>, M. Khan<sup>1</sup>, F. Zafar<sup>1</sup>, S. Shugh<sup>2</sup>, I. Wilmot<sup>1</sup>, T. D. Ryan<sup>1</sup>, C. Chin<sup>1</sup>, J. L. Jefferies<sup>1</sup>, A. Lorts<sup>1</sup>, D. Morales<sup>1</sup>. <sup>1</sup>Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Pediatrics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**6:05 PM (188) *Do the Duration Between Donor Brain Death and Heart Harvest or Administration of Thyroxine (T4) Affect Allograft Function After Pediatric Heart Transplantation?;***

F. I. Lunze, K. Gauvreau, S. I. Colan, R. Narciso, F. Costantino, H. Bastardi, E. D. Blume, T. P. Singh. Cardiology, Boston Children's Hospital, Boston, MA

**6:10 PM (189) *Impact of Initial Norwood Shunt Type on Young HLHS Patients Listed for Heart Transplant: A Multi-Institutional Study;***

W. F. Carlo<sup>1</sup>, S. C. West<sup>2</sup>, M. McCulloch<sup>3</sup>, D. C. Naftel<sup>1</sup>, E. Pruitt<sup>1</sup>, J. K. Kirklin<sup>1</sup>, M. Hubbard<sup>1</sup>, K. M. Molina<sup>4</sup>, R. Gajarski<sup>5</sup>. <sup>1</sup>University of Alabama, Birmingham, AL, <sup>2</sup>Children's Hospital of Pittsburgh, Pittsburgh, PA, <sup>3</sup>Nemours Cardiac Center, Wilmington, DE, <sup>4</sup>Primary Children's Hospital, Salt Lake City, UT, <sup>5</sup>CS Mott Children's Hospital, Ann Arbor, MI

**6:15 PM (190) *Thromboelastography/Platelet Mapping® and Aspirin: Is There Evidence of a Meaningful Dose-Response Relationship in Children Supported With the Berlin Heart EXCOR Ventricular Assist Device?;***

L. J. May<sup>1</sup>, C. Lo<sup>2</sup>, T. M. Tesoro<sup>2</sup>, J. L. Zehnder<sup>3</sup>, S. Chen<sup>1</sup>, J. Lee<sup>2</sup>, M. Desai<sup>4</sup>, D. B. McElhinney<sup>5</sup>, D. N. Rosenthal<sup>1</sup>, K. Maeda<sup>5</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, <sup>2</sup>Department of Pediatrics, Stanford University, Palo Alto, CA, <sup>3</sup>Department of Pathology, Stanford University, Palo Alto, CA, <sup>4</sup>Department of Medicine, Quantitative Sciences Unit, Stanford University, Palo Alto, CA, <sup>5</sup>Department of Cardiothoracic Surgery, Stanford University, Palo Alto, CA

**6:20 PM (191) *Somatic Growth in Pediatric Patients Undergoing Long-Term Ventricular Assist Device Support With a Miniaturized Implantable Device;***

F. Guzman-Pruneda<sup>1</sup>, A. Jeewa<sup>2</sup>, W. J. Dreyer<sup>2</sup>, S. W. Denfield<sup>2</sup>, A. G. Cabrera<sup>2</sup>, J. F. Price<sup>2</sup>, S. Burki<sup>1</sup>, E. D. McKenzie<sup>1</sup>, I. Adachi<sup>1</sup>. <sup>1</sup>Congenital Heart Surgery, Texas Children's Hospital, Houston, TX, <sup>2</sup>Pediatric Cardiology, Texas Children's Hospital, Houston, TX

**6:25 PM (192) *Timing of Ventricular Assist Device Insertion on Post-Transplant Outcomes: An Analysis of the UNOS Database;***

J. Conway<sup>1</sup>, M. Lake<sup>2</sup>, D. Morales<sup>2</sup>, H. Buchholz<sup>1</sup>, A. Lorts<sup>2</sup>. <sup>1</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>2</sup>The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**6:30 PM (193) *Peri-Transplant Acute Kidney Injury in Children: Risk Factors and Impact on Clinical Course;***

C. MacDonald<sup>1</sup>, G. Alton<sup>2</sup>, A. Joffe<sup>3</sup>, C. Morgan<sup>3</sup>, S. Urschel<sup>3</sup>. <sup>1</sup>Nursing, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Nursing, Alberta Health Services, Edmonton, AB, Canada, <sup>3</sup>Medicine, University of Alberta, Edmonton, AB, Canada

- 6:35 PM (194) *Reducing Fluoroscopic Radiation Exposure During Endomyocardial Biopsy in Pediatric Transplant Recipients;***  
 J. G. Gossett<sup>1</sup>, C. L. Sammet<sup>2</sup>, A. Agrawal<sup>1</sup>, K. Rychlik<sup>3</sup>, D. F. Wax<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Ann and Robert H Lurie Children's Hosp, Chicago, IL, <sup>2</sup>Radiology, Ann and Robert H Lurie Children's Hosp, Chicago, IL, <sup>3</sup>Stanley Manne Children's Research Institute, Ann and Robert H Lurie Children's Hosp, Chicago, IL
- 6:40 PM (195) *Comparison of Segmental Versus Longitudinal Intravascular Ultrasound Analysis for Pediatric Cardiac Allograft Vasculopathy;***  
 M. A. Kuhn<sup>1</sup>, R. E. Chinnock<sup>1</sup>, M. Burch<sup>2</sup>, M. J. Fenton<sup>2</sup>. <sup>1</sup>Pediatrics, Loma Linda Univ, Loma Linda, CA, <sup>2</sup>Pediatrics, Great Ormond Street Hospital, London, United Kingdom
- 6:45 PM (196) *Early Statin Therapy Is Not Associated With Improved Outcomes After Heart Transplantation in Children;***  
 S. C. Greenway<sup>1</sup>, R. Butts<sup>2</sup>, D. C. Naftel<sup>3</sup>, E. Pruitt<sup>3</sup>, J. K. Kirklin<sup>3</sup>, S. Urschel<sup>1</sup>, K. R. Knecht<sup>4</sup>, Y. Law<sup>5</sup>. <sup>1</sup>University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Medical University of South Carolina, Charleston, SC, <sup>3</sup>University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>Arkansas Children's Hospital, Little Rock, AR, <sup>5</sup>Seattle Children's Hospital, Seattle, WA
- 6:50 PM (197) *Lymphoproliferative Disorders Late After Pediatric Heart Transplantation: A Multicenter Analysis;***  
 S. C. West<sup>1</sup>, J. M. Friedland-Little<sup>2</sup>, K. Schowengerdt<sup>3</sup>, D. Naftel<sup>4</sup>, E. Pruitt<sup>4</sup>, K. S. Smith<sup>1</sup>, S. Urschel<sup>5</sup>, M. Michaels<sup>6</sup>, J. K. Kirklin<sup>4</sup>, B. Feingold<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, <sup>2</sup>Pediatric Cardiology, University of Michigan, CS Mott Children's Hospital, Ann Arbor, MI, <sup>3</sup>Pediatric Cardiology, Saint Louis University, Cardinal Glennon Children's Medical Center, St Louis, MO, <sup>4</sup>Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>5</sup>Pediatric Cardiology, University of Alberta, Edmonton, AB, <sup>6</sup>Infectious Disease, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA
- 6:55 PM (198) *Psychosocial Milestones and Risk Behaviour in Adolescent Heart Transplant Patients;***  
 M. Kaufman<sup>1</sup>, A. Aujnarain<sup>2</sup>, I. Chen<sup>1</sup>, A. Gold<sup>3</sup>, A. Dipchand<sup>4</sup>. <sup>1</sup>Division of Adolescent Medicine, Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Department of Psychology, The Hospital for Sick Children, Toronto, ON, Canada, <sup>4</sup>Labatt Family Heart Centre, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

**6:00 PM – 7:00 PM**

**MODERATED POSTER SESSION 2** (Agora 2)

WINE AND CHEESE RECEPTION (Rhodes)

**PAST PRESIDENT'S MEETING** (Gallieni 3)

**6:00 PM – 7:30 PM**

**COMMITTEE/COUNCIL LEADERSHIP**

**ORIENTATION** (Gallieni 1 & 2)



## FRIDAY | April 17, 2015

### 7:30 AM – 7:00 PM

Registration Open (Agora 1)

Speaker Ready Room Open (Hermes Lounge)

### 8:00 AM – 9:00 AM

Poster Board Renumbering (Agora 2)

### 8:30 AM – 10:30 AM

#### PLENARY SESSION (APOLLON)

(ALL)

**CHAIRS:** Stephan Schueler, MD, PhD, FRCS and  
Robert L. Kormos, MD

**8:30 AM** *Fighting Transplant Commercialism: The Impact of the Declaration of Istanbul*

Francis L. Delmonico, MD, New England Organ Bank, Waltham, MA, USA

**8:50 AM** *Fighting Transplant Commercialism: A Criminological Approach is Needed*

Willem Weimar, MD, University Hospital Rotterdam-Dijkzigt, Rotterdam, Netherlands

**9:10 AM** **(199) FEATURED ABSTRACT: Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients (ROADMAP);**

J. D. Estep<sup>1</sup>, R. C. Starling<sup>2</sup>, D. A. Horstmanshof<sup>3</sup>, C. A. Milano<sup>4</sup>, C. H. Selzman<sup>5</sup>, K. B. Shah<sup>6</sup>, M. Loebe<sup>1</sup>, N. Moazami<sup>2</sup>, J. W. Long<sup>3</sup>, J. Stehlik<sup>3</sup>, V. Kasirajan<sup>6</sup>, D. C. Haas<sup>6</sup>, J. O'Connell<sup>8</sup>, A. J. Boyle<sup>8</sup>, F. Kalle<sup>8</sup>, D. J. Farrar<sup>8</sup>. <sup>1</sup>Houston Methodist Hospital, Houston, TX, <sup>2</sup>Cleveland Clinic, Cleveland, OH, <sup>3</sup>Integris Baptist, Oklahoma, OK, <sup>4</sup>Duke University, Durham, NC, <sup>5</sup>University of Utah, Utah, UT, <sup>6</sup>Virginia Commonwealth University, Richmond, VA, <sup>8</sup>Abington Memorial Hospital, Abington, PA, <sup>8</sup>Thoratec Corporation, Pleasanton, CA, <sup>8</sup>Piedmont Hospital, Atlanta, GA

**9:25 AM** *Heralding the End of Vascular Obstruction*

Tobias Deuse, MD, PhD, University Heart Center Hamburg, Hamburg, Germany

**9:45 AM** *The Health eHeart Study: Harnessing the Power of the Internet to Advance Clinical Research and Patient Care World-Wide*

Gregory Marcus, MD, UCSF, San Francisco, CA, USA

**10:05 AM** *The Psychology of Judgment and Decision Making*

Alexandra L. Quittner, PhD, University of Miami, Miami, FL, USA

### 9:00 AM – 7:00 PM

Press Office Open (Gallieni 6)

EXHIBITS OPEN (Rhodes)

POSTER HALL OPEN (Agora 2)

## 10:30 AM – 11:00 AM

### ANNUAL BUSINESS MEETING (Apollon)

Coffee Break/Visit Exhibits (Rhodes)

VIEW POSTERS (Agora 2)

## 11:00 AM – 12:30 PM

### CONCURRENT SESSION 22

#### LVADs: Factors Influencing Outcomes (Apollon)

(MCS, DMD, HF, HTX, NHSAH)

**CHAIRS:** Shashank S. Desai, MD and Sangjin Lee, MD

#### 11:00 AM (200) *Duration of Heart Failure Influences the Outcomes After Mechanical Circulatory Support;*

R. Y. Loyaga-Rendon<sup>1</sup>, R. C. Starling<sup>2</sup>, R. S. Cantor<sup>3</sup>, S. V. Pamboukian<sup>1</sup>, J. A. Tallaj<sup>1</sup>, D. A. Acharya<sup>1</sup>, D. C. Naftel<sup>3</sup>, J. K. Kirklin<sup>3</sup>. <sup>1</sup>Cardiovascular Diseases, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Cardiothoracic Surgery, University of Alabama at Birmingham, Birmingham, AL

#### 11:15 AM (201) *Long Term Survival in Continuous Flow Left Ventricular Assist Devices;*

I. Gosev<sup>1</sup>, S. M. Joseph<sup>2</sup>, P. Eckman<sup>3</sup>, A. Kilic<sup>4</sup>, N. Uriel<sup>5</sup>, J. D. Rich<sup>6</sup>, J. N. Katz<sup>6</sup>, J. Cowger<sup>8</sup>, B. Lima<sup>9</sup>, S. McGurk<sup>1</sup>, C. B. Patel<sup>10</sup>. <sup>1</sup>Surgery, Brigham and Women's Hospital, Boston, MA, <sup>2</sup>Medicine, Barnes and Jewish Hospital, St Louis, MO, <sup>3</sup>Medicine, University of Minnesota Medical Center, Minneapolis, MN, <sup>4</sup>Surgery, Wexner Medical Center, Columbus, OH, <sup>5</sup>Medicine, University of Chicago Medicine, Chicago, IL, <sup>6</sup>Medicine, Northwestern Memorial Hospital, Chicago, IL, <sup>7</sup>Medicine, University of North Carolina Hospital, Chapel Hill, NC, <sup>8</sup>Medicine, St Vincent Hospital, Indianapolis, IN, <sup>9</sup>Surgery, Baylor University Medical Center, Dallas, TX, <sup>10</sup>Medicine, Duke University Medical Center, Durham, NC

#### 11:30 AM (202) *Device Implant Strategy and Patient Characteristics Have a Profound Impact on Early, Mid and Late Outcomes After MCS/ DMD Implant;*

D. C. Naftel<sup>1</sup>, F. D. Pagani<sup>2</sup>, M. A. Miller<sup>3</sup>, J. B. Young<sup>4</sup>, S. L. Myers<sup>1</sup>, J. K. Kirklin<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>3</sup>National Heart, Lung, Blood Institute, Bethesda, MD, <sup>4</sup>Lerner College of Medicine, Cleveland Clinic, Cleveland, OH,

#### 11:45 AM (203) *Association Between Age, Bridge to Transplant Continuous Flow LVAD Use, and Outcomes After Heart Transplantation;*

A. Ciarka<sup>1</sup>, L. Edwards<sup>2</sup>, J. Stehlik<sup>3</sup>, L. Lund<sup>4</sup>. <sup>1</sup>Department of Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, <sup>2</sup>ISHLT Transplant Registry, Dallas, TX, <sup>3</sup>University of Utah Health, Salt Lake City, UT, <sup>4</sup>Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

#### 12:00 PM (204) *Pre-Implant Glomerular Filtration Rate (GFR) as a Predictor of Adverse Outcomes Post Left Ventricular Assist Device Placement;*

B. Mohamedali, G. Yost, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL

#### 12:15 PM (205) *Albuminuria Is Common in Patients Undergoing Left Ventricular Assist Device and Predicts Subsequent Renal Recovery;*

M. A. Brisco<sup>1</sup>, A. Hale<sup>1</sup>, D. P. Heyward<sup>1</sup>, M. L. Craig<sup>1</sup>, J. M. Testani<sup>2</sup>. <sup>1</sup>Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC, <sup>2</sup>Program of Applied Translational Research, Yale University School of Medicine, New Haven, CT

**11:00 AM – 12:30 PM**

**CONCURRENT SESSION 23**

**An Update On Short Term Support (Athena)  
(MCS, DMD, HF, HTX, NNSAH)**

**CHAIRS:** Ranjit John, MD and Michel Morshuis, MD

**11:00 AM (206) *Temporary Extracorporeal Membrane Oxygenation: Ten-Year Experience at a Cardiac Transplant Center;***

B. G. Tran<sup>1</sup>, E. Depasquale<sup>1</sup>, J. Meltzer<sup>2</sup>, A. Ardehali<sup>3</sup>, D. Cruz<sup>1</sup>, M. Deng<sup>1</sup>, R. Shemin<sup>3</sup>, A. Nsair<sup>1</sup>. <sup>1</sup>Cardiology, University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Anesthesiology, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Surgery, University of California, Los Angeles, Los Angeles, CA

**11:15 AM (207) *Early Crossover From Extracorporeal Membrane Oxygenation to More Durable Mechanical Circulatory Support Improves Survival;***

R. Cheng, B. Azarbal, J. Herr, D. Ramzy, J. A. Kobashigawa, F. A. Arabia, J. D. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA

**11:30 AM (208) *Management and Outcome of Left Ventricular Distention During Venoaortic Extracorporeal Membrane Oxygenation Support;***

L. Truby<sup>1</sup>, S. Hart<sup>1</sup>, K. Takeda<sup>1</sup>, Y. Naka<sup>1</sup>, P. C. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, A. Garan<sup>2</sup>, V. K. Topkara<sup>2</sup>, D. Mancini<sup>2</sup>, H. Takayama<sup>1</sup>. <sup>1</sup>Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, <sup>2</sup>Department of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

**11:45 AM (209) *A Prospective Multicenter Study to Evaluate Safety and Probable Benefit of a Novel Percutaneous Ventricular Assist Device for Right Ventricular Failure: The RECOVER RIGHT Study;***

M. Anderson<sup>1</sup>, J. Goldstein<sup>2</sup>, L. Morris<sup>3</sup>, C. Milano<sup>4</sup>, R. Kormos<sup>5</sup>, J. Bhama<sup>5</sup>, N. Kapur<sup>6</sup>, A. Bansal<sup>6</sup>, J. Garcia<sup>8</sup>, S. Silvestry<sup>8</sup>, W. Holman<sup>10</sup>, W. O'Neill<sup>11</sup>. <sup>1</sup>Cardiothoracic Surgery, Einstein Healthcare Network, Bryn Mawr, PA, <sup>2</sup>William Beaumont Hospital, Royal Oak, MI, <sup>3</sup>Einstein Healthcare Network, Bryn Mawr, PA, <sup>4</sup>Duke University Medical Center, Durham, NC, <sup>5</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>6</sup>Tufts University Medical Center, Boston, MA, <sup>8</sup>Ochsner Foundation, New Orleans, LA, <sup>8</sup>Massachusetts General Hospital, Boston, MA, <sup>8</sup>Barnes Jewish Hospital, St Louis, MO, <sup>10</sup>University of Alabama, Birmingham, AL, <sup>11</sup>Henry Ford Hospital, Detroit, MI

**12:00 PM (210) *Outcome of the Impella Device for Mechanical Circulatory Support in Patients With Refractory Cardiogenic Shock;***

P. Farahmand, A. Quessard, G. Lebreton, C. d'Alessandro, C. Mastroianni, P. Leprince. Cardio-Thoracic Surgery, Hopital Pitie Salpetriere, Paris, France

**12:15 PM (211) *Feasibility of Long Term Use of External Continuous Flow Ventricular Assist Device;***

B. Li, L. Truby, K. Fujita, S. Ikeda, S. Fukuhara, L. Vargas, S. Hart, Y. Naka, H. Takayama. Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY



11:00 AM – 12:30 PM

CONCURRENT SESSION 24

**Immunosuppression: The Tor Inhibitors Strike Back**

(Clio, Thalie)

(HTX, BSI, HF, ID, NNSAH, PATH, PEDS, PHARM)

**CHAIRS:** Howard J. Eisen, MD and Markus J. Barten, MD, PhD

**11:00 AM (212) *The Effect of Everolimus Initiation and Early Calcineurin Inhibitor Withdrawal on Allograft Vasculopathy in De-Novo Heart Transplant Recipients: Results of the SCHEDULE Trial After 36 Months;***

**S. Arora<sup>1</sup>, O. Solberg<sup>1</sup>, K. Karason<sup>2</sup>, B. Andersson<sup>2</sup>, F. Gustafsson<sup>3</sup>, H. Eiskjær<sup>4</sup>, G. Rådegran<sup>5</sup>, E. Gude<sup>1</sup>, T. Ueland<sup>6</sup>, P. Aukrust<sup>6</sup>, D. Solbu<sup>6</sup>, G. Dellgren<sup>2</sup>, A. Andreassen<sup>1</sup>, L. Gullestad<sup>1</sup>.** <sup>1</sup>Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>2</sup>Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>4</sup>Cardiology, Skejby University Hospital, Aarhus, Denmark, <sup>5</sup>Cardiology, Skåne University Hospital, Lund, Sweden, <sup>6</sup>Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>6</sup>Novartis Norge, Oslo, Norway

**11:15 AM (213) *Long Term Outcomes in Thoracic Transplant Recipients After Conversion to Everolimus With Reduced Calcineurin Inhibitor Within a Multicenter, Open-Label, Randomized Trial;***

**L. Gullestad<sup>1</sup>, H. Eiskjær<sup>2</sup>, F. Gustafsson<sup>3</sup>, G. Riise<sup>4</sup>, K. Karason<sup>5</sup>, G. Dellgren<sup>5</sup>, G. Rådegran<sup>6</sup>, L. Hansson<sup>6</sup>, E. Gude<sup>1</sup>, Ø. Bjørtuft<sup>1</sup>, K. Jansson<sup>8</sup>, D. Solbu<sup>8</sup>, M. Iversen<sup>3</sup>.** <sup>1</sup>Oslo Univ Hospital, Oslo, Norway, <sup>2</sup>Aarhus University Hospital, Aarhus, Denmark, <sup>3</sup>Rigshospitalet, Copenhagen, Denmark, <sup>4</sup>Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>5</sup>Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>6</sup>Skåne University Hospital and Lund University, Lund, Sweden, <sup>8</sup>Linköping University Hospital, Linköping, Sweden, <sup>8</sup>Novartis Norway, Oslo, Norway

**11:30 AM (214) *Use of Rapamycin One-Year Post Heart Transplantation Stabilizes Transplant Allograft Vasculopathy – The Mid America Experience;***

**A. Kao<sup>1</sup>, M. Eaton<sup>1</sup>, C. Knutson<sup>1</sup>, J. Linard<sup>1</sup>, J. House<sup>1</sup>, B. A. Austin<sup>1</sup>, M. P. Everley<sup>1</sup>, T. M. Khumri<sup>1</sup>, S. L. Lawhorn<sup>1</sup>, A. Magalski<sup>1</sup>, A. M. Borkon<sup>2</sup>, D. Safley<sup>1</sup>.** <sup>1</sup>Cardiology, St. Luke's Mid America Heart Institute, Kansas City, MO, <sup>2</sup>Cardiothoracic Surgery, St. Luke's Mid America Heart Institute, Kansas City, MO

**11:45 AM (215) *A Multi-Center, Randomized, Open-Label, Parallel Group Phase IV Trial Investigating the Outcome on Renal Function, Efficacy and Safety of CNI-Reduction or Elimination With Everolimus in De Novo Heart Transplant Recipients: The MANDELA Study Design;***

**T. Deuse<sup>1</sup>, C. Bara<sup>1</sup>, M. Barten<sup>1</sup>, S. Hirt<sup>1</sup>, A. Doesch<sup>1</sup>, C. Knosalla<sup>1</sup>, C. Grininger<sup>1</sup>, J. Stypmann<sup>1</sup>, M. Porstner<sup>2</sup>, P. Wimmer<sup>2</sup>, U. Schulz<sup>1</sup>.** <sup>1</sup>Mandela, Study Group, Germany, <sup>2</sup>Novartis Pharma, Nuremberg, Germany

**12:00 PM (216) *Sirolimus Based Immunosuppression Results in Lower Incidence of Post-Transplantation Lymphoproliferative Disorders in Heart Transplant Recipients;***

**D. Vucicevic<sup>1</sup>, R. C. Daly<sup>2</sup>, D. E. Steidley<sup>1</sup>, R. L. Scott<sup>1</sup>, W. K. Kremers<sup>2</sup>, B. S. Edwards<sup>2</sup>, K. S. Sudhir<sup>3</sup>.** <sup>1</sup>Mayo Clinic Arizona, Scottsdale, AZ, <sup>2</sup>Mayo Clinic Rochester, Rochester, MN, <sup>3</sup>Mayo Clinic Rochester, Rochester, AZ

**12:15 PM (217) *Effect of Everolimus Immunotherapy on HLA Antibody Production in Heart Transplantation;***

P. Rao<sup>1</sup>, L. Hong<sup>2</sup>, D. Gjertson<sup>2</sup>, I. Balazs<sup>3</sup>, M. C. Fishbein<sup>2</sup>, M. Deng<sup>4</sup>, N. Harre<sup>1</sup>, R. Leuchter<sup>1</sup>, H. L. Banchs<sup>5,6</sup>, D. DeNofrio<sup>7</sup>, H. J. Eisen<sup>8</sup>, G. A. Ewald<sup>9</sup>, A. Kfoury<sup>10</sup>, J. A. Kobashigawa<sup>11</sup>, R. C. Starling<sup>12</sup>, G. Torre-Amione<sup>13</sup>, A. Van Bakel<sup>14</sup>, E. F. Reed<sup>1</sup>.

<sup>1</sup>Pathology, UCLA, Los Angeles, CA, <sup>2</sup>Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, <sup>3</sup>Discovery Research, Immucor, Inc., Stamford, CT, <sup>4</sup>Cardiology, UCLA, Los Angeles, CA, <sup>5</sup>Cardiology, University of Puerto Rico, Carolina, PR, <sup>6</sup>Cardiology, University of Puerto Rico, Rio Piedras, PR, <sup>7</sup>Cardiology, Tufts University School of Medicine, Boston, MA, <sup>8</sup>Cardiology, Drexel University College of Medicine, Philadelphia, PA, <sup>9</sup>Cardiovascular Diseases, Washington University, St. Louis, MO, <sup>10</sup>Cardiovascular Medicine, LDS Hospital, Salt Lake City, UT, <sup>11</sup>Heart Transplant, Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>12</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, <sup>13</sup>Cardiology, Methodist, Houston, TX, <sup>14</sup>Cardiology, Medical University of South Carolina, Charleston, SC



11:00 AM – 12:30 PM

CONCURRENT SESSION 25

**Pump Up the Jam, Don't Jam Up the Pump!**  
**VAD-Management and Complications (Erato,Uranie)**  
**(PEDS, DMD-LUNG, HF, HTX, ID, LF, MCS, NHSAH, PH)**

**CHAIRS:** Ivan M. Rebeyka, MD and Brigitte Stiller, MD, PhD

- 11:00 AM (218) *Temporal Distribution of Hematologic Complications During Berlin EXCOR Support;***  
S. Burki<sup>1</sup>, D. H. Mahoney<sup>1</sup>, A. Jeewa<sup>1</sup>, W. Zhang<sup>1</sup>, E. McKenzie<sup>1</sup>, D. L. Morales<sup>2</sup>, C. M. Mery<sup>1</sup>, J. S. Heinle<sup>1</sup>, C. D. Fraser<sup>1</sup>, I. Adachi<sup>1</sup>. <sup>1</sup>Texas Children's Hospital, Houston, TX, <sup>2</sup>Cincinnati Children's Hospital, Cincinnati, OH
- 11:15 AM (219) *New Insights into Thrombosis in ECMO Circuits: Where, How and Why?;***  
S. R. Deshpande<sup>1</sup>, S. Hastings<sup>2</sup>, S. Wagoner<sup>3</sup>, D. Ku<sup>4</sup>, K. Maher<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, <sup>2</sup>Biofluids and Medical Device Research Group, Georgia Institute of Technology, Atlanta, GA, <sup>3</sup>Manager, ECMO Program, Children's Healthcare of Atlanta, Atlanta, GA, <sup>4</sup>Department of Engineering, Georgia Institute of Technology, Atlanta, GA
- 11:30 AM (220) *Impact of a Modified Anti-Thrombotic Protocol on the Risk of Stroke and Thromboembolism in Children Supported With the Berlin Heart Excor Pediatric Ventricular Assist Device;***  
C. A. Lancaster<sup>1</sup>, C. S. Almond<sup>2</sup>, S. A. Hollander<sup>2</sup>, M. L. Stein<sup>3</sup>, A. Lin<sup>4</sup>, L. Doan<sup>2</sup>, J. Murray<sup>4</sup>, D. N. Rosenthal<sup>5</sup>. <sup>1</sup>School of Medicine, University of Kansas, Kansas City, KS, <sup>2</sup>Pediatrics, Stanford University, Palo Alto, CA, <sup>3</sup>Anesthesia, Stanford University, Palo Alto, CA, <sup>4</sup>Pediatrics, LPCH, Palo Alto, CA, <sup>5</sup>Stanford University, Palo Alto, CA
- 11:45 AM (221) *Wound Infections in Children With Ventricular Assist Device Support: Are Intracorporeal Devices Better?;***  
C. J. Vander Pluym<sup>1</sup>, K. R. Schmitt<sup>2</sup>, B. Hawkins<sup>1</sup>, N. Speckmann<sup>2</sup>, E. D. Blume<sup>1</sup>, O. Miera<sup>2</sup>. <sup>1</sup>Cardiology, Boston Children's Hospital, Boston, MA, <sup>2</sup>Cardiology, Deutsches Herzzentrum Berlin & Charité Berlin, Berlin, Germany
- 12:00 PM (222) *Refining of the Pump Exchange Procedure in Children Supported With the Berlin Heart EXCOR Ventricular Assist Device: 10 Years Experience at a Single Institution;***  
K. Maeda, C. Almond, S. A. Hollander, D. N. Rosenthal, B. Kaufman, J. Yeh, M. M. Gowen, P. Shuttleworth, O. Reinhartz. Stanford University, Stanford, CA
- 12:15 PM (223) *Virtual Implantation of the 50cc Total Artificial Heart;***  
R. A. Moore, P. C. Madueme, A. Lorts, D. L. Morales, M. D. Taylor. The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**11:00 AM – 12:30 PM**

**CONCURRENT SESSION 26**

**Heart Failure – Omics, Kines and Stem Cells (Hermes)  
(BSI, HF, PATH)**

**CHAIRS:** Sonja Schrepfer, MD, PhD and  
Pradeep P.A. Mammen, MD, FACC, FAHA

- 11:00 AM (224) *Cytokine Expression in the Myocardium Correlates With Cardiac Structural and Functional Improvement Induced By Mechanical Unloading in Chronic Heart Failure;***  
N. Diakos, L. McCreath, S. Navankasattusas, A. Catino, J. Stehlik, A. G. Kfoury, C. Selzman, A. Koliopoulou, S. H. McKellar, D. Budge, K. Skedros, A. Ragnhildstveit, M. Al-Sari, U. Lam, J. Fang, D. Li, S. G. Drakos. U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT
- 11:15 AM (225) *Thymosin 4 and Its Cleavage Product Ac-SDKP Are Down-Regulated in Left Ventricular Myocardium of Patients With Advanced Heart Failure;***  
H. N. Sabbah, R. C. Gupta, V. Singh-Gupta. Medicine, Henry Ford Hospital, Detroit, MI,
- 11:30 AM (226) *Myocardial Lipid Metabolism in the End-Stage Failing Heart: Evidence for an Energy-Starved State;***  
J. E. Rame<sup>1</sup>, K. Bedi<sup>1</sup>, N. Snyder<sup>2</sup>, J. Brandimarto<sup>2</sup>, C. Mesaros<sup>2</sup>, E. Y. Birati<sup>1</sup>, I. A. Blair<sup>2</sup>, K. B. Margulies<sup>1</sup>. <sup>1</sup>Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Center of Cancer Pharmacology, University of Pennsylvania, Philadelphia, PA
- 11:45 AM (227) *The Effect of Diabetes Mellitus on Cardiac Mitochondria in Patients With End-Stage Heart Failure;***  
V. Melenovsky<sup>1</sup>, J. Benes<sup>1</sup>, J. Pirk<sup>2</sup>, T. Pelikanova<sup>3</sup>, T. Mracek<sup>4</sup>, H. Nuskova<sup>4</sup>, Z. Drahota<sup>4</sup>, J. Kovalcikova<sup>4</sup>, J. Houstek<sup>4</sup>.  
<sup>1</sup>Dept. of Cardiology, IKEM, Prague, Czech Republic, <sup>2</sup>Cardiac Surgery, IKEM, Prague, Czech Republic, <sup>3</sup>Dept. of Diabetology, IKEM, Prague, Czech Republic, <sup>4</sup>Department of Bioenergetics, Institute of Physiology, Academy of Sciences of CR, Prague, Czech Republic
- 12:00 PM (228) *Response to CD34+ Cell Therapy Is Associated With Myocardial Scar Burden in Patients With Ischemic and Non-Ischemic Chronic Heart Failure;***  
B. Vrtovec<sup>1</sup>, G. Poglajen<sup>1</sup>, G. Zemljic<sup>1</sup>, M. Sever<sup>2</sup>, M. Cukjati<sup>3</sup>, F. Haddad<sup>4</sup>, J. C. Wu<sup>4</sup>. <sup>1</sup>Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>National Blood Transfusion Ctr, Ljubljana, Slovenia, <sup>4</sup>Stanford Cardiovascular Institute, Stanford, CA
- 12:15 PM (229) *Metabolic Status Determines the Efficacy of CD34+ Stem Cell Therapy in Patients With Non-Ischemic Dilated Cardiomyopathy;***  
B. Vrtovec<sup>1</sup>, M. Sever<sup>2</sup>, M. Jensterle<sup>3</sup>, G. Poglajen<sup>1</sup>, A. Janez<sup>3</sup>, N. Kravos<sup>3</sup>, F. Haddad<sup>4</sup>, J. C. Wu<sup>4</sup>, U. P. Jorde<sup>5</sup>. <sup>1</sup>Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>Department of Endocrinology, UMC Ljubljana, Ljubljana, Slovenia, <sup>4</sup>Stanford Cardiovascular Institute, Stanford, CA, <sup>5</sup>Albert Einstein College of Medicine, New York, NY

11:00 AM – 12:30 PM

CONCURRENT SESSION 27

**Basic Science 2: Organ Preservation Including Ex-Vivo Management, Ischemia/Reperfusion (Calliope) (ALL)**

**CHAIRS:** Paul Christian Schulze, MD, PhD and Andrew E. Gelman, PhD

**11:00 AM (230) *Nrf2 Inhibits NF- $\kappa$ B Activation and Attenuates Ischemia-Reperfusion Injury in Heart Transplantation;*** H. Kawajiri, L. Tumiati, A. Ghashghai, J. Lazarte, L. Grosman-Rimon, F. Billia, R. Li, M. Badiwala, V. Rao. Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

**11:15 AM (231) *Human Alpha-1 Antitrypsin Improves Lung Function in a Pig Lung Transplant Model;*** I. Iskender, J. Sakamoto, D. Nakajima, M. Chen, H. Lin, L. del Sorbo, Z. Guan, D. Hwang, T. K. Waddell, M. Cypel, S. Keshavjee, M. Liu. Latner Thoracic Research Laboratories, Toronto General Research Institute, University Health Network – University of Toronto, Toronto, ON, Canada

**11:30 AM (232) *Lung Lavage and Surfactant Administration for the Ex-Vivo Pre-Transplant Treatment of Donor Lungs Injured Due to Gastric Acid Aspiration;*** D. Nakajima, A. Ohsumi, I. Iskender, R. Kalaf, M. Chen, R. Coutinho, T. Kanou, L. Maahs, P. Behrens, J. Sakamoto, J. Lee, P. Mordant, M. Hsin, S. Azad, T. K. Waddell, T. Martinu, M. Cypel, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, ON, Canada

**11:45 AM (233) *Ex-Vivo Therapeutic Use of Carbon Monoxide (CO) to Improve Donor Lungs for Transplantation;*** R. Kalaf-Mussi, J. Lee, D. Nakajima, M. Chen, L. Maahs, R. Coutinho, M. Liu, S. Keshavjee, M. Cypel. Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program, University Health Ne, University of Toronto, Toronto, ON, Canada

**12:00 PM (234) *The Effect of Sevoflurane in Pre- and Postconditioning of Ischemia-Reperfusion Injury in a Rat Lung Transplantation Model;*** A. Ohsumi, K. Marseu, P. Slinger, K. McRae, I. Iskender, M. Chen, K. Hashimoto, H. Oishi, H. Kim, Z. Guan, D. Hwang, T. Waddell, M. Liu, S. Keshavjee, M. Cypel. Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, Toronto, ON, Canada

**12:15 PM (235) *Lymphatic Endothelial Cell VEGFR3 Controls Cardiac Allograft Rejection;*** A. Dashkevich<sup>1</sup>, A. Raissadati<sup>2</sup>, G. Zarkada<sup>3</sup>, K. Alitalo<sup>3</sup>, A. Nykanen<sup>2</sup>, K. Lemström<sup>2</sup>. <sup>1</sup>LMU Medical Centre LMU Medical Centre, Munich, Germany, <sup>2</sup>Haartman Institute, University of Helsinki, Helsinki, Finland, <sup>3</sup>Biomedicum, University of Helsinki, Helsinki, Finland

**11:00 AM – 12:30 PM**

## CONCURRENT SYMPOSIUM 28

### **JHLT at ISHLT: The Year in a Capsule (Euterpe)** **(ALL)**

**CHAIRS:** Paul A. Corris, MB, FRCP and Keyur B. Shah, MD

**SESSION SUMMARY:** This session will highlight the most exciting publications in JHLT over the past year, followed by a discussion by one of the senior editorial consultants of the journal to relate the presented articles to the greater body of published literature and discuss how they advance our understanding in the field.

**11:00 AM** *Highlights of Heart Transplantation and Mechanical Circulatory Support*

Manreet Kanwar, MD, Allegheny General Hospital, Pittsburgh, PA

**11:15 AM** *DISCUSSANT: Highlights of Heart Transplantation and Mechanical Circulatory Support*

Luciano Potena, MD, PhD, University of Bologna, Bologna, Italy

**11:20 AM** *Highlights of Lung Transplantation and Pulmonary Hypertension*

Robin Vos, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

**11:35 AM** *DISCUSSANT: Highlights of Lung Transplantation and Pulmonary Hypertension*

Edward R. Garrity, MD, University of Chicago Medical Center, Chicago, IL, USA

**11:40 AM** *Highlights of Pediatrics Heart/ Lung Transplantation*

Jonathan N. Johnson, MD, Mayo Clinic, Rochester, MN, USA

**11:55 AM** *DISCUSSANT: Highlights of Pediatric Heart and Lung Transplantation*

Christian Benden, MD, University Hospital Zurich, Zurich, Switzerland

**12:00 PM** *Highlights of Transplant Infectious Diseases*

Saima Aslam, MD, MS, University of California San Diego, San Diego, CA, USA

**12:15 PM** *DISCUSSANT: Highlights of Transplant Infectious Diseases*

Lara Danziger-Isakov, MD, MPH, Children's Hospital Medical Center, Cincinnati, OH, USA

## **12:30 PM – 2:30 PM**

Lunch Break

## **12:30 PM – 1:30 PM**

Box Lunch Distribution (Rhodes)

## **12:30 PM – 1:30 PM**

**PULMONARY HYPERTENSION  
SCIENTIFIC COUNCIL MEETING (Calliope)**

**MECHANICAL CIRCULATORY  
SUPPORT SCIENTIFIC COUNCIL MEETING (Euterpe)**

**PEDIATRIC TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING (Gallieni 1)**

**INFECTIOUS DISEASES SCIENTIFIC  
COUNCIL MEETING (Gallieni 4)**

**PATHOLOGY SCIENTIFIC COUNCIL MEETING (Gallieni 5)**

## **1:00 PM – 2:30 PM**

**IMACS REGISTRY MEETING (Gallieni 7)**

## **1:30 PM – 2:25 PM**

**PULMONARY TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING (Calliope)**

**HEART FAILURE AND TRANSPLANTATION  
SCIENTIFIC COUNCIL MEETING (Euterpe)**

**PEDIATRIC HEART FAILURE  
WORKFORCE MEETING (Gallieni 1)**

**IPLTC MEETING (Gallieni 4)**

2:30 PM – 4:00 PM

## CONCURRENT SESSION 29

### Transplanting Patients with Machines (Apollon) (MCS, DMD-HEART, HF, HTX, NNSAH)

**CHAIRS:** Joseph G. Rogers, MD and Arnt E. Fiene, MD

**2:30 PM (236) Panel Reactive Antibody Levels Are Associated With Survival in Heart Transplant Recipients Without But Not With a Ventricular Assist Device at the Time of Transplant;**

P. Chiu<sup>1</sup>, J. M. Schaffer<sup>1</sup>, P. E. Oyer<sup>1</sup>, D. Banerjee<sup>2</sup>, J. Woo<sup>1</sup>, R. Ha<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University, School of Medicine, Stanford, CA, <sup>2</sup>Cardiology, Stanford University, School of Medicine, Stanford, CA

**2:45 PM (237) Effect of the 2006 U.S. Donor Heart Allocation Policy Change on Waitlist Complications and Post-Transplant Mortality Among Candidates Supported With Mechanical Circulatory Support;**

O. Wever-Pinzon, M. Farr, Y. Naka, H. Takayama, I. George, P. Colombo, D. Mancini, P. Schulze. Columbia University Medical Center, New York, NY

**3:00 PM (238) Contemporary Use of Continuous Flow Left Ventricular Assist Devices Are No Longer Associated With Post-Transplant Mortality;**

S. Kumar, S. Al-Kindi, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH

**3:15 PM (239) LVAD Bridging to Heart Transplantation With Ex-Vivo Allograft Preservation Shows Significantly Improved Outcomes: A New Standard of Care?;**

D. García Sáez, B. Zych, P. N. Mohite, A. Sabashnikov, N. P. Patil, A. Popov, M. Zerriouh, C. T. Bowles, R. Hards, M. Hedger, G. Edwards, F. De Robertis, M. Amrani, T. Bahrami, N. Banner, A. R. Simon. Harefield Hospital NHS Trust, Harefield, London, United Kingdom

**3:30 PM (240) One-Year Survival of Patients Treated With Left Ventricular Assist Device (LVAD) as Bridge to Transplantation (BTT) or Bridge to Candidacy (BTC) vs. Heart Transplantation (HTx) With Donors Older Than 55 Years;**

E. Ammirati, M. G. Cipriani, M. Varrenti, F. Macera, L. D'Angelo, A. Garascia, F. Oliva, F. M. Turazza, G. Masciocco, A. Cannata, T. Colombo, C. Russo, G. Foti, M. P. Gagliardone, G. Pedrazzini, M. Frigerio. Cardiovascular and Thoracic Department, Niguarda Hospital, Milan, Italy

**3:45 PM (241) The Use of Circulatory Support While Awaiting Heart Transplant in Patients With AL and TTR Amyloidosis: A Report From iCCAT, the International Consortium for Cardiac Amyloid Transplant;**

S. Tabatabai<sup>1</sup>, J. Steiner<sup>1</sup>, M. Vaduganathan<sup>1</sup>, J. Stone<sup>1</sup>, J. Estep<sup>2</sup>, R. Witteles<sup>3</sup>, F. Giuseppe<sup>4</sup>, M. Zucker<sup>5</sup>, D. Baran<sup>5</sup>, D. Seldin<sup>6</sup>, J. Patel<sup>6</sup>, M. Hanna<sup>8</sup>, A. Cordero-Reyes<sup>2</sup>, V. Selby<sup>8</sup>, M. Maurer<sup>10</sup>, M. J. Semigran<sup>1</sup>. <sup>1</sup>Cardiology, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Cardiology, Houston Methodist Hospital, Houston, TX, <sup>3</sup>Cardiology, Stanford University Medical Center, Stanford, CA, <sup>4</sup>Cardiology, University of Padova, Padova, Italy, <sup>5</sup>Cardiology, Newark Beth Israel Medical Center, Newark, NJ, <sup>6</sup>Hematology, Boston University Medical Center, Boston, MA, <sup>8</sup>Cardiology, Cedars Sinai Hospital, Los Angeles, CA, <sup>8</sup>Cardiology, Cleveland Clinic, Cleveland, OH, <sup>8</sup>Cardiology, University of California San Francisco, San Francisco, CA, <sup>10</sup>Cardiology, Columbia Medical Center, New York City, NY



**2:30 PM – 4:00 PM**

**CONCURRENT SESSION 30**

**EVLP – Learning To Handle This Technology (Athena)  
(LTX, DMD)**

**CHAIRS:** Clemens Aigner, MD and Florian M. Wagner, MD

**2:30 PM (242) WITHDRAWN**

**2:45 PM (243) *Post EVLP Cold Preservation Period Is Associated With Clinical Outcomes;***

E. Arango Tomas<sup>1</sup>, P. Sanchez<sup>2</sup>, R. D. Davis<sup>3</sup>, E. Cantu<sup>4</sup>, M. J. Weyant<sup>5</sup>, D. Lederer<sup>1</sup>, P. C. Camp<sup>6</sup>, B. P. Griffith<sup>2</sup>, F. D'Ovidio<sup>1</sup>.  
<sup>1</sup>Columbia University Medical Center, New York, NY, <sup>2</sup>University of Maryland Medical Center, Baltimore, MD, <sup>3</sup>Duke University, Durham, NC, <sup>4</sup>University of Pennsylvania, Philadelphia, PA, <sup>5</sup>University of Colorado Denver, Denver, CO, <sup>6</sup>Brigham and Women's Hospital, Boston, MA

**3:00 PM (244) *Metabolic Assessment of Marginal Donor Lungs During Ex-Vivo Perfusion (EVLP): New Parameters for Decision Making;***

A. Slama, M. Barta, L. Schillab, A. Mitterbauer, P. Jaksch, K. Hoetzenecker, W. Klepetko, C. Aigner. Medical Univ of Vienna, Vienna, Austria

**3:15 PM (245) *Lung Compliance During Ex-Vivo Lung Perfusion Predicts Early Post Transplant Outcomes;***

P. G. Sanchez<sup>1</sup>, G. J. Bittle<sup>1</sup>, E. Cantu, III<sup>2</sup>, F. D Ovidio<sup>3</sup>, M. Weyant<sup>4</sup>, R. D. Davis<sup>5</sup>, B. P. Griffith<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Cardiac Surgery, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Thoracic Surgery, Columbia University, New York, NY, <sup>4</sup>Thoracic Surgery, University of Colorado, Aurora, CO, <sup>5</sup>Cardiac Surgery, Duke University, Durham, NC

**3:30 PM (246) *A Prospective Randomized Trial of Ex-Vivo Lung Perfusion in Standard Donor Lungs: Can It Improve the Results?;***

A. Slama, L. Schillab, M. Barta, A. Mitterbauer, K. Hötzenecker, S. Taghavi, G. Lang, J. Matilla, P. Jaksch, W. Klepetko, C. Aigner. Medical Univ of Vienna, Vienna, Austria

**3:45 PM (247) *Ex-Vivo Lung Perfusate Cell Death Markers May Predict Long Term Outcomes After Transplantation;***

K. Hashimoto, R. Zamel, M. Hsin, H. Kim, T. N. Machuca, T. Saito, S. Azad, T. K. Waddell, M. Cypel, M. Liu, S. Keshajvee. Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, ON, Canada



2:30 PM – 4:00 PM

CONCURRENT SESSION 31

**CAV and Rejection: A Tangled Web** (Clio, Thalie)  
(HTX, BSI, ID, NNSAH, PATH, PEDS, PHARM)

**CHAIRS:** Hannah A. Valantine, MD and Nedim Selimovic, MD, PhD

**2:30 PM (248) Clonal Composition and Specificity of Graft Infiltrating B Cells in Human Cardiac Allograft Vasculopathy;**

C. Moore<sup>1</sup>, B. Gao<sup>1</sup>, S. Nunez<sup>1</sup>, J. Stone<sup>1</sup>, L. Addonizio<sup>2</sup>, M. Givertz<sup>3</sup>, Y. Naka<sup>2</sup>, D. Mancini<sup>2</sup>, S. Restaino<sup>2</sup>, J. C. Madsen<sup>1</sup>, E. Zorn<sup>2</sup>. <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>Columbia University Medical Center, New York, NY, <sup>3</sup>Brigham and Women Hospital, Boston, MA

**2:45 PM (249) Complement Negative AMR: Does It Confer a Different CV Mortality Risk From Other Categories of AMR?;**

M. P. Revelo<sup>1</sup>, D. V. Miller<sup>1</sup>, J. Stehlik<sup>1</sup>, M. D. Everitt<sup>1</sup>, G. L. Snow<sup>2</sup>, D. Budge<sup>1</sup>, J. Fang<sup>1</sup>, J. N. Nicolau<sup>1</sup>, C. Selzman<sup>1</sup>, B. Reid<sup>1</sup>, E. H. Hammond<sup>1</sup>, A. G. Kfoury<sup>1</sup>. <sup>1</sup>U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT, <sup>2</sup>Statistical Data Center, U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**3:00 PM (250) Mixed Cellular and Antibody-Mediated Rejection in Heart Transplantation: A Distinct Entity or Simply the Sum of Two?;**

A. Kfoury, D. Miller, G. Snow, K. Afshar, J. Stehlik, D. Budge, W. Caine, S. McKellar, M. Everitt, R. Alharethi, J. Fang, S. Drakos, E. Gilbert, E. Hammond. UTAH Cardiac Transplant Program, Murray, UT

**3:15 PM (251) Human Leukocyte Antigen-G Polymorphisms as Predictors of Early Cardiac Allograft Vasculopathy;**

J. Lazarte<sup>1</sup>, L. Goldraich<sup>2</sup>, H. Kawajiri<sup>3</sup>, A. Ghashghai<sup>1</sup>, L. Grosman-Rimon<sup>3</sup>, L. Tumiaty<sup>3</sup>, V. Rao<sup>3</sup>, D. Delgado<sup>2</sup>. <sup>1</sup>Faculty of Medicine, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Cardiology, Toronto General Hospital, Toronto, ON, Canada, <sup>3</sup>Cardiovascular Surgery, Toronto General Hospital, Toronto, ON, Canada

**3:30 PM (252) Influence of Angiotensin-Type1-Receptor Antibodies in Chronic Vascular Injury on Heart Transplant Patients;**

L. Borgese<sup>1</sup>, L. Potena<sup>2</sup>, E. Resciniti<sup>1</sup>, S. Capelli<sup>3</sup>, A. Bontadini<sup>3</sup>, S. Iannelli<sup>3</sup>, F. Fruet<sup>3</sup>, M. Sabatino<sup>1</sup>, F. Scardino<sup>1</sup>, M. Masetti<sup>1</sup>, P. Prestinenzi<sup>1</sup>, V. Manfredini<sup>1</sup>, C. Rapezzi<sup>2</sup>, F. Grigioni<sup>1</sup>. <sup>1</sup>University of Bologna, Bologna, Italy, <sup>2</sup>Cardiovascular Department, S.Orsola-Malpighi Hospital, Bologna, Italy, <sup>3</sup>Immunogenetic Unit, S.Orsola-Malpighi Hospital, Bologna, Italy

**(253) WITHDRAWN**

**3:45 PM (332) Three Year Follow Up of the Randomized SCHEDULE Trial With Everolimus Initiation and Early Withdrawal of Calcineurin Inhibitor Therapy in De Novo Heart Transplant Recipients – A Multicenter, Randomized Scandinavian Trial;**

A. K. Andreassen<sup>1</sup>, B. Andersson<sup>2</sup>, F. Gustafsson<sup>3</sup>, H. Eiskjær<sup>4</sup>, G. Rådegran<sup>5</sup>, E. Gude<sup>1</sup>, K. Jansson<sup>6</sup>, D. Solbu<sup>6</sup>, K. Karason<sup>2</sup>, S. Arora<sup>1</sup>, G. Dellgren<sup>8</sup>, I. Gullestad<sup>1</sup>. <sup>1</sup>Dept. of Cardiology, Oslo University Hospital Oslo University Hospital, Oslo, Norway, <sup>2</sup>Dept. of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Dept. of Cardiology, Rigshospitalet, Copenhagen, Denmark, <sup>4</sup>Dept. of Cardiology, Aarhus University Hospital, Skejby, Denmark, <sup>5</sup>Dept. of Cardiology, The Clinic of Heart Failure and Valvular Disease, Skåne University Hospital and Lund University, Lund, Sweden, <sup>6</sup>Dept. of Cardiology, Heart and Medicine Center County Council of Ostergotland and Linköping University, Linköping, Sweden, <sup>7</sup>Novartis Norge AS, Novartis, Oslo, Norway, <sup>8</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

**2:30 PM – 4:00 PM**

## CONCURRENT SESSION 32

### Mechanical Cardiac Support in Children: Outcomes and Registry Data (Erato,Uranie)

(PEDS, BSI, DMD, HF, HTX, ID, LF, MCS, NNSAH, PATH, PH, PHARM, PEEG)

**CHAIRS:** Janet N. Scheel, MD and Christopher Almond, MD

**2:30 PM (254) *The Current Role of Temporary Circulatory Assist Devices in US Children Awaiting Heart Transplant;*** V. V. Yarlagadda, A. Y. Shin, O. Reinhartz, M. Palmon, P. Shuttleworth, K. Maeda, J. Yeh, J. Murray, D. N. Rosenthal, D. B. McElhinney, C. S. Almond. Pediatrics, Stanford University, Palo Alto, CA

**2:45 PM (255) *Is Earlier Better? Influence of Timing of VAD Implantation on Post-Transplant Survival in Pediatric Cardiomyopathy Patients;*** B. C. Keeshan<sup>1</sup>, G. R. Vaughn<sup>1</sup>, M. J. O'Connor<sup>2</sup>, K. Y. Lin<sup>2</sup>, R. E. Shaddy<sup>2</sup>, D. M. McMullan<sup>3</sup>, Y. M. Law<sup>1</sup>, J. W. Rossano<sup>2</sup>. <sup>1</sup>Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>2</sup>Division of Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Pediatric Cardiac Surgery, Seattle Children's Hospital, Seattle, WA

**3:00 PM (256) *Berlin Heart EXCOR Outcomes in Pediatric Patients With Restrictive and Hypertrophic Cardiomyopathy;*** J. A. Su<sup>1</sup>, J. R. Woolley<sup>2</sup>, C. Tjossem<sup>2</sup>, J. Mentee<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA, <sup>2</sup>Berlin Heart Inc., The Woodlands, TX

**3:15 PM (257) *Berlin Heart Post Approval Outcomes in North America;*** R. D. Jaquiss<sup>1</sup>, C. D. Fraser<sup>2</sup>, D. N. Rosenthal<sup>3</sup>, T. Humpl<sup>4</sup>, C. Canter<sup>5</sup>, D. L. Morales<sup>6</sup>, C. Tjossem<sup>6</sup>, R. Kroschwitz<sup>6</sup>. <sup>1</sup>Pediatric Cardiothoracic Surgery, Duke Children's Heart Center, Durham, NC, <sup>2</sup>Cardiothoracic Surgery, Texas Children's Hospital, Houston, TX, <sup>3</sup>Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>4</sup>Pediatric Cardiology, Hospital for Sick Children, Toronto, ON, Canada, <sup>5</sup>Pediatric Cardiology, Washington University in St. Louis, St. Louis, MO, <sup>6</sup>Pediatric Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>6</sup>Berlin Heart, Inc., the Woodlands, TX

**3:30 PM (258) *Adverse Events in Children Implanted With Ventricular Assist Devices in the US: Data From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS);*** D. N. Rosenthal<sup>1</sup>, C. S. Almond<sup>2</sup>, R. D. Jacquiss<sup>3</sup>, C. E. Peyton<sup>4</sup>, S. R. Auerbach<sup>5</sup>, D. L. Morales<sup>6</sup>, D. J. Epstein<sup>6</sup>, R. S. Cantor<sup>8</sup>, R. L. Kormos<sup>9</sup>, D. C. Naftel<sup>9</sup>, R. J. Butts<sup>10</sup>, N. S. Ghanayem<sup>11</sup>, J. K. Kirklin<sup>8</sup>, E. D. Blume<sup>12</sup>. <sup>1</sup>Pediatrics, Stanford University, Palo Alto, CA, <sup>2</sup>Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>3</sup>Pediatric Cardiac Surgery, Duke University School of Medicine, Durham, NC, <sup>4</sup>Children's Hospital Heart Institute, Children's Hospital Colorado, Aurora, CO, <sup>5</sup>Pediatrics, University of Colorado, Aurora, CO, <sup>6</sup>Pediatric Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>6</sup>Pediatric Cardiothoracic Surgery, Washington University School of Medicine, St. Louis, MO, <sup>8</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL, <sup>9</sup>Heart and Vascular Institute, The University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>10</sup>Pediatrics, Medical University of South Carolina, Charleston, SC, <sup>11</sup>Pediatrics (Critical Care Section), Medical College of Wisconsin and Children's Hospital of Wisconsin, Milwaukee, WI, <sup>12</sup>Cardiology, Boston Children's Hospital, Boston, MA

**3:45 PM (259) Utilization and Outcomes of Continuous-Flow Ventricular Assist Devices in Pediatric Patients: A Report From the Pediatric Interagency Registry for Mechanical Circulatory Support (PediMACS);**

J. W. Rossano<sup>1</sup>, A. Lorts<sup>2</sup>, C. J. VanderPluym<sup>3</sup>, A. Jeewa<sup>4</sup>, K. J. Guleserian<sup>5</sup>, M. S. Bleiweis<sup>6</sup>, O. Reinhartz<sup>6</sup>, E. D. Blume<sup>3</sup>, D. N. Rosenthal<sup>8</sup>, D. C. Naftel<sup>8</sup>, R. S. Cantor<sup>8</sup>, J. K. Kirklin<sup>8</sup>.  
<sup>1</sup>Cardiology, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>The Heart Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>3</sup>Cardiology, Boston Children's Hospital, Boston, MA, <sup>4</sup>Cardiology, Texas Children's Hospital/Baylor College of Medicine, Houston, TX, <sup>5</sup>Pediatric Cardiothoracic Surgery, UT Southwestern/Children's Medical Center Dallas, Dallas, TX, <sup>6</sup>Surgery and Pediatrics, University of Florida, Gainesville, FL, <sup>8</sup>Pediatric Cardiothoracic Surgery, Stanford University, Stanford, CA, <sup>8</sup>Pediatrics, Stanford University, Palo Alto, CA, <sup>8</sup>Cardiothoracic Surgery, The University of Alabama at Birmingham, Birmingham, AL

2:30 PM – 4:00 PM

## CONCURRENT SESSION 33

### Emerging Issues in Pediatric Lung Transplant

(Hermes)

(LTX, LF, PEDS)

**CHAIRS:** Christian Benden, MD and Simon Urschel, MD

**2:30 PM (260) *The Era Effect on Pediatric Lung Transplantation Outcomes;***

D. Bobylev<sup>1</sup>, C. Mueller<sup>2</sup>, N. Schwerk<sup>2</sup>, W. Sommer<sup>1</sup>, I. Tudorache<sup>1</sup>, F. Ius<sup>1</sup>, C. Kuehn<sup>1</sup>, M. Avsar<sup>1</sup>, A. Horke<sup>1</sup>, D. Boethig<sup>1</sup>, J. Gottlieb<sup>3</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Pediatric Pneumology and Neonatology, Hannover Medical School, Hannover, Germany, <sup>3</sup>Pulmonary Medicine, Hannover Medical School, Hannover, Germany

**2:45 PM (261) *Cystic Fibrosis Patients and Lung Transplantation: A Changing Relationship;***

M. S. Khan<sup>1</sup>, F. Zafar<sup>1</sup>, R. Bryant III<sup>1</sup>, C. Towe<sup>2</sup>, M. G. Schecter<sup>2</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**3:00 PM (262) *Comparing Serum and BAL Markers of Inflammation and Oxidation Pre and Post Lung Transplant in Children: Defining Biomarkers for Signal in Epithelial-Mesenchymal Transition to Bronchiolitis Obliterans;***

C. K. Conrad<sup>1</sup>, Y. Rosenberg-Hasson<sup>2</sup>. <sup>1</sup>Lucile Packard Children's Hosp, Palo Alto, CA, <sup>2</sup>Human Immune Monitoring Core, Stanford University, Palo Alto, CA

**3:15 PM (263) *Post Transplant De Novo Donor Specific Antibodies Correlate With the Development of Bronchiolitis Obliterans Syndrome Following Pediatric Lung Transplantation;***

R. H. Kerman<sup>1</sup>, E. Melicoff<sup>2</sup>, J. Maddox<sup>2</sup>, M. Ebenbichler<sup>2</sup>, J. Heinle<sup>2</sup>, D. McKenzie<sup>2</sup>, P. Jindra<sup>1</sup>, G. Mallory<sup>2</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Texas Children's Hospital and Baylor College of Medicine, Houston, TX

**3:30 PM (264) *Risk Factors for Bronchiolitis Obliterans in Pediatric Lung Transplantation Across the United States;***

M. S. Khan<sup>1</sup>, F. Zafar<sup>1</sup>, R. Bryant III<sup>1</sup>, C. Towe<sup>2</sup>, J. K. Johnson<sup>2</sup>, M. G. Schecter<sup>2</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**3:45 PM (265) *International Experience in Pediatric Extracorporeal Membrane Oxygenation (ECMO) Bridge to Lung Transplantation;***

J. Y. Wong<sup>1</sup>, A. R. Glanville<sup>2</sup>, G. P. Westall<sup>3</sup>, S. B. Goldfarb<sup>4</sup>, M. Griese<sup>5</sup>, B. Rottier<sup>6</sup>, M. Budev<sup>5</sup>, J. Balcells-Ramirez<sup>8</sup>, N. Schwerk<sup>8</sup>. <sup>1</sup>Division of Pediatric Respiratory Medicine, McMaster University, Hamilton, ON, Canada, <sup>2</sup>Department of Thoracic Medicine, St. Vincent's Hospital, Darlinghurst, Australia, <sup>3</sup>Dept of Respiratory, Alfred Hospital, Melbourne, Australia, <sup>4</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>5</sup>Ludwig-Maximilians University of Munich Hospital, Munich, Germany, <sup>6</sup>Beatrix Children's Hospital/University Medical Center, Groningen, Netherlands, <sup>7</sup>Cleveland Clinic, Cleveland, OH, <sup>8</sup>Pediatric Intensive Care Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain, <sup>9</sup>Hannover Medical School, Hannover, Germany

2:30 PM – 4:00 PM

CONCURRENT SESSION 34

Complement, CAV, and Lung Allograft Pathology

(Calliope)

(PATH, BSI, HTX, PEDS, LTX)

**CHAIRS:** Margaret M. Burke, MD, FRCPath and  
Gerald J. Berry, MD

**2:30 PM (266)** *IgM De Novo Donor Specific HLA Antibodies (dnDSA) Claws Switch to IgG and DQ dnDSA Are Associated With C4d+ Biopsies Conversion to C4d+/C3d+ and Progression of Subclinical Antibody Mediated Rejection in Heart Transplant Recipients;*

M. Askar<sup>1</sup>, R. Rodriguez<sup>2</sup>, L. Klingman<sup>1</sup>, D. Thomas<sup>1</sup>, A. Zhang<sup>1</sup>, H. Morf<sup>3</sup>, N. Hamon<sup>1</sup>, N. Moazami<sup>4</sup>, E. Hsich<sup>5</sup>, D. Taylor<sup>5</sup>, R. Starling<sup>5</sup>, C. Tan<sup>2</sup>. <sup>1</sup>Transplant Center, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Pathology, Cleveland Clinic, Cleveland, OH, <sup>3</sup>School of Medicine, Leipzig University, Leipzig, Germany, <sup>4</sup>Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, <sup>5</sup>Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH,

**2:45 PM (267)** *Capillary Complement Deposition in the Early Posttransplant Period Correlates With Antibody-Mediated Rejection and Not With Ischemic Injury;*

E. Rodriguez, M. Askar, C. D. Tan. Pathology, Cleveland Clinic, Cleveland, OH

**3:00 PM (268)** *Characterization of Antigenic Targets of Local Antibodies Produced in Ectopic Lymphoid Structures in Cardiac Allografts;*

M. Huibers<sup>1</sup>, S. Beerthuis<sup>1</sup>, A. Gareau<sup>2</sup>, E. Siera-de Koning<sup>1</sup>, J. van Kuik<sup>1</sup>, N. de Jonge<sup>3</sup>, T. Lee<sup>4</sup>, H. Otten<sup>5</sup>, R. de Weger<sup>1</sup>. <sup>1</sup>Pathology, UMC Utrecht, Utrecht, Netherlands, <sup>2</sup>Internal Medicine, University of Manitoba, Winnipeg, MB, Canada, <sup>3</sup>Cardiology, UMC Utrecht, Utrecht, Netherlands, <sup>4</sup>Pathology, Surgery, Microbiology and Immunology, Dalhousie University, Halifax, NS, Canada, <sup>5</sup>Immunology, UMC Utrecht, Utrecht, Netherlands

**3:15 PM (269)** *Antibody-Mediated Rejection Is Associated With Worse Survival But Not With Cardiac Allograft Vasculopathy (CAV) in a Large Cohort of 295 Heart Transplant Recipients;*

E. Rodriguez, M. Askar, C. D. Tan. Pathology, Cleveland Clinic, Cleveland, OH

**3:30 PM (270)** *Comparison of Transbronchial Cryobiopsies With Conventional Forceps Biopsies in Evaluation of Lung Allografts;*

A. C. Roden<sup>1</sup>, R. M. Kern<sup>2</sup>, M. C. Aubry<sup>1</sup>, S. M. Jenkins<sup>3</sup>, J. P. Scott<sup>2</sup>, F. Maldonado<sup>2</sup>. <sup>1</sup>Laboratory Medicine & Pathology, Mayo Clinic Rochester, Rochester, MN, <sup>2</sup>Division of Pulmonary & Critical Care Medicine, Mayo Clinic Rochester, Rochester, MN, <sup>3</sup>Biomedical Statistics and Informatics, Mayo Clinic Rochester, Rochester, MN

**3:45 PM (271)** *Pathologic Spectrum of Murine Obliterative Bronchiolitis and Other Features of Chronic Lung Allograft Dysfunction;*

T. Martinu, H. Oishi, D. M. Hwang, M. Cypel, M. Liu, S. Keshavjee. Toronto Lung Transplant Program, University of Toronto & University Health Network, Toronto, ON, Canada

**2:30 PM – 4:00 PM**

## CONCURRENT SESSION 35

### Complex Patients Require Complex Solutions: Predicting Adherence (Euterpe)

(NNSAH, HF, HTX, LTX, MCS)

**CHAIRS:** Christiane Kugler, PhD and Sabina M. De Geest, RN, PhD

**2:30 PM (272) *The Predictive Value of the SIPAT for Clinical Outcomes in End-Stage Heart Failure Candidates;***

S. D. Grogan<sup>1</sup>, C. R. Bruce<sup>2</sup>, A. M. Cordero-Reyes<sup>3</sup>, A. Soliman<sup>4</sup>, J. D. Estep<sup>5</sup>. <sup>1</sup>Transplant Psychiatry, Houston Methodist Hospital, Houston, TX, <sup>2</sup>Medicine & Medical Ethics, Baylor College of Medicine & Houston Methodist Hospital, Houston, TX, <sup>3</sup>Transplant Cardiology Research, Houston Methodist Hospital, Houston, TX, <sup>4</sup>Critical Care Intensivist, Houston Methodist Hospital, Houston, TX, <sup>5</sup>Transplant Cardiology, Houston Methodist Hospital, Houston, TX

**2:45 PM (273) *Patients With Visuospatial Construction Deficits May Successfully Manage LVADs;***

C. M. Murks<sup>1</sup>, C. Juricek<sup>2</sup>, G. Kim<sup>1</sup>, G. Sayer<sup>1</sup>, N. Uriel<sup>1</sup>, T. Ota<sup>2</sup>, V. Jeevanandam<sup>2</sup>, S. Fedson<sup>1</sup>. <sup>1</sup>Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Surgery, University of Chicago, Chicago, IL

**3:00 PM (274) *Cost-Related Non-Adherence and Its Relationship to Medication Non-Adherence Among Adult Heart Transplant Recipients in Ten Countries – A Multicenter Cross-Sectional Study;***

S. Schoenfeld<sup>1</sup>, L. Berben<sup>1</sup>, F. Dobbels<sup>2</sup>, C. L. Russell<sup>3</sup>, S. Scalzo de Almeida<sup>4</sup>, S. M. de Geest<sup>1</sup>. <sup>1</sup>University of Basel, Basel, Switzerland, <sup>2</sup>Health Services Research, KU Leuven, Leuven, Belgium, <sup>3</sup>School of Nursing and Health Studies, University of Missouri-Kansas City, Kansas, MO, <sup>4</sup>Institute of Nursing Science, University of Basel, Basel, Switzerland

**3:15 PM (275) *Variability in Chronic Illness Management Implemented Among Heart Transplant Centers – Preliminary Data From the International BRIGHT Study;***

C. Vetter<sup>1</sup>, L. Berben<sup>1</sup>, F. Dobbels<sup>2</sup>, C. L. Russell<sup>3</sup>, S. M. de Geest<sup>1</sup>. <sup>1</sup>University of Basel, Basel, Switzerland, <sup>2</sup>Health Services Research, KU Leuven, Leuven, Belgium, <sup>3</sup>University of Missouri\_Kansas City, Kansas City, MO

**3:30 PM (276) *A Closer Look at Adherence: Sociodemographic Differences Long-Term After Heart Transplantation;***

C. White-Williams<sup>1</sup>, P. Fazeli<sup>1</sup>, B. Rybarczyk<sup>2</sup>, K. Grady<sup>3</sup>. <sup>1</sup>University of Alabama, Birmingham, AL, <sup>2</sup>Virginia Commonwealth University, Richmond, VA, <sup>3</sup>Northwestern University Hospital, Chicago, IL

**3:45 PM (277) *Long-Term Clinical Impact of an mHealth Intervention for Lung Recipients;***

E. M. Rosenberger<sup>1</sup>, A. DeVito Dabbs<sup>2</sup>, A. F. DiMartini<sup>3</sup>, D. Landsittel<sup>4</sup>, C. A. Bermudez<sup>5</sup>, M. A. Dew<sup>6</sup>. <sup>1</sup>Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>2</sup>Acute and Tertiary Care, University of Pittsburgh School of Nursing, Pittsburgh, PA, <sup>3</sup>Psychiatry, Surgery, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>4</sup>Medicine, Biostatistics, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>5</sup>Cardiothoracic Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, <sup>6</sup>Psychiatry, Psychology, Epidemiology, Biostatistics, and Clinical and Translational Science, University of Pittsburgh School of Medicine, Pittsburgh, PA

**4:00 PM – 4:30 PM**

Coffee Break/Visit Exhibits (Rhodes)

VIEW POSTERS (Agora 2)



4:30 PM – 6:00 PM

CONCURRENT SESSION 36

**Pump Thrombosis – Diagnosis and Outcomes**

(Apollon)

(MCS, BSI, HF, HTX, NNSAH, PATH)

**CHAIRS:** Francis D. Pagani, MD, PhD and Michael McDonald, MD

**4:30 PM (278) *Effect of Device Thrombosis and Malfunction on Clinical Outcomes of Patients Bridging With Continuous-Flow LVADs;***

O. Wever-Pinzon<sup>1</sup>, A. P. Levin<sup>1</sup>, J. Fried<sup>1</sup>, A. R. Garan<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, D. Mancini<sup>1</sup>, Y. Naka<sup>1</sup>, P. Colombo<sup>1</sup>, V. K. Topkara<sup>2</sup>. <sup>1</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>2</sup>Cardiology, Columbia University Medical Center, Englewood, NJ

**4:45 PM (279) *Treatment of Device Thrombus in the HeartWare HVAD: Success and Outcomes Depend Significantly on Initial Treatment Strategy;***

J. M. Stulak<sup>1</sup>, S. Dunlay<sup>2</sup>, N. Haglund<sup>3</sup>, M. E. Davis<sup>4</sup>, F. Masood<sup>5</sup>, F. D. Pagani<sup>5</sup>, K. Aaronson<sup>6</sup>, S. Maltais<sup>4</sup>. <sup>1</sup>Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>3</sup>Cardiovascular Diseases, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>4</sup>Cardiac Surgery, Vanderbilt Heart and Vascular Institute, Nashville, TN, <sup>5</sup>Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, <sup>6</sup>Cardiovascular Diseases, University of Michigan Health System, Ann Arbor, MI

**5:00 PM (280) *From Bench to Bedside: Impact of LVAD Outflow Conduit Anastomosis Position on Outcome;***

V. Tarzia<sup>1</sup>, G. Di Giammarco<sup>2</sup>, G. Bortolussi<sup>1</sup>, D. Marinelli<sup>2</sup>, M. Maccherini<sup>3</sup>, M. Maiani<sup>4</sup>, M. Foschi<sup>2</sup>, S. Bernazzali<sup>3</sup>, V. Tursi<sup>4</sup>, S. Diso<sup>2</sup>, U. Livi<sup>4</sup>, G. Sani<sup>3</sup>, T. Bottio<sup>1</sup>, G. Gerosa<sup>1</sup>. <sup>1</sup>Department of Cardiac, Thoracic and Vascular Sciences, University of Padua, Cardiac Surgery, Padua, Italy, <sup>2</sup>Cardiac Surgery, Chi-eti, Italy, <sup>3</sup>Cardiac Surgery, Siena, Italy, <sup>4</sup>Cardiac Surgery, Udine, Italy

**5:15 PM (281) *Hemolysis, Device Thrombosis, and Risk of CVA in HM II Patients: Role of Watchful Waiting?;***

A. P. Levin<sup>1</sup>, J. Z. Willey<sup>2</sup>, J. A. Fried<sup>1</sup>, C. J. Levin<sup>3</sup>, M. Dionizovik<sup>3</sup>, A. R. Garan<sup>3</sup>, V. Topkara<sup>3</sup>, M. Yuzefpolskaya<sup>3</sup>, P. C. Colombo<sup>3</sup>, H. Takayama<sup>3</sup>, Y. Naka<sup>3</sup>, N. Uriel<sup>4</sup>, U. P. Jorde<sup>5</sup>. <sup>1</sup>Cardiology, Columbia University, New York, NY, <sup>2</sup>Neurology, Columbia University Medical Center, New York, NY, <sup>3</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>4</sup>Cardiology, University of Chicago, Chicago, IL, <sup>5</sup>Cardiology, Montefiore Medical Center / Albert Einstein College of Medicine, Bronx, NY

**5:30 PM (282) *Spontaneous Microbubble Formation Is an Indicator of LVAD Pump Thrombosis;***

L. Letarte<sup>1</sup>, P. Sears-Rogan<sup>1</sup>, S. Boyce<sup>1</sup>, M. Tyson<sup>2</sup>, Z. Wang<sup>1</sup>. <sup>1</sup>Cardiology, Georgetown/Washington Hospital Center, Washington, DC, <sup>2</sup>Cardiology, Washington Hospital Center, Washington, DC

**5:45 PM (283) *One-Year Hospital Charges Do Not Differ Between Redo Left Ventricular Assist Device Patients and Bridge to Transplantation Patients;***

J. Magruder<sup>1</sup>, J. C. Grimm<sup>1</sup>, G. J. Arnaoutakis<sup>1</sup>, A. Kilic<sup>1</sup>, R. J. Tedford<sup>2</sup>, S. D. Russell<sup>2</sup>, C. Sciortino<sup>1</sup>, J. V. Conte<sup>1</sup>, A. S. Shah<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Johns Hopkins, Baltimore, MD, <sup>2</sup>Division of Cardiology, Johns Hopkins, Baltimore, MD

4:30 PM – 6:00 PM

## CONCURRENT SESSION 37

### The Fate of the Right Heart after LVAD (Athena) (MCS, BSI, HF, HTX, NNSAH, PHARM)

**CHAIRS:** Jeffrey J. Teuteberg, MD and Thomas Krabatsch, MD, PhD

- 4:30 PM (284) Discriminatory Power of Commonly Used Indices and Scores in Predicting Early Severe Right Ventricular Failure After Continuous-Flow Left Ventricular Assist Device Implantation;**  
V. Tchanchaleishvili<sup>1</sup>, S. Maltais<sup>2</sup>, S. Dunlay<sup>3</sup>, N. A. Haglund<sup>4</sup>, M. E. Davis<sup>2</sup>, H. T. Massey<sup>5</sup>, F. D. Pagani<sup>6</sup>, K. D. Aaronson<sup>6</sup>, J. M. Stulak<sup>8</sup>. <sup>1</sup>Cardiac Surgery, University of Rochester Medical Center, Rochester, NY, <sup>2</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Cardiovascular Medicine, Mayo Clinic, Rochester, MN, <sup>4</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>5</sup>Cardiovascular Medicine, University of Rochester Medical Center, Rochester, NY, <sup>6</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>8</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN
- 4:45 PM (285) Modeling the Spectrum of Right Ventricular Failure (RVF) After LVAD Therapy;**  
N. A. Loghmanpour<sup>1</sup>, R. L. Kormos<sup>2</sup>, M. K. Kanwar<sup>3</sup>, J. J. Teuteberg<sup>2</sup>, S. Murali<sup>3</sup>, J. F. Antaki<sup>1</sup>. <sup>1</sup>Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, <sup>2</sup>Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA
- 5:00 PM (286) Update on Temporary Mechanical Circulatory Support for Right Ventricular Failure;**  
U. Bansal<sup>1</sup>, K. Jackson<sup>1</sup>, D. G. Winger<sup>2</sup>, J. J. Teuteberg<sup>1</sup>, C. Bermudez<sup>1</sup>, R. L. Kormos<sup>1</sup>, A. Bansal<sup>3</sup>, J. K. Bhama<sup>4</sup>. <sup>1</sup>Heart & Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>2</sup>Clinical and Translational Science Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Department of Cardiothoracic Surgery, Ochsner Clinic, New Orleans, LA, <sup>4</sup>Heart & Vascular Center, University of Iowa Health Care, Iowa City, IA
- 5:15 PM (287) Use of Phosphodiesterase 5 Inhibitors in Continuous-Flow Left Ventricular Assist Device Patients With Pulmonary Hypertension: A Contemporary Analysis;**  
V. K. Topkara<sup>1</sup>, A. Godier-Furnemont<sup>1</sup>, A. Levin<sup>1</sup>, A. Garan<sup>1</sup>, B. Cagliostro<sup>2</sup>, R. Te-Frey<sup>2</sup>, F. Torres<sup>2</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>, U. P. Jorde<sup>3</sup>, D. Mancini<sup>1</sup>, Y. Naka<sup>2</sup>, P. C. Colombo<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, <sup>3</sup>Cardiology, Montefiore Medical Center, New York, NY
- 5:30 PM (288) An Analysis of Early Versus Late Right Heart Failure With an Intrapericardial Continuous Flow LVAD;**  
J. E. Rame<sup>1</sup>, J. J. Teuteberg<sup>2</sup>, E. J. Birks<sup>3</sup>, J. G. Rogers<sup>4</sup>, M. A. Acker<sup>1</sup>, E. Y. Birati<sup>1</sup>, M. S. Slaughter<sup>3</sup>, K. D. Aaronson<sup>5</sup>, K. Leadley<sup>6</sup>, F. D. Pagani<sup>5</sup>, R. L. Kormos<sup>2</sup>. <sup>1</sup>Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>University of Louisville, Louisville, KY, <sup>4</sup>Duke University School of Medicine, Durham, NC, <sup>5</sup>University of Michigan, Ann Arbor, MI, <sup>6</sup>HeartWare, Framingham, MA
- 5:45 PM (289) Outcomes of Patients Complicated With Late Right Heart Failure During Continuous Left Ventricular Device Support: Should Patients Stay on Device or Be Transplanted?;**  
K. Takeda, H. Takayama, S. Fukuhara, J. Han, P. C. Colombo, M. Yuzefpolskaya, V. K. Topkara, D. M. Mancini, Y. Naka. Columbia University, NY, NY

4:30 PM – 6:00 PM

CONCURRENT SESSION 38

Cloudy with a Chance of T-Cells: Rejection Forecast

(Clio, Thalie)

(HTX, BSI, ID, NNSAH, PATH, PEDS, PHARM)

**CHAIRS:** Kiran K. Khush, MD and Luciano Potena, MD, PhD

**4:30 PM (290) *A Novel Human Leukocyte Antigen Score Improves Prediction for Rejection After Heart Transplant;***

E. P. Kransdorf<sup>1</sup>, L. Gragert<sup>2</sup>, M. Cheng<sup>3</sup>, D. E. Steidley<sup>1</sup>, R. L. Scott<sup>1</sup>, M. J. Pando<sup>4</sup>, M. Maier<sup>2</sup>, O. E. Pajaro<sup>5</sup>. <sup>1</sup>Division of Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, <sup>2</sup>Bioinformatics Research, National Marrow Donor Program/Be The Match, Minneapolis, MN, <sup>3</sup>Division of Health Sciences Research, Mayo Clinic Arizona, Scottsdale, AZ, <sup>4</sup>Department of Laboratory Medicine and Pathology, Mayo Clinic Arizona, Scottsdale, AZ, <sup>5</sup>Division of Cardiothoracic Surgery, Mayo Clinic Arizona, Scottsdale, AZ

**4:45 PM (291) *Genetic Risk Score (GRS) Predicts Worse Survival in African American Heart Transplant Recipients at 10 Years;***

B. Coleman<sup>1</sup>, X. Guo<sup>2</sup>, J. Patel<sup>1</sup>, N. Reinsmoen<sup>3</sup>, Y. Jia<sup>2</sup>, J. A. Kobashigawa<sup>1</sup>. <sup>1</sup>Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>2</sup>Los Angeles Biomedical Research Institute, Torrance, CA, <sup>3</sup>HLA Laboratory, Cedars-Sinai Medical Center, Los Angeles, CA

**5:00 PM (292) *Donor-Derived Cell-Free DNA Decreases Following Effective Treatment of Acute Cellular Rejection in Heart Transplant Recipients: The CARGO II Multicenter Trial;***

J. Stypmann<sup>1</sup>, J. Vanhaecke<sup>2</sup>, A. Zuckermann<sup>3</sup>, P. Mohacs<sup>4</sup>, J. Beausang<sup>5</sup>, M. Grskovic<sup>5</sup>, D. Hiller<sup>5</sup>, B. Christie<sup>5</sup>, R. Sit<sup>5</sup>, J. Elechko<sup>5</sup>, R. Woodward<sup>5</sup>, J. Yee<sup>5</sup>, M. Crespo-Leiro<sup>6</sup>. <sup>1</sup>University Hospital Münster, Münster, Germany, <sup>2</sup>University Hospital Leuven, Leuven, Belgium, <sup>3</sup>University of Vienna, Vienna, Austria, <sup>4</sup>University Hospital Bern, Bern, Switzerland, <sup>5</sup>CareDx, Inc, Brisbane, CA, <sup>6</sup>Hospital Universitario A Coruña, La Coruña, Spain

**5:15 PM (293) *Correlation of Longitudinal Gene-Expression Profiling (GEP) Score to Cytomegalovirus (CMV) Infection: Results From the Outcomes AlloMap® Registry (OAR);***

M. Kanwar<sup>1</sup>, J. Yee<sup>2</sup>, G. Ewald<sup>3</sup>, S. Murali<sup>1</sup>. <sup>1</sup>Allegheny Singer Research Institute, Pittsburgh, PA, <sup>2</sup>CareDx, Inc, Brisbane, CA, <sup>3</sup>Washington University, St. Louis, MO

**5:30 PM (294) *Predictive Value of Gene Expression Profiling as Assessed By AlloMap® Score for Long-Term Survival After Heart Transplantation;***

B. Fujita, E. Prashovikj, U. Schulz, J. Sunavsky, U. Fuchs, J. Börgermann, J. Gummert, S. Ensminger. Department for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany

**5:45 PM (295) *The Time Course of Development of Anti-Human Leukocyte Antigen Antibodies Crucial for Monitoring and Potential Intervention Following Heart Transplantation;***

J. A. Kobashigawa, M. Kittleson, F. Liou, R. Shiozaki, S. Siddiqui, L. Piponniau, D. Geft, M. Hamilton, L. Czer, N. Reinsmoen, J. Patel. Cedars-Sinai Heart Institute, Los Angeles, CA

4:30 PM – 6:00 PM

## CONCURRENT SESSION 39

### Advances in Prognostic Stratification in Pulmonary Hypertension (Erato,Uranie)

(PH, HF, HTX, LF, LTX, MCS)

*This session is supported by educational grants from Actelion and Gilead.*

**CHAIRS:** Aaron B. Waxman, MD, PhD and  
Dana P. McClothlin, MD

**4:30 PM (296) *Determinants and Prognostic Significance of Right Ventricular Reverse Remodeling in Idiopathic Pulmonary Arterial Hypertension Receiving Specific Medical Treatment;***

R. Badagliacca<sup>1</sup>, R. Poscia<sup>1</sup>, B. Pezzuto<sup>1</sup>, M. Mezzapesa<sup>1</sup>, M. Nocioni<sup>1</sup>, S. Papa<sup>1</sup>, M. Francone<sup>2</sup>, S. Sciomer<sup>1</sup>, C. Iacoboni<sup>1</sup>, E. Giannetta<sup>3</sup>, F. Fedele<sup>1</sup>, C. Vizza<sup>1</sup>. <sup>1</sup>Cardiovascular and Respiratory Disease, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Radiology, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Experimental Medicine, Sapienza University of Rome, Rome, Italy

**4:45 PM (297) *Concentric Hypertrophy Protects Against Clinical Worsening in Idiopathic Pulmonary Arterial Hypertension: Insights From Magnetic Resonance Imaging;***

R. Badagliacca<sup>1</sup>, R. Poscia<sup>1</sup>, B. Pezzuto<sup>1</sup>, M. Mezzapesa<sup>1</sup>, M. Nocioni<sup>1</sup>, S. Papa<sup>1</sup>, M. Francone<sup>2</sup>, S. Sciomer<sup>1</sup>, C. Iacoboni<sup>1</sup>, E. Giannetta<sup>3</sup>, F. Fedele<sup>1</sup>, C. Vizza<sup>1</sup>. <sup>1</sup>Cardiovascular and Respiratory Science, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Radiology, Sapienza University of Rome, Rome, Italy, <sup>3</sup>Experimental Medicine, Sapienza University of Rome, Rome, Italy

**5:00 PM (298) *Measurement of Contractile Reserve During Exercise Using Cardiac MRI in Pulmonary Hypertension: A Pilot Study;***

N. Morris<sup>1</sup>, H. Seale<sup>2</sup>, W. Strugnall<sup>3</sup>, K. Hall<sup>2</sup>, C. Hamilton-Craig<sup>3</sup>, F. Kermeen<sup>2</sup>. <sup>1</sup>Griffith University, Gold Coast, Australia, <sup>2</sup>Queensland Lung Transplant Service The Prince Charles Hospital, Brisbane, Australia, <sup>3</sup>Richard Slaughter Center of Excellence in CVMRI, The Prince Charles Hospital, Brisbane, Australia

**5:15 PM (299) *Hemodynamic Markers of Pulmonary Vascular Disease in Pulmonary Hypertension Due to Left Heart Disease;***

R. R. Vanderpool, M. T. Gladwin, M. A. Simon. Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA

**5:30 PM (300) *A Non-Invasive Risk Score for the Prediction of Combined Post- and Pre-Capillary Pulmonary Hypertension in Heart Failure With Preserved Ejection Fraction;***

D. D. Dixon<sup>1</sup>, R. Cogswell<sup>2</sup>, M. A. Burke<sup>3</sup>, M. J. Cuttica<sup>1</sup>, B. H. Freed<sup>1</sup>, L. Beussink-Nelson<sup>1</sup>, T. Thenappan<sup>2</sup>, S. J. Shah<sup>1</sup>. <sup>1</sup>Northwestern University, Chicago, IL, <sup>2</sup>University of Minnesota, Minneapolis, MN, <sup>3</sup>Harvard University, Boston, MA

**5:45 PM (301) *Comparison of Pulmonary Artery (PA) Wave Reflections in Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Due to Heart Failure With Preserved Ejection Fraction (PH-HFpEF);***

S. A. Gandhi<sup>1</sup>, A. Singal<sup>2</sup>, N. Gadela<sup>2</sup>, H. Kelner<sup>2</sup>, C. Carlson<sup>2</sup>, M. Pritzker<sup>2</sup>, T. Thenappan<sup>2</sup>. <sup>1</sup>Department of Medicine, University of Minnesota, Minneapolis, MN, <sup>2</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN

4:30 PM – 6:00 PM

CONCURRENT SESSION 40

**Lung AMR: HLA and Beyond (Hermes)**

(LTX, BSI, LF, PATH, PEDS)

**CHAIRS:** Gregory I. Snell, FRACP, MBB and Enrique Diaz Guzman Zavala, MD

**4:30 PM (302) *HLA Matching at the Epitope Level Protects Against Chronic Lung Allograft Dysfunction;***

D. C. Walton<sup>1</sup>, S. J. Hiho<sup>1</sup>, L. S. Cantwell<sup>1</sup>, M. B. Diviney<sup>1</sup>, G. I. Snell<sup>2</sup>, M. A. Paraskeva<sup>2</sup>, G. P. Westall<sup>2</sup>. <sup>1</sup>Victorian Transplantation and Immunogenetics Service, Australian Red Cross Service, Melbourne, Australia, <sup>2</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia

**4:45 PM (303) *A Three Center Study Reveals New Insights into the Impact of Non-HLA Antibodies on the Acute Rejection Process in Lung Transplantation;***

N. L. Reinsmoen<sup>1</sup>, J. Mirocha<sup>2</sup>, C. Ensor<sup>3</sup>, M. Marrari<sup>4</sup>, G. E. Chau<sup>5</sup>, C. Lai<sup>1</sup>, D. Levine<sup>6</sup>, A. Zeevi<sup>6</sup>. <sup>1</sup>HLA & Immunogenetics Laboratory, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>3</sup>Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>4</sup>Division of Transplant Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>5</sup>Lung Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>6</sup>Pulmonary Diseases & Critical Care Medicine, Univ. of Texas Health Science Center, San Antonio, TX, <sup>6</sup>Pathology, Surgery and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

**5:00 PM (304) *The Deleterious Effect of De Novo DQ Donor Specific Antibody in Lung Transplant Is Not Related to the MFI Values of Luminex Single Antigen Assay;***

A. Zhang<sup>1</sup>, T. S. Panchabhai<sup>2</sup>, Y. Sun<sup>3</sup>, H. Morf<sup>4</sup>, M. M. Budev<sup>2</sup>, C. Farver<sup>5</sup>, K. R. McCurry<sup>6</sup>, L. Klingman<sup>1</sup>, M. Askar<sup>1</sup>. <sup>1</sup>Allogen Laboratories, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Respiratory Institute, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Avalon University School of Medicine, Curaçao, Netherlands, <sup>4</sup>Leipzig University School of Medicine, Leipzig, Germany, <sup>5</sup>Anatomic Pathology, Cleveland Clinic, Cleveland, OH, <sup>6</sup>Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

**5:15 PM (305) *New Insights in to the Impact of Auto-Antibodies on the Acute Rejection Process in Lung Transplantation;***

N. L. Reinsmoen<sup>1</sup>, J. Mirocha<sup>2</sup>, C. Ensor<sup>3</sup>, M. Marrari<sup>4</sup>, G. E. Chau<sup>5</sup>, C. Lai<sup>1</sup>, D. Levine<sup>6</sup>, A. Zeevi<sup>6</sup>. <sup>1</sup>HLA & Immunogenetics Laboratory, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>2</sup>Cedars-Sinai Research Institute, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>3</sup>Pharmacy and Therapeutics, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>4</sup>Division of Transplant Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>5</sup>Lung Transplant Center, Cedars-Sinai Health Systems, Los Angeles, CA, <sup>6</sup>Pulmonary Diseases & Critical Care Medicine, Univ. of Texas Health Science Center, San Antonio, TX, <sup>6</sup>Pathology, Surgery and Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

**5:30 PM (306) Donor-Specific HLA Antibodies After Lung Transplantation: Extended Follow-Up From the HALT Study;**

R. R. Hachem<sup>1</sup>, M. Budev<sup>2</sup>, M. Askar<sup>3</sup>, C. Farver<sup>4</sup>, J. Lee<sup>5</sup>, M. Kamoun<sup>6</sup>, G. Dhillon<sup>6</sup>, D. Tyan<sup>8</sup>, D. J. Levine<sup>8</sup>, M. Pollack<sup>10</sup>, L. E. Leard<sup>11</sup>, R. Raja<sup>12</sup>, T. Mohanakumar<sup>13</sup>, R. D. Yusen<sup>1</sup>. <sup>1</sup>Pulmonary & Critical Care Medicine, Washington Univ Sch Med, Saint Louis, MO, <sup>2</sup>Respiratory Institute, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Surgery, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Pathology, Cleveland Clinic, Cleveland, OH, <sup>5</sup>Pulmonary & Critical Care Medicine, University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Pathology, University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Pulmonary & Critical Care Medicine, Stanford University, Palo Alto, CA, <sup>8</sup>Pathology, Stanford University, Palo Alto, CA, <sup>8</sup>Pulmonary & Critical Care Medicine, UT Health Sciences Center, San Antonio, TX, <sup>10</sup>Pathology, UT Health Sciences Center, San Antonio, TX, <sup>11</sup>Pulmonary & Critical Care Medicine, University of California San Francisco, San Francisco, CA, <sup>12</sup>Surgery, University of California San Francisco, San Francisco, CA, <sup>13</sup>Surgery, Washington Univ Sch Med, Saint Louis, MO

**5:45 PM (307) Human Intravenous Immunoglobulins With Rituximab vs. Therapeutic Plasma Exchange With Rituximab for Pre-Emptive Treatment of Early Donors Specific Antibodies After Lung Transplantation: Preliminary Result;**

E. Ius<sup>1</sup>, W. Sommer<sup>1</sup>, D. Kieneke<sup>2</sup>, I. Tudorache<sup>1</sup>, C. Kühn<sup>1</sup>, M. Avsar<sup>1</sup>, T. Siemeni<sup>1</sup>, J. Salman<sup>1</sup>, M. Greer<sup>3</sup>, M. Hallensleben<sup>2</sup>, N. Schwerk<sup>4</sup>, J. Gottlieb<sup>3</sup>, T. Welte<sup>3</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, <sup>2</sup>Department of Transfusion Medicine, Hanover Medical School, Hanover, Germany, <sup>3</sup>Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany, <sup>4</sup>Department of Paediatrics, Hanover Medical School, Hanover, Germany

4:30 PM – 6:00 PM

CONCURRENT SESSION 41

**Heart Matters: Truth and Justice (Calliope)**

(PEEQ, HF, HTX, MCS, NNSAH)

**CHAIRS:** Bruno M. Meiser, MD and  
Kathleen L. Grady, PhD, APN, FAAN

**4:30 PM (308) *The Effect of Everolimus vs. Calcineurin Inhibitors on Quality of Life During 3 Years Follow Up: The Result of a Randomized Controlled Trial (SCHEDULE Trial);***

I. Grov<sup>1</sup>, A. Relbo<sup>1</sup>, K. Karason<sup>2</sup>, F. Gustafsson<sup>3</sup>, H. Eiskjær<sup>4</sup>, G. Rådegran<sup>5</sup>, E. Gude<sup>1</sup>, K. Jansson<sup>6</sup>, D. Solbu<sup>6</sup>, S. Arora<sup>1</sup>, G. Dellgren<sup>8</sup>, A. Andreassen<sup>1</sup>, L. Gullestad<sup>1</sup>. <sup>1</sup>Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>2</sup>Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Copenhagen University Hospital, Copenhagen, Denmark, <sup>4</sup>Skejby University Hospital, Aarhus, Denmark, <sup>5</sup>Skåne University Hospital and Lund University Hospital, Lund, Sweden, <sup>6</sup>Linköping University Hospital, Linköping, Sweden, <sup>8</sup>Novartis Norge AS, Oslo, Norway, <sup>8</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden

**4:45 PM (309) *International Comparison of Heart Failure Rehospitalizations: An Analysis of the Global Comparators Administrative Database;***

V. N. Selby<sup>1</sup>, B. Ide<sup>2</sup>, P. Copeland<sup>3</sup>, P. Bergin<sup>4</sup>, H. P. Brunner-La Rocca<sup>5</sup>, T. E. Meyer<sup>6</sup>, R. Morgan<sup>7</sup>, N. Casey<sup>8</sup>, J. Lewis<sup>8</sup>, T. De Marco<sup>1</sup>. <sup>1</sup>Division of Cardiology, University of California, San Francisco, San Francisco, CA, <sup>2</sup>UCSF Medical Center, San Francisco, CA, <sup>3</sup>Chelsea & Westminster Hospital NHS Foundation Trust, London, United Kingdom, <sup>4</sup>Cardiovascular Medicine, Alfred Hospital, Melbourne, Australia, <sup>5</sup>Department of Cardiology, Maastricht University Medical Center, Maastricht, Netherlands, <sup>6</sup>Medicine (Cardiology), University of Massachusetts Medical Center, Worcester, MA, <sup>7</sup>Chelsea and Westminster Hospital, London, United Kingdom, <sup>8</sup>Dr Foster Intelligence, London, United Kingdom

**5:00 PM (310) *A Comprehensive Analysis of Hospital Charges Between Direct Heart Transplantation and Patients Bridged With a Left Ventricular Assist Device;***

M. R. Danter<sup>1</sup>, M. Djunaidi<sup>1</sup>, M. E. Davis<sup>2</sup>, E. Y. Zavala<sup>3</sup>, N. A. Haglund<sup>4</sup>, S. Maltais<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Transplant Administration, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN,

**5:15 PM (311) *Cardiac Replacement Therapies – A Comparative Analysis of Cost and Survival – Heart Transplantation vs. Circulatory Assist;***

E. Gude<sup>1</sup>, V. Mishra<sup>2</sup>, A. Fiane<sup>3</sup>, B. Persson<sup>2</sup>, O. Geiran<sup>4</sup>, G. Sørensen<sup>5</sup>, T. Hagen<sup>5</sup>. <sup>1</sup>Department of Cardiology, Oslo University Hospital, Oslo, Norway, <sup>2</sup>Department of Finance and Resource Management Unit, Oslo University Hospital, Oslo, Norway, <sup>3</sup>Department of Cardiothoracic Surgery, Oslo University Hospital, Oslo, Norway, <sup>4</sup>Faculty of Medicine, University of Oslo, Oslo, Norway, <sup>5</sup>Department of Health Management and Health Economics, Faculty of Medicine, University of Oslo, Oslo, Norway

**5:30 PM (312) *Impact of Insurance Status on LVAD Utilization and Health Outcomes for Patients Listed for Heart Transplantation;***

A. A. Morris<sup>1</sup>, A. Kelkar<sup>1</sup>, Y. Ko<sup>2</sup>, S. R. Laskar<sup>1</sup>, A. L. Smith<sup>1</sup>, J. D. Vega<sup>1</sup>. <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>Emory Rollins School of Public Health, Atlanta, GA

5:45 PM **(313)** *Quality of Life/Mid-Term Survival of Patients Bridged With ECMO to LVAD;*

S. Unai<sup>1</sup>, K. Yamane<sup>2</sup>, G. Cook<sup>1</sup>, H. Hirose<sup>1</sup>, N. C. Cavarocchi<sup>1</sup>, J. W. Entwistle<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Thomas Jefferson University, Philadelphia, PA, <sup>2</sup>Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA





4:30 PM – 6:00 PM

CONCURRENT SESSION 42

**The Silent Partner (Euterpe)**

(ID, BSI, HTX, LTX, PEDS)

**CHAIRS:** Orla Morrissey, MD and Stanley I. Martin, MD

- 4:30 PM (314) *Microbial Communities and Cytokine Responses Associated With Respiratory Tract Infections Following Lung Transplant (LTx);***  
C. Clancy<sup>1</sup>, J. Shankar<sup>2</sup>, M. Crespo<sup>1</sup>, J. Pilewski<sup>1</sup>, C. Bermudez<sup>1</sup>, W. Nierman<sup>2</sup>, M. Nguyen<sup>1</sup>. <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>JCVI, Rockville, MD
- 4:45 PM (315) *CMV-Specific CD8+ T Cells Persist During Early Chronic Infection With Impaired Function and an EomeshiPD-1hi Exhausted Phenotype in Lung Transplant Recipients With Relapsing Viremia;***  
I. Popescu<sup>1</sup>, M. R. Pipeling<sup>1</sup>, H. Otepka<sup>1</sup>, P. Shah<sup>2</sup>, J. B. Orens<sup>2</sup>, J. F. McDyer<sup>1</sup>. <sup>1</sup>Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Medicine, Johns Hopkins University, Baltimore, MD
- 5:00 PM (316) *Hypogammaglobulinemia Can Be Immunomodulated as a Risk Factor of Infection in Heart Recipients By Preventive Use of Intravenous Immunoglobulin: Results of a Clinical Trial;***  
J. Carbone<sup>1</sup>, P. Diez<sup>2</sup>, M. Arraya<sup>1</sup>, M. Jaramillo<sup>1</sup>, L. Calahorra<sup>1</sup>, J. Fernandez-Yanez<sup>2</sup>, J. Palomo<sup>2</sup>, J. Hortal<sup>3</sup>, P. Munoz<sup>4</sup>, J. Navarro<sup>1</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>3</sup>Anesthesiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>4</sup>Microbiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 5:15 PM (317) *Early Secondary Combined Immunodeficiency After Heart Transplantation: Impact on Development of Severe Infections;***  
J. Carbone<sup>1</sup>, J. Palomo<sup>2</sup>, J. Fernandez-Yanez<sup>2</sup>, P. Diez<sup>2</sup>, P. Muñoz<sup>3</sup>, J. Hortal<sup>4</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>3</sup>Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>4</sup>Anesthesiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 5:30 PM (318) *Mannose-Binding Lectin Serum Levels and Pre-Transplant Genotypes for Personalized Anti-CMV Prophylaxis in Heart Recipients;***  
J. Carbone<sup>1</sup>, M. Arraya<sup>1</sup>, F. Lozano<sup>2</sup>, J. Palomo<sup>3</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Immunology, Hospital Clinic, Barcelona, Spain, <sup>3</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- 5:45 PM (319) *Boosting the Adaptive Immune Response Prevents the High Incidence of Herpes Zoster After Lung or Heart Transplantation;***  
N. M. van Besouw<sup>1</sup>, S. Roest<sup>2</sup>, J. M. Zuijderwijk<sup>1</sup>, R. de Kuiper<sup>1</sup>, J. J. van Weezel<sup>3</sup>, R. A. Hoek<sup>3</sup>, A. A. van der Eijk<sup>4</sup>, W. Weimar<sup>1</sup>, P. T. van Hal<sup>3</sup>, O. C. Manintveld<sup>2</sup>. <sup>1</sup>Internal Medicine-Transplantation, Erasmus MC, Rotterdam, Netherlands, <sup>2</sup>Cardiology, Erasmus MC, Rotterdam, Netherlands, <sup>3</sup>Respiratory Medicine, Erasmus MC, Rotterdam, Netherlands, <sup>4</sup>Viroscience, Erasmus MC, Rotterdam, Netherlands

4:30 PM – 11:59 PM

EXHIBIT HALL STRIKE (Rhodes)

6:00 PM – 7:00 PM

## MINI ORAL SESSION 7

### Mechanical Circulatory Support: Apocalypse Tomorrow (Athena)

(MCS, HF)

**CHAIRS:** David S. Feldman, MD, PhD and Guenther Laufer, MD

**6:00 PM (320) *Contributing Factors to the Successful Medical Management of Suspected Left Ventricular Assist Device Thrombosis;***

M. Bradbury<sup>1</sup>, K. Poppiti<sup>1</sup>, R. Connolly<sup>2</sup>, D. Goffman<sup>1</sup>, N. Burton<sup>1</sup>, S. Desai<sup>1</sup>, P. Shah<sup>1</sup>. <sup>1</sup>Inova Fairfax Hospital, Falls Church, VA, <sup>2</sup>Georgetown University Hospital, Washington, DC, DC

**6:05 PM (321) *The Risk of Hospital Readmissions Following Mechanical Circulatory Support Placement;***

F. Arabia, M. Kittleson, L. Czer, J. Hajj, E. Passano, F. Liou, S. Siddiqui, D. H. Chang, J. Kobashigawa, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA

**(322) WITHDRAWN**

**6:10 PM (515) *Durability and Clinical Impact of Tricuspid Valve Procedures in Patients Receiving Continuous-Flow Left Ventricular Assist Device;***

J. Han<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, P. A. Kurlansky<sup>1</sup>, P. C. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, S. Fukuhara<sup>1</sup>, L. K. Truby<sup>1</sup>, V. K. Topkara<sup>2</sup>, D. M. Mancini<sup>2</sup>, Y. Naka<sup>1</sup>. <sup>1</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Medicine, Columbia University Medical Center, New York, NY

**(323) Moved to Concurrent Session 15**

**6:15 PM (505) *Left Ventricular Assist Device Support Provides Drastic Restoration of Gene Expression Together With Myocardial Recovery in Patients With Advanced Heart Failure;***

K. Kuroda<sup>1</sup>, O. Seguchi<sup>1</sup>, E. Hisamatsu<sup>1</sup>, T. Satoh<sup>1</sup>, S. Nakajima<sup>1</sup>, H. Sunami<sup>1</sup>, T. Sato<sup>1</sup>, S. Muto<sup>2</sup>, M. Nishigori<sup>3</sup>, H. Hata<sup>4</sup>, K. Ohgoh<sup>2</sup>, M. Asakura<sup>5</sup>, M. Yanase<sup>1</sup>, T. Fujita<sup>4</sup>, H. Ishibashi-Ueda<sup>2</sup>, N. Minamino<sup>3</sup>, J. Kobayashi<sup>4</sup>, T. Nakatani<sup>1</sup>. <sup>1</sup>Department of Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>2</sup>Department of Pathology, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>3</sup>Department of Molecular Pharmacology, National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan, <sup>4</sup>Department of Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>5</sup>Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Center, Osaka, Japan

**6:20 PM (324) *Results of the SynCardia temporary Total Artificial Heart (TAH-t) Postmarket Surveillance Study (PSS) vs. Pre-Market Approval (PMA);***

F. A. Arabia<sup>1</sup>, V. Kasirajan<sup>2</sup>, J. G. Copeland<sup>3</sup>, R. G. Smith<sup>4</sup>, D. Covington<sup>4</sup>. <sup>1</sup>Surgery, Cedars-Sinai Med Ctr, Los Angeles, CA, <sup>2</sup>Surgery, Virginia Commonwealth University, Richmond, VA, <sup>3</sup>None, Los Angeles, CA, <sup>4</sup>Artificial Heart, University of Arizona, Tucson, AZ,

**6:25 PM (325) *Discriminatory Performance of Simple Urine Dipstick for Detection of Significant Hemolysis in CF-LVAD Patients;***

M. Gavalas<sup>1</sup>, A. Breskin<sup>2</sup>, A. B. Eisenberger<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, V. K. Topkara<sup>1</sup>, M. R. Torres<sup>3</sup>, M. Tiburcio<sup>3</sup>, J. S. Murphy<sup>3</sup>, B. Cagliostro<sup>1</sup>, R. Te-Frey<sup>3</sup>, K. Ross<sup>3</sup>, M. Flannery<sup>3</sup>, K. Wong<sup>1</sup>, R. A. Garan<sup>1</sup>, D. M. Mancini<sup>1</sup>, K. Takeda<sup>3</sup>, H. Takayama<sup>3</sup>, Y. Naka<sup>3</sup>, R. T. Demmer<sup>4</sup>, P. C. Colombo<sup>1</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>Surgery, Columbia University, New York, NY, <sup>4</sup>Epidemiology, Columbia University, New York, NY

- 6:30 PM (326) Outcomes of Off-Pump Minimally Invasive Exchange of the HeartMate II (HMII) Left Ventricular Assist Device (LVAD);**  
 B. Soleimani<sup>1</sup>, C. Pietras<sup>1</sup>, E. Stephenson<sup>1</sup>, K. High<sup>2</sup>, W. Pae<sup>1</sup>.  
<sup>1</sup>Cardiothoracic Surgery, Penn State Hershey Medical Center, Hershey, PA, <sup>2</sup>Anesthesiology, Penn State Hershey Medical Center, Hershey, PA
- 6:35 PM (327) Anticoagulation Reversal With 4-Factor Prothrombin Complex Concentrate in Left Ventricular Assist Device Patients With Acute Hemorrhagic Stroke;**  
 P. Chen<sup>1</sup>, J. Falvey<sup>2</sup>, L. Lowenstein<sup>3</sup>, A. Miranpuri<sup>4</sup>, W. Hallinan<sup>1</sup>, T. Massey<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Rochester, Rochester, NY, <sup>2</sup>Pharmacology, University of Rochester, Rochester, NY, <sup>3</sup>Medicine, University of Rochester, Rochester, NY, <sup>4</sup>Neurosurgery, University of Rochester, Rochester, NY
- 6:40 PM (328) Gold standard in biventricular circulatory support – excellent results with an old school device;**  
 S. Bartfay<sup>1</sup>, H. Lidén<sup>2</sup>, M. Holmberg<sup>1</sup>, K. Karason<sup>1</sup>, J. Gäbel<sup>2</sup>, B. Redfors<sup>3</sup>, G. Dellgren<sup>2</sup>. <sup>1</sup>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>2</sup>Department of Cardiolothoracic Surgery and Transplantation, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Department of Cardiolothoracic Anesthesia and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Swede,
- 6:45 PM (329) Partial Support for Bridged Patients With Previous Cardiac Surgery Implanted With a Miniaturized Centrifugal Continuous-Flow Pump: Are We There Yet?;**  
 S. Maltais<sup>1</sup>, M. E. Davis<sup>1</sup>, M. Djunaidi<sup>1</sup>, M. R. Danter<sup>1</sup>, J. M. Stulak<sup>2</sup>, M. Xu<sup>3</sup>, N. A. Haglund<sup>4</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN, <sup>3</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN
- 6:50 PM (330) The Use of a Portable Driver for the Total Artificial Heart in the United States: The Freedom Driver System Study;**  
 V. Kasirajan<sup>1</sup>, F. Arabia<sup>2</sup>. <sup>1</sup>Surgery, Va Commonwealth Univ Med, Pauley Heart Center, Richmond, VA, <sup>2</sup>Cardiac Surgery, Cedars Sinai Medical Center, Los Angeles, CA
- 6:55 PM (331) Hemodynamic Response to Nitroprusside as Predictor of Right Ventricular Failure After LVAD Implantation;**  
 D. Mikhalkova, A. Godishala, M. Nassif, J. Vader, G. Ewald, S. LaRue, K. Lavine. Barnes Jewish Hospital Washington University, St Louis, MO

6:00 PM – 7:00 PM

## MINI ORAL SESSION 8

### A Heart Day's Night (Clio, Thalie)

(HTX, BSI, DMD, HF, ID, MCS, NNSAH, PATH, PEDS, PHARM, PEEQ)

**CHAIRS:** Piotr Przybylowski, MD, PhD and Giuseppe Faggian, MD

**(332) Moved to Concurrent Session 31**

**6:00 PM (780) *Effect of Pre-Transplant Mechanical Circulatory Support on Early Cellular Rejection and Subsequent Risk of Allograft Vasculopathy;***

A. Grupper<sup>1</sup>, E. M. Nestorovic<sup>2</sup>, L. D. Joyce<sup>3</sup>, N. M. Milic<sup>4</sup>, J. M. Stulak<sup>3</sup>, B. S. Edwards<sup>1</sup>, N. L. Pereira<sup>1</sup>, R. C. Daly<sup>3</sup>, S. S. Kushwaha<sup>1</sup>. <sup>1</sup>Divisions of Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiac surgery, Hospital for Cardiac Surgery, Clinical Center of Serbia, Belgrade, Serbia, <sup>3</sup>Divisions of Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>4</sup>Institute for Medical Statistics and Informatics, Medical Faculty University of Belgrade, Belgrade, Serbia

**6:05 PM (333) *Neutrophil Gelatinase-Associated Lipocalin (NGAL) in Heart Transplant Recipients After Conversion to Everolimus Therapy;***

J. Stypmann<sup>1</sup>, M. Fobker<sup>2</sup>, K. Rosing<sup>2</sup>, M. Engelen<sup>1</sup>, S. Gunia<sup>3</sup>, A. Dell'Aquila<sup>4</sup>, J. Nofer<sup>2</sup>. <sup>1</sup>Department of Cardiovascular Medicine, University Hospital Münster, Muenster, Germany, <sup>2</sup>Center of Laboratory Medicine, University Hospital Münster, Muenster, Germany, <sup>3</sup>Internal Medicine D, Department of Nephrology, Hypertension and Rheumatology, University Hospital Münster, Muenster, Germany, <sup>4</sup>Department of Cardiothoracic Surgery, University Hospital Münster, Muenster, Germany

**6:10 PM (334) *Complement-Fixing Donor-Specific HLA Antibodies Detected By Novel C3d Assay Are Associated With Antibody Mediated Rejection in Heart Transplant Recipients;***

J. Lan<sup>1</sup>, M. Hickey<sup>1</sup>, M. Cadeiras<sup>2</sup>, E. C. Depasquale<sup>2</sup>, N. Halnon<sup>2</sup>, A. Baas<sup>2</sup>, G. Perens<sup>2</sup>, A. Nsair<sup>2</sup>, M. Kwon<sup>3</sup>, T. Khuu<sup>2</sup>, A. Ardehali<sup>3</sup>, D. Gjertson<sup>1</sup>, J. Alejos<sup>2</sup>, L. Reardon<sup>2</sup>, E. F. Reed<sup>1</sup>, M. Deng<sup>2</sup>, Q. J. Zhang<sup>1</sup>. <sup>1</sup>UCLA Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>3</sup>Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA

**6:15 PM (335) *Three Years Outcome of Virtual Crossmatch Strategy in Heart Transplant Recipients;***

L. Borgese<sup>1</sup>, L. Potena<sup>2</sup>, V. Manfredini<sup>1</sup>, A. Bontadini<sup>3</sup>, S. Iannelli<sup>3</sup>, F. Fruet<sup>3</sup>, S. Capelli<sup>3</sup>, M. Chiavaroli<sup>1</sup>, B. Barra<sup>1</sup>, P. Prestinzi<sup>1</sup>, G. Magnani<sup>2</sup>, F. Grigioni<sup>1</sup>, C. Rapezzi<sup>2</sup>. <sup>1</sup>University of Bologna, Bologna, Italy, <sup>2</sup>Cardiovascular Department, S.Orsola-Malpighi Hospital, Bologna, Italy, <sup>3</sup>Immunogenetic Unit, S. Orsola-Malpighi Hospital, Bologna, Italy

**6:20 PM (336) *Donor-Derived Cell-Free DNA Is Stable in Non-Rejecting Heart Transplant Recipients in the CARGO II Multicenter Trial;***

P. Mohacs<sup>1</sup>, M. Crespo-Leiro<sup>2</sup>, A. Zuckermann<sup>3</sup>, J. Stypmann<sup>4</sup>, D. Hiller<sup>5</sup>, M. Grskovic<sup>5</sup>, J. Beausang<sup>5</sup>, R. Sit<sup>5</sup>, B. Christie<sup>5</sup>, J. Elechko<sup>5</sup>, R. Woodward<sup>5</sup>, J. Yee<sup>5</sup>, J. Vanhaecke<sup>6</sup>. <sup>1</sup>University Hospital Bern, Bern, Switzerland, <sup>2</sup>Hospital Universitario A Coruña, La Coruña, Spain, <sup>3</sup>Medical University of Vienna, Vienna, Austria, <sup>4</sup>University Hospital Münster, Münster, Germany, <sup>5</sup>CareDx, Inc, Brisbane, CA, <sup>6</sup>University Hospital Leuven, Leuven, Belgium

- 6:25 PM (337) Pretransplant Serum BAFF in Heart Transplantation: A Potential New Biomarker for Acute Cellular Rejection Risk;**  
 J. Carbone<sup>1</sup>, L. Calahorra<sup>1</sup>, P. Diez<sup>2</sup>, J. Palomo<sup>2</sup>, J. Fernandez-Yanez<sup>2</sup>, E. Sarmiento<sup>1</sup>. <sup>1</sup>Clinical Immunology, Hospital General Universitario Gregorio Marañón, Madrid, Spain, <sup>2</sup>Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain,
- 6:30 PM (338) Time Course of Immunosuppression Minimization and HLA Class I and Class II Antibody Emergence in Heart Transplantation;**  
 M. Bakir<sup>1</sup>, D. Henriquez-Ticas<sup>1</sup>, E. Chang<sup>1</sup>, J. Maque<sup>1</sup>, J. Chittoor<sup>1</sup>, C. Starling<sup>2</sup>, G. Bondar<sup>1</sup>, N. Wisniewski<sup>1</sup>, S. Adigopula<sup>1</sup>, T. Khuu<sup>1</sup>, E. Reed<sup>1</sup>, J. Zhang<sup>1</sup>, M. Cadeiras<sup>1</sup>, M. Deng<sup>1</sup>. <sup>1</sup>Cardiology, UCLA, Los Angeles, CA, <sup>2</sup>Cardiology, LMU, Los Angeles, CA
- 6:35 PM (339) Deep Sequencing Reveals Dynamics in Circulating miRNAs Following Heart Transplantation;**  
 R. C. Givens<sup>1</sup>, K. M. Akat<sup>2</sup>, D. Briskin<sup>2</sup>, D. J. Brunjes<sup>1</sup>, P. J. Kennel<sup>1</sup>, Y. Naka<sup>3</sup>, H. Takayama<sup>3</sup>, I. George<sup>3</sup>, D. M. Mancini<sup>1</sup>, T. Tuschl<sup>2</sup>, P. C. Schulze<sup>1</sup>. <sup>1</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>2</sup>Howard Hughes Medical Institute and Laboratory for RNA Molecular Biology, The Rockefeller University, New York, NY, <sup>3</sup>Surgery, Columbia University Medical Center, New York, NY
- 6:40 PM (340) The Effect of Everolimus vs. Calcineurin Inhibitors on Surgical Complications: The Results of a De Novo Heart Transplant Randomized Controlled Trial (SCHEDULE Trial);**  
 M. Rashidi<sup>1</sup>, S. Esmaily<sup>2</sup>, A. E. Fiane<sup>1</sup>, F. Gustafsson<sup>3</sup>, H. Eiskjær<sup>4</sup>, G. Rådegran<sup>5</sup>, G. Dellgren<sup>2</sup>. <sup>1</sup>Cardiothoracic Unit, Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>2</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Department of Cardiology, Copenhagen University Hospital, Copenhagen, Denmark, <sup>4</sup>Department of Cardiology, Skejby University Hospital, Aarhus, Denmark, <sup>5</sup>The Clinic for Heart Failure and Valvular Disease, Skane University Hospital and Lund University, Lund, Sweden
- 6:45 PM (341) Non-Invasive Assessment of Vasculopathy Using Coronary Flow Velocity Reserve and 2D-Speckle Tracking Echocardiography During Exercise;**  
 T. S. Clemmensen, H. Eiskjær, B. B. Løgstrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark
- 6:50 PM (342) Everolimus (EVE) vs. Mycophenolate (MMF) De Novo After Heart Transplantation (HTx): Does It Matter for Long Term Outcomes?;**  
 M. Masetti, M. Malossi, L. Potena, P. Prestinenzi, V. Manfredini, F. Barberini, L. Borgese, M. Sabatino, G. Magnani, F. Grigioni, C. Rapezzi. University of Bologna, Bologna, Italy
- 6:55 PM (343) Survival Without Immunosuppression: The NoTAC Trial;**  
 D. A. Baran<sup>1</sup>, P. Rao<sup>2</sup>, D. Deo<sup>2</sup>, J. A. Hernandez-Montfort<sup>1</sup>, P. Dhesi<sup>1</sup>, J. Pieretti<sup>1</sup>, C. Gidea<sup>1</sup>, S. Murthy<sup>1</sup>, M. Camacho<sup>1</sup>, M. J. Zucker<sup>1</sup>. <sup>1</sup>Transplant Center, Newark Beth Israel Med Ctr, Newark, NJ, <sup>2</sup>New Jersey Sharing Network Laboratory, New Providence, NJ

6:00 PM – 7:00 PM

## MINI ORAL SESSION 9

### The Man With The Golden Lungs (Erato,Uranie) (LTX, BSI, DMD, LF, MCS, PATH, PHARM)

**CHAIRS:** Lorriana Leard, MD and Gregor Warnecke, MD

**6:00 PM (344)** *The Impact of Cell Death Signals on Short and Long Term Outcome in Human Lung Transplantation;*  
K. Hashimoto, R. Besla, R. Zamel, H. Kim, T. Saito, S. Azad, T. K. Waddell, M. Cypel, M. Liu, S. Keshavjee. Latner Thoracic Surgery Research Laboratories, University of Toronto, Toronto, ON, Canada

**6:05 PM (345)** *Prior Coronary Artery Bypass Surgery – Is It Still a Contraindication for Lung Transplantation?;*  
S. H. McKellar<sup>1</sup>, B. C. Baird<sup>1</sup>, M. Bowen<sup>1</sup>, S. Raman<sup>2</sup>, B. Cahill<sup>2</sup>, C. H. Selzman<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, University of Utah, Salt Lake City, UT, <sup>2</sup>Pulmonary and Critical Care, University of Utah, Salt Lake City, UT

**6:10 PM (346)** *Elective Lobar Lung Transplantation – A Single Center Experience;*  
B. Sill<sup>1</sup>, C. Oelschner<sup>1</sup>, M. Oldigs<sup>2</sup>, H. Klose<sup>3</sup>, C. Kugler<sup>2</sup>, M. Neuhauss<sup>2</sup>, M. Barten<sup>1</sup>, H. Reichenspurner<sup>1</sup>, T. Deuse<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany, <sup>2</sup>LungenClinic, Grosshansdorf, Germany, <sup>3</sup>University Medical Center Hamburg-Eppendorf, Hamburg, Germany

**6:15 PM (347)** *Early Donor Specific Antibodies After Lung Transplantation Lead to an Increase of CD56+CD16+ NK Cells in Peripheral Blood;*  
J. Salman<sup>1</sup>, F. Ius<sup>1</sup>, A. Knoefel<sup>1</sup>, W. Sommer<sup>1</sup>, C. Kuehn<sup>1</sup>, I. Tudorache<sup>1</sup>, M. Avsar<sup>1</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, C. Falk<sup>3</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department for Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Pneumology, Hannover Medical School, Hannover, Germany, <sup>3</sup>Transplant Immunology, Institute of Transplant Immunology, Integrated Research and Treatment Center, Hannover Medical School, Hannover, Germany

**6:20 PM (348)** *Predictors of Survival in Patients Diagnosed With Restrictive CLAD;*  
S. E. Verleden, D. Ruttens, E. Vandermeulen, H. Bellon, D. E. Van Raemdonck, B. M. Vanaudenaerde, G. M. Verleden, R. Vos. Department of Clinical and Experimental Medicine, Laboratory of Pulmonology, Lung Transplant Unit, KU Leuven, Leuven, Belgium

**6:25 PM (349)** *Peripheral Blood Gene Expression Identifies Damage-Associated Innate Immune Pathways in Patients With Primary Graft Dysfunction After Lung Transplantation;*  
E. Cantu<sup>1</sup>, J. M. Diamond<sup>2</sup>, Y. Suzuki<sup>1</sup>, J. Tiwari<sup>1</sup>, B. Beduhn<sup>1</sup>, J. Nellen<sup>1</sup>, C. Borders<sup>1</sup>, J. Ellis<sup>1</sup>, D. J. Lederer<sup>3</sup>, K. Meyer<sup>4</sup>, R. J. Shah<sup>2</sup>, N. J. Meyer<sup>2</sup>, K. Milewski<sup>1</sup>, J. W. Tobias<sup>2</sup>, D. A. Baldwin<sup>2</sup>, V. M. Van Deerlin<sup>5</sup>, K. M. Olthoff<sup>1</sup>, A. Shaked<sup>1</sup>, J. D. Christie<sup>2</sup>. <sup>1</sup>Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Medicine, Columbia University, New York, NY, <sup>4</sup>Medicine, University of Wisconsin, Madison, WI, <sup>5</sup>Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA

**6:30 PM (350)** **WITHDRAWN**

**6:35 PM (351)** *Lung Transplantation in the Elderly: Influence of Multiple Comorbidities and Extended Criteria Donor Lungs;*  
I. Inci, J. Ehrsam, K. Slankamenac, S. Hillinger, W. Jungraithmayr, I. Schmitt Opitz, D. Schneiter, C. Benden, W. Weder. University Hospital, Zurich, Switzerland

- 6:40 PM (352) Contemporary Survival and Outcomes Following Airway Dehiscence Post Lung Transplantation: A Significant Price to Pay;**  
A. J. Hayanga<sup>1</sup>, J. Aboagye<sup>2</sup>, H. K. Hayanga<sup>3</sup>, E. Murphy<sup>1</sup>, D. Meldrum<sup>1</sup>, J. D'Cunha<sup>4</sup>, A. Khaghani<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Spectrum Health - Michigan State University, Grand Rapids, MI, <sup>2</sup>Cardiothoracic Surgery, Johns Hopkins Medical Institutions, Baltimore, MD, <sup>3</sup>Cardiac Anesthesiology, Johns Hopkins Medical Institutions, Baltimore, MD, <sup>4</sup>Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
- 6:45 PM (353) Sparing Native Upper Lobe or Segment in Living-Donor Lobar Lung Transplantation Due to Small-for-Size Grafts;**  
A. Aoyama<sup>1</sup>, F. Chen<sup>1</sup>, S. Tanaka<sup>1</sup>, E. Miyamoto<sup>1</sup>, M. Takahashi<sup>1</sup>, K. Ohata<sup>1</sup>, T. Kondo<sup>1</sup>, H. Motoyama<sup>1</sup>, K. Hijiya<sup>1</sup>, M. Isomi<sup>1</sup>, K. Minakata<sup>2</sup>, T. Yamada<sup>1</sup>, M. Sato<sup>1</sup>, H. Date<sup>1</sup>. <sup>1</sup>Thoracic Surgery, Kyoto University, Kyoto, Japan, <sup>2</sup>Cardiovascular Surgery, Kyoto University, Kyoto, Japan
- 6:50 PM (354) Non-Invasive Monitoring of Infection and Rejection After Lung Transplantation;**  
I. D. Vlaminc<sup>1</sup>, L. Martin<sup>1</sup>, M. Kertesz<sup>1</sup>, K. N. Patel<sup>2</sup>, M. Kowarsky<sup>1</sup>, C. Strehl<sup>3</sup>, G. Cohen<sup>3</sup>, H. Luikart<sup>3</sup>, N. Neff<sup>1</sup>, J. Okamoto<sup>1</sup>, M. N. Nicolls<sup>2</sup>, D. N. Cornfield<sup>2</sup>, D. Weill<sup>2</sup>, H. A. Valentine<sup>3</sup>, K. K. Khush<sup>3</sup>, S. R. Quake<sup>1</sup>. <sup>1</sup>Bioengineering and Applied Physics, Stanford University School of Medicine, Stanford, CA, <sup>2</sup>Pulmonary and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA, <sup>3</sup>Cardiovascular Medicine, Stanford University School of Medicine, Stanford, CA
- 6:55 PM (355) Exposure to Moxifloxacin and Cytomegalovirus Replication Is Associated With Squamous Cell Carcinoma Development in Lung Transplant Recipients;**  
S. R. Gerber<sup>1</sup>, B. Seifert<sup>2</sup>, I. Inci<sup>3</sup>, A. L. Serra<sup>4</sup>, M. Kohler<sup>1</sup>, C. Benden<sup>1</sup>, G. F. Hofbauer<sup>5</sup>, M. M. Schuurmans<sup>1</sup>. <sup>1</sup>Division of Pulmonology, University Hospital Zurich, Zurich, Switzerland, <sup>2</sup>Division of Biostatistics, Institute for Social and Preventive Medicine, University of Zurich, Zurich, Switzerland, <sup>3</sup>Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland, <sup>4</sup>Division of Nephrology, University Hospital Zurich, Zurich, Switzerland, <sup>5</sup>Division of Dermatology, University Hospital Zurich, Zurich, Switzerland

6:00 PM – 7:00 PM

## MINI ORAL SESSION 10

### Breathless: Insights on Lung Failure and Donor Lungs (Hermes)

(LTX, BSI, DMD, LF)

**CHAIRS:** Jens Gottlieb, MD and Patrick Evrard, MD

**6:00 PM (356) *The Impact of High-Risk Lung Donors on the Survival of Lung Recipients With Interstitial Pulmonary Fibrosis;***

P. G. Sanchez<sup>1</sup>, M. Mulligan<sup>1</sup>, C. Evans<sup>1</sup>, S. Rahimpour<sup>1</sup>, I. Timofte<sup>2</sup>, J. Kim<sup>2</sup>, K. Rajagopal<sup>1</sup>, A. T. Iacono<sup>2</sup>, R. Reed<sup>2</sup>, J. S. Gammie<sup>1</sup>, B. P. Griffith<sup>1</sup>, S. M. Pham<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Medicine, University of Maryland, Baltimore, MD

**6:05 PM (357) *Should We Wait for the Perfect Donor for Lung Transplant Candidates on Mechanical Ventilation?;***

M. Mulligan<sup>1</sup>, P. G. Sanchez<sup>1</sup>, C. F. Evans<sup>1</sup>, S. Rahimpour<sup>1</sup>, I. Timofte<sup>2</sup>, K. Rajagopal<sup>1</sup>, A. T. Iacono<sup>2</sup>, J. Kim<sup>2</sup>, J. S. Gammie<sup>1</sup>, B. P. Griffith<sup>1</sup>, S. M. Pham<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Department of Medicine, University of Maryland, Baltimore, MD

**6:10 PM (358) *An Analysis of In-Hospital Major Morbidity and Early Mortality After Transplantation in the Lung Allocation Score Era;***

N. M. Mollberg<sup>1</sup>, E. Howell<sup>2</sup>, A. Cheng<sup>2</sup>, M. S. Mulligan<sup>2</sup>. <sup>1</sup>Bronson Methodist Hospital, Kalamazoo, MI, <sup>2</sup>University of Washington, Seattle, WA

**6:15 PM (359) *Hyaluronan – The First New Biomarker of Donor Organ Quality Since PO2?;***

T. M. Sladden<sup>1</sup>, L. Samson<sup>1</sup>, P. Hopkins<sup>1</sup>, S. T. Yerkovich<sup>1</sup>, D. C. Chambers<sup>1</sup>. Queensland Lung Transplant Service, The Prince Charles Hospital, Chermside, Australia

**6:20 PM (360) *Treatment With Sodium Nitrite Improves the Pulmonary Function of Rejected Human Lungs in Cellular Ex-Vivo Lung Perfusion Model;***

T. Okamoto<sup>1</sup>, D. Wheeler<sup>2</sup>, R. Chakravarti<sup>3</sup>, Q. Liu<sup>1</sup>, A. Janocha<sup>3</sup>, D. Laskowski<sup>3</sup>, C. Quintini<sup>1</sup>, D. Stuehr<sup>3</sup>, S. Erzurum<sup>3</sup>, R. Dweik<sup>3</sup>, K. R. McCurry<sup>4</sup>. <sup>1</sup>Transplant Center, Cleveland Clinic, Cleveland, OH, <sup>2</sup>Cardiothoracic Anesthesia, Cleveland Clinic, Cleveland, OH, <sup>3</sup>Pathobiology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, <sup>4</sup>Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH

**6:25 PM (361) *Assessing Human Lungs Unsuitable for Transplant By Ex-Vivo Lung Perfusion (EVLP) and Ex-Vivo CT Scan: Does EVLP Cause Inflammation?;***

T. M. Egan<sup>1</sup>, B. Dong<sup>1</sup>, J. Blackwell<sup>1</sup>, K. Birchard<sup>2</sup>, P. Stewart<sup>3</sup>, W. Funkhouser<sup>4</sup>, W. Simmons<sup>1</sup>, E. Gazda<sup>5</sup>, E. Jernigan<sup>1</sup>, A. Venkataraman<sup>1</sup>, S. Reddy<sup>6</sup>, B. Haithcock<sup>1</sup>. <sup>1</sup>Surgery, U. North Carolina Sch Med, Chapel Hill, NC, <sup>2</sup>Radiology, U. North Carolina Sch Med, Chapel Hill, NC, <sup>3</sup>Biostatistics, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC, <sup>4</sup>Pathology, U. North Carolina Sch Med, Chapel Hill, NC, <sup>5</sup>Surgery, U. North Carolina Sch Med, Chapel Hill, NC, <sup>6</sup>Surgery, Duke University, Durham, NC



**6:30 PM (362) Clinical Outcomes of Lung Transplantation in Patients With Telomerase Complex Mutations;**  
S. Tokman<sup>1</sup>, J. P. Singer<sup>1</sup>, M. S. Devine<sup>2</sup>, G. P. Westall<sup>3</sup>, J. Aubert<sup>4</sup>, M. Tamm<sup>5</sup>, G. I. Snell<sup>5</sup>, J. S. Lee<sup>1</sup>, H. J. Goldberg<sup>6</sup>, J. Kukreja<sup>6</sup>, J. A. Golden<sup>1</sup>, L. E. Leard<sup>1</sup>, C. K. Garcia<sup>2</sup>, S. R. Hays<sup>1</sup>.  
<sup>1</sup>Division of Pulmonary and Critical Care Medicine, University of California, San Francisco Medical Center, San Francisco, CA, <sup>2</sup>Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, <sup>3</sup>Division of Respiratory Medicine, Alfred Hospital, Melbourne, Australia, <sup>4</sup>Division of Respiratory Medicine, Lausanne University Hospital, Lausanne, Switzerland, <sup>5</sup>Division of Respiratory Medicine, Basel University Hospital, Basel, Switzerland, <sup>6</sup>Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Boston, MA, <sup>6</sup>Division of Cardiothoracic Surgery, University of California, San Francisco Medical Center, San Francisco, CA

**(363) Moved to Concurrent Session 52**

**6:35 PM (764) Recipient Outcomes in Donation After Circulatory Determination of Death Lung Donors Within the United States;**  
J. J. Mooney<sup>1</sup>, H. Hedlin<sup>1</sup>, P. K. Mohabir<sup>1</sup>, R. V. Guillamet<sup>2</sup>, R. Ha<sup>3</sup>, P. Chiu<sup>3</sup>, K. Patel<sup>1</sup>, D. Weill<sup>1</sup>, M. R. Nicolls<sup>1</sup>, G. S. Dhillon<sup>1</sup>.  
<sup>1</sup>Department of Medicine, Stanford University, Stanford, CA, <sup>2</sup>Department of Medicine, University of New Mexico, Albuquerque, NM, <sup>3</sup>Department of Cardiothoracic Surgery, Stanford University, Stanford, CA

**(364) Moved to Concurrent Session 10**

**6:40 PM (766) Increasing Lung Utilization: Implementation of a Dedicated Donor Screening Program;**  
G. Looor<sup>1</sup>, C. Lyon<sup>2</sup>, J. Morrow<sup>2</sup>, T. Grabowski<sup>2</sup>, R. Kelly<sup>1</sup>, M. Hertz<sup>1</sup>, J. Morancy<sup>1</sup>, J. Patil<sup>1</sup>, D. Frankle<sup>2</sup>.  
<sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Fairview Medical Center, Minneapolis, MN

**6:45 PM (365) Chronic Effects of Air Pollution on Lung Function in Lung Transplant Patients (SysCLAD);**  
M. Benmerad<sup>1</sup>, K. Botturi<sup>2</sup>, C. Pison<sup>3</sup>, A. Magnan<sup>2</sup>, J. Claustre<sup>3</sup>, A. Roux<sup>4</sup>, C. Gomez<sup>5</sup>, R. Kessler<sup>6</sup>, O. Brugière<sup>6</sup>, J. Mornex<sup>8</sup>, S. Mussot<sup>8</sup>, M. Dahan<sup>10</sup>, V. Boussaud<sup>11</sup>, I. Danner-Boucher<sup>2</sup>, C. Dromer<sup>12</sup>, C. Knoop<sup>13</sup>, L. Malherbe<sup>14</sup>, F. Meleux<sup>14</sup>, R. Slama<sup>1</sup>, L. Nicod<sup>15</sup>, V. Siroux<sup>1</sup>.  
<sup>1</sup>Team 12 environmental epidemiology, IN-SERM/UJF U823, La Tronche, France, <sup>2</sup>CHU Nantes, Nantes, France, <sup>3</sup>CHU Grenoble, Grenoble, France, <sup>4</sup>Hôpital Foch, Suresnes, France, <sup>5</sup>AP-HM Hôpital Nord, Marseille, France, <sup>6</sup>CHRU Strasbourg, Strasbourg, France, <sup>8</sup>AP-HP Hôpital Bichat, Paris, France, <sup>8</sup>Université Lyon 1, Lyon, France, <sup>8</sup>Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, <sup>10</sup>CHU Toulouse, Toulouse, France, <sup>11</sup>Hôpital européen Georges-Pompidou, Paris, France, <sup>12</sup>CHU Bordeaux, Bordeaux, France, <sup>13</sup>Hôpital Erasme, Bruxelles, Belgium, <sup>14</sup>INERIS, Verneuil-en-Halatte, France, <sup>15</sup>CHU Vaudois, Lausanne, France

**6:50 PM (366) Internet-Based Telemonitoring System of Daily Home Spirometry in Lung Transplant Recipients;**  
L. Peysson<sup>1</sup>, C. Gomez<sup>1</sup>, P. Giovannetti<sup>1</sup>, B. Coltey<sup>1</sup>, N. Dufeu<sup>1</sup>, F. Brégeon<sup>2</sup>, J. Gaubert<sup>3</sup>, H. Dutau<sup>1</sup>, P. Thomas<sup>4</sup>, M. Reynaud-Gaubert<sup>1</sup>.  
<sup>1</sup>Department of Respiratory Medicine Lung Transplant Team, University North Hospital, Marseille, France, <sup>2</sup>Lung Function Tests Laboratory, University North Hospital, Marseille, France, <sup>3</sup>Radiology Department, University Timone Hospital, Marseille, France, <sup>4</sup>Department of Thoracic and Transplant Surgery, University North Hospital, Marseille, France

**6:55 PM (367) Hypogammaglobulinemia After Lung Transplantation Increases Risk of Recurrent Pneumonia;**  
R. S. Traister, J. Nelson, M. Crespo, F. P. Silveira, J. M. Pilewski, A. A. Petrov. University of Pittsburgh, Pittsburgh, PA

6:00 PM – 7:00 PM

## MINI ORAL SESSION 11

### What's Up, Doc? Bugs, Drugs and PH (Calliope) (PH, HF, HTX, LF, LTX, MCS, PHARM)

**CHAIRS:** Nicolas Manito, MD  
Margaret M. Hannan, MD and  
Rochelle M. Gellatly, PharmD

**6:00 PM (368) *A Retrospective Analysis of the Safety and Efficacy of a 6-Week Pulmonary Rehabilitation Program in Patients With Severe Pulmonary Arterial Hypertension;***

J. G. Weinkauff, G. Miciak, A. Kapasi, K. Jackson, K. Halloran, D. C. Lien. Medicine, University of Alberta, Edmonton, AB, Canada

**6:05 PM (369) *A Study to Explore the Feasibility and Safety of Using an Implantable Hemodynamic Monitor in PAH Patients;***

R. L. Benza<sup>1</sup>, M. Doyle<sup>1</sup>, M. Cham<sup>2</sup>, P. Correa-Jaque<sup>1</sup>, J. White<sup>3</sup>, D. Thompson<sup>1</sup>, R. Agarwal<sup>1</sup>, M. Kanwar<sup>1</sup>, R. Biederman<sup>1</sup>. <sup>1</sup>The Cardiovascular Institute, Allegheny Gen Hosp, Pittsburgh, PA, <sup>2</sup>Blenderhouse Inc., Pittsburgh, PA, <sup>3</sup>St. Jude's, St Paul, MN

**6:10 PM (370) *Characterization and Impact of Pulmonary Hypertension on Outcomes After Left Ventricular Assist Device Implantation;***

V. N. Selby<sup>1</sup>, J. J. Teuteberg<sup>2</sup>, I. E. Allen<sup>3</sup>, R. J. Tedford<sup>4</sup>, R. L. Kormos<sup>5</sup>, T. De Marco<sup>1</sup>. <sup>1</sup>Division of Cardiology, University of California, San Francisco, San Francisco, CA, <sup>2</sup>Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>3</sup>Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, <sup>4</sup>Division of Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD, <sup>5</sup>Department of Surgery, University of Pittsburgh, Pittsburgh, PA

**6:15 PM (371) *Initial Results of the Prospective Registry of Sarcoidosis Associated Pulmonary Hypertension (ReSAPH);***

R. P. Baughman<sup>1</sup>, P. J. Engel<sup>2</sup>, S. Nathan<sup>3</sup>, F. Cordova<sup>4</sup>, O. Shlobin<sup>3</sup>, J. B. Barney<sup>5</sup>, D. Culver<sup>6</sup>. <sup>1</sup>Internal Medicine, University of Cincinnati, Cincinnati, OH, <sup>2</sup>The Christ Hospital, Cincinnati, OH, <sup>3</sup>INOVA, Fairfax, VA, <sup>4</sup>Temple University, Philadelphia, PA, <sup>5</sup>University of Alabama Birmingham, Birmingham, AL, <sup>6</sup>Cleveland Clinic Foundation, Cleveland, OH

**6:20 PM (372) *Pulmonary Hypertension in the Setting of Sjögren's Syndrome;***

M. Lyle<sup>1</sup>, E. Fenstad<sup>2</sup>, R. Crespo-Diaz<sup>3</sup>, T. Osborn<sup>4</sup>, A. Behefar<sup>2</sup>, G. Kane<sup>2</sup>, R. Frantz<sup>2</sup>. <sup>1</sup>Internal Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>3</sup>University of Puerto Rico School of Medicine, Ponce, Puerto Rico, <sup>4</sup>Rheumatology, Mayo Clinic, Rochester, MN

**6:25 PM (373) *Late Diastolic Strain Index Is a Marker of Right Ventricular Fibrosis Content in Precapillary Pulmonary Hypertension;***

D. Boulate<sup>1</sup>, F. Haddad<sup>2</sup>, P. Noly<sup>1</sup>, T. Kuznetsova<sup>3</sup>, G. Giraldeau<sup>4</sup>, P. Dorfmueller<sup>5</sup>, Y. Kobayashi<sup>2</sup>, B. Decante<sup>1</sup>, J. C. Wu<sup>6</sup>, D. Liang<sup>4</sup>, I. Schnittger<sup>4</sup>, M. Humbert<sup>6</sup>, E. Fadel<sup>1</sup>, O. Mercier<sup>1</sup>. <sup>1</sup>Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, <sup>2</sup>Biomarker and Phenotypic Core Laboratory, Cardiovascular Institute, Stanford University, Stanford, CA, <sup>3</sup>Research Unit Hypertension and Cardiovascular Epidemiology, Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium, <sup>4</sup>Cardiovascular Medicine, Stanford University, Stanford, CA, <sup>5</sup>Department of Pathology, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, <sup>6</sup>Cardiovascular Institute, Stanford

University, Stanford, CA, <sup>6</sup>INSERM U<sup>888</sup>, Pulmonary Arterial Hypertension, Pathophysiology and Therapeutic Innovation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France

- 6:30 PM (374) *Tolerability and Biological Effects of Long Acting Octreotide in Patients With Continuous Flow Left Ventricular Assist Devices;***  
R. Malhotra<sup>1</sup>, D. Tang<sup>2</sup>, C. T. DeWilde<sup>1</sup>, M. Basseem<sup>3</sup>, A. Priday<sup>1</sup>, K. Shah<sup>4</sup>. <sup>1</sup>Internal Medicine/Critical Care Medicine, VCU Health System, Richmond, VA, <sup>2</sup>Surgery/Cardiothoracic Surgery, VCU Health System, Richmond, VA, <sup>3</sup>Internal Medicine, VCU Health System, Richmond, VA, <sup>4</sup>Internal Medicine/Cardiology, VCU Health System, Richmond, VA
- 6:35 PM (375) *Ketamine Infusion for Patients Receiving Extracorporeal Membrane Oxygenation Support;***  
B. Tello<sup>1</sup>, M. Avidan<sup>2</sup>. <sup>1</sup>Barnes-Jewish Hospital, St. Louis, MO, <sup>2</sup>Washington University School of Medicine, St. Louis, MO
- 6:40 PM (376) *Pre Operative Administration of Vitamin K Reduces Bleeding in Continuous Flow Devices;***  
A. Bansal<sup>1</sup>, J. Chan<sup>1</sup>, A. Egger<sup>2</sup>, S. Desai<sup>3</sup>, J. K. Bhama<sup>4</sup>, P. Parrino<sup>5</sup>. <sup>1</sup>Division of Cardiothoracic Surgery, The University of Queensland School of Medicine. Ochsner Clinic Foundation, New Orleans, LA, <sup>2</sup>Department of Biostatistics and Research, Ochsner Clinic Foundation, New Orleans, LA, <sup>3</sup>Section of Heart Failure and Transplant Medicine, Ochsner Clinic Foundation, New Orleans, LA, <sup>4</sup>Heart and Vascular Center, University of Iowa Health Care, Iowa City, IA, <sup>5</sup>Division of Cardiothoracic Surgery, The University of Queensland School of Medicine. Ochsner Clinic Foundation, New Orleans, LA,
- 6:45 PM (377) *Decrease in Driveline Infections With Change in Driveline Management Protocol;***  
S. Aslam, P. McCann, M. Belyk, A. Topik, F. Torriani, R. Taplitz, J. Silva-Encisco, D. Barnard, B. Greenberg, J. Copeland, V. Pretorius, E. Adler. Univ. of CA, San Diego, San Diego, CA
- 6:50 PM (378) *Indium-111 Nuclear-Labeled Leukocyte Imaging in Mechanical Circulatory Support Infections;***  
D. Drees, S. Pouch, N. Theodoropoulos, A. Hasan, C. Sai-Sudhakar, S. I. Martin. Ohio State Univ Med, Columbus, OH
- 6:55 PM (379) *The Impact of Preoperative Antimicrobial Prophylaxis on Device-Related Infections in Recipients of Long-Term Mechanical Circulatory Support (MCS);***  
I. El Lakkis<sup>1</sup>, K. Lietz<sup>2</sup>, C. J. Derber<sup>1</sup>, U. M. Kelly<sup>1</sup>, C. D. Wilson<sup>1</sup>, A. C. Hoedt<sup>2</sup>, P. W. Bourassa<sup>2</sup>, B. H. Smith<sup>2</sup>, M. F. McGrath<sup>2</sup>, J. M. Herre<sup>2</sup>, M. L. Mooney<sup>1</sup>. <sup>1</sup>Division of Infectious Diseases, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA, <sup>2</sup>Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA

6:00 PM – 7:00 PM

## MINI ORAL SESSION 12

### Basic Instinct (Euterpe) (ALL)

**CHAIRS:** Kimberly L. Gandy, MD, PhD and Martin Cadeiras, MD

**6:00 PM (380) *CTLA4Ig Administered During T-Cell Priming Suppresses De Novo Alloantibodies and Minimizes Recall Antibody Responses;***

G. D. WU, I. Kim, N. Chai, S. Jordan, A. S. Klein. Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

**(381) *Moved to Concurrent Session 54***

**6:05 PM (742) *Development of the New Polymer Coating (MDM-Coating) for Reduce the Inflammatory Response During ECMO – Evaluation Using a Small Animal ECMO Model;***

Y. Fujii<sup>1</sup>, T. Mizuno<sup>1</sup>, T. Takehisa<sup>2</sup>, M. Shirai<sup>3</sup>, E. Tatsumi<sup>1</sup>. <sup>1</sup>Department of Artificial Organs, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan, <sup>2</sup>Central Research Laboratories, DIC Corporation, Sakura, Japan, <sup>3</sup>Department of Cardiac Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan

**6:10 PM (382) *Phosphodiesterase 3b Inhibition Expands Stable Regulatory T Cells for Cell Therapy in Transplantation;***

S. C. Juvet, A. Whatcott, K. J. Wood, A. Bushell. Transplantation Research Immunology Group, Nuffield Department of Surgical Sciences, University of Oxford, Oxford, United Kingdom

**6:15 PM (383) *Rapamycin Enhances the Suppressive Capacity of Ex-Vivo Expanded Regulatory T Cells (Tregs) Isolated From Pediatric Thymus;***

E. Dijke<sup>1</sup>, R. Hoeppli<sup>2</sup>, T. Ellis<sup>1</sup>, J. Pearcey<sup>1</sup>, I. Larsen<sup>1</sup>, I. Rebeyka<sup>1</sup>, D. Ross<sup>3</sup>, M. Levings<sup>2</sup>, L. West<sup>1</sup>. <sup>1</sup>Pediatrics, University of Alberta/Alberta Transplant Institute, Edmonton, AB, Canada, <sup>2</sup>Surgery, University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Surgery, University of Alberta/Alberta Transplant Institute, Edmonton, AB, Canada

**6:20 PM (384) *Mild Acute Cellular Rejection Is Associated With Systemic Donor-Specific Regulatory and Conventional T Cell Responses;***

J. R. Greenland<sup>1</sup>, C. M. Wong<sup>2</sup>, R. Ahuja<sup>3</sup>, C. Uchida<sup>4</sup>, J. A. Golden<sup>1</sup>, S. R. Hays<sup>1</sup>, L. E. Leard<sup>1</sup>, J. P. Singer<sup>1</sup>, J. Kukreja<sup>2</sup>, P. J. Wolters<sup>1</sup>, G. H. Caughey<sup>3</sup>, Q. Tang<sup>2</sup>. <sup>1</sup>Medicine, University of California, San Francisco, CA, <sup>2</sup>Surgery, University of California, San Francisco, CA, <sup>3</sup>Medicine, VA Medical Center, San Francisco, CA, <sup>4</sup>Radiology, University of California, San Francisco, CA

**6:25 PM (385) *Initial Reperfusion With a Hypocalcemic Cardioplegia Improves the Functional Recovery of DCD Hearts During Ex-Vivo Heart Perfusion;***

C. W. White<sup>1</sup>, E. Ambrose<sup>2</sup>, A. Müller<sup>2</sup>, J. Thliveris<sup>3</sup>, R. C. Arora<sup>1</sup>, G. Tian<sup>4</sup>, J. Nagendran<sup>5</sup>, L. V. Hryshko<sup>2</sup>, D. H. Freed<sup>5</sup>. <sup>1</sup>Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, <sup>2</sup>Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, <sup>3</sup>Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada, <sup>4</sup>Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, <sup>5</sup>Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada

- 6:30 PM (386) *Dual Ex-Vivo Lung Perfusion Technique Contributes to Better Preserving Microcirculation in Lung Grafts Following Transplantation;***  
 K. Noda, S. Haam, J. D’Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
- 6:35 PM (387) *Hydrogen Sulfide (H<sub>2</sub>S) Prevents Ischemia-Reperfusion Injury (IRI) and Prolongs Survival of the Fully MHC-Disparate Lung Graft in CLAWN Miniature Swine;***  
 H. Sahara, M. Sekijima, S. Waki, Y. Ichinari, A. Shimizu, K. Yamada. Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan
- 6:40 PM (388) *Correlation Between Bacterial Count and Levels of Endotoxin and Inflammatory Mediators During Ex-Vivo Treatment of Infection in Human Donor Lungs;***  
 D. Nakajima<sup>1</sup>, M. Cypel<sup>1</sup>, R. Bonato<sup>1</sup>, T. N. Machuca<sup>1</sup>, I. Iskender<sup>1</sup>, V. Linacre<sup>1</sup>, M. Chen<sup>1</sup>, T. K. Waddell<sup>1</sup>, T. Martinu<sup>1</sup>, M. Liu<sup>1</sup>, S. Husain<sup>2</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>Latner Thoracic Surgery Research Laboratories, Toronto General Research Institute, University Health Network, Toronto, ON, Canada, <sup>2</sup>Transplant Infectious Disease Unit, University Health Network, Toronto, ON, Canada
- 6:45 PM (389) *Functional and Biochemical Assessment of Porcine Hearts After Simulated Donation After Circulatory Death;***  
 M. A. Schechter, K. W. Southerland, B. J. Feger, L. Njoroge, D. Linder Jr., D. E. Bowles, C. A. Milano. Surgery, Duke University Medical Center, Durham, NC
- 6:50 PM (390) *Three-Dimensional Human-Heart Derived Scaffolds;***  
 A. N. Patel, J. Theisen, A. A. Winters, D. Grainger, F. Silva, D. Bull. University of Utah, Salt Lake City, UT
- 6:55 PM (391) *Porcine B4GALNT2 a Source of New Xenogenic Glycan;***  
 G. W. Byrne<sup>1</sup>, Z. Du<sup>2</sup>, H. Kogelberg<sup>1</sup>, C. McGregor<sup>1</sup>. <sup>1</sup>Cardiovascular Science, University College London, London, United Kingdom, <sup>2</sup>Department of Surgery, Mayo Clinic, Rochester, MN

## 6:00 PM – 7:00 PM

WINE AND CHEESE RECEPTION (Agora 2)

**MODERATED POSTER SESSION 2 (Agora 2)**

## 8:00 PM – 9:30 PM

**PRESIDENT’S GALA COCKTAIL RECEPTION**

(Negresco Palace)

A Registration Badge and Ticket will be required at the door.

# SATURDAY | *April 18, 2015*

**7:30 AM – 12:15 PM**

Registration Open (Agora 1)

**7:30 AM – 1:45 PM**

Speaker Ready Room Open (Hermes Lounge)

**8:00 AM – 10:00 AM**

**COUNCIL AND COMMITTEE REPORTS  
TO THE BOARD AND MEMBERSHIP (Gallieni 1)**



## Mechanical Circulatory Support – New Surgical Approaches (Athena)

(MCS, HF, HTX, NNSAH)

**CHAIRS:** Andre R. Simon, MD, PhD and Daniel Zimpfer, MD

- 8:15 AM (392) *Minimally Invasive Surgical and Anesthetic Approach for Ventricular Assist Device Implantation: A Single-Centre Experience;***  
 T. Bottio, J. Bejko, G. Bortolussi, M. Gallo, R. Bianco, D. Pittarello, V. Tarzia, G. Gerosa. Cardiac Surgery, Padova, Italy
- 8:30 AM (393) *Single-Centre Experience With the HeartWare HVAD for Biventricular Support;***  
 S. Shehab<sup>1</sup>, D. Robson<sup>1</sup>, P. J. Newton<sup>2</sup>, P. M. Davidson<sup>3</sup>, A. M. Keogh<sup>1</sup>, E. Kotlyar<sup>1</sup>, A. Jabbour<sup>1</sup>, P. S. Macdonald<sup>1</sup>, K. Dhital<sup>1</sup>, E. Granger<sup>1</sup>, P. Spratt<sup>1</sup>, P. C. Jansz<sup>1</sup>, C. S. Hayward<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Unit, St. Vincent's Hospital, Darlinghurst, Australia, <sup>2</sup>Centre for Cardiovascular & Chronic Care, University of Technology Sydney, Broadway, Australia, <sup>3</sup>School of Nursing, Johns Hopkins University, Baltimore, MD
- 8:45 AM (394) *Initial Outcomes of the Left Thoracotomy Technique for a Miniaturized Centrifugal Continuous-Flow Pump Compare Favorably to a Conventional Sternotomy;***  
 S. Maltais<sup>1</sup>, B. Sileshi<sup>1</sup>, M. E. Davis<sup>1</sup>, M. Djunaidi<sup>1</sup>, M. Xu<sup>2</sup>, M. R. Danter<sup>1</sup>, J. M. Stulak<sup>3</sup>, N. A. Haglund<sup>4</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN, <sup>4</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN
- 9:00 AM (395) *Bridging to Transplant With Fully Implantable Biventricular Assist Devices vs. Total Artificial Heart Implantation in Patients With Advanced Biventricular Failure;***  
 A. P. Levin<sup>1</sup>, J. Fried<sup>2</sup>, O. Wever-Pinzon<sup>1</sup>, A. R. Garan<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>1</sup>, M. Yuzefpolskaya<sup>2</sup>, U. P. Jorde<sup>3</sup>, D. M. Mancini<sup>1</sup>, Y. Naka<sup>4</sup>, P. C. Colombo<sup>1</sup>, V. K. Topkara<sup>1</sup>. <sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>3</sup>Cardiology, Montefiore Medical Center / Albert Einstein College of Medicine, New York, NY, <sup>4</sup>Cardiology, Columbia University New York Presbyterian Hospital, Teaneck, NJ
- 9:15 AM (396) *Outcomes of Patients Receiving Temporary Circulatory Support Prior to Durable LVAD;***  
 P. Shah<sup>1</sup>, F. D. Pagani<sup>2</sup>, S. S. Desai<sup>3</sup>, N. A. Burton<sup>4</sup>, S. Maltais<sup>5</sup>, N. A. Haglund<sup>6</sup>, S. M. Dunlay<sup>7</sup>, K. D. Aaronson<sup>8</sup>, J. M. Stulak<sup>9</sup>, M. Davis<sup>5</sup>, C. Salerno<sup>10</sup>, J. A. Cowger<sup>11</sup>. <sup>1</sup>Inova Translational Medicine Institute, Inova Fairfax Hospital, Falls Church, VA, <sup>2</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>3</sup>Heart Failure and Transplantation, Inova Fairfax Hospital, Falls Church, VA, <sup>4</sup>Cardiac Surgery, Inova Fairfax Hospital, Falls Church, VA, <sup>5</sup>Cardiac Surgery, Vanderbilt University, Nashville, TN, <sup>6</sup>Heart Failure and Transplantation, Vanderbilt University, Nashville, TN, <sup>7</sup>Heart Failure and Transplantation, Mayo Clinic, Rochester, MN, <sup>8</sup>Heart Failure and Transplantation, University of Michigan, Ann Arbor, MI, <sup>9</sup>Cardiac Surgery, Mayo Clinic, Rochester, MN, <sup>10</sup>Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, <sup>11</sup>Heart Failure and Transplant, St. Vincent Heart Center of Indiana, Carmel, IN
- 9:30 AM (397) *Japanese Experience of Long-Term Mechanical Circulatory Support With EVAHEART LVAD;***  
 T. Nishinaka, Y. Ichihara, M. Komagamine, N. Umehara, K. Katsube, K. Iizuka, S. Saito, S. Nunoda, K. Yamazaki. Cardiovascular Surgery, Tokyo Women's Medical University, Tokyo, Japan

**8:15 AM – 9:45 AM**

## CONCURRENT SESSION 44

### **The Aortic Valve in LVAD Patients** (Clio, Thalie) (MCS, BSI, HF, HTX, NNSAH, PHARM)

**CHAIRS:** Ana Maria Segura, MD and Mark S. Slaughter, MD

**8:15 AM (398) *Impact of Concomitant Cardiovascular Surgeries at the Time of CF-LVAD Implantation: An INTERMACS Analysis;***

S. Lee<sup>1</sup>, J. B. Young<sup>2</sup>, D. C. Naftel<sup>3</sup>, J. K. Kirklin<sup>3</sup>, N. Moazami<sup>4</sup>, S. L. Myers<sup>3</sup>, M. Strueber<sup>5</sup>, M. G. Dickinson<sup>5</sup>, R. C. Starling<sup>6</sup>,  
<sup>1</sup>Cardiovascular Services, Spectrum Health, Grand Rapids, MI, <sup>2</sup>Cleveland Clinic, Lerner College of Medicine, Cleveland, OH, <sup>3</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>4</sup>Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, OH, <sup>5</sup>Spectrum Health, Grand Rapids, MI, <sup>6</sup>Heart Failure and Cardiac Transplant Medicine, Cleveland Clinic, Cleveland, OH

**8:30 AM (399) *Changes in Aortic Wall Structure, Composition and Stiffness With Continuous-Flow Left Ventricular Assist Devices;***

A. V. Ambardekar<sup>1</sup>, R. B. Dodson<sup>2</sup>, K. S. Hunter<sup>3</sup>, A. N. Babu<sup>4</sup>, R. M. Tuder<sup>5</sup>, J. Lindenfeld<sup>1</sup>. <sup>1</sup>Medicine-Cardiology, University of Colorado, Aurora, CO, <sup>2</sup>Bioengineering and Pediatric Surgery, University of Colorado, Aurora, CO, <sup>3</sup>Bioengineering and Pediatrics-Cardiology, University of Colorado, Aurora, CO, <sup>4</sup>Cardiothoracic Surgery, University of Colorado, Aurora, CO, <sup>5</sup>Medicine-Pulmonary, University of Colorado, Aurora, CO

**8:45 AM (400) *Quantification of Aortic Insufficiency in Patients With Left Ventricular Assist Devices: A Novel Approach Combining Invasive Hemodynamics and Echocardiography;***

J. Grinstein<sup>1</sup>, E. Kruse<sup>1</sup>, G. Sayer<sup>1</sup>, S. Fedson<sup>1</sup>, G. H. Kim<sup>1</sup>, U. P. Jorde<sup>2</sup>, C. Juricek<sup>3</sup>, T. Ota<sup>3</sup>, V. Jeevanandam<sup>3</sup>, R. M. Lang<sup>1</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>Medicine, University of Chicago Medical Center, Chicago, IL, <sup>2</sup>Medicine, Montefiore Medical Center, New York, NY, <sup>3</sup>Surgery, University of Chicago Medical Center, Chicago, IL

**9:00 AM (401) *Intermittent Low Speed Software (ILS) May Reduce the Prevalence of De Novo Aortic Insufficiency in Patients Supported With HeartWare HVAD Pump;***

D. Saeed<sup>1</sup>, R. Westenfeld<sup>2</sup>, A. Albert<sup>1</sup>, B. Maxhera<sup>1</sup>, S. Keymel<sup>2</sup>, U. Boeken<sup>1</sup>, A. Lichtenberg<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany, <sup>2</sup>Division of Cardiology, Pulmonology and Vascular Medicine, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany

**(402) WITHDRAWN**

**9:15 AM (131) *Concurrent Valvular Procedures During HMII Insertion Are Not Associated With Short or Long-Term Decreased Survival;***

R. M. Adamson<sup>1</sup>, W. P. Dembitsky<sup>1</sup>, K. K. Limmer<sup>1</sup>, H. Mehta<sup>2</sup>, P. Hoagland<sup>2</sup>, B. Jaski<sup>2</sup>. <sup>1</sup>Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, <sup>2</sup>Cardiology, Sharp Memorial Hospital, San Diego, CA

**9:30 AM (403) *Impact and Development of Aortic Insufficiency in CF-LVAD Recipients at 5 Years;***

M. Fitzpatrick, C. T. Holley, S. S. Roy, A. C. Alraies, L. Harvey, P. Eckman, R. John. University of Minnesota, Minneapolis, MN



**8:15 AM – 9:45 AM**

**CONCURRENT SESSION 45**

**Candidate Selection – The Who, When and Why**

(Erato,Uranie)

(HF, DMD, HTX, MCS)

**CHAIRS:** Maria G. Crespo-Leiro, MD and Fernando Bacal, MD

**8:15 AM (404) *National Heart Failure Admissions and Associated Mortality Trends in Adults With Congenital Heart Disease in the United States, 1998-2011;***

L. J. Burchill<sup>1</sup>, C. S. Broberg<sup>1</sup>, B. G. Maxwell<sup>2</sup>, J. McLarry<sup>1</sup>, S. Opatowsky<sup>3</sup>. <sup>1</sup>Adult Congenital Heart Disease, Knight Cardiovascular Institute, Oregon Health Sciences University, Portland, OR, <sup>2</sup>Anesthesiology & Critical Care Medicine, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Cardiology, Boston Children's Hospital, Boston, MA

**8:30 AM (405) *Evolution of Status 1A Heart Transplant Candidates;***

J. A. Yang, K. Takeda, Y. Naka, H. Takayama. Division of Cardiothoracic Surgery, Columbia University Medical Center, New York, NY

**8:45 AM (406) *Improvement of Waiting List Survival Among Patients With End-Stage Heart Failure (ESHF) Listed for Heart Transplantation (HT) – Analysis of OPTN/UNOS Data 1990-2013;***

K. Lietz<sup>1</sup>, E. C. DePasquale<sup>2</sup>, M. Deng<sup>2</sup>, M. McGrath<sup>1</sup>, J. M. Herre<sup>1</sup>. <sup>1</sup>Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, <sup>2</sup>Division of Advanced Heart Failure, University of California Los Angeles Medical Center, Los Angeles, CA

**9:00 AM (407) *PDE 5 Inhibition With Udenafil Improves Left Ventricular Systolic/Diastolic Function and Exercise Capacity in Patients With Chronic Systolic Heart Failure: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial (Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Chronic Systolic Heart Failure) (ULTIMATE-SHF);***

K. Kim<sup>1</sup>, H. Kim<sup>2</sup>, J. Yoo<sup>1</sup>. <sup>1</sup>Sejong General Hospital, Seoul, Korea, Republic of, <sup>2</sup>Seoul National University Hospital, Seoul, Korea, Republic of

**9:15 AM (408) *Results of Jehovah's Witnesses Undergoing Surgical Treatment of Advanced CHF;***

Z. E. Asfaw<sup>1</sup>, A. Tanaka<sup>1</sup>, S. Fedson<sup>2</sup>, D. Onsager<sup>1</sup>, C. Juricek<sup>1</sup>, G. Sayer<sup>2</sup>, G. Kim<sup>2</sup>, C. Murks<sup>2</sup>, T. Ota<sup>1</sup>, N. Uriel<sup>2</sup>, V. Jeevanandam<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, University of Chicago, Chicago, IL, <sup>2</sup>Cardiology, University of Chicago, Chicago, IL

**9:30 AM (409) *Outcomes of Heart Transplantation in Adults With Amyloidosis: UNOS Registry Analysis;***

E. C. DePasquale, K. Pandya, K. Lyons, L. Reardon, A. Nsair, M. Deng, A. Ardehali. UCLA, Los Angeles, CA

**8:15 AM – 9:45 AM**

## CONCURRENT SESSION 46

### Emerging Countries Session 2 (Hermes) (ALL)

**CHAIRS:** Stephen C Clark, MD and  
Alejandro M. Bertolotti, Sr, MD

- 8:15 AM (410) *Analysis of a Significant Increase of Heart Transplantation Rates in Slovenia;***  
I. Knezevic<sup>1</sup>, G. Poglajen<sup>2</sup>, J. Ksela<sup>1</sup>, D. Avsec<sup>3</sup>, M. Jelenc<sup>1</sup>, G. Zemljic<sup>2</sup>, R. Okrajsek<sup>2</sup>, M. Sebestjen<sup>2</sup>, S. Frljak<sup>2</sup>, V. Androcec<sup>2</sup>, T. Pintar<sup>1</sup>, B. Vrtovec<sup>2</sup>. <sup>1</sup>Department of Cardiovascular Surgery, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>Sloveniatransplant, Ljubljana, Slovenia
- 8:30 AM (411) *Establishing Standard Heart Allocation Protocol in Iran;***  
S. M. Mirhosseini<sup>1</sup>, K. Najafizadeh<sup>2</sup>, S. Shafaghi<sup>3</sup>. <sup>1</sup>Modarres Hospital, The University of Shahid Beheshti,, Tehran, Iran, Islamic Republic of, <sup>2</sup>The University of Shahid Beheshti, Director of Organ Transplantation Program, Ministry of Health, Tehran, Iran, Islamic Republic of, <sup>3</sup>Organ Allocation Organ Transplant and Special Diseases, Department, Tehran, Iran, Islamic Republic of
- 8:45 AM (412) *Comparison of Heart and Lung Transplantation Rates Between 1994-2004 and 2004-2014: Factors Responsible for the Success of Tamilnadu State Model;***  
P. R. Thangaraj<sup>1</sup>, J. Amalopavanatham<sup>2</sup>, M. Kuppuswamy<sup>1</sup>, S. Thirugnanasambandan<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Apollo Hospital Chennai, Chennai (Madras), India, <sup>2</sup>Vascular Surgery, Madras Medical College, Chennai (Madras), India
- 9:00 AM (413) *Lung Transplantation in a Developing Country: Experience, Lessons Learned and Obstacles in 81 Consecutive Cases;***  
M. A. Villavicencio<sup>1</sup>, E. Larrain<sup>1</sup>, F. Rivera<sup>1</sup>, J. Melo<sup>1</sup>, M. Hurtado<sup>1</sup>, P. Mena<sup>1</sup>, E. Donoso<sup>2</sup>, F. Gajardo<sup>2</sup>. <sup>1</sup>Unidad de Trasplante, Clínica Davila, Santiago, Chile, <sup>2</sup>Unidad de Trasplante, Instituto Nacional del Tórax, Santiago, Chile
- 9:15 AM (414) *“Heart Transplant Team” and Its Impact in the Results of Heart Transplant in a Brazilian Center;***  
L. F. Seguro, F. Marcondes-Braga, M. S. Avila, S. Mangini, D. D. Lourenço Filho, R. H. Santos, F. A. Gaiotto, F. Bacal. Heart Institute (InCor), São Paulo, Brazil
- 9:30 AM (415) *International Collaboration Agreement: The Impact of a New Lung Allocation Policy on Post Transplant Outcomes in Argentina and Uruguay;***  
A. M. Bertolotti<sup>1</sup>, J. M. Osses<sup>2</sup>, J. O. Cáneva<sup>2</sup>, P. Curbelo<sup>3</sup>, R. Ahumada<sup>2</sup>, G. R. Wagner<sup>2</sup>, A. Musetti<sup>3</sup>, M. Candiotti Lehmann<sup>1</sup>, R. R. Favalaro<sup>1</sup>. <sup>1</sup>Intrathoracic Transplantation and Heart Failure Division, University Hospital Favalaro Foundation, Buenos Aires, Argentina, <sup>2</sup>Pneumology and Lung Transplantation, University Hospital Favalaro Foundation, Buenos Aires, Argentina, <sup>3</sup>Pneumology and Lung Transplantation, Hospital Maciel, Montevideo, Uruguay

8:15 AM – 9:45 AM

CONCURRENT SESSION 47

**Enhancing Surgical Therapeutics in Pulmonary Hypertension: Thrombectomy to Transplant (Calliope) (PH, HF, LF, LTX)**

*This session is supported by educational grants from Actelion and Gilead.*

**CHAIRS:** Arne K. Andreassen, MD, PhD and Marc De Perrot, MD

**8:15 AM (416) Pre-operative Use of Pulmonary Arterial Hypertension-Targeted Medication and the Effects on Post-Pulmonary Endarterectomy Morbidity and Mortality;**

T. M. Fernandes<sup>1</sup>, D. S. Poch<sup>1</sup>, D. G. Papamatheakis<sup>1</sup>, N. H. Kim<sup>1</sup>, K. M. Kerr<sup>1</sup>, P. F. Fedullo<sup>1</sup>, V. G. Pretorius<sup>2</sup>, M. M. Madani<sup>2</sup>, W. R. Auger<sup>1</sup>. <sup>1</sup>Division of Pulmonary and Critical Care, University of California, San Diego, La Jolla, CA, <sup>2</sup>Division of Cardiothoracic Surgery, University of California, San Diego, La Jolla, CA

**8:30 AM (417) Echocardiographic Evidence for Right Ventricular Functional Improvement After Balloon Pulmonary Angioplasty in Chronic Thromboembolic Pulmonary Hypertension;**

K. Broch<sup>1</sup>, A. Ragnarsson<sup>2</sup>, R. Andersen<sup>2</sup>, E. Gude<sup>1</sup>, A. Fiane<sup>3</sup>, J. Andreassen<sup>1</sup>, S. Aakhus<sup>1</sup>, A. K. Andreassen<sup>1</sup>. <sup>1</sup>Cardiology, Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>2</sup>Department of Radiology and Nuclear Medicine, Oslo University Hospital Rikshospitalet, Oslo, Norway, <sup>3</sup>Department of Cardiothoracic Surgery, Oslo University Hospital Rikshospitalet, Oslo, Norway

**8:45 AM (418) Outcomes Following Pulmonary Endarterectomy for Chronic Thromboembolic Pulmonary Hypertension in Octogenarians;**

N. B. Langer<sup>1</sup>, O. Mercier<sup>1</sup>, M. Glorion<sup>1</sup>, D. Fabre<sup>1</sup>, S. Mussot<sup>1</sup>, L. Lamrani<sup>1</sup>, J. Lepavec<sup>1</sup>, X. Jais<sup>2</sup>, G. Simonneau<sup>2</sup>, P. Dartevelle<sup>1</sup>, E. Fadel<sup>1</sup>. <sup>1</sup>Department of Thoracic and Vascular Surgery and Heart-Lung Transplantation, Marie Lannelongue Hospital, Le Plessis Robinson, France, <sup>2</sup>Department of Pulmonology and Critical Care Medicine, Kremlin-Bicetre Hospital, Le Kremlin-Bicetre, France

**9:00 AM (419) Six-Years Experience With High Priority Allocation Program for Lung and Heart-Lung Transplantation in Pulmonary Hypertension;**

L. Savale<sup>1</sup>, J. Le Pavec<sup>2</sup>, O. Mercier<sup>2</sup>, S. Mussot<sup>2</sup>, D. Fabre<sup>2</sup>, X. Jais<sup>1</sup>, D. Montani<sup>1</sup>, O. Sitbon<sup>1</sup>, M. Humbert<sup>1</sup>, G. Simonneau<sup>1</sup>, P. Dartevelle<sup>1</sup>, E. Fadel<sup>1</sup>. <sup>1</sup>Hôpital Bicêtre, Le Kremlin Bicetre, France, <sup>2</sup>Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France

**9:15 AM (420) Lung Transplantation for PPH: Postoperatively Prolonged ECMO Improves Early Outcome;**

B. Moser, P. Jaksch, G. Muraközy, P. Nierlich, G. Lang, S. Taghavi, C. Aigner, J. R. Matilla, W. Klepetko. Thoracic Surgery, Medical University Vienna, Vienna, Austria

**9:30 AM (421) Postcapillary Pulmonary Hypertension as a Risk Factor for Post-Transplant Survival in Lung Transplantation – A 22 Year Single Centre Experience;**

B. C. Nyholm, H. Schultz, K. H. Andersen, M. P. Iversen, F. Gustafsson, J. Carlsen. Department of Cardiology, Pulmonary Vascular Programme, Copenhagen University Hospital, Rigshospitalet, DK- Denmark, Copenhagen, Denmark

**8:15 AM – 9:45 AM**

## CONCURRENT SESSION 48

### Old Problems – New Solutions? (Euterpe)

(PEDS, BSI, HF, HTX, NNSAH, PATH)

**CHAIRS:** Scott R. Auerbach, MD and Zsolt Szepefalusi, MD

**8:15 AM (422) *Does the OPTN cPRA Calculator Accurately Predict HLA Antigen Frequencies in Pediatric Donors?*;**  
 S. A. Hollander<sup>1</sup>, D. Tyan<sup>2</sup>, M. A. Fernandez-Vina<sup>2</sup>, D. N. Rosenthal<sup>1</sup>, D. Bernstein<sup>1</sup>, B. D. Kaufman<sup>1</sup>, S. Chen<sup>1</sup>, L. Barkoff<sup>3</sup>, K. Maeda<sup>4</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Pediatrics (Cardiology), Stanford University, Palo Alto, CA, <sup>2</sup>Pathology, Stanford University, Palo Alto, CA, <sup>3</sup>Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA, <sup>4</sup>Cardiothoracic Surgery, Stanford University, Palo Alto, CA

**8:30 AM (423) *Alternative Pre-Transplant Hemodynamic Predictors of Graft Loss in Pediatric Heart Recipients*;**  
 E. L. Albers<sup>1</sup>, M. C. Bradford<sup>2</sup>, M. S. Kemna<sup>1</sup>, J. M. Chen<sup>3</sup>, Y. M. Law<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>2</sup>Biomedical Statistics, Seattle Children's Research Institute, Seattle, WA, <sup>3</sup>Cardiac Surgery, Seattle Children's Hospital, Seattle, WA,

**8:45 AM (424) *Identification of Candidate MicroRNA as Pathological Markers of Pediatric Heart Transplant Rejection*;**  
 A. K. Bhatia<sup>1</sup>, J. H. Phan<sup>2</sup>, C. Cundiff<sup>3</sup>, W. T. Mahle<sup>1</sup>, B. Shehata<sup>3</sup>, H. Jo<sup>4</sup>. <sup>1</sup>Pediatric Cardiology, Emory University, Atlanta, GA, <sup>2</sup>Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, <sup>3</sup>Pathology, Emory University, Atlanta, GA, <sup>4</sup>Biomedical Engineering, Emory University, Atlanta, GA

**9:00 AM (425) *Is Chimerism in Cardiac Transplant Allografts an Indicator of Decreased Longevity? Utilizing Quantitative Real Time PCR in Pediatric Patients*;**  
 T. Roberts<sup>1</sup>, C. A. Cundiff<sup>2</sup>, B. Shehata<sup>2</sup>, W. Mahle<sup>3</sup>, S. R. Deshpande<sup>3</sup>. <sup>1</sup>Department of Pathology, Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Department of Pathology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, <sup>3</sup>Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA

**9:15 AM (426) *Value of Cardiopulmonary Exercise Testing for Prediction of Outcomes in Ambulatory Patients With Dilated Cardiomyopathy*;**  
 C. Chen<sup>1</sup>, C. Manlhiot<sup>2</sup>, P. F. Kantor<sup>3</sup>, B. W. McCrindle<sup>2</sup>, J. Conway<sup>3</sup>. <sup>1</sup>Cardiology Service, Department of Paediatric Subspecialties, KK Women's and Children's Hospital, Singapore, Singapore, <sup>2</sup>The Labatt Family Heart Centre, Division of Cardiology, The Hospital for Sick Children, Toronto, ON, Canada, <sup>3</sup>Division of Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada

**9:30 AM (427) *The Safety of Intravascular Ultrasound in a Multicenter Pediatric Heart Transplant Population: A Study of the International Paediatric Intravascular Ultrasound Consortium*;**  
 S. R. Auerbach<sup>1</sup>, M. J. Fenton<sup>2</sup>, G. Grutter<sup>3</sup>, D. C. Albert<sup>4</sup>, S. Di-Filippo<sup>5</sup>, R. Kozlik-Feldmann<sup>6</sup>, S. Rupp<sup>7</sup>, M. Burch<sup>2</sup>, M. Kuhn<sup>8</sup>. <sup>1</sup>Pediatrics, Division of Cardiology, University of Colorado, Aurora, CO, <sup>2</sup>Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, <sup>3</sup>Department of Pediatric Cardiology and Cardiac Surgery, Bambino Gesù Pediatric Hospital, Rome, Italy, <sup>4</sup>Pediatrics, Division of Cardiology, University Vall d'Hebron Hospital, Barcelona, Spain, <sup>5</sup>Pediatric Cardiology Unit, Louis Pradel Cardiology Hospital, Bron, Hospices Civils de Lyon, Lyon, France, <sup>6</sup>Department of Pediatric Cardiology and Intensive Care Medicine, Munic, Ludwig-Maximilians-University, Munich, Germany, <sup>7</sup>Pediatric Heart Centre, Justus-Liebig-University, Giessen, Germany, <sup>8</sup>Pediatrics, Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA

## 9:45 AM – 10:00 AM

Coffee Break (Agora 1)

## 10:00 AM – 12:00 PM

### PLENARY SESSION

(Athena)

(ALL)

**CHAIRS:** R. Duane Davis, MD and Andrew J. Fisher, FRCP, PhD

#### 10:00 AM *Awards Presentations*

Daniel R. Goldstein, MD and Andrew J Fisher, FRCP, PhD,  
Grants & Awards Committee Co-Chairs

#### 10:20 AM *CONSENSUS REPORT: AMR in Lung Transplantation*

Deborah J Levine, MD, UT Health Science Center,  
San Antonio, TX, USA

#### 10:30 AM *CONSENSUS REPORT: Listing Criteria in Heart Transplantation*

Mandeep R. Mehra, MD, MBBS, FACC, FACP,  
Brigham & Women's Hospital, Boston, MA, USA

#### 10:40 AM (428) *FEATURED ABSTRACT: Effect of Selexipag on Morbidity/Mortality in Pulmonary Arterial Hypertension: Results of the GRIPHON Study;*

N. Galiè<sup>1</sup>, R. Channick<sup>2</sup>, K. Chin<sup>3</sup>, A. Frey<sup>4</sup>, S. Gaine<sup>5</sup>, A. Ghofrani<sup>6</sup>, M. Hoeper<sup>7</sup>, I. Lang<sup>8</sup>, V. McLaughlin<sup>9</sup>, R. Preiss<sup>4</sup>, L. J. Rubin<sup>10</sup>, O. Sitbon<sup>11</sup>, M. Stefani<sup>4</sup>, V. Tapson<sup>12</sup>, G. Simonneau<sup>11</sup>.  
<sup>1</sup>Istituto di Malattie dell'Apparato Cardiovascolare, University of Bologna, Bologna, Italy, <sup>2</sup>Massachusetts General Hospital, Boston, MA, <sup>3</sup>UT Southwestern Medical Center, Dallas, TX, <sup>4</sup>Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, <sup>5</sup>Mater Misericordiae University Hospital, Dublin, Ireland, <sup>6</sup>University of Giessen and Marburg Lung Center, Giessen, Germany, <sup>7</sup>Hannover Medical School and German Center of Lung Research, Hannover, Germany, <sup>8</sup>Medical University of Vienna, Vienna, Austria, <sup>9</sup>University of Michigan Health System, Ann Arbor, MN, <sup>10</sup>University of California, San Diego, CA, <sup>11</sup>Hôpital Universitaire de Bicêtre, Paris, France, <sup>12</sup>Cedars-Sinai Medical Center, Los Angeles, CA.

#### 10:55 AM *Supercooling of Organs for Transplantation*

Korkut Uygun, PhD, Harvard Medical School, Boston, MA, USA

#### 11:15 AM *Going the Distance with DCD Heart Failures*

Kumud K Dhital, MD, PhD, St Vincent's Hospital,  
Sydney, Australia

#### 11:30 AM *PRESIDENT'S DEBATE: The 4 Q's: Quagmire of The Quantity/Quality Quandary:*

#### 11:30 AM *Live Long, Don't Prosper*

Heather J Ross, MD, MHSc, FRCP, Toronto General Hospital,  
Toronto, ON, Canada

#### 11:45 AM *Live Fast, Die Young*

Marshall I Hertz, MD, University of Minnesota, Minneapolis,  
MN, USA

## 12:00 PM – 12:15 PM

Coffee Break (Agora 1)

**12:15 PM – 1:45 PM**

## CONCURRENT SESSION 49

### **LVADs – From Patient Classification to Cost (Athena) (MCS, BSI, HF, HTX, PEEQ)**

**CHAIRS:** Ruchan Akar, MD and Geetha Bhat, MD, PhD

**12:15 PM (429) *INTERMACS Profiles: Heterogeneity of LVAD Patient Classification;***

J. A. Cowger<sup>1</sup>, C. Salerno<sup>2</sup>, F. D. Pagani<sup>3</sup>, S. Maltais<sup>4</sup>, J. M. Stulak<sup>5</sup>, P. Shah<sup>6</sup>. <sup>1</sup>Heart Failure and Transplant, St. Vincent Heart Center of Indiana, Carmel, IN, <sup>2</sup>Cardiac Surgery, St. Vincent Heart Center of Indiana, Carmel, IN, <sup>3</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>4</sup>Cardiac Surgery, Vanderbilt University Medical Center, Nashville, TN, <sup>5</sup>Cardiac Surgery, The Mayo Clinic, Rochester, MN, <sup>6</sup>Heart Failure and Transplant, Inova Fairfax Hospital, Falls Church, VA

**12:30 PM (430) *In ADVANCE BTT, the HVAD Mortality Benefit Varies Markedly With Heart Failure Severity as Measured By the Seattle Heart Failure Model;***

W. C. Levy<sup>1</sup>, C. Mahr<sup>1</sup>, R. Cheng<sup>1</sup>, P. Eckman<sup>2</sup>, K. Leadley<sup>3</sup>, F. Pagani<sup>4</sup>, K. Aaronson<sup>4</sup>. <sup>1</sup>University of Washington, Seattle, WA, <sup>2</sup>University of Minnesota, Minneapolis, MN, <sup>3</sup>HeartWare, Inc, Framingham, MA, <sup>4</sup>University of Michigan, Ann Arbor, MI

**12:45 PM (431) *Trends in Use of Mechanical Circulatory Support as Bridge to Heart Transplantation Across Different Age Groups;***

A. Ciarka<sup>1</sup>, L. Edwards<sup>2</sup>, J. Stehlik<sup>3</sup>, L. Lund<sup>4</sup>. <sup>1</sup>Department of Cardiovascular Diseases, Catholic University of Leuven, Leuven, Belgium, <sup>2</sup>ISHLT Transplant Registry, Dallas, TX, <sup>3</sup>University of Utah, Salt Lake City, UT, <sup>4</sup>Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden

**1:00 PM (432) *Patients Undergoing LVAD Placement Demonstrate Marked Sarcopenia Leading to Overestimation of Pre-Implant Glomerular Filtration Rate;***

M. A. Brisco<sup>1</sup>, A. Hale<sup>1</sup>, M. R. Zile<sup>1</sup>, D. P. Heyward<sup>1</sup>, J. L. Cook<sup>1</sup>, W. Uber<sup>1</sup>, J. Arthur<sup>1</sup>, J. M. Testani<sup>2</sup>. <sup>1</sup>Medicine-Cardiology, Med Univ of South Carolina, Charleston, SC, <sup>2</sup>Program of Applied Translational Research, Yale University, New Haven, CT

**1:15 PM (433) *What Can You Do With an LVAD? Survey of Programs Implanting Durable Devices;***

J. D. Pal, J. W. Smith, S. Andrus, C. Mahr, T. Dardas, R. Cheng, J. Beckman, K. O'Brien, D. Fishbein, W. Levy, N. A. Mokadam. Univ of Washington, Seattle, WA

**1:30 PM (434) *Multi-Disciplinary Team Management Is Cost Effective in Patients During the Index Hospitalization of Left Ventricular Assist Device Implantation;***

M. Pinninti<sup>1</sup>, C. Cho<sup>2</sup>, V. Thohan<sup>3</sup>, O. Cheema<sup>3</sup>, T. Hastings<sup>3</sup>, J. Crouch<sup>4</sup>, F. X. Downey III<sup>4</sup>, N. Z. Sulemanjee<sup>3</sup>. <sup>1</sup>Aurora St. Luke's Medical Center, Milwaukee, WI, <sup>2</sup>Aurora Cardiovascular Services, Aurora St. Luke's Medical Center, Milwaukee, WI, <sup>3</sup>Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI, <sup>4</sup>Aurora Cardiovascular Services - Cardiovascular and Thoracic Surgery, Aurora Sinai/Aurora St. Luke's Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI

12:15 PM – 1:45 PM

CONCURRENT SESSION 50

**LVADs and the Mitral Valve** (Clio, Thalie)  
(MCS, HF, HTX, NNSAH)

**CHAIRS:** Nahush A. Mokadam, MD and Benjamin C. Sun, MD

**12:15 PM (435) *Concomitant Mitral Valve Procedures in Patients Undergoing Implantation of Continuous-Flow LVADs: An INTERMACS Database Analysis;***  
J. O. Robertson<sup>1</sup>, D. C. Naftel<sup>2</sup>, S. L. Myers<sup>2</sup>, R. J. Tedford<sup>3</sup>, S. M. Joseph<sup>1</sup>, J. K. Kirklin<sup>2</sup>, S. C. Silvestry<sup>1</sup>. <sup>1</sup>Washington University, St. Louis, MO, <sup>2</sup>Department of Surgery, University of Alabama at Birmingham, Birmingham, AL, <sup>3</sup>Cardiology, Johns Hopkins Medical Institutions, Baltimore, MD

**12:30 PM (436) *Severity of Mitral Valve Regurgitation at the Time of LVAD Implant Does Not Alter Mid-Term Clinical Outcomes;***  
A. Itoh<sup>1</sup>, A. Keith<sup>1</sup>, S. M. Prasad<sup>2</sup>, A. Abou El Ela<sup>1</sup>, S. M. Joseph<sup>3</sup>, G. A. Ewald<sup>3</sup>, S. C. Silvestry<sup>1</sup>, K. R. Balsara<sup>1</sup>. <sup>1</sup>Surgery, Washington University in St. Louis, Saint Louis, MO, <sup>2</sup>Cardiothoracic Surgery, Mercy Hospital, Springfield, MO, <sup>3</sup>Cardiology, Washington University in St. Louis, Saint Louis, MO

**12:45 PM (437) *The Impact of Concomitant Mitral Repair in Patients Receiving Continuous-Flow Left Ventricular Assist Devices;***  
S. Fukuhara<sup>1</sup>, K. Takeda<sup>1</sup>, J. Han<sup>1</sup>, P. Colombo<sup>2</sup>, P. Kurlansky<sup>1</sup>, D. Mancini<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, V. Topkara<sup>2</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>. <sup>1</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine, Columbia University Medical Center, New York, NY

**1:00 PM (438) *Blood Transfusions Affect the Panel of Reactive Antibodies and Survival After Ventricular Assist Device Implantation;***  
E. Y. Birati<sup>1</sup>, T. C. Hanff<sup>2</sup>, J. A. Mazurek<sup>1</sup>, S. Banerji<sup>1</sup>, E. Grandin<sup>1</sup>, E. Vorovich<sup>1</sup>, D. Pedrotty<sup>1</sup>, A. Kaiser<sup>1</sup>, E. Phillips<sup>1</sup>, M. Acker<sup>3</sup>, L. R. Goldberg<sup>1</sup>, J. Rame<sup>1</sup>, P. Atluri<sup>3</sup>, K. B. Margulies<sup>1</sup>, M. Jessup<sup>1</sup>. <sup>1</sup>Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Internal Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Cardiothoracic surgery, Hospital of the University of Pennsylvania, Philadelphia, PA

**1:15 PM (439) *Three Year Outcomes With Tricuspid Valve Annuloplasty in LVAD Recipients;***  
R. Khodaverdian<sup>1</sup>, J. A. Groves<sup>2</sup>, A. A. Phanco<sup>3</sup>, C. Elkins<sup>1</sup>, J. S. Chaffin<sup>1</sup>, D. A. Horstmanhof<sup>3</sup>, J. Tang<sup>4</sup>, J. W. Long<sup>3</sup>. <sup>1</sup>Oklahoma Cardiovascular Surgeons, Integris Baptist Hospital, Oklahoma City, OK, <sup>2</sup>Cardiology, Integris Baptist Hospital, Oklahoma City, OK, <sup>3</sup>Advanced Cardiac Care, Integris Baptist Hospital, Oklahoma City, OK, <sup>4</sup>Nazhi Zudhi Tranplant Institue, Integris Baptist Hospital, Oklahoma City, OK

**1:30 PM (440) *Impact of Residual Mitral Regurgitation on Right Ventricular Systolic Function After Left Ventricular Assist Device Implantation;***  
H. S. Kemal<sup>1</sup>, S. Ertugay<sup>2</sup>, U. Kahraman<sup>2</sup>, C. Engin<sup>2</sup>, S. Nalbantgil<sup>1</sup>, T. Yagdi<sup>2</sup>, M. Ozbaran<sup>2</sup>. <sup>1</sup>Cardiology, Ege University Faculty of Medicine, Izmir, Turkey, <sup>2</sup>Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey,

**12:15 PM – 1:45 PM**

## CONCURRENT SESSION 51

### Risky Business: Transplant in High Risk Populations

(Erato,Uranie)

(HTX, BSI, HF, ID, NNSAH, PATH, PEDS, PHARM, PEEQ)

**CHAIRS:** Debra L. Isaac, MD and Michael Pham, MD

**12:15 PM (441) *Across the United States Multiorgan Transplantation in Adults With Congenital Heart Disease Is a Frequent Occurrence;***

M. S. Khan<sup>1</sup>, F. Zafar<sup>1</sup>, R. A. Verm<sup>1</sup>, C. Chin<sup>2</sup>, M. G. Schecter<sup>3</sup>, G. Webb<sup>2</sup>, D. L. Morales<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>2</sup>Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>3</sup>Pulmonary Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

**12:30 PM (442) *Survival Benefit of Heart Transplantation in Patients on Veno-Arterial Extra-Corporeal Membrane Oxygenation: Results From a French National Cohort;***

C. Jasseron<sup>1</sup>, C. Cantrelle<sup>1</sup>, C. Legeai<sup>1</sup>, P. Leprince<sup>2</sup>, E. Flecher<sup>3</sup>, A. Sirinelli<sup>4</sup>, O. Huot<sup>1</sup>, R. Dorent<sup>1</sup>. <sup>1</sup>Direction Prélèvement Greffe Organes-Tissus, Agence de la Biomédecine, Saint-Denis La Plaine, France, <sup>2</sup>Hôpital de la Pitié-Salpêtrière, Paris, France, <sup>3</sup>Service de Chirurgie Thoracique Cardiaque et Vasculaire, CHU de Rennes, Rennes, France, <sup>4</sup>CHU Tours, Tours, France

**12:45 PM (443) *Pregnancy Outcomes Following Cardiac Transplantation;***

C. J. Bhagra<sup>1</sup>, S. K. Bhagra<sup>1</sup>, A. Donado<sup>2</sup>, T. Butt<sup>2</sup>, L. Forrest<sup>3</sup>, G. MacGowan<sup>1</sup>, G. Parry<sup>3</sup>. <sup>1</sup>Cardiology, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Cardiothoracic surgery, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, <sup>3</sup>Cardiopulmonary Transplantation, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

**1:00 PM (444) *Center-Specific Variations in Donor Antigen Frequency: Does the OPTN cPRA Calculator Apply to Your Center?;***

S. A. Hollander<sup>1</sup>, D. B. Tyan<sup>2</sup>, M. Fernandez-Vina<sup>1</sup>, D. Bernstein<sup>1</sup>, N. McDonald<sup>3</sup>, K. Maeda<sup>4</sup>, B. D. Kaufman<sup>1</sup>, L. J. May<sup>1</sup>, D. N. Rosenthal<sup>1</sup>, C. S. Almond<sup>1</sup>. <sup>1</sup>Pediatrics (Cardiology), Stanford University, Palo Alto, CA, <sup>2</sup>Pathology, Stanford University, Palo Alto, CA, <sup>3</sup>Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA, <sup>4</sup>Cardiothoracic Surgery, Stanford University, Palo Alto, CA

**1:15 PM (445) *Outcomes of Heart Transplantation in Adults With Congenital Heart Disease: UNOS Registry Analysis;***

K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, J. Alejos, J. Aboulhosn, E. Depasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA

**1:30 PM (446) *Cardiac Replantation: How Far Have We Come?;***

K. Pandya, K. Lyons, A. Nsair, A. Baas, M. Cadeiras, D. Cruz, L. Reardon, M. Deng, A. Ardehali, E. Depasquale. Advanced Heart Failure and Cardiac Transplantation, University of California, Los Angeles, Los Angeles, CA



12:15 PM – 1:45 PM

CONCURRENT SESSION 52

**Understanding Complications and Improving Lung Transplant Outcomes (Hermes)**

(LTX, DMD, LF)

**CHAIRS:** Daniel F. Dilling, MD and  
Helen M. Whitford, MBBS, FRACP

**(447) WITHDRAWN**

**12:15 PM (363) Contemporary Redo Lung Transplantation: An Analysis of the UNOS Database;**

A. Ivengar, E. C. DePasquale, D. Ross, A. Ardehali. David Geffen School of Medicine, University of California - Los Angeles, Los Angeles, CA

**12:30 PM (448) A Novel Risk Score to Predict 1-Year Mortality Following Lung Transplant in the Current Era;**

J. C. Grimm<sup>1</sup>, V. Valero, <sup>3rd</sup>, J. Magruder<sup>1</sup>, A. Kilic<sup>1</sup>, L. L. Silhan<sup>2</sup>, P. D. Shah<sup>2</sup>, C. A. Merlo<sup>2</sup>, A. S. Shah<sup>1</sup>. <sup>1</sup>Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>2</sup>Medicine, The Johns Hopkins Medical Institution, Baltimore, MD

**12:45 PM (449) PGD Is Associated With Persistent Differential Gene Expression After Lung Transplantation;**

J. M. Diamond<sup>1</sup>, E. Cantu<sup>1</sup>, D. J. Lederer<sup>2</sup>, J. Tobias<sup>1</sup>, S. Arcasoy<sup>2</sup>, K. M. Olthoff<sup>1</sup>, B. Chang<sup>1</sup>, R. Feng<sup>1</sup>, K. Meyer<sup>3</sup>, J. Emond<sup>2</sup>, A. Shaked<sup>1</sup>, J. D. Christie<sup>1</sup>. <sup>1</sup>University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Columbia University, New York, NY, <sup>3</sup>University of Wisconsin, Madison, WI

**1:00 PM (450) Pregnancies After Lung Transplantation: A Retrospective Multicenter French Study About 39 Pregnancies;**

C. Bry<sup>1</sup>, D. Hubert<sup>2</sup>, M. Reynaud-Gaubert<sup>3</sup>, C. Dromer<sup>4</sup>, H. Mal<sup>5</sup>, D. Grenet<sup>6</sup>, V. Boussaud<sup>7</sup>, J. Claustre<sup>8</sup>, J. Le Pavec<sup>9</sup>, M. Murriss-Espin<sup>10</sup>, I. Danner-Boucher<sup>1</sup>. <sup>1</sup>Service de Pneumologie, Institut du Thorax, CHU de Nantes, Nantes, France, <sup>2</sup>Service de Pneumologie, Hopital Cochin, Paris, France, <sup>3</sup>Centre de Ressource et de Compétences de la Mucoviscidose Adulte ; Équipe de Transplantation Pulmonaire, CHU Nord, Marseille, France, <sup>4</sup>Service de Pneumologie, CHU Bordeaux, Bordeaux, France, <sup>5</sup>Service de Pneumologie, Hopital Bichat -Claude Bernard, Paris, France, <sup>6</sup>Pneumologie, Hopital FOCH, Suresnes, France, <sup>7</sup>Service de Pneumologie, Hopital Europeen Georges-Pompidou, Paris, France, <sup>8</sup>Clinique Universitaire de Pneumologie, Pôle Thorax et Vaisseaux, CHU de Grenoble, Grenoble, France, <sup>9</sup>Service de Chirurgie Thoracique et Vasculaire, Centre Chirurgical Marie Lannelongue, Le Plessis Robinson, France, <sup>10</sup>CRCM Adulte-Service de Pneumologie-Allergologie, CHU de Toulouse, Toulouse, France

**1:15 PM (451) Lung Retransplantation in the Lung Allocation Score Era;**

J. M. Schaffer<sup>1</sup>, P. Chiu<sup>1</sup>, B. A. Reitz<sup>1</sup>, G. Dhillon<sup>2</sup>, J. Woo<sup>1</sup>, R. Ha<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University, School of Medicine, Stanford, CA, <sup>2</sup>Pulmonary and Critical Care, Stanford University, School of Medicine, Stanford, CA

**1:30 PM (452) Survival and Spirometry Outcomes Following Lung Transplantation From Donors >70 Years – Extended Criteria Coming of Age;**

W. Sommer<sup>1</sup>, F. Ius<sup>1</sup>, J. Salman<sup>1</sup>, M. Avsar<sup>1</sup>, I. Tudorache<sup>1</sup>, C. Kühn<sup>1</sup>, B. Wiegmann<sup>1</sup>, G. Marsch<sup>1</sup>, T. K. Kaufeld<sup>1</sup>, N. Zinne<sup>1</sup>, M. Greer<sup>2</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany

**12:15 PM – 1:45 PM**

## CONCURRENT SESSION 53

### **Beneficence and Nonmaleficence: The Breath Of It All** (Calliope)

(PEEQ, LF, LTX, NNSAH)

**CHAIRS:** Gundeep S. Dhillon, MD and  
Allan R. Glanville, MBBS, MD, FRACP

**12:15 PM (453) *Period of Transplant Influences Elderly Lung Transplant Recipient Survival: We Are Getting Better!***

Y. Ravi<sup>1</sup>, C. B. Sai-Sudhakar<sup>1</sup>, S. Kirkby<sup>2</sup>, S. M. Black<sup>3</sup>, J. D. Tobias<sup>4</sup>, D. Hayes, Jr.<sup>2</sup>, R. S. Higgins<sup>3</sup>, B. A. Whitson<sup>3</sup>. <sup>1</sup>Division of Cardio-Thoracic Surgery, Baylor Scott and White Heart and Vascular Institute, Temple, TX, <sup>2</sup>Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH, <sup>3</sup>Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>4</sup>Department of Anesthesiology & Pain Medicine, Nationwide Children's Hospital, Columbus, OH

**12:30 PM (454) *Delirium After Lung Transplantation: Occurrence and Its Relationship to Morbidity and Mortality;***

Y. Sher<sup>1</sup>, G. Dhillon<sup>2</sup>, J. R. Maldonado<sup>1</sup>. <sup>1</sup>Psychiatry and Behavioral Sciences, Stanford University Medical Center, Stanford, CA, <sup>2</sup>Pulmonary and Critical Care Medicine, Stanford University Medical Center, Stanford, CA

**12:45 PM (455) *Outcomes of Telehealth Care for Lung Transplant Recipients;***

A. Sidhu, C. Chaparro, M. Binnie, C. Chow, J. Granton, M. Davies, L. G. Singer. Toronto Lung Transplant Program, University Health Network, Toronto General Hospital, Toronto, ON, Canada

**1:00 PM (456) *Quality of Life, Depression, Anxiety and Sleep Disruptions in Patients With Bronchiolitis Obliterans;***

A. Gilmour<sup>1</sup>, J. Sheridan<sup>1</sup>, S. Yerkovich<sup>2</sup>, A. Fiene<sup>3</sup>. <sup>1</sup>School of Psychology and Counselling, Queensland University of Technology, Brisbane, Australia, <sup>2</sup>Lung Transplant Service, Queensland Health, Brisbane, Australia, <sup>3</sup>Thoracic Medicine, The Prince Charles Hospital, Brisbane, Australia

**1:15 PM (457) *The Stanford Integrated Psychosocial Assessment for Transplantation (SIPAT): A Two-Year Follow-Up of a Prospective Study of Medical & Psychosocial Outcomes;***

J. R. Maldonado<sup>1</sup>, Y. Sher<sup>1</sup>, A. Tobon<sup>2</sup>. <sup>1</sup>Psychosomatic Medicine Service, Stanford University School of Medicine, Stanford, CA, <sup>2</sup>School of Medicine, Stanford University School of Medicine, Stanford, CA

**1:30 PM (458) *Cost Effectiveness of Ex-Vivo Lung Perfusion Warrants Analysis of Long Term Recipient Outcome and Donor Organ Utilization Rate;***

P. M. Hopkins<sup>1</sup>, D. Chambers<sup>1</sup>, I. Smith<sup>1</sup>, R. Naidoo<sup>1</sup>, D. Wall<sup>1</sup>, S. Yerkovich<sup>1</sup>, W. Hunt<sup>2</sup>. <sup>1</sup>Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, <sup>2</sup>Perfusion Services, The Prince Charles Hospital, Brisbane, Australia

12:15 PM – 1:45 PM

CONCURRENT SESSION 54

Basic Bazaar (Euterpe)

(ALL)

**CHAIRS:** Richard N. Pierson, III, MD and Carla C. Baan, PhD

**(459) WITHDRAWN**

**12:15 PM (381) *The Effects of Kidney Graftectomy on the Tolerance Induced By Heart-Kidney Cotransplantation in Miniature Swine Depends on the MHC Barrier Crossed;***

S. G. Michel<sup>1</sup>, M. L. Madariaga<sup>2</sup>, G. M. LaMuraglia II<sup>2</sup>, V. Villani<sup>2</sup>, M. Sekijima<sup>2</sup>, E. A. Farkash<sup>3</sup>, R. Colvin<sup>3</sup>, J. S. Allan<sup>2</sup>, K. Yamada<sup>2</sup>, D. H. Sachs<sup>2</sup>, J. C. Madsen<sup>2</sup>. <sup>1</sup>Cardiac Surgery, Ludwig-Maximilians-University, Muenchen, Germany, <sup>2</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, <sup>3</sup>Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA

**12:30 PM (460) *Activation of Oncostatin M Receptor in Cardiomyocytes Increases Serum Levels of FGF23 During Heart Failure;***

M. H. Richter<sup>1</sup>, H. Lautze<sup>2</sup>, W. Skwara<sup>1</sup>, M. Schönburg<sup>1</sup>, A. Beiras-Fernandez<sup>3</sup>, I. Werner<sup>3</sup>, S. Kostin<sup>4</sup>, T. Kubin<sup>4</sup>, T. Braun<sup>4</sup>, T. Walther<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, <sup>2</sup>Department of Anesthesiology, Kerckhoff-Klinik GmbH, Bad Nauheim, Germany, <sup>3</sup>Department of Cardiac Surgery, J.-W.- Goethe University, Frankfurt, Germany, <sup>4</sup>Department of Heart and Lung Research, Max- Planck- Institute, Bad Nauheim, Germany

**12:45 PM (461) *Bendavia (MTP-131) – A Novel Mitochondria-Targeting Peptide Reverses Dysregulation of Mitochondrial Fission and Fusion Proteins in the Failing Heart;***

H. N. Sabbah, R. C. Gupta. Medicine, Henry Ford Hospital, Detroit, MI

**1:00 PM (462) *Organ-Preconditioning By CD26/DPP4-Inhibitor Improves Lung Transplants via SDF-1 – Mediated Pathway;***

J. Jang, Y. Yamada, I. Inci, W. Weder, W. Jungraithmayr. Division of Thoracic Surgery, University Hospital Zurich, Zurich, Switzerland

**1:15 PM (463) *IL-17 Mediates Post-Transplant Airway and Parenchymal Lung Fibrosis;***

T. Martinu<sup>1</sup>, W. C. McManigle<sup>1</sup>, F. L. Kelly<sup>1</sup>, M. E. Nelson<sup>1</sup>, J. Sun<sup>1</sup>, H. Zhang<sup>1</sup>, K. M. Gowdy<sup>2</sup>, S. M. Palmer<sup>1</sup>. <sup>1</sup>Medicine, Duke University, Durham, NC, <sup>2</sup>Pharmacology and Toxicology, Brody School of Medicine, East Carolina University, Greenville, NC

**1:30 PM (464) *A-Antigen Specific Tolerance in a Novel Transgenic Mouse Model of ABO-Incompatible Heart Transplantation (ABOi HTx);***

B. Motyka<sup>1</sup>, K. Labonte<sup>1</sup>, F. H. Rahman<sup>1</sup>, J. Pearcey<sup>1</sup>, K. Tao<sup>1</sup>, M. Mengel<sup>2</sup>, B. Sis<sup>3</sup>, P. J. Cowan<sup>4</sup>, L. J. West<sup>5</sup>. <sup>1</sup>Pediatrics, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Laboratory Medicine & Pathology, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Laboratory Medicine & Pathology, University of Alberta, Edmonton, AB, Canada, <sup>4</sup>St Vincent's Hospital, Melbourne, Australia, <sup>5</sup>Pediatrics, Surgery and Medical Microbiology & Immunology, Alberta Transplant Institute, University of Alberta, Edmonton, AB, Canada

2:00 PM – 7:30 PM

ISHLT BOARD OF DIRECTORS MEETING (Gallieni 1)

# MODERATED POSTER SESSIONS

## POSTER SESSION 1 (Agora 2)

Poster presenters and moderators will be present during the evening poster viewing session from 7:00 pm – 8:00 pm.

### ADULT HEART FAILURE

(Agora 2)

(HF, BSI, DMD, HTX, MCS, NNSAH, PATH, PEDS, PH, PEEQ)

**(465)** *BAG3 Variant Is Associated With Ventricular Remodeling But Not Clinical Outcomes in Chronic Heart Failure;*

E. Vorovich<sup>1</sup>, B. French<sup>1</sup>, R. Hu<sup>1</sup>, M. Morley<sup>1</sup>, J. Brandimarto<sup>1</sup>, E. Y. Birati<sup>2</sup>, S. E. Kimmel<sup>3</sup>, T. P. Cappola<sup>1</sup>. <sup>1</sup>Penn Cardiovascular Institute, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, <sup>2</sup>University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Department of Biostatistics and Epidemiology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA

**(466)** *WITHDRAWN*

**(467)** *Clinical Outcomes in Patients Receiving Simultaneous Heart and Abdominal Organ Transplantation;*

S. Fedson<sup>1</sup>, C. Murks<sup>1</sup>, L. Potter<sup>2</sup>, s. Qamar<sup>1</sup>, T. Riley<sup>1</sup>, G. Kim<sup>1</sup>, G. Sayer<sup>1</sup>, N. Uriel<sup>1</sup>, T. Ota<sup>3</sup>, V. Jeevanandam<sup>3</sup>. <sup>1</sup>Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Pharmacy, University of Chicago, Chicago, IL, <sup>3</sup>Surgery, University of Chicago, Chicago, IL

**(468)** *Single Center Outcomes of Combined Heart and Liver Transplantation in the Failing Fontan;*

B. A. D'Souza<sup>1</sup>, S. Fuller<sup>2</sup>, N. Hornsby<sup>1</sup>, J. Wald<sup>1</sup>, K. Krok<sup>3</sup>, A. Shaked<sup>4</sup>, L. Goldberg<sup>1</sup>, A. Pochettino<sup>5</sup>, K. Olthoff<sup>2</sup>, Y. Y. Kim<sup>1</sup>. <sup>1</sup>Cardiology Division, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Surgery, Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Department of Gastroenterology, Penn State Hershey Medical Center, Hershey, PA, <sup>4</sup>Department of Surgery, Hospital of the University of Pennsylvania, Philadelphia, PA, <sup>5</sup>Department of Cardiac Surgery, Mayo Clinic, Rochester, MN

**(469)** *Feasibility of a Long-Term Transfemoral Power Lead for Aortix, a Novel Intravascular Blood Pump;*

W. Clifton<sup>1</sup>, O. Benavides<sup>1</sup>, T. Songkakul<sup>1</sup>, J. Heuring<sup>1</sup>, B. Hertzog<sup>1</sup>, R. Delgado<sup>2</sup>. <sup>1</sup>Procyron, Houston, TX, <sup>2</sup>Texas Heart Institute, Houston, TX

**(470)** *New Scoring System Using Cardiopulmonary Exercise Parameters Can Predict Prognosis in Heart Failure Patients Receiving Guideline-Directed Optimal Medical Therapy Including Beta-Blocker, Angiotensin Converting Enzyme Inhibitor, and Aldosterone Antagonist;*

T. Imamura<sup>1</sup>, K. Kinugawa<sup>1</sup>, T. Inaba<sup>2</sup>, H. Maki<sup>2</sup>, M. Hatano<sup>2</sup>, O. Kinoshita<sup>3</sup>, K. Nawata<sup>3</sup>, M. Ono<sup>3</sup>. <sup>1</sup>Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, <sup>2</sup>Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, <sup>3</sup>Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

**(471)** *Cardiac Retransplantation: Third Time's the Charm?;*

E. C. DePasquale, L. Reardon, A. Nsair, M. Deng, A. Ardehali. UCLA, Los Angeles, CA,

- (472) *Mid-Term Outcome of Acute Fulminant Myocarditis Presenting With Cardiogenic Shock: A Single Centre Experience;***  
 E. Ammirati, M. Lilliu, M. Cipriani, A. Garascia, M. Brambatti, F. M. Turazza, S. Nonnini, R. Paino, C. F. Russo, F. Oliva, M. Frigerio. Ni-guarda Ca' Granda Hospital, Milan, Italy
- (473) *Does Time on Ventricular Assist Device Compromise Post-Transplant Outcome?;***  
 K. Ghafourian, J. Moriguchi, M. Kittleson, L. Czer, E. Passano, F. Liou, J. Yabuno, N. Huie, D. H. Chang, A. Trento, F. Arabia, J. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (474) *Outcomes in Adult Heart Transplant Candidates and Recipients Bridged With Acute Circulatory Support Devices;***  
 S. C. Silvestry<sup>1</sup>, L. B. Edwards<sup>2</sup>, L. Robbins<sup>2</sup>, S. A. Hall<sup>3</sup>, J. G. Rogers<sup>4</sup>, D. M. Meyer<sup>5</sup>. <sup>1</sup>Washington Univ Sch of Med, St. Louis, MO, <sup>2</sup>UNOS, Richmond, VA, <sup>3</sup>Transplant Cardiology and Mechanical Support/Heart Failure, Baylor University Medical Center, Dallas, TX, <sup>4</sup>Internal Medicine, Duke University School of Medicine, Durham, NC, <sup>5</sup>Surgery, University of Texas Southwestern Medical School, Dallas, TX
- (475) *A Novel Minimally Invasive Ovine Model of Ischemic Cardiomyopathy With Advanced Cardiac Imaging Yields Superior Results and Survival;***  
 J. E. Cohen<sup>1</sup>, A. B. Goldstone<sup>1</sup>, Y. Shudo<sup>1</sup>, J. W. MacArthur<sup>2</sup>, J. B. Patel<sup>1</sup>, B. B. Edwards<sup>1</sup>, W. L. Patrick<sup>1</sup>, C. N. Aribeana<sup>1</sup>, Y. Woo<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Stanford University, Stanford, CA, <sup>2</sup>Surgery, University of Pennsylvania, Philadelphia, PA
- (476) *Outcomes in Patients Bridged With Univentricular and Biventricular Devices Prior to Heart Transplantation;***  
 J. C. Grimm<sup>1</sup>, C. M. Sciortino<sup>1</sup>, J. Magruder<sup>1</sup>, V. Valero<sup>3rd</sup>, R. J. Tedford<sup>2</sup>, S. D. Russell<sup>2</sup>, G. J. Whitman<sup>1</sup>, S. C. Silvestry<sup>3</sup>, A. S. Shah<sup>1</sup>. <sup>1</sup>Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>2</sup>Medicine, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>3</sup>Surgery, Barnes Jewish Hospital, St. Louis, MO
- (477) *Strategies for Bridge to Heart Transplantation (HTx) – High Urgent Listing (HU) vs. Mechanical Circulatory Support (MCS);***  
 J. Sunavsky, A. Zittermann, B. Fujita, U. Fuchs, J. F. Gummert, S. Ensminger, U. Schulz. Department for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Bad Oeynhausen, Germany
- (478) *Use of Extra-Corporeal Membrane Oxygenation in Patients Listed for Heart Transplantation;***  
 A. Cheng<sup>1</sup>, J. R. Trivedi<sup>1</sup>, A. Lenneman<sup>2</sup>, E. Birks<sup>2</sup>, M. S. Slaughter<sup>1</sup>. <sup>1</sup>Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, <sup>2</sup>Cardiovascular Medicine, University of Louisville, Louisville, KY
- (479) *Inclusion of Cognitive and Mood Domains in the Assessment of Frailty Enhances Outcome Prediction in Heart Transplant-Eligible Patients With Advanced Heart Failure;***  
 S. Jha<sup>1</sup>, M. K. Hannu<sup>1</sup>, P. Newton<sup>2</sup>, K. Wilhelm<sup>3</sup>, C. Hayward<sup>1</sup>, A. Jabbour<sup>1</sup>, E. Kotlyar<sup>1</sup>, A. M. Keogh<sup>1</sup>, K. Dhital<sup>1</sup>, E. Granger<sup>1</sup>, P. C. Jansz<sup>1</sup>, P. M. Spratt<sup>1</sup>, E. Montgomery<sup>1</sup>, M. Harkess<sup>1</sup>, P. Tunnicliff<sup>1</sup>, S. Shaw<sup>1</sup>, P. MacDonald<sup>1</sup>. <sup>1</sup>Heart & Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, <sup>2</sup>Health Science, University of Technology, Sydney, Australia, <sup>3</sup>Psychiatry, St. Vincent's Hospital, Sydney, Australia
- (480) *Long Term Follow-Up of Coronary Sinus Delivery of Bone Marrow Cells for Congestive Heart Failure;***  
 J. Tuma<sup>1</sup>, A. Carrasco<sup>1</sup>, A. A. Winters<sup>2</sup>, S. Chirinos<sup>1</sup>, A. N. Patel<sup>2</sup>. <sup>1</sup>Maison de Sante, Lima, Peru, <sup>2</sup>University of Utah, Salt Lake City, UT

- (481) *Echocardiographic Assessment of Intrinsic Right Ventricular Dysfunction Using Arrhythmogenic Right Ventricular Cardiomyopathy as a Model;***  
S. Shah, S. H. Baldinger, W. G. Stevenson, N. K. Lakdawala.  
Brigham and Women's Hospital, Boston, MA
- (482) *Post-Exercise Heart Rate Recovery Independently Predicts Clinical Outcome in Patients With Acute Decompensated Heart Failure;***  
J. Youn<sup>1</sup>, S. Lee<sup>2</sup>, S. Lee<sup>2</sup>, Y. Youn<sup>2</sup>, B. Chang<sup>2</sup>, S. Kang<sup>1</sup>. <sup>1</sup>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- (483) *Intra-Coronary Transfusion of Circulatory Derived CD34+ Cells Improves Left Ventricular Function in Patients With Diffuse Coronary Artery Disease and Non Candidates for Coronary Artery Intervention;***  
F. Lee<sup>1</sup>, Y. Chen<sup>2</sup>, S. Chua<sup>2</sup>, M. Fu<sup>2</sup>, S. Pei<sup>3</sup>, H. Yip<sup>2</sup>. <sup>1</sup>Cardiothoracic and Vascular Surgery, Chang Gung Mem Hosp, Kaohsiung, Taiwan, <sup>2</sup>Cardiology, Chang Gung Mem Hosp, Kaohsiung, Taiwan, <sup>3</sup>Hematology and Oncology, Chang Gung Mem Hosp, Kaohsiung, Taiwan
- (484) *Prognosis Estimation in Heart Transplant Candidates With the Transposition of Great Arteries (TGA) After Mustard or Senning Correction in the Childhood: The Retrospective Analysis;***  
M. Hegárová<sup>1</sup>, Z. Dorazilová<sup>1</sup>, V. Melenovský<sup>1</sup>, J. Vrbská<sup>1</sup>, J. Malý<sup>2</sup>, I. Netuka<sup>2</sup>, J. Pirk<sup>2</sup>, I. Málek<sup>1</sup>. <sup>1</sup>Clinic of Cardiology, IKEM, Prague, Czech Republic, <sup>2</sup>Clinic of Cardiovascular Surgery, IKEM, Prague, Czech Republic
- (485) *Outcomes in Cardiac Transplant Recipients According to Pretransplant AT1R Antibody Levels and Donor AT1R Polymorphisms;***  
M. Zacharias<sup>1</sup>, B. Hynes<sup>2</sup>, N. K. Sweitzer<sup>3</sup>, M. R. Johnson<sup>1</sup>, S. Akhter<sup>4</sup>, T. Ellis<sup>2</sup>, R. Dhingra<sup>1</sup>. <sup>1</sup>Department of Medicine; Division of Cardiology, University of Wisconsin, Madison, WI, <sup>2</sup>Department of Pathology, University of Wisconsin, Madison, WI, <sup>3</sup>Department of Medicine; Division of Cardiology, University of Arizona Sarver Heart Center, Tucson, AZ, <sup>4</sup>Department of Surgery; Division of Cardiothoracic Surgery, University of Wisconsin, Madison, WI
- (486) *Single Center Experience With Amyloid Patients in the Current Era of Disease Specific Medications;***  
J. Patel, R. Vescio, M. Kittleson, S. Siddiqui, F. Liou, J. Yabuno, L. Piponniau, B. Kearney, M. Hamilton, L. Czer, J. A. Kobashigawa.  
Cedars-Sinai Heart Institute, Los Angeles, CA
- (487) *MELD XI Predicts Early and Late Survival After Heart Transplantation Even in Patients Bridged With Left Ventricular Assist Device;***  
S. Deo<sup>1</sup>, S. Al Kindi<sup>1</sup>, S. Kumar<sup>1</sup>, G. Oliveira<sup>1</sup>, S. Altarabsheh<sup>2</sup>, B. Sarayepoglu<sup>1</sup>, B. Medallion<sup>1</sup>, M. Gunwale<sup>1</sup>, C. El-Amm<sup>1</sup>, S. J. Park<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University Hospitals, Cleveland, OH, <sup>2</sup>Cardiac Surgery, Queen Alia Heart Institute, Amman, Jordan
- (488) *Bariatric Surgery: A 'Bridge to Transplant' for Morbidly Obese Patients With Advanced Heart Failure;***  
C. Lim<sup>1</sup>, O. M. Fisher<sup>2</sup>, D. Falkenback<sup>2</sup>, D. Boyd<sup>3</sup>, C. Hayward<sup>4</sup>, A. Keogh<sup>4</sup>, K. Samaras<sup>5</sup>, R. Lord<sup>6</sup>, P. Macdonald<sup>4</sup>. <sup>1</sup>Cardiology, National Heart Centre Singapore, Singapore, Singapore, <sup>2</sup>St Vincent's Centre for Applied Medical Research, Sydney, Australia, <sup>3</sup>Department of Anaesthesia, St Vincent's Hospital, Sydney, Australia, <sup>4</sup>Heart Transplant Unit, St Vincent's Hospital, Sydney, Australia, <sup>5</sup>Department of Endocrinology, St Vincent's Hospital, Sydney, Australia, <sup>6</sup>Department of Surgery, St Vincent's Hospital, Sydney, Australia
- (489) *Does a Crumbling Bridging Strategy Put Patient at Risk for Cardiac Transplantation?;***  
S. Mahr, P. Angleitner, T. Haberl, A. Aliabadi, D. Zimpfer, G. Laufer, A. Zuckermann. Cardiac Surgery, Medical University of Vienna, Vienna, Austria

- (490) *Early and Mid-Term Predicted Survival in Transplant Eligible Elderly Patients Is Superior With Transplant Versus Left Ventricular Assist Device Bridge-to-Transplant Therapy;***  
 S. K. Singh<sup>1</sup>, D. K. Pujara<sup>1</sup>, E. Sandoval<sup>2</sup>, J. Anand<sup>1</sup>, L. Simpson<sup>1</sup>, A. B. Civitello<sup>1</sup>, H. R. Mallidi<sup>1</sup>. <sup>1</sup>Transplant and Assist Devices, Baylor College of Medicine, Houston, TX, <sup>2</sup>Transplant and Assist Devices, Texas Heart Institute, Houston, TX
- (491) *Partial Pressure of End-Tidal Carbon Dioxide Predicts the Complication of Secondary Pulmonary Hypertension in Patients With Advanced Heart Failure;***  
 O. Seguchi<sup>1</sup>, A. Nakano<sup>2</sup>, K. Kuroda<sup>1</sup>, E. Hisamatsu<sup>1</sup>, T. Sato<sup>1</sup>, S. Nakajima<sup>1</sup>, T. Sato<sup>1</sup>, H. Sunami<sup>1</sup>, M. Yanase<sup>1</sup>, M. Kitakaze<sup>3</sup>, T. Nakatani<sup>1</sup>. <sup>1</sup>Transplantation, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>2</sup>Development of Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>3</sup>Development of Clinical Research, National Cerebral and Cardiovascular Center, Osaka, Japan
- (492) *Should Surveillance Right Heart Catheterization Be Performed in Patients Listed for Heart Transplantation?;***  
 M. Ahluwalia, A. T. Owens, K. A. Forde-McLean, M. Jessup, R. C. Forde-McLean. Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA
- (493) *Risk of Heart Failure and Death Among Patients With Friedreich Ataxia Admitted for Non-Cardiac Etiologies;***  
 K. Y. Lin, D. Lynch, M. J. O'Connor, J. Rossano. Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA
- (494) *The Independent Predictive Value of Peak Oxygen Consumption, Left ventricular Strain and Atrial Remodelling in Patients With Dilated Cardiomyopathy;***  
 G. Giraldeau, D. Boulate, D. Banerjee, M. Ariyama, M. Wheeler, J. W. Knowles, Y. Kobayashi, M. Perez, J. Wu, I. Schnittger, T. Kouznetsova, J. Myers, F. Haddad, E. A. Ashley. Stanford Hospital, Stanford, CA
- (495) *Management of Chagas Cardiomyopathy Patients Following Cardiac Transplantation: Implications From the Unos Database;***  
 A. Godier-Furnemont, V. K. Topkara, D. Mancini. Cardiology, Columbia University New York Presbyterian Hospital, New York, NY
- (496) *Combined Kidney Transplant in Patients Needing Redo Heart Transplant: Viable Option?;***  
 M. Kittleson<sup>1</sup>, J. Patel<sup>1</sup>, F. Liou<sup>1</sup>, S. Siddiqui<sup>1</sup>, L. Pipponniau<sup>1</sup>, D. H. Chang<sup>1</sup>, A. Hage<sup>1</sup>, M. Hamilton<sup>1</sup>, L. Czer<sup>2</sup>, A. Trento<sup>1</sup>, F. Esmailian<sup>1</sup>, J. A. Kobashigawa<sup>1</sup>. <sup>1</sup>Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>2</sup>MD, Cedars-Sinai Heart Institute, Los Angeles, CA
- (497) *Frailty as a Predictor of Outcomes in Heart Transplant-Eligible Patients With Advanced Heart Failure;***  
 S. R. Jha<sup>1</sup>, M. Hannu<sup>1</sup>, P. Newton<sup>2</sup>, K. Wilhelm<sup>3</sup>, C. Hayward<sup>1</sup>, A. Jabour<sup>1</sup>, E. Kotlyar<sup>1</sup>, A. Keogh<sup>1</sup>, K. Dhital<sup>1</sup>, E. Granger<sup>1</sup>, P. Jansz<sup>1</sup>, P. Spratt<sup>1</sup>, E. Montgomery<sup>1</sup>, P. Tunnicliff<sup>1</sup>, S. Shaw<sup>1</sup>, P. MacDonald<sup>1</sup>. <sup>1</sup>Heart & Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, <sup>2</sup>Health Science, University of Technology, Sydney, Sydney, Australia, <sup>3</sup>Psychiatry, St. Vincent's Hospital, Sydney, Australia
- (498) *Frailty Phenotype Is Associated With Survival as Predicted By the Seattle Heart Failure Model in Heart Failure Patients Referred for Advanced Therapies;***  
 L. A. Goldraich, A. C. Alba, F. Foroutan, J. MacIver, H. J. Ross. Heart Failure and Cardiac Transplant Programs, Peter Munk Cardiac Center, University of Toronto., Toronto, ON, Canada
- (499) *Characteristics and Predictors of Improvement in Patients Delisted for Recovery While Awaiting Heart Transplantation;***  
 S. Kumar, S. Al-Kindi, M. Ige, M. Ginwalla, C. ElAmm, S. Deo, S. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH



## MECHANICAL CIRCULATORY SUPPORT

(Agora 2)

**(MCS, BSI, DMD, HF, HTX, ID, NNSAH, PATH, PEDS, PH, PHARM, PEEQ)**

**(500)** *Moved to Mini Oral Session 1*

**(501)** *Extremes of Obesity and LVAD Patient Morbidity and Mortality;*

C. Henderson<sup>1</sup>, K. Patel<sup>1</sup>, G. Sayer<sup>1</sup>, S. Fedson<sup>1</sup>, G. Kim<sup>1</sup>, T. Ota<sup>2</sup>, C. Juricek<sup>2</sup>, V. Jeevanandam<sup>2</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Surgery, University of Chicago, Chicago, IL

**(502)** *Handgrip Strength Is a Predictor for Length of Stay in Patients Implanted With Left Ventricular Assist Devices;*

G. Yost, M. Gregory, G. Bhat. Center for Heart Transplant and Assist Devices, Advocate Christ Medical Center, Oak Lawn, IL

**(503)** *Outcomes Following an Individualized Management Strategy for Adult Patients on ECMO;*

J. K. Wong, A. L. Melvin, D. J. Joshi, C. Y. Lee, P. A. Knight. Division of Cardiac Surgery, University of Rochester Medical Center, Rochester, NY

**(504)** *Moved to Mini Oral Session 1*

**(505)** *Moved to Mini Oral Session 7*

**(506)** *Hemodynamic and Cerebrovascular Response to an Orthostatic Challenge in Patients With Continuous-Flow Left Ventricular Assist Devices;*

W. K. Cornwell<sup>1</sup>, T. Tarumi<sup>2</sup>, A. Stickford<sup>2</sup>, J. Kibe<sup>1</sup>, C. Fitzsimmons<sup>1</sup>, D. Markham<sup>3</sup>, R. Zhang<sup>2</sup>, Q. Fu<sup>2</sup>, M. Drazner<sup>1</sup>, B. Levine<sup>4</sup>. <sup>1</sup>Cardiology, Univ of Texas SW, Dallas, TX, <sup>2</sup>Institute of Exercise and Environmental Medicine, Dallas, TX, <sup>3</sup>Cardiology, Emory University, Atlanta, GA, <sup>4</sup>Cardiology, Institute of Exercise and Environmental Medicine, Dallas, TX

**(507)** *Comparison of Monitoring Unfractionated Heparin Using Anti-Xa vs. aPTT in Patients With Ventricular Assist Devices;*

J. Waldron, J. Dow, R. Grayburn, N. Gaglianella, L. Baumann Kreuziger. Medical College of Wisconsin, Milwaukee, WI

**(508)** *Substance Abuse and Left Ventricular Assist Device Outcomes: Does a History and Type of Use Matter?;*

A. K. Johnson, A. Rauf, S. Christensen, G. A. Wright, A. C. Miller, S. Stoker, R. Alharethi, W. T. Caine, D. Budge, B. B. Reid, B. Y. Rasmusson, K. Afshar, A. G. Kfoury. Mechanical Circulatory Support, Intermountain Medical Center Intermountain Medical Center, Murray, UT

**(509)** *Echocardiographic and Ambulatory B-Type Natriuretic Peptide Correlates in Patients Supported By a Left Ventricular Assist Device;*

A. K. Mankad<sup>1</sup>, V. P. Raje<sup>2</sup>, G. Merinar<sup>2</sup>, K. B. Shah<sup>2</sup>. <sup>1</sup>Hunter Holmes McGuire Veterans Hospital, Richmond, VA, <sup>2</sup>Medical College of Virginia, Richmond, VA

**(510)** *Extracorporeal Membrane Oxygenation Support in Refractory Cardiogenic Shock: Outcome, Treatment Strategies and Analysis of Risk Factors;*

A. Loforte, E. Pilato, S. Martin Suarez, G. Jafrancesco, S. Castrovinci, M. Cefarelli, L. Potena, M. Masetti, G. Magnani, F. Grigioni, G. Frascaroli, G. Marinelli. Cardiovascular Surgery and Transplantation, S. Orsola-Malpighi Hospital, Bologna University, Bologna, Italy

- (511) *Recirculation During Venovenous Extracorporeal Membrane Oxygenation: A Comparative Mock Circulation Study;***  
A. Xie<sup>1</sup>, I. D. Jayewardene<sup>1</sup>, A. Dinale<sup>2</sup>, P. Macdonald<sup>3</sup>, R. Pye<sup>4</sup>, K. Dhital<sup>5</sup>. <sup>1</sup>Faculty of Medicine, University of New South Wales, Sydney, Australia, <sup>2</sup>Department of Clinical Perfusion, St Vincent's Hospital, Sydney, Australia, <sup>3</sup>Department of Cardiology, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia, <sup>4</sup>Department of Anaesthetics, St Vincent's Hospital, Sydney, Australia, <sup>5</sup>Department of Cardiothoracic Surgery, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia
- (512) *Breaking the Myth of Obesity as a Contraindication to Continuous Flow Left Ventricular Assist Devices;***  
M. McMenamy, F. Arabia, L. Czer, M. Kittleson, R. Jocsou, E. Pasano, F. Liou, J. Yabuno, D. H. Chang, F. Esmailian, J. A. Kobashigawa, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA
- (513) *Rest and Exercise Adaptation of the Right Ventricle in Long-Term Left Ventricular Assist Device Patients: A Prospective, Pilot Study;***  
M. Aymami<sup>1</sup>, E. Donal<sup>2</sup>, J. Guihaire<sup>1</sup>, A. Le Helloco<sup>2</sup>, M. Federspiel<sup>2</sup>, E. Galli<sup>2</sup>, F. Carré<sup>2</sup>, B. Lelong<sup>1</sup>, C. Chabanne<sup>1</sup>, H. Corbineau<sup>1</sup>, E. Flécher<sup>1</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Rennes University Hospital, Rennes, France, <sup>2</sup>Cardiology and Cardiac Functional Explorations Department, Rennes University Hospital, Rennes, France
- (514) *Outcomes After Heart Transplantation of Patients Bridged to Transplant With Short Term Assist Device Support;***  
M. A. Castetl<sup>1</sup>, R. Cartaña<sup>2</sup>, M. Cardona<sup>1</sup>, D. Pereda<sup>2</sup>, E. Sandoval<sup>2</sup>, M. Castilla<sup>2</sup>, M. Farrero<sup>1</sup>, F. Pérez-Villa<sup>1</sup>. <sup>1</sup>Department of Cardiology, Hospital Clinic Barcelona, Barcelona, Spain, <sup>2</sup>Department of Cardiac Surgery, Hospital Clinic Barcelona, Barcelona, Spain
- (515) *Moved to Mini Oral Session 7***
- (516) *Modulation of LV Loading and Arterial Pulsatility Affects PET/CT Coronary Flow Reserve in Continuous Flow LVAD Patients;***  
M. Yuzefpolskaya<sup>1</sup>, M. R. Torres<sup>2</sup>, R. Weinberg<sup>1</sup>, A. Breskin<sup>1</sup>, R. A. Garan<sup>1</sup>, V. K. Topkara<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, D. M. Mancini<sup>1</sup>, Y. Naka<sup>2</sup>, U. P. Jorde<sup>3</sup>, P. C. Colombo<sup>1</sup>, S. Bokhari<sup>1</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Surgery, Columbia University, New York, NY, <sup>3</sup>Medicine, Montefiore Medical Center, Bronx, NY
- (517) *Residual Mitral Regurgitation After Continuous Flow Left Ventricular Assist Device Implantation Impacts Right Ventricular Geometry and Function;***  
H. Kassis<sup>1</sup>, K. Cherukuri<sup>2</sup>, R. Agarwal<sup>1</sup>, M. Kanwar<sup>1</sup>, G. G. Sokos<sup>1</sup>, R. J. Moraca<sup>1</sup>, S. H. Bailey<sup>1</sup>, S. Murali<sup>1</sup>, R. L. Benza<sup>1</sup>, A. Raina<sup>1</sup>. <sup>1</sup>Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, PA, <sup>2</sup>Department of Medicine, Allegheny General Hospital, Pittsburgh, PA
- (518) *Outcomes After Successful Medical Management of Hemolysis in HeartMateII Patients: A Single Center Experience Over 6 Years;***  
D. Karia, D. Horstmanshof, M. Munagala, A. Phancao, N. Chelikani, T. Snyder, H. Wright, J. Chaffin, C. Elkins, R. Khodaverdian, M. Sasevich, J. Neel, K. Nelson, J. Long. Advanced Cardiac Care, Integris Health, Oklahoma City, OK

- (519) *Update on Post-Approval INTERMACs Registry of the HVAD System in Commercial Use;***  
 S. Maltais<sup>1</sup>, G. A. Ewald<sup>2</sup>, M. E. Keebler<sup>1</sup>, K. H. Schlendorf<sup>1</sup>, S. W. Boyce<sup>3</sup>, S. S. Najjar<sup>3</sup>, F. D. Pagani<sup>4</sup>, K. D. Aaronson<sup>4</sup>, V. Jeevanandam<sup>5</sup>, C. A. Milano<sup>6</sup>, J. G. Rogers<sup>6</sup>, R. B. Love<sup>7</sup>, C. W. Mahr<sup>8</sup>, D. T. Pham<sup>9</sup>, M. S. Kiernan<sup>9</sup>, R. L. Kormos<sup>10</sup>, J. J. Teuteberg<sup>10</sup>, S. C. Silvestry<sup>2</sup>, E. C. McGee<sup>11</sup>, R. A. Gordon<sup>11</sup>, H. R. Mallidi<sup>12</sup>, O. H. Frazier<sup>12</sup>.  
<sup>1</sup>Vanderbilt University Medical Center, Nashville, TN, <sup>2</sup>Barnes Jewish Hospital, St Louis, MO, <sup>3</sup>MedStar Heart Institute, Washington, DC, <sup>4</sup>University of Michigan, Ann Arbor, MI, <sup>5</sup>University of Chicago Medicine, Chicago, IL, <sup>6</sup>Duke University School of Medicine, Durham, NC, <sup>7</sup>Medical College of Wisconsin, Milwaukee, WI, <sup>8</sup>University of Washington Medical Center, Milwaukee, WI, <sup>9</sup>Tufts Medical Center, Boston, MA, <sup>10</sup>University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>11</sup>Northwestern Memorial Hospital, Chicago, IL, <sup>12</sup>Texas Heart Institute, Houston, TX
- (520) *The Harmonic Pattern of Ventricular Assist Device Audiosignals: Correlation to Pump Speed and Aortic Valve Opening;***  
 D. Bull<sup>1</sup>, P. Markey<sup>1</sup>, D. Vickers<sup>1</sup>, D. Robson<sup>2</sup>, P. Jansz<sup>2</sup>, N. Lovell<sup>3</sup>, C. Hayward<sup>4</sup>, K. Dhital<sup>2</sup>. <sup>1</sup>Faculty of Medicine, University of New South Wales, Sydney, Australia, <sup>2</sup>Department of Cardiothoracic Surgery, St Vincent's Hospital, Sydney, Australia, <sup>3</sup>Graduate School of Biomedical Engineering, University of New South Wales, Sydney, Australia, <sup>4</sup>Department of Cardiology, St Vincent's Hospital, Sydney, Australia
- (521) WITHDRAWN**
- (522) *Cerebral Hypoxia During Venous Arterial Extracorporeal Membrane Oxygenation: An In-Vitro Study;***  
 A. Xie<sup>1</sup>, I. D. Jayewardene<sup>1</sup>, A. Dinale<sup>2</sup>, P. Macdonald<sup>3</sup>, R. Pye<sup>4</sup>, K. Dhital<sup>5</sup>. <sup>1</sup>Faculty of Medicine, University of New South Wales, Sydney, Australia, <sup>2</sup>Department of Clinical Perfusion, St Vincent's Hospital, Sydney, Australia, <sup>3</sup>Department of Cardiology, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia, <sup>4</sup>Department of Anaesthetics, St Vincent's Hospital, Sydney, Australia, <sup>5</sup>Department of Cardiothoracic Surgery, St Vincent's Hospital; Victor Chang Cardiac Research Institute, Sydney, Australia
- (523) *VKORC1 Genotype Predicts Warfarin Dosing and INR Kinetics in Patients With Continuous-Flow Left Ventricular Assist Devices (CF-LVADs);***  
 V. K. Topkara<sup>1</sup>, A. Levin<sup>1</sup>, K. Mody<sup>1</sup>, A. Garan<sup>1</sup>, B. Cagliostro<sup>2</sup>, M. A. Flannery<sup>2</sup>, R. Te-Frey<sup>2</sup>, F. Torres<sup>2</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>, D. Mancini<sup>1</sup>, Y. Naka<sup>2</sup>, P. Colombo<sup>1</sup>, U. P. Jorde<sup>3</sup>.  
<sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, <sup>3</sup>Cardiology, Montefiore Medical Center, New York, NY
- (524) *Duration of Continuous-Flow Left Ventricular Assist Device Support Does Not Impact Heart Transplant Operative Variables and Long-Term Survival;***  
 E. Lushaj, T. Kohmoto, L. Lozonschi, S. Osaki, M. Murray, S. Akhter. University of Wisconsin, Madison, WI
- (525) *Anatomical and Hemodynamic Response of the Right Ventricle During Increases in Left Ventricular Assist Device Speed;***  
 G. T. Sayer<sup>1</sup>, K. Addetia<sup>1</sup>, S. Fedson<sup>1</sup>, E. Kruse<sup>1</sup>, K. Collins<sup>1</sup>, D. Rodgers<sup>1</sup>, C. Juricek<sup>2</sup>, T. Ota<sup>2</sup>, V. Jeevanandam<sup>2</sup>, R. Lang<sup>1</sup>, N. Uriel<sup>1</sup>.  
<sup>1</sup>Medicine, University of Chicago Medical Center, Chicago, IL, <sup>2</sup>Surgery, University of Chicago Medical Center, Chicago, IL
- (526) *Comparison of Hospitalization Rates With the HeartWare HVAD and HeartMate II Left Ventricular Assist Devices;***  
 D. T. Majure, F. H. Sheikh, M. Hofmeyer, M. Rodrigo, C. Bither, N. Parunashvili, S. W. Boyce, S. S. Najjar. MedStar Heart Institute, Washington, DC

- (527) *Right Ventricular Failure After Left Ventricular Assist Device Implantation: The Importance of Preoperative Hemodynamic Profile;***  
 V. De Simone<sup>1</sup>, M. Cipriani<sup>2</sup>, A. Verde<sup>2</sup>, A. Garascia<sup>2</sup>, F. M. Turazza<sup>2</sup>, F. Macera<sup>2</sup>, V. Pacher<sup>2</sup>, E. Ammirati<sup>2</sup>, F. Milazzo<sup>2</sup>, R. Paino<sup>2</sup>, C. F. Russo<sup>2</sup>, T. Colombo<sup>2</sup>, C. Taglieri<sup>2</sup>, L. Martinelli<sup>2</sup>, M. Frigerio<sup>2</sup>. <sup>1</sup>Cardiology, University Hospital of Verona, Verona, Italy, <sup>2</sup>Cardio-thoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Italy
- (528) *Full Percutaneous Temporary Right Ventricular Support By a Centrifugal Pump in Right Ventricular Failure After Left Ventricular Assist Device Implantation;***  
 G. Lebreton, C. Mastroianni, P. Demondion, A. Genton, P. Leprince. Cardiac Surgery, Pitie Salpetriere Hospital, 75013, France
- (529) *Left Atrial Pressure Monitoring for Early Post-Operative Management Following LVAD Implantation;***  
 I. Rajapreyar, M. Petrovic, S. Nathan, M. H. Akay, B. Kar, P. Loyalka, M. Patel, I. D. Gregoric. Center for Advanced Heart Failure, The University of Texas Health Science Center at Houston, Houston, TX
- (530) *Cardiac Resynchronization Therapy Does Not Reduce Ventricular Arrhythmias After Left Ventricular Assist Device Implantation;***  
 J. W. Schleifer<sup>1</sup>, F. Mookadam<sup>1</sup>, E. Kransdorf<sup>1</sup>, U. Nanda<sup>2</sup>, S. Cha<sup>3</sup>, O. E. Pajaro<sup>4</sup>, D. E. Steidley<sup>1</sup>, R. L. Scott<sup>1</sup>, J. C. Adams<sup>5</sup>, R. Saadiq<sup>6</sup>, T. C. Carvajal<sup>7</sup>, K. Srivathsan<sup>1</sup>. <sup>1</sup>Cardiovascular Diseases, Mayo Clinic Arizona, Scottsdale, AZ, <sup>2</sup>Internal Medicine, Maricopa Medical Center, Phoenix, AZ, <sup>3</sup>Health Science Research, Mayo Clinic Rochester, Rochester, MN, <sup>4</sup>Cardiothoracic Surgery, Mayo Clinic Arizona, Scottsdale, AZ, <sup>5</sup>North Central Heart, Avera Heart Hospital of South Dakota, Sioux Falls, SD, <sup>6</sup>Cardiology and Vascular Medicine, Mayo Clinic Rochester, Rochester, MN, <sup>7</sup>General Surgery, Mayo Clinic Arizona, Scottsdale, AZ
- (531) *The Arrhythmic Burden in Patients Following Left Ventricular Assist Device Implantation – A Single Centre Retrospective Analysis;***  
 K. Chua, Y. Go, C. Sivathasan, C. Lim, D. K. Sim, C. Ching, C. Ng. Cardiology, National Heart Centre Singapore, Singapore, Singapore
- (532) *At Left Ventricular Assist Device (LVAD) Implantation, Morphologic Differences Are Observed Between Patients With Improved Cardiac Function Allowing LVAD Removal and Patients With Prolonged LVAD Support as a Bridge to Transplantation;***  
 A. Segura<sup>1</sup>, A. Hernandez<sup>2</sup>, A. Baldwin<sup>3</sup>, S. Carranza<sup>4</sup>, P. Odegaard<sup>5</sup>, L. Bujal<sup>1</sup>, O. Frazier<sup>6</sup>. <sup>1</sup>Cardiovascular Pathology Research, Texas Heart Institute, Houston, TX, <sup>2</sup>Cardiology, St. Luke's Hospital Medical Center, Houston, TX, <sup>3</sup>Cardiothoracic Surgery, Texas Heart Institute, Houston, TX, <sup>4</sup>Circulatory Support, Texas Heart Institute, Houston, TX, <sup>5</sup>Center for Cardiac Support, CHI St. Luke's Health, Houston, TX, <sup>6</sup>Center for Cardiac Support, Cardiovascular Surgery Research, Texas Heart Institute, Houston, TX
- (533) *Inhibition of ADAMTS-13 By Hemoglobin Reinstates Normal von Willebrand Factor: A Contributor to LVAD Thrombosis?;***  
 C. R. Bartoli, D. J. Restle, J. Kang, M. A. Acker, P. Atluri. Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA
- (534) *Early Clinical Outcomes of LVAD Implantation via Lateral Thoracotomy With Ministernotomy: Comparison to Traditional Median Sternotomy;***  
 M. E. Rodrigo<sup>1</sup>, D. T. Majure<sup>2</sup>, G. Ruiz<sup>2</sup>, F. H. Sheikh<sup>2</sup>, M. Hofmeyer<sup>2</sup>, T. Elliott<sup>2</sup>, M. Hockstein<sup>2</sup>, E. Molina<sup>2</sup>, S. S. Najjar<sup>3</sup>, S. W. Boyce<sup>2</sup>. <sup>1</sup>Cardiology, Medstar Washington Hospital Center, Chevy Chase, MD, <sup>2</sup>Cardiology, Medstar Washington Hospital Center, District of Columbia, DC, <sup>3</sup>Cardiology, Medstar Washington Hospital Center, District of Columbia, MD

- (535) *Reduction in LDH Spikes After Targeted Increase of Anticoagulation for Prevention of Pump Thrombosis;***  
M. Guglin, N. Rajagopalan, A. Hart, T. Tribble, C. Falls. University of Kentucky, Lexington, KY
- (536) *WITHDRAWN***
- (537) *Cellular Microparticles as Predictive Markers for Adverse Events in Patients With Implanted Ventricular Assist Devices;***  
J. Walenga<sup>1</sup>, W. Jeske<sup>1</sup>, J. Schwartz<sup>2</sup>, V. Escalante<sup>1</sup>, B. Menapace<sup>1</sup>, E. Coglianese<sup>3</sup>, E. Kumar<sup>1</sup>, A. Heroux<sup>3</sup>, M. Bakhos<sup>2</sup>. <sup>1</sup>Thoracic-CV Surgery, Loyola University Chicago, Maywood, IL, <sup>2</sup>Thoracic-CV Surgery, Loyola University Health System, Maywood, IL, <sup>3</sup>Heart Failure/Cardiology, Loyola University Health System, Maywood, IL
- (538) *Predictors of Aortic Valve Commissural Fusion in Patients Undergoing Left Ventricular Assist Device Therapy;***  
D. N. Valencia<sup>1</sup>, S. A. Kliethermas<sup>2</sup>, J. I. Bailey<sup>1</sup>, B. Duebner<sup>3</sup>, E. Boyes<sup>3</sup>, J. P. Schwartz<sup>4</sup>, A. L. Heroux<sup>3</sup>, E. Coglianese<sup>3</sup>. <sup>1</sup>Loyola University School of Medicine, Maywood, IL, <sup>2</sup>Department of Public Health Sciences, Loyola University School of Medicine, Maywood, IL, <sup>3</sup>Division of Cardiology, Loyola University Medical Center, Maywood, IL, <sup>4</sup>Division of Cardiovascular Surgery, Loyola University Medical Center, Maywood, IL
- (539) *Effect of Preoperative Atrial Fibrillation on Clinical Outcomes After Continuous Flow-Left Ventricular Assist Device Therapy;***  
E. Lushaj, S. Akhter, T. Kohmoto, L. Lozonschi, M. Murray, M. P. Zacharias, S. Osaki. University of Wisconsin, Madison, WI
- (540) *MELD XI Successfully Predicts Thirty Day Mortality in Patients Who Received Centrimag VAD for Acute Decompensated Heart Failure;***  
L. Truby<sup>1</sup>, A. Abadeer<sup>1</sup>, K. Fujita<sup>1</sup>, P. C. Schulze<sup>2</sup>, M. Farr<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, P. C. Colombo<sup>2</sup>, K. Takeda<sup>2</sup>, D. Mancini<sup>2</sup>, Y. Naka<sup>1</sup>, H. Takayama<sup>1</sup>. <sup>1</sup>Department of Surgery, Columbia University College of Physicians and Surgeons, New York, NY, <sup>2</sup>Department of Cardiology, Columbia University College of Physicians and Surgeons, New York, NY
- (541) *Intra-Operative Indication Extracorporeal Membrane Oxygenation for Cardiopulmonary Support During Lung Transplantation: Risk Factors and Mid-Term Results;***  
F. Lus<sup>1</sup>, W. Sommer<sup>1</sup>, I. Tudorache<sup>1</sup>, M. Avsar<sup>1</sup>, T. Siemeni<sup>1</sup>, J. Salman<sup>1</sup>, M. Greer<sup>2</sup>, J. Puntigam<sup>1</sup>, M. Hoepfer<sup>2</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, C. Kühn<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany
- (542) *The Impact of Perioperative Bleeding on Long-Term Outcomes of Mechanical Circulatory Support;***  
K. Lietz<sup>1</sup>, M. L. Mooney<sup>1</sup>, I. El Lakkis<sup>2</sup>, C. J. Derber<sup>2</sup>, U. M. Kelly<sup>2</sup>, C. D. Wilson<sup>2</sup>, A. C. Hoedt<sup>1</sup>, P. W. Bourassa<sup>1</sup>, B. H. Smith<sup>1</sup>, M. F. McGrath<sup>1</sup>, J. M. Herre<sup>1</sup>. <sup>1</sup>Division of Advanced Heart Failure, Sentara Norfolk General Hospital, Norfolk, VA, <sup>2</sup>Division of Infectious Diseases, Department of Internal Medicine, Eastern Virginia Medical School, Norfolk, VA
- (543) *Radiologic Assessment of HeartMate II Position: Minimal Pump Migration After Long Term Support;***  
R. M. Adamson<sup>1</sup>, B. S. Bower<sup>2</sup>, K. S. Sundareswaran<sup>3</sup>, D. J. Farrar<sup>3</sup>, W. P. Dembitsky<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, <sup>2</sup>Radiology, Sharp Memorial Hospital, San Diego, CA, <sup>3</sup>Research and Scientific Affairs, Thoratec, Pleasanton, CA
- (544) *Usefulness of Implantable Cardioverter Defibrillators in Patients Supported With Ventricular Assist Devices;***  
A. Gkouziouta, S. Adamopoulos, A. Kostopoulou, G. Theodorakis, P. Sfirakis. Heart Failure, MCS and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece

- (545) *Utility of Cardiac Computed Tomography in Detecting Malposition of Left Ventricular Assist Devices Associated With Pump Thrombosis;***  
 M. Kassl, R. Adigun, S. Choi, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, M. Loebe, G. Torre-Amione, S. Chang, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX
- (546) *The Impact of Acute Kidney Injury in Patients With Postcardiotomy Cardiogenic Shock Requiring Mechanical Circulatory Support;***  
 S. Fukuhara<sup>1</sup>, L. Truby<sup>1</sup>, L. Vargas<sup>1</sup>, S. Hart<sup>1</sup>, D. Mancini<sup>2</sup>, P. Colombo<sup>2</sup>, V. Topkara<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, K. Takeda<sup>1</sup>, Y. Naka<sup>1</sup>, H. Takayama<sup>1</sup>. <sup>1</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Medicine, Columbia University Medical Center, New York, NY
- (547) *Japanese Multi-Center Outcomes With the HeartMate II in the Post-Approval Era: Focusing on Results in Patients With Small Body Size;***  
 M. Ono<sup>1</sup>, Y. Sawa<sup>2</sup>, T. Nakatani<sup>3</sup>, R. Tominaga<sup>4</sup>, Y. Matsui<sup>5</sup>, K. Yamazaki<sup>6</sup>, Y. Saiki<sup>7</sup>, H. Niinami<sup>8</sup>, G. Matsumiya<sup>9</sup>, H. Arai<sup>10</sup>. <sup>1</sup>Dept. of Cardiac Surg., Univ. of Tokyo, Tokyo, Japan, <sup>2</sup>Dept. of Cardiovascular Surg., Osaka Univ., Osaka, Japan, <sup>3</sup>Dept. of Transplantation, National Cardiovasc. Research Center, Osaka, Japan, <sup>4</sup>Dept. of Cardiovascular Surg., Kyushu Univ., Fukuoka, Japan, <sup>5</sup>Dept. of Cardiovascular Surg., Hokkaido Univ., Sapporo, Japan, <sup>6</sup>Dept. of Cardiovascular Surg., Tokyo Women's Medical Univ., Tokyo, Japan, <sup>7</sup>Dept. of Cardiovascular Surg., Tohoku Univ., Sendai, Japan, <sup>8</sup>Dept. of Cardiovascular Surg., Saitama Medical Univ., Hidaka, Japan, <sup>9</sup>Dept. of Cardiovascular Surg., Chiba Univ., Chiba, Japan, <sup>10</sup>Dept. of Cardiovascular Surg., Tokyo Medical and Dental Univ., Tokyo, Japan
- (548) *Risk of Neurologic Complications in Patients With Total Artificial Heart;***  
 I. Tchoukina, L. R. Thacker, J. R. Coleman, M. D. Kozak, A. E. Gentry, M. P. Flattery, V. Kasirajan, D. G. Tang, K. B. Shah. Virginia Commonwealth University, Richmond, VA
- (549) *Implantable Cardioverter Defibrillator Therapy in Patients With Continuous Flow Ventricular Assist Device;***  
 S. Pecha, A. Bernhardt, S. Hakmi, Y. Yildirim, M. Barten, S. Willems, F. Wagner, H. Reichenspurner, T. Deuse, A. Aydin. Cardiovascular Surgery, Univ Hospital Hamburg, Hamburg, Germany
- (550) *Overview of a Newly Developed Hub and Spoke Extracorporeal Membrane Oxygenation Inter-Hospital Transport Program;***  
 B. Lima, J. A. Manos, M. Duncan, S. M. Noesges, W. Anonetapipat, E. Stockard, O. O. Hernandez, A. E. Shafii, T. Chamogeorgakis, J. C. MacHannaford, R. L. Smith, S. A. Hall, G. V. Gonzalez-Stawinski. Baylor University Medical Center, Dallas, TX
- (551) *Presence of Multifactorial, Acquired Hypercoagulability After Implantation of Left Ventricular Assist Devices or Total Artificial Hearts;***  
 H. J. Reich<sup>1</sup>, O. Tcherniantchouk<sup>2</sup>, F. A. Arabia<sup>3</sup>, F. Esmailian<sup>3</sup>, D. Ramzy<sup>3</sup>, L. D. Lam<sup>4</sup>, J. Moriguchi<sup>5</sup>, J. A. Dunhill<sup>6</sup>, M. A. De Robertis<sup>7</sup>, L. Czer<sup>5</sup>. <sup>1</sup>Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>3</sup>Cardiothoracic Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4</sup>Pharmacology, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>5</sup>Cardiology, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>6</sup>Hematology and Oncology, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>7</sup>Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA
- (552) *Are Psychosocial Characteristics Predictive of Death and Rehospitalization After Destination Left Ventricular Assist Device;***  
 S. M. Dunlay, S. Schettle, S. Sharma, S. S. Kushwaha, D. F. Snipelisky, J. S. Stulak. Cardiology, Mayo Clinic, Rochester, MN

- (553) *Reliability of the Freedom Driver After Total Artificial Heart Implantation;***  
 C. Runyan, J. Moriguchi, M. Kittleson, L. Czer, E. Passano, F. Liou, D. H. Chang, D. Ramzy, F. Esmailian, J. A. Kobashigawa, F. Arabia. Cedars-Sinai Heart Institute, Los Angeles, CA
- (554) *Risk of Thromboembolic Events After Short Term Discontinuation of Anticoagulation Following a Gastrointestinal Bleed;***  
 F. H. Sheikh, D. T. Majure, M. Hofmeyer, M. E. Rodrigo, N. Parunashvili, G. Ruiz, E. J. Molina, S. W. Boyce, S. S. Najjar. MedStar Heart Institute, Washington, DC
- (555) *Age as Predictor of Clinical Outcomes after LVAD Placement;***  
 L. Harvey<sup>1</sup>, C. Holley<sup>1</sup>, S. Roy<sup>2</sup>, P. Eckman<sup>2</sup>, R. Cogswell<sup>2</sup>, K. Liao<sup>3</sup>, R. John<sup>3</sup>. <sup>1</sup>Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>3</sup>Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN
- (556) *Choice of Initial Device Implant for INTERMACS Profiles 1 and 2 Patients in Cardiogenic Shock Determines Survival to Transplant or Recovery;***  
 R. Cheng, B. Azarbal, F. Esmailian, A. Trento, J. A. Kobashigawa, F. A. Arabia, J. D. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA
- (557) *Bridge to Transplantation With Long-Term Mechanical Assist Device in Adults After Mustard Procedure;***  
 J. Maly<sup>1</sup>, O. Szarszoi<sup>1</sup>, J. Besik<sup>1</sup>, Z. Dorazilova<sup>2</sup>, J. Pirk<sup>1</sup>, I. Netuka<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, IKEM, Prague, Czech Republic, <sup>2</sup>Department of Cardiology, IKEM, Prague, Czech Republic
- (558) *Reduced Continuous-Flow LVAD Speed Does Not Decrease von Willebrand Factor Degradation;***  
 J. Kang<sup>1</sup>, D. M. Zhang<sup>1</sup>, D. J. Restle<sup>1</sup>, F. Kallel<sup>2</sup>, M. A. Acker<sup>1</sup>, P. Atluri<sup>1</sup>, C. R. Bartoli<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Thoratec Corporation, Pleasanton, CA
- (559) *Decreased Pulmonary Artery Compliance Is Associated With Right Heart Failure and Reduced 6-Month Survival After Left Ventricular Assist Device;***  
 E. W. Grandin<sup>1</sup>, J. A. Mazurek<sup>1</sup>, P. Zamani<sup>1</sup>, G. S. Troutman<sup>2</sup>, E. Vorovich<sup>1</sup>, E. Y. Birati<sup>1</sup>, S. Banerji<sup>3</sup>, D. Pedrotty<sup>1</sup>, J. N. Kirkpatrick<sup>1</sup>, K. B. Margulies<sup>1</sup>, P. Atluri<sup>4</sup>, J. E. Rame<sup>1</sup>. <sup>1</sup>Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Penn Cardiovascular Institute, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Division of Cardiovascular Diseases, Albert Einstein Medical Center, Philadelphia, PA, <sup>4</sup>Division of Cardiac Surgery, University of Pennsylvania, Philadelphia, PA
- (560) *High Dose Antiplatelet Therapy Increases Early Bleeding Risk But Does Not Reduce Thrombotic Events in Patients With CF-LVADs;***  
 O. Saeed<sup>1</sup>, A. Shah<sup>1</sup>, C. Guerrero<sup>1</sup>, J. Nguyen<sup>1</sup>, S. Patel<sup>1</sup>, D. Sims<sup>1</sup>, J. Shin<sup>2</sup>, D. D'Alessandro<sup>3</sup>, D. J. Goldstein<sup>3</sup>, U. Jorde<sup>1</sup>. <sup>1</sup>Cardiology, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, <sup>2</sup>Medicine, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY, <sup>3</sup>Cardiothoracic Surgery, Albert Einstein College of Medicine Montefiore Medical Center, Bronx, NY
- (561) *Usefulness of Right Heart Assessment on Ramp Echocardiography After Continuous-Flow LVAD Implantation: A Missed Opportunity?;***  
 E. Joyce<sup>1</sup>, G. C. Stewart<sup>1</sup>, J. Rivero<sup>1</sup>, I. Gosev<sup>2</sup>, M. Hickey<sup>1</sup>, M. Leacche<sup>2</sup>, M. M. Givertz<sup>1</sup>, G. S. Couper<sup>2</sup>, M. R. Mehra<sup>1</sup>. <sup>1</sup>Cardiovascular Division, Department of Medicine, Brigham and Womens Hospital, Boston, MA, <sup>2</sup>Division of Cardiac Surgery, Brigham and Womens Hospital, Boston, MA

- (562) *Echocardiographic Right Heart Strain Analysis May Identify Left Ventricular Assist Device (VAD) Recipients Requiring Subsequent Right VAD Support;***  
 D. Charisopoulou, N. Banner, S. R. Andre, R. Shelley. Advanced Heart Failure and Transplantation, Royal Brompton and Harefield NHS Trust, London, United Kingdom
- (563) *Do Warfarin Polymorphisms (VKORC1 and CYP2C9) Influence Maintenance Anticoagulation Variability in Patients With Continuous Flow Left Ventricular Assist Devices?;***  
 N. A. Haglund<sup>1</sup>, P. B. Miller<sup>2</sup>, M. E. Davis<sup>3</sup>, C. Lai<sup>1</sup>, J. M. Stulak<sup>4</sup>, M. E. Keebler<sup>1</sup>, J. Boord<sup>1</sup>, S. Maltais<sup>3</sup>. <sup>1</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Pharmacology, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Cardiac Surgery, Mayo Clinic, Rochester, TN
- (564) *Are Continuous-Flow LVADs Associated With Vasoplegia at the Time of Heart Transplant?;***  
 L. A. Goldraich, F. Foroutan, H. J. Ross, C. Serrick, M. McDonald, P. Billia, D. Delgado, T. Yau, R. J. Cusimano, V. Rao. Mechanical Circulatory Support and Cardiac Transplant Programs, Peter Munk Cardiac Center, Toronto General Hospital, University Health Network, Toronto, ON, Canada
- (565) *The Use of Octreotide to Treat Refractory Gastrointestinal Bleeding in Patients Supported With a Continuous-Flow Left Ventricular Assist Device;***  
 P. S. Dias, H. Hayes, J. Baumwol. Advanced Heart Failure & Cardiac Transplant Service, Royal Perth Hospital, Perth, Australia
- (566) *Inflammation Mediated Fibrosis Is Regulated Through Distinct Gene-Gene Co-Expression Networks in the Failing Human Myocardium Before and After Left Ventricular Assist Device Support;***  
 V. K. Topkara<sup>1</sup>, A. Godier-Furnemont<sup>2</sup>, N. Bax<sup>2</sup>, B. Fine<sup>1</sup>, A. Garan<sup>1</sup>, M. Yuzefpolskaya<sup>1</sup>, K. Takeda<sup>3</sup>, H. Takayama<sup>3</sup>, Y. Naka<sup>3</sup>, D. Mancini<sup>1</sup>, P. C. Colombo<sup>1</sup>, U. P. Jorde<sup>4</sup>, G. Vunjak-Novakovic<sup>2</sup>. <sup>1</sup>Cardiology, Columbia University New York Presbyterian Hospital, New York, NY, <sup>2</sup>Biomedical Engineering, Columbia University New York Presbyterian Hospital, New York, NY, <sup>3</sup>Cardiothoracic Surgery, Columbia University New York Presbyterian Hospital, New York, NY, <sup>4</sup>Cardiology, Montefiore Medical Center, New York, NY
- (567) *Does the Utilization of a Temporary External Anchoring Suture Increase the Risk of Driveline Infection After Implantation of a Left Ventricular Assist Device;***  
 M. Fudim<sup>1</sup>, C. L. Brown<sup>1</sup>, M. E. Davis<sup>2</sup>, M. Djunaidi<sup>2</sup>, M. R. Danter<sup>3</sup>, F. E. Harrell<sup>4</sup>, N. A. Haglund<sup>1</sup>, S. Maltais<sup>3</sup>. <sup>1</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Biostatistics, Vanderbilt Univ Med Ctr, Nashville, TN
- (568) *Left Ventricular Assist Devices vs. the Total Artificial Heart: Which Causes More Cerebrovascular Accidents?;***  
 C. Runyan, F. Arabia, L. Czer, M. Kittleson, G. Jamero, E. Passano, F. Liou, J. Yabuno, H. Henry, D. H. Chang, J. Kobashigawa, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA
- (569) *Impella 5.0: Effective Short-Term Support in Acute Refractory Cardiogenic Shock of Various Etiologies;***  
 G. Lebreton, C. Mastroianni, A. Quessard, P. Leprince. Cardiac Surgery, Pitie Salpetriere Hospital, <sup>75013</sup>, France
- (570) *Gender Differences in the Risk of Neurological Events and Subsequent Outcome in Left Ventricular Assist Device Patients;***  
 S. Sherazi<sup>1</sup>, V. Kutuyifa<sup>2</sup>, S. McNitt<sup>2</sup>, A. Papernov<sup>2</sup>, W. Hallinan<sup>1</sup>, L. Chen<sup>1</sup>, E. Storzynsky<sup>1</sup>, T. Massey<sup>3</sup>, W. Zareba<sup>2</sup>, J. Alexis<sup>1</sup>. <sup>1</sup>Cardiology, University of Rochester, Rochester, NY, <sup>2</sup>Cardiology Heart Research Follow-up Program, University of Rochester, Rochester, NY, <sup>3</sup>Thoracic and Cardiac Surgery, University of Rochester, Rochester, NY



- (571) *Long-Term Outcomes After Limited Incision Left Ventricular Assist Device Implantation;***  
J. Riebandt<sup>1</sup>, T. Haberl<sup>1</sup>, D. Wiedemann<sup>1</sup>, K. Dimitrov<sup>1</sup>, P. Simon<sup>1</sup>, R. Moayedifar<sup>1</sup>, H. Schima<sup>2</sup>, G. Laufer<sup>1</sup>, D. Zimpfer<sup>1</sup>. <sup>1</sup>Cardiac Surgery, Medical Univ Vienna, Vienna, Austria, <sup>2</sup>Medical Physics and Biomedical Engineering, Medical Univ Vienna, Vienna, Austria
- (572) *Large Incremental Changes in Pump Speed Are Required in Order to See Meaningful Changes in Invasively Measured Hemodynamics in Patients With HeartMate II Continuous Flow Left Ventricular Assist Devices (CF-LVADs);***  
 C. Eshelbrenner, A. M. Cordero-Reyes, A. Bhimaraj, B. H. Trachtenberg, G. Ashrith, M. Loebe, G. Torre-Amione, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX
- (573) *Driveline Infections in Left Ventricular Assist Devices: Review of Management Strategies and Outcomes;***  
 A. Abou el ela<sup>1</sup>, K. R. Balsara<sup>1</sup>, A. Lee<sup>1</sup>, S. M. Joseph<sup>2</sup>, J. Vader<sup>3</sup>, S. J. LaRue<sup>3</sup>, G. A. Ewald<sup>3</sup>, A. Keith<sup>1</sup>, S. C. Silvestry<sup>1</sup>, A. Itoh<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Washington University Medical School, St. Louis, MO, Saint Louis, MO, <sup>2</sup>Cardiovascular Diseases, Washington University Medical School, St. Louis, MO, Saint Louis, MO, <sup>3</sup>Cardiovascular diseases, Washington University Medical School, St. Louis, MO, Saint Louis, MO
- (574) *LVAD Thrombosis Detection Using Third Harmonic Frequency Measured With 3D Accelerometer;***  
I. Schalit<sup>1</sup>, A. Espinoza<sup>1</sup>, G. Sørensen<sup>2</sup>, A. E. Fiane<sup>2</sup>, T. N. Hoel<sup>2</sup>, E. Gude<sup>3</sup>, H. Skulstad<sup>3</sup>, A. S. Thiara<sup>2</sup>, O. Elle<sup>1</sup>, E. Fosse<sup>1</sup>, P. S. Halvorsen<sup>1</sup>. <sup>1</sup>The Intervention Centre, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>2</sup>Department Of Cardiothoracic Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway, <sup>3</sup>Department Of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway
- (575) *High Mortality With Acute Kidney Injury After Mechanical Support for Cardiogenic Shock;***  
 A. I. Abadeer, L. Truby, K. Fujita, L. Vargas, S. Hart, M. Yuzefpolskaya, P. Colombo, K. Takeda, D. Mancini, V. Topkara, P. Kurlansky, Y. Naka, H. Takayama. Department of Surgery, Columbia University Medical Center, New York, NY
- (576) *Detailed Endocardial Mapping Around the Left Ventricular Assist Device Inflow Cannula Facilitates Successful Ablation of Ventricular Tachycardia;***  
J. D. Moss<sup>1</sup>, A. Vohra<sup>2</sup>, J. H. Shin<sup>3</sup>, H. M. Nayak<sup>1</sup>, M. C. Burke<sup>1</sup>, N. Uriel<sup>1</sup>. <sup>1</sup>Section of Cardiology, University of Chicago, Chicago, IL, <sup>2</sup>Department of Medicine, University of Chicago, Chicago, IL, <sup>3</sup>Mid-Atlantic Permanente Medical Group, Upper Marlboro, MD
- (577) *Incidence of Gastrointestinal Bleeds in Patients With Continuous-Flow Left Ventricular Assist Devices Prescribed Serotonergic Agents;***  
J. Schultz<sup>1</sup>, H. Bream-Rouwenhorst<sup>1</sup>, R. Hobbs<sup>1</sup>, D. McDanel<sup>1</sup>, R. Tandon<sup>2</sup>, J. Goerbig-Campbell<sup>3</sup>. <sup>1</sup>Department of Pharmaceutical Care, The University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>2</sup>Department of Internal Medicine, The University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>3</sup>Department of Internal Medicine – Cardiovascular Care, The University of Iowa Hospitals and Clinics, Iowa City, IA
- (578) *Poor Pre-Operative Pulmonary Function Tests (PFTs) Do Not Predict Worse Outcomes in Patients Undergoing LVAD Placement;***  
F. Kamdar<sup>1</sup>, N. Sathnur<sup>1</sup>, D. Nieto<sup>2</sup>, A. Klaassen Kamdar<sup>1</sup>, K. Liao<sup>1</sup>, P. M. Eckman<sup>1</sup>, R. John<sup>1</sup>. <sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Baylor College of Medicine, Houston, TX
- (579) *Mechanical Circulatory Support Is Feasible and Safe as Bridge to Transplant for Patients With Restrictive and Hypertrophic Cardiomyopathy;***  
 S. Al-Kindi, M. Ige, S. Kumar, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH

- (580) *Histopathological Analysis of the Mitral Valve After Long-Term Mechanical Circulatory Support;***  
 H. Hata<sup>1</sup>, T. Fujita<sup>1</sup>, H. Ishibashi-Ueda<sup>2</sup>, T. Nakatani<sup>3</sup>, J. Kobayashi<sup>1</sup>.  
<sup>1</sup>Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>2</sup>Pathology, National Cerebral and Cardiovascular Center, Suita, Japan, <sup>3</sup>Transplantation, National Cerebral and Cardiovascular Center, Suita, Japan
- (581) *Medium-Term Circulatory Support for Cardiogenic Shock in a Developing Country: Do We Need a Long-Term Device?;***  
 M. A. Villavicencio<sup>1</sup>, V. Rossel<sup>2</sup>, R. Larrea<sup>1</sup>, J. P. Peralta<sup>1</sup>, E. Larrain<sup>1</sup>, J. S. Lim<sup>3</sup>, E. Donoso<sup>3</sup>, F. Gajardo<sup>3</sup>, M. Hurtado<sup>1</sup>. <sup>1</sup>Unidad de Trasplante, Clinica Davila, Santiago, Chile, <sup>2</sup>Departamento de Medicina, Universidad de Chile, Santiago, Chile, <sup>3</sup>Unidad de Trasplante, Instituto Nacional del Tórax, Santiago, Chile
- (582) *Subclinical Hemorrhagic Cerebral Lesions Are Prevalent in Patients With Long Term Continuous-Flow LVAD Support;***  
 D. Yoshioka<sup>1</sup>, K. Toda<sup>1</sup>, T. Nakamura<sup>1</sup>, S. Miyagawa<sup>1</sup>, Y. Yoshikawa<sup>1</sup>, S. Fukushima<sup>1</sup>, S. Saito<sup>1</sup>, T. Saito<sup>2</sup>, Y. Sawa<sup>1</sup>. <sup>1</sup>Cardiovascular surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, <sup>2</sup>Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- (583) *Device Geometry Does Not Predict Pump Thrombosis in HeartMate II Patients;***  
 J. J. Han<sup>1</sup>, A. C. Gaffey<sup>1</sup>, R. Sooppan<sup>1</sup>, G. Hung<sup>1</sup>, C. M. Venkataraman<sup>1</sup>, E. Phillips<sup>1</sup>, J. L. Howard<sup>1</sup>, M. A. Acker<sup>1</sup>, J. Eduardo Rame<sup>2</sup>, P. Atluri<sup>1</sup>. <sup>1</sup>Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Cardiology, Hospital of the University of Pennsylvania, Philadelphia, PA
- (584) *Left Ventricular Dimension Decrement Index Early After LVAD Implantation: A Novel Risk Marker for Late Pump Thrombosis;***  
 E. Joyce<sup>1</sup>, G. C. Stewart<sup>1</sup>, M. Hickey<sup>1</sup>, J. Rivero<sup>1</sup>, I. Gosev<sup>2</sup>, M. Leacche<sup>2</sup>, M. M. Givertz<sup>1</sup>, G. S. Couper<sup>2</sup>, M. R. Mehra<sup>1</sup>. <sup>1</sup>Cardiovascular Division, Department of Medicine, Brigham and Womens Hospital, Boston, MA, <sup>2</sup>Division of Cardiac Surgery, Brigham and Womens Hospital, Boston, MA
- (585) *Change of Left Atrial Pressure, LAP Measured With a Wireless Implantable Pressure Sensor (Titan Sensor) During Echocardiographic RAMP-Test in HeartMate II Patients;***  
 L. Hubbert<sup>1</sup>, J. Baranowski<sup>2</sup>, B. Delshad<sup>3</sup>, H. Ahn<sup>3</sup>. <sup>1</sup>Department of Cardiology, and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, <sup>2</sup>Department of Clinical Physiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, <sup>3</sup>Department of Thoracic and Vascular Surgery, and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden
- (586) *The Total Artificial Heart (TAH) Experience at Cedar Sinai Medical Center;***  
 K. J. Koomalsingh<sup>1</sup>, A. Kiankhooy<sup>1</sup>, D. Ramzy<sup>1</sup>, F. Esmailian<sup>1</sup>, A. Trento<sup>1</sup>, J. Moriguchi<sup>2</sup>, J. Kobashigawa<sup>2</sup>, F. Arabia<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Cedar Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Cardiology, Cedar Sinai Medical Center, Los Angeles, CA,
- (587) *Single Center, 23 Year Experience With PFO Management During HeartMate LVAD Implants;***  
 R. M. Adamson<sup>1</sup>, W. P. Dembitsky<sup>1</sup>, K. K. Limmer<sup>1</sup>, H. Mehta<sup>2</sup>, B. Jaski<sup>2</sup>, P. Hoagland<sup>2</sup>. <sup>1</sup>Cardiac Surgery, Sharp Memorial Hospital, San Diego, CA, <sup>2</sup>Cardiology, Sharp Memorial Hospital, San Diego, CA
- (588) *Does Gender Make a Difference After Total Artificial Heart Implantation?;***  
 F. Arabia<sup>1</sup>, L. Czer<sup>1</sup>, M. Kittleson<sup>1</sup>, E. Passano<sup>1</sup>, J. Yabuno<sup>1</sup>, F. Liou<sup>1</sup>, S. Siddiqui<sup>1</sup>, D. H. Chang<sup>1</sup>, D. Ramzy<sup>1</sup>, J. A. Kobashigawa<sup>1</sup>, J. Moriguchi<sup>1</sup>. Cedars-Sinai Heart Institute, Los Angeles, CA

- (589) *Dental Care in Left Ventricular Assist Devices (LVAD) Patients: A Survey of Dentists;***  
P. Kamdar<sup>1</sup>, F. Kamdar<sup>2</sup>, M. Roettger<sup>1</sup>, P. Eckman<sup>2</sup>. <sup>1</sup>Primary Dental Care, University of Minnesota, Minneapolis, MN, <sup>2</sup>Cardiology, University of Minnesota, Minneapolis, MN
- (590) *Renal Function Recover With Left Ventricular Assist Device Support;***  
A. Goodreau<sup>1</sup>, V. Kasirajan<sup>1</sup>, L. G. Wolfe<sup>1</sup>, G. Feldman<sup>2</sup>, M. A. Quader<sup>1</sup>. <sup>1</sup>Cardio-Thoracic Surgery, Virginia Commonwealth University, Richmond, VA, <sup>2</sup>Nephrology, Virginia Commonwealth University, Richmond, VA
- (591) *Preoperative and Postoperative Renal Dysfunction Is an Important Predictor of Survival After LVAD Implantation;***  
L. Harvey<sup>1</sup>, C. Holley<sup>1</sup>, S. Roy<sup>2</sup>, K. Majumder<sup>1</sup>, K. Liao<sup>3</sup>, P. Eckman<sup>2</sup>, R. John<sup>3</sup>. <sup>1</sup>Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Medicine, Division of Cardiology, University of Minnesota, Minneapolis, MN, <sup>3</sup>Surgery, Division of Cardiovascular Surgery, University of Minnesota, Minneapolis, MN
- (592) *Gastrointestinal Bleeding and Pump Thrombosis in Patients Receiving the INCOR Left Ventricular Assist Device: Results From a Retrospective Italian Multicenter Study;***  
A. Iacovoni<sup>1</sup>, P. Centofanti<sup>2</sup>, M. Attisani<sup>2</sup>, A. Verde<sup>3</sup>, M. Maiani<sup>4</sup>, A. Baronetto<sup>2</sup>, A. Terzi<sup>1</sup>, U. Livi<sup>4</sup>, M. Frigerio<sup>3</sup>, M. Rinaldi<sup>2</sup>. <sup>1</sup>Cardiovascular Department Ospedale Papa Giovanni XXIII, Bergamo, Italy, <sup>2</sup>Division of Cardiac Surgery - Città della Salute e della Scienza di Torino, Torino, Italy, <sup>3</sup>Cardiothoracic and Vascular Department, Niguarda Ca' Granda Hospital, Milan, Milano, Italy, <sup>4</sup>Cardiothoracic Department, University Hospital, Udine, Udine, Italy
- (593) *Multidisciplinary Treatment for Acute Fulminant and Nonfulminant Myocarditis;***  
S. Saito<sup>1</sup>, K. Toda<sup>1</sup>, T. Nakamura<sup>1</sup>, S. Miyagawa<sup>1</sup>, Y. Yoshikawa<sup>1</sup>, S. Fukushima<sup>1</sup>, D. Yoshioka<sup>1</sup>, T. Saito<sup>1</sup>, Y. Tsukamoto<sup>2</sup>, T. Ueno<sup>1</sup>, T. Kuratani<sup>1</sup>, Y. Sakata<sup>2</sup>, Y. Sawa<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Osaka University Graduate School of Medicine, Suita, Osaka, Japan, <sup>2</sup>Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Osaka, Japan
- (594) *Aortic Valve Interventions: Durability and Morbidity in Patients on Continuous Flow LVAD Support;***  
J. A. Cowger<sup>1</sup>, C. Salerno<sup>2</sup>, F. D. Pagani<sup>3</sup>, K. D. Aaronson<sup>4</sup>, F. Billia<sup>5</sup>, V. Rao<sup>6</sup>. <sup>1</sup>Cardiovascular Medicine, St. Vincent Heart Center of Indiana, Indianapolis, IN, <sup>2</sup>Cardiac Surgery, St. Vincent Heart Center of Indiana, Indianapolis, IN, <sup>3</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI, <sup>4</sup>Cardiovascular Medicine, University of Michigan, Ann Arbor, MI, <sup>5</sup>Cardiovascular Medicine, University of Toronto, Toronto, ON, Canada, <sup>6</sup>Cardiac Surgery, University of Toronto, Toronto, CA, Toronto, ON, Canada
- (595) *Bilateral Mini-Thoracotomy Versus Association of Upper-Mini-Sternotomy and Left Mini-Thoracotomy for LVAD Implantation: A Propensity Score Analysis;***  
J. Bejko, T. Bottio, M. Gallo, G. Bortolussi, R. Bianco, V. Tarzia, G. Gerosa. Cardiac Surgery, Padova, Italy
- (596) *Palliative Care Effectively Guides Transition to Inpatient Hospice, Home Hospice or Home Services for End-of-Life Care of LVAD Patients;***  
S. Nakagawa<sup>1</sup>, C. Blinderman<sup>1</sup>, B. Cagliostro<sup>1</sup>, M. Flannery<sup>1</sup>, V. K. Topkara<sup>2</sup>, K. Takeda<sup>3</sup>, H. Takayama<sup>3</sup>, Y. Naka<sup>3</sup>, P. C. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>. <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Medicine, Columbia University, New York, NY, <sup>3</sup>Surgery, Columbia University, New York, NY

**(597) *Demography and Outcome Data of the Bern VAD-Program Retrieved From the Euromacs Registry;***

M. Susac<sup>1</sup>, K. Zuk<sup>1</sup>, T. M. de By<sup>2</sup>, B. Gahl<sup>3</sup>, D. Reineke<sup>3</sup>, L. Englberger<sup>3</sup>, B. Hugi-Mayr<sup>3</sup>, J. Zuber-Zibung<sup>1</sup>, J. Gummert<sup>4</sup>, R. Hetzer<sup>5</sup>, P. J. Mohacsi<sup>1</sup>, T. Carrel<sup>3</sup>. <sup>1</sup>Cardiology, University Hospital, Bern, Switzerland, <sup>2</sup>Euromacs Association, Berlin, Germany, <sup>3</sup>Cardiovascular Surgery, University Hospital, Bern, Switzerland, <sup>4</sup>Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Center NRW, Ruhr University Bochum, Bad Oeynhausen, Germany, <sup>5</sup>German Heart Institute Berlin, Euromacs Association, Berlin, Germany

**(598) *Does Transvenous Lead Extraction Improve Outcomes for Ventricular Assist Device Patients?;***

I. Gosev<sup>1</sup>, M. Maytin<sup>2</sup>, J. I. Ejiolor<sup>1</sup>, M. Leacche<sup>1</sup>, S. McGurk<sup>1</sup>, R. M. John<sup>2</sup>, E. Joyce<sup>2</sup>, G. S. Couper<sup>1</sup>, L. M. Epstein<sup>2</sup>. <sup>1</sup>Surgery, Brigham and Women 's Hospital, Boston, MA, <sup>2</sup>Medicine, Brigham and Women 's Hospital, Boston, MA

**(599) *Extracorporeal Membrane Oxygenation for Concomitant Coronary Artery Bypass Grafting and Lung Transplantation;***

F. Ius<sup>1</sup>, W. Sommer<sup>1</sup>, I. Tudorache<sup>1</sup>, M. Avsar<sup>1</sup>, T. Siemeni<sup>1</sup>, J. Salman<sup>1</sup>, M. Greer<sup>2</sup>, J. Puntigam<sup>1</sup>, M. Hoeper<sup>2</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, C. Kühn<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hanover Medical School, Hanover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hanover Medical School, Hanover, Germany

**(600) *WITHDRAWN***

**(601) *The Amount of Blood Product Given During Left Ventricular Assist Device Implantation Is Not Associated With the Need for Right Ventricular Assist Device;***

E. Oliveros, F. Raza, R. Alvarez, D. Schwartz, D. Dries, P. Forfia, E. Tsai, L. Punnoose, A. Shiose, Y. Toyoda, A. Bove, E. Hamad. Temple University Hospital, Philadelphia, PA

**(602) *C-Pulse® System Extra-Aortic Counterpulsation for Heart Failure: Driveline Infections and Management;***

M. S. Slaughter<sup>1</sup>, R. Cecere<sup>2</sup>, B. Sun<sup>3</sup>, S. Huprikar<sup>4</sup>, H. Hotz<sup>5</sup>. <sup>1</sup>Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY, <sup>2</sup>Division of Cardiothoracic Surgery, McGill University Health Center, Montreal, QC, Canada, <sup>3</sup>Division of Cardiothoracic Surgery, Minneapolis Heart Institute Foundation, Minneapolis, MN, <sup>4</sup>Infectious Disease, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, <sup>5</sup>Cardiac Surgery, Cardio Centrum Berlin, Berlin, Germany

**(603) *Pre-Op Renal Failure Is Not Associated With Increased Mortality Following LVAD Implantation;***

K. R. Balsara<sup>1</sup>, A. Keith<sup>1</sup>, A. Abou El Ela<sup>1</sup>, S. M. Joseph<sup>2</sup>, G. A. Ewald<sup>2</sup>, S. C. Silvestry<sup>1</sup>, A. Itoh<sup>1</sup>. <sup>1</sup>Surgery, Washington University in St Louis, St Louis, MO, <sup>2</sup>Medicine, Washington University in St Louis, St Louis, MO

**(604) *The Use of Cardiac Resynchronization Therapy in Patients Supported By Continuous-Flow Left Ventricular Assist Device;***

A. R. Garan<sup>1</sup>, X. Mai<sup>1</sup>, A. P. Levine<sup>1</sup>, V. K. Topkara<sup>1</sup>, S. S. Thomas<sup>2</sup>, M. Yuzefpolskaya<sup>1</sup>, P. C. Colombo<sup>1</sup>, D. Mancini<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>, U. P. Jorde<sup>3</sup>, N. Uriel<sup>4</sup>. <sup>1</sup>Columbia University, New York, NY, <sup>2</sup>Harvard University, Boston, MA, <sup>3</sup>Montefiore Medical Center, New York, NY, <sup>4</sup>University of Chicago, Chicago, IL

**(605) *Sensitization and Changes in B Cell Subsets and Inflammatory Cytokines After VAD Implantation;***

M. H. Kwon<sup>1</sup>, J. M. Schaenman<sup>2</sup>, Y. Korin<sup>3</sup>, P. Rao<sup>3</sup>, N. Harre<sup>3</sup>, N. Wisniewski<sup>2</sup>, C. Krystal<sup>1</sup>, F. Kandarian<sup>3</sup>, T. Sidwell<sup>1</sup>, G. Bondar<sup>2</sup>, M. Cardeiras<sup>2</sup>, M. C. Deng<sup>2</sup>, E. F. Reed<sup>3</sup>. <sup>1</sup>Surgery, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>3</sup>Immunogenetics Center, David Geffen School of Medicine at UCLA, Los Angeles, CA

- (606) *Hepatic Function After Long-Term Continuous-Flow Left Ventricular Assist Device Support;***  
 J. Han<sup>1</sup>, K. Takeda<sup>1</sup>, H. Takayama<sup>1</sup>, P. A. Kurlansky<sup>1</sup>, P. C. Colombo<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, S. Fukuhara<sup>1</sup>, L. K. Truby<sup>1</sup>, V. K. Topkara<sup>2</sup>, D. M. Mancini<sup>2</sup>, Y. Naka<sup>1</sup>. <sup>1</sup>Department of Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Department of Medicine, Columbia University Medical Center, New York, NY
- (607) *Ability to Obtain Blood Pressure Readings By Standard Automated Blood Pressure Monitor Helps Interpreting the Relationship Between Doppler Blood Pressure to Systolic Blood Pressure and Mean Arterial Pressure;***  
 P. C. Colombo<sup>1</sup>, K. Orlanes<sup>2</sup>, G. Lanier<sup>3</sup>, M. Yuzefpolskaya<sup>1</sup>, M. Flannery<sup>2</sup>, R. Te-Frey<sup>2</sup>, Y. Hayashi<sup>1</sup>, K. Wong<sup>1</sup>, M. M. Ahmad<sup>1</sup>, D. M. Mancini<sup>1</sup>, N. Uriel<sup>4</sup>, U. P. Jorde<sup>5</sup>, V. K. Topkara<sup>1</sup>, K. Takeda<sup>2</sup>, H. Takayama<sup>2</sup>, Y. Naka<sup>2</sup>, R. T. Demmer<sup>6</sup>. <sup>1</sup>Medicine, Columbia University, New York, NY, <sup>2</sup>Surgery, Columbia University, New York, NY, <sup>3</sup>Medicine, Westchester Medical Center, Valhalla, NY, <sup>4</sup>Medicine, University of Chicago, Chicago, IL, <sup>5</sup>Medicine, Montefiore Medical Center, Bronx, NY, <sup>6</sup>Epidemiology, Columbia University, New York, NY
- (608) *Development of Pulmonary Hypertension in Patients With Left-Ventricular Assist Devices: Are Frequent Hemodynamic Assessments While on Transplant List Really Necessary?;***  
 R. J. Kalathiya<sup>1</sup>, B. A. Houston<sup>2</sup>, J. Chaisson<sup>1</sup>, G. R. Stevens<sup>2</sup>, C. Sciortino<sup>3</sup>, G. J. Whitman<sup>3</sup>, A. S. Shah<sup>3</sup>, S. D. Russell<sup>2</sup>, R. J. Tedford<sup>2</sup>. <sup>1</sup>Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, <sup>2</sup>Division of Cardiology, Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, <sup>3</sup>Department of Cardiac Surgery, Johns Hopkins Hospital, Baltimore, MD
- (609) *The Effect of Exercise and Resistance Training on Physical Capacity of LVAD Patients – Analysis of Different Age Groups;***  
 N. Reiss<sup>1</sup>, P. Bartsch<sup>1</sup>, M. Altesellmeier<sup>1</sup>, A. Workowski<sup>1</sup>, S. Schulte-Eistrup<sup>1</sup>, H. Warnecke<sup>1</sup>, J. Schmitto<sup>2</sup>, A. Haverich<sup>2</sup>, D. Willemsen<sup>1</sup>. <sup>1</sup>Schuechtermann Clinic Bad Rothenfelde, Bad Rothenfelde, Germany, <sup>2</sup>Medizinische Hochschule, Hannover, Germany
- (610) *Hemodynamic Performance and Early Clinical Result, EVAHEART and HeartMate II;***  
 Y. Matsumoto<sup>1</sup>, T. Fujita<sup>1</sup>, H. Hata<sup>1</sup>, Y. Shimahara<sup>1</sup>, S. Sato<sup>1</sup>, O. Seguchi<sup>2</sup>, T. Nakatani<sup>2</sup>, J. Kobayashi<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan, <sup>2</sup>Transplantation, National Cerebral and Cardiovascular Center, Osaka, Suita, Japan
- (611) *Similar Pressure and Volume Unloading With Different Geometrical Changes Between HVAD and HMII Detected During Hemodynamics 3D Echo Ramp Studies;***  
 N. Uriel<sup>1</sup>, G. T. Sayer<sup>1</sup>, K. Addetia<sup>1</sup>, S. Fedson<sup>1</sup>, K. Collins<sup>1</sup>, G. Kim<sup>1</sup>, E. Kruse<sup>1</sup>, C. Juricek<sup>2</sup>, D. Rodgers<sup>1</sup>, T. Ota<sup>2</sup>, V. Jeevanandam<sup>2</sup>, R. Lang<sup>1</sup>. <sup>1</sup>Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Surgery, University of Chicago, Chicago, IL
- (612) *Outcomes and Predictors of 30-Day and Long-Term Mortality in Case of Cardiopulmonary Resuscitation Requiring Extracorporeal Life Support in the Elderly;***  
 M. Pontailier, P. Demondion, G. Lebreton, P. Leprince. Department of Thoracic & Cardio-Vascular Surgery, Pitié Salpêtrière Hospital, Paris, France
- (613) *Multidisciplinary Approach to Managing GI Bleeding in the LVAD Population;***  
 L. H. Adcock<sup>1</sup>, A. Yehya<sup>2</sup>, T. Hrobowski<sup>2</sup>, K. McCants<sup>2</sup>, D. A. Dean<sup>1</sup>, R. Yanda<sup>3</sup>, P. Stewart<sup>3</sup>. <sup>1</sup>Surgery, Piedmont Heart, Atlanta, GA, <sup>2</sup>Advanced Heart Failure, Piedmont Heart, Atlanta, GA, <sup>3</sup>Digestive Healthcare of Georgia, Atlanta, GA

- (614)** *CentriMag Short Term Ventricular Assist Device as a Bridge to Decision in Critical Cardiogenic Shock (INTERMACS 1) – The Manchester Experience;*  
 S. F. Hashmi, J. Hasan, K. Oommen, S. Shaw, S. G. Williams, N. Yonan, R. V. Venkateswaran. The Transplant Centre, University Hospital of South Manchester, Manchester, United Kingdom
- (615)** *The Effect of Severity of Renal Dysfunction on Clinical Outcomes in Patients With Continuous-Flow Left Ventricular Assist Device Implantation;*  
 M. Pinninti, C. Rivera, C. Cho, V. Thohan, T. Hastings, O. Cheema, F. Downey, J. Crouch, E. Weiss, N. Sulemanjee. Aurora St. Luke's Medical Center, Milwaukee, WI
- (616)** *Long-Term Ventricular Assist Device vs. Inotropic Therapy as a Bridge to Transplant in Heart Failure Patients With Pulmonary Hypertension and High Pulmonary Vascular Resistance: Pulmonary Hemodynamic and Post-Transplant Outcomes;*  
 C. Kunavarapu<sup>1</sup>, B. Menchaca<sup>2</sup>, A. Lonning<sup>2</sup>, M. Lopez<sup>2</sup>, A. Mehr<sup>3</sup>, M. Kwan<sup>1</sup>. <sup>1</sup>Advanced Heart Failure and Transplant, Texas Transplant Institute, San Antonio, TX, <sup>2</sup>Methodist Heart Hospital, San Antonio, TX, <sup>3</sup>Cardiology, University of Texas Health Science Center San Antonio, San Antonio, TX
- (617)** *Time-Dependent Gene Network Analysis Suggests Orchestrated Stage-Specific PMBC-Response to Injury in Mechanical Circulatory Support Related Organ Dysfunction Syndrome;*  
 N. Wisniewski<sup>1</sup>, G. Bondar<sup>1</sup>, M. Cadeiras<sup>1</sup>, Y. Korin<sup>2</sup>, J. Schaenman<sup>3</sup>, E. Chang<sup>1</sup>, M. Bakir<sup>1</sup>, J. Chittoor<sup>1</sup>, J. Maque<sup>1</sup>, V. Groyberg<sup>1</sup>, C. Starling<sup>1</sup>, M. Kwon<sup>1</sup>, X. Chan<sup>1</sup>, P. Ping<sup>1</sup>, E. Reed<sup>2</sup>, M. Deng<sup>1</sup>. <sup>1</sup>Department of Medicine (Cardiology), University of California, Los Angeles, Los Angeles, CA, <sup>2</sup>Department of Pathology, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>Department of Medicine (Microbiology), University of California, Los Angeles, Los Angeles, CA
- (618)** *Does the Specific Type of Caregiver Impact Readmission After Mechanical Circulatory Support Device Placement?;*  
 H. Henry, F. Arabia, M. Kittleson, L. Czer, E. Passano, J. Yabuno, S. Siddiqui, E. Antifantis, D. H. Chang, J. A. Kobashigawa, J. Moriguchi. Cedars-Sinai Heart Institute, Los Angeles, CA
- (619)** *Simple RVOT Doppler Measurements in Addition to Hemodynamic Variables Can Help Identify Need for RVAD at Time of LVAD Placement;*  
 F. Raza, E. Oliveros, A. Mirza, P. Forfia, D. Schwartz, D. Dries, E. Tsai, L. Punnoose, A. Shiose, Y. Toyoda, R. Alvarez, A. Bove, E. Hamad. Cardiovascular Disease, Temple University Hospital, Philadelphia, PA
- (620)** *Extracorporeal Membrane Oxygenation Is an Effective Bridge Strategy to Rescue Cardiovascular Collapse for Subsequent Transplant, Ventricular Assist Device, or Recovery;*  
 A. C. Gaffey<sup>1</sup>, N. Desai<sup>1</sup>, S. F. Lazar<sup>1</sup>, F. H. Mccarthy<sup>1</sup>, J. Han<sup>1</sup>, R. Soopan<sup>1</sup>, C. Venkataraman<sup>1</sup>, K. McDermott<sup>1</sup>, G. Hung<sup>1</sup>, J. Wald<sup>2</sup>, J. Gutsche<sup>3</sup>, M. A. Acker<sup>1</sup>, P. Atrui<sup>1</sup>. <sup>1</sup>Division of Cardiovascular Surgery, Department of Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, <sup>3</sup>Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA
- (621)** *Impella 5.0 as a Bridge to Cardiac Transplantation or Durable Left Ventricular Assist Device;*  
 S. A. Hall, B. Lima, P. Kale, J. J. Kuiper, S. Carey, A. E. Shafii, T. Chamogeorgakis, G. V. Gonzalez-Stawinski. Baylor University Medical Center, Dallas, TX

- (622) *Comparison of GI Bleeding Rates Between Axial Flow and Centrifugal Flow LVADs;***  
 F. H. Sheikh<sup>1</sup>, D. T. Majure<sup>1</sup>, J. Salcedo<sup>2</sup>, M. Hofmeyer<sup>1</sup>, G. Ruiz<sup>1</sup>, M. E. Rodrigo<sup>1</sup>, T. Elliott<sup>1</sup>, E. J. Molina<sup>1</sup>, S. W. Boyce<sup>1</sup>, S. S. Najjar<sup>1</sup>. <sup>1</sup>Med-Star Heart Institute, Washington, DC, <sup>2</sup>MedStar Washington Hospital Center, Washington, DC
- (623) *Long-Term Valvular Function and Outcomes Following Left Ventricular Assist Device Implantation: Is an Aggressive Approach Warranted?;***  
 E. A. Gillaspie<sup>1</sup>, S. Dunlay<sup>2</sup>, S. Sharma<sup>1</sup>, S. Maltais<sup>3</sup>, L. D. Joyce<sup>1</sup>, D. L. Joyce<sup>1</sup>, R. C. Daly<sup>1</sup>, J. M. Stulak<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>3</sup>Cardiac Surgery, Vanderbilt Heart and Vascular Surgery, Nashville, TN
- (624) *Recurrent Ventricular Tachycardia After Implantation of a Left Ventricular Assist Device: Is an Endocardial Ablation an Option?;***  
 J. Fischer<sup>1</sup>, A. L. Meyer<sup>1</sup>, S. Lehmann<sup>1</sup>, S. Eifert<sup>1</sup>, A. Arya<sup>2</sup>, G. Hindricks<sup>2</sup>, F. W. Mohr<sup>1</sup>, J. Garbade<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University Leipzig Heartcenter, Leipzig, Germany, <sup>2</sup>Electrophysiology, University Leipzig Heartcenter, Leipzig, Germany
- (625) *A Patient-Specific Risk Model for Predicting Major Bleeding, Thromboembolic Events and Mortality After a Continuous Flow Left Ventricular Assist Device (CF-LVAD);***  
 N. A. Loghmanpour<sup>1</sup>, J. F. Antaki<sup>1</sup>, P. M. Eckman<sup>2</sup>. <sup>1</sup>Biomedical Engineering, Carnegie Mellon University, Pittsburgh, PA, <sup>2</sup>Cardiovascular Division, University of Minnesota, Minneapolis, MN
- (626) *Experience With Temporary RVAD Support in Patients Receiving the HVAD Left Ventricular Assist Device;***  
 A. Schaefer, A. Bernhardt, M. Silaschi, M. J. Barten, F. M. Wagner, H. Reichensperner, T. Deuse. Department of Cardiovascular Surgery, University Heart Center Hamburg, Hamburg, Germany
- (627) *Prior Sternotomy Does Not Affect Short and Long-Term Ventricular Assist Device Outcomes;***  
 R. Sooppan<sup>1</sup>, J. Han<sup>1</sup>, A. Gaffey<sup>1</sup>, P. Patel<sup>1</sup>, G. Hung<sup>1</sup>, J. Howard<sup>1</sup>, E. Phillips<sup>1</sup>, M. Acker<sup>1</sup>, J. Rame<sup>2</sup>, P. Atluri<sup>1</sup>. <sup>1</sup>Department of Surgery, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Department of Cardiology, University of Pennsylvania, Philadelphia, PA
- (628) *Concomitant Surgical Valve Procedures in Patients Undergoing LVAD Implantation;***  
 T. Haber<sup>1</sup>, J. Riebandt<sup>1</sup>, T. Schloeglhofer<sup>2</sup>, S. Mahr<sup>1</sup>, D. Wiedemann<sup>1</sup>, K. Dimitrov<sup>1</sup>, P. Simon<sup>1</sup>, G. Laufer<sup>1</sup>, D. Zimpfer<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria

**NURSING, HEALTH SCIENCE**

**AND ALLIED HEALTH**

(Agora 2)

**(NNSAH, HF, HTX, LF, LTX, MCS, PEDS)**

- (629) *Distractions During Lung Transplantation Surgery – Do Interruptions Matter?***  
 L. P. Ong, S. Kuravelli, S. Chan, N. Collins, T. Butt, S. C. Clark. Cardiothoracic Surgery, Freeman Hospital, Newcastle upon Tyne, United Kingdom
- (630) *Red Wine Consumption Is Linked to Clinical Improvement and Delisting From the Heart Transplant Waiting List;***  
 H. Spaderna<sup>1</sup>, C. Ziegler<sup>2</sup>, S. Hellwig<sup>2</sup>, J. M. Smits<sup>3</sup>, G. Weidner<sup>4</sup>.  
<sup>1</sup>Health Psychology, University of Trier, Trier, Germany, <sup>2</sup>Health Psychology and Applied Psychological Assessment, University of Wuppertal, Wuppertal, Germany, <sup>3</sup>Eurotransplant International Foundation, Leiden, Netherlands, <sup>4</sup>Biology, San Francisco State University, San Francisco, CA
- (631) WITHDRAWN**
- (632) *Anticoagulation for VAD Patients: Can We Implement an Algorithm for Home Management Safely?***  
 K. Vandersmissen, H. Bollen, J. Driesen, K. Van den Bossche, F. Rega, W. Droogne, B. Meyns. Department Cardiac Surgery, UZLeuven, Leuven, Belgium
- (633) *Variability in Health Care Workers' Practice Patterns and Heart Transplant Patients' Medication Adherence Across 11 Countries – The BRIGHT Study;***  
 S. Scalco de Almeida<sup>1</sup>, L. Berben<sup>1</sup>, E. Baumgartner<sup>1</sup>, K. Denhaerynck<sup>1</sup>, F. Dobbels<sup>2</sup>, C. Russell<sup>3</sup>, S. M. De Geest<sup>1</sup>. <sup>1</sup>Institute of Nursing Science, University of Basel, Basel, Switzerland, <sup>2</sup>Health Services Research, KU Leuven, Leuven, Belgium, <sup>3</sup>School of Nursing, University of Missouri-Kansas City, Kansas City, MO
- (634) *Clinical and Gender Differences in Heart Transplant Recipients in the New Heart Study;***  
 K. T. Hickey<sup>1</sup>, L. V. Doering<sup>2</sup>, B. Chen<sup>2</sup>, E. V. Carter<sup>3</sup>, D. Pickham<sup>4</sup>, C. Castillo<sup>1</sup>, D. M. Mancini<sup>5</sup>, M. Deng<sup>6</sup>, J. Kobashigawa<sup>7</sup>, B. J. Drew<sup>8</sup>.  
<sup>1</sup>Cardiology, Columbia University, New York, NY, <sup>2</sup>School of Nursing, University of California, Los Angeles, Los Angeles, CA, <sup>3</sup>School of Nursing, University of California, San Francisco, San Francisco, CA, <sup>4</sup>Department of Medicine, Stanford School of Medicine, Stanford, CA, <sup>5</sup>Department of Medicine, Columbia University, New York, NY, <sup>6</sup>Cardiology, Ronald Reagan UCLA Medical Center, Santa Monica, CA, <sup>7</sup>Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>8</sup>Department of Physiological Nursing, University of California, San Francisco, San Francisco, CA
- (635) *Parental Role in Care of Long Term Hospitalized Patients and Impact on Attachment and Development;***  
 P. A. Kofflin, L. M. Johnson, R. K. Ameduri. Department of Pediatrics, University of Minnesota, Minneapolis, MN
- (636) *Care After Heart Transplant, No One Better Than Family: Wrong;***  
 E. Stimpson, T. Kao, L. Kim, S. Morrison, J. Patel, M. Kittleson, F. Liou, S. Siddiqui, J. Yabuno, L. Czer, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA



- (637) *A Novel Sternal Instability Assessment Tool for Use Post Lung Transplant: Reliability and Early Results;***  
 L. Fuller<sup>1</sup>, D. El-Ansary<sup>2</sup>, B. Button<sup>1</sup>, J. Bondarenko<sup>1</sup>, S. Marasco<sup>3</sup>, J. Gooi<sup>4</sup>, G. Snell<sup>5</sup>, A. Holland<sup>6</sup>. <sup>1</sup>Physiotherapy Department, The Alfred Hospital, Melbourne, Australia, <sup>2</sup>Physiotherapy Department, The University of Melbourne, Melbourne, Australia, <sup>3</sup>Cardiothoracic Surgery Department, The Alfred Hospital, Melbourne, Australia, <sup>4</sup>Cardiothoracic Surgery Department, The Alfred Hospital, Melbourne, Australia, <sup>5</sup>Lung Transplant Department, The Alfred Hospital, Melbourne, Australia, <sup>6</sup>Physiotherapy Department, LaTrobe University, The Alfred Hospital, Melbourne, Australia
- (638) *Observational Study on Changes in BMI Post Non-CF Lung Transplantation Over a 3 Year Period;***  
 R. Patel, M. Carby, A. Simon, A. Reed. Royal Brompton and Harefield Hospital NHS Trust, Middlesex, United Kingdom
- (639) *Rate of Conversion From Destination LVAD to Bridge-to-Transplant – A Single Center Experience;***  
 D. Eck, M. A. Wigger. Heart Transplant, Vanderbilt Medical Center, Nashville, TN
- (640) *Predictors and Outcomes of Sleep Quality the First Year After Lung Transplantation;***  
 A. Fatigati<sup>1</sup>, M. Alrawashdeh<sup>2</sup>, A. DeVito Dabbs<sup>2</sup>, J. Zaldonis<sup>2</sup>, C. Bermudez<sup>3</sup>. <sup>1</sup>Acute Care, The University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Acute Care, The University of Pittsburgh School of Nursing, Pittsburgh, PA, <sup>3</sup>Division of Cardiothoracic Transplantation, The University of Pittsburgh School of Medicine, Pittsburgh, PA
- (641) *Factors Associated With Behavioral and Emotional Symptoms in School-Aged Youth After Pediatric Heart Transplantation: Preliminary Findings;***  
 C. White-Williams<sup>1</sup>, P. Fazeli<sup>1</sup>, A. Crosswy<sup>1</sup>, M. Hubbard<sup>2</sup>, J. Kirklín<sup>1</sup>. <sup>1</sup>University of Alabama, Birmingham, AL, <sup>2</sup>Children's of Alabama Hospital, Birmingham, AL
- (642) *Quality of Life and Associated Factors in Patients 3 Months After Left Ventricular Assist Device Implantation;***  
 N. Kato<sup>1</sup>, T. Jaarsma<sup>1</sup>, I. Okada<sup>2</sup>, T. Imamura<sup>2</sup>, Y. Kagami<sup>3</sup>, M. Endo<sup>3</sup>, M. Ono<sup>4</sup>, K. Kinugawa<sup>2</sup>. <sup>1</sup>Social and Welfare Studies, Linköping University, Norrköping, Sweden, <sup>2</sup>Therapeutic Strategy for Heart Failure, The University of Tokyo Graduate School of Medicine, Tokyo, Japan, <sup>3</sup>Organ Transplantation, The University of Tokyo Hospital, Tokyo, Japan, <sup>4</sup>Cardiovascular Surgery, The University of Tokyo Graduate School of Medicine, Tokyo, Japan
- (643) *SES, Clinical, and Psychological Factors Are Associated With Trajectories of Self-Care Agency Over the First Year After Lung Transplant;***  
 L. Hu, A. DeVito Dabbs, S. M. Sereika, J. H. Lingler, Y. Zheng, M. A. Dew, C. Bermudez. University of Pittsburgh, Pittsburgh, PA
- (644) *Biological Underpinnings of the Reduction in Heart Failure Symptoms With Mechanical Circulatory Support;***  
 C. S. Lee<sup>1</sup>, J. O. Mudd<sup>1</sup>, J. M. Gelow<sup>1</sup>, C. V. Chien<sup>1</sup>, S. O. Hiatt<sup>1</sup>, K. L. Grady<sup>2</sup>. <sup>1</sup>Oregon Health & Science University, Portland, OR, <sup>2</sup>Feinberg School of Medicine, Northwestern University, Chicago, IL
- (645) *Cognitive Functioning Among De Novo Heart Transplant Recipients on Everolimus-Based Immunosuppression;***  
 B. S. Bürker<sup>1</sup>, S. Andersson<sup>1</sup>, L. Gullestad<sup>2</sup>, E. Gude<sup>2</sup>, A. Relbo<sup>2</sup>, I. Grov<sup>2</sup>, U. F. Malt<sup>3</sup>, A. K. Andreassen<sup>2</sup>, A. E. Fiane<sup>4</sup>, I. H. Haraldsen<sup>1</sup>. <sup>1</sup>Department of Psychosomatic Medicine, Oslo University Hospital – Rikshospitalet, Oslo, Norway, <sup>2</sup>Department of Cardiology, Oslo University Hospital – Rikshospitalet, Oslo, Norway, <sup>3</sup>Department of Research and Education, Oslo University Hospital – Rikshospitalet, Oslo, Norway, <sup>4</sup>Department of Thoracic Surgery, Oslo University Hospital – Rikshospitalet, Oslo, Norway
- (646) *A Randomized Controlled Trial to Assess the Effect of Mindfulness Based Stress Reduction (MBSR) on Stress and Anxiety in Caregivers of Lung Transplant Patients;***  
 A. J. Haines<sup>1</sup>, A. M. Blazek<sup>1</sup>, L. Hoffman<sup>1</sup>, J. Choi<sup>1</sup>, K. Spadaro<sup>2</sup>. <sup>1</sup>Nursing, Acute and Tertiary Care, Univ Pittsburgh Sch Nursing, Pittsburgh, PA, <sup>2</sup>Nursing, Chatham University, Pittsburgh, PA

**(647) *Emotional/Social and Illness-related Factors Influence Eating Behavior in NYHA Class III and IV Heart Failure Patients;***

J. Salyer<sup>1</sup>, M. Flattery<sup>2</sup>, M. Maltby<sup>3</sup>, S. Weinland<sup>4</sup>, K. Shah<sup>5</sup>. <sup>1</sup>Adult Health, VCU School of Nursing & Health System, Richmond, VA, <sup>2</sup>Heart Failure/Transplant Program, VCU Health System, Richmond, VA, <sup>3</sup>Social Work, VCU Health System, Richmond, VA, <sup>4</sup>Psychiatry, MCV School of Medicine & VCU Health System, Richmond, VA, <sup>5</sup>Heart failure/Transplant Program, MCV School of Medicine & VCU Health System, Richmond, VA

**(648) *Patient/Doctor Talk Time During High-Quality in Advanced Heart Failure Indicative of Doctor's Perception of How Well Patient Is Doing;***

F. Raia<sup>1</sup>, L. Robinson<sup>2</sup>, S. Lee<sup>1</sup>, C. Alvarenga<sup>1</sup>, V. M. Rivera<sup>2</sup>, D. Nguyen<sup>2</sup>, J. S. Mistry<sup>1</sup>, G. Tellez<sup>2</sup>, A. Garfinkel<sup>1</sup>, M. Deng<sup>3</sup>. <sup>1</sup>Education and Medicine, UCLA, Los Angeles, CA, <sup>2</sup>Education, UCLA, Los Angeles, CA, <sup>3</sup>Medicine, UCLA, Los Angeles, CA



## PHARMACY AND PHARMACOLOGY

(Agora 2)

(PHARM, ID, LTX, MCS)

- (649)** *The Effect of Dornase Alfa (rhDNase) on Recurrent Gram Negative Infections in Adult Cystic Fibrosis Lung Transplant Recipients;*  
L. J. Stuckey<sup>1</sup>, A. M. Clark<sup>1</sup>, S. Chang<sup>2</sup>, K. M. Chan<sup>3</sup>, C. E. Bartos<sup>4</sup>, T. C. Ojo<sup>3</sup>. <sup>1</sup>Pharmacy Services, University of Michigan Hospital and Health Systems, Ann Arbor, MI, <sup>2</sup>College of Pharmacy, University of Michigan, Ann Arbor, MI, <sup>3</sup>Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan Hospital and Health Systems, Ann Arbor, MI, <sup>4</sup>Transplant Center, University of Michigan Hospital and Health Systems, Ann Arbor, MI
- (650)** *The Addition of a Specialist Pharmacist to Heart Transplant and Ventricular Assist Device Clinics – Early Trends in Patient Care;*  
R. M. Gellatly, C. Livingstone, P. Bergin. Alfred Hospital, Melbourne, Australia
- (651)** *Posaconazole Delayed Release Tablets for Antifungal Prophylaxis in Lung Transplant Patients;*  
J. M. Kozuch<sup>1</sup>, A. A. Feist<sup>1</sup>, G. Yung<sup>2</sup>, L. Awdishu<sup>1</sup>, R. F. Boettger<sup>3</sup>, S. R. Hays<sup>4</sup>. <sup>1</sup>Department of Pharmacy, UC San Diego Health System, San Diego, CA, <sup>2</sup>Division of Pulmonary Critical Care, UC San Diego Health System, San Diego, CA, <sup>3</sup>Department of Pharmacy, University of California, San Francisco Medical Center, San Francisco, CA, <sup>4</sup>Division of Pulmonary Medicine, University of California, San Francisco Medical Center, San Francisco, CA
- (652)** *Serial Monitoring of Plasma Voriconazole Levels in Lung Transplant Recipients: Results From a Single Centre Experience;*  
H. Lyster, S. Soresi, N. Leaver, A. Hall, A. Simon, A. Reed, M. Carby. Royal Brompton & Harefield NHS Foundation Trust, Middlesex, United Kingdom
- (653)** *Influence of Pantoprazole Dosages on Azole Plasma Concentrations in Lung Transplant Recipients;*  
D. Stelzer<sup>1</sup>, F. Ihle<sup>2</sup>, A. Weber<sup>3</sup>, N. Kneidinger<sup>2</sup>, T. Meis<sup>2</sup>, G. Zimmermann<sup>2</sup>, R. Schramm<sup>4</sup>, H. Winter<sup>5</sup>, L. Frey<sup>6</sup>, M. Vogeser<sup>7</sup>, M. Andraschko<sup>3</sup>, J. Behr<sup>2</sup>, C. Neurohr<sup>2</sup>. <sup>1</sup>Department of Internal Medicine V / Hospital Pharmacy, University of Munich, Munich, Germany, <sup>2</sup>Department of Internal Medicine V, University of Munich, Munich, Germany, <sup>3</sup>Hospital Pharmacy, University of Munich, Munich, Germany, <sup>4</sup>Department of Cardiac Surgery, University of Munich, Munich, Germany, <sup>5</sup>Department of Thoracic Surgery, University of Munich, Munich, Germany, <sup>6</sup>Department of Anesthesiology, University of Munich, Munich, Germany, <sup>7</sup>Institute of Laboratory Medicine, University of Munich, Munich, Germany
- (654)** *Rescue Alemtuzumab for Refractory Acute Cellular Rejection and Bronchiolitis Obliterans Syndrome After Lung Transplantation at a Single High-Volume Center;*  
L. C. Rihtarchik, J. F. McDyer, A. Zeevi, J. M. Pilewski, M. Crespo, B. A. Johnson, A. Lichvar, C. Bermudez, R. B. Smith, C. R. Ensor. University of Pittsburgh, Pittsburgh, PA

THURSDAY | April 16, 2015

**POSTER SESSION 2** (Agora 2)

Poster presenters and moderators will be present during the evening poster viewing session from 6:00 pm – 7:00 pm.

**ADULT LUNG FAILURE**

(Agora 2)

(LF, BSI, DMD, LTX, MCS)

**(655) *Clinical Factors Associated With Chronic Lung Allograft Dysfunction (CLAD) in the Swiss Transplant Cohort Study (STCS);***

A. Koutsokera<sup>1</sup>, C. Benden<sup>2</sup>, P. M. Socal<sup>3</sup>, J. P. Antonietti<sup>1</sup>, L. P. Nicod<sup>4</sup>, J. D. Aubert<sup>5</sup>. <sup>1</sup>Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland, <sup>2</sup>Division of Pulmonary Medicine, University Hospital Zurich, Zurich, Switzerland, <sup>3</sup>Respiratory Medicine Department, University Hospital of Geneva (HUG), Geneva, Switzerland, <sup>4</sup>Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV) and SysCLAD (Systems Prediction of Chronic Lung Allograft Dysfunction) Study, Lausanne, Switzerland, <sup>5</sup>Respiratory Medicine Department, Centre Hospitalier Universitaire Vaudois (CHUV) and Swiss Transplant Cohort Study (STCS), Lausanne, Switzerland

**(656) *Improved Outcomes Amongst High Risk Lung Transplant Patients at High Volume Centers: A Case for Regionalization in the US;***

J. C. Grimm<sup>1</sup>, J. Magruder<sup>1</sup>, A. Kilic<sup>1</sup>, V. Valero, <sup>3rd</sup>, S. P. Dungan<sup>1</sup>, P. D. Shah<sup>2</sup>, L. L. Silhan<sup>2</sup>, C. A. Merlo<sup>2</sup>, A. S. Shah<sup>1</sup>. <sup>1</sup>Surgery, The Johns Hopkins Medical Institution, Baltimore, MD, <sup>2</sup>Medicine, The Johns Hopkins Medical Institution, Baltimore, MD

**(657) *Aerosolized Liposomal Cyclosporine A in the Prevention of Bronchiolitis Obliterans Syndrome Following Lung Transplantation;***

C. Neurohr<sup>1</sup>, V. Monforte<sup>2</sup>, C. Knoop<sup>3</sup>, P. Jaksch<sup>4</sup>, J. Parmar<sup>5</sup>, P. Ussetti<sup>6</sup>, A. Sole<sup>7</sup>, J. Müller-Quernheim<sup>8</sup>, J. Borro<sup>9</sup>, R. Kessler<sup>10</sup>, H. Wirtz<sup>11</sup>, J. Behr<sup>1</sup>. <sup>1</sup>Department of Internal Medicine V, University of Munich - Campus Grosshadern, Munich, Germany, <sup>2</sup>Hospital Universitari Vall d'Hebron, Barcelona, Spain, <sup>3</sup>Université Libre de Bruxelles, Brussels, Belgium, <sup>4</sup>University of Vienna, Vienna, Austria, <sup>5</sup>Papworth Hospital, Papworth, United Kingdom, <sup>6</sup>Universitario Puerta de Hierro, Madrid, Spain, <sup>7</sup>Hospital Universitario La Fe, Valencia, Spain, <sup>8</sup>Medical University Hospital, Freiburg, Germany, <sup>9</sup>Complejo Hospitalario Universitario, La Coruna, Spain, <sup>10</sup>Hospitiaux Universitaires de Strasbourg, Strasbourg, France, <sup>11</sup>Medical University Leipzig, Leipzig, Germany

**(658) *Incidence, Management, and Outcome of Non-Anastomotic Stenoses After Lung Transplantation;***

N. M. Mollberg, E. Howell, A. Cheng, M. S. Mulligan. University of Washington, Seattle, WA

**(659) *Survival After Lung Transplant in Alpha-1-Antitrypsin Deficiency Recipients Compared to Other Forms of Chronic Obstructive Pulmonary Disease;***

B. C. Gulack<sup>1</sup>, A. M. Ganapathi<sup>1</sup>, P. J. Speicher<sup>1</sup>, G. Chery<sup>2</sup>, L. D. Snyder<sup>3</sup>, R. D. Davis<sup>1</sup>, M. G. Hartwig<sup>1</sup>. <sup>1</sup>Department of General Surgery, Duke University, Durham, NC, <sup>2</sup>Duke University, Durham, NC, <sup>3</sup>Department of Medicine, Duke University, Durham, NC

- (660) Combined Cytomegalovirus Prophylaxis in Lung Transplantation: A Single Center Experience;**  
F. Calabrese, E. Perissinotto, M. Damin, M. Loy, A. Rebusso, G. Marulli, F. Lunardi, E. Balestro, M. Schiavon, N. Nannini, S. Vuljan, F. Rea. Dept of Cardiothoracic and Vascular Sciences, University of Padova, Padova, Italy
- (661) Everolimus for Calcineurin-Inhibitor Minimization in Lung Transplant Recipients With Chronic Renal Insufficiency: Four-Year Outcomes;**  
K. E. Schoeppler<sup>1</sup>, D. M. Lyu<sup>2</sup>, K. M. Vandervest<sup>2</sup>, T. J. Grazia<sup>2</sup>, J. T. Crossno, Jr<sup>2</sup>, M. R. Zamora<sup>2</sup>. <sup>1</sup>Pharmacy, University of Colorado Hospital, Aurora, CO, <sup>2</sup>Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, Aurora, CO
- (662) Combined Liver-Thoracic Transplantation: Single-Center Experience Within the European Perspective;**  
L. J. Ceulemans<sup>1</sup>, S. Strypstein<sup>1</sup>, D. Ruttens<sup>2</sup>, S. Verleden<sup>2</sup>, D. Monbaliu<sup>3</sup>, P. De Leyn<sup>4</sup>, A. Neyrinck<sup>5</sup>, J. Vanhaecke<sup>6</sup>, B. Meyns<sup>7</sup>, F. Nevens<sup>8</sup>, G. M. Verleden<sup>2</sup>, J. Pirenne<sup>3</sup>, D. Van Raemdonck<sup>4</sup>. <sup>1</sup>Abdominal Transplant and Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>2</sup>Pneumology, University Hospitals Leuven, Leuven, Belgium, <sup>3</sup>Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>4</sup>Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>5</sup>Anesthesiology, University Hospitals Leuven, Leuven, Belgium, <sup>6</sup>Cardiology, University Hospitals Leuven, Leuven, Belgium, <sup>7</sup>Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>8</sup>Hepatology, University Hospitals Leuven, Leuven, Belgium
- (663) Clinical Judgment vs. Lung Allocation Score in Predicting Waitlist Mortality;**  
A. Hirji<sup>1</sup>, H. Zhao<sup>1</sup>, D. C. Lien<sup>2</sup>, R. D. Levy<sup>3</sup>, L. G. Singer<sup>1</sup>. <sup>1</sup>Toronto Lung Transplant Program, University of Toronto, Toronto, ON, Canada, <sup>2</sup>University of Alberta, Edmonton, AB, Canada, <sup>3</sup>University of British Columbia, Vancouver, BC, Canada
- (664) Optimized Mesenchymal Stem Cell Therapy for Chronic Obstructive Pulmonary Disease;**  
J. Tuma<sup>1</sup>, F. Silva<sup>2</sup>, A. A. Winters<sup>2</sup>, C. Bartlett<sup>2</sup>, A. N. Patel<sup>2</sup>. <sup>1</sup>Maison de Sante, Lima, Peru, <sup>2</sup>University of Utah, Salt Lake City, UT
- (665) Elderly Lung Transplant Recipient Long-Term Survival Is Not Impacted By Donor Age;**  
B. A. Whitson<sup>1</sup>, Y. Ravi<sup>2</sup>, A. Pope-Harman<sup>3</sup>, A. Kilic<sup>1</sup>, J. D. Tobias<sup>4</sup>, C. B. Sai-Sudhakar<sup>2</sup>, R. S. Higgins<sup>1</sup>, D. Hayes, Jr.<sup>5</sup>. <sup>1</sup>Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>2</sup>Division of Cardio-Thoracic Surgery, Baylor Scott and White Heart and Vascular Institute, Temple, TX, <sup>3</sup>Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>4</sup>Department of Anesthesia, Nationwide Children's Hospital, Columbus, OH, <sup>5</sup>Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH
- (666) Are Patients With Systemic Sclerosis at Increased Risk in Lung Transplantation?;**  
P. F. Undurraga, P. Mordant, S. Johnson, J. Granton, S. Azad, L. G. Singer, T. K. Waddell, S. Keshavjee, M. dePerrot. Toronto Lung Transplant Program, University of Toronto-UHN, Toronto, ON, Canada
- (667) Frailty Is Associated With Increased Mortality and Hospitalization in COPD;**  
C. C. Kennedy<sup>1</sup>, P. J. Novotny<sup>2</sup>, N. K. LeBrasseur<sup>1</sup>, R. A. Wise<sup>3</sup>, F. C. Sciruba<sup>4</sup>, R. P. Benzo<sup>1</sup>. <sup>1</sup>Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Health Sciences Research-Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, <sup>3</sup>Division of Pulmonary and Critical Care Medicine, Johns Hopkins Bayview Medical Center, Baltimore, MD, <sup>4</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA
- (668) 100 Lung Transplants Delivered in Ireland;**  
A. Gough, A. Wood, J. McCarthy, L. Nolke, H. DG, K. Redmond, D. Eaton, H. Javadpour, J. Egan. Cardiothoracic Transplant, Mater Misericordiae University Hospital, Dublin, Ireland

**(669) *Combined Lung-Kidney Transplantation: An Analysis of the UNOS/OPTN Database;***

H. J. Reich<sup>1</sup>, J. L. Chan<sup>2</sup>, L. Czer<sup>3</sup>, J. Mirocha<sup>4</sup>, A. Annamalai<sup>5</sup>, W. Cheng<sup>6</sup>, S. C. Jordan<sup>7</sup>, G. Chau<sup>8</sup>, D. Ramzy<sup>6</sup>. <sup>1</sup>Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Surgery, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>3</sup>Cardiology, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>4</sup>Biostatistics and Bioinformatics, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>5</sup>Surgery, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>6</sup>Cardiothoracic Surgery, Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>7</sup>Nephrology, Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA, <sup>8</sup>Pulmonology and Critical Care, Lung Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA

## ADULT LUNG TRANSPLANT

(Agora 2)

(LTX, BSI, DMD, ID, LF, MCS, PATH, PEDS, PHARM)

**(670) *Assessment of Human Lungs Recovered From Uncontrolled Donation After Circulatory Determination of Death (uDCDD) Donors By Ex-Vivo Lung Perfusion (EVLP) and CT Scan;***

T. M. Egan<sup>1</sup>, J. Blackwell<sup>1</sup>, S. Gazda<sup>1</sup>, L. Forrest<sup>1</sup>, D. Yuan<sup>2</sup>, B. Haithcock<sup>1</sup>, J. Long<sup>1</sup>, K. Birchard<sup>3</sup>, S. Reddy<sup>4</sup>, N. Casey. <sup>1</sup>Surgery, U. North Carolina Sch Med, Chapel Hill, NC, <sup>2</sup>Surgery, U. North Carolina Sch Med, Chapel Hill, NC, <sup>3</sup>Radiology, U. North Carolina Sch Med, Chapel Hill, NC, <sup>4</sup>Surgery, Duke University, Durham, NC, <sup>5</sup>Carolina Donor Services, Durham, NC

**(671) *Enhanced Donor Organ Quality Assurance Using Novel Point-of-View Video Streaming Technology During Harvesting;***

A. C. Baldwin<sup>1</sup>, H. R. Mallidi<sup>2</sup>, E. Sandoval<sup>3</sup>, W. E. Cohn<sup>2</sup>, G. Dronavalli<sup>4</sup>, A. D. Parulekar<sup>4</sup>, S. K. Singh<sup>2</sup>. <sup>1</sup>Surgery, Yale School of Medicine, New Haven, CT, <sup>2</sup>Transplant and Assist Devices, Baylor College of Medicine, Houston, TX, <sup>3</sup>Cardiothoracic Transplant, Texas Heart Institute, Houston, TX, <sup>4</sup>Pulmonary Medicine and Pulmonary Transplant, Baylor College of Medicine, Houston, TX

**(672) *Long-Term Outcome After Lung Transplantation Is Comparable Between Brain-Dead and Cardiac-Dead Donors;***

D. Ruttens, S. Verleden, E. Vandermeulen, H. Bellon, J. Somers, A. Martens, N. Arne, L. Dupont, B. Vanaudenaerde, R. Vos, D. Van Raemdonck, G. Verleden. KULeuven, Leuven, Belgium

**(673) *Surgical Strategy for Small Adult Chests in Lung Transplantation: Lobar vs. Standard Using a Pediatric Donor;***

B. Mahesh, D. Odell, J. D'Cunha, C. Bermudez, M. Morrell, M. Crespo, J. Pilewski, J. Luketich, N. Shigemura. UPMC Presbyterian, Pittsburgh, PA

**(674) *Survival of Single Lung Transplant Recipients in 50 – 64 Year Age Group;***

N. Sinha<sup>1</sup>, M. Loebe<sup>2</sup>, S. Scheinin<sup>2</sup>, T. Kaleekal<sup>1</sup>, B. Mankidy<sup>1</sup>, S. Jyothula<sup>1</sup>, B. Bruckner<sup>2</sup>, D. Ren<sup>2</sup>, H. Seethamraju<sup>3</sup>, L. Teeter<sup>4</sup>, E. Suarez<sup>2</sup>, A. Gaber<sup>5</sup>. <sup>1</sup>Pulmonary Transplant, Houston Methodist Hospital, Houston, TX, <sup>2</sup>Thoracic Surgery, Houston Methodist Hospital, Houston, TX, <sup>3</sup>Pulmonary, Newark Beth Israel Medical Center, Newark, NJ, <sup>4</sup>Biostatistics, Houston Methodist Hospital, Houston, TX, <sup>5</sup>JC Walter Jr Transplant Center, Houston Methodist Hospital, Houston, TX

- (675) *Heart Failure With Preserved Ejection Fraction Is Not Associated With Increased Mortality After Lung Transplantation;***  
 R. J. Cogswell<sup>1</sup>, M. Hertz<sup>2</sup>. <sup>1</sup>Cardiology, University of Minnesota Division of Cardiology, Minneapolis, MN, <sup>2</sup>Pulmonary and Critical Care, University of Minnesota, Minneapolis, MN
- (676) *The Changing Lung Transplant Candidate in the Post-LAS Era;***  
 C. J. Gries<sup>1</sup>, V. Singh<sup>2</sup>, M. George<sup>1</sup>, J. M. Pilewski<sup>1</sup>. <sup>1</sup>Pulmonary, Allergy and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Medicine, University of Pittsburgh, Pittsburgh, PA
- (677) *The South Australian Lung Transplant Unit – Outcomes From a Satellite Centre;***  
 M. X. Wong<sup>1</sup>, A. Yeo<sup>1</sup>, L. Sultan<sup>1</sup>, M. Kelly<sup>1</sup>, G. Snell<sup>2</sup>, A. R. Glanville<sup>3</sup>, M. Holmes<sup>1</sup>, C. Holmes-Liew<sup>1</sup>. <sup>1</sup>South Australian Lung Transplant Unit, Department of Thoracic Medicine, Royal Adelaide Hospital, Adelaide, Australia, <sup>2</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia, <sup>3</sup>Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia
- (678) *Impact of Age and BMI on Survival in Lung Transplant Recipients;***  
 M. Latran<sup>1</sup>, K. Lane<sup>2</sup>, C. Shen<sup>2</sup>, M. Baz<sup>3</sup>, M. Duncan<sup>3</sup>, C. Hage<sup>3</sup>, D. Roe<sup>3</sup>, Z. Hashmi<sup>4</sup>, T. Wozniak<sup>4</sup>, I. Wang<sup>4</sup>. <sup>1</sup>Pharmacy, Indiana University Health, Indianapolis, IN, <sup>2</sup>Biostatistics, Indiana University School of Medicine, Indianapolis, IN, <sup>3</sup>Pulmonary Critical Care, Indiana University Health, Indianapolis, IN, <sup>4</sup>Transplant Surgery, Indiana University Health, Indianapolis, IN
- (679) *Living Donor Lobar Double Lung Transplantation: Review of Donor and Recipient Results in a Single Canadian Centre;***  
 J. C. Mullen, E. J. Kuurstra, D. Lien, J. Weinkauff, K. Stewart, B. Laing, C. Price, K. Jackson, A. Kapasi. University of Alberta Hospital, Edmonton, AB, Canada
- (680) *Evaluation of Sarcopenia in Lung Transplant Candidates;***  
 D. Rozenberg<sup>1</sup>, S. Mathur<sup>2</sup>, L. Wickerson<sup>3</sup>, N. A. Chowdhury<sup>1</sup>, L. G. Singer<sup>1</sup>. <sup>1</sup>Medicine, Division of Respiratory, Toronto Lung Transplant Program, University of Toronto and Toronto General Hospital, Toronto, ON, Canada, <sup>2</sup>Physical Therapy, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Physical Therapy and Toronto Lung Transplant Program, University of Toronto and Toronto General Hospital, Toronto, ON, Canada
- (681) *Factors Predicting Survival in Early Lung Retransplantation;***  
 A. A. Osho<sup>1</sup>, S. A. Hirji<sup>2</sup>, B. C. Gulack<sup>3</sup>, A. M. Ganapathi<sup>2</sup>, R. D. Davis<sup>2</sup>, M. G. Hartwig<sup>2</sup>. <sup>1</sup>Department of Surgery, Massachusetts General Hospital, Boston, MA, <sup>2</sup>Department of Surgery, Duke University Medical Center, Durham, NC, <sup>3</sup>Department of Surgery, Duke University Medical Center, Durham, NC
- (682) *Early Donor-Specific Anti-HLA Antibodies in Lung Transplantation: Impact on Survival and Risk of Chronic Lung Allograft Dysfunction;***  
 J. Le Pavec<sup>1</sup>, L. Lamrani<sup>1</sup>, C. Suberbielle<sup>2</sup>, G. Thabut<sup>3</sup>, D. Fabre<sup>1</sup>, S. Mussot<sup>1</sup>, P. Dartevielle<sup>1</sup>, O. Mercier<sup>1</sup>, E. Fadel<sup>1</sup>. <sup>1</sup>Service de Chirurgie Thoracique, Hôpital Marie Lannelongue, Le Plessis Robinson, France, <sup>2</sup>Laboratoire d'Histocompatibilité, Hôpital Saint Louis, Paris, France, <sup>3</sup>Service de Pneumologie B, Hôpital Bichat, Paris, France
- (683) *Oropharyngeal Dysphagia and Aspiration After Lung Transplantation in the Current Era;***  
 R. Murthy<sup>1</sup>, D. Williams<sup>1</sup>, S. Kinnebrew<sup>2</sup>, J. Waters<sup>3</sup>, F. Torres<sup>4</sup>, V. Kaza<sup>4</sup>, W. S. Ring<sup>1</sup>, M. Wait<sup>1</sup>, M. Peltz<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Speech Therapy, UT Southwestern Medical Center, Dallas, TX, <sup>3</sup>General Surgery, UT Southwestern Medical Center, Dallas, TX, <sup>4</sup>Internal Medicine, UT Southwestern Medical Center, Dallas, TX

- (684) *AA Does Not Effect Neither 5YS Nor LOS;***  
 T. Floreth<sup>1</sup>, M. P. Davila<sup>2</sup>, S. Mabbott<sup>2</sup>, M. Rolfe<sup>1</sup>. <sup>1</sup>New Lung Associates, Tampa, FL, <sup>2</sup>Tampa General Hospital, Tampa, FL
- (685) *Methotrexate as a Treatment Strategy for Bronchiolitis Obliterans Syndrome (BOS);***  
 S. Sithamparanathan, L. Thirugnanasothy, K. Morley, A. J. Fisher, J. L. Lordan, G. Meachery, G. Parry, P. A. Corris. Institute of Transplantation, Freeman Hospital, The Newcastle upon Tyne NHS Foundation Trust, Newcastle, United Kingdom
- (686) *Large Airway Oximetry and Hypoxia Related Gene Expression in Bronchial Epithelium in Early Post-Lung Transplantation;***  
 S. Shofer<sup>1</sup>, B. Kraft<sup>1</sup>, M. Hartwig<sup>2</sup>, C. Piantadosi<sup>1</sup>. <sup>1</sup>Pulmonary, Allergy, and Critical Care, Duke University Medical Center, Durham, NC, <sup>2</sup>Thoracic Surgery, Duke University Medical Center, Durham, NC
- (687) *Effect of Center Volume on Survival After Lung Re-Transplantation;***  
 A. J. Hayanga<sup>1</sup>, T. Vlahu<sup>2</sup>, J. D'Cunha<sup>3</sup>, H. K. Hayanga<sup>4</sup>, R. Girgis<sup>1</sup>, A. Khaghani<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Spectrum Health - Michigan State University, Grand Rapids, MI, <sup>2</sup>Cardiothoracic Surgery, Spectrum Health, Grand Rapids, MI, <sup>3</sup>Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>4</sup>Cardiac Anesthesiology, Johns Hopkins Medical Institutions, Baltimore, MD
- (688) *Perioperative ECMO Use in Lung Transplantation for Severe Pulmonary Hypertension;***  
 I. Tudorache<sup>1</sup>, W. Sommer<sup>1</sup>, F. Ius<sup>1</sup>, C. Kühn<sup>1</sup>, O. Wiesner<sup>2</sup>, J. Hadem<sup>2</sup>, T. Fühner<sup>2</sup>, M. Avsar<sup>1</sup>, N. Schwerk<sup>3</sup>, D. Böthig<sup>1</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, C. Bara<sup>1</sup>, A. Haverich<sup>1</sup>, M. Höper<sup>2</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Pulmonology, Hannover Medical School, Hannover, Germany, <sup>3</sup>Department of Pediatric Pulmonology, Hannover Medical School, Hannover, Germany
- (689) *Clinical Prediction Model for PGD Among Patients With Pulmonary Hypertension;***  
 M. Porteous<sup>1</sup>, D. J. Lederer<sup>2</sup>, S. M. Palmer<sup>3</sup>, E. Cantu<sup>4</sup>, R. J. Shah<sup>1</sup>, S. Bellamy<sup>5</sup>, V. N. Lama<sup>6</sup>, S. M. Bhorade<sup>7</sup>, M. M. Crespo<sup>8</sup>, K. M. Wille<sup>9</sup>, A. Localio<sup>5</sup>, J. B. Orens<sup>10</sup>, P. D. Shah<sup>10</sup>, A. B. Weinacker<sup>11</sup>, S. Arca-soy<sup>2</sup>, D. S. Wilkes<sup>12</sup>, J. D. Christie<sup>1</sup>, S. M. Kawut<sup>1</sup>, J. M. Diamond<sup>1</sup>. <sup>1</sup>Medicine, University of Pennsylvania, Philadelphia, PA, <sup>2</sup>Medicine, Columbia University Medical Center, New York, NY, <sup>3</sup>Medicine, Duke University, Durham, NC, <sup>4</sup>Surgery, University of Pennsylvania, Philadelphia, PA, <sup>5</sup>University of Pennsylvania, Philadelphia, PA, <sup>6</sup>Medicine, University of Michigan Health System, Ann Arbor, MI, <sup>7</sup>Medicine, Northwestern University, Chicago, IL, <sup>8</sup>Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, <sup>9</sup>Medicine, University of Alabama at Birmingham, Birmingham, AL, <sup>10</sup>Medicine, Johns Hopkins University, Baltimore, MD, <sup>11</sup>Medicine, Stanford University Medical Center, Stanford, CA, <sup>12</sup>Medicine, Indiana University, Indianapolis, IN
- (690) *Intraoperative Cardiopulmonary Support With Extracorporeal Membrane Oxygenation in Lung Transplantation: Favorable Outcomes in High Risk Patients;***  
 F. Ius<sup>1</sup>, W. Sommer<sup>1</sup>, I. Tudorache<sup>1</sup>, M. Avsar<sup>1</sup>, T. Siemeni<sup>1</sup>, J. Salman<sup>1</sup>, M. Greer<sup>2</sup>, J. Optenhöfel<sup>1</sup>, M. Hoepfer<sup>2</sup>, J. Gottlieb<sup>2</sup>, T. Welte<sup>2</sup>, A. Haverich<sup>1</sup>, C. Kühn<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>Department of Cardiothoracic, Transplant and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Department of Respiratory Medicine, Hannover Medical School, Hannover, Germany
- (691) *Neutropenia Following Lung Transplantation;***  
 D. Rosengarten, M. Fakterman, Y. Raviv, V. Rusanov, B. D. Fox, M. R. Kramer. Pulmonary Institute, Rabin Medical Center, Petach tikva, Israel



- (692) *Surfactant Phospholipids as a Marker of Chronic Lung Allograft Dysfunction: A Targeted Lipidomics Approach;***  
 S. Narouji, B. Aramini, C. Kim, R. Chan, B. Zhou, K. Raza, H. Robbins, L. Shah, D. Lederer, S. Arcasoy, J. Sonett, G. Di Paolo, F. D'Ovidio. Columbia University Medical Center, New York, NY
- (693) *Update on the Outcomes of Lung Transplantation After Hematopoietic Stem Cell Transplantation: A Single-Center Experience;***  
 S. Sugimoto, T. Oto, M. Okada, N. Iga, K. Miyoshi, M. Yamane, S. Miyoshi. General Thoracic Surgery, Okayama University Hospital, Okayama, Japan
- (694) *CLAD Is Different Down Under!;***  
 M. Malouf<sup>1</sup>, M. Harkess<sup>1</sup>, A. Middleton<sup>1</sup>, S. Yerkovich<sup>2</sup>, M. Benzmiral<sup>1</sup>, A. Havryk<sup>1</sup>, M. Plit<sup>1</sup>, P. Hopkins<sup>2</sup>, D. Chambers<sup>2</sup>, A. R. Glanville<sup>1</sup>.  
<sup>1</sup>Lung Transplant Unit, St. Vincent's Hospital, Sydney, Australia, <sup>2</sup>Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia
- (695) *Is Systemic Lupus Erythematosus (SLE) Related Lung Disease a Contraindication to Lung Transplantation?;***  
 E. L. Bush<sup>1</sup>, H. Faust<sup>2</sup>, J. Lee<sup>2</sup>, J. P. Singer<sup>1</sup>, S. Hays<sup>2</sup>, L. Leard<sup>2</sup>, M. E. Kleinhenz<sup>2</sup>, G. Dincheva<sup>1</sup>, M. Brzezinski<sup>3</sup>, G. Wieselthaler<sup>1</sup>, C. W. Hoopes<sup>4</sup>, J. A. Golden<sup>2</sup>, J. Kukreja<sup>1</sup>. <sup>1</sup>Division of Cardiothoracic Surgery, Univ California, San Fran, San Francisco, CA, <sup>2</sup>Division of Pulmonary and Critical Care, Univ California, San Fran, San Francisco, CA, <sup>3</sup>Department of Anesthesia, Univ California, San Fran, San Francisco, CA, <sup>4</sup>Division of Cardiothoracic Surgery, University of Kentucky, Lexington, KY
- (696) *Lung Transplant (LT) for Non-Scleroderma Connective Tissue Lung Disease (NS-CTLD): Wasting a Precious Commodity?;***  
 J. Kukreja<sup>1</sup>, E. L. Bush<sup>1</sup>, C. W. Hoopes<sup>2</sup>, G. Dincheva<sup>1</sup>, M. Brzezinski<sup>3</sup>, J. Lee<sup>4</sup>, M. Kleinhenz<sup>4</sup>, L. Leard<sup>4</sup>, S. Hays<sup>4</sup>, J. Golden<sup>4</sup>, J. Singer<sup>4</sup>.  
<sup>1</sup>Cardiothoracic Surgery, Univ of California, San Francisco, CA, <sup>2</sup>Cardiothoracic Surgery, Univ of Kentucky, Lexington, KY, <sup>3</sup>Anesthesia, San Francisco Veterans Administration Hospital, San Francisco, CA, <sup>4</sup>Medicine, Univ of California, San Francisco, CA
- (697) *Lung Transplantation in Patients with Acute Exacerbations of Idiopathic Pulmonary Fibrosis: A Single Center Experience;***  
 L. Mudambi<sup>1</sup>, M. Pendurthi<sup>1</sup>, B. Mankidy<sup>2</sup>, N. Sinha<sup>2</sup>, S. Jyothula<sup>2</sup>, S. Scheinin<sup>2</sup>, B. Bruckner<sup>2</sup>, M. Loebe<sup>2</sup>, T. Kaleelka<sup>2</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>The Houston Methodist Hospital, Houston, TX
- (698) *Effects of Coronary Artery Disease on Lung Transplantation;***  
 J. G. Weinkauff<sup>1</sup>, K. Halloran<sup>1</sup>, A. Kapasi<sup>1</sup>, R. A. Varughese<sup>2</sup>, J. Mullen<sup>3</sup>, S. Meyer<sup>3</sup>, J. Nagendran<sup>1</sup>, D. Freed<sup>3</sup>, B. Laing<sup>3</sup>, D. Helmersen<sup>2</sup>, M. Thakrar<sup>2</sup>, M. Fenton<sup>4</sup>, K. B. Jackson<sup>1</sup>, D. C. Lien<sup>1</sup>. <sup>1</sup>Medicine, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Medicine, University of Calgary, Calgary, AB, Canada, <sup>3</sup>Surgery, University of Alberta, Edmonton, AB, Canada, <sup>4</sup>Medicine, University of Saskatchewan, Saskatoon, SK, Canada
- (699) *Altered Immunosuppressive Properties of Lung Transplant Recipients' Bronchial Epithelium: An Ex-Vivo Model of T-Allogenic Response;***  
 C. Dupin<sup>1</sup>, E. Lhuillier<sup>1</sup>, S. Létuvé<sup>2</sup>, G. Thabut<sup>1</sup>, H. Mal<sup>1</sup>, E. Carosella<sup>3</sup>, M. Prétolani<sup>4</sup>, N. Rouas-Freiss<sup>5</sup>, O. Brugière<sup>1</sup>. <sup>1</sup>Hôpital Bichat, Service de Pneumologie B et Transplantation Pulmonaire, Hôpital Bichat, Paris, France, <sup>2</sup>Hôpital Bichat, Paris, France, INSERM U1152, Paris 7 University, Paris, France, Paris, France, <sup>3</sup>CEA,IMETI, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France, Paris, France, <sup>4</sup>INSERM U1152, Paris 7 University, Paris, France, <sup>5</sup>CEA,IMETI, Hemato-Immunology Research Department, Saint-Louis Hospital, Paris, France

- (700) Extracorporeal Membrane Oxygenation for Severe Primary Graft Dysfunction After Lung Transplantation: Short- and Long-Term Outcome and Quality of Life;**  
 H. Buscher<sup>1</sup>, A. Glanville<sup>2</sup>, C. Lee<sup>1</sup>, A. Jackson<sup>3</sup>, P. Nair<sup>4</sup>, M. Gopalakrishnan<sup>4</sup>. <sup>1</sup>Intensive Care Medicine, St Vincent's Hospital, Sydney, Australia, <sup>2</sup>Lung Transplantation, St Vincent's Hospital, Sydney, Australia, <sup>3</sup>Anaesthesia, St Vincent's Hospital, Sydney, Australia, <sup>4</sup>Intensive care Medicine, St Vincent's Hospital, Sydney, Australia
- (701) Profiling of Peripheral Blood Mononuclear Cells Does Not Accurately Predict the Bronchiolitis Obliterans Syndrome After Lung Transplantation;**  
 K. Budding<sup>1</sup>, E. A. van de Graaf<sup>2</sup>, A. W. Paantjens<sup>1</sup>, T. Kardol-Hoefnagel<sup>1</sup>, J. M. Kwakkel-van Erp<sup>2</sup>, D. A. van Kessel<sup>3</sup>, H. G. Otten<sup>1</sup>. <sup>1</sup>Laboratory of Translational Immunology, University Medical Center Utrecht, Utrecht, Netherlands, <sup>2</sup>Department of Respiratory Medicine, University Medical Center Utrecht, Utrecht, Netherlands, <sup>3</sup>Center of Interstitial Lung Diseases, St Antonius Hospital Nieuwegein, Nieuwegein, Netherlands
- (702) Donor, Recipient and Operative Variables Affect the Time Taken to Reach 'Best' Lung Function Following Transplantation;**  
 J. Fuller<sup>1</sup>, M. Paraskeva<sup>2</sup>, B. Borg<sup>2</sup>, J. Rolland<sup>3</sup>, G. Snell<sup>2</sup>, G. Westall<sup>2</sup>. <sup>1</sup>Monash University, Melbourne, Australia, <sup>2</sup>Department of Allergy, Immunology and Respiratory Medicine, The Alfred Hospital, Melbourne, Australia, <sup>3</sup>Allergy Laboratory, Monash University, Melbourne, Australia
- (703) Analysis of a Modified Cytomegalovirus (CMV) Monitoring Algorithm for CMV Seropositive Lung Transplant Recipients;**  
 K. E. Schoeppler<sup>1</sup>, D. M. Lyu<sup>2</sup>, J. T. Crossno, Jr.<sup>2</sup>, T. J. Grazia<sup>2</sup>, K. M. Vandervest<sup>2</sup>, M. R. Zamora<sup>2</sup>. <sup>1</sup>Pharmacy, University of Colorado Hospital, Aurora, CO, <sup>2</sup>Pulmonary and Critical Care Medicine, University of Colorado Health Sciences Center, Aurora, CO
- (704) Characteristics of De Novo Donor-Specific Anti-HLA Antibodies (DSAs) in Living-Donor Lobar Lung Transplantation Might Be Different From Those in Cadaveric Lung Transplantation;**  
 T. Kondo, F. Chen, A. Ohsumi, M. Takahashi, K. Ohata, K. Hijiya, H. Motoyama, S. Tanaka, E. Miyamoto, T. Yamada, M. Sato, A. Aoyama, H. Date. Thoracic Surgery, Kyoto University, Kyoto, Japan
- (705) Phrenic Nerve Injury During Lung Transplantation Increases Operative Morbidity and Reduces Survival;**  
 V. Aguirre Gutierrez, F. Rosenfeldt, A. Zimmet, S. Marasco, G. Westall. Cardiothoracic Unit, Alfred Hospital, Prahran, Australia
- (706) Kinetics of Peripheral Blood Lymphocyte Subsets in Lung Transplant Recipients;**  
 B. Coiffard<sup>1</sup>, M. Pelardy<sup>2</sup>, C. Gomez<sup>1</sup>, A. Loundou<sup>3</sup>, C. Brunet<sup>2</sup>, B. Coltey<sup>1</sup>, N. Dufeu<sup>1</sup>, P. Thomas<sup>1</sup>, M. Reynaud-Gaubert<sup>1</sup>. <sup>1</sup>Department of Respiratory Medicine, Thoracic Surgery and Lung Transplantation, Assistance Publique - Hopitaux de Marseille (AP-HM), Hôpital Nord, Marseille, France, <sup>2</sup>Laboratory of Haematology, Assistance Publique - Hopitaux de Marseille (AP-HM), Hôpital La Conception, Marseille, France, <sup>3</sup>Department of Public Health, Aix-Marseille University, Medicine School, Marseille, France
- (707) An Innovative Everolimus-Based Quadruple Low Immunosuppressive Regimen Compared to Standard Triple Regimen in Lung Transplant Recipients and Its Impact on Renal Function, Safety and Efficacy: The 4EVERLUNG Study Design;**  
 J. Gottlieb<sup>1</sup>, C. Neurohr<sup>1</sup>, J. Müller-Quernheim<sup>1</sup>, H. Wirtz<sup>1</sup>, T. Deuse<sup>1</sup>, U. Sommerwerck<sup>1</sup>, C. Knosalla<sup>1</sup>, C. Witt<sup>1</sup>, P. Wimmer<sup>2</sup>, M. Porstner<sup>2</sup>, M. Strüber<sup>1</sup>. <sup>1</sup>EverLung Study Team, Germany, Germany, <sup>2</sup>Novartis Pharma GmbH, Nuremberg, Germany

- (708) *Prevalence of Acute and Chronic Renal Failure After Lung Transplantation;***  
 A. Monnier<sup>1</sup>, T. Krummel<sup>1</sup>, O. Collange<sup>2</sup>, G. Haffner<sup>2</sup>, S. Hirschi<sup>3</sup>, T. Dégot<sup>3</sup>, T. Hannedouche<sup>1</sup>, R. Kessler<sup>3</sup>. <sup>1</sup>Nephrology, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, <sup>2</sup>Intensive Care Unit, Hôpitaux Universitaires de Strasbourg, Strasbourg, France, <sup>3</sup>Pneumology, Lung Transplantation Group, Hôpitaux Universitaires de Strasbourg, Strasbourg, France
- (709) *Mast Cell Phenotypes in the Allograft After Lung Transplantation;***  
 A. Banga<sup>1</sup>, N. G. Narula<sup>2</sup>, M. M. Budev<sup>3</sup>, X. Wang<sup>2</sup>, F. Hsieh<sup>3</sup>. <sup>1</sup>Lung Transplant Program, Division of Pulmonary & Critical Care Medicine, UT Southwestern Medical Center, Dallas, TX, <sup>2</sup>Medicine, Mayo Clinic, Jacksonville, FL, <sup>3</sup>Cleveland Clinic, Cleveland, OH
- (710) *Do We Really Need to Rush? Early and Mid Term Results of Lung Transplantation (Ltx) of Organs With Total Ischemic Time (TIT) Over 8 Hours – A Propensity Score Matched, Single-Center Analysis;***  
 B. Zych, D. Garcia-Saez, A. Sabashnikov, P. Mohite, N. Patil, M. Zerriouh, A. Popov, F. De Robertis, M. Amrani, T. Bahrami, A. Reed, M. Carby, A. R. Simon. Department of Cardiothoracic Transplantation and Mechanical Circulatory Support, Harefield Hospital. Royal Brompton and Harefield NHS Foundation Trust, Harefield, United Kingdom
- (711) *Does Lung Implantation By a Resident Affect Short-Term Outcomes?;***  
 D. Williams<sup>1</sup>, R. Murthy<sup>1</sup>, J. Waters<sup>2</sup>, J. M. DiMaio<sup>3</sup>, W. S. Ring<sup>1</sup>, M. Peltz<sup>1</sup>, M. Wait<sup>1</sup>. <sup>1</sup>Cardiovascular and Thoracic Surgery, UT-Southwestern, Dallas, TX, <sup>2</sup>General Surgery, UT-Southwestern, Dallas, TX, <sup>3</sup>SpectralMD, Dallas, TX
- (712) WITHDRAWN**
- (713) *Bile Acid in Bronchial Wash as a Useful Biomarker of Aspiration to Determine the Suitability of Donor Lungs for Transplantation;***  
 D. Nakajima, S. Azad, T. Saito, T. K. Waddell, L. G. Singer, M. Liu, M. Cypel, S. Keshavjee. Toronto Lung Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada
- (714) *Optical Headmounted Wearable Technology in Heart and Lung Organ Procurement;***  
 A. A. Rahim<sup>1</sup>, H. M. Mentis<sup>2</sup>, E. L. Bush<sup>1</sup>, J. Kukreja<sup>1</sup>, G. M. Wieselthaler<sup>1</sup>, P. R. Theodore<sup>1</sup>. <sup>1</sup>Department of Surgery, University of California San Francisco, San Francisco, CA, <sup>2</sup>Department of Information Systems, University of Maryland, Baltimore County, Baltimore, MD
- (715) *Donation After Circulatory Death Mitigates the Deleterious Effects of Severe Primary Graft Dysfunction After Lung Transplantation;***  
 L. A. Teeuwen<sup>1</sup>, E. A. Verschuuren<sup>2</sup>, C. van de Wauwer<sup>1</sup>, M. Mariani<sup>1</sup>, V. Cernak<sup>3</sup>, A. O. Oude-Lansink<sup>4</sup>, M. E. Erasmus<sup>1</sup>, W. van der Bij<sup>2</sup>. <sup>1</sup>Department of Cardiothoracic Surgery, University Medical Centre Groningen, Groningen, Netherlands, <sup>2</sup>Department of Internal Medicine, University Medical Centre Groningen, Groningen, Netherlands, <sup>3</sup>Department of Anesthesiology, University Medical Centre Groningen, Groningen, Netherlands, <sup>4</sup>Department of Critical Care, University Medical Centre Groningen, Groningen, Netherlands
- (716) *Safety and Efficacy of a Protocol for Monitoring Self-Expanding Metal Stents in Post Lung Transplant Central Airway Stenosis;***  
 B. J. Mankidy<sup>1</sup>, J. K. Thachuthara-George<sup>2</sup>, M. Pendurthi<sup>2</sup>, T. Kaleekal<sup>1</sup>, S. Jyothula<sup>1</sup>, N. Sinha<sup>1</sup>, H. Seethamraju<sup>3</sup>, S. Scheinin<sup>4</sup>, B. Bruckner<sup>4</sup>, M. Loebe<sup>4</sup>. <sup>1</sup>Internal Medicine, Houston Methodist Hospital, Houston, TX, <sup>2</sup>Internal Medicine, Baylor College of Medicine, Houston, TX, <sup>3</sup>Internal Medicine, 740 S Limestone, Lexington, KY, <sup>4</sup>Cardiovascular and Thoracic Surgery, Houston Methodist Hospital, Houston, TX

- (717) *Transplantation After Ex-Vivo Lung Perfusion: An Early Follow-Up;***  
 A. Wallinder<sup>1</sup>, G. C. Riise<sup>2</sup>, S. Ricksten<sup>3</sup>, M. Silverborn<sup>4</sup>, G. Dellgren<sup>1</sup>.  
<sup>1</sup>Dep. of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>2</sup>Transplant Institute, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>3</sup>Dep. of Anesthesiology and Intensive Care, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>4</sup>Dep. of Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
- (718) *A Pilot Study of a Novel Dry Powder Tobramycin Inhaler in Cystic Fibrosis (CF) Patients Post Lung Transplantation (LTx);***  
 S. Ivulich<sup>1</sup>, S. Fisher<sup>1</sup>, S. Maleki<sup>1</sup>, B. Levvey<sup>2</sup>, M. Paraskeva<sup>2</sup>, G. Snell<sup>2</sup>.  
<sup>1</sup>Department of Pharmacy, Alfred Hospital, Melbourne, Australia, <sup>2</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia

## BASIC SCIENCE

(Agora 2)

(ALL)

- (719) *Autoantibodies (Non-MHC Antibodies) in a Mouse Model of Chronic Rejection: Profiling By Antigen Microarrays;***  
 K. Anderson, A. Chruscinski, A. Nguyen, W. He, H. Ross, G. Levy.  
 Multiorgan Transplant, University of Toronto, Toronto, ON, Canada
- (720) *Combination Therapy Using Imatinib and Vatalanib Improves the Long-Term Outcome After Rat Lung Transplantation;***  
 M. von Suesskind, L. Keil, C. Schmid, S. W. Hirt, K. Lehle. Cardiothoracic Surgery, University medical Center, Regensburg, Regensburg, Germany
- (721) *VEGF-B Overexpression Enhances Ischemia-Reperfusion Injury and the Innate Immune Response in Rat Heart Transplants;***  
 A. Raissadati<sup>1</sup>, R. Tuuminen<sup>1</sup>, A. Dashkevich<sup>1</sup>, S. Syrjälä<sup>1</sup>, R. Arnau-dova<sup>1</sup>, E. Rouvinen<sup>1</sup>, M. Keränen<sup>1</sup>, R. Krebs<sup>1</sup>, K. Alitalo<sup>2</sup>, A. Nykänen<sup>1</sup>, K. Lemström<sup>1</sup>. <sup>1</sup>University of Helsinki, Transplantation Laboratory, Haartman Institute and Helsinki University Central Hospital, Cardiac Surgery, Heart and Lung Center, Helsinki, Finland, <sup>2</sup>Molecular/Cancer Biology Program, Institute for Molecular Medicine Finland and Helsinki University Central Hospital, Research Programs Unit, Biomedicum Helsinki, University of Helsinki, Helsinki, Finland
- (722) *Treatment With Donor Specific Alloantigen and Anti-CD4 mAb 3 Days After Lung Transplantation Differentially Affects Putative Effector and Regulatory T Cell Populations;***  
 J. Hahn<sup>1</sup>, K. Jansson<sup>1</sup>, W. Sommer<sup>1</sup>, M. Avsar<sup>1</sup>, T. Siemeni<sup>1</sup>, J. Salman<sup>1</sup>, A. Knoefel<sup>1</sup>, B. Schröder<sup>2</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>.  
<sup>1</sup>Heart-, Thoracic-, Transplantation- and Vascular Surgery, Hannover Medical School, Hannover, Germany, <sup>2</sup>Veterinary School of Medicine, Hannover, Germany
- (723) *IL-25 Attenuates Obliterative Bronchiolitis By Regulating the Polarization of Macrophages in Murine Orthotopic Tracheal Transplantation Models;***  
 X. Zhou<sup>1</sup>, J. Liu<sup>2</sup>, Q. Meng<sup>1</sup>, J. Li<sup>1</sup>, Z. Guo<sup>2</sup>, Z. Liu<sup>2</sup>, H. Fan<sup>2</sup>. <sup>1</sup>Institute of Heart Failure, Shanghai East Hospital, Tongji University, Shanghai, China, <sup>2</sup>Department of Heart Failure, Shanghai East Hospital, Tongji University, Shanghai, China

- (724)** *Evidence That CTLA4Ig Attenuates Recall Alloantibody Responses By Interacting With Antibody Forming Cells;*  
I. Kim, G. Wu, N. Chai, S. Jordan, A. Klein. Transplant Surgery, Cedars-Sinai Med Ctr, Los Angeles, CA
- (725)** *Elevated Peripheral Blood Counts of CD127 Low, FoxP3+ CD4+CD25 High T Cells in Lung Transplant Recipients Leads to Less Severe Donor-Specific Transplant Arteriosclerosis in Humanized Mice;*  
A. Knoefel<sup>1</sup>, T. Siemeni<sup>1</sup>, N. Frank<sup>1</sup>, N. Madrahimov<sup>1</sup>, D. Jonigk<sup>2</sup>, J. Salman<sup>1</sup>, W. Sommer<sup>1</sup>, K. Jansson<sup>1</sup>, M. Avsar<sup>1</sup>, A. Haverich<sup>1</sup>, G. Warnecke<sup>1</sup>. <sup>1</sup>HTTG, MHH, Hannover, Germany, <sup>2</sup>Pathology, MHH, Hannover, Germany
- (726)** *Histone Deacetylase 2 is Decreased in Peripheral Blood Cytotoxic/Pro-Inflammatory CD8+ T and NKT-Like Lymphocytes Following Lung Transplant;*  
G. Hodge. Royal Adelaide Hospital, Adelaide, Australia
- (727)** *The Impact of Perfusate Oxygenation During Ex-Vivo Lung Perfusion on Post-transplant Outcomes: Deoxygenated vs. Fully-Oxygenated;*  
K. Noda, S. Haam, J. D'Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
- (728)** *Ex-Vivo Administration of Human Mesenchymal Stem Cells Ameliorates Injury in Pig Lungs Through an Increase in Parenchymal VEGF and a Decrease in Circulating IL-8;*  
P. Mordant<sup>1</sup>, D. Nakajima<sup>1</sup>, R. Kalaf<sup>1</sup>, I. Iskender<sup>1</sup>, L. Maahs<sup>1</sup>, P. Behrens<sup>1</sup>, R. Coutinho<sup>1</sup>, R. K. Iyer<sup>2</sup>, J. E. Davies<sup>2</sup>, M. Cypel<sup>1</sup>, M. Liu<sup>1</sup>, T. K. Waddell<sup>1</sup>, S. Keshavjee<sup>1</sup>. <sup>1</sup>Latner Thoracic Surgery Research Laboratories, University Health Network, Toronto, ON, Canada, <sup>2</sup>Tissue Regeneration Therapeutics (TRT) Inc., Toronto, ON, Canada
- (729)** *A Modified Biventricular Working Heterotopic Rat Heart Transplant Model With Pressure Volume Loops Cardiac Function Analysis;*  
W. Oriyanhan, D. D'Alessandro, R. Bello, Y. Xia, M. Follis, G. Moreno, R. Michler. Cardiothoracic Surgery, Montefiore Medical Center, Bronx, NY
- (730)** *PDGF-B Is Protective During Ischemia-Reperfusion Injury in Rat Cardiac Allografts;*  
A. Dashkevich<sup>1</sup>, R. Tuuminen<sup>2</sup>, M. Keränen<sup>2</sup>, A. Raissadati<sup>2</sup>, R. Krebs<sup>2</sup>, J. Jokinen<sup>2</sup>, S. Ylä-Herttua<sup>3</sup>, A. Nykanen<sup>2</sup>, K. Lemström<sup>2</sup>. <sup>1</sup>LMU Medical Centre, LMU Medical Centre, Munich, Germany, <sup>2</sup>Haartman Institute, University of Helsinki, Helsinki, Finland, <sup>3</sup>University of Eastern Finland, Kuopio, Finland
- (731)** *Mitochondrial Calcium: The Missing Link Between Hypoxia and Quality in Lung Grafts During Ex-Vivo Lung Perfusion;*  
K. Noda, S. Haam, J. D'Cunha, J. D. Luketich, C. A. Bermudez, N. Shigemura. Department of Cardiothoracic Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA
- (732)** *Cardiac Troponin I Levels in Preservation Solution Predict Primary Graft Dysfunction After Heart Transplant;*  
M. A. Schechter<sup>1</sup>, K. W. Southerland<sup>1</sup>, M. J. Watson<sup>1</sup>, B. J. Feger<sup>1</sup>, R. Mishra<sup>1</sup>, J. N. Schroder<sup>1</sup>, L. R. Dibernardo<sup>2</sup>, M. Kuchibhatla<sup>3</sup>, M. A. Daneshmand<sup>1</sup>, C. B. Patel<sup>4</sup>, J. G. Rogers<sup>4</sup>, C. A. Milano<sup>1</sup>, D. E. Bowles<sup>1</sup>. <sup>1</sup>Surgery, Duke, Durham, NC, <sup>2</sup>Pathology, Duke, Durham, NC, <sup>3</sup>Biostatistics and Bioinformatics, Duke, Durham, NC, <sup>4</sup>Division of Cardiology, Department of Medicine, Duke, Durham, NC
- (733)** *Circulating Histone-Induced Lung Injury: A Novel Model of Damaged Lungs From Brain-Dead Donors;*  
T. Murayama<sup>1</sup>, M. Anraku<sup>1</sup>, T. Murakawa<sup>1</sup>, T. Yoshioka<sup>1</sup>, M. Inui<sup>1</sup>, N. Hiyama<sup>1</sup>, M. Kawashima<sup>1</sup>, T. Tsuchiya<sup>1</sup>, J. Ichinose<sup>1</sup>, H. Hino<sup>1</sup>, K. Nagayama<sup>1</sup>, J. Nitadori<sup>1</sup>, K. Kakimi<sup>2</sup>, J. Nakajima<sup>1</sup>. <sup>1</sup>Thoracic Surgery, The University of Tokyo, Bunkyo ku, Japan, <sup>2</sup>Immunotherapeutics, The University of Tokyo, Bunkyo ku, Japan

- (734) *Acute Hyperglycemia Exacerbates Ischemia-Reperfusion Injury of the Lung By Activating TLR4 Signaling Pathway;***  
 M. Takahashi<sup>1</sup>, F. Chen, T. Menju, K. Ohata, T. Kondo, H. Motoyama, K. Hijiya, T. Yamada, M. Sato, A. Aoyama, H. Date. Department of Thoracic Surgery, Kyoto University, Graduate School of Medicine, Kyoto, Japan
- (735) *Impact of Initial Acidic Reperfusion on the Functional Recovery of DCD Hearts During Ex-Vivo Heart Perfusion;***  
 C. W. White<sup>1</sup>, E. Ambrose<sup>2</sup>, A. Müller<sup>2</sup>, J. Thliveris<sup>3</sup>, R. C. Arora<sup>1</sup>, G. Tian<sup>4</sup>, J. Nagendran<sup>5</sup>, L. V. Hryshko<sup>2</sup>, D. H. Freed<sup>5</sup>. <sup>1</sup>Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, <sup>2</sup>Institute of Cardiovascular Sciences, St. Boniface Research Center, Winnipeg, MB, Canada, <sup>3</sup>Human Anatomy and Cell Science, University of Manitoba, Winnipeg, MB, Canada, <sup>4</sup>Institute for Biodiagnostics, National Research Council Canada, Winnipeg, MB, Canada, <sup>5</sup>Mazankowski Alberta Heart Institute, University of Alberta, Edmonton, AB, Canada,
- (736) *Determination of Optimum Ventilation Strategy for Ex-Vivo Lung Perfusion: Comparing Negative and Positive Pressure Ventilation;***  
 K. Nelson<sup>1</sup>, S. M. Black<sup>2</sup>, E. Eren<sup>3</sup>, D. Hayes, Jr.<sup>4</sup>, C. Dumond<sup>2</sup>, S. Bennett<sup>2</sup>, S. Ghadiali<sup>1</sup>, B. A. Whitson<sup>2</sup>. <sup>1</sup>Department of Biomedical Engineering, The Ohio State University, Columbus, OH, <sup>2</sup>Department of Surgery, The Ohio State University Wexner Medical Center, Columbus, OH, <sup>3</sup>University of Toledo, Toledo, OH, <sup>4</sup>Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH
- (737) *Protective Effect of Nebulized Rho-Kinase Inhibitor on Ischemia Reperfusion Injury in Isolated Rat Lung Perfusion Model;***  
 K. Ohata, F. Chen, M. Takahashi, T. Kondo, H. Motoyama, K. Hijiya, T. Yamada, M. Sato, T. Menju, A. Aoyama, T. Sato, M. Sonobe, M. Omasa, H. Date. Department of Thoracic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- (738) *Hypoxic Pulmonary Vasoconstriction Is a More Accurate Parameter Than P/F Ratio to Measure Lung Function on Ex-Vivo Lung Perfusion;***  
 A. F. Alzamil<sup>1</sup>, S. Hatami<sup>1</sup>, C. W. White<sup>2</sup>, N. S. Aboelnazar<sup>1</sup>, S. Bozso<sup>3</sup>, V. Vasanthan<sup>3</sup>, D. H. Freed<sup>4</sup>, J. Nagendran<sup>4</sup>. <sup>1</sup>Department of Surgery, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Cardiac Surgery, University of Manitoba, Winnipeg, MB, Canada, <sup>3</sup>Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB, Canada, <sup>4</sup>Cardiac Surgery, University of Alberta, Edmonton, AB, Canada
- (739) *Telomere Integrity as a Genetic Marker of Effective Treatment for Advanced Heart Failure;***  
 C. M. Statz<sup>1</sup>, J. Brown<sup>2</sup>, A. M. Ras<sup>1</sup>, K. D. Ballard<sup>1</sup>, D. Desai<sup>3</sup>, D. Fusco<sup>1</sup>, J. Hammond<sup>1</sup>, J. A. Gluck<sup>1</sup>, D. Wencker<sup>4</sup>. <sup>1</sup>Cardiology, Hartford Hospital, Hartford, CT, <sup>2</sup>Allied Health Sciences, University of Connecticut, Storrs, CT, <sup>3</sup>Molecular and Cell Biology, University of Connecticut, Storrs, CT, <sup>4</sup>Center for Advanced Heart Failure and Transplant, University of Kansas Medical Center, Kansas City, KS
- (740) *Carbon Monoxide Attenuates Hyperacute Dysfunction and Microangiopathy in GalT-KO Pulmonary Xenotransplantation;***  
 H. Sahara<sup>1</sup>, H. Nagashima<sup>2</sup>, M. Sekijima<sup>1</sup>, K. Miura<sup>1</sup>, A. Kawai<sup>1</sup>, S. Waki<sup>1</sup>, K. Nakano<sup>2</sup>, H. Matsunari<sup>2</sup>, A. Shimizu<sup>1</sup>, K. Yamada<sup>1</sup>. <sup>1</sup>Center for Advanced Biomedical Science and Swine Research, Kagoshima University, Kagoshima, Japan, <sup>2</sup>Department of Life Sciences, School of Agriculture, Meiji University, Kawasaki, Japan
- (741) *Xenogenic glycans: Human Antibody Reactivity and Their Impact on Xenograft Rejection;***  
 G. W. Byrne<sup>1</sup>, Y. Lin<sup>2</sup>, Z. Du<sup>2</sup>, H. Kogelberg<sup>1</sup>, C. McGregor<sup>1</sup>. <sup>1</sup>Cardiovascular Science, University College London, London, United Kingdom, <sup>2</sup>Department of Surgery, Mayo Clinic, Rochester, MN
- (742) *Moved to Mini Oral Session 12***

- (743) *Immunosuppression Using CD40 Costimulation Blockade in a Preclinical Cardiac Xenotransplantation Model;***  
 J. Abicht<sup>1</sup>, T. Mayr<sup>2</sup>, S. Guethoff<sup>2</sup>, F. Werner<sup>1</sup>, I. Lutzmann<sup>2</sup>, M. C. Langenmayer<sup>3</sup>, E. Wolf<sup>4</sup>, D. Ayares<sup>5</sup>, K. Reimann<sup>6</sup>, B. Reichart<sup>7</sup>, P. Brenner<sup>2</sup>. <sup>1</sup>Department of Anaesthesiology (LMU), Munich, Germany, <sup>2</sup>Department of Cardiac Surgery (LMU), Munich, Germany, <sup>3</sup>Department of Veterinary Pathology (LMU), Munich, Germany, <sup>4</sup>Department of Molecular Animal Breeding and Biotechnology(LMU), Munich, Germany, <sup>5</sup>Revivacor Inc., Blacksburg, VA, <sup>6</sup>MassBiologics, University of Massachusetts, Boston, MA, <sup>7</sup>Walter-Brendel-Centre (LMU), Munich, Germany
- (744) WITHDRAWN**
- (745) *MicroRNA Expression Pattern in Patients with Ventricular Tachycardia and End-Stage Heart Failure;***  
 T. Calway, T. Bak, G. H. Kim. University of Chicago, Chicago, IL
- (746) *Ex-Vivo Delivery of Inhaled Hydrogen Gas to the Donor Lung Ameliorates Post-Transplant Lung Injury in Pigs;***  
 J. Lee, R. Kalaf, H. Kim, M. Chen, D. Nakajima, I. Iskender, L. Maahs, R. Coutinho, P. Behrens, M. Liu, S. Keshavjee, M. Cypel. Latner Thoracic Surgery Research Laboratories, Toronto Lung Transplant Program, University Health Network, University of Toronto, Toronto, ON, Canada
- (747) *The Heterotopic Thoracic Cardiac Xenotransplantation Model (Pig-to-Baboon): Results With and Without a Myelodepressive Protocol;***  
 P. Brenner<sup>1</sup>, J. Abicht<sup>2</sup>, S. Guethoff<sup>3</sup>, S. Buchholz<sup>3</sup>, T. Mayr<sup>3</sup>, A. Bauer<sup>4</sup>, S. Blanck<sup>5</sup>, B. Kessler<sup>6</sup>, E. Wolf<sup>7</sup>, C. Becker<sup>8</sup>, D. Ayares<sup>9</sup>, C. Belka<sup>10</sup>, C. Hagl<sup>1</sup>, B. Reichart<sup>1</sup>. <sup>1</sup>Dept. of Cardiac Surgery, University of Munich (LMU), Munich, Germany, <sup>2</sup>Dept. of Anesthesiology, University of Munich, Munich, Germany, <sup>3</sup>Dept. of Cardiac Surgery, University of Munich, Munich, Germany, <sup>4</sup>Dept. of Anesthesiology, University of Munich, Munich, Germany, <sup>5</sup>Walter-Brendel-Centre, University of Munich (LMU), Munich, Germany, <sup>6</sup>Institute of Molecular Animal Breeding and Biotechnology, University of Munich (LMU), Munich, Germany, <sup>7</sup>Institut of Molecular Animal Breeding and Biotechnology, University of Munich (LMU), Munich, Germany, <sup>8</sup>Dept. of Radiology, University of Munich (LMU), Munich, Germany, <sup>9</sup>Revivacor Inc., Blacksburg, VA, <sup>10</sup>Dept. of Radiation Oncology, University of Munich (LMU), Munich, Germany
- (748) *Blockade of Glycoproteins Ib and IIb/IIIa Reduces Platelet Sequestration and PVR Rise in a Xenogeneic Lung Perfusion Model;***  
 L. Burdorf<sup>1</sup>, A. Riner<sup>1</sup>, E. Rybak<sup>1</sup>, D. Harris<sup>1</sup>, S. Dahi<sup>1</sup>, T. Zhang<sup>1</sup>, D. Parsell<sup>1</sup>, F. Ali<sup>1</sup>, E. Schwartz<sup>1</sup>, E. Kang<sup>1</sup>, X. Cheng<sup>1</sup>, E. Sievert<sup>1</sup>, G. Braileanu<sup>1</sup>, K. Quinn<sup>1</sup>, A. Shah<sup>1</sup>, A. Shah<sup>1</sup>, S. De Meyer<sup>2</sup>, H. Deckmyn<sup>1</sup>, C. J. Phelps<sup>3</sup>, D. L. Ayares<sup>3</sup>, R. N. Pierson III<sup>1</sup>, A. M. Azimzadeh<sup>1</sup>. <sup>1</sup>Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Laboratory for Thrombosis Research, KU Leuven Campus Kortrijk, Leuven, Belgium, <sup>3</sup>Revivacor, Inc., Blacksburg, VA
- (749) *Extended Life-Support Duration in a Xenogeneic Lung Transplantation Model Using Pigs With Multiple Genetic Modifications;***  
 L. Burdorf, E. Rybak, T. Zhang, D. Harris, S. Dahi, N. Kubicki, J. Woodall, D. Parsell, X. Cheng, E. Schwartz, E. Kang, E. Sievert, G. Braileanu, C. Phelps, D. Ayares, A. M. Azimzadeh, R. N. Pierson III. Surgery, University of Maryland, Baltimore, MD
- (750) *Lineage Tracing of Host and Graft Cells After Lung Transplant and During Club Cell Ablation Induces Allograft Rejection;***  
 A. T. Perl<sup>1,2</sup>, J. Woods<sup>3</sup>, A. Gelman<sup>4</sup>, M. Schecter<sup>5</sup>, C. Towe<sup>5</sup>. <sup>1</sup>Pulmonary Biology, Cincinnati Children's Hospital, Cincinnati, OH, <sup>2</sup>Pulmonary Biology, Perinatal Institute, Cincinnati, OH, <sup>3</sup>Radiology, Cincinnati Children's Hospital, Cincinnati, OH, <sup>4</sup>Cardiothoracic Surgery, Washington University, St Louis, MO, <sup>5</sup>Pediatric Lung Transplant Program, Cincinnati Children's Hospital, Cincinnati, OH

DONOR MANAGEMENT

ORGAN PRESERVATION HEART

(Agora 2)

(DMD-HEART, HTX)

**(751) *Ex-Vivo Heart Perfusion Using the Organ Care System Reduces the Donor Heart Cold Ischemia Time;***

A. Ardehalil<sup>1</sup>, C. Eisenring<sup>2</sup>, J. Kobashigawa<sup>3</sup>. <sup>1</sup>UCLA Sch of Med, Los Angeles, CA, <sup>2</sup>Surgery, UCLA Sch of Med, Los Angeles, CA, <sup>3</sup>Medicine, Cedars Sinai Medical Center, Los Angeles, CA

**(752) *Ex-Vivo Heart Perfusion Using the Transmedics Organ Care System – A Single Center Experience;***

A. M. Bernhardt, S. Hakmi, B. Sill, M. Silaschi, M. J. Barten, H. Reichenspurner, F. M. Wagner. Department of Cardiovascular Surgery, Univ Heart Ctr Hamburg, Hamburg, Germany

**(753) *Twelve Hour Hypothermic Machine Perfusion for Donor Heart Preservation Leads to Improved Ultrastructural Characteristics Compared to Conventional Cold Storage;***

S. G. Michel<sup>1</sup>, G. M. LaMuraglia II<sup>2</sup>, M. L. Madariaga<sup>2</sup>, M. K. Selig<sup>3</sup>, E. A. Farkash<sup>3</sup>, J. S. Allan<sup>2</sup>, L. M. Anderson<sup>4</sup>, J. C. Madsen<sup>2</sup>. <sup>1</sup>Cardiac Surgery, Ludwig-Maximilians-University, Muenchen, Germany, <sup>2</sup>Transplantation Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Boston, MA, <sup>3</sup>Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, <sup>4</sup>Paragonix Technologies, Braintree, MA

**(754) *The Potential of Transplanting Hearts From Donation After Circulatory Determined Death (DCD) Donors Within the United Kingdom;***

S. Messer<sup>1</sup>, J. Lannon<sup>2</sup>, E. Wong<sup>2</sup>, C. Hopkinson<sup>2</sup>, S. Fielding<sup>3</sup>, R. Axell<sup>4</sup>, A. Ali<sup>1</sup>, S. Tsui<sup>1</sup>, S. Large<sup>5</sup>. <sup>1</sup>Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, <sup>2</sup>Statistics and Clinical Studies, NHS Blood and Transplant, Bristol, United Kingdom, <sup>3</sup>Research and Development, Papworth Hospital, Cambridgeshire, United Kingdom, <sup>4</sup>Clinical Engineering, Addenbrookes Hospital, Cambridgeshire, United Kingdom, <sup>5</sup>Cardiothoracic Surgery, Papworth Hospital, Cambridgeshire, United Kingdom

**(755) *Donor-Recipient Weight Matching in Adult Heart Transplantation;***

H. Bergenfeldt<sup>1</sup>, B. Andersson<sup>2</sup>, J. Nilsson<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Skane University Hospital, Lund, Sweden, <sup>2</sup>Surgery, Skane University Hospital, Lund, Sweden

**(756) *The Value of Elective Status 1A Time and the Effects of Delayed Transplant Listing Among Registrants With Mechanical Circulatory Support;***

T. F. Dardas<sup>1</sup>, K. D. Aaronson<sup>2</sup>, R. K. Cheng<sup>1</sup>, W. Levy<sup>1</sup>, C. Masri<sup>1</sup>, D. M. Mancini<sup>3</sup>, N. A. Mokadam<sup>4</sup>, K. D. O'Brien<sup>1</sup>, F. D. Pagani<sup>5</sup>, J. Pal<sup>4</sup>, P. C. Schulze<sup>3</sup>, J. Smith<sup>4</sup>, C. Mahr<sup>1</sup>. <sup>1</sup>Internal Medicine, University of Washington, Seattle, WA, <sup>2</sup>Internal Medicine, University of Michigan, Ann Arbor, MI, <sup>3</sup>Internal Medicine, Columbia University, New York, NY, <sup>4</sup>Surgery, University of Washington, Seattle, WA, <sup>5</sup>Cardiac Surgery, University of Michigan, Ann Arbor, MI

**(757) *Is There a Risk of Cocaine and Methamphetamine Use in Heart Donors?;***

J. Rush, M. Kittleson, J. Patel, E. Stimpson, T. Kao, F. Liou, T. Aintablian, S. Siddiqui, D. H. Chang, L. Czer, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA



**(758) *Effects of Coronary Angiography on Heart Procurement in Older Donors: Results From a French National Prospective Study;***

C. Cantrelle<sup>1</sup>, C. Jasseron<sup>1</sup>, I. Pipien<sup>1</sup>, K. Pavaday<sup>1</sup>, E. Epailly<sup>2</sup>, C. Legeai<sup>1</sup>, M. Redonnet<sup>3</sup>, O. Huot<sup>1</sup>, R. Dorent<sup>1</sup>. <sup>1</sup>Medical & Scientific, Agence de la Biomedecine, La Plaine Saint Denis, France, <sup>2</sup>Chirurgie Thoracique, Hopitaux Universitaire de Strasbourg, Strasbourg, France, <sup>3</sup>Chirurgie Thoracique, Hopital Charles Nicolle, Rouen, France

**(759) *Improving Donor Selection and Management: Insights From Eurotransplant Donor Score and Pathology Examination of Discarded Hearts;***

M. Sabatino<sup>1</sup>, B. Barra<sup>1</sup>, L. Potena<sup>1</sup>, O. Leone<sup>2</sup>, V. Manfredini<sup>1</sup>, M. Masetti<sup>1</sup>, N. Alvaro<sup>3</sup>, L. Borgese<sup>1</sup>, G. Marinelli<sup>1</sup>, C. Rapezzi<sup>4</sup>, F. Gri-gioni<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, <sup>2</sup>Pathology, Academic Hospital S. Orsola-Malpighi, Bologna, Italy, <sup>3</sup>Emilia Romagna Organ Procurement Organization, Academic Hospital S. Orsola-Malpighi, Bologna, Italy, <sup>4</sup>Cardi-ology, University of Bologna, Bologna, Italy

**(760) *Donor Time Management in Heart Transplantation – A Single-Center Experience;***

P. Lo<sup>1</sup>, N. Sugianto<sup>1</sup>, E. Granger<sup>2</sup>, P. Jansz<sup>2</sup>, P. Spratt<sup>2</sup>, C. Hayward<sup>2</sup>, A. Jabbour<sup>2</sup>, A. Keogh<sup>2</sup>, E. Kotlyar<sup>2</sup>, P. Macdonald<sup>2</sup>, K. Dhital<sup>2</sup>. <sup>1</sup>Fac-ulty of Medicine, University of New South Wales, Kensington, Aus-tralia, <sup>2</sup>Heart and Lung Transplant Unit, St Vincent's Hospital, Darlinghurst, Australia

**(761) *Restoring Function to the DCD Human Heart Using ECMO Followed By Transportation and Functional Assessment on the TransMedics Organ Care System;***

S. Messer<sup>1</sup>, R. Axell<sup>2</sup>, P. White<sup>2</sup>, M. Roman<sup>1</sup>, S. Colah<sup>3</sup>, T. Tritton<sup>1</sup>, A. Whitehouse<sup>1</sup>, O. Bermudez<sup>1</sup>, M. Goddard<sup>4</sup>, S. Tsui<sup>1</sup>, A. Ali<sup>1</sup>, S. Large<sup>5</sup>. <sup>1</sup>Transplant Surgery, Papworth Hospital, Cambridgeshire, United Kingdom, <sup>2</sup>Clinical Engineering, Addenbrookes Hospital, Cam-bridgeshire, United Kingdom, <sup>3</sup>Cambridge Perfusion Services, Pa-pworth Hospital, Cambridgeshire, United Kingdom, <sup>4</sup>Department of Pathology, Papworth Hospital, Cambridgeshire, United King-dom, <sup>5</sup>Cardiothoracic Surgery, Papworth Hospital, Cam-bridgeshire, United Kingdom

**(762) *'Pharmacological Conditioning' Can Allow the Use of Aged Donor Hearts in Cardiac Transplantation;***

G. Kumarasinghe<sup>1</sup>, L. Gao<sup>2</sup>, M. Hicks<sup>2</sup>, A. Doyle<sup>2</sup>, H. Chew<sup>1</sup>, A. Iyer<sup>2</sup>, A. Jabbour<sup>1</sup>, P. Macdonald<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Unit, St. Vincent's Hospital, Darlinghurst, Australia, <sup>2</sup>Cardiac Transplanta-tion Laboratory, Victor Chang Cardiac Research Institute, Dar-linghurst, Australia

DONOR MANAGEMENT

ORGAN PRESERVATION LUNG

(Agora 2)

(LTX, DMD)

- (763)** *Radiographic Atelectasis Contributes to Donor Hypoxemia and Decreased Lung Utilization: Findings From 418 Donors in the Bold Study;*  
 L. B. Ware<sup>1</sup>, D. R. Jantz<sup>1</sup>, J. Nguyen<sup>2</sup>, J. Singer<sup>3</sup>, N. Neidlinger<sup>2</sup>, M. A. Matthay<sup>3</sup>. <sup>1</sup>Vanderbilt University, Nashville, TN, <sup>2</sup>California Transplant Donor Network, Oakland, CA, <sup>3</sup>University of California San Francisco, San Francisco, CA
- (764)** *Moved to Mini Oral Session 10*
- (765)** *Increasing Donor Lung Utilization: A Focus on Donor Age;*  
 C. T. Holley<sup>1</sup>, R. F. Kelly<sup>2</sup>, R. Z. Brown<sup>3</sup>, M. I. Hertz<sup>4</sup>, K. D. Rudser<sup>3</sup>, C. W. Quinlan<sup>5</sup>, I. Cich<sup>5</sup>, S. J. Shumway<sup>2</sup>, G. Loo<sup>2</sup>. <sup>1</sup>Surgery, University of Minnesota, Minneapolis, MN, <sup>2</sup>Cardiothoracic Surgery, University of Minnesota, Minneapolis, MN, <sup>3</sup>Biostatistics, University of Minnesota, Minneapolis, MN, <sup>4</sup>Pulmonology, University of Minnesota, Minneapolis, MN, <sup>5</sup>University of Minnesota, Minneapolis, MN
- (766)** *Moved to Mini Oral Session 10*
- (767)** *Donation After Circulatory Determination of Death Donor Characteristics and Lung Donor Utilization Within the United States;*  
 J. J. Mooney<sup>1</sup>, H. Hedlin<sup>1</sup>, P. K. Mohabir<sup>1</sup>, R. V. Guillamet<sup>2</sup>, R. Ha<sup>3</sup>, P. Chiu<sup>3</sup>, K. Patel<sup>1</sup>, D. Weill<sup>1</sup>, M. R. Nicolls<sup>1</sup>, G. S. Dhillon<sup>1</sup>. <sup>1</sup>Department of Medicine, Stanford University, Stanford, CA, <sup>2</sup>Department of Medicine, University of New Mexico, Albuquerque, NM, <sup>3</sup>Department of Cardiothoracic Surgery, Stanford University, Stanford, CA
- (768)** *Health of Potential Uncontrolled Donation After Circulatory Determination of Death (uDCDD) Lung Donors: Impact on the Size of the uDCDD Donor Pool;*  
 T. M. Egan<sup>1</sup>, J. Requard<sup>2</sup>, S. Gazda<sup>1</sup>, N. Casey<sup>3</sup>. <sup>1</sup>Surgery, U. North Carolina Sch Med, Chapel Hill, NC, <sup>2</sup>Lung Banks of America, Chapel Hill, NC, <sup>3</sup>Carolina Donor Services, Durham, NC
- (769)** *The University of Minnesota Lung Donor Quality Index (UMN-DLQI): A Consensus-Based Scoring Tool for Lung Donor Evaluations;*  
 G. Loo<sup>1</sup>, D. Radosevich<sup>1</sup>, I. Cich<sup>1</sup>, C. Lyon<sup>2</sup>, J. Morrow<sup>2</sup>, T. Grabowski<sup>2</sup>, C. Holley<sup>1</sup>, R. Kelly<sup>1</sup>, M. Hertz<sup>1</sup>. <sup>1</sup>University of Minnesota, Minneapolis, MN, <sup>2</sup>Fairview Medical Center, Minneapolis, MN
- (770)** *Donor Age and Ischemic Time Are the Only Marginal Donor Criteria That Effect Survival for Lung Transplantation;*  
 E. M. Schumer, J. R. Trivedi, M. Bousamra, II, V. H. van Berkel. Department of Cardiovascular and Thoracic Surgery, University of Louisville, Louisville, KY
- (771)** *Differential Outcomes for Long Term Ex-Vivo Lung Perfusion in a Porcine Model – With or Without Red Cells?;*  
 W. Sommer, J. Salman, M. Avsar, T. Siemeni, K. Jansson, K. Hoefler, C. Kühn, I. Tudorache, A. Haverich, G. Warnecke. Cardiothoracic Surgery, Hannover Medical School, Hannover, Germany
- (772)** *Impact of Age and Smoking History on the Selection of Donors for Lung Transplantation;*  
 H. Schultz<sup>1</sup>, C. H. Møller<sup>2</sup>, M. Zemtsovski<sup>3</sup>, M. Perch<sup>1</sup>, J. Carlsen<sup>1</sup>, M. Iversen<sup>1</sup>. <sup>1</sup>Cardiology, Section of Lung Transplantation, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, <sup>2</sup>Cardiothoracic Surgery, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark, <sup>3</sup>Thoracic Anaesthesia, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark

**(773) *Marginal Donors: “It’s Not What You’ve Got – It’s What You Do With It”;***

S. Kotecha<sup>1</sup>, J. Hobson<sup>1</sup>, J. Fuller<sup>2</sup>, B. Levvey<sup>1</sup>, G. Snell<sup>1</sup>, G. Westall<sup>1</sup>.  
<sup>1</sup>Lung Transplant Service, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne, Australia, <sup>2</sup>Monash University, Melbourne, Australia

**(774) *Ultrastructural Changes in Epithelial and Endothelial Barriers During Ex-Vivo Lung Perfusion;***

D. A. Neil<sup>1</sup>, A. Andreasson<sup>2</sup>, M. Roman<sup>3</sup>, R. Romano<sup>4</sup>, J. Mascaro<sup>1</sup>, S. Tsui<sup>3</sup>, A. Simon<sup>4</sup>, N. Yonan<sup>5</sup>, N. Marczin<sup>4</sup>, J. Dark<sup>2</sup>, A. J. Fisher<sup>2</sup>.  
<sup>1</sup>Queen Elizabeth Hospital, Birmingham, United Kingdom, <sup>2</sup>Free-man Hospital and Newcastle University, Newcastle upon Tyne, United Kingdom, <sup>3</sup>Papworth Hospital, Papworth Everard, United Kingdom, <sup>4</sup>Harefield Hospital and Imperial College London, London, United Kingdom, <sup>5</sup>Wythenshawe Hospital, Manchester, United Kingdom

**(775) *Prolonged Lung Preservation at 24 Hours Using Donor Whole Blood Perfusion in the Organ Care System (OCS);***

G. Loo<sup>r</sup>, B. Howard, T. Iles, L. Mattison, P. Meyer, T. Day, A. Panoskaltis-Mortari, R. Kelly, P. Iaizzo. University of Minnesota, Minneapolis, MN

**(776) *Lung Allocation Score Exception Requests Submitted to the OPTN/UNOS Lung Review Board: Characteristics and Trends;***

K. M. Wille<sup>1</sup>, L. B. Edwards<sup>2</sup>, L. Robbins Callahan<sup>2</sup>, A. R. McKoy<sup>2</sup>, B. C. Cahill<sup>3</sup>, E. P. Trulock<sup>4</sup>, L. F. Angel<sup>5</sup>, K. M. Chan<sup>6</sup>. <sup>1</sup>Univ of Alabama at Birmingham, Birmingham, AL, <sup>2</sup>United Network for Organ Sharing, Richmond, VA, <sup>3</sup>University of Utah, Salt Lake City, UT, <sup>4</sup>Washington University School of Medicine, St. Louis, MO, <sup>5</sup>University of Texas Health Sciences Center at San Antonio, San Antonio, TX, <sup>6</sup>Pulmonary-Critical Care, Univ of Michigan, Ann Arbor, MI

**(777) *WITHDRAWN***

HEART TRANSPLANTATION

(Agora 2)

(ALL)

- (778)** *An Evaluation of IgG, C1q and CDC in Detection of Anti-HLA Antibodies in Incidence of AMR in Heart Allograft Recipients;*  
 R. Vasilescu<sup>1</sup>, E. Ho<sup>1</sup>, L. Li<sup>1</sup>, G. Vlad<sup>1</sup>, D. M. Mancini<sup>2</sup>. <sup>1</sup>Pathology and Cell Biology, Columbia University, New York, NY, <sup>2</sup>Department of Medicine, Columbia University, New York, NY
- (779)** *Safety of the Use of Prothrombin Complex in Anticoagulated Patients Before Heart Transplantation;*  
 J. González-Costello<sup>1</sup>, D. Couto<sup>1</sup>, P. Domènech<sup>2</sup>, G. Muntané<sup>1</sup>, S. Ortega<sup>3</sup>, J. Roca<sup>1</sup>, J. Salazar-Mendiguchía<sup>1</sup>, A. Miralles<sup>1</sup>, F. Sbraga<sup>1</sup>, A. Cequier<sup>1</sup>, N. Manito<sup>1</sup>. <sup>1</sup>Area de Malalties del Cor, Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>2</sup>Area de Trombosi i Hemostàsia, Hospital Universitari de Bellvitge, Barcelona, Spain, <sup>3</sup>Banc de Sang i Teixits, Hospital Universitari de Bellvitge, Barcelona, Spain
- (780)** *Moved to Mini Oral Session 8*
- (781)** *The Influence of Donor Brain Injury and Death Time on Heart Recipients Outcome;*  
 A. Galeone<sup>1</sup>, M. Laali<sup>1</sup>, S. Ouldamar<sup>1</sup>, S. Varnous<sup>1</sup>, N. Ait-Hamou<sup>2</sup>, A. Pavie<sup>1</sup>, P. Leprince<sup>1</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, La Pitié-Salpêtrière Hospital, Paris, France, <sup>2</sup>Department of Anesthesiology, La Pitié-Salpêtrière Hospital, Paris, France
- (782)** *Comparing Induction Immunosuppression With Basiliximab or Rabbit Anti-Thymocyte Globulin After Cardiac Transplantation: A Contemporary Experience;*  
 O. Kiamanesh<sup>1</sup>, A. Khosla<sup>2</sup>, E. Johansson<sup>2</sup>, S. Virani<sup>2</sup>, M. Davis<sup>2</sup>, A. Cheung<sup>3</sup>, J. Bashir<sup>3</sup>, A. Ignaszewski<sup>2</sup>, B. Munt<sup>2</sup>, A. Kaan<sup>2</sup>, M. Toma<sup>2</sup>. <sup>1</sup>Medicine, University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Division of Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada
- (783)** *The Impact of Anti Angiotensin II Type 1 Receptor Antibodies in Human Leucocyte Antigen Antibodies Negative Recipients on Post – Heart Transplantation Outcome;*  
 M. Urban<sup>1</sup>, T. Gazdic<sup>2</sup>, T. Slavcev<sup>3</sup>, I. Netuka<sup>1</sup>. <sup>1</sup>Cardiac Surgery, IKEM, Prague, Czech Republic, <sup>2</sup>Cardiology, IKEM, Prague, Czech Republic, <sup>3</sup>Department of Immunology, IKEM, Prague, Czech Republic
- (784)** *Low Level Donor Specific Antibodies at Transplant Does Not Appear to Be Associated With the development of Cardiac Allograft Vasculopathy After Heart Transplantation;*  
 M. Kittleson, J. Patel, F. Liou, S. Siddiqui, J. Yabuno, D. H. Chang, D. Ramzy, L. Czer, F. Esmailian, N. Reinsmoen, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (785)** *Perioperative Prognostic Factors for Fontan Patients Undergoing Orthotopic Heart Transplant;*  
 C. J. Berg<sup>1</sup>, B. Bauer<sup>1</sup>, A. Hageman<sup>2</sup>, L. C. Reardon<sup>2</sup>. <sup>1</sup>David Geffen School of Medicine at UCLA, Los Angeles, CA, <sup>2</sup>Ahmanson/UCLA Adult Congenital Heart Disease Center, Los Angeles, CA
- (786)** *Histopathological and Immunological Diagnostic Findings for Cardiac Allograft Antibody-Mediated Rejection Following Mechanical Circulatory Support;*  
 K. Wassilew<sup>1</sup>, D. Kemper<sup>2</sup>, N. Lachmann<sup>3</sup>, M. Niemann<sup>3</sup>, C. Schönemann<sup>3</sup>. <sup>1</sup>Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>3</sup>Laboratory for Tissue Typing, Institute of Transfusion Medicine and Cell Therapy, Charité- Universitätsmedizin Berlin, Berlin, Germany

**(787) *Left Ventricular Assist Device-Associated Allosensitization – Much More Than a Nuisance;***

B. Ko, C. A. Willis, S. G. Drakos, D. Hurst, A. G. Kfoury, G. Snow, J. C. Delgado, E. H. Hammond, C. H. Selzman, R. Alharethi, S. McKellar, J. Nativi-Nicolau, E. M. Gilbert, P. Revelo, D. Miller, B. Reid, J. C. Fang, D. D. Eckels, J. Stehlik. U.T.A.H. Cardiac Transplant Program, Salt Lake City, UT

**(788) *Significance of Subthreshold Values of Complement Activation in Myocardium After Cardiac Transplantation.;***

I. Malek<sup>1</sup>, T. Gazdi<sup>1,2</sup>, M. Hegarova<sup>1</sup>, L. Voska<sup>3</sup>, J. Pirk<sup>2</sup>. <sup>1</sup>Clinic of Cardiology, IKEM, Prague, Czech Republic, <sup>2</sup>Clinic of Cardiovascular Surgery, IKEM, Prague, Czech Republic, <sup>3</sup>Department of Pathology, IKEM, Prague, Czech Republic

**(789) *Is It Important to Reduce the Heart Rate in Patients Early After Heart Transplantation?;***

H. Bedanova<sup>1</sup>, J. Ondrasek<sup>1</sup>, P. Fila<sup>1</sup>, V. Horvath<sup>1</sup>, M. Orban<sup>2</sup>, P. Nemeck<sup>1</sup>. <sup>1</sup>Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic, <sup>2</sup>ICRC, Brno, Czech Republic

**(790) *Use of Circulatory Arrest During Heart Transplantation Does Not Worsen Perioperative Survival;***

R. A. Sorabella<sup>1</sup>, S. Krishnamoorthy<sup>1</sup>, M. Najjar<sup>1</sup>, E. Castillero<sup>1</sup>, A. Bader<sup>1</sup>, P. Flanagan<sup>1</sup>, P. C. Schulze<sup>2</sup>, D. Mancini<sup>2</sup>, Y. Naka<sup>1</sup>, H. Takayama<sup>1</sup>, I. George<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, Columbia University College of Physicians and Surgeons, New York, NY, <sup>2</sup>Cardiology, Columbia University College of Physicians and Surgeons, New York, NY

**(791) *Development of Hypertension in Heart Transplant Recipients Treated With Everolimus Compared to a Cyclosporine Based Regimen;***

A. K. Andreassen<sup>1</sup>, H. Eiskjaer<sup>2</sup>, E. Gude<sup>1</sup>, D. Mølbak<sup>2</sup>, W. Stuefloten<sup>1</sup>, L. Gullestad<sup>1</sup>. <sup>1</sup>Dept. of Cardiology, Oslo University Hospital Oslo University Hospital, Oslo, Norway, <sup>2</sup>Dept. of Cardiology, Aarhus University Hospital, Skejby, Denmark

**(792) *Determinants of Restrictive Physiology in HTx Patients;***

T. S. Clemmensen, H. Eiskjaer, B. B. Løgsttrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark

**(793) *Routine Use of Donor Heart De Vega Tricuspid Annuloplasty in Orthotopic Heart Transplantation;***

N. R. Teman<sup>1</sup>, A. H. Wu<sup>2</sup>, M. Masood<sup>1</sup>, M. A. Romano<sup>1</sup>, T. M. Koelling<sup>2</sup>, K. D. Aaronson<sup>2</sup>, F. D. Pagan<sup>1</sup>, J. W. Haft<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Michigan Health System, Ann Arbor, MI, <sup>2</sup>Internal Medicine, University of Michigan Health System, Ann Arbor, MI

**(794) *Rapid Progression of Allograft Coronary Artery Stenosis Is Decreased in Patients Who Received Antithymocyte Globulin Induction at Time of Transplant;***

R. Cheng, C. Vanichsarn, B. Azarbal, L. S. Czer, M. M. Kittleson, J. K. Patel, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA

**(795) *Outcomes of Alcohol Cardiomyopathy Post Heart Transplantation;***

K. J. Lyons, K. A. Pandya, A. Nsaïr, A. S. Baas, M. Cadeiras, D. Cruz, L. C. Reardon, A. Ardehali, M. C. Deng, E. Depasquale. University of Los Angeles California, Los Angeles, CA

**(796) *Clinical Relevance of ISHLT Definition of Primary Graft Dysfunction After Heart Transplantation: A Two Centers Experience;***

G. Vitale<sup>1</sup>, M. Sabatino<sup>1</sup>, V. Manfredini<sup>1</sup>, L. Potena<sup>1</sup>, G. Di Cesaro<sup>2</sup>, S. Martin-Suarez<sup>1</sup>, G. Raffa<sup>2</sup>, G. Marinelli<sup>1</sup>, C. Rapezzi<sup>1</sup>, F. Clemenza<sup>2</sup>, F. Grigioni<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, <sup>2</sup>ISMETT, Palermo, Italy

**(797) *Gene Expression Profiling to Optimize Immunosuppression in Long-Term Heart Transplant Recipients;***

M. E. Maydosz, C. W. May, S. Desai, L. Cantwell, S. Phillips, P. Shah. Heart Failure/Transplant, Inova Transplant Center, Falls Church, VA

- (798) Identification of Clinically Relevant Unacceptable Antigens By Use of Titration Studies of Heart Transplant Patient Sera;**  
 R. H. Kerman<sup>1</sup>, H. Mallidi<sup>1</sup>, W. Etheridge<sup>1</sup>, A. Civitello<sup>2</sup>, P. Jindra<sup>1</sup>.  
<sup>1</sup>Surgery, Baylor College of Medicine, Houston, TX, <sup>2</sup>Cardiology, Baylor College of Medicine, Houston, TX
- (799) Prevalence and Risk Factors for De Novo HLA Donor-Specific Antibodies in Adult Heart Transplant Recipients;**  
 L. A. Goldreich<sup>1</sup>, A. C. Alba<sup>1</sup>, H. J. Ross<sup>1</sup>, K. Tinckam<sup>2</sup>. <sup>1</sup>Cardiac Transplant Program, Peter Munk Cardiac Center, University of Toronto., Toronto, ON, Canada, <sup>2</sup>Histocompatibility Laboratory, University Health Network, University of Toronto., Toronto, ON, Canada
- (800) Drop in Estimated Glomerular Filtration Rate at 1 Year After Heart Transplantation – Concern for Poor Outcome;**  
 K. Ghafourian, J. Patel, M. Kittleson, E. Passano, F. Liou, S. Siddiqui, J. Yabuno, D. Geft, D. H. Chang, L. Czer, A. Trento, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (801) Modified BMI Does Not Predict Adverse Outcomes in Patients With Cardiac Amyloid Undergoing Heart Transplantation: A Report From iCCAT (International Consortium for Cardiac Amyloid Transplantation);**  
 M. Vaduganathan<sup>1</sup>, S. Tabatabai<sup>1</sup>, J. K. Steiner<sup>1</sup>, J. R. Stone<sup>1</sup>, J. D. Estep<sup>2</sup>, R. M. Witteles<sup>3</sup>, G. Feltrin<sup>4</sup>, M. J. Zucker<sup>5</sup>, D. A. Baran<sup>5</sup>, D. C. Seldin<sup>6</sup>, J. Patel<sup>7</sup>, M. Hanna<sup>8</sup>, A. Cordero-Reyes<sup>2</sup>, V. Selby<sup>9</sup>, M. J. Semigran<sup>1</sup>, M. S. Maurer<sup>10</sup>. <sup>1</sup>Massachusetts General Hospital, Boston, MA, <sup>2</sup>The Methodist Hospital, Houston, TX, <sup>3</sup>Stanford University School of Medicine, Stanford, CA, <sup>4</sup>University of Padua, Padua, Italy, <sup>5</sup>Newark Beth Israel Medical Center, Newark, NJ, <sup>6</sup>Boston University School of Medicine, Boston, MA, <sup>7</sup>Cedars-Sinai Heart Institute, Los Angeles, CA, <sup>8</sup>Cleveland Clinic, Cleveland, OH, <sup>9</sup>University of California San Francisco, San Francisco, CA, <sup>10</sup>New York-Presbyterian Hospital / Columbia University Medical Center, New York, NY
- (802) Donor Hypernatremia Is an Independent Predictor of 1-Year Mortality Following Cardiac Transplantation;**  
 M. A. Schechter<sup>1</sup>, C. B. Patel<sup>2</sup>, J. G. Rogers<sup>2</sup>, M. A. Daneshmand<sup>1</sup>, J. N. Schroder<sup>1</sup>, C. A. Milano<sup>1</sup>. <sup>1</sup>Department of Surgery, Duke University Medical Center, Durham, NC, <sup>2</sup>Department of Medicine, Duke University Medical Center, Durham, NC
- (803) Recipients With Shorter Cardiopulmonary Bypass Time Achieve Improvement of Parasympathetic Reinnervation Within 6 Months After Heart Transplantation;**  
 T. Imamura<sup>1</sup>, K. Kinugawa<sup>1</sup>, D. Nitta<sup>2</sup>, T. Inaba<sup>2</sup>, H. Maki<sup>2</sup>, M. Hatano<sup>2</sup>, O. Kinoshita<sup>3</sup>, K. Nawata<sup>3</sup>, M. Ono<sup>3</sup>. <sup>1</sup>Department of Therapeutic Strategy for Heart Failure, University of Tokyo, Tokyo, Japan, <sup>2</sup>Department of Cardiovascular Medicine, University of Tokyo, Tokyo, Japan, <sup>3</sup>Department of Cardiac Surgery, University of Tokyo, Tokyo, Japan
- (804) Dietary-Derived Trimethylamine N-Oxide (TMAO) Levels Are Associated With Coronary Allograft Vasculopathy Following Heart Transplantation;**  
 S. M. Zeltzer<sup>1</sup>, Z. Wang<sup>1</sup>, L. Li<sup>1</sup>, J. Coughlin<sup>1</sup>, T. Hudec<sup>1</sup>, M. Askar<sup>2</sup>, D. O. Taylor<sup>3</sup>, R. Starling<sup>3</sup>, S. Hazen<sup>1</sup>, W. H. Tang<sup>1</sup>. <sup>1</sup>Cellular and Molecular Medicine, Cleveland Clinic Cleveland Clinic, Cleveland, OH, <sup>2</sup>Transplantation Center, Cleveland Clinic Cleveland Clinic, Cleveland, OH, <sup>3</sup>Cardiovascular Medicine, Cleveland Clinic Cleveland Clinic, Cleveland, OH
- (805) Viral Presence in the Donor Heart, Its Evolution and Impact on Rejections in the Early Period After Heart Transplantation;**  
 J. Krejci<sup>1</sup>, E. Ozabalova<sup>1</sup>, P. Hudec<sup>1</sup>, J. Godava<sup>1</sup>, T. Freiburger<sup>2</sup>, E. Nemcova<sup>2</sup>, H. Bedanova<sup>2</sup>, P. Nemecek<sup>2</sup>, L. Spinarova<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Diseases, St. Anne's University Hospital – ICRC, Brno, Czech Republic, <sup>2</sup>Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Republic

- (806) *Cost Implications of Mechanical Circulatory Support for Primary Graft Dysfunction Following Heart Transplantation;***  
 A. A. Ali<sup>1</sup>, M. Schechter<sup>2</sup>, K. Southerland<sup>2</sup>, L. Harling<sup>3</sup>, J. Schroder<sup>2</sup>, C. Milano<sup>2</sup>. <sup>1</sup>Papworth Hospital, Cambridge, United Kingdom, <sup>2</sup>Cardiothoracic Surgery, Duke University Medical Center, Durham, NC, <sup>3</sup>Imperial College, London, United Kingdom
- (807) *Pre-Transplant Red Cell Distribution Width Predicts Short Term Outcome After Heart Transplantation;***  
 G. Poglajen<sup>1</sup>, B. Podgorsek<sup>1</sup>, M. Sever<sup>2</sup>, I. Knezevic<sup>1</sup>, F. Haddad<sup>3</sup>, U. P. Jorde<sup>4</sup>, B. Vrtovec<sup>1</sup>. <sup>1</sup>Advanced Heart Failure and Transplantation Center, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Department of Hematology, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>Stanford Cardiovascular Institute, Stanford, CA, <sup>4</sup>Albert Einstein College of Medicine, New York, NY
- (808) *Moderate-to-Severe Left Ventricular Primary Graft Dysfunction Negatively Affects Long-Term Survival After Heart Transplantation in Asian Patients;***  
 B. Chong<sup>1</sup>, H. Kim<sup>1</sup>, S. Jung<sup>1</sup>, J. Kim<sup>2</sup>, M. Kim<sup>2</sup>, J. Kim<sup>1</sup>, J. Park<sup>3</sup>, S. Choo<sup>1</sup>, T. Yun<sup>3</sup>, C. Chung<sup>1</sup>, J. Lee<sup>1</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, Seoul, Korea, Republic of, <sup>2</sup>Division of Cardiology, Asan Medical Center, Seoul, Korea, Republic of, <sup>3</sup>Division of Pediatric Cardiac Surgery, Asan Medical Center, Seoul, Korea, Republic of
- (809) *Clinical Profiles and Outcomes of Cardiac Transplant Recipients Using Allomap and Cylex Immuknow Assays;***  
 S. R. Krim, P. T. Campbell, S. Desai, S. Mandras, A. Bansal, H. Patel, C. Eiswirth, H. O. Ventura. Cardiology, Ochsner Heart and Vascular Institute, New Orleans, LA
- (810) *Inverse Monocytic Subset Profile in Blood and Tissue During Human Heart Transplant Rejection With a Simultaneous Predominance of M2 Macrophages at the Tissue Level;***  
 T. P. van den Bosch<sup>1</sup>, M. D. Kraaij<sup>1</sup>, K. Caliskan<sup>2</sup>, A. A. Constantinescu<sup>2</sup>, O. C. Manintveld<sup>1</sup>, P. J. Leenen<sup>3</sup>, C. C. Baan<sup>1</sup>, M. C. van Groningen<sup>4</sup>, A. T. Rowshani<sup>1</sup>. <sup>1</sup>Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands, <sup>2</sup>Cardiology, Erasmus Medical Center, Rotterdam, Netherlands, <sup>3</sup>Immunology, Erasmus Medical Center, Rotterdam, Netherlands, <sup>4</sup>Pathology, Erasmus Medical Center, Rotterdam, Netherlands
- (811) *Pathogenicity of Pre-Transplant Donor-Specific Anti-HLA Antibodies in Heart Transplant Recipients;***  
 M. Kubanek<sup>1</sup>, T. Gazdic<sup>2</sup>, E. Svobodova<sup>3</sup>, A. Slavcev<sup>3</sup>, I. Netuka<sup>2</sup>, J. Pirk<sup>2</sup>, I. Malek<sup>1</sup>. <sup>1</sup>Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>2</sup>Cardiac Surgery, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, <sup>3</sup>Immunogenetics, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
- (812) *Gene-Expression Profiling to Monitor for Rejection – Which Patients Are Being Offered This Strategy?;***  
 J. Teuteberg<sup>1</sup>, T. Wolf<sup>2</sup>, P. Prasad<sup>2</sup>, G. Ewald<sup>3</sup>. <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>CareDx, Inc, Brisbane, CA, <sup>3</sup>Washington University, St. Louis, MO
- (813) *Extracorporeal Photopheresis in the Treatment of Complicated Acute Rejection After Heart Transplantation;***  
 S. Wallner<sup>1</sup>, J. Gökler<sup>2</sup>, U. Just<sup>3</sup>, R. Knobler<sup>3</sup>, T. Horner-Golden<sup>3</sup>, A. Zuckermann<sup>1</sup>. <sup>1</sup>Department for Cardiac Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Department for General Surgery, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Department for Dermatology, Medical University of Vienna, Vienna, Austria
- (814) *Prognostic Value of Multislice Computed Tomography Coronary Angiography in Cardiac Transplant Recipients;***  
 C. Yu<sup>1</sup>, P. S. MacDonald<sup>1</sup>, A. M. Keogh<sup>1</sup>, C. S. Hayward<sup>1</sup>, E. Kotlyar<sup>1</sup>, J. M. Otton<sup>1</sup>, J. Huang<sup>1</sup>, M. Chang<sup>1</sup>, D. Boshell<sup>2</sup>, B. Milner<sup>1</sup>, J. McCrohon<sup>1</sup>, N. Sammel<sup>1</sup>, M. Feneley<sup>1</sup>, A. Jabbour<sup>1</sup>. <sup>1</sup>Cardiology, St Vincent's Hospital, Sydney, Australia, <sup>2</sup>Radiology, St Vincent's Hospital, Sydney, Australia

- (815) *Chronic Kidney Disease After Heart Transplantation: A Single Centre Retrospective Study at Skåne University Hospital in Lund 1988-2010;***  
 C. Söderlund, G. Rådegran. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
- (816) *High Prevalence of Myocardial Fibrosis in Patients After Heart Transplantation;***  
 M. R. Silva Filho<sup>1</sup>, D. T. Setuguti<sup>2</sup>, V. O. Carvalho<sup>1</sup>, L. A. Benvenuti<sup>1</sup>, L. F. Silva<sup>3</sup>, E. A. Bocchi<sup>1</sup>. <sup>1</sup>Cardiology, INCOR - FMUSP, São Paulo, Brazil, <sup>2</sup>HCFMUSP, São Paulo, Brazil, <sup>3</sup>Pathology, FMUSP, São Paulo, Brazil,
- (817) *Cardiac Allograft Vasculopathy Assessed By Quantitative Coronary Angiography: A Single Center Prospective Study;***  
 M. Pazdernik<sup>1</sup>, I. Malek<sup>1</sup>, V. Melenovsky<sup>1</sup>, R. Maxian<sup>1</sup>, J. Binova<sup>1</sup>, J. Franekova<sup>2</sup>, A. Jabor<sup>2</sup>, V. Karmazin<sup>1</sup>, M. Hegarova<sup>1</sup>, J. Kautzner<sup>1</sup>. <sup>1</sup>Department of Cardiology, IKEM, Prague, Czech Republic, <sup>2</sup>Department of Laboratory Methods, IKEM, Prague, Czech Republic
- (818) *Vessel Shrinkage (Negative Remodeling) Is the Main Mechanism of Lumen Compromise in Allograft Vasculopathy – A Long-Term Serial Intravascular Ultrasound Study;***  
 K. Goto<sup>1</sup>, I. Iakovou<sup>2</sup>, A. Gkouziouta<sup>2</sup>, A. Maehara<sup>1</sup>, G. S. Mintz<sup>1</sup>, G. Karavolias<sup>2</sup>, V. Leontiadis<sup>2</sup>, V. Voudris<sup>2</sup>, G. Pavlides<sup>2</sup>, S. Adamopoulos<sup>2</sup>. <sup>1</sup>Cardiovascular Research Foundation, Clinical Trial Center, Columbia University Medical Center, Center for Interventional Vascular Therapy, New York USA, NY, <sup>2</sup>Cardiology Department, Onassis Cardiac Surgery Centre, Athens, Greece
- (819) *Potential Value of C4d Capillary Deposition in Myocardial Biopsies and NTproBNP, hs CRP in Serum as Markers of Prognosis in Patients After Heart Transplantation;***  
 T. Zielinski<sup>1</sup>, M. Sobieszczanska-Malek<sup>1</sup>, K. Komuda<sup>1</sup>, M. Karczmaz<sup>1</sup>, A. Browarek<sup>1</sup>, W. Grajkowska<sup>2</sup>, P. Kluge<sup>2</sup>, M. Pronicki<sup>1</sup>, S. Szymanska<sup>2</sup>, A. Parulski<sup>3</sup>, P. Bekta<sup>4</sup>, M. Karcz<sup>4</sup>, J. Wisniewska<sup>1</sup>, J. Rozanski<sup>3</sup>, J. Korewicki<sup>1</sup>. <sup>1</sup>Heart Failure and Transplantology, Institute of Cardiology, Warsaw, Poland, <sup>2</sup>Pathology Department, Children Health Memorial Hospital, Warsaw, Poland, <sup>3</sup>Cardiac Surgery and Transplantation, Institute of Cardiology, Warsaw, Poland, <sup>4</sup>Cardiology and Angiology, Institute of Cardiology, Warsaw, Poland
- (820) *Common Carotid Artery Wall Rigidity Index Is a Marker of Cardiac Allograft Rejection;***  
 A. O. Shevchenko<sup>1</sup>, I. U. Tunyuaeva<sup>2</sup>, A. A. Nasyrova<sup>2</sup>, I. M. Ilynsky<sup>3</sup>, O. P. Shevchenko<sup>4</sup>, S. V. Gautier<sup>5</sup>, V. N. Poptzov<sup>6</sup>. <sup>1</sup>Cardiology Dept., Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, <sup>2</sup>Functional Diagnostics Dept., Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, <sup>3</sup>Pathology Dept., Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, <sup>4</sup>Science Dept., Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, <sup>5</sup>Transplantology Dept., Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation, <sup>6</sup>Intensive Care Unit, Academician V.I.Shumakov Federal Research Center of Transplantology and Artificial Organs, Moscow, Russian Federation
- (821) *Anti-Human Leukocyte Antigen Antibody Class Affects Outcomes After Heart Transplant;***  
 F. Liou, M. Kittleston, J. Patel, S. Siddiqui, M. Luu, B. Kearney, D. Ramzy, D. H. Chang, L. Czer, N. Reinsmoen, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (822) *Echocardiographic Assessment of Right Heart Function in Heart Transplant Recipients and the Relation to Central Hemodynamics;***  
 T. S. Clemmensen, H. Eiskjær, B. B. Løgstrup, S. H. Poulsen. Department of Cardiology, Aarhus University Hospital, Skejby, Denmark, Aarhus N, Denmark



- (823)** *Heart Transplantation With Generic Immunosuppression: A Developing Country Experience;*  
M. A. Villavicencio<sup>1</sup>, E. Larrain<sup>1</sup>, R. Larrea<sup>1</sup>, J. Peralta<sup>1</sup>, V. Rossel<sup>2</sup>, J. Sung<sup>2</sup>, P. Rojo<sup>3</sup>, M. Hurtado<sup>1</sup>, E. Donoso<sup>2</sup>, F. Gajardo<sup>2</sup>. <sup>1</sup>Unidad de Trasplante, Clínica Davila, Santiago, Chile, <sup>2</sup>Unidad de Trasplante, Instituto Nacional del Tórax, Santiago, Chile
- (824)** *Risk Factors for Hospital Admissions for Rejection Following Heart Transplantation: The Real Story;*  
S. Siddiqui, M. Kittleson, J. Patel, F. Liou, T. Aintablian, D. H. Chang, A. Hage, L. Czer, F. Esmailian, J. A. Kobashigawa. Cedars-Sinai Heart Institute, Los Angeles, CA
- (825)** *Acute Cellular Rejection Later Than One Year After Heart Transplantation: A Single Centre Retrospective Study at Skåne University Hospital in Lund 1988-2010;*  
C. Söderlund, G. Rådegran. Department of Cardiology, Clinical Sciences, Lund University, Lund, Sweden
- (826)** *Cardiomyocyte Cell Targets of Humoral Rejection in Cardiac Transplantation: Experimental Modeling in Rats;*  
A. Nguyen, R. Dorent, L. Louedec, A. Nicoletti, P. Nataf, J. Michel. Cardiovascular Surgery Department, Bichat-Claude Bernard Hospital, Paris, France
- (827)** *Title: A Tailored Immunosuppression Strategy After Heart Transplantation (HTx) Based on Preoperative Risk Prediction: Impact on One-year Rejection (REJ) and Infection (INF) Rates at a Single Center;*  
M. Kanwar, A. Raina, O. Pappas, R. Agarwal, E. Horn, G. Sokos, S. Bailey, S. Murali, R. Benza. Cardiology, Allegheny General Hospital, Pittsburgh, PA
- (828)** *Parasympathetic Reinnervation Accompanied By Improved Post-Exercise Heart Rate Recovery and Quality of Life in Heart Transplant Recipients;*  
T. Imamura<sup>1</sup>, K. Kinugawa<sup>1</sup>, T. Inaba<sup>2</sup>, H. Maki<sup>2</sup>, M. Hatano<sup>2</sup>, O. Kinoshita<sup>3</sup>, K. Nawata<sup>3</sup>, M. Ono<sup>3</sup>. <sup>1</sup>Department of Therapeutic Strategy for Heart Failure, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, <sup>2</sup>Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan, <sup>3</sup>Department of Cardiac Surgery, Graduate School of Medicine, University of Tokyo, Tokyo, Japan
- (829)** *Serum-Derived Exosomal Proteome Analysis of Patients With Heart Failure and After Heart Transplantation;*  
P. J. Kennel, R. Givens, D. Brunjes, E. Chen, E. Castillero, H. Takayama, Y. Naka, I. George, D. Mancini, P. C. Schulze. Columbia University Medical Center, New York City, NY
- (830)** *Echocardiographic Evaluation of Ventricular Function Early After Heart Transplantation;*  
A. C. Ingvarsson<sup>1</sup>, A. W. Evaldsson<sup>1</sup>, G. Rådegran<sup>1</sup>, J. Waktare<sup>2</sup>, M. Stagmo<sup>1</sup>, A. Roijer<sup>1</sup>, C. J. Meurling<sup>1</sup>. <sup>1</sup>Department of Cardiology, Clinical Sciences Lund University, Skane University Hospital, Lund, Sweden, <sup>2</sup>Liverpool Heart and Chest Hospital, Liverpool, United Kingdom
- (831)** *Gender-Mismatched Heart Transplants and Gene-Expression Profiling Score--Lessons From the Outcomes AlloMap® Registry (OAR);*  
N. Sulemanjee<sup>1</sup>, P. Prasad<sup>2</sup>, T. Wolf<sup>2</sup>, V. Thohan<sup>1</sup>. <sup>1</sup>Aurora Research Institute, St Luke's Medical Center, Milwaukee, WI, <sup>2</sup>CareDx, Inc, Brisbane, CA
- (832)** *Exploring the Role of Non-HLA Antibodies in Primary Graft Dysfunction After Cardiac Transplantation;*  
P. Shah<sup>1</sup>, A. M. Jackson<sup>2</sup>, M. C. Philogene<sup>2</sup>, S. S. Desai<sup>3</sup>, N. A. Burton<sup>4</sup>, H. Nayer<sup>5</sup>, A. B. Cochrane<sup>6</sup>. <sup>1</sup>Inova Translational Medicine Institute, Inova Fairfax Hospital, Falls Church, VA, <sup>2</sup>Immunogenetics Laboratory, Johns Hopkins University, Baltimore, MD, <sup>3</sup>Heart Failure and Transplantation, Inova Fairfax Hospital, Falls Church, VA, <sup>4</sup>Cardiac Surgery, Inova Fairfax Hospital, Falls Church, VA, <sup>5</sup>Pathology, Inova Fairfax Hospital, Falls Church, VA, <sup>6</sup>Pharmacy, Inova Fairfax Hospital, Falls Church, VA

- (833) *Optical Coherence Tomography Assessment of Coronary Artery Disease and Cardiac Allograft Vasculopathy: A Comparison With Intravascular Ultrasound;***  
 P. Mendes, K. Posina, K. Tanaka, S. Kumar, S. Al-Kindi, G. Attizzani, G. Oliveira, H. Bezerra. University Hospitals Case Medical Center, Cleveland, OH
- (834) *Primary Graft Dysfunction After Cardiac Transplantation Following Continuous-Flow Left Ventricular Device Support;***  
 K. Takeda, H. Takayama, P. C. Colombo, M. Yuzefpolskaya, S. Fukuhara, V. Topkara, M. A. Farr, D. M. Mancini, Y. Naka. Columbia University, NY, NY
- (835) *Cancer Risk After Heart Transplantation Highly Elevated in Comparison to General Population;***  
 S. Jäämaa<sup>1</sup>, B. Salmela<sup>1</sup>, E. Pukkala<sup>2</sup>, K. Lemström<sup>1</sup>, J. Lommi<sup>1</sup>.  
<sup>1</sup>Heart and Lung Center, Helsinki University Central Hospital, Helsinki, Finland, <sup>2</sup>Finnish Cancer Registry, Helsinki, Finland

## INFECTIOUS DISEASES

(Agora 2)

(ALL)

- (836) *Worldwide Survey of Paramyxoviridae Respiratory Infection Perceptions and Practices Among Adult Lung Transplant Centers;***  
 C. R. Ensor<sup>1</sup>, E. J. Kwak<sup>1</sup>, C. A. Merlo<sup>2</sup>, R. K. Avery<sup>2</sup>, L. Danziger-Isakov<sup>3</sup>, A. R. Glanville<sup>4</sup>, M. H. Nguyen<sup>1</sup>, J. B. Orens<sup>2</sup>, J. M. Pilewski<sup>1</sup>, B. A. Potoski<sup>1</sup>, M. R. Zamora<sup>5</sup>, J. F. McDyer<sup>1</sup>. <sup>1</sup>University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Johns Hopkins University, Baltimore, MD, <sup>3</sup>Children's Hospital Medical Center of Cincinnati, Cincinnati, OH, <sup>4</sup>St. Vincent's Hospital, Sydney, Australia, <sup>5</sup>University of Colorado, Denver, CO
- (837) *Mycobacterium abscessus and Lung Transplantation: An International Survey;***  
 H. Bills<sup>1</sup>, G. Snell<sup>2</sup>, B. Levvey<sup>2</sup>, O. Morrissey<sup>3</sup>. <sup>1</sup>Infectious Diseases, Central Clinical School, Monash University, Melbourne, Australia, <sup>2</sup>Lung Transplant Service, Alfred Hospital, Melbourne, Australia, <sup>3</sup>Infectious Diseases, Alfred Hospital, Melbourne, Australia
- (838) *Mycobacterium Abscessus in Lung Transplant Recipients: The University of Pennsylvania Experience;***  
 T. Pena, L. Frye, V. Ahya, J. Diamond, D. Hadjiliadis, J. Christie, R. Shah. Pulmonary, Allergy & Critical Care, University of Pennsylvania, Philadelphia, PA
- (839) *Viral Pneumonia Accelerates Graft Death and CLAD in Lung Transplant Recipients;***  
 P. R. Allyn<sup>1</sup>, E. L. Duffy<sup>2</sup>, R. M. Humphries<sup>3</sup>, R. Saggari<sup>4</sup>, S. S. Weight<sup>4</sup>, J. A. Belperio<sup>4</sup>, D. J. Ross<sup>5</sup>, A. Ardehali<sup>6</sup>, C. Tseng<sup>2</sup>, A. L. Gregson<sup>1</sup>. <sup>1</sup>Department of Medicine, Division of Infectious Diseases, University of California Los Angeles, Los Angeles, CA, <sup>2</sup>Department of Medicine, Statistics Core, University of California Los Angeles, Los Angeles, CA, <sup>3</sup>Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, CA, <sup>4</sup>Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California Los Angeles, Los Angeles, CA, <sup>5</sup>Department of Medicine, Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, CA, <sup>6</sup>Department of Surgery, Division of Cardiothoracic Surgery, University of California, Los Angeles, Los Angeles, CA

- (840) *Everolimus and Valganciclovir Prophylaxis: How to Chase CMV But Not the Patient: Insights From PROTECT Randomized Study;***  
 B. Perciaccante<sup>1</sup>, G. Bianchi<sup>1</sup>, L. Potena<sup>1</sup>, P. Prestinenzi<sup>1</sup>, A. Chiereghin<sup>2</sup>, T. Lazzarotto<sup>2</sup>, M. Masetti<sup>1</sup>, C. Rapezzi<sup>1</sup>, G. Magnani<sup>1</sup>, F. Grigioni<sup>1</sup>. <sup>1</sup>Heart and Lung Transplant Program, University of Bologna, Bologna, Italy, <sup>2</sup>Microbiology Department, University of Bologna, Bologna, Italy
- (841) *Hepatitis B Vaccination in Heart Transplant Recipients: Response Rate and Risk Factors for Loss of Immunity;***  
 E. S. Sukerman<sup>1</sup>, I. Echenique<sup>2</sup>, M. Angarone<sup>1</sup>, R. Gordon<sup>3</sup>, A. Anderson<sup>3</sup>, J. Rich<sup>3</sup>, A. Sauer<sup>3</sup>, T. Abicht<sup>4</sup>, V. Stosor<sup>1</sup>. <sup>1</sup>Infectious Diseases, Northwestern University, Chicago, IL, <sup>2</sup>Infectious Diseases, Cleveland Clinic, Weston, FL, <sup>3</sup>Cardiology, Northwestern University, Chicago, IL, <sup>4</sup>Cardiac Surgery, Northwestern University, Chicago, IL
- (842) *The Utility of Novel Multi-Stage Testing for the Diagnosis of Pulmonary Aspergillosis in a Cohort of Lung Transplant Recipients;***  
 A. Shah<sup>1</sup>, A. Abdolrasouli<sup>1</sup>, S. Soresi<sup>2</sup>, S. Herbst<sup>1</sup>, A. Reed<sup>2</sup>, M. Carby<sup>2</sup>, C. R. Thornton<sup>3</sup>, L. Drumright<sup>1</sup>, S. Shaunak<sup>1</sup>, D. Armstrong-James<sup>1</sup>. <sup>1</sup>Medicine, Imperial College London, London, United Kingdom, <sup>2</sup>Lung Transplant Unit, Royal Brompton and Harefield NHS Trust, London, United Kingdom, <sup>3</sup>School of Biosciences, Exeter University, Exeter, United Kingdom
- (843) *Mortality From Aspergillosis After Heart Transplantation;***  
 S. Al-Kindi, S. Kumar, M. Ige, C. ElAmm, M. Ginwalla, S. Deo, S. J. Park, G. H. Oliveira. University Hospitals Case Medical Center, Cleveland, OH
- (844) *Lung Transplant Recipients (LTRs) With Granulomas in the Explanted Lungs: Assessment of Outcomes Related to Non-Tuberculous Mycobacteria;***  
 D. Kabbani<sup>1</sup>, H. Kozlowski<sup>2</sup>, C. Chaparro<sup>3</sup>, L. Singer<sup>3</sup>, C. Rotstein<sup>2</sup>, S. Keshavjee<sup>4</sup>, S. Husain<sup>2</sup>. <sup>1</sup>Infectious Diseases, University of Alberta, Edmonton, AB, Canada, <sup>2</sup>Infectious Diseases, University Health Network of University of Toronto, Toronto, ON, Canada, <sup>3</sup>Lung Transplant Program, University Health Network of University of Toronto, Toronto, ON, Canada, <sup>4</sup>Lung Transplant Program, University Health Network of University of Toronto, Toronto, ON, Canada
- (845) *Most Effective In Vitro Antimicrobials for Treatment of Stenotrophomonas Maltophilia Infections in Cystic Fibrosis Lung Transplant Recipients;***  
 A. Perry<sup>1</sup>, D. Tierney<sup>1</sup>, J. D. Perry<sup>1</sup>, S. Peart<sup>1</sup>, G. Meachery<sup>2</sup>, F. K. Gould<sup>1</sup>. <sup>1</sup>Microbiology Department, Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>2</sup>Department of Cardiopulmonary Transplantation, Freeman Hospital, Newcastle upon Tyne, United Kingdom



FRIDAY | April 17, 2015

## POSTER SESSION 3 (Agora 2)

Poster presenters and moderators will be present during the evening poster viewing session from 6:00 pm – 7:00 pm.

### EMERGING COUNTRIES

(Agora 2)

(ALL)

- (846)** *Identification of Emerging Micro RNA Markers for Heart Failure Development Using a Bioinformatic Approach;*  
H. E. Verdejo, P. F. Castro, R. Artigas, I. Wichmann, A. Corvalan. Facultad de Medicina, Pontificia Universidad Catolica de Chile, Santiago, Chile
- (847)** *Left Heart Disease Is Prevalent Among Patients With Echocardiographically Determined Pulmonary Hypertension;*  
T. Weitsman, G. Weisz, R. Farkash, D. Meerkin, M. Klutstein, A. Butnaru, D. Rosenmann, T. Hasin. Cardiology, Shaare Zedek Medical Center, Jerusalem, Israel
- (848)** *Modulation of Circulating Endothelial Progenitor Cells and Hsp27 Following Application of Ampaltzer Occluder in Patients With Flow-Induced Pulmonary Hypertension;*  
C. Hsu<sup>1</sup>, J. Roan<sup>2</sup>, J. Wang<sup>3</sup>, C. Huang<sup>4</sup>, J. Chen<sup>5</sup>, C. Lam<sup>6</sup>. <sup>1</sup>Institute of Clinical Medicine, Nat 'I Cheng Kung Univ, Tainan, Taiwan, <sup>2</sup>Division of Cardiovascular Surgery, Nat 'I Cheng Kung Univ Hosp, Tainan, Taiwan, <sup>3</sup>Department of Pediatrics, Nat 'I Cheng Kung Univ Hosp, Tainan, Taiwan, <sup>4</sup>Department of Anesthesiology, Nat 'I Cheng Kung Univ Hosp, Tainan, Taiwan, <sup>5</sup>Department of Internal Medicine, Nat 'I Cheng Kung Univ Hosp, Tainan, Taiwan, <sup>6</sup>Department of Anesthesiology, Buddhist Tzu-Chi General Hospital and Tzu-Chi University School of Medicine, Hualien, Taiwan
- (849)** *Pulmonary Hypertension: ECG-Gating CT Angiographic Evaluation of Functional Parameters Focusing on RVOT as Diagnostic Criteria;*  
Y. Tsai<sup>1</sup>, C. Hsu<sup>2</sup>, C. Wang<sup>1</sup>. <sup>1</sup>Department of Diagnostic Radiology, National Cheng-Kung University College of Medicine and Hospital, Tainan, Taiwan, <sup>2</sup>Department of Internal Medicine, Cardiovascular Division, National Cheng-Kung University College of Medicine and Hospital, Tainan, Taiwan
- (850)** *Predicting Factors of a Fulminant Course of Critical Pulmonary Hypertension;*  
W. T. Li<sup>1</sup>, C. H. Hsu<sup>2</sup>, C. J. Shih<sup>3</sup>. <sup>1</sup>Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, <sup>2</sup>Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan, <sup>3</sup>Department of Surgery, National Cheng Kung University Hospital, Tainan, Taiwan
- (851)** *Evolution of a VAD Program at Ankara University After Reimbursement Issue Resolved in Turkey;*  
R. A. Akar<sup>1</sup>, T. Sayin<sup>2</sup>, M. Sirlak<sup>1</sup>, B. Inan<sup>1</sup>, S. Durdu<sup>1</sup>, Z. Eyleten<sup>1</sup>, C. Ozdol<sup>2</sup>, M. Cakici<sup>1</sup>, E. Ozcinar<sup>1</sup>, M. Gereci<sup>1</sup>, I. Dincer<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Surgery, Ankara University School of Medicine, Ankara, Turkey, <sup>2</sup>Department of Cardiology, Ankara University School of Medicine, Ankara, Turkey

- (852) *Outcomes of Patients Implanted With Heartmate II LVAD Versus Heartware HVAD in an Asian Population;***  
 L. L. Chan<sup>1</sup>, C. Lim<sup>1</sup>, C. Sivathanan<sup>2</sup>, C. Lim<sup>2</sup>, T. Tan<sup>2</sup>, J. Soon<sup>2</sup>, K. Kerk<sup>2</sup>, D. Sim<sup>1</sup>. <sup>1</sup>Cardiology, National Heart Centre Singapore, Singapore, Singapore, <sup>2</sup>Cardiothoracic and Vascular Surgery, National Heart Centre Singapore, Singapore, Singapore
- (853) *Incidence of Tuberculosis Post Lung Transplantation: Single Centre Experience in Argentina;***  
 G. R. Wagner<sup>1</sup>, J. M. Osses<sup>1</sup>, J. O. Caneva<sup>1</sup>, J. R. Ahumada<sup>1</sup>, T. P. Ibañez<sup>1</sup>, R. R. Favalaro<sup>2</sup>, A. M. Bertolotti<sup>1</sup>. <sup>1</sup>Lung Transplantation and Pneumology, Fundación Favalaro, Buenos Aires, Argentina, <sup>2</sup>Intrathoracic Transplantation and Heart Failure Division, Fundación Favalaro, Buenos Aires, Argentina
- (854) *Therapeutical Implications of Clinical Characteristics of Patients With Chagas Cardiomyopathy and Decompensated Heart Failure;***  
 V. S. Issa, G. C. Lima, S. M. Ayub-Ferreira, S. G. Lage, M. T. Oliveira Jr, J. Nicolau, E. A. Bocchi. Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
- (855) *Tacrolimus Monotherapy After Pediatric Heart Transplantation;***  
 A. Szabó, L. Ablonczy, C. Vilmányi, A. Szatmári. Pediatric Cardiac Center, Gottsegen György Hungarian Institute of Cardiology, Budapest, Hungary
- (856) *Is Heart Transplantation a Therapeutic Intervention in Multi-Drug Resistant Ventricular Assist Related Infections?;***  
 A. Gkouziouta, S. Chatzianastasiou, N. Kogerakis, D. Degiannis, S. Adamopoulos, G. Saroglou, P. Sfirakis. Heart Failure, MCS and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece
- (857) *Impact of Native Lung Pneumonectomy in Single-Lung Transplant Recipients;***  
 V. Rusanov<sup>1</sup>, D. Rosengarten<sup>1</sup>, B. Fox<sup>1</sup>, B. Medalion<sup>2</sup>, M. Saute<sup>2</sup>, M. R. Kramer<sup>1</sup>. <sup>1</sup>Pulmonary Institute, Rabin Medical Center, Petach-Tikva, Israel, <sup>2</sup>Cardiothoracic Surgery, Rabin Medical Center, Petach-Tikva, Israel
- (858) *The Outcomes of VAD Implantation in Ege University: The Largest Experience of Turkey;***  
 M. Ozbaran<sup>1</sup>, T. Yagdi<sup>1</sup>, C. Engin<sup>1</sup>, S. Nalbantgil<sup>2</sup>, S. Ertugay<sup>1</sup>, M. Zoghi<sup>2</sup>. <sup>1</sup>Cardiovascular Surgery, Ege University Medical School Hospital, Izmir, Turkey, <sup>2</sup>Cardiology, Ege University Medical School Hospital, Izmir, Turkey
- (859) *Extracorporeal Membrane Oxygenation for Bridge to Heart Transplantation;***  
 S. S. Wang, N. H. Chi, C. H. Wang, S. C. Huang, N. K. Chou, H. Y. Yu, I. H. Wu, Y. S. Chen, W. J. Ko. Cardiovascular Surgery, National Taiwan University Hospital, Taipei, Taiwan
- (860) *High Performance Liquid Chromatography Measured Metabolites of Endogenous Catecholamines and Their Relations to Chronic Kidney Disease and High Blood Pressure in Heart Transplant Recipients;***  
 P. Przybyłowski<sup>1</sup>, G. Wasilewski<sup>1</sup>, M. Wilusz<sup>2</sup>, K. Sztefko<sup>2</sup>, L. Janik<sup>1</sup>, E. Nowak<sup>1</sup>, J. Małyżko<sup>3</sup>. <sup>1</sup>Jagiellonian University Medical College, Krakow, Poland, <sup>2</sup>Dep. of Clinical Biochemistry, Jagiellonian University Medical College, Krakow, Poland, <sup>3</sup>Department of Nephrology and Transplantology, Medical University, Białystok, Poland
- (861) *Influence of Proliferation Signal Inhibitors on Vascular Endothelial Growth Factor Production in Heart Transplant Recipients;***  
 M. Zakliczynski, N. Kamienska, M. Zembala. Silesian Center for Heart Disease, Zabrze, Poland

- (862) *CHA2DS2-Vasc and HAS-BLED Scores as Predictors of Ischemic and Hemorrhagic Stroke Risk After Left Ventricular Assist Device Implantation;***  
H. S. Kemal<sup>1</sup>, S. Ertugay<sup>2</sup>, S. Nalbantgil<sup>1</sup>, M. Zoghi<sup>1</sup>, C. Engin<sup>2</sup>, T. Yagdi<sup>2</sup>, M. Ozbaran<sup>2</sup>. <sup>1</sup>Cardiology, Ege University Faculty of Medicine, Izmir, Turkey, <sup>2</sup>Cardiovascular Surgery, Ege University Faculty of Medicine, Izmir, Turkey
- (863) *Early Atropine Administration During Dobutamine Stress Echocardiography After Heart Transplant: Worth It?;***  
M. S. Lofrano-Alves, T. Weber, D. Rangel, J. Majeski, F. Bacal, W. Mathias Jr, E. Bocchi. Cardiology, University of Sao Paulo, Sao Paulo, Brazil
- (864) *How Long Is Too Long? Extended Biventricular Assist Device Support as a Bridge to Heart Transplantation in a Low Organ Donation Environment;***  
P. Sfirakis, A. Gkouziouta, L. Louca, N. Kogerakis, S. Lakoumenta, G. Karavolias, S. Adamopoulos. Heart Failure, MCS and Transplant Unit, Onassis Cardiac Surgery Centre, Athens, Greece
- (865) *Infarct Atypical Late Gadolinium Enhancement in Cardiac Transplant Patients Predicts 3-Year Survival;***  
E. Simsek<sup>1</sup>, S. Nalbantgil<sup>1</sup>, N. Ceylan<sup>2</sup>, M. Zoghi<sup>2</sup>, H. S. Kemal<sup>2</sup>, S. Ertugay<sup>3</sup>, C. Engin<sup>3</sup>, T. Yagdi<sup>3</sup>, M. Ozbaran<sup>3</sup>. <sup>1</sup>Cardiology, Batman State Hospital, Batman, Turkey, <sup>2</sup>Radiology, Ege University School of Medicine, Izmir, Turkey, <sup>3</sup>Cardiovascular Surgery, Ege University School of Medicine, Izmir, Turkey
- (866) *Lung Transplantation for Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience;***  
H. Jung, W. Yu, C. Lee, S. Haam, J. Lee, H. Paik. Department of Thoracic and Cardiovascular Surgery, Yonse University College of Medicine, Seoul, Korea, Republic of
- (867) *Relationship Between Types of Social Support, Coping Strategies and Depression in Heart Transplant Recipients;***  
I. Milaniak<sup>1</sup>, E. Wilczek – Rużyczka<sup>2</sup>, K. Wierzbicki<sup>3</sup>, P. Przybylowski<sup>3</sup>. <sup>1</sup>John Paul II Hospital 2. Andrzej Frycz Modrzewski Krakow University, Faculty of Health and Medical Science, 3. Polish Transplant Coordinating Centre Poltransplant, Krakow, Poland, <sup>2</sup>Andrzej Frycz Modrzewski Krakow University, Faculty of Psychology and Humanities, Krakow, Poland, <sup>3</sup>John Paul II Hospital 2. Jagiellonian University Collegium Medicum, Krakow, Poland
- (868) *Integrating Pedometer to the 6MWT in Patients With PH;***  
V. E. Gregorietti<sup>1</sup>, G. R. Bortman<sup>2</sup>, R. E. Ferreyra<sup>3</sup>, S. V. Perrone<sup>1</sup>. <sup>1</sup>Transplante Cardiaco- Pulmonay Hypertension, Hospital El Cruce, Buenos Aires, Argentina, <sup>2</sup>Transplante Cardiaco, Sanatorio Trinidad Mitre, Buenos Aires, Argentina, <sup>3</sup>Cardiology, Sanatorio Trinidad Mitre, Buenos Aires, Argentina
- (869) *Atrial Flutter After Cardiac Transplantation: Electrophysiologic Characterization and Catheter Ablation;***  
P. Avellana, C. Hadid, A. Ini, D. Radlovachki, D. Di Toro, C. Labadet, L. Ahualli. Hospital Cosme Argerich, Buenos Aires, Argentina
- (870) *If You Do Not Give – You Will Be the Last One to Get! A New Organ Allocation Policy in Israel Enhances Organ Donation;***  
J. Lavee<sup>1</sup>, T. Ashkenazi<sup>2</sup>, J. B. Kessler<sup>3</sup>, A. Roth<sup>4</sup>, A. Stoler<sup>5</sup>. <sup>1</sup>Heart Transplantation Unit, Leviev Heart Center, Sheba Medical Center, Ramat Gan, Israel, <sup>2</sup>Israel National Transplant Center, Ministry of Health, Tel Aviv, Israel, <sup>3</sup>Business Economics and Public Policy Department, Wharton University of Pennsylvania, Philadelphia, PA, <sup>4</sup>Department of Economics, Stanford University, Stanford, CA, <sup>5</sup>Driehaus College of Business, De Paul University, Chicago, IL
- (871) *ECMO as a Bridge-to-Transplant in Patients With Cardiogenic Shock;***  
I. Knezevic<sup>1</sup>, G. Poglajen<sup>2</sup>, J. Ksela<sup>1</sup>, V. Androcec<sup>2</sup>, M. Racic<sup>1</sup>, M. Jelenc<sup>1</sup>, B. Vrtovec<sup>2</sup>. <sup>1</sup>Department of Cardiovascular Surgery, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia

- (872) *Doubts and Misconceptions Concerning Organ Transplantation and Their Influence on One's Attitude Towards Organ Donation – The Problematic Background of Social Education. A Report From Poland;***  
 E. Nowak<sup>1</sup>, R. Pfitzner<sup>2</sup>, P. Przybyłowski<sup>3</sup>, A. Kozynacka<sup>4</sup>, L. Durajski<sup>5</sup>, P. Przybyłowski<sup>2</sup>. <sup>1</sup>Department of Internal Medicine and Angiology, Brothers Hospitallers' of St. John of God Hospital, Krakow, Poland, <sup>2</sup>Department of Cardiovascular Surgery and Transplantology, Jagiellonian University Medical College, Krakow, Poland, <sup>3</sup>Ludwik Rydygier's Hospital, Krakow, Poland, <sup>4</sup>Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland, <sup>5</sup>Children's Memorial Health Institute, Warsaw, Poland
- (873) *Low Serum Testosterone May Be Associated With Graft Dysfunction Early After Heart Transplantation;***  
 G. Poglajen<sup>1</sup>, M. Jensterle<sup>2</sup>, N. Kravos<sup>2</sup>, F. Haddad<sup>3</sup>, B. Vrtovec<sup>1</sup>. <sup>1</sup>Advanced Heart Failure and Transplantation Ctr, UMC Ljubljana, Ljubljana, Slovenia, <sup>2</sup>Department of Endocrinology, UMC Ljubljana, Ljubljana, Slovenia, <sup>3</sup>Stanford Cardiovascular Institute, Stanford, CA
- (874) *Survival Outcomes With Extracorporeal Membrane Oxygenation (ECMO) in Variable Indications: A 5-Year Single Center Experience;***  
 J. Kim<sup>1</sup>, S. Lee<sup>1</sup>, H. Lee<sup>2</sup>, W. Cho<sup>1</sup>, D. Kim<sup>1</sup>. <sup>1</sup>Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of, <sup>2</sup>Pusan National University Hospital, Busan, Korea, Republic of
- (875) *Analysis of Perception of Own Body and Attitudes Towards Organ Donation Within Polish and Turkish Societies;***  
 E. Makuch<sup>1</sup>, K. Boniecka<sup>2</sup>, B. Aygör<sup>1</sup>, H. Liberska<sup>2</sup>, A. Akar<sup>1</sup>. <sup>1</sup>Department of Cardiovascular and Thoracic, Ankara University, Ankara, Turkey, <sup>2</sup>Psychology, Kazimierz Wielki University, Bydgoszcz, Poland



## PATHOLOGY

(Agora 2)

(PATH, BSI, HF, HTX, LF, LTX, MCS)

**(876)** *Comparative Analysis of the Impact of Stenotic Microvasculopathy on Survival After Heart Transplantation in Two Major European Transplant Centers;*

K. Aumayr<sup>1</sup>, R. Ullrich<sup>1</sup>, A. Zuckermann<sup>2</sup>, K. Wassilew<sup>3</sup>. <sup>1</sup>Clinical Department of Pathology, Medical University Vienna, Vienna, Austria, <sup>2</sup>Surgery and Cardiac Surgery, Medical University Vienna, Vienna, Austria, <sup>3</sup>Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**(877)** *Both Recipient and Donor Cells Are Involved in Human Cardiac Allograft Vasculopathy;*

M. Huijbers<sup>1</sup>, N. de Jonge<sup>2</sup>, E. Siera-de Koning<sup>1</sup>, A. Gareau<sup>3</sup>, R. de Weger<sup>1</sup>. <sup>1</sup>Pathology, UMC Utrecht, Utrecht, Netherlands, <sup>2</sup>Cardiology, UMC Utrecht, Utrecht, Netherlands, <sup>3</sup>Internal Medicine, University of Manitoba, Winnipeg, MB, Canada

**(878)** *Is Pannus an Innocent Bystander in Mechanical Circulatory Support Thrombosis? Examining the Pathology of 50 Explanted Devices;*

A. Luk<sup>1</sup>, A. C. Alba<sup>1</sup>, H. J. Ross<sup>1</sup>, D. Delgado<sup>1</sup>, F. Bilia<sup>1</sup>, M. McDonald<sup>1</sup>, J. MacIver<sup>1</sup>, F. Foroutan<sup>1</sup>, O. Bolonna<sup>2</sup>, R. J. Cusimano<sup>3</sup>, V. Rao<sup>3</sup>, T. M. Yau<sup>3</sup>, J. Butany<sup>4</sup>. <sup>1</sup>Division of Cardiology, University of Toronto, Toronto, ON, Canada, <sup>2</sup>Department of Pathology, University of Toronto, Toronto, ON, Canada, <sup>3</sup>Division of Cardiovascular Surgery, University of Toronto, Toronto, ON, Canada, <sup>4</sup>Department of Pathology, University Health Network, Toronto, ON, Canada

**(879)** *Recurrence of Amyloid in Endomyocardial Biopsies Following Orthotopic Heart Transplantation;*

P. Kumar<sup>1</sup>, F. Liou<sup>2</sup>, J. Patel<sup>2</sup>, L. S. Czer<sup>2</sup>, J. A. Kobashigawa<sup>2</sup>, D. J. Luthringer<sup>1</sup>. <sup>1</sup>Pathology, Cedars Sinai Med Ctr, Los Angeles, CA, <sup>2</sup>Cardiology, Cedars Sinai Heart Institute, Los Angeles, CA

**(880)** *Incidental Primary Malignant Neoplasms in Explanted Lungs at Transplantation;*

P. Sojitra<sup>1</sup>, A. Muralidhar<sup>2</sup>, S. Quddus<sup>3</sup>, D. F. Dilling<sup>3</sup>, S. Mehrotra<sup>1</sup>, V. Ananthanarayanan<sup>1</sup>. <sup>1</sup>Pathology, Loyola University Medical Center, Maywood, IL, <sup>2</sup>Internal Medicine, Loyola University Medical Center, Maywood, IL, <sup>3</sup>Pulmonary and Critical Care Medicine, Loyola University Medical Center, Maywood, IL

**(881)** *Comparative Analysis of Distribution of Acute Cellular Rejection and Antibody-Mediated Rejection With Emphasis on Time After Heart Transplantation in Two European Transplant Centers;*

K. Wassilew<sup>1</sup>, T. Haber<sup>2</sup>, A. Zuckermann<sup>2</sup>, K. Aumayr<sup>3</sup>. <sup>1</sup>Cardiac Pathology Unit, Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Cardiac Surgery Department, Medical University Vienna, Vienna, Austria, <sup>3</sup>Clinical Department of Pathology, Medical University Vienna, Vienna, Austria

**(882)** *Cardiac Post-Transplant Biopsy Tissue Processing and Reporting Protocols for Rejection: A Comparative Survey of Routine Practice Across Three European Centres;*

A. Chaturvedi<sup>1</sup>, K. Aumayr<sup>2</sup>, K. Wassilew<sup>3</sup>. <sup>1</sup>Department of Histopathology, University Hospital of South Manchester (U.K.), Manchester, United Kingdom, <sup>2</sup>Clinical Department of Pathology, Medical University Vienna, Vienna, Austria, <sup>3</sup>Division Cardiac Pathology, Department of Cardiovascular and Thoracic Surgery, Deutsches Herzzentrum Berlin, Berlin, Germany

**(883)** *Cytokine and MicroRNA Profiles of Ectopic Lymphoid Structures in Cardiac Allograft Vasculopathy;*

M. Huijbers<sup>1</sup>, J. van Kuik<sup>1</sup>, S. Beerthuijzen<sup>1</sup>, E. Siera-de Koning<sup>1</sup>, N. de Jonge<sup>2</sup>, R. de Weger<sup>1</sup>. <sup>1</sup>Pathology, UMC Utrecht, Utrecht, Netherlands, <sup>2</sup>Cardiology, UMC Utrecht, Utrecht, Netherlands

PEDIATRICS

(Agora 2)

(PEDI, BSI, DMD, HF, HTX, ID, MCS, NNSAH, PATH, PH, PHARM, PEEQ)

**(884) *Early Detection of Cardiac Allograft Vasculopathy (CAV) With Optical Coherence Tomography (OCT) in Pediatric Heart Transplant Recipients – Comparison to Angiographic Assessment;***

S. Schubert<sup>1</sup>, E. Wellnhofer<sup>2</sup>, B. Peters<sup>1</sup>, M. Kanaan<sup>1</sup>, F. Berger<sup>1</sup>.  
<sup>1</sup>Dept. of Congenital Heart Disease/Pediatric Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Dept. of Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**(885) *Do Pain and Withdrawal Issues Significantly Affect the Post-Transplant Recovery of Pediatric Ventricular Assist Device Recipients?;***

D. Guadiz<sup>1</sup>, P. Shah<sup>2</sup>, J. Mentzer<sup>2</sup>, M. Horn<sup>2</sup>, D. Dechant<sup>2</sup>, C. Buckley<sup>2</sup>, S. Turkel<sup>2</sup>, I. Brook<sup>2</sup>, C. Herrington<sup>2</sup>, J. Szmuszkovicz<sup>1</sup>. <sup>1</sup>Cardiothoracic Transplant, Children's Hospital Los Angeles, Los Angeles, CA, <sup>2</sup>Children's Hospital Los Angeles, Los Angeles, CA

**(886) *Somatic Growth in Children With Ventricular Assist Device Support;***

C. J. Vander Pluym<sup>1</sup>, K. R. Schmitt<sup>2</sup>, B. Hawkins<sup>1</sup>, J. Voelkner<sup>2</sup>, O. Miera<sup>2</sup>. <sup>1</sup>Cardiology, Boston Children's Hospital, Boston, MA, <sup>2</sup>Cardiology, Deutsches Herzzentrum Berlin, Berlin, Germany

**(887) *Incidence and Long-Term Outcome in Patients With Protein Losing Enteropathy (PLE) After the Fontan Operation;***

K. N. Pundji<sup>1</sup>, K. Pundji<sup>2</sup>, J. N. Johnson<sup>1</sup>, Z. Li<sup>3</sup>, P. W. O'Leary<sup>1</sup>, D. J. Driscoll<sup>1</sup>, F. Cetta<sup>1</sup>. <sup>1</sup>Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, <sup>2</sup>Mayo Medical School, Mayo Clinic, Rochester, MN, <sup>3</sup>Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN

**(888) WITHDRAWN**

**(889) *Strain Analysis and Wall Motion Abnormalities Detection By Cardiac Magnetic Resonance: Utility in the Diagnosis of Coronary Allograft Vasculopathy;***

N. N. Dedieu<sup>1</sup>, M. Fenton<sup>1</sup>, M. Silva Nodgueira Viera<sup>2</sup>, J. Wong<sup>2</sup>, G. Greil<sup>2</sup>, M. Burch<sup>1</sup>, T. Hussain<sup>2</sup>. <sup>1</sup>Paediatric Cardiology, Great Ormond St Hospital, London, United Kingdom, <sup>2</sup>Imaging Science, Kings' College London, London, United Kingdom

**(890) *Eligibility for Cardiac Resynchronization Therapy for Systolic Heart Failure in Children With Cardiomyopathy;***

A. R. Patel<sup>1</sup>, J. D. Rossano<sup>2</sup>, P. F. Kantor<sup>3</sup>, J. A. Towbin<sup>4</sup>, S. D. Colan<sup>5</sup>, M. D. Everitt<sup>6</sup>, J. L. Jefferies<sup>4</sup>, D. A. Dodd<sup>7</sup>, J. N. Silva<sup>8</sup>, C. M. Janson<sup>9</sup>, J. D. Wilkinson<sup>10</sup>, T. J. LaRocca<sup>1</sup>, S. E. Lipshultz<sup>1</sup>. <sup>1</sup>University of California – San Francisco, San Francisco, CA, <sup>2</sup>Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Stollery Children's Hospital, Edmonton, AB, Canada, <sup>4</sup>Cincinnati Children's Hospital Medical Center, Cincinnati, OH, <sup>5</sup>Boston Children's Hospital, Boston, MA, <sup>6</sup>Primary Children's Hospital, Salt Lake City, UT, <sup>7</sup>Vanderbilt University, Nashville, TN, <sup>8</sup>St. Louis Children's Hospital, St. Louis, MO, <sup>9</sup>Montefiore Medical Center, New York City, NY, <sup>10</sup>Wayne State University School of Medicine, Detroit, MI, <sup>11</sup>Wayne State University School of Medicine, Detroit, OH

**(891) *Pediatric Heart Transplantation for Anthracycline Cardiomyopathy: A UNOS Database Review;***

M. J. Bock, S. Sehgal, K. Gambetta, B. S. Marino, C. L. Backer, E. Pahl. Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

**(892) *Pre-Transplant Ventricular Assist Device Utilization Varies By Hospital Environment;***

T. Chan<sup>1</sup>, M. S. Kemna<sup>2</sup>, E. Albers<sup>3</sup>, B. J. Hong<sup>3</sup>, Y. M. Law<sup>3</sup>, J. M. Chen<sup>2</sup>, D. M. McMullan<sup>2</sup>. <sup>1</sup>Critical Care, Seattle Children's Hospital, Seattle, WA, <sup>2</sup>Cardiac Surgery, Seattle Children's Hospital, Seattle, WA, <sup>3</sup>Cardiology, Seattle Children's Hospital, Seattle, WA

- (893) Sudden Cardiac Death in Pediatric Patients Awaiting Heart Transplantation: Implantable Cardioverter Defibrillators Provide No Survival Benefit;**  
I. El-Assaad<sup>1</sup>, S. G. Al-Kindi<sup>2</sup>, G. H. Oliveira<sup>2</sup>, G. J. Boyle<sup>3</sup>, P. F. Aziz<sup>3</sup>.  
<sup>1</sup>Pediatrics, Cleveland Clinic Children's, Cleveland, OH, <sup>2</sup>Advanced Heart Failure Center, University Hospitals Case Medical Center, Cleveland, OH, <sup>3</sup>Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH
- (894) Variations in Criteria and Practices for Heart Transplantation Listing Among Pediatric Transplant Cardiologists;**  
A. Patel, E. Pahl, J. G. Gossett. Pediatric Cardiology, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern Feinberg School of Medicine, Chicago, IL
- (895) Influence of Chronic Kidney Disease (CKD) in Outcomes Post Heart Transplant (HT) in Pediatric Recipients;**  
L. C. Reardon, A. Nsair, M. C. Deng, A. Ardehali, J. Alejos, E. C. DePasquale. UCLA, Los Angeles, CA
- (896) Single Drug Immunosuppression for Infant Heart Transplant Recipients;**  
S. M. Stack<sup>1</sup>, J. Eshelman<sup>2</sup>, B. A. Pietra<sup>3</sup>, S. D. Miyamoto<sup>1</sup>, S. R. Auerbach<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Children's Hospital Colorado, Aurora, CO, <sup>2</sup>Pharmacy, Children's Hospital Colorado, Aurora, CO, <sup>3</sup>Pediatric Cardiology, University of Florida, Gainesville, FL
- (897) Risk Factors for Declining Renal Function Over Time in a Cohort of Pediatric Heart Transplant Recipients;**  
A. Kempenaar, C. Manlihot, B. W. McCrindle, A. I. Dipchand. Labatt Family Heart Centre, The Hospital for Sick Children, Toronto, ON, Canada
- (898) Outcome, Prevalence and Risk Factors for Stroke Following Pediatric Heart Transplantation: An Analysis of the ISHLT Registry;**  
C. Morgan, C. Manlihot, B. W. McCrindle, A. Dipchand. Cardiology, Hospital for Sick Children, Toronto, ON, Canada
- (899) Acute Pancreatitis in Pediatric Patients With Ventricular Assist Devices;**  
J. E. Ryan, W. S. Moore II, M. Priest, M. A. McCulloch, C. Pizarro, R. R. Davies. Cardiac Center, Nemours/Alfred I duPont Hospital for Children, Wilmington, DE
- (900) Discharge Outcomes in Children Supported With Continuous Flow Left Ventricular Assist Devices;**  
S. Chen<sup>1</sup>, A. Lin<sup>1</sup>, E. Liu<sup>1</sup>, L. J. May<sup>1</sup>, L. N. Doan<sup>2</sup>, K. Maeda<sup>3</sup>, O. Reinhart<sup>2</sup>, S. A. Hollander<sup>1</sup>, C. S. Almond<sup>1</sup>, D. N. Rosenthal<sup>1</sup>. <sup>1</sup>Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>2</sup>Spectrum Child Health, Stanford University, Palo Alto, CA, <sup>3</sup>Department of Cardiovascular Surgery, Stanford University, Palo Alto, CA
- (901) Mid-term Outcomes After Transplantation Following Resuscitative Bilateral Pulmonary Artery Banding in High-Risk Single Ventricle Neonates and Infants: Single Center Experience;**  
R. A. Murthy<sup>1</sup>, V. A. Sebastian<sup>1</sup>, A. W. Nugent<sup>2</sup>, J. M. Forbess<sup>1</sup>, K. J. Guleserian<sup>1</sup>. <sup>1</sup>Cardiothoracic Surgery, UT Southwestern Medical Center/ Children's Medical Center, Dallas, TX, <sup>2</sup>Cardiothoracic Surgery, UT Southwestern Medical/Children's Medical Center, Dallas, TX
- (902) Biomarkers to Risk Stratify Outcome in Acute Pediatric Heart Failure: Pilot Study of Asymmetric Dimethylarginine;**  
A. Rock<sup>1</sup>, S. Haymond<sup>1</sup>, A. Andrei<sup>2</sup>, E. Pahl<sup>1</sup>. <sup>1</sup>Lurie Children's Hospital, Northwestern University, Chicago, IL, <sup>2</sup>Northwestern University, Chicago, IL
- (903) Effect of Induction Therapy on Graft Survival in Primary Pediatric Heart Transplantation: A Propensity Score Analysis of the UNOS Database;**  
R. J. Butts, M. Davis, A. Savage, A. Burnette, M. Kavarana, A. Atz, P. Nietert. Medical Univ of South Carolina, Charleston, SC

- (904) *New Onset Diabetes Mellitus After Heart Transplant in Children;***  
 S. Sehgal<sup>1</sup>, M. J. Bock<sup>1</sup>, H. L. Palac<sup>2</sup>, J. G. Gossett<sup>1</sup>, B. S. Marino<sup>1</sup>, C. L. Backer<sup>1</sup>, E. Pahl<sup>1</sup>. <sup>1</sup>Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, <sup>2</sup>Department of Preventative Medicine, Northwestern University, Chicago, IL
- (905) *Two Viable Surgical Options for Varying Degree of Pulmonary Vein Stenosis in Pediatric Heart Transplant Recipients;***  
 E. Jean-St-Michel<sup>1</sup>, O. Honjo, C. Manliot, A. Dipchand. Hospital for Sick Children, Toronto, ON, Canada
- (906) *Cirrhosis in Patients Following the Fontan Operation: Incidence and Long-Term Outcomes;***  
 K. Pundi<sup>1</sup>, K. N. Pundi<sup>2</sup>, J. N. Johnson<sup>2</sup>, Z. Li<sup>3</sup>, D. J. Driscoll<sup>2</sup>, F. Cetta<sup>2</sup>. <sup>1</sup>Mayo Clinic College of Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Department of Pediatrics, Division of Pediatric Cardiology, Mayo Clinic, Rochester, MN, <sup>3</sup>Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN
- (907) *How Should the Effect of Persantine Be Measured Using Thromboelastography: Correlation and Agreement Between Percent ADP Inhibition and ADP Net G;***  
 M. Massicotte<sup>1</sup>, J. Conway<sup>2</sup>, L. May<sup>3</sup>, H. Buchholz<sup>4</sup>, C. Lo<sup>5</sup>, A. Bruce<sup>6</sup>, T. Tesoro<sup>7</sup>, D. Rosenthal<sup>8</sup>, C. Almond<sup>8</sup>. <sup>1</sup>Thrombosis KIDCLOT, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, <sup>2</sup>Cardiology, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, <sup>3</sup>Cardiology, Stanford University, Stanford, CA, <sup>4</sup>Cardiac Surgery, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, <sup>5</sup>Hematology, Stanford University, Stanford, CA, <sup>6</sup>Hematology, University of Alberta/Stollery Childrens Hospital, Edmonton, AB, Canada, <sup>7</sup>Pharmacy, Stanford University, Stanford, CA, <sup>8</sup>Cardiology, Stanford University, Stanford, CA, Canada
- (908) *Immune Profiling Pre/Post Berlin VAD Implant and Pre/Post Transplantation of Pediatric Heart Failure Patients;***  
 R. H. Kerman<sup>1</sup>, P. Jindra<sup>2</sup>, A. Jeewa<sup>3</sup>, S. Burki<sup>3</sup>, C. Fraser<sup>3</sup>, I. Adachi<sup>3</sup>. <sup>1</sup>Baylor College of Medicine, Houston, TX, <sup>2</sup>Surgery, Baylor College of Medicine, Houston, TX, <sup>3</sup>Texas Children's Hospital and Baylor College of Medicine, Houston, TX
- (909) *HLA Donor Specific Antibody Production in ABO-Compatible Versus Incompatible Heart Transplant Recipients;***  
 C. Chen<sup>1</sup>, P. Warner<sup>2</sup>, E. L. Albers<sup>1</sup>, M. S. Kerna<sup>1</sup>, L. C. Permut<sup>3</sup>, B. J. Hong<sup>1</sup>, Y. M. Law<sup>1</sup>. <sup>1</sup>Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>2</sup>Immunogenetics/HLA Laboratory, Puget Sound Blood Center, Seattle, WA, <sup>3</sup>Cardiac Surgery, Seattle Children's Hospital, Seattle, WA
- (910) *Automated Analysis of Histopathological Whole Slide Images to Diagnose Pediatric Heart Transplant Rejection;***  
 A. K. Bhatia<sup>1</sup>, J. H. Phan<sup>2</sup>, S. Kothari<sup>2</sup>, B. Shehata<sup>3</sup>, M. Wang<sup>2</sup>. <sup>1</sup>Pediatric Cardiology, Emory University, Decatur, GA, <sup>2</sup>Biomedical Engineering, Georgia Institute of Technology, Atlanta, GA, <sup>3</sup>Pathology, Emory University, Atlanta, GA
- (911) *Supporting Pediatric Patients With Short Term Continuous Flow Devices: The Edmonton Experience;***  
 J. Conway, M. AlAkabi, D. Granoski, S. Islam, L. Ryerson, V. Anand, G. Guerra, A. Mackie, I. Rebeyka, H. Buchholz. Stollery Children's Hospital, Edmonton, AB, Canada,
- (912) *Comparison of Right and Left Ventricular Systolic Function Indices in Duchenne Muscular Dystrophy: A Longitudinal Cardiac Magnetic Resonance Study;***  
 M. Mehmood<sup>1</sup>, K. N. Hor<sup>2</sup>, H. Al-Khalidi<sup>3</sup>, D. W. Benson<sup>4</sup>, J. L. Jعفرis<sup>5</sup>, M. D. Taylor<sup>6</sup>, G. F. Egnaczyk<sup>7</sup>, S. V. Raman<sup>8</sup>, S. Basu<sup>2</sup>, L. Cripe<sup>9</sup>, W. Mazur<sup>7</sup>. <sup>1</sup>Wright State University, Dayton, OH, <sup>2</sup>Nationwide Children's Hospital, Columbus, OH, <sup>3</sup>Duke University Medical Center, Durham, NC, <sup>4</sup>Children's Hospital of Wisconsin, Milwaukee, WI, <sup>5</sup>Cincinnati Children's Hospital, Cincinnati, OH, <sup>6</sup>Cincinnati Children's Hospital, Cincinnati, OH, <sup>7</sup>The Christ Hospital, Cincinnati, OH, <sup>8</sup>Ohio State University, Dayton, OH, <sup>9</sup>Nationwide Children's Hospital, Columbus, OH

- (913)** *Iron Deficiency in Pediatric Heart Failure Patients;*  
D. Higgins, J. Otero, J. Freeburg, C. Jefferis Kirk, M. Kemna, E. Albers, Y. Law. Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA
- (914)** *What Is the Role for Neurodevelopmental Criteria in Patient Selection for Pediatric Heart and Lung Transplantation?;*  
K. P. Daly, D. Freiburger, M. Oliva, C. Harrison, D. S. Kamin. Boston Children's Hospital, Boston, MA
- (915)** *Multicenter Review of Heartware Ventricular Assist Device in Small Children;*  
O. Miera<sup>1</sup>, R. Kirk<sup>2</sup>, H. Buchholz<sup>3</sup>, K. R. Schmitt<sup>1</sup>, I. Rebeyka<sup>3</sup>, N. Wrightson<sup>2</sup>, F. Berger<sup>1</sup>, M. Griselli<sup>2</sup>, J. Conway<sup>3</sup>. <sup>1</sup>Deutsches Herzzentrum Berlin, Berlin, Germany, <sup>2</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom, <sup>3</sup>Stollery Children's Hospital, Edmonton, AB, Canada
- (916)** *Conversion to Proliferation Signal Inhibitors in Pediatric Heart Transplant Patients;*  
C. Castleberry, B. Taylor, A. Hohlbein, T. D. Ryan, J. L. Jefferies, I. Wilmot, A. Lorts, C. Chin. Pediatric Cardiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
- (917)** *A Novel Non-Invasive Assay for the Detection of Rejection Using Cell-Free DNA;*  
P. M. Gordon<sup>1</sup>, N. Chang<sup>1</sup>, U. Sajid<sup>1</sup>, V. Suresh<sup>1</sup>, L. Dimnik<sup>2</sup>, R. E. Lamont<sup>1</sup>, J. S. Parboosingh<sup>1</sup>, R. T. Pon<sup>1</sup>, D. Isaac<sup>3</sup>, S. C. Greenway<sup>4</sup>. <sup>1</sup>Alberta Children's Hospital Research Institute, Calgary, AB, Canada, <sup>2</sup>Molecular Diagnostic Laboratory, Calgary, AB, Canada, <sup>3</sup>Cardiac Sciences, University of Calgary, Calgary, AB, Canada, <sup>4</sup>Paediatrics, Alberta Children's Hospital Research Institute, Calgary, AB, Canada
- (918)** *Prolonged JTc Interval Increases Risk of Life-Threatening Arrhythmias in Children With Dilated Cardiomyopathy;*  
S. Chen<sup>1</sup>, K. S. Motonaga<sup>1</sup>, S. A. Hollander<sup>1</sup>, C. S. Almond<sup>1</sup>, D. N. Rosenthal<sup>1</sup>, B. D. Kaufman<sup>1</sup>, L. J. May<sup>1</sup>, D. T. Dao<sup>2</sup>, A. M. Dubin<sup>1</sup>, S. R. Ceresnak<sup>1</sup>. <sup>1</sup>Division of Pediatric Cardiology, Stanford University, Palo Alto, CA, <sup>2</sup>Department of Surgery, NYU Langone Medical Center, New York City, NY
- (919)** *Beyond 35% Ejection Fraction: Choosing Resynchronization Pacing for Congenital Heart Patients as a Bridge to Transplant;*  
P. Karpawich, Y. Sanil, H. Singh, K. Zelin. Cardiology, The Children's Hospital of Michigan, Wayne State University, Detroit, MI
- (920)** *Pacemaker Implantation in Pediatric Heart Transplant Recipients Is Predicted By Biatrial Anastomosis and Donor Age But Does Not Affect Survival;*  
I. El-Assaad<sup>1</sup>, S. G. Al-Kindi<sup>2</sup>, G. H. Oliveira<sup>2</sup>, G. J. Boyle<sup>3</sup>, P. F. Aziz<sup>3</sup>. <sup>1</sup>Pediatrics, Cleveland Clinic Children's, Cleveland, OH, <sup>2</sup>Advanced Heart Failure Center, University Hospitals Case Medical Center, Cleveland, OH, <sup>3</sup>Pediatric Cardiology, Cleveland Clinic Children's, Cleveland, OH
- (921)** *Variability in Cardiomyopathy Admissions and Transplant Volume at US Children's Hospitals;*  
M. J. O'Connor<sup>1</sup>, N. Wang<sup>1</sup>, J. Long<sup>2</sup>, Y. Huang<sup>2</sup>, K. Lin<sup>1</sup>, T. Singh<sup>3</sup>, J. L. Jefferies<sup>4</sup>, R. Shaddy<sup>1</sup>, J. Rossano<sup>1</sup>. <sup>1</sup>Division of Cardiology, The Children's Hospital of Philadelphia, Philadelphia, PA, <sup>2</sup>Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, <sup>3</sup>Department of Cardiology, Boston Children's Hospital, Boston, MA, <sup>4</sup>Division of Cardiology, Cincinnati Children's Hospital, Cincinnati, OH
- (922)** *Simple Score to Determine Risk of Early Rejection After Pediatric Heart Transplantation;*  
R. J. Butts<sup>1</sup>, A. Savage<sup>1</sup>, A. M. Atz<sup>1</sup>, M. Heal<sup>1</sup>, A. Burnette<sup>2</sup>, M. Kavarana<sup>3</sup>, S. Chowdhury<sup>1</sup>. <sup>1</sup>Pediatrics, Medical University of South Carolina, Charleston, SC, <sup>2</sup>Transplant Services, Medical University of South Carolina, Charleston, SC, <sup>3</sup>Surgery, Medical University of South Carolina, Charleston, SC

- (923)** *Total Lymphoid Irradiation to Successfully Treat Refractory Rejection in Pediatric Heart Transplant Recipients;*  
 L. E. Hernandez, P. A. Kofflin, R. K. Ameduri. Department of Pediatrics, University of Minnesota, Minneapolis, MN
- (924)** *Cardiac Allograft Vasculopathy in Young Adults Who Underwent Heart Transplant in Childhood – A Serial Intravascular Ultrasound Study;*  
 M. A. Kuhn<sup>1</sup>, L. N. Stoletny<sup>2</sup>, M. G. Stevenson<sup>2</sup>, B. M. Gordon<sup>1</sup>, A. J. Razzouk<sup>3</sup>, R. E. Chinnock<sup>1</sup>. <sup>1</sup>Pediatrics, Loma Linda Univ, Loma Linda, CA, <sup>2</sup>Cardiology, Loma Linda Univ, Loma Linda, CA, <sup>3</sup>Cardiothoracic Surgery, Loma Linda Univ, Loma Linda, CA
- (925)** *Incidence and Outcomes of Acute Kidney Injury Following Lung Transplantation in Pediatric Population: Retrospective Review;*  
 M. Gazzaneo<sup>1</sup>, A. Akcan-Arikan<sup>1</sup>, O. Papadias<sup>1</sup>, R. Abelt<sup>2</sup>, E. Melicoff<sup>1</sup>, S. Kim<sup>1</sup>, N. Crews<sup>1</sup>, G. Mallory<sup>1</sup>. <sup>1</sup>Pediatric Pulmonary Transplantation, Texas Childrens Hospital, Houston, TX, <sup>2</sup>Pediatric Pulmonary, Texas Childrens Hospital, Houston, TX
- (926)** *Adenovirus Infection After Pediatric Lung Transplantation: A Pediatric Center Experience and Development of a Clinical Practice Guideline;*  
 N. Crews, M. Ebenbichler, S. Kim, S. Nicholas, E. Melicoff, M. Gazzaneo, G. Mallory. Pediatric Pulmonary Transplantation, Texas Childrens Hospital, Houston, TX
- (927)** *Photopheresis for Chronic Rejection in Pediatric Lung Transplant Recipients;*  
 J. A. Blatter<sup>1</sup>, D. Manley<sup>1</sup>, A. Faro<sup>1</sup>, P. Michelson<sup>1</sup>, A. M. Beck<sup>1</sup>, K. Geile<sup>1</sup>, U. S. Boston<sup>2</sup>, P. Eghtesady<sup>2</sup>, S. Sweet<sup>1</sup>. <sup>1</sup>Department of Pediatrics, Washington University School of Medicine in St. Louis, Saint Louis, MO, <sup>2</sup>Department of Cardiothoracic Surgery, Washington University School of Medicine in St. Louis, Saint Louis, MO

(Agora 2)

(MCS, HF, HTX, MCS, NHSAH)

- (928)** *Degree of BNP Reduction Is Associated With Quality of Life After Left Ventricular Assist Device (LVAD) Implant;*  
C. V. Chien<sup>1</sup>, J. M. Gelow<sup>1</sup>, J. O. Mudd<sup>1</sup>, C. Puckett<sup>1</sup>, S. Hiatt<sup>2</sup>, C. S. Lee<sup>2</sup>. <sup>1</sup>Knight Cardiovascular Institute, Oregon Health & Sci Univ, Portland, OR, <sup>2</sup>Oregon Health & Sci Univ, Portland, OR
- (929)** *Moved to Mini Oral Session 5*
- (930)** *Caretaker's Expectations and Roles in the Decision to Implant Continue Flow Left Ventricular Assist Devices;*  
E. Stahl<sup>1</sup>, A. Smith<sup>2</sup>, R. Laskar<sup>2</sup>, D. Vega<sup>3</sup>, D. Nguyen<sup>3</sup>, A. Morris<sup>2</sup>, R. Cole<sup>2</sup>, D. Gupta<sup>2</sup>. <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>Division of Cardiology, Emory University, Atlanta, GA, <sup>3</sup>Division of Cardiothoracic Surgery, Emory University, Atlanta, GA
- (931)** *Reconceptualizing Shared Decision Making for Heart Failure;*  
C. R. Bruce, R. Volk, J. S. Blumenthal-Barby. Center for Medical Ethics & Health Policy, Baylor College of Medicine, Houston, TX
- (932)** *Acceptability, Feasibility and Implementation of Preparedness Planning for Patients Receiving Left Ventricular Assist Device as Destination Therapy – A Single-Center, 5-Year Experience;*  
K. M. Swetz<sup>1</sup>, B. P. Verdoorn<sup>2</sup>, A. J. Luckhardt<sup>3</sup>, S. M. Dunlay<sup>4</sup>, J. M. Stulak<sup>3</sup>. <sup>1</sup>Medicine, Section of Palliative Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Medicine, Section of Primary Care Medicine/Geriatrics, Mayo Clinic, Rochester, MN, <sup>3</sup>Cardiovascular Surgery, Mechanical Circulatory Support Program, Mayo Clinic, Rochester, MN, <sup>4</sup>Medicine, Division of Cardiovascular Medicine, Mayo Clinic, Rochester, MN
- (933)** *Patient Expectations of Continue Flow Left Ventricular Assist Devices;*  
E. Stahl<sup>1</sup>, A. Smith<sup>2</sup>, R. Laskar<sup>2</sup>, D. Vega<sup>3</sup>, D. Nguyen<sup>3</sup>, A. Morris<sup>2</sup>, R. Cole<sup>2</sup>, D. Gupta<sup>2</sup>. <sup>1</sup>Emory University, Atlanta, GA, <sup>2</sup>Division of Cardiology, Emory University, Atlanta, GA, <sup>3</sup>Division of Cardiothoracic Surgery, Emory University, Atlanta, GA
- (934)** *Outcome After Lung Transplantation of Patients on Extracorporeal Respiratory or Circulatory Support;*  
A. Oude Lansink-Hartgring<sup>1</sup>, W. van der Bij<sup>2</sup>, M. E. Erasmus<sup>3</sup>, V. Cernak<sup>4</sup>, K. M. Vermeulen<sup>5</sup>, W. M. van den Bergh<sup>1</sup>. <sup>1</sup>Department of Critical Care, University Medical Center Groningen, Groningen, Netherlands, <sup>2</sup>Department of Pulmonary Diseases and Lung Transplantation, University Medical Center Groningen, Groningen, Netherlands, <sup>3</sup>Department of Cardiothoracic Surgery, University Medical Center Groningen, Groningen, Netherlands, <sup>4</sup>Department of Anesthesiology, University Medical Center Groningen, Groningen, Netherlands, <sup>5</sup>Department of Epidemiology, University Medical Center Groningen, Groningen, Netherlands
- (935)** *Does Identifying Patients That Need Inpatient Rehabilitation After Continuous-Flow Left Ventricular Assist Device Placement Improve Outcomes?;*  
S. Bensouda<sup>1</sup>, M. E. Davis<sup>2</sup>, M. Djunaidi<sup>1</sup>, M. R. Danter<sup>1</sup>, N. F. So<sup>3</sup>, S. Maltais<sup>1</sup>, N. A. Haglund<sup>4</sup>. <sup>1</sup>Cardiac Surgery, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>2</sup>Vanderbilt Univ Med Ctr, Nashville, TN, <sup>3</sup>PM&R, Vanderbilt Univ Med Ctr, Nashville, TN, <sup>4</sup>Cardiovascular Medicine, Vanderbilt Univ Med Ctr, Nashville, TN

- (936) *Assessment of Patients' and Caregivers' Informational and Decisional Needs for Left Ventricular Assist Device Placement: Implications for Informed Consent and Shared Decision Making;***  
 J. Blumenthal-Barby<sup>1</sup>, K. Kostick<sup>1</sup>, E. Delgado<sup>1</sup>, R. Volk<sup>2</sup>, H. Kaplan<sup>1</sup>, L. Wilhelms<sup>1</sup>, S. McCurdy<sup>3</sup>, J. Estep<sup>4</sup>, M. Loebe<sup>4</sup>, C. Bruce<sup>1</sup>. <sup>1</sup>Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, <sup>2</sup>Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX, <sup>3</sup>The University of Texas School of Public Health, Houston, TX, <sup>4</sup>Houston Methodist DeBakey Heart & Vascular Center and J.C. Walter Jr. Transplant Center, Houston, TX
- (937) *Cost Analysis of Leading Causes for LVAD Patient Readmissions;***  
 A. A. Schmitt, T. Seiger, S. Anders, D. Sandler, N. Nair, T. B. Icenogle. Transplant and Mechanical Heart Program, Providence Sacred Heart Medical Center, Spokane, WA
- (938) *Depression as a Predictor of Compliance and Morbidities After Orthotopic Heart Transplantation;***  
 M. Delibasic<sup>1</sup>, B. Mohamedali<sup>2</sup>, N. Dobrilovic<sup>3</sup>, J. Raman<sup>3</sup>. <sup>1</sup>Department of Internal Medicine, Mercy Hospital and Medical Center, Chicago, IL, <sup>2</sup>Section of Cardiology, Department of Internal Medicine, Rush University Medical Center, Chicago, IL, <sup>3</sup>Cardiovascular and Thoracic Surgery Department, Rush University Medical Center, Chicago, IL
- (939) *Development and Validation of Patient-Centered Knowledge Scale for LVAD Placement;***  
 K. M. Kostick<sup>1</sup>, C. Minard<sup>2</sup>, E. Delgado<sup>1</sup>, L. Wilhelms<sup>1</sup>, C. Bruce<sup>1</sup>, J. D. Estep<sup>3</sup>, M. Loebe<sup>3</sup>, R. Volk<sup>4</sup>, J. S. Blumenthal-Barby<sup>1</sup>. <sup>1</sup>Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, TX, <sup>2</sup>Dan L. Duncan Institute for Clinical and Translational Research, Baylor College of Medicine, Houston, TX, <sup>3</sup>DeBakey Heart and Vascular Center, Houston Methodist Hospital, Houston, TX, <sup>4</sup>Health Services Research, The University of Texas M.D. Anderson Cancer Center, Houston, TX
- (940) *Results of the HVAD Outpatient Management and Monitoring Survey for Optimal Outcomes;***  
 T. Schlöglhofer<sup>1</sup>, D. Robson<sup>2</sup>, J. Bancroft<sup>3</sup>, G. Soerensen<sup>4</sup>, F. Kaufmann<sup>5</sup>, L. Sweet<sup>6</sup>, N. Wrightson<sup>7</sup>. <sup>1</sup>Department of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>St. Vincent's Hospital, Sydney, Australia, <sup>3</sup>Prince Charles Hospital, Brisbane, Australia, <sup>4</sup>Department of Cardiothoracic and Vascular Surgery, Oslo University Hospital, Oslo, Norway, <sup>5</sup>Department of Cardiothoracic and Vascular Surgery, German Heart Institute Berlin, Berlin, Germany, <sup>6</sup>HeartWare Inc., Framingham, MA, <sup>7</sup>Freeman Hospital, Newcastle upon Tyne, United Kingdom
- (941) *Functional Outcomes of Left Ventricular Assist Device Patients Receiving Inpatient Rehabilitation;***  
 L. A. Coyle, K. Milkevitch, R. Adair, A. Tatoes, G. Bhat. Advocate Christ Medical Center, Oak Lawn, IL
- (942) *System of Donor Hospital Transplant Coordinators Maintained and Financed By National Transplant Organization Improves Donation Rates;***  
 T. Danek<sup>1</sup>, J. Czerwiński<sup>2</sup>, I. Milaniak<sup>3</sup>, M. Trujnara<sup>4</sup>, A. Parulski<sup>5</sup>, P. Przybyłowski<sup>6</sup>, R. Danielewicz<sup>2</sup>. <sup>1</sup>Polish Transplant Coordinating Center Poltransplant, Warszawa, Poland, <sup>2</sup>Polish Transplant Coordinating Center Poltransplant, <sup>3</sup>Department of Surgical and Transplant Nursing, Medical University of Warsaw, Warszawa, Poland, <sup>4</sup>John Paul II Hospital, <sup>5</sup>Andrzej Frycz Modrzewski Krakow University, Faculty of Health and Medical Science, <sup>6</sup>Polish Transplant Coordinating Center Poltransplant, Warszawa/Krakow, Poland, <sup>7</sup>Department of Anaesthesiology and Intensive Therapy, Międzyzyleski Specialistic Hospita, Warszawa, Poland, <sup>8</sup>Department of Cardiosurgery, The Cardinal Stefan Wyszyński Institute of Cardiology, Warszawa, Poland, <sup>9</sup>Jagiellonian University Collegium Medicum, Krakow, Poland



## PULMONARY HYPERTENSION

(Agora 2)

(PH, BSI, HF, HTX, LF, LTX, MCS, NHSAH, PHARM)

(943) *WITHDRAWN*

(944) *De Novo Development of Pulmonary Arterial Hypertension in Association With Pregnancy: A Retrospective Case Series;*

L. Harper<sup>1</sup>, J. Swiston<sup>2</sup>, R. Levy<sup>2</sup>, N. Brunner<sup>3</sup>, J. Grewal<sup>3</sup>, M. Idrees<sup>2</sup>, M. Kiess<sup>3</sup>. <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Division of Respiriology, University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Division of Cardiology, University of British Columbia, Vancouver, BC, Canada

(945) *Pulmonary Arterial Hypertension in the Setting of Pregnancy;*

M. Lyle<sup>1</sup>, E. Fenstad<sup>2</sup>, K. Arendt<sup>3</sup>, R. Frantz<sup>2</sup>, H. Connolly<sup>1</sup>, C. Warnes<sup>2</sup>, G. Kane<sup>2</sup>. <sup>1</sup>Internal Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN, <sup>3</sup>Anesthesiology, Mayo Clinic, Rochester, MN

(946) *The Reliability of 6-Minute Walk Test to Predict Exercise Capacity in Patients With Pulmonary Hypertension;*

T. Fujino<sup>1</sup>, M. Hatano<sup>1</sup>, A. Yao<sup>2</sup>, D. Nitta<sup>1</sup>, H. Muraoka<sup>1</sup>, S. Minatsuki<sup>1</sup>, T. Imamura<sup>3</sup>, T. Inaba<sup>1</sup>, H. Maki<sup>1</sup>, K. Kinugawa<sup>3</sup>, I. Komuro<sup>1</sup>. <sup>1</sup>Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan, <sup>2</sup>Division for Health Service Promotion, The University of Tokyo, Tokyo, Japan, <sup>3</sup>Department of Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan

(947) *Muscular Efficiency in Patients With Idiopathic Pulmonary Arterial Hypertension (iPAH): Impact on Clinical Severity and Survival;*

G. Valli<sup>1</sup>, R. Badagliacca<sup>1</sup>, S. Papa<sup>1</sup>, M. Internullo<sup>2</sup>, R. Poscia<sup>1</sup>, B. Pezzuto<sup>1</sup>, M. Nocioni<sup>1</sup>, M. Mezzapesa<sup>1</sup>, F. Pesce<sup>1</sup>, G. Manzi<sup>1</sup>, P. Palange<sup>2</sup>, C. Vizza<sup>1</sup>. <sup>1</sup>Cardiovascular and Respiratory Disease, Sapienza University of Rome, Rome, Italy, <sup>2</sup>Clinical Medicine, Sapienza University of Rome, Rome, Italy

(948) *Normalized Right Isovolumic Relaxation Time and Post-Stress Myocardial Deformation Imaging Reveal Early Signs of Precapillary Pulmonary Hypertension: Insights From a Large Animal Model of Chronic Pressure Overload and Clinical Validation;*

D. Boulate<sup>1</sup>, G. Giraldeau<sup>2</sup>, J. Guihaire<sup>3</sup>, B. Decante<sup>1</sup>, M. Skhiri<sup>2</sup>, I. Schnittger<sup>2</sup>, M. Humbert<sup>4</sup>, J. C. Wu<sup>5</sup>, R. T. Zamanian<sup>6</sup>, E. Fadel<sup>1</sup>, O. Mercier<sup>1</sup>, F. Haddad<sup>7</sup>. <sup>1</sup>Laboratory of Surgical Research, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, <sup>2</sup>Cardiovascular Medicine, Stanford University, Stanford, CA, <sup>3</sup>Adult Cardiac Surgery, Centre Hospitalo Universitaire de Rennes, Rennes, France, <sup>4</sup>INSERM U999, Pulmonary Arterial Hypertension, Pathophysiology and Therapeutic Innovation, Marie Lannelongue Surgical Center, Le Plessis Robinson, France, <sup>5</sup>Cardiovascular Institute, Stanford University, Stanford, CA, <sup>6</sup>Pulmonary and Critical Care Medicine, Stanford University, Stanford, CA, <sup>7</sup>Biomarker and Phenotypic Core Laboratory, Cardiovascular Institute, Stanford University, Stanford, CA

(949) *The Potential Utility of Serial NT-proBNP Measurements in Determining a Therapeutic Response in Group I Pulmonary Artery Hypertension;*

A. M. Wolfson<sup>1</sup>, M. Maitland<sup>2</sup>, V. Thomeas<sup>2</sup>, C. Glassner-Kolman<sup>3</sup>, M. Gomberg-Maitland<sup>3</sup>. <sup>1</sup>Internal Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Internal Medicine / Hematology-Oncology, University of Chicago, Chicago, IL, <sup>3</sup>Internal Medicine / Cardiology, University of Chicago, Chicago, IL

- (950) *Outcomes After Lung Transplantation for Pulmonary Hypertension Associated With End-Stage Pulmonary Disease;***  
 R. A. Varughese<sup>1</sup>, K. Halloran<sup>2</sup>, D. C. Lien<sup>2</sup>, A. Kapasi<sup>2</sup>, M. Thakrar<sup>1</sup>, D. Helmersen<sup>1</sup>, M. Fenton<sup>3</sup>, K. B. Jackson<sup>2</sup>, J. G. Weinkauff<sup>2</sup>. <sup>1</sup>Department of Medicine, University of Calgary, Calgary, AB, Canada, <sup>2</sup>Department of Medicine, University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Department of Medicine, University of Saskatchewan, Saskatoon, SK, Canada
- (951) *Impact of Left Ventricular Diastolic Dysfunction on Outcome Following Lung Transplant in Patients With Pulmonary Arterial Hypertension;***  
 A. Abriel<sup>1</sup>, M. de Perrot<sup>2</sup>, S. Azad<sup>2</sup>, J. Granton<sup>2</sup>. <sup>1</sup>Soroka Medical Center, Ben-Gurion University, Sheva, Israel, <sup>2</sup>Toronto General Hospital, Toronto, ON, Canada
- (952) *The Diastolic Pulmonary Gradient Improves Rapidly After LVAD Implantation in Patients With End-Stage Heart Failure;***  
 R. J. Cogswell<sup>1</sup>, M. Colvin<sup>1</sup>, T. Thenappan<sup>1</sup>, C. Masri<sup>2</sup>. <sup>1</sup>Cardiology, University of Minnesota Division of Cardiology, Minneapolis, MN, <sup>2</sup>Cardiology, University of Washington, Division of Cardiology, Seattle, WA
- (953) *Echocardiographic Predictors of Combined Pre- and Post-Capillary Pulmonary Hypertension in a Population of Systolic Heart Failure With WHO Group II Pulmonary Hypertension;***  
 G. Ashrith, N. Fida, A. M. Cordero-Reyes, J. Amione-Guerra, A. Bhimaraj, B. H. Trachtenberg, G. Torre-Amione, S. Nagueh, J. D. Estep. Cardiology, Houston Methodist Hospital, Houston, TX
- (954) *Partial Pulmonary-Right Heart Oxygenator (PROxy) Support System: A Novel Strategy for Management of Severe Pulmonary Hypertension;***  
 M. Biscotti<sup>1</sup>, O. Wever-Pinzon<sup>2</sup>, M. Yuzefpolskaya<sup>2</sup>, H. Takayama<sup>1</sup>, Y. Naka<sup>1</sup>, E. B. Rosenzweig<sup>3</sup>, M. Bacchetta<sup>1</sup>. <sup>1</sup>Surgery, Columbia University Medical Center, New York, NY, <sup>2</sup>Cardiology, Columbia University Medical Center, New York, NY, <sup>3</sup>Pediatric Cardiology, Columbia University Medical Center, New York, NY
- (955) *Right Ventricular Outflow Tract Doppler Envelope Mid-Systolic Notching Predicts Pulmonary Vascular Disease in Patients With Advanced Lung Disease;***  
 J. Svetlichnaya, V. Selby, J. Singer, L. Klein, M. Janmohamed, S. Hays, J. Kukreja, T. De Marco. University of California San Francisco, San Francisco, CA
- (956) *Measures of Gas Exchange During Six Minute Walk Test Predict Changes in Disease Severity in Pulmonary Artery Hypertension;***  
 H. E. Seale<sup>1</sup>, J. Harris<sup>1</sup>, K. Hall<sup>1</sup>, F. Kermeen<sup>1</sup>, N. R. Morris<sup>2</sup>. <sup>1</sup>Queensland Lung Transplant Service, The Prince Charles Hospital, Brisbane, Australia, <sup>2</sup>School of Allied Health Sciences, Griffith University, Gold Coast, Australia
- (957) *Is Tricuspid Annular Calcification a Novel Marker of End-Stage Pulmonary Hypertension?;***  
 F. Kermeen<sup>1</sup>, T. Butler<sup>2</sup>, D. Seaton<sup>3</sup>, B. Shearer<sup>3</sup>, K. Aldridge<sup>3</sup>, J. Chan<sup>2</sup>. <sup>1</sup>Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia, <sup>2</sup>Cardiology Department, The Prince Charles Hospital, Brisbane, Australia, <sup>3</sup>Queensland Nuclear Imaging, The Prince Charles Hospital, Brisbane, Australia
- (958) *A Comparative Study of Right Ventricular Strain to Established Echocardiographic Parameters in Pulmonary Hypertension;***  
 D. Seaton<sup>1</sup>, A. Yamada<sup>2</sup>, J. Chan<sup>3</sup>, B. Shearer<sup>1</sup>, K. Aldridge<sup>1</sup>, F. Kermeen<sup>4</sup>. <sup>1</sup>Queensland Nuclear Imaging, The Prince Charles Hospital, Brisbane, Australia, <sup>2</sup>Heart Foundation Research Centre, Griffith University, Gold Coast, Australia, <sup>3</sup>Cardiology Department, The Prince Charles Hospital, Brisbane, Australia, <sup>4</sup>Queensland Lung Transplant Unit, The Prince Charles Hospital, Brisbane, Australia

**(959) *Inhaled Treprostinil in Group-3 Pulmonary Hypertension;***

M. Agarwal<sup>1</sup>, A. B. Waxman<sup>2</sup>. <sup>1</sup>Pulmonary Critical Care and Cardiovascular Medicine, Brigham & Women's Hospital, Boston, MA, <sup>2</sup>Center for Pulmonary Heart Disease, Brigham & Women's Hosp, Boston, MA



JUNIOR FACULTY CASE REPORTS

(Agora 2)

(ALL)

- (960) *Successful Bridge to Heart Transplantation With 21 Months' LVAD Support Under the Condition of VF-Fontan Circulation;***  
 Y. Itoda<sup>1</sup>, K. Nawata<sup>1</sup>, H. Yamauchi<sup>1</sup>, O. Kinoshita<sup>1</sup>, M. Kimura<sup>1</sup>, D. Arima<sup>1</sup>, T. Imamura<sup>2</sup>, M. Endo<sup>3</sup>, K. Kinugawa<sup>2</sup>, M. Ono<sup>1</sup>. <sup>1</sup>Cardiac Surgery, The University of Tokyo Hospital, Tokyo, Japan, <sup>2</sup>Department of Therapeutic Strategy for Heart Failure, The University of Tokyo Hospital, Tokyo, Japan, <sup>3</sup>Department of Organ Transplantation, The University of Tokyo Hospital, Tokyo, Japan
- (961) *Rare Case of T-Lymphocytic Vascular Rejection of Lung Allograft Successfully Treated With Rabbit Anti-Thymocyte Globulin;***  
 V. Patel, R. Walia, A. Kalya, A. Omar, J. Haung, E. Kuo, S. Hashimi, M. Smith, R. Bremner. Norton Thoracic Institute, Phoenix, AZ
- (962) *Successful Combined Lung-Liver Transplantation in Patients With Progressive Hepatic Epithelioid Hemangioendothelioma and Pulmonary Metastases;***  
 L. J. Ceulemans<sup>1</sup>, S. Strypstein<sup>1</sup>, A. Neyrinck<sup>2</sup>, P. De Leyn<sup>3</sup>, F. Nevens<sup>4</sup>, J. Pirenne<sup>5</sup>, G. M. Verleden<sup>6</sup>, D. Van Raemdonck<sup>3</sup>. <sup>1</sup>Abdominal Transplant and Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>2</sup>Anesthesiology, University Hospitals Leuven, Leuven, Belgium, <sup>3</sup>Thoracic Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>4</sup>Hepatology, University Hospitals Leuven, Leuven, Belgium, <sup>5</sup>Abdominal Transplant Surgery, University Hospitals Leuven, Leuven, Belgium, <sup>6</sup>Pneumology, University Hospitals Leuven, Leuven, Belgium
- (963) *Successful Usage of Venovenous ECMO Using Dual Lumen Catheter for Bridge to Redo Heart-Lung Transplantation;***  
 A. Shiose, J. Gomez-Abraham, G. Wheatley, T. S. Guy, E. Hamad, D. Dries, R. J. Alvarez, N. Patel, F. Cordova, G. J. Criner, Y. Toyoda. Temple University Hospital, Philadelphia, PA
- (964) *Severe, Reversible Right Ventricular Failure in a Patient With Hashimoto's Thyroiditis;***  
 H. S. Magdo, K. R. Schumacher, M. S. Si, R. J. Gajarski, J. M. Friedland-Little. Congenital Heart Center, C.S. Mott Children's Hospital, University of Michigan, Ann Arbor, MI
- (965) *Ehrlichiosis Induced Hemophagocytic Lymphohistiocytosis in a Lung Transplant Recipient;***  
 P. R. Aguilar, R. R. Hachem. Pulmonary & Critical Care Medicine, Washington Univ Sch Med, Saint Louis, MO
- (966) *Acute Left Coronary Compression Due to Type A Dissection – Cardiac Transplantation as Life Saving Treatment in a Young Marfan Patient;***  
 J. Dumfarth<sup>1</sup>, D. Hofer<sup>1</sup>, G. Poelzl<sup>2</sup>, D. Baumgartner<sup>3</sup>, M. Kaufmann<sup>4</sup>, S. Eschertzhuber<sup>4</sup>, M. Grimm<sup>1</sup>, H. Antretter<sup>1</sup>. <sup>1</sup>Dept. for Cardiac Surgery, University Clinic Innsbruck, Innsbruck, Austria, <sup>2</sup>Dept. for Cardiology, University Clinic Innsbruck, Innsbruck, Austria, <sup>3</sup>Dept. for Pediatric Cardiology, University Clinic Innsbruck, Innsbruck, Austria, <sup>4</sup>Dept. for Anesthesiology and Intensive Care, University Clinic Innsbruck, Innsbruck, Austria
- (967) *Pulmonary Vein Stenosis Complicated By Early Thrombosis Post Single Lung Transplant;***  
 A. Daly, D. Eaton, J. J. Egan, K. C. Redmond. Professor Eoin O'Malley National Centre for Cardiothoracics, Mater Misericordiae University Hospital, Dublin 7, Ireland
- (968) *Secondary Hemochromatosis After Total Artificial Heart Implantation;***  
 I. Tchoukina, D. G. Tang, M. P. Flattery, K. B. Shah. Virginia Commonwealth University, Richmond, VA

- (969) *Prolonged Resuscitation and Cardiogenic Shock After Intoxication With European Yew (Taxus baccata): Complete Recovery After Intermittent Mechanical Circulatory Support;***  
 C. Baum<sup>1</sup>, S. Bohnen<sup>1</sup>, B. Sill<sup>2</sup>, S. Philipp<sup>3</sup>, S. Kluge<sup>4</sup>, H. Reichen-spurner<sup>2</sup>, S. Blankenberg<sup>1</sup>, G. Söffker<sup>4</sup>, M. J. Barten<sup>2</sup>, K. Sydow<sup>1</sup>.  
<sup>1</sup>General and Interventional Cardiology, UHZ Hamburg, Hamburg, Germany, <sup>2</sup>Cardiovascular Surgery, UHZ Hamburg, Hamburg, Germany, <sup>3</sup>General Cardiology and Intensive Care Medicine, Elbekliniken Stade, Stade, Germany, <sup>4</sup>Intensive Care Medicine, UKE Hamburg, Hamburg, Germany
- (970) *Evaluating Quality in Ex-Vivo Lung Perfusion.;***  
 P. G. Sanchez<sup>1</sup>, G. J. Bittle<sup>1</sup>, K. Rajagopal<sup>1</sup>, I. Timofte<sup>2</sup>, J. Kim<sup>2</sup>, A. T. Iacono<sup>2</sup>, J. S. Gammie<sup>1</sup>, S. M. Pham<sup>1</sup>, B. P. Griffith<sup>1</sup>. <sup>1</sup>Cardiac Surgery, University of Maryland, Baltimore, MD, <sup>2</sup>Medicine, University of Maryland, Baltimore, MD
- (971) *Excellent Outcomes in HIT With Therapeutic Apheresis Prior to CPB in Patients Undergoing Heart Transplantation;***  
 R. Tandon<sup>1</sup>, A. Tandon<sup>2</sup>, K. Light-McGroary<sup>3</sup>, V. Cotarlan<sup>2</sup>. <sup>1</sup>University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>2</sup>Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>3</sup>Cardiology, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA
- (972) *Transapical Transcatheter Aortic Valve Implantation (TA-TAVI) After Long-Term Heart Transplantation;***  
 M. Stelzmüller<sup>1</sup>, K. Uyanik-Ünal<sup>1</sup>, B. Mora<sup>2</sup>, S. Sandner<sup>1</sup>, G. Laufer<sup>1</sup>, A. Zuckermann<sup>1</sup>, W. Wisser<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, Medical University Vienna, Vienna, Austria, <sup>2</sup>Department of Cardiac Thoracic Anaesthesia and Intensive Care, Medical University Vienna, Vienna, Austria
- (973) *Transthyretin Familial Cardiac Amyloidosis Donour Selection: Heart vs. Heart Liver Transplantation;***  
 K. J. Lyons, G. A. Fishbein, E. Depasquale, R. Ardehali, A. S. Baas, M. Cadeiras, D. Cruz, M. C. Deng. University of Los Angeles California, Los Angeles, CA
- (974) *Assessing Myocardial Recovery and Reserve Using Dobutamine Trans-Oesophageal Echocardiography (TOE) and Exercise Right Heart Catheterization (RHC) to Allow Safe Explantation of a Left Ventricular Assist Device (LVAD);***  
 M. B. Stokes, P. Bergin, D. M. Kaye. Heart Centre, The Alfred Hospital, Prahan, Victoria, Australia
- (975) *Temporary and Durable Mechanical Circulatory Support for Single Ventricular Failure;***  
 J. L. Hermsen<sup>1</sup>, J. W. Smith<sup>1</sup>, C. Mahr<sup>2</sup>, K. K. Stout<sup>2</sup>, A. Rubio<sup>3</sup>, T. K. Jones<sup>4</sup>, E. D. Verrier<sup>1</sup>, F. R. Shaw<sup>1</sup>, E. V. Krieger<sup>2</sup>, J. D. Pal<sup>1</sup>, J. A. Beckman<sup>2</sup>, N. A. Mokadam<sup>5</sup>. <sup>1</sup>Cardiothoracic Surgery, Univ Washington Med Ctr, Seattle, WA, <sup>2</sup>Cardiology, Univ Washington Med Ctr, Seattle, WA, <sup>3</sup>Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>4</sup>Cardiology, Seattle Children's Hospital, Seattle, WA, <sup>5</sup>Univ Washington Med Ctr, Seattle, WA
- (976) *A Case of Interferon- $\alpha$  Induced Pulmonary Arterial Hypertension After Living Liver Transplantation;***  
 T. Ko, M. Hatano, D. Nitta, H. Muraoka, S. Minazuki, T. Imamura, T. Inaba, H. Maki, A. Yao, K. Kinugawa, I. Komuro. Department of Cardiovascular Medicine, The University of Tokyo, Tokyo, Japan
- (977) *Novel Aortic Valve Closure in Patient With Aortic Insufficiency After Placement of Left Ventricular Assist Device (LVAD);***  
 B. A. Smith<sup>1</sup>, N. Uriel<sup>1</sup>, V. Jeevanandam<sup>2</sup>, G. Kim<sup>1</sup>, G. Sayer<sup>1</sup>, S. Fedson<sup>1</sup>, T. Ota<sup>2</sup>, A. Shah<sup>1</sup>. <sup>1</sup>Medicine, University of Chicago, Chicago, IL, <sup>2</sup>Surgery, University of Chicago, Chicago, IL
- (978) *Informed Transplant Refusal of a Pediatric Patient;***  
 C. R. Bruce<sup>1</sup>, B. Trachtenberg<sup>2</sup>. <sup>1</sup>Center for Medical Ethics & Health Policy, Baylor College of Medicine, Houston, TX, <sup>2</sup>Houston Methodist DeBakey Heart & Vascular Center, Houston Methodist Hospital, Houston, TX

- (979) *Minimally Invasive Percutaneous Vascular Access With Pre-Closure During Subcostal Exchange of Heartmate II;***  
 U. S. Ahmad, S. Ramee. Cardiothoracic Surgery, Ochsner Clinic Foundation, New Orleans, LA
- (980) *Role of Electron Microscopic Evaluation in Transplant Decisions of Advanced Chemotherapy Induced Cardiomyopathy;***  
 J. Youn<sup>1</sup>, S. Lee<sup>2</sup>, S. Lee<sup>2</sup>, Y. Youn<sup>2</sup>, B. Chang<sup>2</sup>, S. Kang<sup>1</sup>. <sup>1</sup>Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of, <sup>2</sup>Division of Cardiovascular Surgery, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of
- (981) *Nocardia Infections After Lung Transplantation: A Case Series;***  
 V. Rossetti<sup>1</sup>, L. Morlacchi<sup>1</sup>, M. Pappaletta<sup>1</sup>, P. Tarsia<sup>1</sup>, P. Mendogni<sup>2</sup>, F. Blasi<sup>1</sup>. <sup>1</sup>U.O. Broncopneumologia; Dipartimento di Fisiopatologia e dei Trapianti, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy, <sup>2</sup>U.O. Chirurgia Toracica e dei Trapianti di Polmone, IRCCS Fondazione Ca' Granda Ospedale Maggiore Policlinico di Milano; Università degli Studi di Milano, Milano, Italy
- (982) *LVAD Implantation for Cardiac Allograft Failure in a Child: Achieving Long-Term Survival Without Wound or Infectious Complications;***  
 S. M. Haldeman, R. Davies, S. Gidding, M. McCulloch, C. Pizarro. Cardiology, A.I duPont Hospital for Children, Wilmington, DE
- (983) *Early Progression of MGUS to Multiple Myeloma in a Heart Transplant Recipient: A Cautionary Tale;***  
 J. A. Hernandez-Montfort<sup>1</sup>, D. A. Baran<sup>2</sup>, I. Sabnani<sup>1</sup>, P. Dhesis<sup>1</sup>, S. Murthy<sup>1</sup>, J. Pieretti<sup>1</sup>, C. Gidea<sup>1</sup>, M. Camacho<sup>1</sup>, M. J. Zucker<sup>1</sup>. <sup>1</sup>Heart Failure and Cardiac Transplant, Newark Beth Israel Medical Center, Jersey City, NJ, <sup>2</sup>Transplant Center, Newark Beth Israel Medical Center, Jersey City, NJ
- (984) *Left Ventricular Assist Device Associated Culture-Negative Bartonella Henselae Endocarditis (Cat Scratch Fever);***  
 A. K. Mankad<sup>1</sup>, H. Kapoor<sup>2</sup>, K. B. Shah<sup>2</sup>. <sup>1</sup>Hunter Holmes McGuire Veterans Medical Center, Richmond, VA, <sup>2</sup>Medical College of Virginia, Richmond, VA
- (985) *Mechanical Circulatory Support in a Child With Single Ventricle Heart Disease and MAPCAs;***  
 W. F. Carlo, F. B. Pearce, J. K. Kirklin. University of Alabama, Birmingham, AL
- (986) *Surgical Treatment for Tricuspid Valve Regurgitation Occurring Early After Heart Transplantation;***  
 E. Bollano<sup>1</sup>, H. Liden<sup>2</sup>, K. Karason<sup>1</sup>, G. Dellgren<sup>2</sup>. <sup>1</sup>Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden, <sup>2</sup>Cardiothoracic surgery, Sahlgrenska University Hospital, Gothenburg, Sweden
- (987) *EBV Associated Smooth Muscle Cell Tumor Secondary to Intestinal Post Transplant Lymphoproliferative Disease (PTLD) in a Child After Heart Transplant;***  
 N. Alami Laroussi<sup>1</sup>, J. Conway<sup>1</sup>, L. West<sup>1</sup>, S. Desai<sup>2</sup>, L. Mc Gonigle<sup>3</sup>, B. Dicken<sup>4</sup>, S. Urschel<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Stollery Children's Hospital, Edmonton, AB, Canada, <sup>2</sup>Pediatric Hematology Oncology, Stollery Children's Hospital, Edmonton, AB, Canada, <sup>3</sup>Pediatrics, Stollery Children's Hospital, Edmonton, AB, Canada, <sup>4</sup>Pediatric Surgery, Stollery Children's Hospital, Edmonton, AB, Canada
- (988) *Pulmonary Hypertension in Antisynthetase Syndrome;***  
 M. Lyle<sup>1</sup>, E. Fenstad<sup>2</sup>, R. Frantz<sup>2</sup>, G. Kane<sup>2</sup>. <sup>1</sup>Internal Medicine, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiovascular Diseases, Mayo Clinic, Rochester, MN

- (989) *Percutaneous Closure Device for the Management of Post-Operative Cardiogenic Shock Due to Severe Aortic Insufficiency After LVAD Implantation: Lessons Learned;***  
F. H. Sheikh, L. Satler, Z. Wang, D. T. Majure, G. Ruiz, M. Hofmeyer, M. E. Rodrigo, E. J. Molina, S. W. Boyce, S. S. Najjar. MedStar Heart Institute, Washington, DC
- (990) *Heart Transplantation in Situs Inversus – A Case Report;***  
J. Y. Song<sup>1</sup>, Y. C. Lin<sup>2</sup>, C. Y. Lin<sup>2</sup>, C. S. Tsai<sup>2</sup>. <sup>1</sup>Division of Cardiovascular Surgery, Department of Surgery, Armed Forces Taichung General Hospital, Taichung, Taiwan, <sup>2</sup>Division of Cardiovascular Surgery, Department of Surgery, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan
- (991) *Serious Infection of the Left Ventricular Titanium Plug Used at the Time of HeartWare HVAD Explantation;***  
B. Maxhera, A. Albert, A. Mehdiani, U. Boeken, A. Lichtenberg, D. Saeed. Cardiovascular Surgery, Heinrich-Heine University Dusseldorf, Dusseldorf, Germany
- (992) *Patient With JC-virus Infection and Progressive Multifocal Leukoencephalopathy After Heart Transplantation, Over 2 Years of Clinically Stable Infection on Low Dose Immunosuppression;***  
P. Sundbom<sup>1</sup>, L. Hubbert<sup>1</sup>, C. Dahle<sup>2</sup>, L. Serrander<sup>3</sup>. <sup>1</sup>Department of Cardiology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden, <sup>2</sup>Department of Neurology and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden, <sup>3</sup>Department of Infectious Diseases and Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden
- (993) *Development of Reye-Like Syndrome after Left Ventricular Assist Device Implantation for Mitochondrial Cardiomyopathy;***  
T. Motokawa<sup>1</sup>, O. Seguchi<sup>1</sup>, E. Hisamatsu<sup>1</sup>, K. Kuroda<sup>1</sup>, T. Sato<sup>1</sup>, S. Nakajima<sup>1</sup>, H. Sunami<sup>1</sup>, T. Sato<sup>1</sup>, M. Yanase<sup>1</sup>, Y. Matsumoto<sup>1</sup>, H. Hata<sup>1</sup>, T. Fujita<sup>1</sup>, Y. Ikeda<sup>1</sup>, H. Ueda<sup>1</sup>, Y. Goto<sup>2</sup>, J. Kobayashi<sup>1</sup>, T. Nakatani<sup>1</sup>. <sup>1</sup>National Cerebral and Cardiovascular Center, Osaka, Japan, <sup>2</sup>National Center of Neurology and Psychiatry, Tokyo, Japan
- (994) *Obesity and Early Loss of Mobility in Two Adolescents With Becker Muscular Dystrophy Following HeartMate II Implantation;***  
S. A. Hollander<sup>1</sup>, S. Rizzuto<sup>2</sup>, A. M. Hollander<sup>2</sup>, A. Lin<sup>3</sup>, E. Liu<sup>3</sup>, J. M. Murray<sup>3</sup>, C. S. Almond<sup>1</sup>, D. N. Rosenthal<sup>1</sup>. <sup>1</sup>Pediatrics (Cardiology), Stanford University, Palo Alto, CA, <sup>2</sup>Rehabilitation Services, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA, <sup>3</sup>Pediatric Heart Transplantation, Lucile Packard Children's Hospital, Stanford, Palo Alto, CA
- (995) *Severe Outflow Graft Obstruction Presenting Four Years Post-Implant in a Centrifugal Flow LVAD: Percutaneous or Surgical Management?;***  
S. M. Jani, D. T. Majure, G. Weissman, W. G. Weigold, F. H. Sheikh, M. E. Rodrigo, M. Hofmeyer, G. Ruiz, S. S. Najjar, S. W. Boyce. MedStar Heart Institute, Washington, DC
- (996) *Eosinophilia, Rash and Overwhelming Sepsis in a Heart Transplant Recipient: DRESS vs Hyper IgE Syndrome;***  
R. Tandon<sup>1</sup>, A. Tandon<sup>2</sup>, J. L. Goerbig-Campbell<sup>3</sup>. <sup>1</sup>Medicine, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>2</sup>Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, <sup>3</sup>Cardiology, University of Iowa University of Iowa Hospitals and Clinics, Iowa City, IA
- (997) *First Successful Percutaneous Right Heart and Respiratory Support With Single Double Lumen Catheter and Oxygenator;***  
A. Shiose, T. Yoshiya, D. Edmundowicz, B. O'Neill, R. Bashir, B. O'Murchu, J. Gomez-Abraham, G. Wheatley, T. S. Guy, L. Punnoose, D. R. Schwartz, E. Tsai, P. Forfia, D. Dries, R. J. Alvarez, E. Hamad, H. Cohen. Temple University Hospital, Philadelphia, PA

- (998) *Cutaneous Alternariosis Infection in a Heart Transplant Recipient;***  
 L. Ahualli, P. Avellana, A. Inji, D. Radlovachki, E. Maiolo, M. Ajzensz-  
 los, S. Belforte. Hospital Cosme Argerich, Buenos Aires, Argentina
- (999) *Successful Bilateral Lung Transplant in HIES;***  
 E. A. Lendermon<sup>1</sup>, A. F. Freeman<sup>2</sup>, K. N. Olivier<sup>2</sup>, J. M. Pilewski<sup>1</sup>, E. J. Kwak<sup>3</sup>, J. D'Cunha<sup>4</sup>, C. R. Ensor<sup>5</sup>, M. M. Crespo<sup>1</sup>, S. M. Holland<sup>2</sup>, C. A. Bermudez<sup>4</sup>, J. F. McDyer<sup>1</sup>. <sup>1</sup>Division of Pulmonary, Allergy, and Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, <sup>2</sup>Laboratory of Clinical Infectious Disease, NIAID, National Institutes of Health, Bethesda, MD, <sup>3</sup>Division of Infectious Disease, University of Pittsburgh, Pittsburgh, PA, <sup>4</sup>Division of Cardiothoracic Surgery, University of Pittsburgh, Pittsburgh, PA, <sup>5</sup>Pharmacy and Therapeutics, University of Pittsburgh, Pittsburgh, PA
- (1000) *Circulatory Support Using Two Continuous Flow Assist Devices: A Case Series Employing a Novel Operative Approach;***  
 D. P. Cork<sup>1</sup>, H. A. Tran<sup>1</sup>, J. Silva<sup>1</sup>, B. Greenberg<sup>1</sup>, D. Barnard<sup>1</sup>, E. D. Adler<sup>1</sup>, V. Pretorius<sup>2</sup>. <sup>1</sup>Cardiology, University of California, San Diego, La Jolla, CA, <sup>2</sup>Cardiothoracic Surgery, University of California, San Diego, La Jolla, CA,
- (1001) *Laparoscopic Sleeve Gastrectomy as a Bridge to Transplant for Morbidly Obese LVAD Patients;***  
 F. Ricci, D. Majure, S. Boyce, E. Molina, M. Hofmeyer, F. Sheikh, G. Ruiz, M. E. Rodrigo, S. Najjar. Cardiology-Heart Failure, Washington Hospital Center, Washington, DC
- (1002) *Prostate as Sanctuary Site: Relapsed Blastomycosis in a Lung Transplant Recipient;***  
 M. E. Clement<sup>1</sup>, S. G. Norfolk<sup>2</sup>, J. M. Reynolds<sup>2</sup>, C. R. Wolfe<sup>1</sup>, E. K. Maziarz<sup>1</sup>. <sup>1</sup>Division of Infectious Diseases, Duke University Medical Center, Durham, NC, <sup>2</sup>Division of Pulmonary Medicine, Duke University Medical Center, Durham, NC
- (1003) *Severe Early Biventricular Manifestation of Arrhythmogenic Cardiomyopathy in Two Pediatric Patients With Compound Heterozygous Desmosomal Gene Mutations;***  
 J. M. Friedland-Little, P. Arscott, H. S. Magdo, R. J. Gajarski, K. R. Schumacher. University of Michigan C.S. Mott Children's Hospital, Ann Arbor, MI
- (1004) *Successful Utilization of a Lung From a Donor on Venoarterial Extracorporeal Membrane Oxygenator;***  
 N. Sinha. Pulmonary Transplant, Houston Methodist Hospital, Houston, TX
- (1005) *Interventional Treatment of LVAD Outflow Graft Stenosis By Introduction of Bare Metal Stents in Two Cases;***  
 T. Haber<sup>1</sup>, D. Wiedemann<sup>1</sup>, J. Riebandt<sup>1</sup>, J. Horvat<sup>2</sup>, J. Kastner<sup>3</sup>, W. Matzek<sup>4</sup>, G. Laufer<sup>1</sup>, D. Zimpfer<sup>1</sup>. <sup>1</sup>Division of Cardiac Surgery, Medical University of Vienna, Vienna, Austria, <sup>2</sup>Center of Medical Physics and Biomedical Engineering, Medical University of Vienna, Vienna, Austria, <sup>3</sup>Department of Cardiology, Medical University of Vienna, Vienna, Austria, <sup>4</sup>Department of Interventional Radiology, Medical University of Vienna, Vienna, Austria
- (1006) *HeartWare Ventricular Assist Device (HVAD) for Management of Systemic Right Ventricular Failure and Pulmonary Hypertension in a Patient With Dextro-Transposition of the Great Arteries (d-TGA) and Previous Atrial Switch Procedure;***  
 M. B. Stokes, A. S. Leet. Heart Centre, Alfred Hospital, Prahan, Australia
- (1007) *Successful Treatment of Disseminated Acanthamoebiasis in a Lung Transplant Recipient;***  
 C. Lee<sup>1</sup>, D. Brezhnev<sup>1</sup>, V. H. Chan<sup>1</sup>, P. C. Zakowski<sup>2</sup>, S. Ghandehari<sup>1</sup>, G. E. Chau<sup>1</sup>, J. A. Falk<sup>1</sup>. <sup>1</sup>Pulmonary and Critical Care, Cedars Sinai Medical Center, Los Angeles, CA, <sup>2</sup>Infectious Disease, Cedars Sinai Medical Center, Los Angeles, CA



**(1008)** *Portopulmonary Hypertension Female Complicated with Left Ventricle Collapse and Cardiogenic Shock, Survived after Extracorporeal Membrane Oxygenation Support and Specific Pulmonary Hypertension Medications Use: Up to 4 Years Follow Up Report;*

M. Huang<sup>1</sup>, C. Hsu<sup>2</sup>, P. Chen<sup>2</sup>. <sup>1</sup>Cardiology, National Cheng Kung University, Tainan, Taiwan, <sup>2</sup>Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan

**(1009)** *Post-Transplant Lymphoproliferative Disorder After Heart Transplantation in Japanese Pediatric Recipients;*

J. Narita<sup>1</sup>, S. Kogaki<sup>1</sup>, R. Higeno<sup>1</sup>, S. Mihara<sup>1</sup>, K. Takahashi<sup>1</sup>, K. Ozono<sup>1</sup>, N. Fukushima<sup>2</sup>, Y. Sawa<sup>2</sup>. <sup>1</sup>Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan, <sup>2</sup>Cardiovascular Surgery, Osaka University Graduate School of Medicine, Osaka, Japan

**(1010)** *Calcineurin Inhibitor-Free Immunosuppression With Basiliximab in Critically Ill Pediatric Heart Transplant Recipients;*

G. R. Vaughn, B. J. Hong, M. S. Kemna, Y. M. Law, E. L. Albers. Pediatric Cardiology, Seattle Children's Hospital, Seattle, WA

**(1011)** *Severe Autoimmune Cytopenia After Pediatric Heart Transplantation;*

H. T. Henderson<sup>1</sup>, M. D. Deel<sup>2</sup>, S. G. Kreissman<sup>2</sup>, J. A. Rothman<sup>2</sup>, M. P. Carboni<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Duke University, Durham, NC, <sup>2</sup>Pediatric Hematology & Oncology, Duke University, Durham, NC

**(1012)** *Effective Treatment of Refractory Angina With Ranolazine in a Heart Transplant Recipient;*

P. S. Bains<sup>1</sup>, M. Toma<sup>2</sup>, S. A. Virani<sup>2</sup>, A. Ignaszewski<sup>2</sup>, B. Munt<sup>2</sup>, A. Cheung<sup>3</sup>, J. Bashir<sup>3</sup>, A. Kaan<sup>4</sup>, E. Johansson<sup>4</sup>, M. K. Davis<sup>2</sup>. <sup>1</sup>University of British Columbia, Vancouver, BC, Canada, <sup>2</sup>Division of Cardiology, University of British Columbia, Vancouver, BC, Canada, <sup>3</sup>Division of Cardiac Surgery, University of British Columbia, Vancouver, BC, Canada, <sup>4</sup>St. Paul's Hospital, Vancouver, BC, Canada

**(1013)** *Post-Operative Lung Allograft Dysfunction Secondary to Partial Left Anomalous Pulmonary Venous Disruption;*

A. Goodarzi<sup>1</sup>, B. Mankidy<sup>2</sup>, N. Sinha<sup>2</sup>, S. Jyothula<sup>2</sup>, T. Kaleekal<sup>2</sup>, S. Scheinin<sup>3</sup>. <sup>1</sup>Pulmonary and Critical Care, Baylor College of Medicine, Houston, TX, <sup>2</sup>Medicine, Houston Methodist Hospital, Houston, TX, <sup>3</sup>Surgery, Houston Methodist Hospital, Houston, TX

**(1014)** *Adult Lung Transplantation for Hereditary Hemorrhagic Telangiectasia;*

M. A. Yu, D. Watkins, L. E. Leard, J. P. Singer, E. L. Bush, J. Kukreja, S. R. Hays, J. A. Golden. University of California, San Francisco, San Francisco, CA,

**(1015)** *Treatment of End-Stage Cardiomyopathy in a Young Man With Duchenne Muscular Dystrophy Using a Centrifugal Flow Ventricular Assist Device;*

D. Stoller<sup>1</sup>, F. Araj<sup>2</sup>, A. Amin<sup>2</sup>, J. Thibodeau<sup>2</sup>, C. Ramaciotti<sup>3</sup>, M. H. Drazner<sup>2</sup>, D. M. Meyer<sup>4</sup>, P. P. Mammen<sup>5</sup>. <sup>1</sup>Department of Internal Medicine, University of Texas Southwestern, Dallas, TX, <sup>2</sup>Department of Internal Medicine, Heart Failure Program, University of Texas Southwestern, Dallas, TX, <sup>3</sup>Department of Pediatrics, University of Texas Southwestern, Dallas, TX, <sup>4</sup>Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern, Dallas, TX, <sup>5</sup>Department of Internal Medicine, Heart Failure Program, and Hamon Center for Regenerative Science, University of Texas Southwestern, Dallas, TX

**(1016)** *Atrioventricular Block After Heart Transplantation in Pediatric Age: A Possible Sign of Rejection?;*

M. A. Castelluzzo<sup>1</sup>, F. Parisi<sup>1</sup>, D. Di Carlo<sup>1</sup>, S. Alfieri<sup>2</sup>, G. Grutter<sup>1</sup>. <sup>1</sup>Cardiology and Cardiac Surgery, Bambino Gesù Children Hospital, Rome, Italy, <sup>2</sup>Cardiology and Cardiac Surgery, Bambino Gesù Children's Hospital, Rome, Italy

- (1017)** *Role of Total Artificial Heart in Patients With a Body Surface Area Less Than 1.7 m<sup>2</sup> Having a Good Outcome After Pectoralis Major Muscle Flap Chest Closure;*  
 J. A. Gomez-Abraham, T. Yoshizumi, A. Shiose, Y. Toyoda. Cardiovascular Surgery, Temple University School of Medicine, Philadelphia, PA
- (1018)** *HeartMate II Left Ventricular Assist Device Implantation as an Alternative to Total Artificial Heart Placement in a Patient With Giant Mural Ventricular Thrombus;*  
 D. Schibilsky<sup>1</sup>, C. Haller<sup>1</sup>, M. Lenglinger<sup>1</sup>, B. Woernle<sup>1</sup>, H. Magunia<sup>2</sup>, T. Walker<sup>1</sup>, P. Rosenberger<sup>1</sup>, C. Schlensak<sup>1</sup>. <sup>1</sup>Department of Thoracic and Cardiovascular Surgery, University Medical Center, Tübingen, Germany, <sup>2</sup>Department of Anesthesiology and Intensive Care Medicine, University Medical Center, Tübingen, Germany,
- (1019)** *Implantation of a Subcutaneous Implantable Cardioverter-Defibrillator in a Patient With a HeartMate II Left Ventricular Assist Device;*  
 F. Raissi Shabari, A. Sundara Raman, B. Kar, P. Loyalka, R. Hariharan. University of Texas Houston, Houston, TX
- (1020)** *Double Donor Lobectomy Following Bilateral Sequential Single Lung Transplantation: A Case for Split Bilateral Lung Transplants;*  
 H. Tetteh<sup>1</sup>, N. A. Burton<sup>2</sup>, E. A. Lefrak<sup>2</sup>, S. Ahmad<sup>3</sup>, O. A. Slobin<sup>3</sup>, C. M. Rosner<sup>2</sup>, S. D. Nathan<sup>3</sup>. <sup>1</sup>Department of Surgery, Uniformed Services University of the Health Sciences, Bethesda, MD, <sup>2</sup>Inova Heart and Vascular Institute, Inova Fairfax Hospital, Falls Church, VA, <sup>3</sup>Lung Transplant and Advanced Lung Disease Program, Inova Fairfax Hospital, Falls Church, VA
- (1021)** *Right Ventricular Failure After Pediatric Heart Transplant: A Case of Mechanical Support in a High-Risk Patient;*  
 L. J. May<sup>1</sup>, J. Conway<sup>2</sup>, I. M. Rebeyka<sup>3</sup>, H. Buchholz<sup>3</sup>, D. B. Ross<sup>3</sup>, S. Urschel<sup>2</sup>. <sup>1</sup>Department of Pediatrics (Cardiology), Stanford University, Palo Alto, CA, <sup>2</sup>Department of Pediatrics (Cardiology), University of Alberta, Edmonton, AB, Canada, <sup>3</sup>Department of Cardiothoracic Surgery, University of Alberta, Edmonton, AB, Canada
- (1022)** *A Case of Fatal Hyperammonemia in a Lung Transplant Recipient in Australia;*  
 K. P. Lim<sup>1</sup>, T. Law<sup>2</sup>, P. Thyagarajan<sup>3</sup>, R. Larbalestier<sup>2</sup>, K. Ho<sup>3</sup>, G. Dobb<sup>3</sup>, M. Lavender<sup>1</sup>, J. P. Wrobel<sup>1</sup>, M. Musk<sup>1</sup>. <sup>1</sup>Advanced Lung Disease Unit, Royal Perth Hospital, Perth, Australia, <sup>2</sup>Cardiothoracic Surgery Department, Royal Perth Hospital, Perth, Australia, <sup>3</sup>Department of Critical Care, Royal Perth Hospital, Perth, Australia
- (1023)** *WITHDRAWN*
- (1024)** *Patient With Pulmonary Hypertension Secondary to ANCA Vasculitis Treated Successfully With Steroid and Cyclophosphamide;*  
 P. Su<sup>1</sup>, L. Tsai<sup>1</sup>, C. Hsu<sup>2</sup>. <sup>1</sup>Department of Internal Medicine, National Cheng Kung University Hospital, Tainan, Taiwan, <sup>2</sup>Institute of Clinical Medicine, National Cheng Kung University, Tainan, Taiwan
- (1025)** *Successful Percutaneous Trans-Catheter Treatment of Left Ventricular Assist Device Outflow Graft Stenosis With a Covered Stent;*  
 S. Kalantari-Tannenbaum, E. Retzer, G. Sayer, G. Kim, S. Fedson, C. Juricek, V. Jeevanandam, A. Shah, N. Uriel. Medicine, University of Chicago, Chicago, IL
- (1026)** *Dobutamine Induced Eosinophilic Myocarditis and Right Heart Failure Requiring Emergent Biventricular Assist Device Implantation;*  
 V. P. Raje<sup>1</sup>, N. P. Lewis<sup>2</sup>, G. J. Katlaps<sup>2</sup>, K. B. Shah<sup>1</sup>, A. Mankad<sup>2</sup>. <sup>1</sup>Medical College of Virginia, Richmond, VA, <sup>2</sup>Hunter Holmes McGuire Veterans Medical Center, Richmond, VA

- (1027) *Thrombus or Not a Thrombus? Left Ventricular Assist Device Dysfunction Due to Fibrosis;***  
 L. Glade<sup>1</sup>, J. D. Vega<sup>2</sup>, D. Nguyen<sup>2</sup>, R. T. Cole<sup>3</sup>, A. Morris<sup>3</sup>, S. R. Laskar<sup>3</sup>, D. Gupta<sup>1</sup>. <sup>1</sup>Cardiology, Emory University School of Medicine, Atlanta, GA, <sup>2</sup>Cardiothoracic Surgery, Emory University Hospital, Atlanta, GA, <sup>3</sup>Cardiology, Emory University Hospital, Atlanta, GA
- (1028) *Cobalt-Chromium Toxicity: How to Recognize and Treat a Heavy Metal Heart;***  
 R. A. Davey, M. Kanwar, A. Raina, G. Sokos, R. Agarwal, R. Benza, S. Bailey, S. Murali. Advanced Heart Failure and Transplantation, Allegheny General Hospital, Pittsburgh, PA
- (1029) *Vertebroplasty in a Lung Transplant Patient: Pulmonary Cement Embolism and Active Bleeding, an Exceptional Complication;***  
 D. Bennett<sup>1</sup>, A. Fossi<sup>1</sup>, M. Bellini<sup>2</sup>, P. Paladini<sup>3</sup>, L. Luzzi<sup>3</sup>, A. Cerase<sup>2</sup>, L. Voltolini<sup>3</sup>, P. Rottoli<sup>1</sup>. <sup>1</sup>Respiratory Diseases and Lung Transplantation, University of Siena, Siena, Italy, <sup>2</sup>Neuroimaging and Neurointerventional Radiology, University of Siena, Siena, Italy, <sup>3</sup>Thoracic Surgery, University of Siena, Siena, Italy,
- (1030) *Concomitant Pulmonary Thromboembolism and Orthotopic Cardiac Transplantation Following Biventricular Assist Device Implantation;***  
 A. Ghodsizad<sup>1</sup>, A. Lubitz<sup>2</sup>, J. Gomez-Abraham<sup>1</sup>, A. Shiose<sup>1</sup>, E. Leotta<sup>1</sup>, T. Yoshizumi<sup>1</sup>, J. Cooper<sup>3</sup>, D. Schwartz<sup>3</sup>, E. A. Hamad<sup>3</sup>, R. J. Alvarez<sup>3</sup>, D. Dries<sup>3</sup>, Y. Toyoda<sup>1</sup>. <sup>1</sup>Department of Cardiac Surgery, Temple University Hospital, Philadelphia, PA, <sup>2</sup>Department of Cardiac Surgery, Temple University Hospital, PA, <sup>3</sup>Department of Cardiology, Temple University Hospital, Philadelphia, PA
- (1031) *HVAD Insertion Via Right Ventricular Interposition: A Novel Strategy for Biventricular Support;***  
 D. Joyce<sup>1</sup>, J. Stulak<sup>1</sup>, S. Kushwaha<sup>2</sup>, R. Daly<sup>1</sup>, L. D. Joyce<sup>1</sup>. <sup>1</sup>Cardiovascular Surgery, Mayo Clinic, Rochester, MN, <sup>2</sup>Cardiology, Mayo Clinic, Rochester, MN
- (1032) *Cardio-Pulmonary Transplantation After 82 Days of Novalung as a Bridge;***  
 M. N. Garg, D. H. Freed, J. Nagendran. Cardio Thoracic Surgery, Mazankowski Alberta Heart Institute, Edmonton, AB, Canada
- (1033) *17 Year Old Fontan Patient – Acute Embolic Myocardial Infarction, Heart Failure With Successful Bridge to Transplantation With Impella Device;***  
 S. R. Deshpande<sup>1</sup>, A. Dalal<sup>1</sup>, D. Kim<sup>1</sup>, M. Jokhadar<sup>2</sup>. <sup>1</sup>Pediatric Cardiology, Emory University Children's Healthcare of Atlanta, Atlanta, GA, <sup>2</sup>Department of Cardiology, Emory University, Atlanta, GA
- (1034) *Scedosporium apiospermum Involving the "Native Valve": Fungal Endocarditis in an Orthotopic Heart Transplant Recipient;***  
 M. E. Clement, E. K. Maziarz. Division of Infectious Diseases, Duke University Medical Center, Durham, NC
- (1035) *Severe Pulmonary Arterial Hypertension in a Pediatric Patient With Hemitruncus Arteriosus;***  
 J. A. Su<sup>1</sup>, S. R. Kumar<sup>2</sup>, A. L. Cheng<sup>1</sup>, C. D. Lew<sup>3</sup>, R. K. Chang<sup>4</sup>, F. F. Ing<sup>1</sup>, J. R. Szmuszkovicz<sup>1</sup>. <sup>1</sup>Pediatric Cardiology, Children's Hospital of Los Angeles, Los Angeles, CA, <sup>2</sup>Cardiothoracic Surgery, Children's Hospital of Los Angeles, Los Angeles, CA, <sup>3</sup>Pediatric Pulmonology, Children's Hospital of Los Angeles, Los Angeles, CA, <sup>4</sup>Pediatric Cardiology, Harbor-UCLA, Torrance, CA

# INDEPENDENT EVENTS



# APPROVED EDUCATIONAL ACTIVITIES

CONDUCTED BY INDUSTRY

*during the*  
ISHLT 35<sup>th</sup> Annual Meeting  
and Scientific Sessions

NOTE: These are independent events and are not an official part of the ISHLT Annual Meeting and Scientific Sessions.

# WEDNESDAY, APRIL 15, 2015

**TITLE:** *CTEPH Futures Think Tank:  
How can we do more for CTEPH  
Patients Today and Tomorrow?*

CONDUCTED BY BAYER

This is a closed meeting.  
Attendance by invitation only.

**TIME:** **1:00 pm - 2:30 pm**

**LOCATION:** Rizzo 6 in the Rhodes Exhibit Hall,  
Acropolis Congress Center

## **MEDIA CHAIR:**

**Jacqui Thornton (UK)**, Health correspondent and Chair, UK

**Marc Humbert (FR)**, Director, Université Paris-Sud 11 & Vice Chairman, National Reference Centre for Pulmonary Hypertension, Department of Respiratory and Intensive Care Medicine, Hospital Antoine Bécélère, Clamart, France

**Deepa Gopalan (UK)**, Consultant Radiologist, Papworth, UK

**Eckhard Mayer (DE)**, Director, Thoracic surgery, Kerckhoff Clinic, Germany

**Paul Corris (UK)**, Professor of Thoracic Medicine Institute of Cellular Medicine,

# INDEPENDENT EVENTS

## THURSDAY, APRIL 16, 2015

**TITLE:** *Deeper Dive into HeartWare  
Clinical and Real-World Results*

CONDUCTED BY HEARTWARE

**TIME:** 12:45 pm - 2:15 pm

**LOCATION:** Clio/Thalie Rooms,  
Acropolis Congress Center

## THURSDAY, APRIL 16, 2015

**TITLE:** *AlloMap: New Advancements in  
Post-Heart Transplant Rejection  
Surveillance*

CONDUCTED BY CAREDX

**TIME:** 12:45 pm - 2:15 pm

**LOCATION:** Euterp Room,  
Acropolis Congress Center

*Opening Introductions,*  
James Yee, MD (CareDx)

*Use of AlloMap in the AMR Era: Application of  
EIMAGE Results and Cedars-Sinai Experience,*  
Jon Kobashigawa, MD (Cedars-Sinai)

*New CARGO II Results from Bad Oeynhausen,*  
Uwe Schulz, MD (Bad Oeynhausen)

*Presentation of the PRME study a Multi-center  
AlloMap Trial Funded by France,*  
Laurent Sebbag, MD (Lyon)

*Evolution of AlloMap Use at Baylor University  
Medical Center, Dallas,*  
Shelley Hall, MD (Baylor)

*Use of Cell-free DNA in the Detection of Heart  
Transplant Rejection (and new findings with AlloMap),*  
Jon Kobashigawa, MD (Cedars-Sinai)

*Panel Discussion/Q&A: Drs. Kobashigawa and Schulz,*  
Drs. Kobashigawa and Schulz

*Closing Comments,*  
Jon Kobashigawa, MD

## THURSDAY, APRIL 16, 2015

**TITLE:** *CTEPH Patient Care: The Path to Avoid Missed Opportunities*

CONDUCTED BY BAYER

**TIME:** **4:00 pm - 5:00 pm**

**LOCATION:** Rizzo 7 in the Rhodes Exhibit Hall, Acropolis Congress Center

**CHAIR:** Ardeschir Ghofrani (Giessen, Germany)

**4:00 PM:** *Opening and Introduction,*  
Ardeschir Ghofrani, University of Giessen, Giessen, Germany

**4:05 PM:** *CTEPH Patient Journey: From Diagnosis to Surgery,*  
Stephan Rosenkranz, University of Cologne, Cologne, Germany

**4:25 PM:** *CTEPH Patient Journey: Best Practice in Diagnosis and Management,*  
Raymond L. Benza, Allegheny General Hospital, Pittsburgh, PA, USA

**4:50 PM:** *Q & A, Facilitated by*  
Ardeschir Ghofrani, University of Giessen, Giessen, Germany

**5:00 PM:** *Adjourn*


# ISHLT 2015 EXHIBITORS



## ALPHABETICAL LISTING:


ALERE HOME MONITORING	10
BAYER HEALTHCARE	32
BERLIN HEART	33
CARDIAC ASSIST	14
CARMAT	16
DIAXONHIT/CAREDX INC.	34
ELSEVIER	20
EVAHEART	11
HEARTWARE	42
INSTITUT GEORGES LOPEZ	7-8
ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY (IMACS)	57
ISHLT REGISTRY	58
JARVIK HEART	13
LOPHIUS BIOSCIENCES GMBH	12
LUNG BIOTECHNOLOGY	17
MAQUET GETINGE GROUP	54-55
MILLAR, INC.	2
MINNETRONIX, INC.	5
ONE LAMBDA	53
PHTS - PEDIATRIC HEART TRANSPLANT STUDY	56
RELIANTHEART	18-19
SCANLAN INTERNATIONAL, INC.	1
SUNSHINE HEART	9
SYNCARDIA SYSTEMS, INC.	15
TEVA	6
THORATEC CORPORATION	22
TRANSMEDICS INC	23
UNITED THERAPEUTICS EUROPE LIMITED	52
VIVOLINE MEDICAL AB	3-4
WISEPRESS	21
XVIVO PERFUSION AB	43

# EXHIBIT HALL AND POSTERS



## LISTING BY BOOTH NUMBER:

- |       |                             |
|-------|-----------------------------|
| 1     | SCANLAN INTERNATIONAL, INC. |
| 2     | MILLAR, INC.                |
| 3-4   | VIVOLINE MEDICAL AB         |
| 5     | MINNETRONIX, INC.           |
| 6     | TEVA                        |
| 7-8   | INSTITUT GEORGES LOPEZ      |
| 9     | SUNSHINE HEART              |
| 10    | ALERE HOME MONITORING       |
| 11    | EVAHEART                    |
| 12    | LOPHIUS BIOSCIENCES GMBH    |
| 13    | JARVIK HEART                |
| 14    | CARDIAC ASSIST              |
| 15    | SYNCARDIA SYSTEMS, INC.     |
| 16    | CARMAT IMMEUBLE             |
| 17    | LUNG BIOTECHNOLOGY          |
| 18-19 | RELIANTHEART                |
| 20    | ELSEVIER                    |



- 21** WISEPRESS
- 22** THORATEC CORPORATION
- 23** TRANSMEDICS INC
- 32** BAYER HEALTHCARE
- 33** BERLIN HEART
- 34** DIAXONHIT/CAREDX INC.
- 42** HEARTWARE
- 43** XVIVO PERFUSION AB
- 52** UNITED THERAPEUTICS  
EUROPE LIMITED
- 53** ONE LAMBDA
- 54-55** MAQUET GETINGE GROUP
- 56** PHTS - PEDIATRIC HEART  
TRANSPLANT STUDY
- 57** ISHLT MECHANICALLY  
ASSISTED CIRCULATORY  
SUPPORT REGISTRY (IMACS)
- 58** ISHLT REGISTRY

## ALERE HOME MONITORING

10

30 S. Keller Road, Suite 100 B  
Orlando, FL 32810

[www.alere.com/us/en/health-solutions/home-a-monitoring/vadcare-program.html](http://www.alere.com/us/en/health-solutions/home-a-monitoring/vadcare-program.html)

Alere Home Monitoring, through its Alere VADCare® Program, provides equipment and services for VAD patients and hospital VAD departments. Our newest offering, the Alere VADWatch® Telemonitoring Program allows VAD Coordinators and Physicians to monitor patients after discharge by providing them with alerts when critical patient values are outside of a pre-established acceptable range. The Alere VAD-Watch® Tele-monitoring Program is perfectly designed to help reduce hospital readmissions. In addition, we enable VAD patients to monitor their INR at home using our industry leading home anticoagulation monitoring services.

## BAYER HEALTHCARE

32

Müllerstr. 178  
13353 Berlin  
Germany

[www.healthcare.bayer.com](http://www.healthcare.bayer.com)

Bayer HealthCare is one of the world's leading, innovative companies in the healthcare and medical products industry. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. More information at [www.healthcare.bayer.com](http://www.healthcare.bayer.com).

Wiesenweg 10  
12247 Berlin  
Germany  
[www.berlinheart.de](http://www.berlinheart.de)

Berlin Heart is the only company worldwide that develops, produces, and distributes implantable and paracorporeal ventricular assist devices for patients of every age and body size.

EXCOR<sup>®</sup> is a paracorporeal pulsatile VAD for uni- or biventricular support in newborns, children, adolescents, and adults. EXCOR<sup>®</sup> Pediatric is leading the worldwide market of pediatric VADs.

INCOR<sup>®</sup> is an implantable axial-flow LVAD for adults. INCOR<sup>®</sup> is the only 3rd generation axial flow pump with CE-mark approval.

The Berlin Heart EXCOR<sup>®</sup> Pediatric Ventricular Assist Device (EXCOR<sup>®</sup> Pediatric) is approved for use by the FDA under a Humanitarian Device Exemption. All other products are not FDA approved.

240 Alpha Drive  
Pittsburgh, PA 15238  
[www.cardiacassist.com](http://www.cardiacassist.com)

CardiacAssist, inventor of the TandemHeart<sup>®</sup> Extracorporeal Circulatory Support System, offers versatile MCS treatment options. Our classic Left Ventricular Bypass System leverages a unique transeptal cannula to completely bypass the LV to unload the ventricle up to 90%. The newly launched, PROTEK Duo<sup>™</sup> Veno-Venous procedure kit provides a new percutaneous option for Extracorporeal Life Support. CardiacAssist also manufactures a top-of-the-line Arterial Cannulae, PROTEK17/15. Stop by our booth to learn more about our products.

## CARMAT

16

Immeuble l'Etendard, CS 40533  
36, avenue de l'Europe  
78941 Vélizy-Villacoublay, FRANCE  
[www.carmatsa.com/](http://www.carmatsa.com/)

CARMAT develops a bioprosthetic artificial heart that features bovine pericardial tissue for blood contacting surfaces and fully enclosed controls based on embedded sensors and electronics.

## DIAXONHIT/CAREDX INC.

34

Diaxonhit (Exclusive Distributor in Europe)  
63-65 Boulevard Massena, 75013  
Paris FRANCE  
[www.diaxonhit.com](http://www.diaxonhit.com)

CareDx Inc. (Legal Manufacturer)  
3260 Bayshore Boulevard  
Brisbane, California, USA  
[www.caredxinc.com](http://www.caredxinc.com)

AlloMap is a blood test used to aid in the identification of heart transplant recipients with stable allograft function who have a low probability of moderate/severe acute cellular rejection at the time of testing in conjunction with standard clinical assessment.

AlloMap can be used as a non-invasive method for the surveillance monitoring of stable transplant recipients showing no signs of rejection.

AlloMap is indicated for use in patients over 15 years and at least 2 months (>55 days) post-transplantation.

AlloMap is performed in a single laboratory in Europe under exclusive license to Diaxonhit, assessing the gene expression profile of RNA.

Radarneg 29  
Amsterdam, The Netherlands 1043NX  
www.elsevierhealth.com

ELSEVIER is a leading publisher of health science publications, advancing medicine by delivering superior reference information and decision support tools to doctors, nurses, health practitioners and students. With an extensive media spectrum-print, online and handheld, we are able to supply the information you need in the most convenient format.

6655 Travis St. STE 590  
Houston, TX 77030 USA

The EVAHEART Left Ventricular Assist System (LVAS)<sup>™</sup> is a continuous-flow, hydraulically levitated centrifugal pump designed to support patients with end-stage heart failure as bridge-to-transplant therapy. The EVAHEART LVAS has been commercially available in Japan since 2010, and has successfully obtained CE marking approval.

Evaheart, Inc. (EVI) is a medical device company based in the Texas Medical center of Houston. EVI was established to gain regulatory approval and commercialize the EVAHEART LVAS in North America and to start distribution in Europe. Under an FDA-approved IDE, a bridge-to-transplant (BTT) clinical trial of the EVAHEART LVAS is currently ongoing in the US.

## HEARTWARE

42

500 Old Connecticut Path  
Framingham, MA 01701 USA  
[www.heartware.com](http://www.heartware.com)

HeartWare is a global medical device company dedicated to delivering safe, high-performing and transformative therapies that enable patients with heart failure to get back to life. The company's innovative technologies are creating advances in the miniaturization of Ventricular Assist Devices (VADs) leading to less invasive surgical procedures and increasing the patient population who may be suitable for VAD therapy. HeartWare's breakthrough innovations begin with the HVAD® Pump, designed to be implanted next to the heart in the pericardial space avoiding the more invasive surgical procedures required with older LVAD technologies. The HVAD Pump is commercially available around the world.

## INSTITUT GEORGES LOPEZ

7-8

Parc Tertiaire du Bois Dieu  
RNS - 1, Allée des Chevreuils  
Lissieu 69380 France  
[www.igl-group.com](http://www.igl-group.com)

### IGL

As an international leader, GROUPE IGL develops manufactures and markets its proprietary products.

Celsior

Solution for organ preservation.

Celsior is an historical reference for heart preservation.



## **ISHLT (IMACS)**

**57**

### **ISHLT MECHANICALLY ASSISTED CIRCULATORY SUPPORT REGISTRY**

701 19TH Street South  
LHRB 790, Birmingham, AL 35294  
[www.ishlt.org/registries/mcsdDatabase.asp](http://www.ishlt.org/registries/mcsdDatabase.asp)

IMACS is an international registry intended to enroll and follow patients who receive durable mechanically assisted circulatory support devices (MCSD) in all countries and hospitals that wish to participate. Durable devices are defined as those devices that are capable of allowing patient discharge with the device in place.

The primary goal of the IMACS Registry is to create, implement and analyze a registry that contains high standards for complete enrollment of patients and complete and accurate submission of MCSD data that allows participating centers to engage in important outcomes research about mechanical support devices.

## **ISHLT REGISTRY**

**58**

700 North 4th Street  
Richmond, Virginia 23219  
E-mail: [ishlthelp@unos.org](mailto:ishlthelp@unos.org)

The ISHLT Transplant Registry was created to collect on-going, current information on the worldwide thoracic organ transplantation experience. Our registry is the only one of its kind. The data we maintain is utilized for scientific study and contributes to the body of knowledge regarding thoracic transplantation. Our goal is to identify overall and best practices for improving cardiothoracic patient care.

This year the exhibit will make center-specific information available for review by ISHLT Transplant Registry and DCD Registry participants. Data screens can be reviewed and we will provide guidance on enrollment, submission of data and data request services.

## JARVIK HEART

13

333 West 52nd St  
New York, NY 10019  
[www.jarvikheart.com](http://www.jarvikheart.com)

Jarvik Heart, Inc. is a privately held, New York based company that develops and manufactures miniaturized heart assist devices for the treatment of severe heart failure. The Jarvik 2000 is a battery-powered axial-flow left ventricular assist device (LVAD). It is the smallest implantable blood pump available for the long-term treatment of Heart Failure.

## LOPHIUS BIOSCIENCES GMBH

12

Josef-Engert-Straße 13  
93053 Regensburg  
Germany  
[www.Lophius.com](http://www.Lophius.com)

Lophius Biosciences GmbH is an innovative biotech company located in Regensburg, Germany. We are focusing on development, clinical validation and marketing of T cell based research tools and diagnostic systems for early diagnosis and immunomonitoring in the fields of transplantation, infectious and autoimmune diseases. We use our expertise in immunology and infectious diseases to improve personalized therapies with our diagnostic kits. The T Cell Tools are suitable for the development of adjuvant free vaccines as well as for the ex vivo expansion of T cells, the identification of new T cell epitopes and to test novel drugs and immune therapies.

1040 Spring Street  
Silver Spring, MD  
[www.lungbiotechnology.com](http://www.lungbiotechnology.com).

Lung Biotechnology is focused on the commercialization, research and development of unique products to address the unmet medical needs of patients. We believe serving others is more than just a responsibility - it's a privilege. We try to breathe life into everything we do, and pride ourselves on contributing time and resources to help patients with fatal lung diseases.

Kehler Str. 31  
76437 Rastatt, Germany  
[www.maquet.com](http://www.maquet.com)

The CARDIOHELP System is the world's smallest portable heart-lung support system designed to treat and to transport patients needing extracorporeal life support (ECLS). The system offers short term and prolonged ECLS as a bridge to transplant, bridge to explant, bridge to bridge and bridge to destination.

CARDIOSAVE represents a giant leap forward in functionality and versatility. With its large touchscreen display, dramatically smaller and lighter design, and seamless transition from in-hospital use to transport mode, this revolutionary IABP redefines counterpulsation therapy.

## MILLAR, INC.

2

6001-A Gulf Freeway  
Houston, Texas 77023 USA  
[www.millar.com](http://www.millar.com)

Millar is committed to making the improbable possible in cardiovascular diagnostics and research by delivering products that enable a deeper understanding of hemodynamic function. From clean, pressure waveforms with the Mikro-Cath™ pressure catheter to plotting the complete cardiac cycle with the Inca® PV Loop System, expert insight is within reach. Millar is a unique provider of cardiovascular products that cover device and drug development from the first animal model through the final clinical trial.

## MINNETRONIX, INC.

5

1635 Energy Park Drive  
Saint Paul, Minnesota 55108 USA  
[www.minnetronix.com](http://www.minnetronix.com)

Minnetronix offers leading expertise in Customizable VAD Power and Control Technology for ventricular assist devices - from today's percutaneous systems to future fully implantable solutions. Minnetronix brings heart assist developers unparalleled proven experience, robust enabling intellectual property, quality systems, and end-to-end service from design through verification and manufacturing.

Technologies include the Magic™ PE Percutaneous Controller, the Magic™ TE Transcutaneous Power Controller, and proprietary TETS technologies. Minnetronix has completed 24 VAD-related programs for 14 customers, including current commercial scale production of power and control for a PMA-approved VAD System. The company is FDA Registered, and ISO 13485 Certified.

## **ONE LAMBDA**

**53**

### **PART OF THERMO FISHER SCIENTIFIC**

21001 Kittridge Street  
Canoga Park, CA 91303 USA  
[www.onelambda.com](http://www.onelambda.com)

One Lambda, Inc. is a leader in transplant diagnostics and offers a broad range of products to support clinicians and laboratories in the management of transplant patients. Donor specific antibody (DSA) testing and monitoring are specific tools which support this process. Visit the One Lambda booth to discover how we can help you improve the standard of care in DSA monitoring, featuring our LABScreen® Single Antigen assays and our recent introduction of our biomarker products.

## **PHTS**

**56**

### **PEDIATRIC HEART TRANSPLANT STUDY**

701 19th Street South, LHRB 781  
Birmingham, AL 35294 USA  
[www.uab.edu/medicine/phts](http://www.uab.edu/medicine/phts)

The Pediatric Heart Transplant Study (PHTS) is an international registry established in 1993 for pediatric patients listed for heart transplantation. PHTS is dedicated to the advancement of the science and treatment of children during listing for and following heart transplantation. The purposes of the group are to establish and maintain a prospective, event driven database for heart transplantation, to encourage and stimulate basic and clinical research in the field of pediatric heart transplantation, and to promote new therapeutic strategies. The ultimate goal is to improve patient outcomes. The registry resides at the University of Alabama at Birmingham.

## RELIANTHEART

18-19

ReliantHeart Inc. USA  
8965 Interchange Drive  
Houston, Texas 77054 USA

ReliantHeart Inc. EUROPE  
Erfstraat 10a  
5405 BE, Uden  
The Netherlands  
[www.reliantheart.com/](http://www.reliantheart.com/)

**LVAD**, Full Flow 92 Grams, remotely monitored True Flow Measurement.

<https://www.youtube.com/watch?v=jqrcU7mp6bY>

**VAD Maintenance System** to service multiple LVADs; HVAD, HMII and HA5.

<http://reliantheart.com/for-medical-professionals/future-innovation/>

### **Forward Compatibility**

Forward compatibility is the ability of a design to gracefully accept input intended for later versions of itself. Our philosophy is to leave no patient behind.

<http://reliantheart.com/for-medical-professionals/comparison-of-popular-european-lvads/>

## SCANLAN INTERNATIONAL, INC.

1

One Scanlan Plaza  
Saint Paul, Minnesota 55107 USA  
[www.scanlaninternational.com](http://www.scanlaninternational.com)

Highest quality surgical products designed and manufactured by the Scanlan family since 1921. Over 3,000 titanium and stainless steel instrument designs including needle holders, forceps, scissors, clamps and specialty instruments. Featured instruments include the SCANLAN® LEGACY titanium needle holders and forceps, full line of VATS / MIS Thoracoscopic instruments including the Chitwood Clamp, Knot Pusher, and SUPER CUT™ Suture Cutter; Axial Handle needle holders and forceps, SUPER CUT™ Scissors and Rendina needle holder. Single-use products include: VASCU-STATT® bulldog clamps, Aorta/Vein Punch and A/C Locator® graft markers. Also offering custom instrument designs and modifications for your individual needs.

## SUNSHINE HEART

9

12988 Valley View Road  
Eden Prairie, MN 55344 USA  
[www.Sunshineheart.com](http://www.Sunshineheart.com)

The C-Pulse® Heart Assist System is a balloon counter-pulsation technology used to treat patients with moderate to severe heart failure (Class III/ Ambulatory Class IV). The implantable device is placed outside the bloodstream and gives patients the ability to disconnect from the system. Preliminary results of the C-Pulse System have indicated relief of heart failure symptoms, improved quality of life and cardiac function, and reduced the need for heart failure hospitalization. The C-Pulse implant procedure can be performed minimally invasively. The European Post-Market Study (OPTIONS HF) and the US Investigational Pivotal Trial (COUNTER HF™) are currently underway.

## SYNCARDIA SYSTEMS, INC.

15

1992 E. Silverlake Rd.  
Tucson, AZ 85713 USA  
[www.syncardia.com](http://www.syncardia.com)

The SynCardia temporary Total Artificial Heart (TAH-t) is the world's only FDA, Health Canada and CE approved Total Artificial Heart. The TAH-t is currently approved as a bridge to transplant for patients dying from end-stage biventricular failure. The 13.5 lb Freedom® portable driver has received CE approval in Europe and FDA approval in the U.S. The Freedom driver is designed to provide mobility for stable TAH-t patients both inside and outside the hospital. Visit the booth for updates on our growing clinical experience, and the Destination Therapy and 50cc Adult/Pediatric TAH-t clinical studies.

## TEVA

6

Piet Heinkade 107  
Amsterdam, The Netherlands 1019GM  
[www.tevapharm.com](http://www.tevapharm.com)



6035 Stoneridge Dr.  
Pleasanton, CA 94588 USA  
[www.thoratec.com](http://www.thoratec.com)

Thoratec® Corporation is a world leader in device-based mechanical circulatory support therapies. For over 35 years, the company has innovated and delivered technologies to save, support and restore failing hearts, allowing advanced heart failure patients to reclaim their lives. Thoratec is committed to discovering new, groundbreaking ways to serve a broader patient population through improved clinical outcomes, less-invasive procedures, and significant enhancements to quality of life. Thoratec's portfolio includes the HeartMate and CetriMag® product lines.

200 Minuteman Road  
Suite 302  
Andover MA 01810 USA  
[www.transmedics.com](http://www.transmedics.com)

TransMedics is dedicated to enabling increased utilization of donor organs for transplantation while enhancing patient outcomes and improving cost-effectiveness of transplant programs. The TransMedics® Organ Care System is a portable, advanced ex-vivo perfusion, monitoring and organ recruitment platform for heart and lung transplantation that is intended to maintain donor organs in a functioning state from donor to recipient.

The OCS™ HEART and LUNG systems are CE-marked and in clinical use in leading European transplant centers, and pivotal FDA clinical trials have concluded in leading global Heart & Lung transplant centers comparing the OCS™ to cold storage.

**EUROPE LIMITED**

Unither House  
Curfew Bell Road  
Chertsey, Surrey, KT16 9FG, United Kingdom  
[www.unither.com](http://www.unither.com)

United Therapeutics Corporation is a biotechnology company focused on the development and commercialisation of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions including pulmonary arterial hypertension (PAH). From the United States to Europe to Asia Pacific, we are proud of our multicultural business environment where employees can collaborate with people all over the world. As a group, we are relentless in our pursuit of “medicines for life”<sup>®</sup> and continue our research into treatments for cancer and some of the world’s most complicated viral illnesses.

EU/CORP/FEB15/004 date of preparation February 2015

## VIVOLINE MEDICAL AB

3-4

Vivoline Medical AB  
Propellervägen 15  
224 78 Lund, Sweden  
[www.vivoline.se](http://www.vivoline.se)

Vivoline Medical is a Swedish research-based company which develops and manufactures equipment in the field of thoracic transplantation. The first product on the market was Vivoline<sup>®</sup> LS1, now spread over a large part of the world. Vivoline<sup>®</sup> LS1 is the world's leading system, designed for making EVLP in an automatic way and thus helping medical centers to increase efficiency and meet the needs for transplantable organs.

The future-oriented company Vivoline Medical will show a new version of lung evaluation system in the booth at ISHLT 2015.

## WISEPRESS.COM

21

The Old Lamp Works  
25 High Path  
London SW19 2JL  
United Kingdom  
[www.wisepress.com](http://www.wisepress.com)

Box 53015  
SE - 400 14 Göteborg  
Sweden  
[www.xvivoperfusion.com](http://www.xvivoperfusion.com)

XVIVO manufactures and markets solutions for transplantation designed to preserve and evaluate organs and tissues prior to transplantation. The XPS™ is a flexible and comprehensive platform for normothermic EVLP empowering the user to remain in control of the entire process. Our principle solutions are Perfadex® for hypothermic flushing and preservation of donor lungs during transport and STEEN Solution™ for normothermic ex vivo lung evaluation and assessment. Our products are CE-marked and approved by the FDA.

**XVIVO aims to:**

- minimize ischemia-reperfusion injury by improving the solutions used for ex-vivo preservation of organs.
- extend the safe ex-vivo preservation time for organs prior to transplantation.
- increase organ availability and transplantation success rates by introduction of new transplantation concepts and techniques























*Le coffre-fort  
voyage...*

*Voyez-vous  
l'année  
prochaine!*

**Safe travels...  
See you next year!**



14673 Midway Road, Suite 200  
Addison, Texas 75001  
P. 972.490.9495 F. 972.490.9499  
[www.isHLT.org](http://www.isHLT.org)



# FUTURE MEETINGS



**2016**

**36th Annual Meeting  
and Scientific Sessions**

**WASHINGTON DC**

**April 27-30, 2016**

**2017**

**37th Annual Meeting  
and Scientific Sessions**

**SAN DIEGO, CA**

**April 5-8, 2017**



# EVNHEART



## *RESPECT PULSATILITY*

INVESTIGATIONAL DEVICE. LIMITED BY FEDERAL  
(OR UNITED STATES) LAW TO INVESTIGATIONAL USE.

